0001213900-15-002097.txt : 20150326 0001213900-15-002097.hdr.sgml : 20150326 20150326095833 ACCESSION NUMBER: 0001213900-15-002097 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20141231 FILED AS OF DATE: 20150326 DATE AS OF CHANGE: 20150326 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUCELL CORP /DE/ CENTRAL INDEX KEY: 0000811641 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 010382980 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12934 FILM NUMBER: 15726488 BUSINESS ADDRESS: STREET 1: 56 EVERGREEN DR CITY: PORTLAND STATE: ME ZIP: 04103 BUSINESS PHONE: 2078782770 MAIL ADDRESS: STREET 1: 56 EVERGREEN DRIVE CITY: PORTLAND STATE: ME ZIP: 04103 10-K 1 f10k2014_immucellcorp.htm ANNUAL REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

☒   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2014

 

☐   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

001-12934

(Commission file number)

 

ImmuCell Corporation

(Exact name of Registrant as specified in its charter)

 

Delaware   01-0382980
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer
Identification No.)
     
56 Evergreen Drive, Portland, Maine   04103
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number: (207) 878-2770

 

Securities registered pursuant to Section 12(b) of the Act:

None

 

Securities registered pursuant to Section 12(g) of the Act:

 

Common Stock, par value $0.10 per share

(Title of class)

 

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐  No ☒

 

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes £ No ☒

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No £

 

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes ☒ No £

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. Large accelerated filer £ Accelerated filer £ Non-accelerated filer £ Smaller reporting company ☒

 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes £ No ☒

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates at June 30, 2014 was approximately $9,582,000 based on the closing sales price on June 30, 2014 of $4.40 per share.

 

The number of shares of the Registrant’s common stock outstanding at March 18, 2015 was 3,028,034.

 

Documents incorporated by reference: Portions of the Registrant’s definitive Proxy Statement to be filed in connection with the 2015 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.

 

 

 

 
 

 

ImmuCell Corporation

 

TABLE OF CONTENTS

December 31, 2014

 

  PART I  
     
ITEM 1. Description of Business 1
     
ITEM 1A. Risk Factors 11
     
ITEM 2. Description of Property 18
     
ITEM 3. Legal Proceedings 18
     
ITEM 4. Mine Safety Disclosures 18
     
PART II  
     
ITEM 5. Market for Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 19
     
ITEM 6. Selected Financial Data 19
     
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
     
ITEM 7A. Quantitative and Qualitative Disclosures about Market Risk 30
     
ITEM 8. Financial Statements 30
     
ITEM 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure 30
     
ITEM 9A Controls and Procedures 30
   
ITEM 9B. Other Information 31
     
PART III  
     
ITEM 10. Directors, Executive Officers and Corporate Governance 32
     
ITEM 11. Executive Compensation 32
     
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 32
     
ITEM 13. Certain Relationships and Related Transactions, and Director Independence 32
     
ITEM 14. Principal Accounting Fees and Services 32
     
ITEM 15. Exhibits and Financial Statement Schedules 32
     
  Audited Financial Statements F-1 to F-20
     
  Signatures

 
 

 

ImmuCell Corporation

 

PART I

 

ITEM 1 – DESCRIPTION OF BUSINESS

 

Summary

 

ImmuCell Corporation was founded in 1982 and completed an initial public offering of common stock in 1987. After achieving approval from the U.S. Department of Agriculture (USDA) to sell First Defense® in 1991, we focused most of our efforts during the 1990’s developing human product applications of the underlying milk protein purification technology. Beginning in 1999, we re-focused our business strategy on First Defense® and other products for the dairy and beef industries. Our purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. We are investigating new products utilizing the technology underlying First Defense® (milk antibodies) and Mast Out® (Nisin). We have experienced consistent growth in product sales over the past four years. These animal health product opportunities are generally less expensive to develop than the human health product opportunities that we had worked on during the 1990’s. As a result, we recorded nine consecutive years of profitability during the years ended December 31, 1999 to December 31, 2007. Our strategic decision to continue developing Mast Out® after the product rights were returned to us in 2007 caused us to increase our spending on product development expenses that had been funded by a partner from late 2004 to mid-2007. The resulting significant and controlled investment in the development of Mast Out® resulted in net losses for each year during the four-year period that began on January 1, 2008 and ended on December 31, 2011. Resulting principally from increased gross margin from sales of First Defense® and reduced product development spending on Mast Out®, we returned to profitability during the years ended December 31, 2012 and 2013. As anticipated, we incurred a net loss during the six-month period ended June 30, 2014 and the twelve-month period ended December 31, 2014 due to a non-recurring, infrequent and unusual investment pertaining to Mast Out®. As planned, we did return to profitability during the six-month period ended December 31, 2014.

 

During 2000, we began the development of Mast Out®, our Nisin-based treatment for subclinical mastitis in lactating dairy cows. No sales of this product can be made without prior approval of our New Animal Drug Application (NADA) by the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA). Nisin is an antibacterial peptide that has been demonstrated in clinical studies to be an effective aid in the reduction of mastitis-causing organisms in dairy cows. Mastitis is a very common infection in dairy cows that results in inflammation of the mammary gland. Because dairy producers are required to discard milk for a period during and after treatment with all currently marketed mastitis treatment products due to concerns about antibiotic residue in milk, it is generally current practice to only treat mastitis when the disease has progressed to the clinical stage where the milk from an infected cow cannot be sold. We believe that Mast Out® could revolutionize the way that mastitis is treated by making earlier treatment of subclinically infected cows economically feasible by not requiring a milk discard during, or for a period of time after, treatment. No other FDA-approved mastitis treatment product on the market can offer this value proposition. Mast Out® could also be used as a tool to improve milk quality, allowing producers to increase milk revenue by earning higher milk quality premiums. Regulatory achievements to-date have significantly reduced the product development risks for Mast Out® in the areas of safety and effectiveness. Our primary focus, with respect to Mast Out®, has now turned to the manufacturing objectives required for FDA approval.

 

As we make process improvements, we are investing in personnel, equipment and facility modifications to increase the efficiency and quality of our operations. In 2006, we initiated our ongoing efforts to maintain compliance with current Good Manufacturing Practice (cGMP) regulations in all of our manufacturing operations, which requires a sustained investment that further enhances the quality of all of our products. Compliance is required for Wipe Out® Dairy Wipes and for Mast Out® and may open access to international markets for First Defense® where such standards are imposed. We have elected to enforce these quality standards across all of our product lines. During the first quarter of 2013, the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA) conducted a routine inspection of our facilities and operations. The report from this inspection was very favorable, and we responded to the few, minor observations that were noted.

 

1
 

 

ImmuCell Corporation

 

During the sixteen-year period that began January 1, 1999 (the year we first re-focused our business strategy on First Defense® and other products for the dairy and beef industries) and ended on December 31, 2014, we invested the aggregate of approximately $20,749,000 in product development expenses, averaging approximately $1,297,000 per year during this period. During these sixteen years, we have funded our operations and improved our net financial position, as demonstrated in the following table (in thousands, except for percentages):

 

   As of
December 31,
1998		   Net $ increase  over sixteen-year period   As of
December 31,
2014		   Net % increase over sixteen-year period 
Cash, cash equivalents, short-term investments and long-term investments  $1,539+  $2,296=  $3,835    149%
Net working capital  $1,866+  $2,594=  $4,460    139%
Total assets  $3,145+  $7,907=  $11,052    251%
Stockholders’ equity  $2,248+  $7,010=  $9,258    312%

 

We had approximately 2,429,000 shares of common stock outstanding as of December 31, 1998 in comparison to 3,027,000 shares as of December 31, 2014. There were 479,633 and 253,000 shares of common stock reserved for issuance under stock options that were outstanding as of December 31, 1998 and 2014, respectively.

 

Animal Health Products

 

Our lead product, First Defense®, is manufactured from hyperimmune cows’ colostrum (the milk that a cow produces immediately after giving birth) utilizing our proprietary vaccine and milk protein purification technologies. The target disease, bovine enteritis (calf scours), causes diarrhea and dehydration in newborn calves and often leads to serious sickness and even death. First Defense® is the only USDA-licensed, orally delivered scours preventive product on the market for calves with claims against E. coli K99 and coronavirus (two leading causes of scours). First Defense® provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Our milk antibody products provide Immediate Immunity™ during the first few critical days of life when calves need this protection most. Studies have shown that calves that scour are more susceptible to other diseases later in life and under-perform calves that do not contract scours. The direct, two-part mode-of-action of First Defense® delivers specific immunoglobulins at the gut level to immediately protect against disease, while also providing additional antibodies that are absorbed into the bloodstream. These circulating antibodies function like a natural timed-release mechanism, as they are re-secreted into the gut later to provide extended protection. A single dose of First Defense® provides a guaranteed level of protection proven to reduce mortality and morbidity from two major causes of calf scours. First Defense® is convenient to use. A calf needs to receive only one bolus of First Defense® within the first twelve hours after birth (the earlier the better). The product is stored at room temperature and no mixing is required before it is given to the calf. There is no required slaughter withdrawal period for calves that are given First Defense®. We are a leader in the scours prevention market with this product. The third quarter of 2014 marked the 23rd anniversary of the original USDA approval of this product in 1991. During the first quarter of 2015, we sold the 15,000,000th dose of First Defense®. We believe that these milestones demonstrate the value of our technology and the long-term market acceptance of our product. In 2011, we began selling nutritional and feed supplement product applications (that are not delivered in the capsule format) of our First Defense TechnologyTM, which is a unique whey protein concentrate that is purified utilizing our proprietary milk protein processing methods that does not carry the claims of our USDA-licensed product. We utilize one production line and one quality system for all of our milk-based products.

 

During 1999, we acquired Wipe Out® Dairy Wipes, which is our second leading source of product sales. That transaction included the purchase of certain equipment, trademarks and a license of intellectual property, including several issued patents, covering the product and rights to develop skin and environmental sanitizing applications of the Nisin technology. Wipe Out® Dairy Wipes consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking. Milking regulations require that the teat area of cows be cleaned, sanitized and dried before each milking. Producers use a variety of methods including dips and paper or cloth towels. Our wipes are made from a non-woven fabric that is strong enough to allow for a vigorous cleaning. The wiping process can also help promote milk letdown. Wipe Out® Dairy Wipes are manufactured in compliance with cGMP regulations, as required by federal law.

 

2
 

 

ImmuCell Corporation

 

As a product line extension, we have been developing a pet application of the Nisin technology underlying Wipe Out® Dairy Wipes, since many skin infections in pets are caused by Nisin-susceptible bacteria. During 2006, we completed a collaborative study of Nisin susceptibility in methicillin-resistant staphylococcal isolates from dogs with skin infections (dermatitis) with investigators at the University of Pennsylvania School of Veterinary Medicine. One hundred isolates of methicillin-resistant canine Staphylococcus aureus (MRSA), intermedius and schleiferi were tested and found to be highly susceptible to Nisin’s antibacterial activity. During 2008, we completed a clinical feasibility study in collaboration with the University of Tennessee to evaluate the effectiveness of Nisin impregnated wipes used to treat skin infections in dogs. During the first quarter of 2013, we initiated sales of Nisin-based wipes for pets in a 120-count canister (PrevaTM wipes) to Bayer HealthCare Animal Health of St. Joseph, Missouri for commercial sales to pet owners.

 

During 2001, we began to offer our own, internally developed California Mastitis Test (CMT). CMT can be used for bulk tank as well as individual cow sample monitoring and can be used to determine which quarter of the udder is mastitic. This test can be performed at cow-side for early detection of mastitis. CMT products are also made by other manufacturers and are readily available to the dairy producer. The wholesale price of our product is generally lower than the competitive products that were present in the market when we initiated commercial sales.

 

Sales and Markets

 

Our sales and marketing team currently consists of one vice president and five regional managers. Our inside sales and customer service representative performs the order entry and inside sales duties, and our facility manager processes all shipments. The manner in which we sell and distribute our products depends, in large measure, upon the nature of the particular product, its intended users and the country in which it is sold. The distribution channel selected is intended to address the particular characteristics of the marketplace for a given product. First Defense® is sold primarily through major animal health distributors who, in turn, sell directly to veterinary clinics, fleet stores and direct to farms. Sales are normally seasonal, with higher sales expected during the first quarter. Sales of this product into the beef industry are highly seasonal because most beef calves are born between January and April each year. Harsh winter weather and severe temperature fluctuations cause stress to calves, and calves under stress are more susceptible to scours. We sell Wipe Out® Dairy Wipes, and CMT to distributors, bovine veterinarians and directly to producers.

 

First Defense® is generally sold through large, financially strong distributors, which we believe has resulted in minimal bad debt with respect to this product. We provide for a 50% account credit for domestic distributors on expired First Defense® product, which has a two-year shelf life, resulting in an immaterial amount of returns. Promotional merchandise is given to certain customers at times because we believe it enhances brand recognition. Additionally, advertising, training meetings, incentive programs, direct mail initiatives and face-to-face solution selling are tactics we use to create brand loyalty.

 

International product sales represented approximately 15%, 16% and 20% of our total product sales for the years ended December 31, 2014, 2013 and 2012, respectively. The majority of these international sales were to Canada. We currently price our products in U.S. dollars. To the extent that the value of the dollar declines with respect to any other currency, our competitive position may be enhanced. Conversely, an increase in the value of the dollar in any country in which we sell products may have the effect of increasing the local price of our products, thereby leading to a potential reduction in demand. The value of the Canadian dollar has declined recently, but this has not correlated with a decrease in our sales into Canada. Generally, our international sales are generated through relationships with in-country distributors that have knowledge of the local regulatory and marketing requirements.

 

We continue our efforts to grow sales of First Defense® in North America, where there are approximately 38,200,000 dairy and beef cows in the United States and 4,859,000 dairy and beef cows in Canada. We believe that even greater market opportunities exist in other international territories. There are estimated to be approximately 61,300,000 dairy and beef cows in China, 35,500,000 in the European Union, 21,088,000 in Australia and New Zealand, 9,950,000 in Mexico, 1,430,000 in South Korea and 1,355,000 in Japan. However, industry practices, economic conditions and cause of disease may differ in these foreign markets from what we experience in North America. We introduced First Defense® into South Korea in 2005 and its equivalent into Japan in 2007 through collaborations with in-country distributors.

 

3
 

 

ImmuCell Corporation

 

With Mast Out®, we are working to expand our product line to include a treatment for subclinical mastitis for the mother cow. Mastitis (inflammation of the mammary gland) is the most costly and common disease affecting the dairy industry. It is estimated to cost the U.S. dairy industry approximately $2 billion per year. The disease diminishes the saleable quantity and overall value of milk, in addition to causing other herd health and productivity losses. These losses include the cost of treatment products, reduced milk production, discarded milk and increased cull cows. We estimate that the existing U.S. market for intramammary infusion antibiotics used to treat clinical mastitis infections in lactating cows is approximately $40,000,000 to $60,000,000 per year and that similar market opportunities also exist outside of the United States and for the treatment of dry (non-lactating) cows.

 

It is difficult to estimate the potential size of the subclinical mastitis market because this market is largely unserved at this point. We have estimated that first year sales of our product could be approximately $5,400,000 and that sales could grow to approximately $31,700,000 by the tenth year after market launch. Actual sales results could be higher or lower. Key assumptions underlying these estimates include there being 7,868,000 cows in lactation in the United States and the treatment of 1.15 quarters per cow on average with three doses per treatment at approximately $8.99 per dose. We believe that approximately 20-30% of the U.S. dairy herd is affected by subclinical mastitis caused by gram positive organisms falling within the Mast Out® claim spectrum. We assumed that 2.2% of all cows in lactation would be treated during the first year after market launch and that 13% would be treated during the tenth year after market launch. Achieving this level of sales would require a commercial-scale production plant that we do not have today.

 

While the benefit of treating clinical mastitis is widely known, subclinical mastitis (those cases where cows have infected udders, but still produce saleable milk) is associated with its own significant economic losses and is recognized as a substantial contributor to clinical mastitis cases. Some industry experts have estimated that subclinical mastitis costs the U.S. dairy industry approximately $1 billion per year. There is a growing awareness of the cascade of adverse events and conditions associated with subclinical mastitis, including reduced or foregone milk quality premiums, lower milk production, shorter shelf life for fluid milk, lower yields and less flavor for cheese, higher rates of clinical mastitis, lower conception rates, increased abortions and increased cull rates. It is difficult to evaluate the potential size of the as-yet undeveloped subclinical mastitis treatment market because intervention strategies for subclinical disease are considered inadequate and generally not cost-effective. Because the milk from cows treated with traditional antibiotics must be discarded, most dairy producers simply do not treat subclinically infected cows or they cull the affected animals from the herd. Common milk discard periods cover the duration of treatment and extend from 36 to 96 hours after last treatment, depending on the antibiotic. On average, a cow produces approximately 60 to 80 pounds of milk per day. While milk prices vary significantly, at an average value of $18.00 per 100 pounds, a cow produces approximately $10.80 to $14.40 worth of milk per day. These estimated figures would result in milk discard costs ranging from approximately $38 to $158 per treated animal, which is a significant barrier to the routine treatment of subclinical mastitis with traditional antibiotics. We believe Mast Out® (an alternative to traditional antibiotics) will not be subject to this milk discard requirement in the United States. The ability to treat such cases without a milk discard could revolutionize the way mastitis is managed in a herd. Mast Out® could be uniquely positioned in the market as a treatment for subclinical mastitis that prevents some subsequent cases of clinical mastitis. It is common practice to move sick cows from their regular herd group to a sick cow group for treatment and the related milk discard. This movement causes stress on the cow and a reduction in milk production. Cows treated with Mast Out® would not have to be moved allowing this costly drop in production to be avoided. Mast Out® likely will be priced at a premium to the traditional antibiotic products currently on the market, which are all sold subject to a milk discard requirement. However, we believe that the product’s value proposition demonstrates a return on investment to the producer that will justify this premium.

 

Many fear that the possible overuse of antibiotics in livestock may be a contributing factor to the rising problem of bacterial drug resistance, which undermines the effectiveness of drugs to combat human illnesses. The FDA is committed to addressing this public health risk. Citing concerns about untreatable, life-threatening infections in humans, new FDA and European regulations are aimed at restricting the use of cephalosporins in food animals and at improving milk quality. In late 2011, The Dutch Veterinary Society proposed strict guidelines for veterinary use of antibiotics in the EU. Regulators have recently increased their monitoring of antibiotic residues in milk and meat. During the first quarter of 2012, the USDA reduced the allowable level of somatic cell counts (SCC) in milk from 750,000 (cells per milliliter) to 400,000 at the individual farm level (not a blended calculation of comingled milk) in order to qualify for an EU health certification for export. This current environment could be favorable to the introduction of a new product such as Mast Out® as an alternative to traditional antibiotics. We continue to believe that this innovative product opportunity justifies ongoing product development efforts.

 

4
 

 

ImmuCell Corporation

 

Competition

 

Our competition in the animal health market includes other biotechnology companies and major animal health companies. Many of these competitors have substantially greater financial, marketing, manufacturing and human resources and more extensive product development capabilities than we do. We would consider any company that sells an antibiotic to treat mastitis, such as Zoetis (formerly Pfizer Animal Health, a division of Pfizer, Inc.), Merck Animal Health and Boehringer Ingelheim, to be among the potential competitors for Mast Out®. We expect the FDA to grant a period of five years of market exclusivity for Mast Out® (meaning the FDA would not grant approval to a second NADA with the same active drug for a period of five years after the first NADA approval is granted) under Section 512(c)(2)F of the Federal Food, Drug, and Cosmetic Act.

 

Zoetis, Elanco Animal Health (a division of Eli Lilly and Company) and Boehringer Ingelheim sell products that compete directly with First Defense® in preventing newborn calf scours. We believe that First Defense® offers two significant competitive advantages over these other USDA-approved scours preventatives. First, First Defense® is the only product that provides protection against both E. coli and coronavirus, the two leading causes of calf scours. Second, First Defense®, being derived from colostrum, offers Immediate ImmunityTM through antibodies that function both at the gut level and are absorbed into the blood stream for future protection. To complement this, First Defense® is easier to use, requires no mixing or refrigeration, and can be administered without delaying maternal colostrum. We believe that the immediate and preformed immunity (Immediate Immunity™) that First Defense® provides to the calf is a competitive advantage over such vaccine products.

 

First Defense® competes against scours vaccines that are given to the dam (mother cow) to increase her production of antibodies that can then be transferred through her colostrum to the calf and against vaccines and other products that are given to newborn calves. Despite the best-managed dam vaccine program, colostrum quality is naturally variable and newborn calves do not always get the antibodies they need from maternal colostrum. Further, we know that newborn calves respond poorly, if at all, to vaccines and that the immune system must be given time to develop a response to vaccines. Zoetis sells a modified-live virus, vaccine product (Calf-Guard®) for use in the prevention of scours. Like First Defense®, Calf-Guard® carries a claim against coronavirus infections, but this product does not carry a claim against E. coli infections like First Defense® does. Calf-Guard® carries a claim against rotavirus that First Defense® does not currently carry. First Defense® is priced at a premium to Calf-Guard®. It is common practice to delay colostrum feeding when dosing a calf with Calf-Guard® to wait for a vaccine response to be mounted, but we encourage the feeding of four quarts of high quality colostrum immediately after birth when dosing a calf with First Defense®, which is standard practice for good calf health. Because the antibodies in First Defense® would likely work to inactivate a modified-live vaccine, rendering it useless or less useful, our product label historically included a precaution that First Defense® should not be used within five days of such a vaccine. During the first quarter of 2015, the USDA granted us permission to remove this precaution from our label because our product is compatible with the feeding of antibodies from colostrum. We believe that this precaution should be required on the Calf-Guard® label to prevent inactivation of that product by First Defense® or colostrum. We also compete for market share against an Elanco product (Bovine Ecolizer® + C20). This product, which was acquired through Elanco’s January 2015 acquisition of Novartis Animal Health, carries claims to prevent scours in newborn calves caused by E. Coli and Clostridium perfringens. We also compete for market share against a Boehringer Ingelheim product (Bar-Guard-99™). This product carries claims to prevent scours in newborn calves caused by E. coli. These latter two products are both derived from equine serum in contrast to the bovine colostrum used for First Defense®. Equine antibodies are less efficiently absorbed into the bloodstream, so fewer antibodies are re-secreted for additional protection. There are several other products on the market, some with claims and some without, that are delivered to newborn calves to prevent scours.

 

There are many products on the market that may be used in place of Wipe Out® Dairy Wipes, and our product sells at a premium to most of them. These products include teat dips, teat sprays and other disposable and washable towel products offered by several different companies. Competitive advantages of Wipe Out® Dairy Wipes include that they are convenient to use, they do not irritate the udder and they do not adulterate the milk. Our product is differentiated from most others as the One Step Cow Prep® because a second drying process is not required when using our product.

 

5
 

 

ImmuCell Corporation

 

We may not be aware of competition that we face, or may face in the future, from other companies. Our competitive position will be highly influenced by our ability to attract and retain key scientific and managerial personnel, to develop proprietary technologies and products, to obtain USDA or FDA approval for new products, to effectively promote and market our products, to have available properly licensed, efficient and effective raw material and finished product manufacturing resources and to continue to profitably sell our current products. We currently compete on the basis of product performance, price and distribution capability. We continue to monitor our network of independent distributors to maintain our competitive position.

 

Product Development

 

Our lead product development initiative is Mast Out®, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. During 2000, we acquired an exclusive license from Nutrition 21, Inc. (formerly Applied Microbiology Inc. or AMBI) to develop and market Nisin-based products for animal health applications, which allowed us to initiate the development of Mast Out®. In 2004, we paid Nutrition 21 approximately $965,000 to buy out this royalty and milestone-based license to Nisin, thereby acquiring control of the animal health applications of Nisin. Nisin, the same active ingredient contained in Wipe Out® Dairy Wipes, is an antibacterial peptide known to be effective against most gram positive and some gram negative bacteria. In our pivotal effectiveness study, statistically significant Mast Out® cure rates were associated with a statistically significant reduction in milk somatic cell count, which is an important measure of milk quality. Nisin is a well characterized substance, having been used in food preservation applications for over 50 years. Food-grade Nisin, however, cannot be used in pharmaceutical applications because of its low purity. Our Nisin technology includes methods to achieve pharmaceutical-grade purity.

 

During the fifteen-year period that began on January 1, 2000 (the year we began the development of Mast Out®) and ended on December 31, 2014, we invested the aggregate of approximately $11,032,000 in the development of Mast Out®. This estimated allocation to Mast Out® reflects only direct expenditures and includes no allocation of product development or administrative overhead expenses. Approximately $2,891,000 of this investment was offset by product licensing revenues and grant income related to Mast Out®.

 

In 2004, we entered into a product development and marketing agreement with Pfizer Animal Health (now doing business as Zoetis since 2013) covering Mast Out®. Under that agreement (as amended and supplemented and later terminated), we received $2,375,000 in payments. Zoetis elected to terminate the agreement in 2007. Soon thereafter, Zoetis returned to us all rights, data, information, files, regulatory filings, materials and stocks of Nisin and Nisin producing cultures relating to the development of Mast Out®. We believe that the decision of Zoetis to terminate the agreement was not based on any unanticipated efficacy or regulatory issues. Rather, we believe the decision was primarily driven by a marketing concern relating to their fear that the milk from treated cows could interfere with the manufacture of certain cultured dairy products.

 

Milk from cows treated with any of the intramammary mastitis treatment products on the market today must be discarded for a specified period of time during and after treatment. We believe that all milk from cows treated with Mast Out® will be saleable in the United States. This is a significant competitive advantage for our product. Due to this zero milk discard feature, there is a risk that Nisin from milk of cows treated with Mast Out® could interfere with the manufacture of certain (but not all) commercial cultured dairy products, such as some kinds of cheese and yogurt, if a process tank contains milk from a high enough percentage of treated cows. The impact of this potential interference ranges from a delay in the manufacturing process, which does happen at times for other reasons, to the less likely stopping of a cheese starter culture. Milk from cows that have been treated with Mast Out® that is sold exclusively for fluid milk products presents no such risk. We worked with scientists and mastitis experts to conduct a formal risk assessment to quantify the impact that milk from treated cows may have on cultured dairy products. This study concluded that the dilution of milk from treated cows through comingling with milk from untreated cows during normal milk hauling and storage practices reduces the risk of interference with commercial dairy cultures to a negligible level when Mast Out® is used in accordance with the product label. Monitoring of several important variables relevant to the manufacture of cheese would be advisable if Mast Out® were to be used as part of a whole herd (“blitz”) treatment protocol. We do not see this as a significant problem as modern “precision dairying” practices support reducing the indiscriminate use of drug treatments.

 

6
 

 

ImmuCell Corporation

 

The commercial introduction of Mast Out® in the United States is subject to approval of our New Animal Drug Application (NADA) by the U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA), which approval cannot be assured. Foreign regulatory approvals would be required for sales in key markets outside of the United States, which would involve some similar and some different requirements. The NADA is comprised of five principal Technical Sections that are subject to the FDA’s phased review. By statute, each Technical Section submission is generally subject to a six-month review cycle by the FDA. Each Technical Section can be reviewed and approved separately. Upon review and assessment by the FDA that all requirements for a Technical Section have been met, the FDA may issue a Technical Section Complete Letter. The current status of our work on these Technical Sections is as follows:

 

1) Environmental Impact: During the third quarter of 2008, we received the Environmental Impact Technical Section Complete Letter from the FDA.

 

2) Target Animal Safety: During the second quarter of 2012, we received the Target Animal Safety Technical Section Complete Letter from the FDA.

 

3) Effectiveness: During the third quarter of 2012, we received the Effectiveness Technical Section Complete Letter from the FDA. The draft product label carries claims for the treatment of subclinical mastitis in lactating cows associated with Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus uberis, and coagulase-negative staphylococci in lactating dairy cattle.

 

4) Human Food Safety (HFS): The HFS Technical Section submission was made during the fourth quarter of 2010. This Technical Section includes several subsections such as: a) toxicology, b) total metabolism, c) effects of drug residues in food on human intestinal microbiology, d) effects on bacteria of human health concern (antimicrobial resistance) and e) pivotal residue chemistry. During the second quarter of 2011, we announced that the FDA had accepted the subsections described above and granted Mast Out® a zero milk discard period and a zero meat withhold period during and after treatment. Before we can obtain this Technical Section Complete Letter, we must adapt our analytical method that measures Nisin residues in milk around the assigned tolerance limit and transfer that method to a FDA laboratory. We first submitted the validated analytical method to the FDA during the fourth quarter of 2012. We have submitted additional data, which we believe to be responsive to the FDA’s review comments, during the third quarter of 2013 and the first quarter of 2014. We are working to complete the method transfer to the FDA laboratory. Due to additional regulatory requirements, completion of the HFS Technical Section is currently anticipated by the end of 2015.

 

5) Chemistry, Manufacturing and Controls (CMC): Obtaining FDA approval of the CMC Technical Section defines the critical path to approval of our NADA by the FDA and to initial commercial sales. We are party to agreements with two manufacturers to produce inventory for us utilizing our proprietary technologies and processes. First, a long-term, exclusive supply agreement with Plas-Pak Inc. of Norwich, Connecticut covers the proprietary syringe that was developed specifically for treating cows with Mast Out®. These syringes were used for all pivotal studies of Mast Out®. Second, an exclusive Contract Manufacture Agreement with Norbrook Laboratories Limited of Newry, Northern Ireland, an FDA-approved Drug Product manufacturer, covers the formulation of the pharmaceutical-grade Nisin into Drug Product, the sterile-fill of syringes and the final packaging. Norbrook provided these services for clinical material used in all pivotal studies of Mast Out®. Recent communications with Norbrook have given us significant concern about Norbrook’s readiness to provide the services needed to address the FDA regulatory requirements followed by commercial-scale production services. We intend to continue to seek to work with Norbrook to arrive at a resolution satisfactory to us. However, there can be no assurance that we will be able to reach a workable arrangement with Norbrook on a timely basis or at all. As a result, we have begun to explore alternative ways of fulfilling these needs (while expressly reserving our legal rights under our contract with Norbrook). Because we have not yet identified another third party ready, willing and able to do so, we may need to conduct further modifications to our own facilities in order perform the sterile-fill of syringes. Due to the preliminary status of this contingency planning, we are unsure as to the cost of such alternatives or the impact of an alternative approach on our desired and previously projected timing for completing the CMC Technical Section and commercialization of Mast Out®. During the fourth quarter of 2012, we withdrew our first submission to the FDA of the CMC Technical Section because of changes we have made to our regulatory filing and manufacturing strategies. Our goal is to make the first submission of the CMC Technical Section to the FDA during the fourth quarter of 2015. Given our concerns with Norbrook as our Drug Product manufacturer, we may elect to submit the Drug Substance (Active Pharmaceutical Ingredient) portion of the CMC Technical Section first and follow with the Drug Product portion (formulation, sterile-fill and packaging) after the first FDA review of the Drug Substance submission. It is common for each CMC Technical Section submission to require two, six-month review periods by the FDA.

 

7
 

 

ImmuCell Corporation

 

The selection of and (if applicable) the financing for the Drug Substance (pharmaceutical-grade Nisin) commercial production facility is a critical decision. We have considered four options: 1) having this work done by a qualified contract manufacturer, 2) building a new facility, 3) leasing and modifying an existing facility or 4) transferring our technology to a partner’s facility. Our initial plan was to have the Drug Substance produced for us under a Development and Manufacturing Agreement with Lonza Sales, Ltd. of Basel, Switzerland, in order to avoid the investment in a manufacturing facility. By the end of 2011, we determined that the cost of goods under this contract would not be commercially feasible and that the required minimum volumes were too large to permit efficient, continuous production. This contract was terminated during the fourth quarter of 2014 by mutual consent. During the latter part of 2012, we engaged an engineering firm to estimate the cost of controlling the production of the Drug Substance ourselves in a plant that we either built or leased. We do not have the estimated amount of approximately $13,000,000 to pay for this investment (without some combination of new debt, equity or partner funding), and there is a risk that the actual cost could be higher than we estimated. Alternatively, a somewhat smaller plant could cost a few million dollars less and still be able to meet market demand at launch and for a few years thereafter. We presented this product opportunity to a variety of large and small animal health companies. During the second quarter of 2013, we received a non-refundable $250,000 exclusive license option fee from a prospective partner that considered manufacturing the Drug Substance in a plant of its own. During the third quarter of 2013, this prospective partner decided not to execute a license for the development and marketing of Mast Out® because it had determined that, in its opinion, it could not cost effectively commercialize the product. While recognizing the commercial and near-term financial advantages which could have been realized via this partnering agreement, we believe that, among the currently available options, the greatest long-term value for our stockholders could be achieved by retaining full product ownership through an independent strategy at this stage. However, given the need to find funding for the commercial-scale Nisin plant described above, we are open to considering alternative partnering arrangements. We are encouraged by the feedback from prospective partners, following their due diligence, that our novel mastitis treatment can achieve FDA approval and have a significant, positive impact on the dairy industry. We continue to believe in the potential value of making this unique treatment option available to dairy producers in order to reduce their reliance on penicillin and cephalosporin-based products. We are continuing our pursuit of FDA approval by completing the HFS Technical Section and the CMC Technical Section on our own. We believe that the evolution of our thinking relating to these strategic alternatives demonstrates the flexibility and creativity required to solve this challenge and bring this ground-breaking product innovation to market.

 

At the beginning of the third quarter of 2014, we substantially completed an investment in facility modifications and processing equipment necessary to produce Drug Substance at small-scale. The four primary goals of this investment are to: 1) establish the equivalence of the Drug Substance produced in this plant to the Drug Substance that was used in our clinical studies, 2) produce the validation batches required to complete the CMC Technical Section, 3) optimize process yields and verify the related cost of production and 4) produce inventory for test marketing and limited initial sales in the United States after FDA approval. In short, we aim to secure regulatory approval of the product and demonstrate its commercial viability. In preparation for the submission of the CMC Technical Section to the FDA, we are validating this new equipment and production space while optimizing the production process. We believe that success with these efforts will enhance our position in any further financing or partnering discussions, should we elect to pursue either of these paths to fund expanded manufacturing capacity for the commercialization of Mast Out®. This investment and the resulting short-term loss is the vehicle by which we expect to optimize the long-term value of this asset for our stockholders. We intend to take all appropriate steps to pursue a successful commercialization of Mast Out®. This strategy allows us to advance the regulatory approval process while controlling our decision of whether and when to invest in large-scale production on our own, or with a partner.

 

After obtaining the final Technical Section Complete Letter and after preparing materials responsive to other administrative requirements, the administrative NADA submission will be assembled for review by the FDA. This final administrative submission is subject to a statutory sixty-day review period. Given this, we believe we could be in a position to achieve the NADA approval and test market the product around the end of 2016. The concerns discussed above related to the sterile-filling of the Mast Out® syringes could cause this timeline to be extended by at least one year. At some point, a further investment to increase our production capacity of Drug Substance would be required to meet anticipated market demand. Our options include doing the work on our own (with externally generated financing) or through an alliance with others, the out-licensing of the product or the sale of the product rights.

 

8
 

 

ImmuCell Corporation

 

In addition to our work on Mast Out®, we are actively exploring further improvements, extensions or additions to our current First Defense® product line. For example, we currently are developing treatments that could prevent calf scours caused by enteric pathogens in addition to E. coli K99 and bovine coronavirus (the current disease claims for First Defense®). In connection with that effort, during the second quarter of 2009 we entered into an exclusive license with the Baylor College of Medicine covering the underlying rotavirus vaccine technology used to generate the specific antibodies. This perpetual license (if not terminated for cause) is subject to milestone and royalty payments. Results from pilot studies completed during the first quarter of 2009 justified continued product development. We completed a pivotal effectiveness study of this experimental formulation during the third quarter of 2011 without seeing the anticipated level of effectiveness needed for regulatory approval and market acceptance. After optimizing the challenge model, we directed our efforts to conducting additional pilot studies of different formulations of this antibody preparation. Having achieved positive results from these pilot studies, we initiated a second pivotal effectiveness study at Cornell University College of Veterinary Medicine during the second quarter of 2014 and completed the enrollment of calves during the fourth quarter of 2014. During the first quarter of 2015, we announced positive results from this pivotal study. If approved by the USDA, this would be the first passive antibody product with disease claims against the three leading causes of calf scours, E. coli, coronavirus and rotavirus, providing Immediate Immunity™ to newborn calves. Having submitted these results to the USDA for review, we are working to complete the other laboratory and manufacturing objectives required for product license approval. This could position us to achieve product licensure and market launch in 2016. As additional opportunities arise to commercialize our own technology, or licensable technology, we may begin new development projects. While we continue to pursue internally funded product development programs, we also remain interested in acquiring new products and technologies that fit with our sales and marketing focus on the dairy and beef industries.

 

Patents, Proprietary Information and Trademarks

 

In connection with the December 1999 acquisition of Wipe Out® Dairy Wipes and the April 2000 license to all veterinary applications of Nisin from Nutrition 21, Inc., we acquired a license to six patents. In November 2004, we bought out certain future milestone and royalty obligations under the 1999 and 2000 licenses, which principally resulted in a fully paid, perpetual license related to the animal health applications of Nisin. Five of these six patents have expired. In 2004, we were issued U.S. Patent No. 6,794,181 entitled “Method of Purifying Lantibiotics” covering a manufacturing process for Drug Substance (pharmaceutical-grade Nisin).

 

During 2000, we were issued U.S. Patent No. 6,074,689 entitled “Colonic Delivery of Protein or Peptide Compositions” covering the method of formulation that can be used to deliver proteins to the colon. In 1999, we acquired an exclusive license for pharmaceutical applications to U.S. Patent No. 5,773,000 entitled “Therapeutic Treatment of Clostridium difficile Associated Diseases” from GalaGen, Inc. In 2002, we acquired ownership of this patent from the court administering the bankruptcy proceedings of GalaGen. These patents are included in a royalty-bearing license we granted to Immuron, Ltd. (formerly known as Anadis) of Australia in 2008 for their use in the development of milk antibody products for humans.

 

In the future, we may file additional patent applications for certain products under development. There can be no assurance that patents will be issued with respect to any pending or future applications. In some cases, we have chosen (and may choose in the future) not to seek patent protection for certain products or processes. Instead, we have sought (and may seek in the future) to maintain the confidentiality of any relevant proprietary technology through operational measures and contractual agreements. Reliance upon trade secret, rather than patent, protection may cause us to be vulnerable to competitors who successfully replicate our manufacturing techniques and processes. Additionally, there can be no assurance that others may not independently develop similar trade secrets or technology or obtain access to our unpatented trade secrets or proprietary technology. Other companies may have filed patent applications and may have been issued patents involving products or technologies potentially useful to us or necessary for us to commercialize our products or achieve our business goals. There can be no assurance that we will be able to obtain licenses to such patents on terms that are acceptable.

 

9
 

 

ImmuCell Corporation

 

We have registered certain trademarks with the U.S. Patent and Trademark Office in connection with the sale of our products. We own federal trademark registrations of the following trademarks: ImmuCell; First Defense®, our calf scours preventive product; Wipe Out® Dairy Wipes and the related design and the trademark “One Step Cow Prep®”, our pre-milking wipe product; and Mast Out®, our mastitis treatment product under development. During the first quarter of 2015, we applied to register the following marks: Immediate Immunity™, First Defense Technology™ and Your Calf Crew™.

 

Government Regulation

 

We believe that we are in compliance with current regulatory requirements relating to our business and products. The manufacture and sale of animal health biologicals within the United States is generally regulated by the USDA. We have received USDA and Canadian Food Inspection Agency approval for First Defense®. Mast Out® is regulated by the FDA, Center for Veterinary Medicine, which regulates veterinary drugs. Regulations in the European Union will likely require that Mast Out® be sold subject to a milk discard requirement in that territory, although the duration of the milk discard requirement may be shorter than the discard requirement applicable to competitive antibiotic products in that market. The manufacture of Wipe Out® Dairy Wipes also is regulated by the FDA. Comparable agencies exist in foreign countries and foreign sales of our products will be subject to regulation by such agencies. Many countries have laws regulating the production, sale, distribution or use of biological products, and we may have to obtain approvals from regulatory authorities in countries in which we propose to sell our products. Depending upon the product and its applications, obtaining regulatory approvals may be a relatively brief and inexpensive procedure or it may involve extensive clinical tests, incurring significant expenses and an approval process of several years’ duration. We generally rely on in-country experts to assist us with or to perform international regulatory applications.

 

Employees

 

We currently employ 34 full-time employees and 1 part-time employee. Approximately 17 full-time equivalent employees are engaged in manufacturing operations, 7.5 full-time equivalent employees in sales and marketing, 5.5 full-time equivalent employees in product development activities and 4.5 full-time equivalent employees in finance and administration. At times, manufacturing personnel are also utilized, as needed, in the production of clinical material for use in product development. All of our employees are required to execute non-disclosure, non-compete and invention assignment agreements intended to protect our rights in our proprietary products. We are not a party to any collective bargaining agreement and consider our employee relations to be excellent.

 

Executive Officers of the Company

 

Our executive officers as of March 18, 2015 were as follows:

 

MICHAEL F. BRIGHAM (Age: 54, Officer since 1991, Director since 1999) was appointed to serve as President and Chief Executive Officer in February 2000, while maintaining the titles of Treasurer and Secretary, and was appointed to serve as a Director of the Company in March 1999. He previously had been elected Vice President of the Company in December 1998 and had served as Chief Financial Officer since October 1991. He has served as Secretary since December 1995 and as Treasurer since October 1991. Prior to that, he served as Director of Finance and Administration since originally joining the Company in September 1989. Mr. Brigham has been a member of the Board of Directors of the United Way of York County since 2011, serving as its Treasurer. Mr. Brigham served as the Treasurer of the Board of Trustees of the Kennebunk Free Library from 2005 to 2011. He re-joined the Finance Committee of the library in 2012. Prior to joining the Company, he was employed as an audit manager for the public accounting firm of Ernst & Young. Mr. Brigham earned his Masters in Business Administration from New York University in 1989.

 

BOBBI JO BROCKMANN (Age: 38, Officer since February 2015) was promoted to Vice President of Sales and Marketing in February 2015. She joined the Company as Director of Sales and Marketing in January 2010. Prior to that, she had been employed as Director of Sales since May 2008 and Sales Manager from February 2004 to April 2008 at APC, Inc. of Ankeny, Iowa, a developer and marketer of functional protein products for animal health and nutrition. Prior to that, she held other sales and marketing positions at APC, W & G Marketing Company, Inc. of Ames, Iowa, The Council for Agricultural Science and Technology of Ames, Iowa and Meyocks Group Advertising of West Des Moines, Iowa after graduating from Iowa State University.

 

10
 

 

ImmuCell Corporation

 


JOSEPH H. CRABB, Ph.D. (Age: 60, Officer since 1996, Director since 2001) served as Chair of the Board of Directors from June 2009 to February 2013. He was appointed a Director of the Company in March 2001, having previously served in that capacity during the period from March 1999 until February 2000. Before that, he was elected Vice President of the Company in December 1998, while maintaining the title of Chief Scientific Officer. He has served as Chief Scientific Officer since September 1998. Prior to that, he served as Vice President of Research and Development since March 1996. Prior to that, he served as Director of Research and Development and Senior Scientist since originally joining the Company in November 1988. Concurrent with his employment, he has served on national study sections and advisory panels, served as a peer reviewer, and held several adjunct faculty positions. Prior to joining the Company in 1988, Dr. Crabb earned his Ph.D. in Biochemistry from Dartmouth Medical School and completed postdoctoral studies in microbial pathogenesis at Harvard Medical School, where he also served on the faculty.

 

Public Information

 

As a reporting company, we file quarterly and annual reports with the Securities and Exchange Commission (SEC) on Form 10-Q and Form 10-K. We also file current reports on Form 8-K, whenever events warrant or require such a filing. The public may read and copy any materials that we file with the SEC at the SEC’s Public Reference Room at 450 Fifth Street, N.W., Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an internet site that contains reports, proxy and information statements and other information about us that we file electronically with the SEC at http://www.sec.gov. Our internet address is http://www.immucell.com.

 

ITEM 1A – RISK FACTORS

 

Safe Harbor Statement

 

This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to: projections of future financial performance; the scope and timing of future product development work and commercialization of our products; future costs of product development efforts; the estimated prevalence rate of subclinical mastitis; future market share of and revenue generated by products still in development; future sources of financial support for our product development, manufacturing and marketing efforts; the future adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships to meet demand for our products on a timely basis; the amount and timing of future investments in facility modifications and production equipment; the future adequacy of our working capital and the availability of third party financing; timing and future costs of a facility to produce the Drug Substance (active pharmaceutical ingredient) for Mast Out®; the timing and outcome of pending or anticipated applications for future regulatory approvals; future regulatory requirements relating to our products; future expense ratios and margins; future compliance with bank debt covenants; future realization of deferred tax assets; costs associated with sustaining compliance with cGMP regulations in our current operations and attaining such compliance for the facility to produce the Drug Substance for Mast Out®; factors that may affect the dairy and beef industries and future demand for our products; the cost-effectiveness of additional sales and marketing expenditures and resources; the accuracy of our understanding of our distributors’ ordering patterns; anticipated changes in our manufacturing capabilities and efficiencies; anticipated competitive and market conditions; and any other statements that are not historical facts. Forward-looking statements can be identified by the use of words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts” and similar words and expressions. In addition, there can be no assurance that future developments affecting us will be those that we anticipate. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated product markets, alignment between our manufacturing resources and product demand, the uncertainties associated with product development and Drug Substance manufacturing, our potential reliance upon third parties for financial support, products and services, changes in laws and regulations, decision making by regulatory authorities, currency fluctuations and other risks detailed from time to time in filings we make with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements are based on our current expectations, but actual results may differ materially due to various factors, including the risk factors summarized below and uncertainties otherwise referred to in this Annual Report.

 

11
 

 

ImmuCell Corporation

 

Projection of net income: After nine consecutive years of reporting net income, we reported net losses for the years ended December 31, 2008, 2009, 2010 and 2011, due in large part to our product development strategy. By reducing our investment in the development of Mast Out® and increasing sales of First Defense®, we were able to record net operating income of $245,000 and net income of $90,000 during the year ended December 31, 2012. We continued this positive trend by recording a net operating (loss) of just ($20,000) and net income of $117,000 during the year ended December 31, 2013. The 2013 results included a $250,000 exclusive license option fee. Given our strategic decision to invest approximately $973,000 during 2014 in facilities for the manufacture of the Drug Substance, we recorded a net (loss) of ($167,000) during the year ended December 31, 2014 as expected, despite a return to profitability during the last six months of 2014. We expect the sales growth trend for First Defense®, and the profitability trend recorded during the last six months of 2014, to continue into 2015. Generally speaking, our financial performance can differ significantly from management projections, due to numerous factors that are difficult to predict or that are beyond our control. Stronger than expected sales of First Defense®, for example, could increase our net income. Conversely, weaker than expected sales of First Defense® could lead to less profits or an operating loss. Large investments in product development can result in a net loss.

 

Reliance on sales of First Defense®: We are heavily reliant on the market acceptance of First Defense® to generate product sales and fund our operations. Our business would not have been profitable during the nine consecutive years in the period ended December 31, 2007, or during the years ended December 31, 2012 and 2013, or during the second half of 2014, without the gross margin that we earned on sales of First Defense®.

 

Concentration of sales: Approximately 83% of our product sales were made to customers in the U.S. dairy and beef industries during both of the years ended December 31, 2014 and 2013. During the year ended December 31, 2014, 96% of our product sales were made to customers in the dairy and beef industries throughout the world, in comparison to 97% during 2013. A large portion of our product sales (61%, 60% and 55% for the years ended December 31, 2014, 2013, and 2012, respectively) was made to two large distributors (adjusting for an acquisition made by one of these distributors). A large portion of our trade accounts receivable (71% and 65% as of December 31, 2014 and 2013, respectively) was due from these two distributors. We have a good history with these distributors, but the concentration of sales and accounts receivable with a small number of customers does present a risk to us, including risks related to such customers experiencing financial difficulties or altering the basis on which they do business with us.

 

Economics of the dairy and beef industries:

 

●All cattle and calves in the United States as of July 1, 2014 totaled 95,000,000 head, which is 3% below the 97,800,000 head reported on July 1, 2012 (this data point was not reported as of July 1, 2013). The July 2014 amount was the lowest inventory count as of July 1st in decades. All cattle and calves in the United States as of January 1, 2015 totaled 89,800,000, which is 1.5% higher than January 1, 2014. According to a Purdue University Extension economist, this is the first increase in the cattle inventory since 2007 suggesting a faster rebuilding of the U.S. herd than had been anticipated.

 

●From 1998 through 2014, the size (annual average) of the U.S. dairy herd ranged from approximately the low of 9,011,000 (2004) to the high of 9,315,000 (2008). The average for 2013 was 9,215,000 which represents a slight reduction from the average of 9,232,000 reported for 2012. This average increased slightly to 9,255,000 during 2014.

 

●While the number of cows in the U.S. herd and the production of milk per cow directly influence the supply of milk, demand for milk is also influenced by very volatile international demand for milk products. The Class III milk price (an industry benchmark that reflects the value of product used to make cheese) is an important indicator because it defines our customers’ revenue level. This milk price (measured in dollars per hundred pounds of milk) in each of the first eleven months of 2014 was the highest ever for those months, and nine out of ten of the highest Class III milk prices of all time occurred during 2014. The annual average price level for 2011 of $18.37 was higher than the annual average reached in any of the previous 30 years. This annual average price level for 2014 of $22.34 (peaking at $24.60 in September 2014) was the highest level since these records were first reported in 1980. This strong price level has declined recently. The December 2014 price was $17.82, and the January 2015 price was $16.18, and the February 2015 price decreased further to $15.46.

 

12
 

 

ImmuCell Corporation

 

The recent annual fluctuations in this milk price level are demonstrated in the following table:

 

Average Class III Milk Price for
the year ended December 31,		   (Decrease)
Increase
2011   2012    
$18.37   $17.44   (5%)
         
2012   2013    
$17.44   $17.99   3%
         
2013   2014    
$17.99   $22.34   24%

 

The actual level of milk prices may be less important than its level relative to feed costs. The 2014 improvement in milk prices has been matched by slightly lower feed costs. One measure of this relationship is known as the milk-to-feed price ratio, which represents the amount of feed that one pound of milk can buy. It is considered profitable to buy feed and produce milk if this ratio meets or exceeds 3.0. This benchmark level means that a dairy producer could buy 3.0 pounds of feed for every pound of milk sold. The 2012 ratio of 1.52 was the lowest recorded since this ratio was first reported in 1985. The highest annual average this ratio has ever reached since 1985 was 3.64 in 1987. Since this ratio reached 3.24 in 2005, it has not exceeded this benchmark level of 3.0. The annual average of 2.54 for 2014 was the highest this ratio has been since 2007 (2.81). The following table demonstrates the annual volatility and the low values of this ratio recently:

 

Average Milk-To-Feed Price Ratio for
the year ended December 31,		   (Decrease)
Increase
2011   2012    
$1.88   $1.52   (19%)
         
2012   2013    
$1.52   $1.74   14%
         
2013   2014    
$1.74   $2.54   45%

 

Approximately half of all U.S. dairy farms (more than 23,000) representing more than 60% of the nation’s total milk production signed up for the Margin Protection Program (MPP) under the 2014 federal farm bill. This voluntary program provides financial assistance to participating farmers when the margin (the difference between the price of milk and feed costs) falls below the selected coverage level. To display the margin between milk revenue and the MPP feed cost over the years, Dr. D. Scott Brown of the University of Missouri charted the relationship of revenue to expenses graphically in the following table (the 2014 figures are preliminary and the 2015 figures are projected):

 

13
 

 

ImmuCell Corporation

 

Reprinted by permission from the December 2014 issue of Hoard’s Dairyman.

Copyright 2014 by W.D. Hoard and Sons Company, Fort Atkinson, Wisconsin.

 

An increase in feed costs also has a negative impact on the beef industry. Widespread severe drought conditions in key U.S. agricultural regions during 2012 drove feed costs higher and the inventory of all cattle and calves lower. The recent positive trend in these market indices has resulted in an increase in the value of milk cows. The 2014 annual average price for a milk cow increased to $1,835. This annual average price since 1970 was only higher when it reached $1,840 in 2007 and $1,953 in 2008. The industry data referred to above is compiled from USDA databases. Recently, the value of newborn bull calves has risen to the unusually high level of approximately $300 to $400. At this price, producers are more likely to invest in First Defense® for their bull calves. Given our focus on the dairy and beef industries, the financial insecurity of our primary end users is a risk to our ability to maintain and grow sales at a profitable level. It also heightens the challenge of selling premium-priced animal health products (such as Mast Out®) into such a market.

 

Product development risks: The development of new products is subject to financial, scientific, regulatory and market risks. Our current business growth strategy relies heavily on the development of Mast Out®, which requires (and will continue to require) a substantial investment. Our efforts will be subject to inspection and approval by the FDA. There is no assurance whether or when we will obtain all of the data necessary to support regulatory approval for this product.

 

Regulatory requirements for Mast Out®: The commercial introduction of Mast Out® in the United States will require us to obtain appropriate FDA approval for this product. It presently is uncertain when or if this approval will be achieved. We are exposed to additional regulatory compliance risks through the subcontractors that we choose to work with to produce Mast Out®, who also need to satisfy certain regulatory requirements in order to provide us with the products and services we need. International regulatory approvals would be required for sales outside of the United States. European regulatory authorities are not expected to approve a product with a zero milk discard claim, which would remove a significant competitive advantage of Mast Out® in that territory. However, the assigned milk discard period may be shorter for Mast Out® than it is for other products on the market in Europe.

 

Risks associated with Mast Out® funding strategy: Completing the development of Mast Out® through to the submission of the administrative NADA to the FDA involves a great deal of risk. Our current strategy is to build our own small-scale Drug Substance production plant in order to gain NADA approval, obtain better production cost data and test market the product. This facility must be approved by the FDA. Uncertainty concerning the availability and terms of financing to develop a larger-scale commercial production plant or alternatively the availability and terms of potential partnering arrangements is a risk that, if materialized, could delay or preclude meaningful commercialization of Mast Out®.

 

14
 

 

ImmuCell Corporation

 

Uncertainty of market size and product sales estimates: Even assuming that Mast Out® achieves regulatory approval in the United States with a zero milk discard requirement, estimating the size of the market for this product is subject to numerous uncertainties. Some of the uncertainties surrounding our product include the development of the subclinical mastitis treatment market, coverage of relevant pathogens, the effect of a premium selling price on market penetration, cost of manufacture, integration of milk from treated cows with susceptible cheese starter cultures and market acceptance.

 

Competition from others: Many of our competitors are significantly larger and more diversified in the relevant markets than we are and have substantially greater financial, marketing, manufacturing and human resources and more extensive product development capabilities than we do, including greater ability to withstand adverse economic or market conditions and declining revenues and/or profitability. Zoetis, Elanco and Boehringer Ingelheim, among other companies, sell products that compete directly with First Defense® in preventing scours in newborn calves. The market for the treatment of mastitis in dairy cows is highly competitive, and presently is dominated by large companies such as Zoetis, Merck and Boehringer Ingelheim. There is no assurance that Mast Out® will compete successfully in this market. We may not be aware of other companies that compete with us or intend to compete with us in the future.

 

Access to raw materials: Our policy is to maintain more than one source of supply for the components used to manufacture and test our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies. The loss of farms from which we buy raw material for First Defense® could make it difficult for us to produce enough inventory until supply agreements are reached with replacement farms on suitable terms. We are dependent on our manufacturing facility and operations at 56 Evergreen Drive in Portland, Maine for the production of First Defense® and Wipe Out® Dairy Wipes. The specific antibodies that we purify for First Defense® and the Nisin we produce by fermentation for Wipe Out® Dairy Wipes are not readily available from other sources. We will also be reliant on this facility for the production of the Drug Substance required to obtain regulatory approval. We expect to be dependent on Plas-Pak and (subject to the performance issues discussed above under ITEM 1- DESCRIPTION OF BUSINESS, “Product Development”) Norbrook for a significant portion of the manufacture of Mast Out® if that product proceeds to commercialization. Any significant damage to or other disruption in the services at these facilities could adversely affect the production of inventory and result in significant added expenses and loss of sales.

 

Risk of sales order backlog: Given our recent and significant increase in sales demand, our manufacturing resources (internal and third party) are no longer sufficient to avoid a backlog of orders. Until we complete the additional investments required to further increase our production capacity, we are at risk of losing customers that are unable to acquire our product on a timely basis. We understand that the competitive products marketed by Elanco and Boehringer Ingelheim are experiencing a disruption in supply to the market.

 

Small size; dependence on key personnel: We are a small company with 34 full-time employees and 1 part-time employee. As such, we rely on certain key employees to support different operational functions, with limited redundancy in capacity. The loss of any of these key employees could adversely affect our operations until a qualified replacement is hired and trained. Our competitive position will be highly influenced by our ability to attract and retain key scientific, managerial and sales and marketing personnel, to develop proprietary technologies and products, to obtain USDA or FDA approval for new products and to continue to profitably sell our current products. We currently compete on the basis of product performance, price and distribution capability. We continue to monitor our network of independent distributors to maintain our competitive position.

 

Failure to protect intellectual property: In some cases, we have chosen (and may choose in the future) not to seek patent protection for certain products or processes. Instead, we have sought (and may seek in the future) to maintain the confidentiality of any relevant proprietary technology through operational safeguards and contractual agreements. Reliance upon trade secret, rather than patent, protection may cause us to be vulnerable to competitors who successfully replicate our manufacturing techniques and processes. Additionally, there can be no assurance that others may not independently develop similar trade secrets or technology or obtain access to our unpatented trade secrets or proprietary technology. Other companies may have filed patent applications and may have been issued patents involving products or technologies potentially useful to us or necessary for us to commercialize our products or achieve our business goals. There can be no assurance that we will be able to obtain licenses to such patents on terms that are acceptable. There is also a risk that competitors could challenge the claims in patents that have been issued to us.

 

15
 

 

ImmuCell Corporation

 

No expectation to pay any dividends or repurchase stock for the foreseeable future: We do not anticipate paying any dividends to, or repurchasing stock from, our stockholders for the foreseeable future. Instead, we expect to use cash to fund product development costs and investments in our facility and production equipment. Any debt or equity financing we obtain to assist in funding our product development programs may include terms prohibiting or restricting our paying dividends or repurchasing stock for a lengthy period. Stockholders must be prepared to rely on sales of their common stock after price appreciation to earn an investment return, which may never occur. Any determination to pay dividends in the future will be made at the discretion of our Board of Directors and will depend on our financial condition, results of operations, contractual restrictions, restrictions imposed by applicable laws, current and anticipated needs for liquidity and other factors our Board of Directors deems relevant.

 

Market for common stock: Our common stock trades on the NASDAQ Stock Market (NasdaqCM: ICCC). Our average daily trading volume is lower than the volume for most other companies and the bid/ask stock price spread can be larger, which could result in investors facing difficulty selling their stock for proceeds that they may expect or desire. There has been a significant increase in the stock market activity of animal health companies since early 2013 in comparison to years past. Listed in chronological order by date of financing, companies such as Zoetis (ZTS), Aratana Therapeutics (PETX), Kindred (KIN), Phibro (PAHC), Parnell (PARN) and Nexvet Biopharma (NVET) have completed initial public offerings since 2013. The stock price of some of these companies has been volatile.

 

Stock market valuation: There are companies in the animal health sector with market capitalization values that greatly exceed our current market capitalization of approximately $20,000,000. Some of these companies have no product sales. We currently have annual product sales approaching $8,000,000. Before gross margin from the sale of new products is achieved, our market capitalization may be heavily dependent on the perceived potential for growth from our products under development.

 

Certain provisions might discourage, delay or prevent a change in control of our Company or changes in our management: Provisions of our certificate of incorporation, our bylaws, our Common Stock Rights Plan or Delaware law may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. These provisions include:

 

●limitations on the removal of directors; advance notice requirements for stockholder proposals and nominations;

 

●the ability of our Board of Directors to alter or repeal our bylaws;

 

●the ability of our Board of Directors to refuse to redeem rights issued under our Common Stock Rights Plan or otherwise to limit or suspend its operation that would work to dilute the stock ownership of a potential hostile acquirer, likely preventing acquisitions that have not been approved by our Board of Directors; and

 

●Section 203 of the Delaware General Corporation Law, which prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder (generally defined as a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder) unless the business combination is approved in a prescribed manner.

 

The existence of the foregoing provisions and anti-takeover measures could depress the trading price of our common stock or limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of our Company, thereby reducing the likelihood of obtaining a premium for our common stock in an acquisition.

 

Regulatory requirements for First Defense®: First Defense® is sold in the United States subject to a product license from the Center for Veterinary Biologics, USDA, which was first obtained in 1991. Similar regulatory oversight risks exist in territories outside of the United States where we sell our products. The potency of serial lots is directly traceable to the original serial used to obtain the product performance claims (the “Reference Standard”). Due to the unique nature of the First Defense® label claims, host animal re-testing is not required as long as periodic laboratory analyses continue to support the stability of stored Reference Standard. To date, these analyses have demonstrated strong stability. However, if the USDA were not to approve requalification of the Reference Standard, additional clinical studies could be required to meet regulatory requirements and allow for continued sales of the product.

 

16
 

 

ImmuCell Corporation

 

Regulatory requirements for Wipe Out® Dairy Wipes: While the FDA regulates the manufacture and sale of Wipe Out® Dairy Wipes, this type of product is permitted to be sold without a NADA approval, in accordance with the FDA’s Compliance Policy Guide 7125.30 (“Teat Dips and Udder Washes for Dairy Cows and Goats”). This policy guide could be withdrawn at the FDA’s discretion, in which case we would likely discontinue sales of the product. The manufacture of Wipe Out® Dairy Wipes is subject to Part 211 of the cGMP regulations. As a result, our operations are subject to inspection by the FDA. During the second quarter of 2007, the FDA inspected our facilities and operations and issued a Warning Letter to us, citing deficiencies in specific areas of the cGMP regulations. We filed an initial response to the FDA during the second quarter of 2007, and we responded to a request for additional information during the second quarter of 2008. During the first quarter of 2013, the FDA again inspected our facilities and operations. The report from this inspection was very favorable, and we responded to the few, minor observations that were noted. We remain subject to the risk of adverse action by the FDA in this respect.

 

Product risks generally: The sale of our products is subject to financial, efficacy, regulatory, competitive and other market risks. We cannot be sure that we will be able to maintain the regulatory compliance required to continue selling our products. There is no assurance that we will continue to achieve market acceptance at a profitable price level or that we can continue to manufacture our products at a low enough cost to result in a sufficient gross margin to justify their continued manufacture and sale.

 

Product liability: The manufacture and sale of our products entails a risk of product liability. Our exposure to product liability is mitigated to some extent by the fact that our products are principally directed towards the animal health market. We have maintained product liability insurance in an amount which we believe is reasonable in relation to our potential exposure in this area. We have no history of claims of this nature being made.

 

Risks associated with USDA and international regulatory oversight: First Defense® is subject to the jurisdiction of the Center for Veterinary Biologics, USDA. Similar regulatory oversight risks exist in territories outside of the United States where we sell our products.

 

Exposure to risks associated with the financial downturn and global economic crisis: The U.S. economy appears to be coming out of a recession, which was caused principally by the housing, credit and financial crises of the late 2000’s. However, such recent positive indications could prove temporary and further downturn could occur, and the European economy remains sluggish and precarious. The credit markets continue to be very turbulent and uncertain. Sales and financial performance are still down at many businesses. This extraordinary period of instability facing the U.S. economy and the financial markets has been troubling for nearly all Americans. Some observers believe that the national unemployment rate is too high, the housing market remains problematic for the overall U.S. economy, the United States has taken on too much national debt and the equity markets are overvalued. A continued and prolonged economic downturn could have a corresponding negative effect on our business and operations, including the demand for our products in the U.S. market and our ability to penetrate international markets.

 

Bovine diseases: The potential for epidemics of bovine diseases such as Foot and Mouth Disease, Bovine Tuberculosis, Brucellosis and Bovine Spongiform Encephalopathy (BSE) presents a risk to us and our customers. Documented cases of BSE in the United States have led to an overall tightening of regulations pertaining to ingredients of animal origin, especially bovine. First Defense® is considered a veterinary medicine rather than a feed ingredient, and it is manufactured from bovine milk (colostrum), which is not considered a BSE risk material. Future regulatory action to increase protection of the human food supply could affect First Defense®, although presently we do not anticipate that this will be the case.

 

Biological terrorism: The threat of biological terrorism is a risk to both the economic health of our customers and our ability to economically acquire and collect good quality raw material from our contract farms. Any act of widespread bioterrorism against the dairy industry could adversely affect our operations.

 

Cost burdens of our reporting obligations as a public company: Operating a public company involves substantial costs to comply with reporting obligations under federal securities laws and the provisions of the Sarbanes-Oxley Act of 2002.

 

17
 

 

ImmuCell Corporation

 

ITEM 2 – DESCRIPTION OF PROPERTY

 

We own a 34,850 square foot building at 56 Evergreen Drive in Portland, Maine. We currently use this space for substantially all of our office, laboratory and manufacturing needs. When we originally purchased this building in 1993, its size was 15,000 square feet, including 5,000 square feet of unfinished space on the second floor. In 2001, we completed a construction project that added approximately 5,200 square feet of new manufacturing space on the first floor and approximately 4,100 square feet of storage space on the second floor. In 2007, we built out the 5,000 square feet of unfinished space on the second floor into usable office space. After moving first floor offices into this new space on the second floor, we modified and expanded the laboratory space on the first floor and added approximately 2,500 additional square feet of storage space on the second floor. During 2009, we added 350 square feet of cold storage space connected to our first floor production area and added an additional 600 square feet to the second floor storage area. During the third quarter of 2014, we initiated construction of a two-story addition connected to our facility to provide us with approximately 7,100 additional square feet for cold storage, production and warehouse space for our operations. This work was completed during the first quarter of 2015. We funded these investments with available cash.

 

We rent approximately 550 square feet of office and warehouse space in New York on a short-term basis to support our farm operations. We maintain property insurance in amounts that approximate replacement cost and a modest amount of business interruption insurance. We also maintain access to certain animals, primarily cows, through contractual relationships with commercial dairy farms.

 

ITEM 3 – LEGAL PROCEEDINGS

 

None

 

ITEM 4 – MINE SAFETY DISCLOSURES

 

None

 

18
 

  

ImmuCell Corporation

 

PART II

 

ITEM 5 – MARKET FOR COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our common stock trades on the NASDAQ Capital Market tier of the NASDAQ Stock Market under the symbol ICCC. No dividends have been declared or paid on the common stock since the Company’s inception, and we do not anticipate or contemplate the payment of cash dividends in the foreseeable future. The following table sets forth the high and low sales price information for our common stock as reported by the NASDAQ Stock Market during the period January 1, 2013 through December 31, 2014:

 

   2014   2013 
   Three Months Ended   Three Months Ended 
    March 31    June 30    September 30    December 31    March 31    June 30    September 30    December 31 
High  $4.95   $5.30   $5.68   $5.44   $4.50   $3.95   $5.10   $4.86 
Low  $4.06   $3.30   $4.17   $3.96   $3.52   $3.25   $3.19   $4.01 

 

As of March 18, 2015, we had 8,000,000 common shares authorized and 3,028,034 common shares outstanding, and there were approximately 900 shareholders of record. The last sales price of our common stock on March 18, 2015 was $6.45 per share as quoted on the NASDAQ Stock Market.

 

Equity Compensation Plan Information

 

The table below summarizes the common stock reserved for issuance upon the exercise of stock options outstanding as of December 31, 2014 or that could be granted in the future:

 

    Number of shares to
be issued upon
exercise of
outstanding options		    Weighted-average exercise price of outstanding options    Number of shares remaining
available for future issuance
under stock-based compensation
plans (excluding shares reflected
in first column of this table)		 
Equity compensation plans approved by stockholders   253,000   $3.42    202,500 
                
Equity compensation plans not approved by stockholders   --    --    -- 
                
Total   253,000   $3.42    202,500 

 

ITEM 6 – SELECTED FINANCIAL DATA

 

The selected financial data set forth below has been derived from our audited financial statements. The information should be read in conjunction with the audited financial statements and related notes appearing elsewhere in this Form 10-K and in earlier reports filed with the SEC (in thousands, except for per share amounts).

 

   Year Ended December 31, 
   2014   2013   2012   2011   2010 
Statement of Operations Data:                    
Product sales  $7,597   $6,007   $5,390   $5,111   $4,386 
Gross margin   4,449    3,061    3,054    2,814    2,302 
Product development expenses   2,179    1,154    918    1,720    1,493 
Selling and administrative expenses   2,476    1,926    1,892    1,726    1,500 
Net operating (loss) income   (206)   (20)   245    (633)   (690)
(Loss) income before income taxes   (255)   205    192    (697)   (683)
Net (loss) income  $(167)  $117   $90   $(410)  $(385)

 

19
 

 

ImmuCell Corporation

 

   Year Ended December 31, 
   2014   2013   2012   2011   2010 
Per Common Share:                         
Basic net (loss) income  $(0.06)  $0.04   $0.03   $(0.14)  $(0.13)
Diluted net (loss) income  $(0.06)  $0.04   $0.03   $(0.14)  $(0.13)
Cash dividend  $0   $0   $0   $0   $0 
                          
Statement of Cash Flows Data:                         
Net cash provided by (used for) operating activities  $302   $1,099   $344   $(37)  $(809)

 

   As of December 31, 
   2014   2013   2012   2011   2010 
Balance Sheet Data:                          
Cash, cash equivalents, short-term investments and long-term investments  $3,835   $5,255   $4,914   $4,960   $4,626 
Total assets   11,052    10,961    11,030    10,991    10,751 
Current liabilities   1,009    636    666    635    525 
Net working capital   4,460    6,632    6,697    6,516    6,441 
Long-term liabilities   785    929    1,170    1,336    944 
Stockholders’ equity  $9,258   $9,396   $9,195   $9,020   $9,282 
                          
Per Outstanding Common Share:                         
Cash, cash equivalents, short-term investments and long-term investments  $1.27   $1.74   $1.63   $1.65   $1.56 
Stockholders’ equity  $3.06   $3.11   $3.05   $3.00   $3.12 

 

ITEM 7 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Financial Condition

 

We had approximately $3,835,000 in available cash, cash equivalents, short-term investments and long-term investments as of December 31, 2014. The table below summarizes the changes in selected, key balance sheet items (in thousands, except for percentages):

 

   As of December 31,   (Decrease)
Increase		 
    2014    2013    $    % 
Cash, cash equivalents, short-term investments and long-term investments  $3,835   $5,255   $(1,420)   (27%)
Net working capital   4,460    6,632    (2,172)   (33%)
Total assets   11,052    10,961    91    0.8%
Stockholders’ equity  $9,258   $9,396   $(138)   (1.5%)

 

Net cash provided by operating activities amounted to $302,000 during the year ended December 31, 2014 compared to net cash provided by operating activities of $1,099,000 during 2013. Capital investments of $1,536,000 during 2014 compared to capital investments of $598,000 during 2013. Together with gross margin earned from ongoing product sales, we believe that we have sufficient capital resources to meet our working capital requirements and to finance our ongoing business operations during at least the next twelve months.

 

During the third quarter of 2010, we agreed to terms of certain credit facilities with TD Bank, N.A. aggregating up to approximately $2,100,000, which are secured by substantially all of our assets. These credit facilities are comprised of a $1,000,000 ten-year mortgage loan, a $600,000 fifty-four month note and a $500,000 line of credit. Proceeds from the $1,000,000 mortgage loan were received during the third quarter of 2010. Proceeds from the $600,000 note were received during the first quarter of 2011. As of December 31, 2014, our outstanding bank debt balance was approximately $896,000. The $500,000 line of credit is available as needed. We chose debt financing because we believed that, in the market environment around 2010, the option to generate funds through the sale of equity securities at an acceptable level of stockholder dilution was unlikely.

 

20
 

 

ImmuCell Corporation

 

Since 1999, our strategy has been focused on selling and developing products that improve animal health and productivity in the dairy and beef industries. These product opportunities are generally less expensive to develop than the human health product opportunities that we had worked on during the 1990’s. We have funded most of our product development expenses principally from product sales and were profitable for each of the nine years in the period ended December 31, 2007. Our cumulative investment of approximately $20,749,000 during the sixteen-year period ended December 31, 2014 was offset, in part, by $4,130,000 in licensing revenue, technology sales and grant income. Our strategic decision to continue developing Mast Out® after the product rights were returned to us in 2007 caused us to increase our spending on product development expenses that were previously funded by a former partner from late 2004 to mid-2007. As a result, we incurred net losses of $469,000, $216,000, $385,000 and $410,000 during the years ended December 31, 2008, 2009, 2010 and 2011, respectively. Having largely completed the significant clinical studies, we reduced product development expenses during 2012, as anticipated, and were profitable during 2012 and 2013. These expenses increased again, as we invested to complete the regulatory approval process, resulting in a net loss during the first half of 2014. After completing this investment, we returned to profitable results during the second half of 2014. We may, on occasion, seek additional research grant support as a means of leveraging the funds that we are able to spend developing new products.

 

During the third quarter of 2013, our Board of Directors approved the aggregate investment of approximately $3,000,000 in two projects. The first investment involved acquiring processing equipment and modifying a portion of our facility to produce the Drug Substance for Mast Out® to complete the Mast Out® product development initiative. This project was substantially completed during the third quarter of 2014. We hope the work performed in this plant will support and facilitate the raising of capital or the enlistment of a partner to fund expanded manufacturing capacity for the commercialization of Mast Out®. This specifically targeted increase in product development expenses resulted in a net loss during the first six months of 2014 and (despite a return to profitability during the last six months of 2014) during the year ended December 31, 2014. The purpose of this investment is discussed in greater detail under ITEM 1 – DESCRIPTION OF BUSINESS, “Product Development,” above. The second investment involved acquiring manufacturing equipment and constructing a two-story addition to our facility, providing us with approximately 7,100 square feet of cold storage, production and warehouse space to increase our production capacity. Additionally, this investment allows us to better integrate the production of pharmaceutical-grade Nisin into our operations. This project was initiated in September 2014 and was completed during February 2015. The following table details the spending on these two projects:

 

    Expenses    Capital
Expenditures		    Total Expenses
and Capital
Expenditures		 
Three-month period ended December 31, 2013  $110,000   $21,000   $131,000 
Year ended December 31, 2014   973,000    1,492,000(1)   2,465,000 
Fifteen-month period ended December 31, 2014   1,083,000    1,513,000    2,596,000 
Budgeted and not yet spent   10,000    394,000(2)   404,000 
Total investment  $1,093,000   $1,907,000   $3,000,000 

 

(1)This figure includes approximately $1,271,000 that was recorded as construction in progress as of December 31, 2014. Approximately $230,000 of this construction in progress amount was capitalized during 2014 but was not paid for until 2015.

 

(2)We had made commitments to contractors and vendors to spend approximately $326,000 of this amount as of December 31, 2014.

 

21
 

 

ImmuCell Corporation

 

As of January 1, 2015, we had additional authorization from our Board of Directors to spend up to approximately $1,640,000 on new manufacturing equipment and other routine and necessary capital expenditures. Most of this investment authorization is intended to pay for the acquisition of First Defense® production equipment to increase our liquid processing capacity by approximately 50% and our freeze-drying capacity by approximately 100%. We have already begun to increase our production capacity, but due to the long order lead time on some of this critical equipment, we do not expect to fully complete this investment program until the first quarter of 2016. These investments, together with the 7,100 square foot facility addition, described in the previous paragraph, are necessary to increase our production capacity to fill our current backlog of orders created by the increased sales demand that we are experiencing.

 

Results of Operations

 

2014 Compared to 2013

 

Product Sales

 

Product sales for the year ended December 31, 2014 increased by 26%, or $1,590,000, to $7,597,000 from $6,007,000 in 2013. Domestic product sales increased by 27%, or $1,376,000, during the year ended December 31, 2014, and international sales increased by 23%, or $214,000, in comparison to 2013. For the three-month period ended December 31, 2014, product sales increased by 41%, or $646,000, in comparison to the three-month period ended December 31, 2013. We believe that our increased investment in sales and marketing personnel and efforts is helping us introduce First Defense® to new customers and that our product sales benefited from the relatively strong prices of milk, cows and calves, as well as a stable to moderately lower cost of feed. We have not implemented significant or frequent price increases believing that we could benefit more from higher unit sales than through a higher average selling price per unit. We generally held our product selling prices without increase during the seven year period ended December 31, 2007. During the first quarter of 2008, we implemented a modest increase to the selling price of First Defense®. We did not implement another price increase until the third quarter of 2014. This strategy recognizes that while selling a premium-priced product, we must be very efficient with our manufacturing costs to maintain a healthy gross margin.

 

Our total product sales during the six-month period ended December 31, 2014 increased by 42%, or $1,181,000, in comparison to the same period in 2013. This positive trend has continued into the first quarter of 2015, and this new level of sales demand for First Defense® has exceeded our production capacity and available inventory. We project that sales (shipped to customers) of First Defense® during the first quarter of 2015 will be approximately 62% over the first quarter of 2014. Based upon orders received as of March 18, 2015 that we expect to be in excess of our finished goods inventory available to ship during the balance of the first quarter of 2015, we estimate that we will have a backlog of orders for First Defense® aggregating at least $795,000 as of March 31, 2015. This estimate of the backlog as of March 31, 2015 will be further increased by orders received after March 18, 2015. The 62% projected increase in sales of First Defense® during the first quarter of 2015 over the first quarter of 2014 would be increased further to approximately 105% if we could ship the $795,000 in orders discussed above before April 1, 2015. We are making the investments necessary to increase our production capacity to meet the growing sales demand for First Defense®.

 

22
 

 

ImmuCell Corporation

 

Our lead product, First Defense®, continues to benefit from wide acceptance by dairy and beef producers as an effective tool to prevent bovine enteritis (scours) in newborn calves. Sales of First Defense®, and related product line extensions aggregated 91.6% and 91.4% of our total product sales during the years ended December 31, 2014 and 2013, respectively. Sales of First Defense® and related product line extensions increased by 27%, 14% and 5% during the years ended December 31, 2014, 2013 and 2012, respectively, in comparison to the prior years. Domestic sales of First Defense® and related product line extensions increased by 29%, and international sales increased by 15% during the year ended December 31, 2014 in comparison to 2013. Sales of First Defense® and related product line extensions increased by 44% and 43% during the three-month and six-month periods ended December 31, 2014, respectively, in comparison to 2013. With the single exception of the second quarter of 2012, we have realized consistently positive sales growth of First Defense® and related product line extensions during the last ten consecutive quarters and for sixteen of the last seventeen quarters in comparison to the same quarters of the prior year, as demonstrated in the following table:

 

 

We believe that the long-term growth in sales of First Defense® and related product line extensions may reflect, at least in part, the success of our strategic decision initiated in 2010 to invest in additional sales and marketing efforts. Our sales and marketing team currently consists of one vice president and five regional managers. Our inside sales and customer service representative performs all order entry and inside sales duties, and our facility manager processes all shipments. We launched a new communications campaign at the end of 2010 that continues to emphasize how the unique ability of First Defense® to provide Immediate ImmunityTM generates a dependable return on investment for dairy and beef producers. Preventing newborn calves from becoming sick helps them to reach their genetic potential.

 

Competition for resources that dairy producers allocate to their calf enterprises has been increased by the many new products that have been introduced to the calf market. Our sales are normally seasonal, with higher sales expected during the first quarter. Warm and dry weather reduces the producer’s perception of the need for a disease preventative product like First Defense®, but heat stress on calves caused by extremely hot summer weather can increase the incidence of scours. The severe heat and drought conditions during the summer of 2012 in many key agricultural regions in North America caused a significant increase in the cost of feed. Harsher winter weather benefits our sales. The animal health distribution segment has been aggressively consolidating over the last few years. Larger distributors have been acquiring smaller distributors. Beef herd numbers were reduced because of the 2012 drought conditions in many parts of North America. This has resulted in an increase in the value of newborn calves, as producers re-build their herd levels. Such an upswing increases a producer’s likelihood to invest in First Defense® for their calf crop.

 

We are selling new product applications of First Defense® product line under the description First Defense TechnologyTM, which is a unique whey protein concentrate that is processed utilizing our proprietary milk protein purification methods, for the nutritional and feed supplement markets without the claims of our USDA-licensed product. Through our First Defense TechnologyTM, we are selling concentrated whey proteins in different formats. During the first quarter of 2011, we initiated sales of First Defense TechnologyTM in a bulk powder format (no capsule), which is delivered with a scoop and mixed with colostrum for feeding to calves. During the fourth quarter of 2011, Milk Products, LLC of Chilton, Wisconsin launched commercial sales of their product, Ultra Start® 150 Plus, a colostrum replacer with First Defense TechnologyTM Inside. During the first quarter of 2012, we initiated a limited launch of a tube delivery format of our First Defense TechnologyTM in a gel solution.

 

23
 

 

ImmuCell Corporation

 

We sell topical wipes that are pre-moistened with a Nisin-based formulation in two product formats. Since 1999, we have been selling Wipe Out® Dairy Wipes (our second leading source of product sales) for use in preparing the teat area of a cow for milking. Sales of Wipe Out® Dairy Wipes decreased by 2% during the year ended December 31, 2014 in comparison to the same period during 2013. We are competing aggressively on selling price to earn new business against less expensive products and alternative teat sanitizing methods. We believe that sales growth potential for Wipe Out® Dairy Wipes is limited because most of our sales of this product tend to be to smaller dairies that are under continued financial pressures. Such pressures are forcing many small dairy producers out of business. While our product is a high quality tool, there are less expensive ways to sanitize a cow’s udder prior to milking, and many producers opt for a less expensive solution. During the first quarter of 2013, we initiated sales of Nisin-based wipes for pets in a 120-count canister (Preva™ wipes) to Bayer HealthCare Animal Health of St. Joseph, Missouri for commercial sales to pet owners. Sales of this product line extension turned the 2% decrease in sales of Wipe Out® Dairy Wipes (discussed above) into an 8% aggregate increase in sales of all topical product applications during the year ended December 31, 2014 in comparison to the same period during 2013.

 

Sales of our California Mastitis Test (CMT) (our third leading source of product sales) increased by 8% during the year ended December 31, 2014 in comparison to the same period during 2013. We make and sell bulk reagents for Isolate™ (formerly known as Crypto-Scan®), which is a drinking water test that is sold by our distributor in Europe. Sales of Isolate™ increased by 111% during the year ended December 31, 2014 in comparison to the same period during 2013. Sales of these bulk reagents aggregated slightly more than 2% and slightly more than 1% of product sales during the years ended December 31, 2014 and 2013, respectively.

 

Gross Margin

 

Changes in the gross margin on product sales are summarized in the following table for the respective periods (in thousands, except for percentages):

 

   For the Three-Month
Periods Ended
December 31,		   Increase 
    2014    2013    Amount    % 
Gross margin  $1,343   $608   $735    121%
Percent of product sales   61%   39%   22%   56%

 

   For the Six-Month
Periods Ended
December 31,		   Increase 
    2014    2013    Amount    % 
Gross margin  $2,421   $1,224   $1,196    98%
Percent of product sales   61%   44%   17%   39%

 

   For the Years Ended
December 31,		   Increase 
    2014    2013    Amount    % 
Gross margin  $4,449   $3,061   $1,388    45%
Percent of product sales   59%   51%   8%   15%

 

The gross margin as a percentage of product sales was 59% and 51% during the years ended December 31, 2014 and 2013, respectively. This compares to gross margin percentages of 57% and 55% during the years ended December 31, 2012 and 2011, respectively. Our objective for the foreseeable future is to maintain the full-year gross margin percentage over 50%, and we have achieved this objective during all of the full-year periods being reported. The gross margin as a percentage of product sales was 61% and 44% during the six-month periods ended December 31, 2014 and 2013, respectively. We believe the 61% ratio during the second half of 2014 was unusually high and not sustainable over time going forward. We reduced production output during the last six months of 2013 in order to replace and repair certain pieces of critical process equipment, which resulted in an increase in cost of goods sold during that period. The use of more expensive subcontractors during this period also increased our costs. This production slow-down resulted in a few, short delays in shipping customer orders of First Defense® during the first quarter of 2014. These investments were completed during the fourth quarter of 2013, and our gross margin percentage was again in line with historical norms during 2014. Our inventory balance was reduced by 23%, or $366,000, to $1,207,000 at December 31, 2013 from $1,573,000 as of June 30, 2013. This level of investment as of June 30, 2013 helped us prevent a backlog of orders, while we slowed inventory production to replace and repair the critical pieces of process equipment, discussed above. Largely due to the significant increase in product sales experienced especially during the second half of 2014, our inventory balance was reduced to $946,000 as of December 31, 2014. We are investing in production growth during 2015 to increase our inventory levels and keep up with growing sales. A number of factors account for the variability in our costs, resulting in some fluctuations in gross margin percentages from quarter to quarter. The gross margin on First Defense® is affected by biological yields from our raw material, which do vary over time. Like most U.S. manufacturers, we have been experiencing increases in the cost of raw materials that we purchase. The costs for production of First Defense® and Wipe Out® Dairy Wipes have increased due to increased labor costs and other expenses associated with our efforts to sustain compliance with cGMP regulations in our production processes. We have been able to minimize the impact of these cost increases by implementing yield improvements. Product mix also affects gross margin in that we earn a higher gross margin on First Defense® and a lower gross margin on Wipe Out® Dairy Wipes.

 

24
 

 

ImmuCell Corporation

 

Product Development Expenses

 

Product development expenses increased by 89%, or $1,025,000, to $2,179,000 during the year ended December 31, 2014, as compared to $1,154,000 during 2013. Product development expenses aggregated 29% and 19% of product sales in 2014 and 2013, respectively. The majority of our product development budget from 2000 through 2014 has been focused on the development of Mast Out®. The balance of our efforts have been primarily focused on other improvements, extensions or additions to our First Defense® product line. The other improvements, extensions, or additions to our current product line include the potential to prevent scours in calves caused by pathogens other than those within the current First Defense® disease claims (E. coli K99 and coronavirus) such as rotavirus. We also remain interested in acquiring other new products and technologies that fit with our sales focus on the dairy and beef industries.

 

Sales and Marketing Expenses

 

Sales and marketing expenses increased by approximately 33%, or $330,000, to $1,317,000 in 2014, increasing to 17% of product sales in 2014 from 16% in 2013. We continue to leverage the efforts of our small sales force by using veterinary distributors. These expenses have increased due principally to a strategic decision to invest more to support First Defense® sales. This investment may have created, at least in part, our recent increase in product sales. Our current budgetary objective in 2015 is to invest up to 20% of product sales in sales and marketing expenses on an annual basis.

 

Administrative Expenses

 

Administrative expenses increased by approximately 23%, or $220,000, to $1,159,000 during the year ended December 31, 2014 as compared to $939,000 during 2013. We strive to be efficient with these expenses while funding costs associated with complying with the Sarbanes-Oxley Act of 2002 and other costs associated with being a publicly-held company. Prior to 2014, we had limited our investment in investor relations spending. Beginning in the second quarter of 2014, we initiated an investment in a more actively managed investor relations program. Additionally, we continue to provide full disclosure of the status of our business and financial condition in three quarterly reports and one annual report each year, as well as in Current Reports on Form 8-K when legally required or deemed appropriate by management. Additional information about us is available in our annual Proxy Statement. All of these reports are filed with the SEC and are available on-line or upon request to the Company.

 

Net Operating (Loss) Income

 

The net operating (loss) during the year ended December 31, 2014 of ($206,000) increased from a net operating (loss) of ($20,000) during 2013. In contrast, we recorded net operating income of $245,000 during the year ended December 31, 2012.

 

25
 

 

ImmuCell Corporation

 

Other (expenses) revenues, net

 

Interest income increased by approximately 24%, or $3,000, to $16,000 during the year ended December 31, 2014, in comparison to $12,000 during 2013. Interest expense decreased by approximately 13%, or $9,000, to $58,000 during the year ended December 31, 2014, in comparison to $67,000 during 2013. During the second quarter of 2013, we received a $250,000 exclusive option payment from a prospective partner for the development and marketing of Mast Out®. This payment was recorded as deferred revenue upon receipt. During the third quarter of 2013, this prospective partner decided not to execute a license after its final due diligence. Accordingly, the deferred revenue was recognized during the third quarter of 2013. At the same time, $48,000 in capitalized expenses pertaining to the development of Mast Out® were written off. During the first quarter of 2013, we received a payment of approximately $62,000, as an eligible member of the mutual insurance company that provided products liability insurance to us when it was acquired by another insurance company through a sponsored demutualization transaction that was effective as of January 1, 2013. No such similar sources of revenue occurred during 2014. As a result, other (expenses) of ($49,000) during the year ended December 31, 2014 contrast to other revenues of $225,000 during 2013.

 

(Loss) Income Before Income Taxes and Net (Loss) Income

 

Our (loss) before income taxes of ($255,000) during the year ended December 31, 2014 is in contrast to income before income taxes of $205,000 during 2013. We recorded an income tax (benefit) expense of (35%) and 43% of the (loss) income before income taxes during the years ended December 31, 2014 and 2013, respectively. Our net (loss) of ($167,000), or ($0.06) per share, during the year ended December 31, 2014 is in contrast to net income of $117,000, or $0.04 per share, during 2013.

 

2013 Compared to 2012

 

Product Sales

 

Product sales for the year ended December 31, 2013 increased by 11.5%, or $617,000, to $6,007,000 from $5,390,000 in 2012. Domestic product sales increased by 18%, or $763,000, during the year ended December 31, 2013, and international sales decreased by 13%, or $146,000, in comparison to 2012. For the three-month period ended December 31, 2013, product sales increased by 10%, or $138,000, in comparison to the three-month period ended December 31, 2012. We believe that our increased investment in sales and marketing personnel and efforts is helping us introduce First Defense® to new customers and that our product sales benefited from the relatively strong prices of milk, cows and calves, which gains were partially offset by the increased cost of feed. Our lead product, First Defense®, continues to benefit from wide acceptance by dairy and beef producers as an effective tool to prevent bovine enteritis (scours) in newborn calves.

 

26
 

 

ImmuCell Corporation

 

Sales of our lead product, First Defense®, and the related product line extensions aggregated 91% and 89% of our total product sales during the years ended December 31, 2013 and 2012, respectively. Sales of First Defense® increased by 14%, 5% and 21% during the years ended December 31, 2013, 2012 and 2011, respectively, in comparison to the prior years. Sales of First Defense® increased by 17% and 16% during the three-month and six-month periods ended December 31, 2013, respectively, in comparison to 2012. Domestic sales of First Defense® increased by 18%, and international sales decreased by less than 1% during the year ended December 31, 2013 in comparison to 2012. With the single exception of the second quarter of 2012, we have realized consistently positive sales growth of First Defense® during the last six consecutive quarters and for twelve of the last thirteen quarters, as demonstrated in the following table:

 

 

Competition for resources that dairy producers allocate to their calf enterprises has been increased by the many new products that have been introduced to the calf market. Our sales are normally seasonal, with higher sales expected during the first quarter. Warm and dry weather reduces the producer’s perception of the need for First Defense® . Heat stress on calves caused by extremely hot summer weather can increase the incidence of scours. The severe heat and drought conditions during the summer of 2012 in many key agricultural regions in North America caused a significant increase in the cost of feed that has offset some improvement in milk prices. The combination of mild weather during the spring 2012 beef calving season and the increasing cost of feed created a very challenging environment in which to sell a disease prevention product. The harsher winter weather in late 2013 and early 2014 may have benefited our sales. The animal health distribution segment has been aggressively consolidating over the last few years. Larger distributors have been acquiring smaller distributors. Although beef herd numbers are down currently because of the 2012 drought conditions in many parts of North America, the value of newborn calves has increased as producers re-build their herd levels. Such an upswing increases a producer’s likelihood to invest in First Defense® for their calf crop.

 

Sales of Wipe Out® Dairy Wipes decreased by 7% during the year ended December 31, 2013 in comparison to the same period during 2012. We competed aggressively on selling price to earn new business against less expensive products and alternative teat sanitizing methods. We believe that sales growth potential for Wipe Out® Dairy Wipes is limited because most of our sales of this product tend to be to smaller dairies that are under continued financial pressures. Such pressures are forcing many small dairy producers out of business. While our product is a high quality tool, there are less expensive ways to sanitize a cow’s udder prior to milking, and many producers opt for a less expensive solution. During the first quarter of 2013, we initiated sales of Nisin-based wipes for pets in a 120-count canister (Preva™ wipes) to Bayer HealthCare Animal Health of St. Joseph, Missouri for commercial sales to pet owners. This new source of sales turned the 7% decrease in sales of Wipe Out® Dairy Wipes into a 21% aggregate increase in sales of all topical product applications during the year ended December 31, 2013 in comparison to the same period during 2012.

 

Sales of our California Mastitis Test (CMT) (our third leading source of product sales) decreased by 7% during the year ended December 31, 2013 in comparison to the same period during 2012. We make and sell bulk reagents for Isolate™ (formerly known as Crypto-Scan®), which is a drinking water test that is sold by our distributor in Europe. Sales of IsolateTM decreased by 61% during the year ended December 31, 2013 in comparison to the same period during 2012. Sales of these bulk reagents aggregated slightly more than 1% and slightly less than 4% of product sales during the years ended December 31, 2013 and 2012, respectively. This decrease was largely the result of the timing of an order that was moved from the fourth quarter of 2013 to the first quarter of 2014.

 

27
 

 

ImmuCell Corporation

 

Gross Margin

 

Changes in the gross margin on product sales are summarized in the following table for the respective periods (in thousands, except for percentages):

 

   For the Three-Month
Periods Ended
December 31,		   (Decrease) 
    2013    2012    Amount    % 
Gross margin  $608   $750   $(143)   (19%)
Percent of product sales   39%   53%   (14%)   (26%)

 

   For the Six-Month
Periods Ended
December 31,		   (Decrease) 
    2013    2012    Amount    % 
Gross margin  $1,223   $1,371   $(148)   (11%)
Percent of product sales   44%   55%   (11%)   (20%)

 

   For the Years Ended
December 31,		   Increase
(Decrease)		 
    2013    2012    Amount    % 
Gross margin  $3,061   $3,054   $6    0.2%
Percent of product sales   51%   57%   (6%)   (10%)

 

The gross margin as a percentage of product sales was 51% and 57% during the years ended December 31, 2013 and 2012, respectively. This compares to gross margin percentages of 55% and 52% during the years ended December 31, 2011 and 2010, respectively. Our objective is to maintain the full-year gross margin percentage over 50%, and we have achieved this objective during all of the full-year periods being reported. We reduced production output during the last six months of 2013 in order to replace and repair certain pieces of critical process equipment, which resulted in an increase in cost of goods sold during that period. These investments were completed during the fourth quarter of 2013. A number of factors account for the variability in our costs, resulting in some fluctuations in gross margin percentages from quarter to quarter. The gross margin on First Defense® is affected by biological yields from our raw material, which do vary over time. Like most U.S. manufacturers, we have been experiencing increases in the cost of raw materials that we purchase. The costs for production of First Defense® and Wipe Out® Dairy Wipes have increased due to increased labor costs and other expenses associated with our efforts to sustain compliance with cGMP regulations in our production processes. We have been able to minimize the impact of these cost increases by implementing yield improvements. Product mix also affects gross margin in that we earn a higher gross margin on First Defense® and a lower gross margin on Wipe Out® Dairy Wipes. Our inventory balance was reduced by 27%, or $442,000, to $1,207,000 as of December 31, 2013 from $1,649,000 as of December 31, 2012. Our inventory balance was reduced by 23%, or $366,000, to $1,207,000 at December 31, 2013 from $1,573,000 as of June 30, 2013. This level of investment as of December 31, 2012 and June 30, 2013 helped us prevent a backlog of orders, while we slowed inventory production to replace and repair certain pieces of critical process equipment during the second half of 2013.

 

Product Development Expenses

 

Product development expenses increased by 26%, or $237,000, to $1,154,000 during the year ended December 31, 2013, as compared to $918,000 during 2012. Product development expenses aggregated 19% and 17% of product sales in 2013 and 2012, respectively. The majority of our product development budget from 2000 through 2013 has been focused on the development of Mast Out®. The balance of our efforts have been primarily focused on other improvements, extensions or additions to our First Defense® product line. The other improvements, extensions, or additions to our current product line include the potential to prevent scours in calves caused by pathogens other than those within the current First Defense® disease claims (E. coli K99 and coronavirus) such as rotavirus.

 

28
 

 

ImmuCell Corporation

 

Sales and Marketing Expenses

 

Sales and marketing expenses increased by approximately 1%, or $14,000, to $987,000 in 2013, decreasing to 16% of product sales in 2013 from 18% in 2012. We continue to leverage the efforts of our small sales force by using veterinary distributors.

 

Administrative Expenses

 

Administrative expenses increased by approximately 2%, or $21,000, to $939,000 during the year ended December 31, 2013 as compared to $918,000 during 2012. We strive to be efficient with these expenses while funding costs associated with complying with the Sarbanes-Oxley Act of 2002 and other costs associated with being a publicly-held company.

 

Other revenues (expenses), net

 

During the second quarter of 2013, we received a $250,000 exclusive option payment from a prospective partner for the development and marketing of Mast Out®. This payment was recorded as deferred revenue upon receipt. During the third quarter of 2013, this prospective partner decided not to execute a license after its final due diligence. Accordingly, the deferred revenue was recognized during the third quarter of 2013. At the same time, $48,000 in capitalized expenses pertaining to the development of Mast Out® were written off. During the first quarter of 2013, we received a payment of approximately $62,000, as an eligible member of the mutual insurance company that provided products liability insurance to us when it was acquired by another insurance company through a sponsored demutualization transaction that was effective as of January 1, 2013. Interest income decreased by approximately 27%, or $5,000, to $12,000 in 2013, in comparison to $17,000 during 2012. Interest expense decreased by approximately 11%, or $9,000, to $67,000 in 2013, in comparison to $75,000 during 2012.

 

Income Before Income Taxes and Net Income

 

Our income before income taxes of $205,000 during the year ended December 31, 2013 compares to income before income taxes of $192,000 during 2012. We recorded an income tax expense of 43% and 53% of the income before income taxes during the years ended December 31, 2013 and 2012, respectively. Our net income of $117,000, or $0.04 per share, during the year ended December 31, 2013 compares to net income of $90,000, or $0.03 per share, during 2012.

 

Critical Accounting Policies

 

The financial statements are presented on the basis of accounting principles that are generally accepted in the United States. All professional accounting standards that were effective and applicable to us as of December 31, 2014 have been taken into consideration in preparing the financial statements. The preparation of financial statements requires that we make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, income taxes, contingencies and the useful lives and carrying values of intangible and long lived assets. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We have chosen to highlight certain policies that we consider critical to the operations of our business and understanding our financial statements.

 

We recognize revenue in accordance with Staff Accounting Bulletin (SAB) No. 104, “Revenue Recognition”, which supersedes SAB No. 101, “Revenue Recognition in Financial Statements”. SAB No. 104 requires that four criteria are met before revenue is recognized. These include i) persuasive evidence that an arrangement exists, ii) delivery has occurred or services have been rendered, iii) the seller’s price is fixed and determinable and iv) collectability is reasonably assured. We recognize revenue at the time of shipment (including to distributors) for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably assured. We recognize service revenue at the time the service is performed. All product development costs and patent costs are expensed as incurred.

 

29
 

 

ImmuCell Corporation

  

Inventory includes raw materials, work-in-process and finished goods and are recorded at the lower of standard cost which approximates cost on the first-in, first-out method or market (net realizable value). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead.

 

ITEM 7A – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We believe that neither inflation nor interest rates nor currency exchange rates have had a significant effect on our revenues and expenses. However, future increases in inflation or interest rates or the value of the U.S. dollar could affect our customers and the demand for our products. We hope to increase the level of our future sales of products outside the United States. The cost of our products to international customers could be affected by currency fluctuations. The decline of the U.S. dollar against other currencies could make our products less expensive to international customers. Conversely, a stronger U.S. dollar could make our products more costly for international customers. We hedged our interest rate exposure to a $1,000,000 mortgage with an interest rate swap agreement that effectively converted a floating interest rate to the fixed rate of 6.04%. The interest rate on our $600,000 note is variable. If the London Interbank Offered Rate plus 3.25% exceeds 4.25%, our interest payments will increase over the current amount.

 

ITEM 8 – FINANCIAL STATEMENTS

 

Our financial statements, together with the notes thereto and the report of the independent registered public accounting firm thereon, are set forth on Pages F-1 through F-20 at the end of this report. The index to these financial statements is as follows:

 

Report of Baker Newman & Noyes, LLC, Independent Registered Public Accounting Firm   F-1
Balance Sheets as of December 31, 2014 and 2013   F-2
Statements of Operations for the years ended December 31, 2014, 2013 and 2012   F-3
Statements of Comprehensive (Loss) Income for the years ended December 31, 2014, 2013 and 2012   F-4
Statements of Stockholders’ Equity for the years ended December 31, 2012, 2013 and 2014   F-5
Statements of Cash Flows for the years ended December 31, 2014, 2013 and 2012   F-6
Notes to Financial Statements   F-7 to F-20

 

ITEM 9 – CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None

 

ITEM 9A – CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures. Our management, with the participation of the individual who serves as our principal executive and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2014. Based on this evaluation, that officer concluded that our disclosure controls and procedures were effective as of that date. Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

30
 

 

ImmuCell Corporation

 

Management’s Annual Report on Internal Control Over Financial Reporting. The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

 

Management conducted an evaluation of the effectiveness of the internal controls over financial reporting based on the framework in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. This evaluation included a review of the documentation of controls, evaluation of the design effectiveness of controls, testing the operating effectiveness of the controls and a conclusion on this evaluation. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2014. Based on management’s assessment and those criteria, management believes that the internal control over financial reporting as of December 31, 2014 was effective.

 

This Annual Report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting. Management’s internal control report was not subject to attestation by the Company’s independent registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management’s report.

 

Changes in Internal Controls over Financial Reporting. There was no change in our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B – OTHER INFORMATION

 

None

 

31
 

 

ImmuCell Corporation

 

PART III

 

ITEM 10 – DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Information with respect to our directors is incorporated herein by reference to the section of our 2015 Proxy Statement titled “Election of the Board of Directors”, which we intend to file with the Securities and Exchange Commission within 120 days after December 31, 2014. The information required by this item with respect to our executive officers is contained in Item 1 of Part I of this Annual Report on Form 10-K under the heading “Executive Officers of the Company”. There is no family relationship between any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer.

 

ITEM 11 – EXECUTIVE COMPENSATION

 

Information regarding cash compensation paid to our executive officers is incorporated herein by reference to the section of our 2015 Proxy Statement titled “Executive Officer Compensation”, which we intend to file with the Securities and Exchange Commission within 120 days after December 31, 2014.

 

ITEM 12 – SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

Information regarding ownership of our common stock by certain owners and management is incorporated herein by reference to the section of our 2015 Proxy Statement titled “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters”, which we intend to file with the Securities and Exchange Commission within 120 days after December 31, 2014.

 

ITEM 13 – CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

Information regarding certain relationships and related transactions, and director independence is incorporated herein by reference to the section of our 2015 Proxy Statement titled “Certain Relationships and Related Transactions and Director Independence”, which we intend to file with the Securities and Exchange Commission within 120 days after December 31, 2014.

 

ITEM 14 – PRINCIPAL ACCOUNTING FEES AND SERVICES

 

Information regarding our principal accounting fees and services is incorporated by reference to the section of our 2015 Proxy Statement titled “Principal Accounting Fees and Services”, which we intend to file with the Securities and Exchange Commission within 120 days after December 31, 2014.

 

ITEM 15 – EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

3.1   Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 of the Company’s 1987 Registration Statement No. 33-12722 on Form S-1 as filed with the Commission).
3.2   Certificate of Amendment to the Company’s Certificate of Incorporation effective July 23, 1990 (incorporated by reference to Exhibit 3.2 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2008).
3.3   Certificate of Amendment to the Company’s Certificate of Incorporation effective August 24, 1992 (incorporated by reference to Exhibit 3.3 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2008).
3.4   Bylaws of the Company as amended (incorporated by reference to Exhibit 3.4 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2008).
4.1   Rights Agreement dated as of September 5, 1995, between the Company and American Stock Transfer and Trust Co., as Rights Agent, which includes as Exhibit A thereto the form of Right Certificate and as Exhibit B thereto the Summary of Rights to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2009).

 

32
 

 

ImmuCell Corporation

 

4.1A   First Amendment to Rights Agreement dated as of June 30, 2005 (incorporated by reference to Exhibit 4.1A of the Company’s Current Report on Form 8-K filed on July 5, 2005).
4.1B   Second Amendment to Rights Agreement dated as of June 30, 2008 (incorporated by reference to Exhibit 4.1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2008).
4.1C   Third Amendment to Rights Agreement dated as of August 9, 2011 (incorporated by reference to Exhibit 4.1 of the Company’s Quarterly Report on Form 10-Q for the three-month period ended June 30, 2011).
4.1D   Fourth Amendment to Rights Agreement dated as of June 16, 2014 (incorporated by reference to Exhibit 4.1D of the Company’s Current Report on Form 8-K filed on June 17, 2014).
10.1+   Form of Indemnification Agreement (updated) entered into with each of the Company’s Directors and Officers (incorporated by reference to Exhibit 10.3A to the Company’s Annual Report on Form 10-KSB for the year ended December 31, 2006).
10.2+   2000 Stock Option and Incentive Plan of the Company (incorporated by reference to Exhibit 10.6 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2008).
10.3+   Form of Incentive Stock Agreement (incorporated by reference to Exhibit 10.7 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2008).
10.4+   Amendment to Employment Agreement between the Company and Michael F. Brigham dated March 26, 2010 (incorporated by reference to Exhibit 10.6 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2009).
10.5+   Amendment to Employment Agreement between the Company and Joseph H. Crabb dated March 26, 2010 (incorporated by reference to Exhibit 10.7 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2009).
10.6+   2010 Stock Option and Incentive Plan of the Company (incorporated by reference to Exhibit 10.6 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2010).
10.7+   Form of Incentive Stock Option Agreement (incorporated by reference to Exhibit 10.7 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2010).
10.8   Commercial Promissory Note for $1,000,000 between the Company and TD Bank, N.A. dated August 13, 2010 (incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q for the three-month period ended June 30, 2010).
10.9   Commercial Promissory Note for $600,000 between the Company and TD Bank, N.A. dated August 13, 2010 (incorporated by reference to Exhibit 10.3 of the Company’s Quarterly Report on Form 10-Q for the three-month period ended June 30, 2010).
10.10   Line of Credit Agreement and Promissory Note for up to $500,000 between the Company and TD Bank, N.A. dated August 13, 2010 (incorporated by reference to Exhibit 10.4 of the Company’s Quarterly Report on Form 10-Q for the three-month period ended June 30, 2010).
10.11(1)   Loan Agreement between the Company and TD Bank, N.A. dated August 13, 2010 (incorporated by reference to Exhibit 10.5 of the Company’s Quarterly Report on Form 10-Q for the three-month period ended June 30, 2010).
10.12(1)   Contract Manufacture Agreement between the Company and Norbrook Laboratories Limited dated as of September 27, 2010 (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the three-month period ended September 30, 2010).
14   Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14 of the Company’s Current Report on Form 8-K filed on March 20, 2014).
23   Consent of Baker Newman & Noyes, LLC.
31   Certifications required by Rule 13a-14(a).
32   Certification pursuant to Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

101.INS   XBRL Instance Document.
101.SCH   XBRL Taxonomy Extension Schema Document.
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document.

 

 

+ Management contract or compensatory plan or arrangement.
(1)   Confidential treatment as to certain portions has been requested, which portions have been omitted and
    filed separately with the Securities and Exchange Commission.

 

33
 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders

ImmuCell Corporation

 

We have audited the accompanying balance sheets of ImmuCell Corporation (the Company) as of December 31, 2014 and 2013, and the related statements of operations, comprehensive (loss) income, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2014. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of ImmuCell Corporation as of December 31, 2014 and 2013, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2014, in conformity with U.S. generally accepted accounting principles.

 

Portland, Maine   /s/ Baker Newman & Noyes
March 26, 2015   Limited Liability Company

 

F-1
 

 

ImmuCell Corporation

 

BALANCE SHEETS

 

   As of December 31, 
   2014   2013 
ASSETS
CURRENT ASSETS:        
Cash and cash equivalents  $850,028   $2,270,385 
Short-term investments   2,489,000    2,985,000 
Inventory   945,755    1,206,508 
Accounts receivable, net   1,005,292    631,410 
Prepaid expenses and other assets   148,399    159,117 
Current portion of deferred tax asset   30,463    15,212 
Total current assets   5,468,937    7,267,632 
           
PROPERTY, PLANT AND EQUIPMENT, net   3,837,647    2,524,765 
           
LONG-TERM PORTION OF DEFERRED TAX ASSET   1,230,340    1,154,681 
           
LONG-TERM INVESTMENTS   496,000    0 
           
OTHER ASSETS, net   18,930    13,636 
           
TOTAL ASSETS  $11,051,854   $10,960,714 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:          
Accounts payable and accrued expenses  $851,677   $445,229 
Current portion of bank debt   150,382    190,390 
Deferred revenue   6,690    0 
Total current liabilities   1,008,749    635,619 
           
LONG-TERM LIABILITIES:          
Long-term portion of bank debt   745,920    896,224 
Interest rate swap   38,817    33,002 
Total long-term liabilities   784,737    929,226 
           
TOTAL LIABILITIES   1,793,486    1,564,845 
           
STOCKHOLDERS’ EQUITY:          
Common stock, $0.10 par value per share, 8,000,000 shares authorized, 3,261,148 shares issued at December 31, 2014 and 2013   326,115    326,115 
Capital in excess of par value   10,042,305    10,011,339 
Accumulated deficit   (574,567)   (407,408)
Treasury stock, at cost, 234,114 and 235,114 shares at December 31, 2014 and 2013, respectively   (512,154)   (514,341)
Accumulated other comprehensive loss   (23,331)   (19,836)
Total stockholders’ equity   9,258,368    9,395,869 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $11,051,854   $10,960,714 

 

The accompanying notes are an integral part of these financial statements.

 

F-2
 

 

ImmuCell Corporation

 

STATEMENTS OF OPERATIONS

 

   For the Years Ended December 31, 
   2014   2013   2012 
             
Product sales  $7,596,874   $6,007,176   $5,389,935 
Cost of goods sold   3,147,837    2,946,570    2,335,676 
Gross margin   4,449,037    3,060,606    3,054,259 
                
Product development expenses   2,179,079    1,154,200    917,600 
Sales and marketing expenses   1,317,122    986,766    973,217 
Administrative expenses   1,159,234    939,192    918,441 
Operating expenses   4,655,435    3,080,158    2,809,258 
                
NET OPERATING (LOSS) INCOME   (206,398)   (19,552)   245,001 
                
Other (expenses) revenues, net   (49,053)   224,812    (52,849)
                
(LOSS) INCOME BEFORE INCOME TAXES   (255,451)   205,260    192,152 
                
Income tax (benefit) expense   (88,292)   87,865    102,640 
                
NET (LOSS) INCOME  ($167,159)  $117,395   $89,512 
                
Weighted average common shares outstanding:               
Basic   3,027,001    3,019,407    3,018,296 
Diluted   3,027,001    3,085,048    3,108,419 
                
NET (LOSS) INCOME PER SHARE:               
Basic  ($0.06)  $0.04   $0.03 
Diluted  ($0.06)  $0.04   $0.03 

 

The accompanying notes are an integral part of these financial statements.

 

F-3
 

 

ImmuCell Corporation

 

STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

 

   For the Years Ended December 31, 
   2014   2013   2012 
Net (loss) income  ($167,159)  $117,395   $89,512 
Other comprehensive (loss) income:               
Interest rate swap, before taxes   (5,815)   50,384    (15,486)
Income tax applicable to interest rate swap   2,320    (20,100)   6,178 
Other comprehensive (loss) income, net of taxes   (3,495)   30,284    (9,308)
Total comprehensive (loss) income  ($170,654)  $147,679   $80,204 

 

The accompanying notes are an integral part of these financial statements.

 

F-4
 

 

ImmuCell Corporation

 

STATEMENTS OF STOCKHOLDERS’ EQUITY

 

                           Accumulated     
                           Other     
           Capital in               Comprehensive   Total 
   Common Stock   Excess of   Accumulated   Treasury Stock   (Loss)   Stockholders’ 
   Shares   Amount   Par Value   Deficit   Shares   Amount   Income   Equity 
BALANCE,                                
December 31, 2011   3,261,148   $326,115   $9,911,914   ($614,315)   257,114   ($562,469)  ($40,812)  $9,020,433 
                                         
Net income   0    0    0    89,512    0    0    0    89,512 
                                         
Other comprehensive (loss), net of taxes   0    0    0    0    0    0    (9,308)   (9,308)
                                         
Exercise of stock options   0    0    17,986    0    (15,000)   32,814    0    50,800 
                                         
Tax benefits related to stock options   0    0    7,261    0    0    0    0    7,261 
                                         
Stock-based compensation   0    0    35,985    0    0    0    0    35,985 
                                         
BALANCE,                                        
December 31, 2012   3,261,148    326,115    9,973,146    (524,803)   242,114    (529,655)   (50,120)   9,194,683 
                                         
Net income   0    0    0    117,395    0    0    0    117,395 
                                         
Other comprehensive income, net of taxes   0    0    0    0    0    0    30,284    30,284 
                                         
Exercise of stock options   0    0    6,436    0    (7,000)   15,314    0    21,750 
                                         
Tax benefits related to stock options   0    0    398    0    0    0    0    398 
                                         
Stock-based compensation   0    0    31,359    0    0    0    0    31,359 
                                         
BALANCE,                                        
December 31, 2013   3,261,148    326,115    10,011,339    (407,408)   235,114    (514,341)   (19,836)   9,395,869 
                                         
Net (loss)   0    0    0    (167,159)   0    0    0    (167,159)
                                         
Other comprehensive (loss), net of taxes   0    0    0    0    0    0    (3,495)   (3,495)
                                         
Exercise of stock options   0    0    962    0    (1,000)   2,187    0    3,149 
                                         
Stock-based compensation   0    0    30,004    0    0    0   5 0    30,004 
                                         
BALANCE,                                        
December 31, 2014   3,261,148   $326,115   $10,042,305   ($574,567)   234,114   ($512,154)  ($23,331)  $9,258,368 

 

The accompanying notes are an integral part of these financial statements.

 

F-5
 

 

ImmuCell Corporation

 

STATEMENTS OF CASH FLOWS

 

   For the Years Ended December 31, 
   2014   2013   2012 
CASH FLOWS FROM OPERATING ACTIVITIES:            
Net (loss) income  ($167,159)  $117,395   $89,512 
Adjustments to reconcile net (loss) income to net cash provided by operating activities:               
Depreciation   446,045    414,307    399,640 
Amortization   2,876    2,894    2,876 
Deferred income taxes   (88,590)   87,166    94,370 
Stock-based compensation   30,004    31,359    35,985 
Loss on disposal of fixed assets   4,519    35,179    12,265 
Changes in:               
Receivables   (373,882)   (20,056)   (227,558)
Inventory   260,753    442,494    17,463 
Prepaid expenses and other assets   2,548    45,917    (123,628)
Accounts payable and accrued expenses   178,560    (57,995)   51,715 
Deferred revenue   6,690    0    (8,250)
Net cash provided by operating activities   302,364    1,098,660    344,390 
                
CASH FLOWS FROM INVESTING ACTIVITIES:               
Purchase of property, plant and equipment   (1,535,558)   (597,697)   (275,395)
Maturities of short-term investments   2,985,000    2,489,000    4,178,000 
Purchases of short-term investments   (2,489,000)   (3,234,000)   (2,240,000)
Purchases of long-term investments   (496,000)   0    0 
Net cash (used for) provided by investing activities   (1,535,558)   (1,342,697)   1,662,605 
                
CASH FLOWS FROM FINANCING ACTIVITIES:               
Debt principal repayments   (190,312)   (181,445)   (172,853)
Proceeds from exercise of stock options   3,149    21,750    50,800 
Tax benefits related to stock options   0    398    7,261 
Net cash (used for) financing activities   (187,163)   (159,297)   (114,792)
                
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS   (1,420,357)   (403,334)   1,892,203 
                
BEGINNING CASH AND CASH EQUIVALENTS   2,270,385    2,673,719    781,516 
                
ENDING CASH AND CASH EQUIVALENTS  $850,028   $2,270,385   $2,673,719 
                
INCOME TAXES PAID  $252   $0   $708 
                
INTEREST EXPENSE PAID  $58,413   $67,015   $75,681 
                
NON-CASH ACTIVITIES:               
Capital expenditures included in accounts payable and accrued expenses  $251,383   $23,495   $4,550 
Net change in fair value of interest rate swap  $3,495   ($30,284)  $9,308 

 

The accompanying notes are an integral part of these financial statements.

 

F-6
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements

 

1. BUSINESS OPERATIONS

 

ImmuCell Corporation (the Company) is a growing animal health company whose purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. The Company was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987, in conjunction with its initial public offering of common stock. The Company has developed products that provide significant, immediate immunity to newborn dairy and beef cattle and is in the late stages of developing a new product that addresses mastitis, the most significant cause of economic loss to the dairy industry. The Company is subject to certain risks associated with its stage of development including dependence on key individuals, competition from other larger companies, the successful sale of existing products and the development and acquisition of additional commercially viable products with appropriate regulatory approvals, where applicable.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

(a) Basis of presentation

 

We have prepared the accompanying audited financial statements reflecting all adjustments, all of which are of a normal recurring nature, that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB Accounting Standards Codification™ (Codification). Certain prior year accounts have been reclassified to conform with the 2014 financial statement presentation.

 

(b) Cash, Cash Equivalents and Short-Term Investments

 

We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $567,000 and $1,770,000 at December 31, 2014 and 2013, respectively. Short-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than three months from their purchase dates and not more than twelve months from the balance sheet date and are held at different financial institutions that are insured by the FDIC, within the FDIC limits per financial institution. See Note 3.

 

(c) Inventory

 

Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or market (net realizable value). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. See Note 4.

 

(d) Trade Receivables

 

Trade receivables are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded as income when received. A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Interest is charged on past due trade receivables. See Note 5.

 

F-7
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements (continued)

 

(e) Property, Plant and Equipment

 

We depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The cost of our building (which was acquired in 1993) and the 2001 and 2007 additions thereto are being depreciated through 2023. We anticipate depreciating the building addition that was completed during the first quarter of 2015 over twenty-five years. Related building improvements are depreciated over ten year periods. Large and durable fixed assets are depreciated over their useful lives that are generally estimated to be ten years. Other fixed assets and computer equipment are depreciated over their useful lives that are generally estimated to be five and three years, respectively. See Note 7.

 

(f) Intangible Assets

 

We amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. In connection with certain credit facilities entered into during the third quarter of 2010, we incurred debt issue costs of $26,489, which costs are being amortized to other expenses, net over the terms of the credit facilities. See Notes 6 and 9.

 

We continually assess the realizability of these assets in accordance with the impairment provisions of Codification Topic 360, Accounting for the Impairment or Disposal of Long-Lived Assets. If an impairment review is triggered, we evaluate the carrying value of long-lived assets by determining if impairment exists based on estimated undiscounted future cash flows over the remaining useful life of the assets and comparing that value to the carrying value of the assets. If the carrying value of the asset is greater than the estimated future cash flows, the asset is written down to its estimated fair value. The cash flow estimates that are used contain our best estimates, using appropriate and customary assumptions and projections at the time. We also review the estimated useful life of intangible assets at the end of each reporting period, making any necessary adjustments.

 

(g) Disclosure of Fair Value of Financial Instruments and Concentration of Risk

 

Financial instruments consist mainly of cash, cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable, bank debt and an interest rate swap. Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, long-term investments and accounts receivable. We make short-term and long-term investments in financial instruments that are insured by the FDIC. We account for fair value measurements in accordance with Codification Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and requires additional disclosures about fair value measurements. The estimated fair value of cash, cash equivalents, short-term investments, long-term investments, accounts receivable and accounts payable approximate their carrying value due to their short maturities. The estimated fair value of bank debt approximates its carrying value because the interest rates are variable. The interest rate swap is carried at fair value. See Note 9.

 

Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area.

 

We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies.

 

F-8
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements (continued)

 

(h) Interest Rate Swap Agreement

 

All derivatives are recognized on the balance sheet at their fair value. We entered into an interest rate swap agreement in 2010. On the date the agreement was entered into, we designated the derivative as a hedge of the variability of cash flows to be paid related to our long-term debt. The agreement has been determined to be highly effective in hedging the variability of identified cash flows, so changes in the fair market value of the interest rate swap agreement are recorded as comprehensive (loss) income, until earnings are affected by the variability of cash flows (e.g. when periodic settlements on a variable-rate asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreement and the related hedged items. We also formally assess, both at this interest rate swap agreement’s inception and on an ongoing basis, whether the agreement is highly effective in offsetting changes in cash flow of hedged items. See Note 9.

 

(i) Revenue Recognition

 

We recognize revenue in accordance with Staff Accounting Bulletin (SAB) No. 104, “Revenue Recognition”, which supersedes SAB No. 101, “Revenue Recognition in Financial Statements”. SAB No. 104 requires that four criteria are met before revenue is recognized. These include i) persuasive evidence that an arrangement exists, ii) delivery has occurred or services have been rendered, iii) the seller’s price is fixed and determinable and iv) collectability is reasonably assured. We recognize revenue at the time of shipment (including to distributors) for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably assured. We recognize service revenue at the time the service is performed.

 

(j) Expense Recognition

 

Advertising costs are expensed when incurred, which is generally during the month in which the advertisement is published. Advertising expenses amounted to $66,193, $151,080 and $174,314 during the years ended December 31, 2014, 2013 and 2012, respectively. All product development expenses are expensed as incurred, as are all related patent costs.

 

(k) Income Taxes

 

We account for income taxes in accordance with Codification Topic 740, Income Taxes, which requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. We believe it is more likely than not that the deferred tax assets will be realized through future taxable income and future tax effects of temporary differences between book income and taxable income. Accordingly, we have not established a valuation allowance for the deferred tax assets. Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. We have evaluated the positions taken on our filed tax returns. We have concluded that no uncertain tax positions exist as of December 31, 2014. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 11.

 

(l) Stock-Based Compensation

 

We account for stock-based compensation in accordance with Codification Topic 718, Compensation-Stock Compensation, which generally requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model, as detailed in Note 12(a). Accordingly, we recorded $30,004, $31,359, and $35,985 of compensation expense pertaining to stock-based compensation, which resulted in a decrease (increase) in income (loss) before income taxes of approximately $0.01 per share during the years ended December 31, 2014, 2013 and 2012, respectively. Codification Topic 718 requires us to reflect gross tax savings resulting from tax deductions in excess of expense reflected in our financial statements as a financing cash flow.

 

F-9
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements (continued)

 

(m) Net (Loss) Income Per Common Share

 

Net (Loss) Income per common share has been computed in accordance with Codification Topic 260-10, Earnings Per Share. The Net (Loss) per common share has been computed by dividing the Net (Loss) by the weighted average number of common shares outstanding during the period, without giving consideration to outstanding stock options because the impact would be anti-dilutive. The basic Net Income per share has been computed by dividing Net Income by the weighted average number of common shares outstanding during this period. Diluted Net Income per share has been computed by dividing Net Income by the weighted average number of shares outstanding during the period plus all outstanding stock options with an exercise price that is less than the average market price of the common stock during the period less the number of shares that could have been repurchased at this average market price with the proceeds from the hypothetical stock option exercises.

 

   Year Ended December 31, 
   2014   2013   2012 
Weighted average number of shares outstanding   3,027,001    3,019,407    3,018,296 
Effect of dilutive stock options   0    65,641    90,123 
Diluted number of shares outstanding   3,027,001    3,085,048    3,108,419 
Outstanding stock options not included in the calculation because the effect would be anti-dilutive   253,000    63,875    39,750 

 

For additional disclosures regarding the outstanding common stock options, see Note 12(a).

 

(n) Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual amounts could differ from those estimates.

 

(o) New Accounting Pronouncements

 

We adopted Accounting Standards Update (ASU) No. 2011-05, Presentation of Comprehensive Income (Loss) (Topic 220) during the three-month period ended March 31, 2012, and retrospective application was required. Under ASU 2011-05, we have the option to present the total of comprehensive (loss) income, the components of net (loss) income, and the components of other comprehensive (loss) income either in a single continuous statement of comprehensive (loss) income or in two separate but consecutive statements. We elected to present two separate but consecutive statements. The statements of other comprehensive (loss) income immediately follow the statements of operations and include the components of other comprehensive (loss) income and a total for other comprehensive (loss) income, along with a total for comprehensive (loss) income. The adoption of Topic 220 only impacts the presentation of the financial statements.

 

In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. ASU 2014-09 is effective for the Company on January 1, 2017. Early application is not permitted. ASU 2014-09 permits the use of either the retrospective or cumulative effect transition method. We have evaluated the effect that ASU 2014-09 would have on our financial statements and related disclosures. We expect that ASU 2014-09 will have no significant effect on our ongoing financial reporting, but we continue to evaluate this pending accounting standard.

 

F-10
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements (continued)

 

3. CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND LONG-TERM INVESTMENTS

 

Cash, cash equivalents, short-term investments and long-term investments consisted of the following:

 

   As of December 31,   (Decrease) 
   2014   2013   Increase 
Cash and cash equivalents  $850,028   $2,270,385   ($1,420,357)
Short-term investments   2,489,000    2,985,000    (496,000)
Subtotal   3,339,028    5,255,385    (1,916,357)
Long-term investments   496,000    0    496,000 
Total  $3,835,028   $5,255,385   ($1,420,357)

 

4. INVENTORY

 

Inventory consisted of the following:

 

   As of December 31,   Increase 
   2014   2013   (Decrease) 
Raw materials  $306,444   $270,355   $36,089 
Work-in-process   355,745    783,060    (427,315)
Finished goods   283,566    153,093    130,473 
Total  $945,755   $1,206,508   ($260,753)

 

5. ACCOUNTS RECEIVABLE

 

Accounts receivable consisted of the following:

 

   As of December 31,   Increase 
   2014   2013   (Decrease) 
Trade accounts receivable, gross  $1,004,990   $609,638   $395,352 
Accumulated allowance for bad debt and product returns   (16,194)   (13,952)   (2,242)
Trade accounts receivable, net   988,796    595,686    393,110 
Other receivables   16,496    35,676    (19,180)
Income taxes receivable   0    48    (48)
Accounts receivable, net  $1,005,292   $631,410   $373,882 

 

6. PREPAID EXPENSES AND OTHER ASSETS

 

Prepaid expenses and other assets consisted of the following:

 

   As of December 31,   (Decrease) 
   2014   2013   Increase 
Prepaid expenses and other assets  $133,119   $159,117   ($25,998)
Security deposits   15,280    0    15,280 
Current subtotal   148,399    159,117    (10,718)
                
Debt issue costs   26,489    26,489    0 
Accumulated amortization of debt issue costs   (16,479)   (13,603)   (2,876)
Security deposits   8,920    750    8,170 
Long-term subtotal   18,930    13,636    5,294 
                
Total  $167,329   $172,753   ($5,424)

 

F-11
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements (continued)

 

7. PROPERTY, PLANT AND EQUIPMENT

 

Property, plant and equipment consisted of the following, at cost:

 

   As of December 31,   Increase 
   2014   2013   (Decrease) 
Laboratory and manufacturing equipment  $3,522,465   $3,182,686   $339,779 
Building and improvements   2,969,891    2,940,239    29,652 
Office furniture and equipment   470,607    354,243    116,364 
Construction in progress(1)   1,270,672    9,600    1,261,072 
Land   50,000    50,000    0 
Property, plant and equipment, gross   8,283,635    6,536,768    1,746,867 
Accumulated depreciation   (4,445,988)   (4,012,003)   (433,985)
Property, plant and equipment, net  $3,837,647   $2,524,765   $1,312,882 

 

(1) As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015.

 

8. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses consisted of the following:

 

   As of December 31,   Increase 
   2014   2013   (Decrease) 
Accounts payable – capital  $251,383   $23,496   $227,887 
Accounts payable – trade   204,810    199,716    5,094 
Accrued payroll   145,176    75,310    69,866 
Accrued clinical studies   131,945    0    131,945 
Accrued professional fees   42,250    50,500    (8,250)
Accrued other   76,113    96,207    (20,094)
Total  $851,677   $445,229   $406,448 

 

F-12
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements (continued)

 

9. BANK DEBT

 

During the third quarter of 2010, we agreed to terms of certain credit facilities with TD Bank, N.A. (a wholly owned subsidiary of TD Financial Group, which is a multinational bank with approximately $944 billion in assets and over 22 million clients world wide) aggregating up to approximately $2,100,000, which are secured by substantially all of our assets. These credit facilities are comprised of a $1,000,000 ten-year mortgage loan, a $600,000 fifty-four month note and a $500,000 line of credit, which is renewable annually. Proceeds from the $1,000,000 mortgage were received during the third quarter of 2010. Based on a 15-year amortization schedule, a balloon principal payment of $451,885 will be due in the third quarter of 2020. We hedged our interest rate exposure on this mortgage loan with an interest rate swap agreement that effectively converted a floating interest rate based on the London Interbank Offered Rate (LIBOR) of 3.41% as of December 31, 2014 to the fixed rate of 6.04%. All derivatives are recognized on the balance sheet at their fair value. The agreement has been determined to be highly effective in hedging the variability of the identified cash flows and has been designated as a cash flow hedge of the variability in the hedged interest payments. Changes in the fair value of the interest rate swap agreement are recorded in other comprehensive (loss) income, net of taxes. The original notional amount of the interest rate swap agreement of $1,000,000 amortizes in accordance with the amortization of the mortgage loan. The notional amount of the interest rate swap was $799,964 as of December 31, 2014. Payments required by the interest rate swap totaled $22,116, $23,096 and $23,903 during the years ended December 31, 2014, 2013 and 2012, respectively. As the result of our decision to hedge this interest rate risk, we recorded other comprehensive (loss) income, net of taxes, in the amount of ($3,495), $30,284, and ($9,308) during the years ended December 31, 2014, 2013 and 2012, respectively, which reflects the change in fair value of the interest rate swap (liability) asset, net of taxes. The fair value of the interest rate swap has been determined using observable market-based inputs or unobservable inputs that are corroborated by market data. Accordingly, the interest rate swap is classified as level 2 within the fair value hierarchy provided in Codification Topic 820, Fair Value Measurements and Disclosures. Proceeds from the $600,000 note were received during the first quarter of 2011. Interest on the note is variable at the higher of 4.25% per annum or the LIBOR plus 3.25% per annum. As of December 31, 2014, the effective interest rate on this note was 4.25%. The $500,000 line of credit is available as needed and has been extended through May 31, 2015 and is renewable annually thereafter. The line of credit was unused as of December 31, 2014 and 2013. Interest on any borrowings against the line of credit would be variable at the higher of 4.25% per annum or the LIBOR plus 3.5% per annum. These credit facilities are subject to certain financial covenants. We are in compliance with all applicable covenants as of December 31, 2014. Principal payments due under debt outstanding as of December 31, 2014 are reflected in the following table by the year that payments are due:

 

Period  $1,000,000
mortgage		   $600,000
note		   Total 
Year ending December 31, 2015  $54,044   $96,338   $150,382 
Year ending December 31, 2016   57,384    0    57,384 
Year ending December 31, 2017   61,056    0    61,056 
Year ending December 31, 2018   64,876    0    64,876 
Year ending December 31, 2019   68,908    0    68,908 
After December 31, 2019   493,696    0    493,696 
Total  $799,964   $96,338   $896,302 

 

10. OTHER (EXPENSES) REVENUES, NET

 

Other (expenses) revenues, net, consisted of the following:

 

   Year Ended December 31, 
   2014   2013   2012 
License option fee(1)  $0   $250,000   $0 
Royalty income   0    (3,000)   15,166 
Interest income   15,552    12,493    17,202 
Interest expense   (57,827)   (66,689)   (75,274)
Debt issuance amortization   (2,876)   (2,894)   (2,876)
Other gains (losses)   (3,902)   34,902    (7,067)
Other (expenses) revenues, net  ($49,053)  $224,812   ($52,849)

 

(1) During the second quarter of 2013, we received a $250,000 exclusive option fee from a prospective partner for the development and marketing of Mast Out®. This payment was recorded as deferred revenue upon receipt. During the third quarter of 2013, this prospective partner decided not to execute a license after its final due diligence. Accordingly, the deferred revenue was recognized during the third quarter of 2013. At the same time, $47,604 in capitalized expenses pertaining to the development of Mast Out® were written off.

 

F-13
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements (continued)

 

11. INCOME TAXES

 

Our income tax (benefit) expense aggregated ($88,292), $87,865 and $102,640 (amounting to 35%, 43% and 53% of the (loss) income before income taxes, respectively) for the years ended December 31, 2014, 2013 and 2012, respectively. The income tax provision consisted of the following:

 

   Year Ended December 31, 
   2014   2013   2012 
Current  $252   $301   $708 
                
Federal   (77,986)   74,713    89,788 
State   (10,558)   12,851    12,144 
Deferred   (88,544)   87,564    101,932 
Total  ($88,292)  $87,865   $102,640 

 

The actual income tax (benefit) expense differs from the expected tax computed by applying the U.S. federal corporate tax rate of 34% to income before income tax as follows:

 

   Year Ended December 31, 
   2014   2013   2012 
Computed expected tax (benefit) expense  ($86,853)  $69,788   $65,332 
State income taxes, net of federal (benefit) expense   (6,968)   8,482    8,015 
Share-based compensation   10,201    10,526    9,766 
Research and development tax credit   (19,405)   (21,887)   (10,813)
Other   14,733    20,956    30,340 
Total income tax (benefit) expense  ($88,292)  $87,865   $102,640 

 

The significant components of our deferred tax asset consisted of the following:

 

   As of December 31, 
   2014   2013 
Product rights  $130,036   $165,527 
Property, plant and equipment   225,229    52,094 
Research and development tax credit   266,078    235,567 
Federal net operating loss carryforward   464,998    525,012 
State net operating loss carryforward   165,901    201,698 
Interest rate swap   15,486    13,166 
Prepaid expenses and other   (6,925)   (23,171)
Deferred tax asset  $1,260,803   $1,169,893 

 

We have a state net operating loss carryforward of approximately $1,858,000 that expires in 2028 through 2031, if not utilized before then, and a federal net operating loss carryforward of approximately $1,368,000 that expires in 2029 through 2031, if not utilized before then. The $965,000 licensing payment that we made during the fourth quarter of 2004 was treated as an intangible asset and is being amortized over 15 years, for tax return purposes only. Approximately $1,112,000 of our investment to produce pharmaceutical-grade Nisin for Mast Out® was expensed as incurred for our books. Included in this amount is approximately $820,000 ($65,000 during the fourth quarter of 2013 and $755,000 during the year ended December 31, 2014) that will be capitalized and depreciated over statutory periods for tax return purposes only.

 

F-14
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements (continued)

 

Deferred tax assets are recognized only when it is probable that sufficient taxable income will be available in future periods against which deductible temporary differences and credits may be utilized. However, the amount of the deferred tax asset could be reduced if projected income is not achieved due to various factors, such as unfavorable business conditions. If projected income is not expected to be achieved, we would decrease the deferred tax asset to the amount that we believe can be realized.

 

Net operating loss carryforwards, credits, and other tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the event of a change in ownership, as defined.

 

The Company files income tax returns in the U.S. federal jurisdiction and several state jurisdictions. With few exceptions, the Company is no longer subject to income tax examinations by tax authorities for years before 2011. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying financial statements.

 

12. STOCKHOLDERS’ EQUITY

 

(a) Stock Option Plans

 

In June 2000, our stockholders approved the 2000 Stock Option and Incentive Plan (the “2000 Plan”) pursuant to the provisions of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of the Company’s common stock at i) no less than fair market value on the date of grant in the case of incentive stock options and ii) no less than 85% of fair market value on the date of grant in the case of non-qualified stock options. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case by case basis. Originally, 250,000 shares of common stock were reserved for issuance under the 2000 Plan. The stockholders of the Company approved an increase in this number to 500,000 shares in June 2001. All options granted under the 2000 Plan expire no later than ten years from the date of grant. The 2000 Plan expired in February 2010, after which date no further options could be granted under the 2000 Plan. However, outstanding options under the 2000 Plan may be exercised in accordance with their terms.

 

In June 2010, our stockholders approved the 2010 Stock Option and Incentive Plan (the “2010 Plan”) pursuant to the provisions of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of the Company’s common stock at i) no less than fair market value on the date of grant in the case of incentive stock options and ii) no less than 85% of fair market value on the date of grant in the case of non-qualified stock options. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case by case basis. At that time, 300,000 shares of common stock were reserved for issuance under the 2010 Plan. All options granted under the 2010 Plan expire no later than ten years from the date of grant.

 

F-15
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements (continued)

 

Activity under the stock option plans described above was as follows:

 

   2000 Plan   2010 Plan   Weighted Average Exercise Price   Aggregate Intrinsic Value 
Outstanding at December 31, 2011   186,500    49,500   $3.19   $344,000 
Grants   0    2,000   $5.93      
Terminations   (8,000)   (2,000)  $4.75      
Exercises   (15,000)   0   $3.39      
Outstanding at December 31, 2012   163,500    49,500   $3.13   $185,000 
Grants   0    26,000   $4.67      
Terminations   0    (1,000)  $3.15      
Exercises   (6,000)   (1,000)  $3.11      
Outstanding at December 31, 2013   157,500    73,500   $3.30   $223,000 
Grants   0    25,000   $4.69      
Terminations   0    (2,000)  $5.75      
Exercises   0    (1,000)  $3.15      
Outstanding at December 31, 2014   157,500    95,500   $3.42   $364,000 
                     
Exercisable at December 31, 2014   157,500    42,500   $3.08   $357,000 
                     
Reserved for future grants   0    202,500           

 

During the year ended December 31, 2014, one employee exercised stock options covering 1,000 shares. These options were exercised for cash, resulting in total proceeds of $3,149. During the year ended December 31, 2013, four employees exercised stock options covering the aggregate of 7,000 shares. These options were exercised for cash, resulting in total proceeds of $21,750. During the year ended December 31, 2012, one employee exercised 15,000 stock options. These options were exercised for cash, resulting in total proceeds of $50,800. At December 31, 2014, 253,000 shares of common stock were reserved for future issuance under all outstanding stock options described above, and an additional 202,500 shares of common stock were reserved for the potential issuance of stock options in the future under the 2010 Plan. The weighted average remaining life of the options outstanding under the 2000 Plan and the 2010 Plan as of December 31, 2014 was approximately four years and nine months. The weighted average remaining life of the options exercisable under these plans as of December 31, 2014 was approximately four years. The exercise prices of the options outstanding as of December 31, 2014 ranged from $1.70 to $7.00 per share. The 25,000 stock options granted during 2014 had exercise prices between $4.25 and $4.80 per share. The 26,000 stock options granted during 2013 had exercise prices between $4.15 and $4.69 per share. The 2,000 stock options granted during 2012 had exercise prices between $5.61 and $6.25 per share. The aggregate intrinsic value of options exercised during 2014, 2013 and 2012 approximated $1,000, $8,000 and $25,000, respectively. The weighted-average grant date fair values of options granted during 2014, 2013 and 2012 were $2.26, $2.23 and $2.86 per share, respectively. As of December 31, 2014, total unrecognized stock-based compensation related to non-vested stock options aggregated $95,560. That cost is expected to be recognized at a declining rate over the remaining vesting period of the outstanding non-vested stock options, including $26,778 during 2015. The fair value of each stock option grant has been estimated on the date of grant by an independent appraiser using the Black-Scholes option pricing model, for the purpose discussed in Note 2(l), with the following weighted-average assumptions:

 

   2014   2013   2012 
Risk-free interest rate   2.0%   1.6%   0.97%
Dividend yield   0%   0%   0%
Expected volatility   49%   49%   48.7%
Expected life   6 years    6 years    6.5 years 

 

The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term, while the other assumptions are derived from averages of our historical data.

 

F-16
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements (continued)

 

(b) Common Stock Rights Plan

 

In September 1995, our Board of Directors adopted a Common Stock Rights Plan (The Rights Plan) and declared a dividend of one common share purchase right (a “Right”) for each of the then outstanding shares of the common stock of the Company. Each Right entitles the registered holder to purchase from the Company one share of common stock at an initial purchase price of $70.00 per share, subject to adjustment. The description and terms of the Rights are set forth in a Rights Agreement between the Company and American Stock Transfer & Trust Co., as Rights Agent.

 

The Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being called the Distribution Date).

 

Upon the Distribution Date, the holder of each Right not owned by the Acquiring Person would be entitled to purchase common stock at a discount to the initial purchase price of $70.00 per share, effectively equal to one half of the market price of a share of common stock on the date the Acquiring Person becomes an Acquiring Person. If, after the Distribution Date, the Company should consolidate or merge with any other entity and the Company were not the surviving company, or, if the Company were the surviving company, all or part of the Company’s common stock were changed or exchanged into the securities of any other entity, or if more than 50% of the Company’s assets or earning power were sold, each Right would entitle its holder to purchase, at the Rights’ then-current purchase price, a number of shares of the acquiring company’s common stock having a market value at that time equal to twice the Right’s exercise price.

 

At any time after a person or group becomes an Acquiring Person and prior to the acquisition by such person or group of 50% or more of the outstanding common stock, the Board of Directors of the Company may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment). At any time prior to 14 days following the date that any person or group becomes an Acquiring Person (subject to extension by the Board of Directors), the Board of Directors of the Company may redeem the then outstanding Rights in whole, but not in part, at a price of $0.005 per Right, subject to adjustment.

 

On June 8, 2005, our Board of Directors voted to authorize an amendment of the Rights Agreement to extend the Final Expiration Date by an additional three years, to September 19, 2008. As of June 30, 2005, we entered into an amendment to the Rights Agreement with the Rights Agent reflecting such extension. On June 6, 2008 our Board of Directors voted to authorize an amendment of the Rights Agreement to extend the Final Expiration Date by an additional three years, to September 19, 2011 and to increase the ownership threshold for determining “Acquiring Person” status from 15% to 18%. As of June 30, 2008, we entered into an amendment to the Rights Agreement with the Rights Agent reflecting such extension and threshold increase. On August 5, 2011, our Board of Directors voted to authorize amendments of the Rights Agreement to extend the Final Expiration Date by an additional three years to September 19, 2014 and to increase the ownership threshold for determining “Acquiring Person” status from 18% to 20%. As of August 9, 2011, we entered into an amendment to the Rights Agreement with the Rights Agent reflecting such extension and threshold increase. On June 10, 2014, our Board of Directors voted to authorize an amendment to the Rights Agreement to extend the final expiration date by an additional three years to September 19, 2017. As of June 16, 2014, we entered into an amendment to the Rights Agreement with the Rights Agent reflecting such extension. No other changes have been made to the terms of the Rights or the Rights Agreement.

 

Our Board of Directors believes that there is some risk that the potential value of the Mast Out® product development initiative is not fairly reflected in the market price of our common stock, as it fluctuates from time to time, and that opportunistic buyers could take advantage of that disparity to the detriment of our stockholders. If this were to happen and result in a potential threat through an unsolicited acquisition effort or otherwise, our Board of Directors feels that the Rights Plan could enhance stockholder value by providing management with negotiating leverage.

 

F-17
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements (continued)

 

13. COMMITMENTS AND CONTINGENT LIABILITIES

 

Our bylaws, as amended, in effect provide that the Company will indemnify its officers and directors to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings to each director through a separate indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically unlimited and is impossible to determine. We maintain directors’ and officers’ liability insurance, which may provide reimbursement to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification obligations were grandfathered under the provisions of Codification Topic 460, Guarantees. Accordingly, we have recorded no liability for such obligations as of December 31, 2014. Since our incorporation, we have had no occasion to make any indemnification payment to any of our officers or directors for any reason.

 

As of December 31, 2014 we had committed to contracts and purchase orders covering approximately $326,000 related to our 7,100 square foot facility addition and an additional $550,000 principally related to the production of inventory.

 

We enter into agreements with third parties in the ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging any of these indemnification obligations, and based on our analysis of the nature of the risks involved, we believe that the fair value of these agreements is minimal. Accordingly, we have recorded no liabilities for such obligations as of December 31, 2014.

 

The development, manufacturing and marketing of animal health care products entails an inherent risk that liability claims will be asserted against us. We feel that we have reasonable levels of liability insurance to support our operations.

 

14. SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION

 

We principally operate in the business segment described in Note 1. Pursuant to Codification Topic 280, Segment Reporting, we operate in one reportable business segment, that being the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Almost all of our internally funded product development expenses are in support of such products. The significant accounting policies of this segment are described in Note 2.

 

Our primary customers for the majority of our product sales (83%, 83% and 80% for the years ended December 31, 2014, 2013 and 2012, respectively) are in the U.S. dairy and beef industries. Product sales to international customers, who are also in the dairy and beef industries, aggregated 13%, 14% and 16% of our total product sales for the years ended December 31, 2014, 2013 and 2012, respectively. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:

 

   Year Ended December 31, 
   2014   2013   2012 
Animal Health International, Inc.   38%   38%   35%
MWI Veterinary Supply Company(1)   23%   22%   20%

 

(1) Assumes that the November 2013 acquisition of IVESCO by MWI had occurred as of the beginning of the periods being reported.

 

F-18
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements (continued)

 

Accounts receivable due from significant customers amounted to the percentages of total trade accounts receivable as detailed in the following table:

 

   As of December 31, 
   2014   2013 
Animal Health International, Inc.   45%   39%
MWI Veterinary Supply Company   26%   26%
Robert J. Matthews Company   *    10%

 

*Amount is less than 10%.

 

15. RELATED PARTY TRANSACTIONS

 

Dr. David S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc. (formerly Stearns Veterinary Outlet, Inc.), a domestic distributor of ImmuCell products (First Defense®, Wipe Out® Dairy Wipes, and CMT) and of J-t Enterprises of Melrose, Inc., an exporter. His affiliated companies purchased $426,358, $395,042 and $326,513 of products from ImmuCell during the years ended December 31, 2014, 2013 and 2012, respectively, on terms consistent with those offered to other distributors of similar status. We made marketing-related payments of $7,330, $6,010 and $1,000 to these affiliate companies during the years ended December 31, 2014, 2013 and 2012, respectively. Our accounts receivable (subject to standard and customary payment terms) due from these affiliated companies aggregated $18,796 and $31,445 as of December 31, 2014 and 2013, respectively.

 

16. EMPLOYEE BENEFITS

 

We have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum amount allowed by the Internal Revenue Service. Prior to August 2012 we matched 50% of each employee’s contribution to the plan up to a maximum match of 4% of each employee’s base compensation. Since August 2012 we have matched 100% of the first 3% of each employee’s salary that is contributed to the Plan and 50% of the next 2% of each employee’s salary that is contributed to the Plan. Under this matching plan, we paid $65,633, $56,036 and $51,145 into the plan for the years ended December 31, 2014, 2013 and 2012, respectively.

 

F-19
 

 

ImmuCell Corporation

 

Notes to Audited Financial Statements (continued)

 

17. UNAUDITED QUARTERLY FINANCIAL DATA

 

The following tables present the quarterly information for the years ended December 31, 2014, 2013 and 2012, respectively:

 

   Three Months Ended 
   March 31   June 30   September 30   December 31 
Fiscal 2014:                
Product sales  $2,081,752   $1,539,719   $1,770,129   $2,205,275 
Gross margin   1,149,895    878,523    1,077,896    1,342,722 
Product development expenses   594,209    760,672    361,232    462,965 
Net operating income (loss)   12,561    (458,667)   40,853    198,856 
Net (loss) income   (13,335)   (294,781)   10,330    130,626 
Net (loss) income per common share:                    
Basic  ($0.00)  ($0.10)  $0.00   $0.04 
Diluted  ($0.00)  ($0.10)  $0.00   $0.04 
                     
Fiscal 2013:                    
Product sales  $1,846,734   $1,366,493   $1,234,701   $1,559,248 
Gross margin   1,053,567    783,677    615,717    607,644 
Product development expenses   266,479    271,858    290,853    325,010 
Net operating income (loss)   326,666    23,722    (159,967)   (209,975)
Net income (loss)   204,310    6,452    57,336    (150,703)
Net income (loss) per common share:                    
Basic  $0.07   $0.00   $0.02   ($0.05)
Diluted  $0.07   $0.00   $0.02   ($0.05)
                     
Fiscal 2012:                    
Product sales  $1,717,109   $1,175,126   $1,076,749   $1,420,951 
Gross margin   1,012,568    670,518    620,958    750,215 
Product development expenses   247,807    211,706    223,771    234,316 
Net operating income (loss)   281,233    37,397    (86,126)   12,497 
Net income (loss)   154,761    15,187    (63,574)   (16,862)
Net income (loss) per common share:                    
Basic  $0.05   $0.01   ($0.02)  ($0.01)
Diluted  $0.05   $0.01   ($0.02)  ($0.01)

 

18. SUBSEQUENT EVENTS

 

We have adopted the disclosure provisions of Codification Topic 855-10-50-1, Subsequent Events, which provides guidance to establish general standards of accounting for and disclosures of events that occur after the balance sheet date but before financial statements are issued. Entities are required to disclose the date through which subsequent events were evaluated as well as the rationale for why that date was selected. This disclosure should alert all users of financial statements that an entity has not evaluated subsequent events after that date in the set of financial statements being presented. Codification Topic 855-10-50-1 requires additional disclosures only, and therefore did not have an impact on our financial condition, results of operations, earnings per share or cash flows. Public entities must evaluate subsequent events through the date that financial statements are issued. Accordingly, we have evaluated subsequent events through the time of filing on March 26, 2015, the date we have issued this Annual Report on Form 10-K.

 

F-20
 

 

ImmuCell Corporation

 

Signatures

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ImmuCell Corporation
  Registrant
   
Date: March 26, 2015 By: /s/ Michael F. Brigham
   

Michael F. Brigham

President, Chief Executive Officer and
Principal Financial Officer

 

POWER OF ATTORNEY

 

We, the undersigned directors of ImmuCell Corporation, hereby severally constitute and appoint Michael F. Brigham our true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for us and in our stead, in any and all capacities, to sign any and all amendments to this report and all documents relating thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing necessary or advisable to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or to be done by virtue hereof.

 

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Date: March 18, 2015 By: /s/ Michael F. Brigham
    Michael F. Brigham, President,
Chief Executive Officer,
Principal Financial Officer and Director
     
Date: March 18, 2015 By: /s/ Joseph H. Crabb
    Joseph H. Crabb, Ph.D., Director
     
Date: March 18, 2015 By: /s/ David S. Cunningham
    David S. Cunningham, Director
     
Date: March 18, 2015 By: /s/ Linda Rhodes
    Linda Rhodes, VMD, Ph.D., Director
     
Date: March 18, 2015 By: /s/ Jonathan E. Rothschild
    Jonathan E. Rothschild, Director
     
Date: March 18, 2015 By: /s/ David S. Tomsche
    David S. Tomsche, DVM, Director
     
Date: March 18, 2015 By: /s/ Paul R. Wainman
    Paul R. Wainman, Director

 

 
 

 

ImmuCell Corporation

 

EXHIBIT INDEX

 

Exhibit 23 Consent of Baker Newman & Noyes, LLC    
       
Exhibit 31 Certifications required by Rule 13a-14(a)    
       
Exhibit 32 Certification pursuant to Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002    
       
101.INS XBRL Instance Document.    
       
101.SCH XBRL Taxonomy Extension Schema Document.    
       
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document.    
       
101.DEF XBRL Taxonomy Extension Definition Linkbase Document.    
       
101.LAB XBRL Taxonomy Extension Label Linkbase Document.    
       
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document.    
       

 

 

 
 EX-23 2 f10k2014ex23_immucellcorp.htm CONSENT OF BAKER NEWMAN & NOYES, LLC

ImmuCell Corporation

 

EXHIBIT 23

CONSENT OF BAKER NEWMAN & NOYES, LLC

 

 

CONSENT OF INDEPENDENT Registered Public Accounting Firm

 

 

To the Board of Directors

ImmuCell Corporation

 

 

We consent to the incorporation by reference in Registration Statement No. 333-02631, No. 333-65514 and No. 333-167721 on Form S-8 of ImmuCell Corporation of our report, dated March 26, 2015, relating to our audit of the financial statements which appears in this Annual Report on Form 10-K of ImmuCell Corporation for the year ended December 31, 2014.

 

 

Portland, Maine   /s/ Baker Newman & Noyes
March 26, 2015   Limited Liability Company
     
     
     

 

 

 EX-31 3 f10k2014ex31_immucellcorp.htm CERTIFICATION

ImmuCell Corporation

 

EXHIBIT 31

CERTIFICATIONS REQUIRED BY RULE 13a-14(a)

 

I, Michael F. Brigham, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of ImmuCell Corporation (the Company);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

 

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Company is made known to me by others within the Company, particularly during the period in which this report is being prepared;

 

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s Board of Directors (or persons performing the equivalent functions):

 

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

 

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

Date: March 26, 2015

 

/s/ Michael F. Brigham    
Michael F. Brigham    
President, Chief Executive Officer and Principal Financial Officer  
     
     

 

 

 EX-32 4 f10k2014ex32_immucellcorp.htm CERTIFICATION

ImmuCell Corporation

 

EXHIBIT 32

CERTIFICATION REQUIRED BY SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K of ImmuCell Corporation (the “Company”) for the period ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael F. Brigham, President, Chief Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the Exchange Act); and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition, results of operations and cash flows of the Company.

 

This certification is provided pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (Item 601(b)(32)) promulgated under the Securities Act of 1933, as amended (the Securities Act), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

/s/ Michael F. Brigham    
Michael F. Brigham    
President, Chief Executive Officer and Principal Financial Officer  
March 26, 2015    
     

 

 

A signed original of this written statement required by Section 906 has been provided to ImmuCell Corporation and will be retained by ImmuCell Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

 

 EX-101.INS 5 iccc-20141231.xml XBRL INSTANCE FILE 0000811641 iccc:PlanTwoThoushandMember 2000-06-30 0000811641 iccc:PlanTwoThoushandMember 2000-06-01 2000-06-30 0000811641 iccc:PlanTwoThoushandAndTenMember 2000-06-01 2000-06-30 0000811641 iccc:PlanTwoThoushandMember 2001-06-30 0000811641 us-gaap:IndefinitelivedIntangibleAssetsMember 2004-10-01 2004-12-31 0000811641 iccc:PlanTwoThoushandAndTenMember 2010-06-30 0000811641 us-gaap:MortgagesMember 2010-07-01 2010-09-30 0000811641 iccc:NotePayableMember 2010-07-01 2010-09-30 0000811641 2010-09-30 0000811641 us-gaap:MortgagesMember 2010-09-30 0000811641 iccc:NotePayableMember 2010-09-30 0000811641 us-gaap:LineOfCreditMember 2010-09-30 0000811641 us-gaap:InterestRateSwapMember 2010-09-30 0000811641 2011-01-01 2011-03-31 0000811641 us-gaap:MaximumMember 2011-08-09 0000811641 us-gaap:MinimumMember 2011-08-09 0000811641 us-gaap:MaximumMember 2011-09-19 0000811641 us-gaap:MinimumMember 2011-09-19 0000811641 2011-12-31 0000811641 iccc:PlanTwoThoushandMember 2011-12-31 0000811641 iccc:PlanTwoThoushandAndTenMember 2011-12-31 0000811641 us-gaap:CommonStockMember 2011-12-31 0000811641 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000811641 us-gaap:RetainedEarningsMember 2011-12-31 0000811641 us-gaap:TreasuryStockMember 2011-12-31 0000811641 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-12-31 0000811641 2012-01-01 2012-03-31 0000811641 2012-04-01 2012-06-30 0000811641 2012-07-01 2012-09-30 0000811641 2012-10-01 2012-12-31 0000811641 2012-01-01 2012-12-31 0000811641 iccc:PlanTwoThoushandMember 2012-01-01 2012-12-31 0000811641 iccc:PlanTwoThoushandAndTenMember 2012-01-01 2012-12-31 0000811641 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0000811641 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0000811641 us-gaap:RetainedEarningsMember 2012-01-01 2012-12-31 0000811641 us-gaap:TreasuryStockMember 2012-01-01 2012-12-31 0000811641 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-01-01 2012-12-31 0000811641 us-gaap:SalesRevenueNetMember iccc:PrimaryCustomersMember 2012-01-01 2012-12-31 0000811641 us-gaap:SalesRevenueNetMember iccc:ForeignCustomersMember 2012-01-01 2012-12-31 0000811641 iccc:MwiVeterinarySupplyCompanyMember 2012-01-01 2012-12-31 0000811641 iccc:AnimalHealthInternationalIncMember 2012-01-01 2012-12-31 0000811641 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-12-31 0000811641 2012-12-31 0000811641 iccc:PlanTwoThoushandMember 2012-12-31 0000811641 iccc:PlanTwoThoushandAndTenMember 2012-12-31 0000811641 us-gaap:CommonStockMember 2012-12-31 0000811641 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0000811641 us-gaap:RetainedEarningsMember 2012-12-31 0000811641 us-gaap:TreasuryStockMember 2012-12-31 0000811641 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-12-31 0000811641 2013-01-01 2013-03-31 0000811641 2013-04-01 2013-06-30 0000811641 2013-07-01 2013-09-30 0000811641 2013-10-01 2013-12-31 0000811641 2013-01-01 2013-12-31 0000811641 iccc:PlanTwoThoushandMember 2013-01-01 2013-12-31 0000811641 iccc:PlanTwoThoushandAndTenMember 2013-01-01 2013-12-31 0000811641 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0000811641 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0000811641 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0000811641 us-gaap:TreasuryStockMember 2013-01-01 2013-12-31 0000811641 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-01-01 2013-12-31 0000811641 us-gaap:SalesRevenueNetMember iccc:PrimaryCustomersMember 2013-01-01 2013-12-31 0000811641 us-gaap:SalesRevenueNetMember iccc:ForeignCustomersMember 2013-01-01 2013-12-31 0000811641 iccc:MwiVeterinarySupplyCompanyMember 2013-01-01 2013-12-31 0000811641 iccc:AnimalHealthInternationalIncMember 2013-01-01 2013-12-31 0000811641 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-12-31 0000811641 2013-12-31 0000811641 iccc:PlanTwoThoushandMember 2013-12-31 0000811641 iccc:PlanTwoThoushandAndTenMember 2013-12-31 0000811641 us-gaap:CommonStockMember 2013-12-31 0000811641 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000811641 us-gaap:RetainedEarningsMember 2013-12-31 0000811641 us-gaap:TreasuryStockMember 2013-12-31 0000811641 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0000811641 iccc:MwiVeterinarySupplyCompanyMember 2013-12-31 0000811641 iccc:AnimalHealthInternationalIncMember 2013-12-31 0000811641 iccc:RobertJMatthewsCompanyMember 2013-12-31 0000811641 2014-01-01 2014-03-31 0000811641 2014-04-01 2014-06-30 0000811641 2014-06-30 0000811641 2014-07-01 2014-09-30 0000811641 2014-10-01 2014-12-31 0000811641 2014-01-01 2014-12-31 0000811641 iccc:PlanTwoThoushandMember 2014-01-01 2014-12-31 0000811641 iccc:PlanTwoThoushandAndTenMember 2014-01-01 2014-12-31 0000811641 iccc:NotePayableMember 2014-01-01 2014-12-31 0000811641 us-gaap:LineOfCreditMember 2014-01-01 2014-12-31 0000811641 us-gaap:InterestRateSwapMember 2014-01-01 2014-12-31 0000811641 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0000811641 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0000811641 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0000811641 us-gaap:TreasuryStockMember 2014-01-01 2014-12-31 0000811641 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-12-31 0000811641 us-gaap:SalesRevenueNetMember iccc:PrimaryCustomersMember 2014-01-01 2014-12-31 0000811641 us-gaap:SalesRevenueNetMember iccc:ForeignCustomersMember 2014-01-01 2014-12-31 0000811641 iccc:MwiVeterinarySupplyCompanyMember 2014-01-01 2014-12-31 0000811641 iccc:AnimalHealthInternationalIncMember 2014-01-01 2014-12-31 0000811641 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0000811641 us-gaap:ManufacturingFacilityMember 2014-01-01 2014-12-31 0000811641 us-gaap:BuildingImprovementsMember 2014-01-01 2014-12-31 0000811641 us-gaap:OfficeEquipmentMember 2014-01-01 2014-12-31 0000811641 us-gaap:ConstructionInProgressMember 2014-01-01 2014-12-31 0000811641 us-gaap:LandMember 2014-01-01 2014-12-31 0000811641 us-gaap:StateAndLocalJurisdictionMember 2014-01-01 2014-12-31 0000811641 us-gaap:DomesticCountryMember 2014-01-01 2014-12-31 0000811641 iccc:BuildingAdditionMember 2014-01-01 2014-12-31 0000811641 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2014-01-01 2014-12-31 0000811641 us-gaap:ComputerEquipmentMember 2014-01-01 2014-12-31 0000811641 us-gaap:OtherAssetsMember 2014-01-01 2014-12-31 0000811641 us-gaap:SalesRevenueNetMember 2014-01-01 2014-12-31 0000811641 us-gaap:InvestmentIncomeMember 2014-01-01 2014-12-31 0000811641 2014-12-31 0000811641 iccc:PlanTwoThoushandMember 2014-12-31 0000811641 iccc:PlanTwoThoushandAndTenMember 2014-12-31 0000811641 us-gaap:MortgagesMember 2014-12-31 0000811641 us-gaap:InterestRateSwapMember 2014-12-31 0000811641 us-gaap:MaximumMember 2014-12-31 0000811641 us-gaap:MinimumMember 2014-12-31 0000811641 us-gaap:CommonStockMember 2014-12-31 0000811641 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000811641 us-gaap:RetainedEarningsMember 2014-12-31 0000811641 us-gaap:TreasuryStockMember 2014-12-31 0000811641 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000811641 iccc:MwiVeterinarySupplyCompanyMember 2014-12-31 0000811641 iccc:AnimalHealthInternationalIncMember 2014-12-31 0000811641 iccc:RobertJMatthewsCompanyMember 2014-12-31 0000811641 us-gaap:StateAndLocalJurisdictionMember 2014-12-31 0000811641 us-gaap:DomesticCountryMember 2014-12-31 0000811641 us-gaap:NotesPayableToBanksMember 2014-12-31 0000811641 2013-10-01 2014-12-31 0000811641 us-gaap:InvestmentIncomeMember 2013-10-01 2014-12-31 0000811641 2015-03-18 iso4217:USD xbrli:shares iso4217:USDxbrli:shares xbrli:pure utr:sqft IMMUCELL CORP /DE/ 0000811641 --12-31 Smaller Reporting Company ICCC 10-K false 2014-12-31 FY 2014 No No Yes 9582000 3028034 781516 2673719 2270385 850028 2985000 2489000 1206508 945755 631410 1005292 159117 148399 15212 30463 7267632 5468937 2524765 3837647 1154681 1230340 0 496000 13636 18930 10960714 11051854 445229 851677 190390 150382 0 6690 635619 1008749 896224 745920 33002 38817 929226 784737 1564845 1793486 326115 326115 10011339 10042305 -407408 -574567 514341 512154 -19836 -23331 9020433 326115 9911914 -614315 -562469 -40812 9194683 326115 9973146 -524803 -529655 -50120 9395869 326115 10011339 -407408 -514341 -19836 9258368 326115 10042305 -574567 -512154 -23331 10960714 11051854 8000000 8000000 0.10 0.10 3261148 3261148 235114 234114 1717109 1175126 1076749 1420951 5389935 1846734 1366493 1234701 1559248 6007176 2081752 1539719 1770129 2205275 7596874 2335676 2946570 3147837 1012568 670518 620958 750215 3054259 1053567 783677 615717 607644 3060606 1149895 878523 1077896 1342722 4449037 247807 211706 223771 234316 917600 266479 271858 290853 325010 1154200 594209 760672 361232 462965 2179079 973217 986766 1317122 918441 939192 1159234 2809258 3080158 4655435 281233 37397 -86126 12497 245001 326666 23722 -159967 -209975 -19552 12561 -458667 40853 198856 -206398 52849 -224812 49053 192152 205260 -255451 102640 87865 -88292 154761 15187 -63574 -16862 89512 0 0 89512 0 0 204310 6452 57336 -150703 117395 0 0 117395 0 0 -13335 -294781 10330 130626 -167159 0 0 -167159 0 0 3018296 3019407 3027001 3108419 3085048 3027001 0.05 0.01 -0.02 -0.01 0.03 0.07 0.00 0.02 -0.05 0.04 -0.00 -0.10 0.00 0.04 -0.06 0.05 0.01 -0.02 -0.01 0.03 0.07 0.00 0.02 -0.05 0.04 -0.00 -0.10 0.00 0.04 -0.06 -15486 50384 -5815 6178 -20100 2320 -9308 30284 -3495 80204 147679 -170654 3261148 257114 3261148 242114 3261148 235114 3261148 234114 -9308 0 0 0 0 -9308 30284 0 0 0 0 30284 -3495 0 0 0 0 -3495 50800 17986 0 32814 0 21750 6436 0 15314 0 3149 962 0 2187 0 -15000 0 0 -15000 15000 -6000 -1000 0 -7000 7000 0 -1000 0 -1000 1000 7261 0 7261 0 0 0 398 0 398 0 0 0 35985 0 35985 0 0 0 31359 0 31359 0 0 0 30004 0 30004 0 0 0 399640 414307 446045 2876 2894 2876 101932 87564 -88544 35985 31359 30004 -12265 -35179 -4519 227558 20056 373882 -17463 -442494 -260753 123628 -45917 -2548 51715 -57995 178560 -8250 0 6690 344390 1098660 302364 275395 597697 1535558 4178000 2489000 2985000 2240000 3234000 2489000 0 0 496000 1662605 -1342697 -1535558 172853 181445 190312 50800 50800 21750 21750 3149 3149 7261 398 0 -114792 -159297 -187163 1892203 -403334 -1420357 708 0 252 75681 67015 58413 4550 23495 251383 9308 -30284 3495 <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>1.</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>BUSINESS OPERATIONS</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">ImmuCell Corporation (the Company) is a growing animal health company whose purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. The Company was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987, in conjunction with its initial public offering of common stock. The Company has developed products that provide significant, immediate immunity to newborn dairy and beef cattle and is in the late stages of developing a new product that addresses mastitis, the most significant cause of economic loss to the dairy industry. The Company is subject to certain risks associated with its stage of development including dependence on key individuals, competition from other larger companies, the successful sale of existing products and the development and acquisition of additional commercially viable products with appropriate regulatory approvals, where applicable.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>2.</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: justify; text-indent: 0px;"><b>(a)</b></td><td style="padding: 0px; text-align: justify; text-indent: 0px;"><b>Basis of presentation</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We have prepared the accompanying audited financial statements reflecting all adjustments, all of which are of a normal recurring nature, that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB<i>&#160;Accounting Standards Codification</i>&#8482; (Codification). Certain prior year accounts have been reclassified to conform with the 2014 financial statement presentation.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(b)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Cash, Cash Equivalents and Short-Term Investments</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $567,000 and $1,770,000 at December 31, 2014 and 2013, respectively. Short-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than three months from their purchase dates and not more than twelve months from the balance sheet date and are held at different financial institutions that are insured by the FDIC, within the FDIC limits per financial institution. See Note 3.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: justify; text-indent: 0px;"><b>(c)</b></td><td style="padding: 0px; text-align: justify; text-indent: 0px;"><b>Inventory</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or market (net realizable value). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. See Note 4.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(d)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Trade Receivables</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Trade receivables are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded as income when received. A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Interest is charged on past due trade receivables. See Note 5.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(e)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Property, Plant and Equipment</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The cost of our building (which was acquired in 1993) and the 2001 and 2007 additions thereto are being depreciated through 2023. We anticipate depreciating the building addition that was completed during the first quarter of 2015 over twenty-five years. Related building improvements are depreciated over ten year periods. Large and durable fixed assets are depreciated over their useful lives that are generally estimated to be ten years. Other fixed assets and computer equipment are depreciated over their useful lives that are generally estimated to be five and three years, respectively. See Note 7.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(f)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Intangible Assets</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. In connection with certain credit facilities entered into during the third quarter of 2010, we incurred debt issue costs of $26,489, which costs are being amortized to other expenses, net over the terms of the credit facilities. See Notes 6 and 9.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We continually assess the realizability of these assets in accordance with the impairment provisions of Codification Topic 360,&#160;<i>Accounting for the Impairment or Disposal of Long-Lived Assets</i>. If an impairment review is triggered, we evaluate the carrying value of long-lived assets by determining if impairment exists based on estimated undiscounted future cash flows over the remaining useful life of the assets and comparing that value to the carrying value of the assets. If the carrying value of the asset is greater than the estimated future cash flows, the asset is written down to its estimated fair value. The cash flow estimates that are used contain our best estimates, using appropriate and customary assumptions and projections at the time. We also review the estimated useful life of intangible assets at the end of each reporting period, making any necessary adjustments.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(g)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Disclosure of Fair Value of Financial Instruments and Concentration of Risk</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Financial instruments consist mainly of cash, cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable, bank debt and an interest rate swap. Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, long-term investments and accounts receivable. We make short-term and long-term investments in financial instruments that are insured by the FDIC. We account for fair value measurements in accordance with Codification Topic 820,&#160;<i>Fair Value Measurements and Disclosures</i>, which defines fair value, establishes a framework for measuring fair value and requires additional disclosures about fair value measurements. The estimated fair value of cash, cash equivalents, short-term investments, long-term investments, accounts receivable and accounts payable approximate their carrying value due to their short maturities. The estimated fair value of bank debt approximates its carrying value because the interest rates are variable. The interest rate swap is carried at fair value. See Note 9.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(h)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Interest Rate Swap Agreement</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">All derivatives are recognized on the balance sheet at their fair value. We entered into an interest rate swap agreement in 2010. On the date the agreement was entered into, we designated the derivative as a hedge of the variability of cash flows to be paid related to our long-term debt. The agreement has been determined to be highly effective in hedging the variability of identified cash flows, so changes in the fair market value of the interest rate swap agreement are recorded as comprehensive (loss) income, until earnings are affected by the variability of cash flows (e.g. when periodic settlements on a variable-rate asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreement and the related hedged items. We also formally assess, both at this interest rate swap agreement&#8217;s inception and on an ongoing basis, whether the agreement is highly effective in offsetting changes in cash flow of hedged items. See Note 9.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(i)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Revenue Recognition</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We recognize revenue in accordance with Staff Accounting Bulletin (SAB) No. 104, &#8220;Revenue Recognition&#8221;, which supersedes SAB No. 101, &#8220;Revenue Recognition in Financial Statements&#8221;. SAB No. 104 requires that four criteria are met before revenue is recognized. These include i) persuasive evidence that an arrangement exists, ii) delivery has occurred or services have been rendered, iii) the seller&#8217;s price is fixed and determinable and iv) collectability is reasonably assured. We recognize revenue at the time of shipment (including to distributors) for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably assured. We recognize service revenue at the time the service is performed.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(j)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Expense Recognition</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Advertising costs are expensed when incurred, which is generally during the month in which the advertisement is published. Advertising expenses amounted to $66,193, $151,080 and $174,314 during the years ended December 31, 2014, 2013 and 2012, respectively. All product development expenses are expensed as incurred, as are all related patent costs.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(k)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Income Taxes</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We account for income taxes in accordance with Codification Topic 740,&#160;<i>Income Taxes</i>,<i>&#160;</i>which requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. We believe it is more likely than not that the deferred tax assets will be realized through future taxable income and future tax effects of temporary differences between book income and taxable income. Accordingly, we have not established a valuation allowance for the deferred tax assets. Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. We have evaluated the positions taken on our filed tax returns. We have concluded that no uncertain tax positions exist as of December 31, 2014. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 11.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(l)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Stock-Based Compensation</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We account for stock-based compensation in accordance with Codification Topic 718,&#160;<i>Compensation-Stock Compensation</i>, which generally requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model, as detailed in Note 12(a). Accordingly, we recorded $30,004, $31,359, and $35,985 of compensation expense pertaining to stock-based compensation, which resulted in a decrease (increase) in income (loss) before income taxes of approximately $0.01 per share during the years ended December 31, 2014, 2013 and 2012, respectively. Codification Topic 718 requires us to reflect gross tax savings resulting from tax deductions in excess of expense reflected in our financial statements as a financing cash flow.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(m)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Net (Loss) Income Per Common Share</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Net (Loss) Income per common share has been computed in accordance with Codification Topic 260-10,&#160;<i>Earnings Per Share.&#160;</i>The Net (Loss) per common share has been computed by dividing the Net (Loss) by the weighted average number of common shares outstanding during the period, without giving consideration to outstanding stock options because the impact would be anti-dilutive. The basic Net Income per share has been computed by dividing Net Income by the weighted average number of common shares outstanding during this period. Diluted Net Income per share has been computed by dividing Net Income by the weighted average number of shares outstanding during the period plus all outstanding stock options with an exercise price that is less than the average market price of the common stock during the period less the number of shares that could have been repurchased at this average market price with the proceeds from the hypothetical stock option exercises.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Year Ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">Weighted average number of shares outstanding</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; font-size: 10pt;">3,027,001</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; font-size: 10pt;">3,019,407</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; font-size: 10pt;">3,018,296</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Effect of dilutive stock options</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">65,641</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">90,123</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">Diluted number of shares outstanding</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,027,001</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,085,048</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,108,419</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; font-size: 10pt;">Outstanding stock options not included in the calculation because the effect would be anti-dilutive</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">253,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">63,875</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">39,750</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">For additional disclosures regarding the outstanding common stock options, see Note 12(a).</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(n)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Use of Estimates</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual amounts could differ from those estimates.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-indent: 0px;"><b>(o)</b></td><td style="padding: 0px; text-indent: 0px;"><b>New Accounting Pronouncements</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We adopted Accounting Standards Update (ASU) No. 2011-05,&#160;<i>Presentation of Comprehensive Income (Loss)</i>&#160;(Topic 220) during the three-month period ended March 31, 2012, and retrospective application was required. Under ASU 2011-05, we have the option to present the total of comprehensive (loss) income, the components of net (loss) income, and the components of other comprehensive (loss) income either in a single continuous statement of comprehensive (loss) income or in two separate but consecutive statements. We elected to present two separate but consecutive statements. The statements of other comprehensive (loss) income immediately follow the statements of operations and include the components of other comprehensive (loss) income and a total for other comprehensive (loss) income, along with a total for comprehensive (loss) income. The adoption of Topic 220 only impacts the presentation of the financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2014, the FASB issued Accounting Standards Update No. 2014-09,&#160;<i>Revenue from Contracts with Customers&#160;</i>(ASU 2014-09), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. ASU 2014-09 is effective for the Company on January 1, 2017. Early application is not permitted. ASU 2014-09 permits the use of either the retrospective or cumulative effect transition method. We have evaluated the effect that ASU 2014-09 would have on our financial statements and related disclosures. We expect that ASU 2014-09 will have no significant effect on our ongoing financial reporting, but we continue to evaluate this pending accounting standard.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-indent: 0px;"><b>3.</b></td><td style="padding: 0px; text-align: justify; text-indent: 0px;"><b>CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND LONG-TERM INVESTMENTS</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Cash, cash equivalents, short-term investments and long-term investments consisted of the following:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">As of December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;" colspan="2">(Decrease)</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Increase</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">Cash and cash equivalents</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">850,028</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">2,270,385</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">($</td><td style="width: 141px; text-align: right; font-size: 10pt;">1,420,357</td><td style="width: 15px; text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Short-term investments</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">2,489,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">2,985,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(496,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Subtotal</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">3,339,028</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,255,385</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(1,916,357</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Long-term investments</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">496,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">496,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Total</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,835,028</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">5,255,385</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">($</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,420,357</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">)</td></tr></table></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-indent: 0px;"><b>4.</b></td><td style="padding: 0px; text-indent: 0px;"><b>INVENTORY</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Inventory consisted of the following:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">As of December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;" colspan="2">Increase</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Decrease)</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: justify; font-size: 10pt;">Raw materials</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">306,444</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">270,355</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">36,089</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">Work-in-process</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">355,745</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">783,060</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(427,315</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Finished goods</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">283,566</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">153,093</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">130,473</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Total</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">945,755</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,206,508</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">($</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">260,753</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">)</td></tr></table></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: justify; text-indent: 0px;"><b>5.</b></td><td style="padding: 0px; text-align: justify; text-indent: 0px;"><b>ACCOUNTS RECEIVABLE</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accounts receivable consisted of the following:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">As of December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;" colspan="2">Increase</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Decrease)</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">Trade accounts receivable, gross</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">1,004,990</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">609,638</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">395,352</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Accumulated allowance for bad debt and product returns</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(16,194</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(13,952</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(2,242</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Trade accounts receivable, net</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">988,796</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">595,686</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">393,110</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Other receivables</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">16,496</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">35,676</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(19,180</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Income taxes receivable</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">48</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(48</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Accounts receivable, net</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,005,292</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">631,410</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">373,882</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr></table></div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: justify; text-indent: 0px;"><b>6.</b></td><td style="padding: 0px; text-align: justify; text-indent: 0px;"><b>PREPAID EXPENSES AND OTHER ASSETS</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">Prepaid expenses and other assets consisted of the following:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">As of December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;" colspan="2">(Decrease)</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Increase</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">Prepaid expenses and other assets</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">133,119</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">159,117</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">($</td><td style="width: 141px; text-align: right; font-size: 10pt;">25,998</td><td style="width: 15px; text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Security deposits</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">15,280</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">15,280</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;">Current subtotal</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">148,399</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">159,117</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(10,718</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Debt issue costs</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">26,489</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">26,489</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Accumulated amortization of debt issue costs</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(16,479</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(13,603</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(2,876</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Security deposits</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">8,920</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">750</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">8,170</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;">Long-term subtotal</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">18,930</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">13,636</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">5,294</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Total</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">167,329</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">172,753</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">($</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">5,424</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">)</td></tr></table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: justify; text-indent: 0px;"><b>7.</b></td><td style="padding: 0px; text-align: justify; text-indent: 0px;"><b>PROPERTY, PLANT AND EQUIPMENT</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Property, plant and equipment consisted of the following, at cost:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">As of December 31,</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;" colspan="2">Increase</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2014</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2013</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">(Decrease)</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1003px; text-align: left; font-stretch: normal;">Laboratory and manufacturing equipment</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;">3,522,465</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">3,182,686</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">339,779</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">Building and improvements</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">2,969,891</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">2,940,239</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">29,652</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Office furniture and equipment</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">470,607</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">354,243</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">116,364</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Construction in progress<sup>(1)</sup></font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">1,270,672</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">9,600</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">1,261,072</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">Land</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">50,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">50,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">0</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 10pt; font-stretch: normal;">Property, plant and equipment, gross</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">8,283,635</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">6,536,768</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">1,746,867</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Accumulated depreciation</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(4,445,988</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(4,012,003</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(433,985</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; padding-left: 10pt; font-stretch: normal;">Property, plant and equipment, net</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">3,837,647</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">2,524,765</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">1,312,882</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><sup>&#160;</sup></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><sup>(1)&#160;</sup>As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015.</p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: justify; text-indent: 0px;"><b>8.</b></td><td style="padding: 0px; text-align: justify; text-indent: 0px;"><b>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accounts payable and accrued expenses consisted of the following:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">As of December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;" colspan="2">Increase</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Decrease)</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">Accounts payable &#8211; capital</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">251,383</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">23,496</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">227,887</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Accounts payable &#8211; trade</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">204,810</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">199,716</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,094</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Accrued payroll</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">145,176</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">75,310</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">69,866</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Accrued clinical studies</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">131,945</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">131,945</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Accrued professional fees</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">42,250</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">50,500</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(8,250</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Accrued other</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">76,113</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">96,207</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(20,094</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Total</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">851,677</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">445,229</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">406,448</td></tr></table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>9.</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>BANK DEBT</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; font-stretch: normal;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; text-indent: 0.5in; font-stretch: normal;">During the third quarter of 2010, we agreed to terms of certain credit facilities with TD Bank, N.A. (a wholly owned subsidiary of TD Financial Group, which is a multinational bank with approximately $944 billion in assets and over 22 million clients world wide) aggregating up to approximately $2,100,000, which are secured by substantially all of our assets. These credit facilities are comprised of a $1,000,000 ten-year mortgage loan, a $600,000 fifty-four month note and a $500,000 line of credit, which is renewable annually. Proceeds from the $1,000,000 mortgage were received during the third quarter of 2010. Based on a 15-year amortization schedule, a balloon principal payment of $451,885 will be due in the third quarter of 2020. We hedged our interest rate exposure on this mortgage loan with an interest rate swap agreement that effectively converted a floating interest rate based on the London Interbank Offered Rate (LIBOR) of 3.41% as of December 31, 2014 to the fixed rate of 6.04%. All derivatives are recognized on the balance sheet at their fair value. The agreement has been determined to be highly effective in hedging the variability of the identified cash flows and has been designated as a cash flow hedge of the variability in the hedged interest payments. Changes in the fair value of the interest rate swap agreement are recorded in other comprehensive (loss) income, net of taxes. The original notional amount of the interest rate swap agreement of $1,000,000 amortizes in accordance with the amortization of the mortgage loan. The notional amount of the interest rate swap was $799,964 as of December 31, 2014. Payments required by the interest rate swap totaled $22,116, $23,096 and $23,903 during the years ended December 31, 2014, 2013 and 2012, respectively. As the result of our decision to hedge this interest rate risk, we recorded other comprehensive (loss) income, net of taxes, in the amount of ($3,495), $30,284, and ($9,308) during the years ended December 31, 2014, 2013 and 2012, respectively, which reflects the change in fair value of the interest rate swap (liability) asset, net of taxes. The fair value of the interest rate swap has been determined using observable market-based inputs or unobservable inputs that are corroborated by market data. Accordingly, the interest rate swap is classified as level 2 within the fair value hierarchy provided in Codification Topic 820,&#160;<i>Fair Value Measurements and Disclosures</i>. Proceeds from the $600,000 note were received during the first quarter of 2011. Interest on the note is variable at the higher of 4.25% per annum or the LIBOR plus 3.25% per annum. As of December 31, 2014, the effective interest rate on this note was 4.25%. The $500,000 line of credit is available as needed and has been extended through May 31, 2015 and is renewable annually thereafter. The line of credit was unused as of December 31, 2014 and 2013. Interest on any borrowings against the line of credit would be variable at the higher of 4.25% per annum or the LIBOR plus 3.5% per annum. These credit facilities are subject to certain financial covenants. We are in compliance with all applicable covenants as of December 31, 2014. Principal payments due under debt outstanding as of December 31, 2014 are reflected in the following table by the year that payments are due:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; font-stretch: normal;">&#160;</p><table style="width: 1567px; border-collapse: collapse;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Period</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">$1,000,000&#160;<br />mortgage</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">$600,000<br />note</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: justify; font-size: 10pt;">Year ending December 31, 2015</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">54,044</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">96,338</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">150,382</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">Year ending December 31, 2016</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">57,384</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">57,384</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; font-size: 10pt;">Year ending December 31, 2017</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">61,056</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">61,056</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">Year ending December 31, 2018</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">64,876</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">64,876</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; font-size: 10pt;">Year ending December 31, 2019</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">68,908</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">68,908</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt; font-size: 10pt;">After December 31, 2019</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">493,696</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">493,696</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 10pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Total</td><td style="font: 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">799,964</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">96,338</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">896,302</td></tr></table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="text-align: justify; padding: 0px; text-indent: 0px; width: 0.5in;"><b>10.</b></td><td style="text-align: justify; padding: 0px; text-indent: 0px;"><b>OTHER (EXPENSES) REVENUES, NET</b></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: left; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: left; text-indent: 36pt;">Other (expenses) revenues, net, consisted of the following:</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: left; text-indent: 36pt;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center;">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; font-size: 10pt; text-align: left;">License option fee<sup>(1)</sup></td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt; text-align: left;">$</td><td style="width: 142px; font-size: 10pt; text-align: right;">0</td><td style="width: 16px; font-size: 10pt; text-align: left;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt; text-align: left;">$</td><td style="width: 141px; font-size: 10pt; text-align: right;">250,000</td><td style="width: 15px; font-size: 10pt; text-align: left;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt; text-align: left;">$</td><td style="width: 141px; font-size: 10pt; text-align: right;">0</td><td style="width: 15px; font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left;">Royalty income</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">0</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">(3,000</td><td style="font-size: 10pt; text-align: left;">)</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">15,166</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-size: 10pt; text-align: left;">Interest income</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">15,552</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">12,493</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">17,202</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left;">Interest expense</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">(57,827</td><td style="font-size: 10pt; text-align: left;">)</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">(66,689</td><td style="font-size: 10pt; text-align: left;">)</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">(75,274</td><td style="font-size: 10pt; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-size: 10pt; text-align: left;">Debt issuance amortization</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">(2,876</td><td style="font-size: 10pt; text-align: left;">)</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">(2,894</td><td style="font-size: 10pt; text-align: left;">)</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">(2,876</td><td style="font-size: 10pt; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt;">Other gains (losses)</td><td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">(3,902</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">34,902</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">(7,067</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-size: 10pt; text-align: left; padding-bottom: 4pt;">Other (expenses) revenues, net</td><td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">($</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">49,053</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">)</td><td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">224,812</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">($</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">52,849</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">)</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: left;"><b>&#160;</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><sup>(1)</sup>&#160;During the second quarter of 2013, we received a $250,000 exclusive option fee from a prospective partner for the development and marketing of&#160;<b>Mast Out<sup>&#174;</sup></b>. This payment was recorded as deferred revenue upon receipt. During the third quarter of 2013, this prospective partner decided not to execute a license after its final due diligence. Accordingly, the deferred revenue was recognized during the third quarter of 2013. At the same time, $47,604 in capitalized expenses pertaining to the development of&#160;<b>Mast Out<sup>&#174;&#160;</sup></b>were written off.</p> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>11.</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>INCOME TAXES</b></td></tr></table><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: justify; text-indent: 36pt; font-size-adjust: none; font-stretch: normal;">Our income tax (benefit) expense aggregated ($88,292), $87,865 and $102,640 (amounting to 35%, 43% and 53% of the (loss) income before income taxes, respectively) for the years ended December 31, 2014, 2013 and 2012, respectively. The income tax provision consisted of the following:</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</p><table style="width: 100%; border-collapse: collapse;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font: 10pt/normal times new roman, times, serif; text-align: center; font-size-adjust: none; font-stretch: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 64%; text-align: justify; padding-left: 10pt; font-size: 10pt;">Current</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-size: 10pt;">252</td><td style="width: 1%; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-size: 10pt;">301</td><td style="width: 1%; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-size: 10pt;">708</td><td style="width: 1%; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; font-size: 10pt;">Federal</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(77,986</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">74,713</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">89,788</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt; font-size: 10pt;">State</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(10,558</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">12,851</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">12,144</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;">Deferred</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(88,544</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">87,564</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">101,932</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Total</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">($</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">88,292</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">)</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">87,865</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">102,640</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: left; text-indent: 36pt; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: justify; text-indent: 36pt; font-size-adjust: none; font-stretch: normal;">The actual income tax (benefit) expense differs from the expected tax computed by applying the U.S. federal corporate tax rate of 34% to income before income tax as follows:</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: left; text-indent: 36pt; font-size-adjust: none; font-stretch: normal;">&#160;</p><table style="width: 100%; border-collapse: collapse;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font: 10pt/normal times new roman, times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 64%; text-align: left; font-size: 10pt;">Computed expected tax (benefit) expense</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt;">($</td><td style="width: 9%; text-align: right; font-size: 10pt;">86,853</td><td style="width: 1%; text-align: left; font-size: 10pt;">)</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-size: 10pt;">69,788</td><td style="width: 1%; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-size: 10pt;">65,332</td><td style="width: 1%; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">State income taxes, net of federal (benefit) expense</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(6,968</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">8,482</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">8,015</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Share-based compensation</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">10,201</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">10,526</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">9,766</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Research and development tax credit</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(19,405</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(21,887</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(10,813</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Other</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">14,733</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">20,956</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">30,340</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Total income tax (benefit) expense</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">($</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">88,292</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">)</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">87,865</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">102,640</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-indent: 36pt; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: justify; text-indent: 36pt; font-size-adjust: none; font-stretch: normal;">The significant components of our deferred tax asset consisted of the following:</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">&#160;</p><table style="width: 100%; border-collapse: collapse;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">As of December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 76%; text-align: justify; font-size: 10pt;">Product rights</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-size: 10pt;">130,036</td><td style="width: 1%; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-size: 10pt;">165,527</td><td style="width: 1%; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">Property, plant and equipment</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">225,229</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">52,094</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; font-size: 10pt;">Research and development tax credit</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">266,078</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">235,567</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">Federal net operating loss carryforward</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">464,998</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">525,012</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; font-size: 10pt;">State net operating loss carryforward</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">165,901</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">201,698</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">Interest rate swap</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">15,486</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">13,166</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 1.5pt; font-size: 10pt;">Prepaid expenses and other</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(6,925</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(23,171</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Deferred tax asset</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,260,803</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,169,893</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: left; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: justify; text-indent: 36pt; font-size-adjust: none; font-stretch: normal;">We have a state net operating loss carryforward of approximately $1,858,000 that expires in 2028 through 2031, if not utilized before then, and a federal net operating loss carryforward of approximately $1,368,000 that expires in 2029 through 2031, if not utilized before then. The $965,000 licensing payment that we made during the fourth quarter of 2004 was treated as an intangible asset and is being amortized over 15 years, for tax return purposes only. Approximately $1,112,000 of our investment to produce pharmaceutical-grade Nisin for <b>Mast Out<font style="font-family: symbol;"><sup>&#174;</sup></font></b> was expensed as incurred for our books. Included in this amount is approximately $820,000 ($65,000 during the fourth quarter of 2013 and $755,000 during the year ended December 31, 2014) that will be capitalized and depreciated over statutory periods for tax return purposes only.</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: left; text-indent: 36pt; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: justify; text-indent: 36pt; font-size-adjust: none; font-stretch: normal;">Deferred tax assets are recognized only when it is probable that sufficient taxable income will be available in future periods against which deductible temporary differences and credits may be utilized. However, the amount of the deferred tax asset could be reduced if projected income is not achieved due to various factors, such as unfavorable business conditions. If projected income is not expected to be achieved, we would decrease the deferred tax asset to the amount that we believe can be realized.</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: justify; text-indent: 36pt; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: justify; text-indent: 36pt; font-size-adjust: none; font-stretch: normal;">Net operating loss carryforwards, credits, and other tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the event of a change in ownership, as defined.</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: justify; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;">The Company files income tax returns in the U.S. federal jurisdiction and several state jurisdictions. With few exceptions, the Company is no longer subject to income tax examinations by tax authorities for years before 2011. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying financial statements.</p> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-align: left; text-indent: 0px; padding: 0px;"><b>12.</b></td><td style="text-align: left; text-indent: 0px; padding: 0px;"><b>STOCKHOLDERS&#8217; EQUITY</b></td></tr></table><p style="text-align: left; font: 10pt times new roman, times, serif; margin: 0px;">&#160;</p><table style="font: 10pt/normal times new roman, times, serif; width: 100%; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-align: left; text-indent: 0px; padding: 0px;"><b>(a)</b></td><td style="text-align: left; text-indent: 0px; padding: 0px;"><b>Stock Option Plans</b></td></tr></table><p style="text-align: left; font: 10pt times new roman, times, serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 0.5in;">In June 2000, our stockholders approved the 2000 Stock Option and Incentive Plan (the &#8220;2000 Plan&#8221;) pursuant to the provisions of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of the Company&#8217;s common stock at i) no less than fair market value on the date of grant in the case of incentive stock options and ii) no less than 85% of fair market value on the date of grant in the case of non-qualified stock options. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case by case basis. Originally, 250,000 shares of common stock were reserved for issuance under the 2000 Plan. The stockholders of the Company approved an increase in this number to 500,000 shares in June 2001. All options granted under the 2000 Plan expire no later than ten years from the date of grant. The 2000 Plan expired in February 2010, after which date no further options could be granted under the 2000 Plan. However, outstanding options under the 2000 Plan may be exercised in accordance with their terms.</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">In June 2010, our stockholders approved the 2010 Stock Option and Incentive Plan (the &#8220;2010 Plan&#8221;) pursuant to the provisions of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of the Company&#8217;s common stock at i) no less than fair market value on the date of grant in the case of incentive stock options and ii) no less than 85% of fair market value on the date of grant in the case of non-qualified stock options. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case by case basis. At that time, 300,000 shares of common stock were reserved for issuance under the 2010 Plan. All options granted under the 2010 Plan expire no later than ten years from the date of grant.</p><p style="text-align: left; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">&#160;</p><p style="text-align: left; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">Activity under the stock option plans described above was as follows:</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;"></p><table style="width: 100%; border-collapse: collapse;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: center; font: 10pt times new roman, times, serif;" colspan="2">2000 Plan</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: center; font: 10pt times new roman, times, serif;" colspan="2">2010 Plan</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: center; font: 10pt times new roman, times, serif;" colspan="2">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: center; font: 10pt times new roman, times, serif;" colspan="2">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 52%; font: 10pt times new roman, times, serif;">Outstanding at December 31, 2011</td><td style="width: 1%; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 9%; text-align: right; font: 10pt times new roman, times, serif;">186,500</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 9%; text-align: right; font: 10pt times new roman, times, serif;">49,500</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="width: 9%; text-align: right; font: 10pt times new roman, times, serif;">3.19</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="width: 9%; text-align: right; font: 10pt times new roman, times, serif;">344,000</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt times new roman, times, serif; padding-left: 10pt;">Grants</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">2,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">5.93</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt times new roman, times, serif; padding-left: 10pt;">Terminations</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">(8,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">(2,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">4.75</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif; padding-left: 10pt;">Exercises</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: right; font: 10pt times new roman, times, serif;">(15,000</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 1.5pt; text-align: right; font: 10pt times new roman, times, serif;">3.39</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: right;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt times new roman, times, serif;">Outstanding at December 31, 2012</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">163,500</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">49,500</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">3.13</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">185,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt times new roman, times, serif; padding-left: 10pt;">Grants</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">26,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">4.67</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt times new roman, times, serif; padding-left: 10pt;">Terminations</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">(1,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">3.15</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif; padding-left: 10pt;">Exercises</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: right; font: 10pt times new roman, times, serif;">(6,000</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: right; font: 10pt times new roman, times, serif;">(1,000</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 1.5pt; text-align: right; font: 10pt times new roman, times, serif;">3.11</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: right;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt times new roman, times, serif;">Outstanding at December 31, 2013</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">157,500</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">73,500</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">3.30</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">223,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt times new roman, times, serif; padding-left: 10pt;">Grants</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">25,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">4.69</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt times new roman, times, serif; padding-left: 10pt;">Terminations</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">(2,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">5.75</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif; padding-left: 10pt;">Exercises</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: right; font: 10pt times new roman, times, serif;">(1,000</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 1.5pt; text-align: right; font: 10pt times new roman, times, serif;">3.15</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: right;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">Outstanding at December 31, 2014</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: right; font: 10pt times new roman, times, serif;">157,500</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: right; font: 10pt times new roman, times, serif;">95,500</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 4pt; text-align: right; font: 10pt times new roman, times, serif;">3.42</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 4pt; text-align: right; font: 10pt times new roman, times, serif;">364,000</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">Exercisable at December 31, 2014</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: right; font: 10pt times new roman, times, serif;">157,500</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: right; font: 10pt times new roman, times, serif;">42,500</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 4pt; text-align: right; font: 10pt times new roman, times, serif;">3.08</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 4pt; text-align: right; font: 10pt times new roman, times, serif;">357,000</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">Reserved for future grants</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: right; font: 10pt times new roman, times, serif;">202,500</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt; text-align: right;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt; text-align: right;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt; text-align: left;">&#160;</td></tr></table><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">During the year ended December 31, 2014, one employee exercised stock options covering 1,000 shares. These options were exercised for cash, resulting in total proceeds of $3,149. During the year ended December 31, 2013, four employees exercised stock options covering the aggregate of 7,000 shares. These options were exercised for cash, resulting in total proceeds of $21,750. During the year ended December 31, 2012, one employee exercised 15,000 stock options. These options were exercised for cash, resulting in total proceeds of $50,800. At December 31, 2014, 253,000 shares of common stock were reserved for future issuance under all outstanding stock options described above, and an additional 202,500 shares of common stock were reserved for the potential issuance of stock options in the future under the 2010 Plan. The weighted average remaining life of the options outstanding under the 2000 Plan and the 2010 Plan as of December 31, 2014 was approximately four years and nine months. The weighted average remaining life of the options exercisable under these plans as of December 31, 2014 was approximately four years. The exercise prices of the options outstanding as of December 31, 2014 ranged from $1.70 to $7.00 per share. The 25,000 stock options granted during 2014 had exercise prices between $4.25 and $4.80 per share. The 26,000 stock options granted during 2013 had exercise prices between $4.15 and $4.69 per share. The 2,000 stock options granted during 2012 had exercise prices between $5.61 and $6.25 per share. The aggregate intrinsic value of options exercised during 2014, 2013 and 2012 approximated $1,000, $8,000 and $25,000, respectively. The weighted-average grant date fair values of options granted during 2014, 2013 and 2012 were $2.26, $2.23 and $2.86 per share, respectively. As of December 31, 2014, total unrecognized stock-based compensation related to non-vested stock options aggregated $95,560. That cost is expected to be recognized at a declining rate over the remaining vesting period of the outstanding non-vested stock options, including $26,778 during 2015. The fair value of each stock option grant has been estimated on the date of grant by an independent appraiser using the Black-Scholes option pricing model, for the purpose discussed in Note 2(l), with the following weighted-average assumptions:</p><p style="text-align: left; font: 10pt times new roman, times, serif; margin: 0px;">&#160;</p><table style="width: 100%; border-collapse: collapse;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center;">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center;" colspan="2">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center;" colspan="2">2013</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center;" colspan="2">2012</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-size: 10pt; width: 64%; text-align: left;">Risk-free interest rate</td><td style="font-size: 10pt; width: 1%;">&#160;</td><td style="font-size: 10pt; width: 1%; text-align: left;">&#160;</td><td style="font-size: 10pt; width: 9%; text-align: right;">2.0</td><td style="font-size: 10pt; width: 1%; text-align: left;">%</td><td style="font-size: 10pt; width: 1%;">&#160;</td><td style="font-size: 10pt; width: 1%; text-align: left;">&#160;</td><td style="font-size: 10pt; width: 9%; text-align: right;">1.6</td><td style="font-size: 10pt; width: 1%; text-align: left;">%</td><td style="font-size: 10pt; width: 1%;">&#160;</td><td style="font-size: 10pt; width: 1%; text-align: left;">&#160;</td><td style="font-size: 10pt; width: 9%; text-align: right;">0.97</td><td style="font-size: 10pt; width: 1%; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left;">Dividend yield</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">0</td><td style="font-size: 10pt; text-align: left;">%</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">0</td><td style="font-size: 10pt; text-align: left;">%</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">0</td><td style="font-size: 10pt; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-size: 10pt; text-align: left;">Expected volatility</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">49</td><td style="font-size: 10pt; text-align: left;">%</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">49</td><td style="font-size: 10pt; text-align: left;">%</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">48.7</td><td style="font-size: 10pt; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left;">Expected life</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">6 years</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">6 years</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">6.5 years</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr></table><p style="text-align: left; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term, while the other assumptions are derived from averages of our historical data.</p><p style="text-align: left; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">&#160;&#160;</p><table style="font: 10pt/normal times new roman, times, serif; width: 100%; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-align: justify; text-indent: 0px; padding: 0px;"><b>(b)</b></td><td style="text-align: justify; text-indent: 0px; padding: 0px;"><b>Common Stock Rights Plan</b></td></tr></table><p style="text-align: left; font: 10pt times new roman, times, serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 0.5in;">In September 1995, our Board of Directors adopted a Common Stock Rights Plan (The Rights Plan) and declared a dividend of one common share purchase right (a &#8220;Right&#8221;) for each of the then outstanding shares of the common stock of the Company. Each Right entitles the registered holder to purchase from the Company one share of common stock at an initial purchase price of $70.00 per share, subject to adjustment. The description and terms of the Rights are set forth in a Rights Agreement between the Company and American Stock Transfer &amp; Trust Co., as Rights Agent.</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">The Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being called the Distribution Date).</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 0.5in;">Upon the Distribution Date, the holder of each Right not owned by the Acquiring Person would be entitled to purchase common stock at a discount to the initial purchase price of $70.00 per share, effectively equal to one half of the market price of a share of common stock on the date the Acquiring Person becomes an Acquiring Person. If, after the Distribution Date, the Company should consolidate or merge with any other entity and the Company were not the surviving company, or, if the Company were the surviving company, all or part of the Company&#8217;s common stock were changed or exchanged into the securities of any other entity, or if more than 50% of the Company&#8217;s assets or earning power were sold, each Right would entitle its holder to purchase, at the Rights&#8217; then-current purchase price, a number of shares of the acquiring company&#8217;s common stock having a market value at that time equal to twice the Right&#8217;s exercise price.</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 0.5in;">At any time after a person or group becomes an Acquiring Person and prior to the acquisition by such person or group of 50% or more of the outstanding common stock, the Board of Directors of the Company may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment). At any time prior to 14 days following the date that any person or group becomes an Acquiring Person (subject to extension by the Board of Directors), the Board of Directors of the Company may redeem the then outstanding Rights in whole, but not in part, at a price of $0.005 per Right, subject to adjustment.</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 0.5in;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">On June 8, 2005, our Board of Directors voted to authorize an amendment of the Rights Agreement to extend the Final Expiration Date by an additional three years, to September 19, 2008. As of June 30, 2005, we entered into an amendment to the Rights Agreement with the Rights Agent reflecting such extension. On June 6, 2008 our Board of Directors voted to authorize an amendment of the Rights Agreement to extend the Final Expiration Date by an additional three years, to September 19, 2011 and to increase the ownership threshold for determining &#8220;Acquiring Person&#8221; status from 15% to 18%. As of June 30, 2008, we entered into an amendment to the Rights Agreement with the Rights Agent reflecting such extension and threshold increase. On August 5, 2011, our Board of Directors voted to authorize amendments of the Rights Agreement to extend the Final Expiration Date by an additional three years to September 19, 2014 and to increase the ownership threshold for determining &#8220;Acquiring Person&#8221; status from 18% to 20%. As of August 9, 2011, we entered into an amendment to the Rights Agreement with the Rights Agent reflecting such extension and threshold increase. On June 10, 2014, our Board of Directors voted to authorize an amendment to the Rights Agreement to extend the final expiration date by an additional three years to September 19, 2017. As of June 16, 2014, we entered into an amendment to the Rights Agreement with the Rights Agent reflecting such extension. No other changes have been made to the terms of the Rights or the Rights Agreement.</p><p style="text-align: left; font: 10pt times new roman, times, serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">Our Board of Directors believes that there is some risk that the potential value of the <b>Mast Out</b><sup>&#174;</sup> product development initiative is not fairly reflected in the market price of our common stock, as it fluctuates from time to time, and that opportunistic buyers could take advantage of that disparity to the detriment of our stockholders. If this were to happen and result in a potential threat through an unsolicited acquisition effort or otherwise, our Board of Directors feels that the Rights Plan could enhance stockholder value by providing management with negotiating leverage.</p> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-align: left; text-indent: 0px; padding: 0px;"><b>13.</b></td><td style="text-align: left; text-indent: 0px; padding: 0px;"><b>COMMITMENTS AND CONTINGENT LIABILITIES</b></td></tr></table><p style="text-align: left; font: 10pt times new roman, times, serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 0.5in;">Our bylaws, as amended, in effect provide that the Company will indemnify its officers and directors to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings to each director through a separate indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically unlimited and is impossible to determine. We maintain directors&#8217; and officers&#8217; liability insurance, which may provide reimbursement to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification obligations were grandfathered under the provisions of Codification Topic 460<i>, Guarantees</i>. Accordingly, we have recorded no liability for such obligations as of December 31, 2014. Since our incorporation, we have had no occasion to make any indemnification payment to any of our officers or directors for any reason.</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 0.5in;">As of December 31, 2014 we had committed to contracts and purchase orders covering approximately $326,000 related to our 7,100 square foot facility addition and an additional $550,000 principally related to the production of inventory.</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">We enter into agreements with third parties in the ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging any of these indemnification obligations, and based on our analysis of the nature of the risks involved, we believe that the fair value of these agreements is minimal. Accordingly, we have recorded no liabilities for such obligations as of December 31, 2014.</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;">The development, manufacturing and marketing of animal health care products entails an inherent risk that liability claims will be asserted against us. We feel that we have reasonable levels of liability insurance to support our operations.</p> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>14.</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We principally operate in the business segment described in Note 1. Pursuant to Codification Topic 280,&#160;<i>Segment Reporting</i>, we operate in one reportable business segment, that being the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Almost all of our internally funded product development expenses are in support of such products. The significant accounting policies of this segment are described in Note 2.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Our primary customers for the majority of our product sales (83%, 83% and 80% for the years ended December 31, 2014, 2013 and 2012, respectively) are in the U.S. dairy and beef industries. Product sales to international customers, who are also in the dairy and beef industries, aggregated 13%, 14% and 16% of our total product sales for the years ended December 31, 2014, 2013 and 2012, respectively. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding: 0px 0px 1.5pt; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">Year Ended December 31,</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="padding: 0px 0px 1.5pt; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2014</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2013</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2012</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1003px; text-align: left; text-indent: 0px; font-stretch: normal;">Animal Health International, Inc.</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 142px; text-align: right; text-indent: 0px; font-stretch: normal;">38</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-stretch: normal;">%</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-stretch: normal;">38</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-stretch: normal;">%</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-stretch: normal;">35</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-stretch: normal;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">MWI Veterinary Supply Company<sup>(1)</sup></font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px; font-stretch: normal;">23</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">%</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px; font-stretch: normal;">22</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">%</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px; font-stretch: normal;">20</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">%</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><sup>(1)&#160;</sup>Assumes that the November 2013 acquisition of IVESCO by MWI had occurred as of the beginning of the periods being reported.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accounts receivable due from significant customers amounted to the percentages of total trade accounts receivable as detailed in the following table:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">As of December 31,</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2014</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2013</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1191px; text-align: left; font-stretch: normal;">Animal Health International, Inc.</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;">45</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">%</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">39</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">MWI Veterinary Supply Company</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">26</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">%</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">26</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Robert J. Matthews Company</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">*</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">10</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">%</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">*Amount is less than 10%.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-indent: 0px;"><b>15.</b></td><td style="padding: 0px; text-indent: 0px;"><b>RELATED PARTY TRANSACTIONS</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Dr. David S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc. (formerly Stearns Veterinary Outlet, Inc.), a domestic distributor of ImmuCell products (<b>First Defense<font style="font-family: symbol;"><sup>&#174;</sup></font></b>,&#160;<b>Wipe Out<font style="font-family: symbol;"><sup>&#174;&#160;</sup></font>Dairy Wipes</b>,<b>&#160;</b>and<b>&#160;CMT</b>) and of J-t Enterprises of Melrose, Inc., an exporter. His affiliated companies purchased $426,358, $395,042 and $326,513 of products from ImmuCell during the years ended December 31, 2014, 2013 and 2012, respectively, on terms consistent with those offered to other distributors of similar status. We made marketing-related payments of $7,330, $6,010 and $1,000 to these affiliate companies during the years ended December 31, 2014, 2013 and 2012, respectively. Our accounts receivable (subject to standard and customary payment terms) due from these affiliated companies aggregated $18,796 and $31,445 as of December 31, 2014 and 2013, respectively.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-indent: 0px;"><b>16.</b></td><td style="padding: 0px; text-indent: 0px;"><b>EMPLOYEE BENEFITS</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum amount allowed by the Internal Revenue Service. Prior to August 2012 we matched 50% of each employee&#8217;s contribution to the plan up to a maximum match of 4% of each employee&#8217;s base compensation. Since August 2012 we have matched 100% of the first 3% of each employee&#8217;s salary that is contributed to the Plan and 50% of the next 2% of each employee&#8217;s salary that is contributed to the Plan. Under this matching plan, we paid $65,633, $56,036 and $51,145 into the plan for the years ended December 31, 2014, 2013 and 2012, respectively.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>17.</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>UNAUDITED QUARTERLY FINANCIAL DATA</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The following tables present the quarterly information for the years ended December 31, 2014, 2013 and 2012, respectively:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">Three Months Ended</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">March 31</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">June 30</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September&#160;30</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December&#160;31</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Fiscal 2014:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; font-size: 10pt;">Product sales</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">2,081,752</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">1,539,719</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">1,770,129</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">2,205,275</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Gross margin</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,149,895</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">878,523</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,077,896</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,342,722</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Product development expenses</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">594,209</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">760,672</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">361,232</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">462,965</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Net operating income (loss)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">12,561</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(458,667</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">40,853</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">198,856</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Net (loss) income</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(13,335</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(294,781</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">10,330</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">130,626</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Net (loss) income per common share:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Basic</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.00</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.10</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.00</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.04</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Diluted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.00</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.10</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.00</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.04</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Fiscal 2013:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Product sales</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,846,734</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,366,493</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,234,701</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,559,248</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Gross margin</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,053,567</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">783,677</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">615,717</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">607,644</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Product development expenses</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">266,479</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">271,858</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">290,853</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">325,010</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Net operating income (loss)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">326,666</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">23,722</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(159,967</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(209,975</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Net income (loss)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">204,310</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">6,452</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">57,336</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(150,703</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Net income (loss) per common share:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Basic</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.07</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.00</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.02</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.05</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Diluted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.07</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.00</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.02</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.05</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Fiscal 2012:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Product sales</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,717,109</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,175,126</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,076,749</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,420,951</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Gross margin</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,012,568</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">670,518</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">620,958</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">750,215</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Product development expenses</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">247,807</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">211,706</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">223,771</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">234,316</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Net operating income (loss)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">281,233</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">37,397</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(86,126</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">12,497</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Net income (loss)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">154,761</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">15,187</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(63,574</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(16,862</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Net income (loss) per common share:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Basic</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.05</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.01</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.02</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.01</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Diluted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.05</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.01</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.02</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.01</td><td style="text-align: left; font-size: 10pt;">)</td></tr></table></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>18.</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>SUBSEQUENT EVENTS</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We have adopted the disclosure provisions of Codification Topic 855-10-50-1,&#160;<i>Subsequent Events</i>, which provides guidance to establish general standards of accounting for and disclosures of events that occur after the balance sheet date but before financial statements are issued. Entities are required to disclose the date through which subsequent events were evaluated as well as the rationale for why that date was selected. This disclosure should alert all users of financial statements that an entity has not evaluated subsequent events after that date in the set of financial statements being presented. Codification Topic 855-10-50-1 requires additional disclosures only, and therefore did not have an impact on our financial condition, results of operations, earnings per share or cash flows. Public entities must evaluate subsequent events through the date that financial statements are issued. Accordingly, we have evaluated subsequent events through the time of filing on March 26, 2015, the date we have issued this Annual Report on Form 10-K.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: justify; text-indent: 0px;"><b>(a)</b></td><td style="padding: 0px; text-align: justify; text-indent: 0px;"><b>Basis of presentation</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We have prepared the accompanying audited financial statements reflecting all adjustments, all of which are of a normal recurring nature, that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB<i>&#160;Accounting Standards Codification</i>&#8482; (Codification). Certain prior year accounts have been reclassified to conform with the 2014 financial statement presentation.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(b)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Cash, Cash Equivalents and Short-Term Investments</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $567,000 and $1,770,000 at December 31, 2014 and 2013, respectively. Short-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than three months from their purchase dates and not more than twelve months from the balance sheet date and are held at different financial institutions that are insured by the FDIC, within the FDIC limits per financial institution. See Note 3.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: justify; text-indent: 0px;"><b>(c)</b></td><td style="padding: 0px; text-align: justify; text-indent: 0px;"><b>Inventory</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or market (net realizable value). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. See Note 4.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(d)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Trade Receivables</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Trade receivables are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded as income when received. A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Interest is charged on past due trade receivables. See Note 5.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>e)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Property, Plant and Equipment</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The cost of our building (which was acquired in 1993) and the 2001 and 2007 additions thereto are being depreciated through 2023. We anticipate depreciating the building addition that was completed during the first quarter of 2015 over twenty-five years. Related building improvements are depreciated over ten year periods. Large and durable fixed assets are depreciated over their useful lives that are generally estimated to be ten years. Other fixed assets and computer equipment are depreciated over their useful lives that are generally estimated to be five and three years, respectively. See Note 7.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(f)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Intangible Assets</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. In connection with certain credit facilities entered into during the third quarter of 2010, we incurred debt issue costs of $26,489, which costs are being amortized to other expenses, net over the terms of the credit facilities. See Notes 6 and 9.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We continually assess the realizability of these assets in accordance with the impairment provisions of Codification Topic 360,&#160;<i>Accounting for the Impairment or Disposal of Long-Lived Assets</i>. If an impairment review is triggered, we evaluate the carrying value of long-lived assets by determining if impairment exists based on estimated undiscounted future cash flows over the remaining useful life of the assets and comparing that value to the carrying value of the assets. If the carrying value of the asset is greater than the estimated future cash flows, the asset is written down to its estimated fair value. The cash flow estimates that are used contain our best estimates, using appropriate and customary assumptions and projections at the time. We also review the estimated useful life of intangible assets at the end of each reporting period, making any necessary adjustments.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(g)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Disclosure of Fair Value of Financial Instruments and Concentration of Risk</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Financial instruments consist mainly of cash, cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable, bank debt and an interest rate swap. Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, long-term investments and accounts receivable. We make short-term and long-term investments in financial instruments that are insured by the FDIC. We account for fair value measurements in accordance with Codification Topic 820,&#160;<i>Fair Value Measurements and Disclosures</i>, which defines fair value, establishes a framework for measuring fair value and requires additional disclosures about fair value measurements. The estimated fair value of cash, cash equivalents, short-term investments, long-term investments, accounts receivable and accounts payable approximate their carrying value due to their short maturities. The estimated fair value of bank debt approximates its carrying value because the interest rates are variable. The interest rate swap is carried at fair value. See Note 9.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(h)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Interest Rate Swap Agreement</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">All derivatives are recognized on the balance sheet at their fair value. We entered into an interest rate swap agreement in 2010. On the date the agreement was entered into, we designated the derivative as a hedge of the variability of cash flows to be paid related to our long-term debt. The agreement has been determined to be highly effective in hedging the variability of identified cash flows, so changes in the fair market value of the interest rate swap agreement are recorded as comprehensive (loss) income, until earnings are affected by the variability of cash flows (e.g. when periodic settlements on a variable-rate asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreement and the related hedged items. We also formally assess, both at this interest rate swap agreement&#8217;s inception and on an ongoing basis, whether the agreement is highly effective in offsetting changes in cash flow of hedged items. See Note 9.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(i)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Revenue Recognition</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We recognize revenue in accordance with Staff Accounting Bulletin (SAB) No. 104, &#8220;Revenue Recognition&#8221;, which supersedes SAB No. 101, &#8220;Revenue Recognition in Financial Statements&#8221;. SAB No. 104 requires that four criteria are met before revenue is recognized. These include i) persuasive evidence that an arrangement exists, ii) delivery has occurred or services have been rendered, iii) the seller&#8217;s price is fixed and determinable and iv) collectability is reasonably assured. We recognize revenue at the time of shipment (including to distributors) for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably assured. We recognize service revenue at the time the service is performed.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(j)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Expense Recognition</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Advertising costs are expensed when incurred, which is generally during the month in which the advertisement is published. Advertising expenses amounted to $66,193, $151,080 and $174,314 during the years ended December 31, 2014, 2013 and 2012, respectively. All product development expenses are expensed as incurred, as are all related patent costs.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(k)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Income Taxes</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We account for income taxes in accordance with Codification Topic 740,&#160;<i>Income Taxes</i>,<i>&#160;</i>which requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. We believe it is more likely than not that the deferred tax assets will be realized through future taxable income and future tax effects of temporary differences between book income and taxable income. Accordingly, we have not established a valuation allowance for the deferred tax assets. Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. We have evaluated the positions taken on our filed tax returns. We have concluded that no uncertain tax positions exist as of December 31, 2014. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 11.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(l)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Stock-Based Compensation</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We account for stock-based compensation in accordance with Codification Topic 718,&#160;<i>Compensation-Stock Compensation</i>, which generally requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model, as detailed in Note 12(a). Accordingly, we recorded $30,004, $31,359, and $35,985 of compensation expense pertaining to stock-based compensation, which resulted in a decrease (increase) in income (loss) before income taxes of approximately $0.01 per share during the years ended December 31, 2014, 2013 and 2012, respectively. Codification Topic 718 requires us to reflect gross tax savings resulting from tax deductions in excess of expense reflected in our financial statements as a financing cash flow.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(m)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Net (Loss) Income Per Common Share</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Net (Loss) Income per common share has been computed in accordance with Codification Topic 260-10,&#160;<i>Earnings Per Share.&#160;</i>The Net (Loss) per common share has been computed by dividing the Net (Loss) by the weighted average number of common shares outstanding during the period, without giving consideration to outstanding stock options because the impact would be anti-dilutive. The basic Net Income per share has been computed by dividing Net Income by the weighted average number of common shares outstanding during this period. Diluted Net Income per share has been computed by dividing Net Income by the weighted average number of shares outstanding during the period plus all outstanding stock options with an exercise price that is less than the average market price of the common stock during the period less the number of shares that could have been repurchased at this average market price with the proceeds from the hypothetical stock option exercises.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Year Ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">Weighted average number of shares outstanding</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; font-size: 10pt;">3,027,001</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; font-size: 10pt;">3,019,407</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; font-size: 10pt;">3,018,296</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Effect of dilutive stock options</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">65,641</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">90,123</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">Diluted number of shares outstanding</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,027,001</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,085,048</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,108,419</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; font-size: 10pt;">Outstanding stock options not included in the calculation because the effect would be anti-dilutive</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">253,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">63,875</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">39,750</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">For additional disclosures regarding the outstanding common stock options, see Note 12(a).</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-align: left; text-indent: 0px;"><b>(n)</b></td><td style="padding: 0px; text-align: left; text-indent: 0px;"><b>Use of Estimates</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual amounts could differ from those estimates.</p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0.5in; text-indent: 0px;"><b>(o)</b></td><td style="padding: 0px; text-indent: 0px;"><b>New Accounting Pronouncements</b></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We adopted Accounting Standards Update (ASU) No. 2011-05,&#160;<i>Presentation of Comprehensive Income (Loss)</i>&#160;(Topic 220) during the three-month period ended March 31, 2012, and retrospective application was required. Under ASU 2011-05, we have the option to present the total of comprehensive (loss) income, the components of net (loss) income, and the components of other comprehensive (loss) income either in a single continuous statement of comprehensive (loss) income or in two separate but consecutive statements. We elected to present two separate but consecutive statements. The statements of other comprehensive (loss) income immediately follow the statements of operations and include the components of other comprehensive (loss) income and a total for other comprehensive (loss) income, along with a total for comprehensive (loss) income. The adoption of Topic 220 only impacts the presentation of the financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2014, the FASB issued Accounting Standards Update No. 2014-09,&#160;<i>Revenue from Contracts with Customers&#160;</i>(ASU 2014-09), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. ASU 2014-09 is effective for the Company on January 1, 2017. Early application is not permitted. ASU 2014-09 permits the use of either the retrospective or cumulative effect transition method. We have evaluated the effect that ASU 2014-09 would have on our financial statements and related disclosures. We expect that ASU 2014-09 will have no significant effect on our ongoing financial reporting, but we continue to evaluate this pending accounting standard.</p></div> <div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Year Ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">Weighted average number of shares outstanding</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; font-size: 10pt;">3,027,001</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; font-size: 10pt;">3,019,407</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; font-size: 10pt;">3,018,296</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Effect of dilutive stock options</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">65,641</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">90,123</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">Diluted number of shares outstanding</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,027,001</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,085,048</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,108,419</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; font-size: 10pt;">Outstanding stock options not included in the calculation because the effect would be anti-dilutive</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">253,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">63,875</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">39,750</td><td style="text-align: left; font-size: 10pt;"></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p></div> <div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">As of December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;" colspan="2">(Decrease)</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Increase</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">Cash and cash equivalents</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">850,028</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">2,270,385</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">($</td><td style="width: 141px; text-align: right; font-size: 10pt;">1,420,357</td><td style="width: 15px; text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Short-term investments</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">2,489,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">2,985,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(496,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Subtotal</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">3,339,028</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,255,385</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(1,916,357</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Long-term investments</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">496,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">496,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Total</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,835,028</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">5,255,385</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">($</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,420,357</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">)</td></tr></table></div> <div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">As of December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;" colspan="2">Increase</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Decrease)</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: justify; font-size: 10pt;">Raw materials</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">306,444</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">270,355</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">36,089</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">Work-in-process</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">355,745</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">783,060</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(427,315</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Finished goods</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">283,566</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">153,093</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">130,473</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Total</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">945,755</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,206,508</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">($</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">260,753</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">)</td></tr></table></div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; text-indent: 0.5in; font-stretch: normal;"></p><table style="width: 1567px; border-collapse: collapse;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">As of December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;" colspan="2">Increase</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Decrease)</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">Trade accounts receivable, gross</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">1,004,990</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">609,638</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">395,352</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Accumulated allowance for bad debt and product returns</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(16,194</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(13,952</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(2,242</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Trade accounts receivable, net</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">988,796</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">595,686</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">393,110</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Other receivables</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">16,496</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">35,676</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(19,180</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Income taxes receivable</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">48</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(48</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 10pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Accounts receivable, net</td><td style="font: 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">1,005,292</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">631,410</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">373,882</td></tr></table> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">As of December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;" colspan="2">(Decrease)</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Increase</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">Prepaid expenses and other assets</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">133,119</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">159,117</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">($</td><td style="width: 141px; text-align: right; font-size: 10pt;">25,998</td><td style="width: 15px; text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Security deposits</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">15,280</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">15,280</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;">Current subtotal</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">148,399</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">159,117</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(10,718</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Debt issue costs</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">26,489</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">26,489</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Accumulated amortization of debt issue costs</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(16,479</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(13,603</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(2,876</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Security deposits</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">8,920</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">750</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">8,170</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;">Long-term subtotal</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">18,930</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">13,636</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">5,294</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Total</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">167,329</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">172,753</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">($</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">5,424</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">)</td></tr></table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">As of December 31,</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;" colspan="2">Increase</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2014</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2013</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">(Decrease)</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1003px; text-align: left; font-stretch: normal;">Laboratory and manufacturing equipment</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;">3,522,465</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">3,182,686</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">339,779</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">Building and improvements</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">2,969,891</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">2,940,239</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">29,652</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Office furniture and equipment</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">470,607</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">354,243</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">116,364</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Construction in progress<sup>(1)</sup></font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">1,270,672</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">9,600</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">1,261,072</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">Land</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">50,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">50,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">0</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 10pt; font-stretch: normal;">Property, plant and equipment, gross</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">8,283,635</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">6,536,768</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">1,746,867</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Accumulated depreciation</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(4,445,988</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(4,012,003</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(433,985</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; padding-left: 10pt; font-stretch: normal;">Property, plant and equipment, net</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">3,837,647</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">2,524,765</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">1,312,882</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><sup>&#160;</sup></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><sup>(1)&#160;</sup>As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; text-indent: 0.5in; font-stretch: normal;"></p><table style="width: 1567px; border-collapse: collapse;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">As of December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;" colspan="2">Increase</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Decrease)</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">Accounts payable &#8211; capital</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">251,383</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">23,496</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">227,887</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Accounts payable &#8211; trade</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">204,810</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">199,716</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,094</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Accrued payroll</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">145,176</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">75,310</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">69,866</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Accrued clinical studies</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">131,945</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">131,945</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Accrued professional fees</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">42,250</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">50,500</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(8,250</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Accrued other</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">76,113</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">96,207</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(20,094</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 10pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Total</td><td style="font: 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">851,677</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">445,229</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;">406,448</td></tr></table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Period</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">$1,000,000&#160;<br />mortgage</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">$600,000<br />note</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: justify; font-size: 10pt;">Year ending December 31, 2015</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">54,044</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">96,338</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">150,382</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">Year ending December 31, 2016</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">57,384</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">57,384</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; font-size: 10pt;">Year ending December 31, 2017</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">61,056</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">61,056</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">Year ending December 31, 2018</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">64,876</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">64,876</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; font-size: 10pt;">Year ending December 31, 2019</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">68,908</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">68,908</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt; font-size: 10pt;">After December 31, 2019</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">493,696</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">493,696</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Total</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">799,964</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">96,338</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">896,302</td></tr></table> <div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">License option fee<sup>(1)</sup></td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">0</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">250,000</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">0</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Royalty income</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(3,000</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">15,166</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Interest income</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">15,552</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">12,493</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">17,202</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Interest expense</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(57,827</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(66,689</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(75,274</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Debt issuance amortization</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(2,876</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(2,894</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(2,876</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Other gains (losses)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(3,902</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">34,902</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(7,067</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">Other (expenses) revenues, net</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">($</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">49,053</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">)</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">224,812</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">($</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">52,849</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">)</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><sup>(1)</sup>&#160;During the second quarter of 2013, we received a $250,000 exclusive option fee from a prospective partner for the development and marketing of&#160;<b>Mast Out<sup>&#174;</sup></b>. This payment was recorded as deferred revenue upon receipt. During the third quarter of 2013, this prospective partner decided not to execute a license after its final due diligence. Accordingly, the deferred revenue was recognized during the third quarter of 2013. At the same time, $47,604 in capitalized expenses pertaining to the development of&#160;<b>Mast Out<sup>&#174;&#160;</sup></b>were written off.</p></div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 989.67px; text-align: justify; padding-left: 10pt; font-size: 10pt;">Current</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">252</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">301</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">708</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; font-size: 10pt;">Federal</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(77,986</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">74,713</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">89,788</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt; font-size: 10pt;">State</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(10,558</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">12,851</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">12,144</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;">Deferred</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(88,544</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">87,564</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">101,932</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Total</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">($</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">88,292</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">)</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">87,865</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">102,640</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">Computed expected tax (benefit) expense</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">($</td><td style="width: 142px; text-align: right; font-size: 10pt;">86,853</td><td style="width: 16px; text-align: left; font-size: 10pt;">)</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">69,788</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">65,332</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">State income taxes, net of federal (benefit) expense</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(6,968</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">8,482</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">8,015</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Share-based compensation</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">10,201</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">10,526</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">9,766</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Research and development tax credit</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(19,405</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(21,887</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(10,813</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Other</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">14,733</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">20,956</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">30,340</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Total income tax (benefit) expense</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">($</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">88,292</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">)</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">87,865</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">102,640</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr></table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">As of December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: justify; font-size: 10pt;">Product rights</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">130,036</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">165,527</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">Property, plant and equipment</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">225,229</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">52,094</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; font-size: 10pt;">Research and development tax credit</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">266,078</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">235,567</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">Federal net operating loss carryforward</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">464,998</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">525,012</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; font-size: 10pt;">State net operating loss carryforward</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">165,901</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">201,698</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; font-size: 10pt;">Interest rate swap</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">15,486</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">13,166</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 1.5pt; font-size: 10pt;">Prepaid expenses and other</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(6,925</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(23,171</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Deferred tax asset</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,260,803</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,169,893</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px; text-indent: 36pt;"></p><table style="width: 100%; border-collapse: collapse;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: center; font: 10pt times new roman, times, serif;" colspan="2">2000 Plan</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: center; font: 10pt times new roman, times, serif;" colspan="2">2010 Plan</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: center; font: 10pt times new roman, times, serif;" colspan="2">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: center; font: 10pt times new roman, times, serif;" colspan="2">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 52%; font: 10pt times new roman, times, serif;">Outstanding at December 31, 2011</td><td style="width: 1%; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 9%; text-align: right; font: 10pt times new roman, times, serif;">186,500</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 9%; text-align: right; font: 10pt times new roman, times, serif;">49,500</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="width: 9%; text-align: right; font: 10pt times new roman, times, serif;">3.19</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; font: 10pt times new roman, times, serif;">&#160;</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="width: 9%; text-align: right; font: 10pt times new roman, times, serif;">344,000</td><td style="width: 1%; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt times new roman, times, serif; padding-left: 10pt;">Grants</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">2,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">5.93</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt times new roman, times, serif; padding-left: 10pt;">Terminations</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">(8,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">(2,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">4.75</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif; padding-left: 10pt;">Exercises</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: right; font: 10pt times new roman, times, serif;">(15,000</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 1.5pt; text-align: right; font: 10pt times new roman, times, serif;">3.39</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: right;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt times new roman, times, serif;">Outstanding at December 31, 2012</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">163,500</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">49,500</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">3.13</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">185,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt times new roman, times, serif; padding-left: 10pt;">Grants</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">26,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">4.67</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt times new roman, times, serif; padding-left: 10pt;">Terminations</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">(1,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">3.15</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif; padding-left: 10pt;">Exercises</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: right; font: 10pt times new roman, times, serif;">(6,000</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: right; font: 10pt times new roman, times, serif;">(1,000</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 1.5pt; text-align: right; font: 10pt times new roman, times, serif;">3.11</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: right;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt times new roman, times, serif;">Outstanding at December 31, 2013</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">157,500</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">73,500</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">3.30</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">223,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt times new roman, times, serif; padding-left: 10pt;">Grants</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">25,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">4.69</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt times new roman, times, serif; padding-left: 10pt;">Terminations</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: right; font: 10pt times new roman, times, serif;">(2,000</td><td style="text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="text-align: right; font: 10pt times new roman, times, serif;">5.75</td><td style="text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif; padding-left: 10pt;">Exercises</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 1.5pt solid; text-align: right; font: 10pt times new roman, times, serif;">(1,000</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">)</td><td style="padding-bottom: 1.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 1.5pt; text-align: right; font: 10pt times new roman, times, serif;">3.15</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: right;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">Outstanding at December 31, 2014</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: right; font: 10pt times new roman, times, serif;">157,500</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: right; font: 10pt times new roman, times, serif;">95,500</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 4pt; text-align: right; font: 10pt times new roman, times, serif;">3.42</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 4pt; text-align: right; font: 10pt times new roman, times, serif;">364,000</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">Exercisable at December 31, 2014</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: right; font: 10pt times new roman, times, serif;">157,500</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: right; font: 10pt times new roman, times, serif;">42,500</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 4pt; text-align: right; font: 10pt times new roman, times, serif;">3.08</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="padding-bottom: 4pt; text-align: right; font: 10pt times new roman, times, serif;">357,000</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td><td style="font-size: 10pt; text-align: right;">&#160;</td><td style="font-size: 10pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">Reserved for future grants</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: right; font: 10pt times new roman, times, serif;">0</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 4pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 4pt double; text-align: right; font: 10pt times new roman, times, serif;">202,500</td><td style="padding-bottom: 4pt; text-align: left; font: 10pt times new roman, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt; text-align: right;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt; text-align: left;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt; text-align: right;">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt; text-align: left;">&#160;</td></tr></table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-size: 10pt;">Risk-free interest rate</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; font-size: 10pt;">2.0</td><td style="width: 16px; text-align: left; font-size: 10pt;">%</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; font-size: 10pt;">1.6</td><td style="width: 15px; text-align: left; font-size: 10pt;">%</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; font-size: 10pt;">0.97</td><td style="width: 15px; text-align: left; font-size: 10pt;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Dividend yield</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">%</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">%</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0</td><td style="text-align: left; font-size: 10pt;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Expected volatility</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">49</td><td style="text-align: left; font-size: 10pt;">%</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">49</td><td style="text-align: left; font-size: 10pt;">%</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">48.7</td><td style="text-align: left; font-size: 10pt;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Expected life</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">6 years</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">6 years</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">6.5 years</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr></table> <div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding: 0px 0px 1.5pt; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">Year Ended December 31,</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="padding: 0px 0px 1.5pt; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2014</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2013</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2012</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding: 0px 0px 1.5pt; text-indent: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1003px; text-align: left; text-indent: 0px; font-stretch: normal;">Animal Health International, Inc.</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 142px; text-align: right; text-indent: 0px; font-stretch: normal;">38</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-stretch: normal;">%</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-stretch: normal;">38</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-stretch: normal;">%</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-stretch: normal;">35</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-stretch: normal;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">MWI Veterinary Supply Company<sup>(1)</sup></font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px; font-stretch: normal;">23</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">%</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px; font-stretch: normal;">22</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">%</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px; font-stretch: normal;">20</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px; font-stretch: normal;">%</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><sup>(1)&#160;</sup>Assumes that the November 2013 acquisition of IVESCO by MWI had occurred as of the beginning of the periods being reported.</p></div> <div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">As of December 31,</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2014</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2013</td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1191px; text-align: left; font-stretch: normal;">Animal Health International, Inc.</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;">45</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">%</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">39</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">MWI Veterinary Supply Company</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">26</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">%</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">26</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Robert J. Matthews Company</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">*</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">10</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">%</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">*Amount is less than 10%.</p></div> <div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">Three Months Ended</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">March 31</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">June 30</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September&#160;30</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December&#160;31</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Fiscal 2014:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; font-size: 10pt;">Product sales</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">2,081,752</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; font-size: 10pt;">1,539,719</td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">1,770,129</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">2,205,275</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Gross margin</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,149,895</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">878,523</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,077,896</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,342,722</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Product development expenses</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">594,209</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">760,672</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">361,232</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">462,965</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Net operating income (loss)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">12,561</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(458,667</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">40,853</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">198,856</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Net (loss) income</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(13,335</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(294,781</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">10,330</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">130,626</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Net (loss) income per common share:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Basic</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.00</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.10</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.00</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.04</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Diluted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.00</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.10</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.00</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.04</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Fiscal 2013:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Product sales</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,846,734</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,366,493</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,234,701</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,559,248</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Gross margin</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,053,567</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">783,677</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">615,717</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">607,644</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Product development expenses</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">266,479</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">271,858</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">290,853</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">325,010</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Net operating income (loss)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">326,666</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">23,722</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(159,967</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(209,975</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Net income (loss)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">204,310</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">6,452</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">57,336</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(150,703</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Net income (loss) per common share:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Basic</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.07</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.00</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.02</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.05</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Diluted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.07</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.00</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.02</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.05</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Fiscal 2012:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Product sales</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,717,109</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,175,126</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,076,749</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">1,420,951</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Gross margin</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,012,568</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">670,518</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">620,958</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">750,215</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Product development expenses</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">247,807</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">211,706</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">223,771</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">234,316</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Net operating income (loss)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">281,233</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">37,397</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(86,126</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">12,497</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-size: 10pt;">Net income (loss)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">154,761</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">15,187</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(63,574</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(16,862</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-size: 10pt;">Net income (loss) per common share:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Basic</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.05</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.01</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.02</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.01</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt; font-size: 10pt;">Diluted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.05</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">0.01</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.02</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">($</td><td style="text-align: right; font-size: 10pt;">0.01</td><td style="text-align: left; font-size: 10pt;">)</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p></div> 90123 65641 0 39750 63875 253000 0.01 0.01 0.01 174314 151080 66193 250000 26489 1770000 567000 P10Y P25Y P10Y P3Y P5Y 5255385 3339028 5255385 3835028 -496000 -1916357 496000 -1420357 270355 306444 783060 355745 153093 283566 36089 -427315 130473 609638 1004990 -13952 -16194 595686 988796 35676 16496 48 0 395352 -2242 393110 -19180 -48 159117 133119 0 15280 26489 26489 13603 16479 750 8920 172753 167329 -25998 -15280 -10718 0 2876 -8170 5294 -5424 3182686 3522465 2940239 2969891 354243 470607 9600 1270672 50000 50000 6536768 8283635 4012003 -4445988 1746867 339779 29652 116364 1261072 0 -433985 1312882 23496 251383 199716 204810 75310 145176 0 131945 50500 42250 96207 76113 445229 851677 -227887 5094 69866 131945 -8250 -20094 406448 150382 54044 96338 57384 57384 0 61056 61056 0 64876 64876 0 68908 68908 0 493696 493696 0 896302 799964 96338 2100000 1000000 600000 500000 ten-year fifty-four month The $500,000 line of credit is available as needed and has been extended through May 31, 2015 and is renewable annually thereafter 451885 will be due in the third quarter of 2020 0.0604 0.0341 1000000 799964 600000 <div>Interest on the note is variable at the higher of 4.25% per annum or the LIBOR plus 3.25 %</div> <div>Interest on any borrowings against the line of credit would be variable at the higher of 4.25% per annum or the LIBOR plus 3.5%</div> <div>London Interbank Offered Rate (LIBOR) of 3.41%</div> 23903 23096 22116 a wholly owned subsidiary of TD Financial Group, which is a multinational bank with approximately $944 billion in assets and over 22 million clients world wide 965000 0 -250000 0 15166 -3000 0 17202 12493 15552 75274 66689 57827 2876 2894 2876 -7067 34902 -3902 -52849 224812 -49053 250000 47604 708 301 252 89788 74713 -77986 12144 12851 -10558 65332 69788 -86853 8015 8482 -6968 9766 10526 10201 -10813 -21887 -19405 30340 20956 14733 165527 130036 52094 225229 235567 266078 525012 464998 1368000 201698 165901 1858000 13166 15486 -23171 -6925 1169893 1260803 0.53 0.43 0.35 0.34 2028 through 2031 2029 through 2031 P15Y 186500 49500 163500 49500 157500 73500 157500 95500 2000 0 2000 26000 0 26000 25000 0 25000 -8000 -2000 0 -1000 0 -2000 157500 42500 0 202500 3.19 3.13 3.30 3.42 7.00 1.70 5.93 4.67 4.69 4.75 3.15 5.75 3.39 3.11 3.15 3.08 344000 185000 223000 364000 357000 0.0097 0.016 0.020 0.00 0.00 0.00 0.487 0.49 0.49 P6Y6M P6Y P6Y <div>No less than 85% of fair market value on the date of grant in the case of non-qualified stock options.</div> <div>No less than 85% of fair market value on the date of grant in the case of non-qualified stock options.</div> 250000 500000 300000 253000 202500 P4Y9M P4Y9M P4Y P4Y 5.61 4.15 4.25 6.25 4.69 4.80 25000 8000 1000 2.86 2.23 2.26 95560 26778 70.00 0.20 0.18 0.18 0.15 0.20 0.50 0.005 326000 550000 7100 0.80 0.16 0.20 0.35 0.83 0.14 0.22 0.38 0.83 0.13 0.23 0.38 0.10 0.26 0.39 0.10 0.26 0.45 326513 395042 426358 31445 18796 1000 6010 7330 One month 0.50 0.04 August 2012 we have matched 100% of the first 3% of each employee's salary that is contributed to the Plan and 50% of the next 2% of each employee's salary that is contributed to the Plan. 51145 56036 65633 94370 87166 -88590 65000 755000 820000 1112000 As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015. During the second quarter of 2013, we received a $250,000 exclusive option fee from a prospective partner for the development and marketing of Mast Out. This payment was recorded as deferred revenue upon receipt. During the third quarter of 2013, this prospective partner decided not to execute a license after its final due diligence. Accordingly, the deferred revenue was recognized during the third quarter of 2013. At the same time, $47,604 in capitalized expenses pertaining to the development of Mast Out were written off. Assumes that the November 2013 acquisition of IVESCO by MWI had occurred as of the beginning of the periods being reported. Amount is less than 10% EX-101.SCH 6 iccc-20141231.xsd XBRL SCHEMA FILE 001 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Statements of Operations link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Statements of Comprehensive (Loss) Income link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Statements of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 007 - Statement - Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Business Operations link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Cash, Cash Equivalents, Short-Term and Long-Term Investments link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Inventory link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Accounts Receivable link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Prepaid Expenses and Other Assets link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Property, Plant And Equipment link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Bank Debt link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Other (Expenses) Revenues, Net link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Commitments and Contingent Liabilities link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Segment And Significant Customer Information link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Employee Benefits Employee link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Unaudited Quarterly Financial Data Unaudited link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Cash, Cash Equivalents, Short-Term and Long-Term Investments (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Inventory (Tables) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Accounts Receivable (Tables) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Prepaid Expenses and Other Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Property, Plant And Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Bank Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Other (Expenses) Revenues, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Segment And Significant Customer Information (Tables) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Unaudited Quarterly Financial Data Unaudited (Tables) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Cash, Cash Equivalents, Short-Term and Long-Term Investments (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Inventory (Details) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Accounts Receivable (Details) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Prepaid Expenses and Other Assets (Details) link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Property, Plant And Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Bank Debt (Details) link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - Bank Debt (Details Textual) link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - Other (Expenses) Revenues, Net (Details) link:presentationLink link:definitionLink link:calculationLink 051 - Disclosure - Other (Expenses) Revenues, Net (Details Textuals) link:presentationLink link:definitionLink link:calculationLink 052 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 053 - Disclosure - Income Taxes (Details 1) link:presentationLink link:definitionLink link:calculationLink 054 - Disclosure - Income Taxes (Details 2) link:presentationLink link:definitionLink link:calculationLink 055 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 056 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 057 - Disclosure - Stockholders' Equity (Details 1) link:presentationLink link:definitionLink link:calculationLink 058 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 059 - Disclosure - Commitments and Contingent Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 060 - Disclosure - Segment And Significant Customer Information (Details) link:presentationLink link:definitionLink link:calculationLink 061 - Disclosure - Segment And Significant Customer Information (Details 1) link:presentationLink link:definitionLink link:calculationLink 062 - Disclosure - Segment And Significant Customer Information (Details Textual) link:presentationLink link:definitionLink link:calculationLink 063 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 064 - Disclosure - Employee Benefits Employee (Details) link:presentationLink link:definitionLink link:calculationLink 065 - Disclosure - Unaudited Quarterly Financial Data Unaudited (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 iccc-20141231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 iccc-20141231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 iccc-20141231_lab.xml XBRL LABEL FILE EX-101.PRE 10 iccc-20141231_pre.xml XBRL PRESENTATION FILE GRAPHIC 11 image_001.gif GRAPHIC begin 644 image_001.gif M1TE&.#EA(`(%`7<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y M!`$`````+`0`!``8`OP`AP``````````,P``9@``F0``S```_P`S```S,P`S M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9 M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,` M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_ M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;, M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D` M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9 M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_ M_\P``,P`,\P`9LP`F/($,:!`"@E2"3*$^J3,ERI0'\*#4ITJ-&B2(\J3O8,.*'4NV MK-FS:-.J7@P!L>7+F#-KWLRYLV>QK:KNQ68M"[9G2R!9.T'+FA(SGV/+GDV[ MMNW;@ZE6U0K-!392D7\'QTV\N/'CR),CQKO[:IX``VAA2U;C*G6N)UO!U/Z2 M.TOO*\&C_Q2??;OY[N>_IP^_?GS[\NCCJY?/GKY[^_#GZZ^__W[__/P%Z)^` M``YH8($(:O>>@O@Q^)^#!$)XH(0)DD?AA19FN"!Y6BEV$F\F*`*<9,-AI:!) MY9VHXHHLMNCBBS#&*..,--9HXXTXYJCCCCSVZ../0`8IY)!$MIA5*WF9M%4G M8"!3'39.?J6D656-XV4'//P':-$HI`P]J7BDC)6)9HIJGFFFR^Q9Q` M5UV3Q&.P8?-<`&"`-66;?/;IYY]H>GBF6MH!:NBAB";J66@EC;;6GHI&*NFD ME,*E6TEM%5KIIIQVZFE6;PZ:%J2?EFKJJ6T*FJFHJ+;JZJO%(?_9:*:.PFKK MK;ANMB6F;&F:ZZ_`!OO7F[6.6FRD3T73G&<``K;_4$SI,BHZS&IT$'25DVPXQ5 MT0[WZZ_`2E,&]#-"P^4)SW,E4T)TE5YZKEF^^NG8#"58G!7*CBV[9``(A'VQ MG`*L$$#$8[]]5;(E:O6=UD$' M-%L^%QP7U`,,36FHM`(JYP!E)*MWS"?+G;*R*$/Y=K*A)RTSM:316R+*(B/L MF!D[1V8R5MW^BPTT>.48<6[OS1/*P`DZCIK<[1SWLM5]E M#<7[/JQ`*4;'[.\`=5[O[Y-Q1P`M5E-#H/B_XE=W?NO9*PV!5LQBF0#D]AG.&*M>CMJ8F;&F+;T<3W>VX MTBR_26=FZTN=M.CF0,F![BH36Y?2E">Z@_EN.C?+WF]NEB<7-FR$,;R9R]3% ML,H@\&:J\Y>S_P3(L.`437H9])?8;*@[=T&`9VO'T!3YL M["P`L)F:P':V2.C`Y@JX<]P,$7:5G='L>I5S8&5B!X&G14U:!HK3^)\FKT4**R81"=#`IOIS)LC%@N*;IP!?,TV!! M.AY,IC-)TP)#[8J"9.D:N@I7)GT-!W&5Z2)LVA4P6M!3@X>3F[Y8H/]*N\60 MD.7;G=HDACTE?FMB@TMFQ;[E1W=[W9W>U@/5>HOLS4.:QIEH"(**-..?BMR&D/HQ8(VTCF90:.? M4R;\*'HH8F7.3V!\S,I0]U`B(HRIV!+`(\)FS'RJ+EHO\]?^XL8PQI4.&U#M MISACJ,!M`FV7V_KER_;'U*`-H$P[>Y+XLIG&!^+K;?<;JD7-0+E$-,Z$0A6J M'P/:4404;FCK8YC>FE8WMPX-D&2%1/T8"`GN_2U<`82.7_&G6<(AK(O["VG0 MQA=!JGS(7'\ZHF(?>D(.ZC.-`AOF`IVE+QW_),N$K?6G2]NE4X(F=%Z_M2D* MZ95-NK'6@Q)-H1G"JE%Z,.^$/M]C:K_;R*^'L+7!W MJE#I2DZ\T;TN47$H-J%B15_0;5/'YBA'/PW6>G,"Z&SY]:_)!@**TLP0N&K.HBZKD`.]:3%4.LT)JKRM)I4\'::M]IZ%7+ MS/)2?*&[Z'<53-K]YK:D+MV*,AN,#'$U.!GB>L;.[$@O:^;R*DY"\<(J]PR2 M#=9J94V&P$CZ)ZVMRD^3^9N[L`;/FHDNA8.KLHN-.YFRN@MN&=QM"V\6&29* MSH97C&%PC.MBRCV3_X="G*A%->Q2,]_U9B;95CO'.BLQ(]+RZ0S#"TZ`<3J`BGWM)/F.L5?='D70'F2=!\U%U;P6K5`*^U MHF(FM(LMC&BS=9'0!S.;"^MTZM8J,UDT4)>K_36#0-X5S$XU6U85<#W<=HN7 M7?R=B_45,=GZDWE=<>^K\QKI&V)%70I@11(06>T(,*:+PYG:8P2@,0$J,'<# MV.R?)$@H=&YL4A)]M[PSE:1-I]/>\XY47//-[[2<\\G]WE2\`TYPL!A5TP5/ MN,)=Q>Y1N7OA$(^XH>9[5(E;_.+F)`FO)HCQCGN<39E^%+X_3O*2VT:"-O^+ MS'9QJQ5UFOSE,)\-'$=3FM.DYAI1&$L<8\[SGEOFWUDADS6D\+BNN-SG2$^Z M8`Z./Q<\LW?*ODJ#-#3U#5F]ZEA_$-6U?G6N9SU"6P=[U\7^]0F%W>QC1WO9 M*Y1VMJ\=0VV'^]NYTR'3#NH:=-@IF;C"H!05Z>^`#[S@!T_XPAO^\(A/O.(5 M="31C(U\1XNZB4:N],I;WBU.'F%CK1$B,R&]$R>+,5HZ0=LY9+FWLO-Q(8GUK)?Q'NV4-%5[UX+2>8+#YN"P M)^S>7>.VG,Y4#9<<^HM=PX=AP8J&1Y5V7RN0,N@;(_J825E.+-!6ND(_0LG/_S?QM7]\87V/X4_WEP3YMRUYX#"D M(#8+*!G017[B=Q:S5W1I\8`^-W,5QV_KIQ6J%P"#\@PG\`AYL%C%QT$/D`?D MHV1Z4&(ETWS/1WSX)7E]08`!P"X/H`H@2(H#;_IR^B`X>T1Q8V:#=?&(9CZ!P.(R>?MH=)\#E(@T.W)(>6 M@V6!,(>DID_J4GY$E`"?_Y1],L<"3;A^DLB$5\`"5,)TA$)YP.)Z5\&$V("% MUP9,)F`Y&(B![`(!X4<:I>@)`L-\>MA*?)4$D">#=O)6I.%K<]-\RP=)>;`L M.(86=3@VJEB*K`@)KNB#C4%E)S.'SP!ML/@;\P-6##B-L+@YZK:+]Y,'M),T M%X4:.Z6$M]$*F/B)J:<5':@<#?(%):!L1:-B0'@TE0$-G2<\">D:Y"46P\@R$9"/O[&/!=,O?V.11:=D MTH&0#`4F'!DG'IF0%2@Q"3D=!#F$N%0BJ#B.Y0B/6-%ZY9@<%(=P`>=Z+BF* MU?_&7:?H++K'+/$T`"28)YY08CO92AGFA5N!0"9X&K27/_X2@U_QD&1(?D&I M8"XHCF3H%45F/06%)S3E.R-IDN(7EDR95G_H68M4?Y&(#2YICI)()9DWA>KW M>ZB$%:)8D-;3>?^'E;$H)_$G'7E(>F4X0F:`#-#%EWC)+,[RD5C!>0UI%E(I M@WZ)-?PXF.Q"?L]P/"MI&^38EFR9>N28B7FQ M<9M(<)=XCED!@D!6?M/B/B>X),R#,LEHB]'H?,Q";B^8E$DP'!BH?,[AB]"6 M%I'9";TI.K_IDTNBEIEY;1%`;;MX=W_H"MV4%=&8!V7_4`))@UO/$"*=8(0R M%P"T^9+GV)[(L8YG<73O1HGM)XI820J5LY?UAX')X%&QY8]SD"?I(CF(B9)9 MV49[R$/EETY-V(3%XI\`JH"$=IH@53!PJ$H9"E/T,@"LP!I:H:`5931.=8;T M@IF+\I99`8^MJ1P:2)/]1I=.:'[!T@HWN*+M"9_'(87M1J,^*BDM:HYU>15! M&I^OR8E2@J0_NJ18$J2JF8[)(9]*E^8F*6" MH*+)$9<]^J5HBB:IJ:-/&)-&VAQ=FJ9R:B4VRJ;O.:3QB7ZH-:=\*I-D*J1$ MZJ;'\:)QVJ>&2APVZH$YBJ<[_ZH;5,HQCWJHDFH91=J617H;H8Z<>II+H96,JFE[BEC@>CI=JJE]&:8OJG.ZIQDJJN"H7:\JH M;>J:MWDH7E0J?T%H]B0(@-;M8QG%5A;*%@[L%IKM5V;M5L+ME;+M6%+MF-[M5Y;MF@KMF'[M6;; MMFKKMFO[MFE[MG)[MW&;MW:KMW"[MW[;MX!;MX'+ME8;`&):ER"(MW\KN(Q+ MN(Y+MX][M56H(*UWL@R"B8,+N9K+';+*HI.[N)&KN)D[MZ3KKU6DKM9RKU^>KC0^RC*ZX',*Y.K6JCHV[WN6:SLFQRQBZV["ZX(6ZP*V[L, MNZ>4LK,7F\!>>J.'N[^#VKFT^;Z$$K1&*\&U\;&:6BDTNQ(;S`*N&W/>:Z>H MY,#'D;TNJ:UN0:RRB\(>:[[=6BGSJ[LXN:2&*\)70<*QXJ:6JJ^9`L'/RL.X M(:T93"DSW):>R*3]F[_(6[Q*_*E`_"@FO*APZ:BC*BE'_*3T^G+&Z[]++!<5 MF\`6R[L]K+N?&,-PX;SW&KY@?+$?W!7E.I]MG"8>3,9L.<=R,::7F,>4J,?O M%L7;2Q>&>[()-4O(`R'&:"&E94&?B&*3 M"9O%7N'!)U*Y)S+#P:*^;(K#'^/#71P7&XNM%GS*=*RE=RRH)TS)\UF_TSHI M)_N]<>P55ZRCMCDNMFNGIBR,QSNPAJP620RH+-PK`:RH`\P6\+G#EE+`R6K% MAQN/<_&.;&K'UL+`(CS,7*/#X@K.X6RT@0K`[GO,9]&>64K+9H'!YKHIE7B\ M1PP7FJR_G,PIB"R[Y%P6P_*WH%'-W1`VW,Z'R\K6P6YQBK[GS)];:!DE+$ MT;S+73&;YO]\T;]BT"X9T@YYT-C*T)#9Q';IT^GDQUBQS&J1>NEL*51LP+CL M*%B=3A3,L;K]%>R,JG`!SW`LSU'-Q:;M%H?_C:._W,T\ MK<3)[16LO:+3_=J>3=OSB=/&>L=UN=#7[=#SJ=I4$M'M&=QH4=$BK-^ODM'' M6]Y\E]EE+.`#OMSI?;#.G>#8@4JVW=4MS:HOO=AXVMUM0=.RZ]^NXMY#:N!; M<=?YR^!=<=Y!C;OK?=N_7<$B+G5+7&W\<5K_,QL4=5D[.'W MFM6+O-4KWG+BG-NW[<&S?=UF+>%H/1IJ7=Q;T=;8C"6>O,$H(8D\+M&Q/1<@+J1Y?<9[[<1%KM&?/1:#K7/VK1S?[9XT3A8PC:=O7AL@V,"`G.4@ MC=7%?.5?[>-Z#>1%?N)='=KQ#,.DC==._ZZH5KW1:WX9T>V_?'[#B_Z!=S[0 MSTV'-GSFX3S>;LG>98';:?P6O/W0,'S-5@+ED7[5UYSL)/Z)N([E0*WI ME\SETCX6"IVO\]VT([1DO<-R1]+HR('?0WKJ8<'?1DONLF'L;[5YZSG7'SI?NW@">OI8?&B7X((Y20M.0<:B5XE<8ZCSN7?WH^?]K[_M.X&RYV6,LZQ0OUBNL[P:7Y-;S[VU$@T0Z1SNKQU^< MQP.?&6F]S4OOUI.M\IZ!A6+*["\/\V_!Y30?%E^NO6$>\XONR)S=UM7^%>SF M\4$GO"W7$)>H(J"L';\M$G*O$',G._]P91Y]\,$H_M@>SY$3H^ MWH/_$3(OI.0($LR[T!\A[D7MP18Q*%Q*3DL2=5F[%V5;SVUYCFI[MJ#_^:(? M^J0_^J8?C[I<^JHO^B4_NW*[^K!_^K(?^V>;^`=]@[.?^UI>];2?^[,^WN2H M^[Y/[5@H_*L/J_EN_*FLI?M5EAIFC?F"5IJUP![$_Z])>A\0G_?_*, MT>38R_P\;?42SX21+N\#&^]MO?528ON]"M^3[O-F_YJ,T49XTI/6NQ6>V,[R M/QLH'^P`(0C;0((%#1Y$./"*P(57#"X,T"KA1(H5+5[$R,)AP88$`V`$.?!C M1XZ"''X,B1$E-I($K[!("7*E0I,$:\:TV"K`39>),>+.EPI=`$0(0A%2B MT8&MEAJL.92E(!8"F5[%BK!HR8W86#S-.O"KU(9?PY[%&I%KP9EG`Y"]V39K M*YA3NQ*5.[]=NT[UGH_ZBZKN>$O3/,[BLRRJZH6!D M,4+&5FL0IYG(RC&EP%04*;/Q]JOPMKK0Z_"J%`T,43ZC6@'`,?S$FY(F)INL M\;K??',.K2Y1.S%+`GW#IL>49@O-S)`>Y*G(L"144<3(8'K1224[^\E-H(8C M[BKC#M(/1((&%),T_?^2H_&JS<@BM%#,WIJPS`@#Y$Q-C-ICS])+/PQ03S\U M(B])IGA"[RSZH@S3QRJ5N]"E0!W-;#H@NSS+Q313A5712"5]M-7G-+T(3>I$ M=0U(+#6$ M2HY7M,ZK[(H`WH4W7GB)30C3/.D5C],+/37J,/CTC:PQR?Q.)O+M2:(2&_$ZGC^4EV2!VJ=MVL?7_ M[L5,YCCM'+$^;$,:^*%7040Y)G>7GG=K;ZUBU&R==^T9I[')?I>T!=.<]$IU M94M.$+CC#?G%O=]MNJ`-<0X<)*HB#?LB$J,U\;C86J(YJX=5C!PK6_]U>6)R M?VH[)DB![/S,&SNNFU*%C#[H1P.5_CLFI+G2^^_""3.=I:BS6E+0Q'-"5>V7 M"\9OJ-U!VAG$RK4=_;OC;88,S%AW11TA4">,WB!A+6.I^AM8C)][&^[9 M*:0S-(!YP[.O\2?B,_.*8'85Z$9K?9Q4W]TF,W3BETK;QBOUE\G7`I0]C]2N M(00DWY58)S[7Z8LDL=O;^%['&7XQ"V@"O,JI^A09_^`9$(-A61B>GA>IY0'E M`J'G&0N!DB+3"Z]7$!9TSWO;LZ'KOC>8X5U$*.U:7T(6E\*)P`]% MUC+?_<36/)PI,251:PD`-9,\KDA1,Q>TXKDV!YX(D>EN1O)@#GTTM;M`D(%C MC%0%<>*OW)Q//`)S8A&!YYL>:@9ME9D?"+=8DL^\1T59K,C!-G4E3I61&5$"N)Q6M:X@UAM+24T(4.2F)F;"0:0$RE> M@$XY-"IR9I4)V0N/NF@L119G>DF+9`/#*#M=BDR-*?.CLK`6$PW&L5X%P^`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`BX&0XET0>!\\+;JB/MXTP[EA_W%^XRNR#Y=IOE9] MU'U-DE4#^K>(@17PTAZZF@0/6*)QC7%%MU?A>FD4&]=0`B):,!!KG(`6UE"" M&?X+5]/56'I/KJN7I'RHS\"7+4J&#DN?EQPJ,TC%Y]I>B\FFHYN&^@>WRQW0*45Y.6M3M8NMY"6*--6,C&348R+'GS-&XDCF0=%UN1O`< M;:6*&B0/C>B3@;M>CHV*K3LI6:CEEB`W)DBF-_UI M3J>.,L)9"+Z%HY@75>7>_\XWP/^%(W!\$XHVA])WP@F^\'R?DTF@8OC``SYQ MB0_\6_N97L453O&-5WR&+D%7QT4><>&LUE<[(7G*)XXNK'9/XQ'?2H&[9YF1 M3YR,,8LDQV&.ZTC67..!ZK?/1PX6QDBI(,0>"#*0C0VE+SNX='3V1XTKH"-G M6V34KDASM:.1<7]TQ-C#IK:MZ\*NAUO6+O:&L: M&]!P,YH5\5\A&_F]+*XZD9LT^+%1-TB$SYP$>($!&WEXE^F=/F$:@_ZSPL5PK*;NDE5[BVV' M]U@U)?__J[!K\Z7:ACQ!4SQKF;#8W)%7^QD-Q_.9*ZZ=Z(U9J?-,/[_W.,Y;V&?@:WW88]A9+1"<;L.KO^SGT3[\=(];AL30BL=0R.^8$FTX!.^F6&_!.HW!8R9GP(YRFL?Z(N? MPPH\A9"^_6L.5".0J!H6&TJ\5B,\D<"S6,,1"$R_6GN[LD*J)`/@_>-$]ZK*>EG*A22&L`R0W(N,RP*\O\-`4O.P$KRX[ZB-[M$]_]3R'Y%IK729 M0MH!,RN4PSJ#0>9;.U\SON;+B=^:OZ?C,OO3L-G30"`,(1[T$L\3C2-\ER3, M)\!20NUYE$2*PR`Y.X=*N^YJP<9J.T:L0?)2'ALB&>$0MB]TG.K["R*DB=IC M"I2R.K0`J>H00='QC2:+I#PO_:/;O(,AHD,-G:Q)?1O+$:1DM2Q"SD MPXH0/0[2"CRS,T#<#PY$)4)D"59<&P]C1)/3C!#[P$Y+6&Q`@;I"$AH42XO,1%RT0I MO,RC0602L-0*U710BC1` MME2A_V'-8#G!^13*VY0T[JJRR"2_=!Q)RNA.F?M.9'S(OX$_B41/^O.5:+S( M6:G'/;O0:M.V&ETIL@O)B:E/N43*1]1/W8G),R'/$W5)2*-#2NL,!&4?FY1' M0/FUSB+#!N5)0I,=8UH4/().E7!,[22H#/52*N30C_DRTSG(>-DU_QIKRO,K MT".*2P7+P5)L48KL0>PSG0B-49[14.9*SKW"4:^33?OD41VET.RRTC"51-U$ MU$2E2\K$2W<$1IED%"85(@45#S!TK\$T)YTD5+A)0L3$ MP\ADR*.D-01K2C5M4RQ!1Q5]F=";#'1HP)=CH;-;_G,N!3->"[!0!C4KE*ZM5S2F,3=&]65'Y M$TU$?-&N'!2QS,A:1-G7N]&CO;-.55@>/51VC4*&[=`?I\!T M55*.T%BAVM:2";6-JO5-#[#ZEE=`T^5.H.M:F_4BF1;QS M3-N&_5%H35?!6JQT?-3`Y<5,6!7>P)Q5GJU5GS6(:XB"2YDCT@Q8T_3! M7J5=Y@+6R(4E_*2)2#+6A^UU)E63TRK:^6,NV6:N0M; M-I,"'LN)OO-6?#3)ZN73R;U<^BQ7_=6BEN6;B5E7W4U9=^U=[HS6IUF_!2[& M$&%'K(6;GCK/@KB&TU4].7I&?PU7H_T;9]HP+07@''TX[+VSS-6UAE;D$F[XS7@6[/82%V^`R7=RIH(O;,W@ZFXE]C`;20O@:,YDZ@-%-:U M(#;B>P,0J?V8(P9B?8.(5GL_X6)BBGLU$+EB+*:X(U:\CG&Y+V[BA"I@_[+! M8BHVXL^<69?SXBR6N!&%"-DAXSI&8ISE*BE.8^$"K0FDXSTF.A9-B$[(X*.A MLQ="&LP@;T#M6>4GVTTICX.WP\6FX1=X@IUS]C=F"YEX92=6\W59`&6 MX9OUI;T%FS552'L5W*HDW*,PW(-(!GB1L]7;2B!J9D"EWKT!X<8=8?Y[1!/6 ML$CT"-BL7-B=Y`*R93)]5IPARB]JB1B.F[N4X'><2G8#RAUFG">MEE'6YB<2 M5Y<3&^G39:B:W=LUC3/N7Z',76#&T%3M73R>VO^\?5%C#A!X_L0]I-4^5%XJ MF0PZ2F2S%%AP#N?_.>="A!B1SC8H9IKNC>07MEQU-E0Q]N2/$PL83%]E#DX* M),Z.-B3&MGM!6A_YM^/"WDYX=6"(QF%B MMD-[A=!\A;!]/=S\0)R?YE,/[N?B&EV#)F%!"5:T1EA,1E,5'J0@]5ZI/HC^ M;&=OZTS@-=^LM8@9,Q#W15/GXV&>CKY.'.J3`M;#!FH@[6;)S;Z2=K)?3FB6 M76J&CL+P`U$@.=,!#JN:S=DO,U&^1M$&Y>HB$N22.63A$6MR!1W(9@E';FRD MY2:4'MJ77FFGI9X@56G_EW78F;):F9CGBY6HK:7K"%2NKXT95";L"S0G6'XB M@59LYDIGIEG;LV9K5EKHB%8)E67JNK9;I7S@S0:T79)SZ;GS;QACZ'@ M9[[5:FZW:W9LTW%N16[MV&XOR(7LLV0+WBWN%?3.$C?Q MK`YEH,I,\[96C$9>C=9*CI;&T5QMTPAIUS[$08%L>QR,M>;PUF1L0<7EEO[> MVB1P88[G=2;0%;]"PW;R)LGIWR1%HN)6C[VI&\^ZH)X*&[+P?_[P/`41SQQ! M_R4'E@'=CL>,:A%//P6.\@0Z\<\.J^!U\:#8:OFV,:_^V7ZE,2WG/[*N\(G) M\3"G9(,E]*%UZWF!:^R1:R-'<9&(6,M&-!J6=%XL<+^=M(QU\)MLOP:5<.M% ME.BV,"Z?XT.',OJF[:($DH%F)3//30]_=)G=%YIETS=GX,G4ZIV=X);.:"[0RG/]1(]2`$<$7'[6_3[15F\P(ZF=].5LI92.*>]F.Y M4^2V">6^:;C2M[@8W]3()\4K?7L]3I?W;W>]:MT;QI'7"3!<^FQXG/WW_M&]L<=I/]EY^]QWM%RSAC(QFOM MX&2`A_<6_MS.U0D%?U])%>'?Y-AP-VYM1V.BIO"4?^YF1T(5VG"R64/;#7+< M=4-4E?=,/K#0WG8X5W%_CSQ]3^^^YLR>\$SXLU6"AYV#\?-JM&Z9C\ULKOE? M112(U]XN]^_]*6J=/QW"C1+/FG&B M".N#K_$J(O=`&O2&#S1#QWQ*3G3`6?37)'`7/G(8OFL8[WEU'%S$UW22+UW7 M$;*S#_20\/&.^/3]E?N7-UG_"[5X[H9Z6@Q[KB]?FM_X[=1L6D_FP;?JD'=( MTI9\"NEU57%1U6Y^2B9VHVYD0._]"8]DB*_D%'[VM_YW@SVGO]D;*]J ME+=W&2OEO*1RP$21X1=!` M;`$6,FS8L"#$B!(#&$08\>`5AQH92NP(L14+B!@_;M08TB-*D`D+CL0FJ*3# MDR@[JK0H$N%+F`QESH1H$UO+@BQT-EPY$\`5``!:]6R*K96@C@BT+-&K0B@'6PFQ;MNO7JEGGVKU;->C> M`'V;_U*,^W9@8+<%*5*-2!>FXL5I5^;,&OEI`+"'@>[EZ=2FX:N!/7L$(,CT MX,NM4EL,+8C%XXUDW4YM##'P;-J>`>]-/;.KZZNQ-?I&*3-TX.(H!=\TFCBR M5LTMG[L%:9MEQKVJ><:MK)-T4Y63"7J'"7YF:^FO`V^EF13J98GP)6)4?W"X MP_:_R8;&WU"Y1WCE959OD5UE7UC^,02@1'BYUAF##;9E&'5N9?;73Q6659A] M&FXX((%9G3=3*XR!")2"Z=9KA;I(U(ANGB;( MH"FQMMM/.8YE(`L(]GE9CX\B>I==<1V:5:L*U0EB2O"NA*W,.5)4"M*S2F1)PM%T-.Y7]E)'IZ1'7FE MH+@>R^>N3@E)8;U&%JJ0B,&&%1S`TBI[HES-?OCN>@8KB^.HU87DVJ]$K6A4 M7.&6A"UY2LG8$30GT'*-$HJ0F-K_L(95K).?,UUU9<&S&DAP9RT;YU5_Q2K; M*UB5+C>L;3YWQ-B3"H?''5C1?K==H=::Q+1]3L=T,<)AL>?4FQ]+E$P-!'%- MTU/P,36V5:P*=`54:0MTZ%!MS_7VLV3+_13=3!W$JMD"I;V>VWV_S6K=@<]M MM]YX.UFXWXEW-;C@=>M]]MZ'GP4WY6[7R/C@!ZE=>-J5>XX7YHVK%#GDK'Y> M>>B,"U;ZYFB?WG?J@H/4>N1LOQY2['+/;CCKHB4.-^ZBBZX2VKP__GO?P>?N MDN:LY_TZ\,*KBII'I.Q`D/7R";(]]]US?S;XX6,DOOC>FW\^B^2KOS[Z[7^_ M/OSENX]^__SU@S__^?;KCW_^^M??_MWZYS_X\<]\`V1?`;UW0`0F\'T+E%\# MT_?`\+GO(^]I&3*ZAHT,DLAF,RJ+!S\(0H&)T"_"0H0RG*49*RE*8DE< M!%4H.K%QC3DX-*`9%:$\_9G1C7:4I/"TZ$$]2A"3$B2D!;VHNE;*T9-6]*$P M72A+"0*-$A1RGS<%*$OOZ37+1&%K#QC!-`(HRT&*,9G&H-)9CA&E%H M(5*5NH2FBI&J4B4C-IY0QA(^`PSK%-G_,[9*,D@L%1)KA0@4("'"LIZ5%FU= M:UK=J@2VN@">8IVK69V:5[PR=:W)@,#(]OK!K+;UJU55`B):0!#'BI"Q6Y4J M54D6V95"5K(E9"Q3I1J%QVYVG4G-ZP?I*MC"[M4:4>A"7Y4:6)$!MJ[/B()> MFZJ$+F"!J'H(A`932PC;LK:IKXVM-:1`5!"FDHXD4P0I>(`]'@S1>M=0K@S7 M6MT=1'>ZT(AM"Y^[760$D;P%^>YR%ULR\VZ0N^7<@37Z>@TZZ+.$XGTO>\D[ MQ$Z,583BE:X0@XC>`$]7A??%GH#!BXT!&[ADU04P@SE;7_4J(K]!C.]R(^Q? M![]7IRXHR#,B_Y",GE:6PP1A+X8UBEW%T)*.T.BMA;^&#:X)-0``/N$S^BIC MKEGX&0P9@%P_^V%/`)C(I#"K$)&,C4XH^;.2/3+VP$!D@DPY&0MI68%CO6H#4\>^87OK@59EXGFD&LX,4^ M&0RN2+).L>"500(9JUJF,H"?@=UKU(&MP74RH)/\9S*OLYT!>'1/P"G'^9IL MN]LMR'-/R&D"!WB[R:#HFB,S:D]W6*-+2.^,5OW>3^C M#,'R962-8`_#\]/VU;6Q(ZSA#PJ;U!$>];$[W6H-0\,$$XXULJ<=V__LC=C` MV1[V@O<\U6NG!)EG[(0&W\S!#3Z:R2=$]XDUF,$W/R.CZ]XGDCV1;REO&=$M MS$._L4%D?5.9W_Y^Z+X+/F6!BUD/0?Z@)](M\ M^#KEO&1,SPC@!U]XFR.2A_[BN^`N5VIOP[H"A@"TH`%'^9X9RG+TQ"B<$=EH M(4.F5T6$++'UK?;#XP/T\XKLN4)?Z]/GL'/%+%VG754$9DT6:OO.H9!9+_JX M29'13J1:,5UG^E-+5O2MSQC7P3Z[U7-+[`6SEMQ4ASO=AS[WO3,;[T\OV=RK M[M\PHWWK`U8MX/L>]*OS?<9E=XO@G;KU%)__U]IER:86?Q?[\9TH7ZRZ_*Y][\/P`&H`#* MB5$-H`$>(`(FX!(UEP(VH`,^(`2V&`1.(`56(#=IF@5FH`9N8#$YR5)T$@>& MH`B.(!U!$ZN4RU*LA@J:BPJN!@NVX`NN8`K"X`S*8`NZ8`WBX`VBX`[&H`[> MH`_R(!#FH!#28`\2G6$0)B$2+N$1-N$0.J$1/J$41B$5VN`46F$5_F`6%B$6 M=J$6>B$7?J$8AB$9*B$4@J$97N$8IN$6LB$:,J$:EF'6F$92T"& MVB$?YF$?XB$@[J$?#F(@_J$@%B(A'J(B&B(C)F(C(B(D+J(C3F(D/J(D5B(E E7J(F6B(G9F(G8B(H;J(GCF(H?J(HEB(IGJ(JFB(K3B(`!`0`.S\_ ` end GRAPHIC 12 image1.jpg GRAPHIC begin 644 image1.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#UK0M"TJZT M&QGGT^WDEDA5G=D!+$CJ:QX+G13Z?RJI?>&3JUX)-3OFN+>,3"&%8@A42*4.6')PK$#IZG.*`.3 MO]3M--FAMKKPOIPN+B`74.UB4"8.48[>'R`H[$L*Z/1[/0M8:X>'2+-8(R%1 MB`6?U.W'"YX![X)Z8J2+PI)AVN=5FFF:W2S$JH$(@!RR\?Q-W;\@*L:5X:@T MK6+F^AE&R12J1"-5V`D$@D-6(C;&X9QQ3+6UMS9P$P1?ZM?X!Z4`4/[&\.?\^>G_DM' M]C>'/^?/3_R6M3[);?\`/O%_WP*/LEM_S[Q?]\"@#+_L;PY_SYZ?^2T?V-X< M_P"?/3_R6M3[);?\^\7_`'P*/LEM_P`^\7_?`H`R_P"QO#G_`#YZ?^2T?V-X M<_Y\]/\`R6M3[);?\^\7_?`H^R6W_/O%_P!\"@#+_L;PY_SYZ?\`DM']C>'/ M^?/3_P`EK4^R6W_/O%_WP*/LEM_S[Q?]\"@#+_L;PY_SYZ?^2T?V-X<_Y\]/ M_):U/LEM_P`^\7_?`H^R6W_/O%_WP*`,O^QO#G_/GI_Y+1_8WAS_`)\]/_): MU/LEM_S[Q?\`?`H^R6W_`#[Q?]\"@#+_`+&\.?\`/GI_Y+1_8WAS_GST_P#) M:U/LEM_S[Q?]\"C[);?\^\7_`'P*`,O^QO#G_/GI_P"2T?V-X<_Y\]/_`"6M M3[);?\^\7_?`H^R6W_/O%_WP*`,O^QO#G_/GI_Y+1_8WAS_GST_\EK4^R6W_ M`#[Q?]\"C[);?\^\7_?`H`R_[&\.?\^>G_DM']C>'/\`GST_\EK4^R6W_/O% M_P!\"C[);?\`/O%_WP*`,O\`L;PY_P`^>G_DM']C>'/^?/3_`,EKDM(\=F]U MZVCN])L+?1[Z6\BMK@2?O$^S??:4$8"G!Q@\=ZZ/PMJ1\1V4VIMI<-MITLI^ MP%E_>31#_EHPQP&/('ICUH`M?V-X<_Y\]/\`R6C^QO#G_/GI_P"2UC^*O%UI MX?U2RT;3]#?5];O%,D5E`%3"#JSN>%'!_*L'5_'=_90:(T_AV/1Y[C6$L+V& M_57"QE=Q>-U(4C'\73@T`=M_8WAS_GST_P#):/[&\.?\^>G_`)+1INM^&M7M M;BZTZ_TVZM[?_721.A6/C/S'L,=ZCTGQ#X6UV26/2M1TV\>%=\BPNK%5]<>E M`$G]C>'/^?/3_P`EH_L;PY_SYZ?^2U5@\5^#KJXM;>#6-)DFN_\`4(LJ9DY( MX'U!'X5+JWB/PKH-RMMJNI:99SLNX1S.JMCUQ0!+_8WAS_GST_\`):/[&\.? M\^>G_DM1W?B+PM8:;;:C=ZEID%G=#,$TCJ%E'7Y?6M*T_LZ^M8[JT%M/;RKN M26(*RL/4$=:`*/\`8WAS_GST_P#):/[&\.?\^>G_`)+4-SXE\)V>JC2[G5-* MBOB0OD/(@8$]`1V-CD'(SZB@# MM?[&\.?\^>G_`)+1_8WAS_GST_\`):RO&'BFT\+3:;96^C'4]4U.0QVEI&4C MWE<9)=N`.14^G:_`-!FU/Q-I$7APPRF*1+R6-EZ`@JXX8'./J#0!>_L;PY_S MYZ?^2T?V-X<_Y\]/_):P/$_B_3;;X?:KXB\-S:9?O9J-K*!(@8LHPP!!Z&M: M7Q#H&EZ/I]YKEYIUBUU"C@3%4W$J"<`\XH`L_P!C>'/^?/3_`,EH_L;PY_SY MZ?\`DM+?:QX.6(*RL/4$4`4O[&\.?\^>G_`)+1_8WAS_GST_\`):X.+XFWMQ'J5Y;>`)[G M2M.N9(+BZ@N8V9=A^8B,J">.?ZUVEOXF\,3>&;;Q$]U9V^F7"@I-<;4Y/&TY M_BSD8]J`+']C>'/^?/3_`,EH_L;PY_SYZ?\`DM87BGQ9I]I\/-3\2>')=-OV MM5&QE`DCW;@"&VGW]JJZ5XIFN_B`FBW-M81V/]AQZB\GE882,1GDG`7!/;\: M`.G_`+&\.?\`/GI_Y+1_8WAS_GST_P#):BTKQ%X5URZDMM+U+3+R>-=S1PNC M,!ZX':DM?$OA.^D\NUU32I7\IIR%E0XC4X9CZ`$'DT`3?V-X<_Y\]/\`R6C^ MQO#G_/GI_P"2T[1]7\/>((Y9-(N["^6(A9#`5;:3TSBN6U'QE;:1\39=#U(Z M99Z-'I8NVGG4(WF&3:!N)QCVQF@#I_[&\.?\^>G_`)+1_8WAS_GST_\`):2/ M6_#4PT\QWVG.-1)%F592)R.H7U(JU%=:/-JD^F126CWT"!Y;=0I=%/0D=LT` M5O[&\.?\^>G_`)+1_8WAS_GST_\`):X2_P#B@]G?ZX(O!4EUIFB7)@O+R*XC MR@!QN$9&3Z]?J179S^)_"MII5CJ5[?V%I:WT:R6[7!5"ZD9&`?:@"Q_8WAS_ M`)\]/_):/[&\.?\`/GI_Y+2W6L^'+&&VGNK[388;I6:"1W0+(%&XE3T.!S6/ M8:S_`&GXV6UL[C0;C1)=.%S$L3[KEF+8W8Z;.V:`-?\`L;PY_P`^>G_DM']C M>'/^?/3_`,EJ&T\2^$[[5#IEIJFE37P)7R(Y$+9'4`=S5/Q3XHT'0+.^@^VZ M7'K$=I)-!:S,NYF"DJ-N0><=.]`&E_8WAS_GST_\EH_L;PY_SYZ?^2U7\&WO M_"0>#=)U:[M;9;B[MEED$<>%!/H#FMS[);?\^\7_`'P*`,O^QO#G_/GI_P"2 MT?V-X<_Y\]/_`"6M3[);?\^\7_?`H^R6W_/O%_WP*`,O^QO#G_/GI_Y+1_8W MAS_GST_\EK4^R6W_`#[Q?]\"C[);?\^\7_?`H`R_[&\.?\^>G_DM']C>'/\` MGST_\EK4^R6W_/O%_P!\"C[);?\`/O%_WP*`,O\`L;PY_P`^>G_DM']C>'/^ M?/3_`,EK4^R6W_/O%_WP*/LEM_S[Q?\`?`H`R_[&\.?\^>G_`)+1_8WAS_GS MT_\`):U/LEM_S[Q?]\"C[);?\^\7_?`H`R_[&\.?\^>G_DM']C>'/^?/3_R6 MM3[);?\`/O%_WP*/LEM_S[Q?]\"@#+_L;PY_SYZ?^2T?V-X<_P"?/3_R6M3[ M);?\^\7_`'P*/LEM_P`^\7_?`H`R_P"QO#G_`#YZ?^2T?V-X<_Y\]/\`R6I= M1O-/TV2"%K,SW-P3Y5O!$&=P/O'G``&1DDCJ/6JDNOZ)!H-QJ\D)6&W8I+#Y M'[U9`<&/9_>]OQZ+_O@4?9+;_GWB_P"^!0!E_P!C>'/^?/3_`,EH_L;PY_SYZ?\`DM:G MV2V_Y]XO^^!1]DMO^?>+_O@4`>)ZC(\>IW<<3E8EF<(%/``8XQ[44W5>-8O0 M.`+B3`'^\:*`/8/#?_(M:;_U[I_*M2LOPW_R+6F_]>Z?RK4H`****`(;O_CS MG_ZYM_*BT_X\X/\`KFO\J+O_`(\Y_P#KFW\J+3_CS@_ZYK_*@":BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#RC5?"FEZ[XPO[/1] M*\J"V#3:K<;G"W$K?,+:,$[5#$*TA4#(P#U-+\,=3UB\UP1S7FHW-O\`V8'U M%+N,JEK>^81Y48*@*-N?E'&`*]6HH`\I\423^#_B_:^+[NRNKC1;K3OL4L]O M$9#;/NR"0.<'C\S5#QWJ^G^.[?PJ]I8WDVGC7XH9?M-JR+*NWYB`>2O."3WS M7LM%`'C&HV4ND>-?'W]C:'#,K:)"4LQ;YAF;@$;!PW&>.]<]X%:>Z^)6E7GG MW%TKZ7.LLG]D+91QOLR8QM`#X)ZGVKZ(HH`^;K70((O@)87J:4%U0ZLKM,(/ MWW$Q&I=<=>-K/R/&6CZM#J$MOX M=?2$ALM0M]+2^B!R3MV$$+N'.0,_KCT;X4Z9!IG@A8K2YO+BWDN)98I+JT^S M,03U6/)PI()'UZ"NPL;&VTRPM[&SB6&VMXUBBC7HJ@8`JQ0!\W^796O@?7?" MFI>&[NX\8W5Y+Y;BQ+M,S."LBRXX7'/7L?6NX@T0P_%WPQ'?6<M>L44`>??%!O"DMO8VGBBTU':Q:2UO;*%V,#C'`9P^RF<;OO")1@#Z=N>]:7BNQO+3QE8ZCJ-W=:?I MLVBP0V]VNDK?H&"C=&58'::1H^D^!_"[MJ6KQ2VTEU-I]U M<:-YD9#-RDD/S8#=5]LFO5_AU4N-QPP3^'=][ M'O74T4`>$^$/&EIX8TKQ/IDMAJ-UJMQJMT]M:PVCMYNXX7YL8Z@_A55/#ESX M/TSP!/XETN:[TJQ-R]]"D7G"WEE.4+(,YQD?B/S^@**`/GO4+)K[PY\1]:T? M2[BST/4([9+.$P&/SG1AO=8\<#.>W?ZULO'?P^.=0GM=.-W,/!:K%!)$629^ M/D([Y].]>UT4`?.?@9[B\^)GA:\,L\Q^SSI.%T=;.*V^ MU:$6T-QI\,<20:NNF_8GN,9^1UP-Q7/7W]ZR_%DVFZ=\L>,KR+R[C7KQI(U/)2!,JBY_/]*[G6])AU[1;O2KB:>& M"ZC,4CP,%?:>H!(/4&[5--^'&G!+S4-.;5IW(O;,Q$H2", MQY.%)Y&>H-;FMZ5=O\4?$%II%N87D\)O#:F--B!RW`!Z`U[#10!\[VZ:=K'A MSPGX0CD$\]?UXJQJL=E8:K\0M.USP]=W^ MK:I*\NFR+9F7?'M.PJ^/E"]21[<5F1^$[N7P]'H=SJ M*+8+&(98X803*H;.X,W*LW?K@\C%`&EJFGWO]M66KV"13200RV\D$LA0,CE3 MD-@X(*#J.037.KX8U34K?4?M,KV%\US/<*J;)()#)&$4@D9RJK@G`();CD5R MGB$W$WC+Q*^IZCJUKHL<\-I'?6-_+'_9LA@C8,\2D*8R6Y;L>O!R*_\`8VH+ M/'9F^UE]:L4\V?3UUFX$>K6__/:WV%],SR6Q?S0\3;B2&4K@@\\#/ MK7I=`!1110`4444`>%ZM_P`AF^_Z^)/_`$(T4:M_R&;[_KXD_P#0C10![!X; M_P"1:TW_`*]T_E69>^+EL]Z?RK.N/`^CSWRW"I+&OEW"21),^U_.QO."<`]?SH`S;_`,;: MAILT-MCZRNL-:9K=+02A`A$`.67C^)N[?EBK&E^&H-*U>YOH9? MED4JD0C5=@)!()'+#Y1C/09%`&G?2QQVQQR6$7_? M`H^RV_\`SPB_[X%`"?;+;_GXA_[[%'VRV_Y^(?\`OL4OV6W_`.>$7_?`H^RV M_P#SPB_[X%`"?;+;_GXA_P"^Q1]LMO\`GXA_[[%+]EM_^>$7_?`H^RV__/"+ M_O@4`)]LMO\`GXA_[[%'VRV_Y^(?^^Q2_9;?_GA%_P!\"C[+;_\`/"+_`+X% M`"?;+;_GXA_[[%'VRV_Y^(?^^Q2_9;?_`)X1?]\"C[+;_P#/"+_O@4`,DO[. M*-Y)+N!(T!9F:0``#J2:S[?Q5H=TDS1:E#B*/S7#Y0[/[P#`$CCJ,TSQ-HG] MJ^'+RRM881/(H*!E`#$,&VDXX!QC\:QKN6XF\1V-\?#MW$+6SN!&C+&3/,VT MB/*DA>%.&8@$T`='8:[I>IQ/):7L3B-RC@G:RMZ$'!'45;^V6W_/Q#_WV*P? M"VGNMO=7.HV#Q:A=2^=<>;&@7.T`*F"?E4`#)Y/7O6_]EM_^>$7_`'P*`$^V M6W_/Q#_WV*/MEM_S\0_]]BE^RV__`#PB_P"^!1]EM_\`GA%_WP*`$^V6W_/Q M#_WV*/MEM_S\0_\`?8I?LMO_`,\(O^^!1]EM_P#GA%_WP*`$^V6W_/Q#_P!] MBC[9;?\`/Q#_`-]BE^RV_P#SPB_[X%'V6W_YX1?]\"@!/MEM_P`_$/\`WV*/ MMEM_S\0_]]BE^RV__/"+_O@4?9;?_GA%_P!\"@!/MEM_S\0_]]BC[9;?\_$/ M_?8I?LMO_P`\(O\`O@4?9;?_`)X1?]\"@!/MEM_S\0_]]BC[9;?\_$/_`'V* M7[+;_P#/"+_O@4?9;?\`YX1?]\"@!/MEM_S\0_\`?8H^V6W_`#\0_P#?8I?L MMO\`\\(O^^!1]EM_^>$7_?`H`3[9;?\`/Q#_`-]BC[9;?\_$/_?8I?LMO_SP MB_[X%'V6W_YX1?\`?`H`3[9;?\_$/_?8H^V6W_/Q#_WV*7[+;_\`/"+_`+X% M'V6W_P">$7_?`H`3[9;?\_$/_?8H^V6W_/Q#_P!]BE^RV_\`SPB_[X%'V6W_ M`.>$7_?`H`3[9;?\_$/_`'V*/MEM_P`_$/\`WV*7[+;_`//"+_O@4?9;?_GA M%_WP*`$^V6W_`#\0_P#?8H^V6W_/Q#_WV*7[+;_\\(O^^!1]EM_^>$7_`'P* M`$^V6W_/Q#_WV*/MEM_S\0_]]BE^RV__`#PB_P"^!1]EM_\`GA%_WP*`$^V6 MW_/Q#_WV*/MEM_S\0_\`?8I?LMO_`,\(O^^!1]EM_P#GA%_WP*`$^V6W_/Q# M_P!]BC[9;?\`/Q#_`-]BE^RV_P#SPB_[X%'V6W_YX1?]\"@!/MEM_P`_$/\` MWV*/MEM_S\0_]]BE^RV__/"+_O@4?9;?_GA%_P!\"@!/MEM_S\0_]]BC[9;? M\_$/_?8I?LMO_P`\(O\`O@4?9;?_`)X1?]\"@!/MEM_S\0_]]BC[9;?\_$/_ M`'V*7[+;_P#/"+_O@4?9;?\`YX1?]\"@!/MEM_S\0_\`?8H^V6W_`#\0_P#? M8I?LMO\`\\(O^^!1]EM_^>$7_?`H`3[9;?\`/Q#_`-]BC[9;?\_$/_?8I?LM MO_SPB_[X%'V6W_YX1?\`?`H`3[9;?\_$/_?8H^V6W_/Q#_WV*7[+;_\`/"+_ M`+X%'V6W_P">$7_?`H`3[9;?\_$/_?8H^V6W_/Q#_P!]BE^RV_\`SPB_[X%' MV6W_`.>$7_?`H`3[9;?\_$/_`'V*/MEM_P`_$/\`WV*7[+;_`//"+_O@4?9; M?_GA%_WP*`.%O?B9]FU&[M8=&:=+>9X?-^U*N\J<$@8/%0_\+2E_Z%]O_`Q? M_B:XW4P%U_5U4``7\^`/]\U6H`N:5JK:QXV\0WVG+]EURXE0+IMV^ZUU*!8( MP\!;&WS!RP.,C=SD9Q;!T]=)B82W4'AZ&XQ!<'B[\-7?3RWSSY.3CG(`.#E2 M",;1`3#XB.H0_:-!6^B:Y>VR+O391"FRZ0CG:.AQR-N>1N%=*#J`U=")+27Q M#);_`+J8X%GXEM`/NM_"LH4_AGNAX`-;P)+@F2R8& M;=!SR`IS@>A&"1BO3?LMO_SPB_[X%`"?;+;_`)^(?^^Q1]LMO^?B'_OL4OV6 MW_YX1?\`?`H^RV__`#PB_P"^!0`GVRV_Y^(?^^Q1]LMO^?B'_OL4OV6W_P"> M$7_?`H^RV_\`SPB_[X%`'B&J\ZQ>D<@W$F"/]XT4:KQK%Z!P!<2<#_>-%`'L M'AO_`)%K3?\`KW3^5:E9?AO_`)%K3?\`KW3^5:E`!1110!#=_P#'G/\`]<'_7-?Y47?_'G/_P!WN) M(@T@>$!F*$<`%N3Z]R0*B_X1'P]VT#6`#ZZE=#CJ,_O./ER3Z<#DG`N^(BX^ M(VBE;I;5!I=YYDI'.WS+?@>A)P,_ESBM(O)D@^(4)&<@+C)W`'&#QE\*/;(' M.30!RUOI=GHWC[PQ_9MEJ%BEP]TDZW%[-()`(695VNY''!)'0\9.#CTVO/[Y ML^/_``<&U3[:WFWA4#``'DL"QQ_M9`[`#`[FO0*`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**QM: MU&Z@OM-TVR,<=Q?R./.D7<(T12S';D9/0#GO[50CU742FKVEQ?VMK+IAY'T-:-` M!1110`4444`%%%%`!1110`4444`%%%%`!1110!X3JO\`R,.L?]A"?_T,U5JU MJO\`R,.L?]A"?_T,U5H`9X5POB+4VLI#8:XUV$L;N8'[+>_N4+6DO;D?,._. M1T(.T18C2[M7L[F+0HI]VHZ:I_TKP]==?/A(Y\K/S?+Q@Y'&Y:Q_#P=_^$G2 M:-=3TK[1&=1TM!_I$4?E)MNH2.=RD'@?W1CD5T2-=&^TZ6+4X7U5XMNBZZW^ MHU>#K]ENL?Q^_7/(YR"`;?P_-^?%_B0ZE/:W4QM;#9>VN`MW'B;9*0.C$<$= M...,5Z)7F/PP%DOBKQ4EE87&FA4M/.L)_P#EUE_?%T3MLR=PQQ\W'I7IU`!1 M110`4444`>%ZM_R&;[_KXD_]"-%&K?\`(9OO^OB3_P!"-%`'L'AO_D6M-_Z] MT_E65=^+7T_6[BTN([:2"&WFN)#;S%I(5C`/S@@#YL]CQ^M:OAO_`)%K3?\` MKW3^55+WPS_:MXLFIWSW-O&)A%"(E0J)%*'+#DX5B!T]3DB@#&O_`!MJ.FS0 MVUSID`N+BW%U"4E8H$P@R*`-*^ECCM)1)(B%HVQN8#/%,M;RV%I"#<0Y$:_P`8 M]*DO8T>SF+HK8C;&X9QQ3+6V@-G`3!'_`*M?X!Z4`2?;+7_GYA_[[%'VRU_Y M^8?^^Q3OLUO_`,\(O^^!1]FM_P#GA%_WP*`&_;+7_GYA_P"^Q1]LM?\`GYA_ M[[%.^S6__/"+_O@4?9K?_GA%_P!\"@!OVRU_Y^8?^^Q1]LM?^?F'_OL4[[-; M_P#/"+_O@4?9K?\`YX1?]\"@!OVRU_Y^8?\`OL4?;+7_`)^8?^^Q3OLUO_SP MB_[X%'V:W_YX1?\`?`H`;]LM?^?F'_OL4?;+7_GYA_[[%.^S6_\`SPB_[X%' MV:W_`.>$7_?`H`;]LM?^?F'_`+[%'VRU_P"?F'_OL4[[-;_\\(O^^!1]FM_^ M>$7_`'P*`&_;+7_GYA_[[%'VRU_Y^8?^^Q3OLUO_`,\(O^^!1]FM_P#GA%_W MP*`&_;+7_GYA_P"^Q1]LM?\`GYA_[[%.^S6__/"+_O@4?9K?_GA%_P!\"@!O MVRU_Y^8?^^Q1]LM?^?F'_OL4[[-;_P#/"+_O@4?9K?\`YX1?]\"@#BM>DCG^ M)6@F&W2]D73;PHH8$(=\'S'TXS[\UK!)<#'AV-5P,Q)XUVZ=C]2'R?;^\PSQ MU5<#"@T`9.HLT7CKPBTUA%81^?=;OF'S'[,0!QQ@+@?7@<#)[G[9:_\`/S#_ M`-]BN!O/LDWCWP>(KV6]'F79S+DA1Y#<^F6.6'MC'RXKT#[-;_\`/"+_`+X% M`#?MEK_S\P_]]BC[9:_\_,/_`'V*=]FM_P#GA%_WP*/LUO\`\\(O^^!0`W[9 M:_\`/S#_`-]BC[9:_P#/S#_WV*=]FM_^>$7_`'P*/LUO_P`\(O\`O@4`-^V6 MO_/S#_WV*/MEK_S\P_\`?8IWV:W_`.>$7_?`H^S6_P#SPB_[X%`#?MEK_P`_ M,/\`WV*/MEK_`,_,/_?8IWV:W_YX1?\`?`H^S6__`#PB_P"^!0`W[9:_\_,/ M_?8H^V6O_/S#_P!]BG?9K?\`YX1?]\"C[-;_`//"+_O@4`-^V6O_`#\P_P#? M8H^V6O\`S\P_]]BG?9K?_GA%_P!\"C[-;_\`/"+_`+X%`#?MEK_S\P_]]BC[ M9:_\_,/_`'V*=]FM_P#GA%_WP*/LUO\`\\(O^^!0`W[9:_\`/S#_`-]BC[9: M_P#/S#_WV*=]FM_^>$7_`'P*/LUO_P`\(O\`O@4`-^V6O_/S#_WV*/MEK_S\ MP_\`?8IWV:W_`.>$7_?`H^S6_P#SPB_[X%`#?MEK_P`_,/\`WV*/MEK_`,_, M/_?8IWV:W_YX1?\`?`H^S6__`#PB_P"^!0`W[9:_\_,/_?8H^V6O_/S#_P!] MBG?9K?\`YX1?]\"C[-;_`//"+_O@4`-^V6O_`#\P_P#?8H^V6O\`S\P_]]BG M?9K?_GA%_P!\"C[-;_\`/"+_`+X%`#?MEK_S\P_]]BC[9:_\_,/_`'V*=]FM M_P#GA%_WP*/LUO\`\\(O^^!0`W[9:_\`/S#_`-]BC[9:_P#/S#_WV*=]FM_^ M>$7_`'P*/LUO_P`\(O\`O@4`4-2M]-U-(?-NQ'+`_F0S0S!7C;!!(/N"00<@ M@UB/X6TV5;B&76[B2">Y2[<-,N\RJ,99OXEX7Y2,`J,>E=5]FM_^>$7_`'P* M/LUO_P`\(O\`O@4`06TUM;VZ1&_$Q48\R612S?7&*E^V6O\`S\P_]]BG?9K? M_GA%_P!\"C[-;_\`/"+_`+X%`#?MEK_S\P_]]BC[9:_\_,/_`'V*=]FM_P#G MA%_WP*/LUO\`\\(O^^!0`W[9:_\`/S#_`-]BC[9:_P#/S#_WV*=]FM_^>$7_ M`'P*/LUO_P`\(O\`O@4`-^V6O_/S#_WV*/MEK_S\P_\`?8IWV:W_`.>$7_?` MH^S6_P#SPB_[X%`#?MEK_P`_,/\`WV*/MEK_`,_,/_?8IWV:W_YX1?\`?`H^ MS6__`#PB_P"^!0`W[9:_\_,/_?8H^V6O_/S#_P!]BG?9K?\`YX1?]\"C[-;_ M`//"+_O@4`-^V6O_`#\P_P#?8H^V6O\`S\P_]]BG?9K?_GA%_P!\"C[-;_\` M/"+_`+X%`#?MEK_S\P_]]BC[9:_\_,/_`'V*=]FM_P#GA%_WP*/LUO\`\\(O M^^!0!X;J;*^OZNRD%3?SX(.0?G-5JLZF`NOZN%``%_/@#_?-5J`(_#?EKK&I M.=VF7G]H(NG:X,&-)S#'_H\P_P">;C'7@G.,$"N@=(S%JD4ND,;?=NU_PZAR M\#DY%Y:$&'.#X7WO?^)H;9DU/,B&_\/2X_TNU\I,R19_Y:J<_7 M@<'::WT=#'I(G&6A8GFSNQU(XV_-UQV8<@&S\/;AT\4>(&N]9 MM]2B>SL3:WP(5IX/WVPOZN.02.N,\&MWQ3J[PZEHEM;7MPL-Q+*)EL2C2,%C M)'4'`S6!\.[>(^,?%@FT1=+N=EH;JUP"@F/F[GC/=&X8$8ZGC.:]!ETNPFN( M+B2TA:6`L8F*#*$C!Q^%`'*KJFIIXKBT8:@#:2;;\7+E-Z0J`K0'W+[3G^Z3 MZ5UWVRU_Y^8?^^Q49TNP-Z+PVD/V@1F(2;!G82"1^8%3?9K?_GA%_P!\"@!O MVRU_Y^8?^^Q1]LM?^?F'_OL4[[-;_P#/"+_O@4?9K?\`YX1?]\"@#P_53G5[ MTCD&>3!'^\:*75>-8O0.`+B3@?[QHH`]@\-_\BUIO_7NG\JU*R_#?_(M:;_U M[I_*M2@`HHHH`AN_^/.?_KFW\J+3_CS@_P"N:_RHN_\`CSG_`.N;?RHM/^/. M#_KFO\J`)J***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#GKK7=0>Z MU)=,LH)H=-(6G4DCKWIVH>&YYY-1;3]5EL%U%<7"K$K_-MV;U)^Z=H`/7H.E1)X;O6G MT6=K^&W.EH42""##R MXSS*=\&%]QW/;CGC-7`=&.")+]L\AB?O=\G/'/\`K#GLH)^7`H`I:F+W_A/? M!YNX+>$>?=\1<[F^SGG/H!A?4XSP,"M+7&MY?%=E:ZM*(]+:TD>-9)-D$#9BY;$MV"\^?E!MV..>PKT*6&*=- MDT22)G.UU!'ZT`>;7$D5[X-N<7]HR)+=C3YKJ[96\A6(5D(.68=`3[5Z!I4Q MN='LIR)E,D".1/\`ZP94'YO?U]Z(M*T^%Y&CLX%,C^8V$&-_3=CH#QUJY0`5 MSDFOW;^)[O2+<6""WCB8?:)BKREPQPH`[;?UKHZS(=$MHM MF27[QR,YO+IKEMP`VDJJX'M\M7Z`"BBB@`HHHH`****`"BBB@`HHHH`**S]; MU1-%T:YU%XS*(5!$8.-[$@*,]LDCFLX:U>Z;J<-IK8M%CGMY9TGM]P6/R\%U M8-U&&!#>QXH`Z&BL/PWK-[K"WYO;-;1H+C9''D[O+**Z[L]&PPR.U;E`!111 M0`4444`%%%%`!1110!QJ^,-;O;[4(M(\)R7MO97;VC3M?Q1;G3&["GG'-2_\ M)#XO_P"A&;_P:PUA>'#IYNO$8NGNGD_MNZ`2+H`2OR_\"QD^H3GY0:W`=&., M2W[YZ,3]_/.3GCYO]8<]E!/RX%`&AX;\0SZX^I6]YICZ=>:?.L$T+3+*,M&K M@AEXZ.*WJXGP((1KGB[[.DBPG4(BOF@[FS;1?,<\_-][GUKMJ`"BN=\8,196 M`E9ET]KV,7Q!(`APWWB/X=VP'MC.>,U@QW)^W:Y;>%AYUD1;1LMFZ8A=M_FO M&"P&=FWIQN^AH`]`HKF?`("^$+:);>>!(I9HT2<@MM$K8YR<^GX5TU`!1110 M`4444`%%%%`!1110!BWOB..VN;J&&QN[P6:AKIX%7$61NQR06.WG"Y.,>HI9 MO$=O%)9,+:X>RO'B2*]0*8RTGW.,[L'@9QCD53O-'UBVGUAM(>R9=3&_-RS` MPR;`F1@'<,*IQQ@YZU3L=$U8SZ-YMM;KIVFP1I#:2W!WI*HVF1MJE7('W>1U M)Z]`#SK5?^1AUC_L(3_^AFJM6M5_Y&'6/^PA/_Z&:JT`1Z'L6?5GOU:RLUU* M/[+KL!_>:==&&,#S!_SR<84YX[-U!'2,MT;[4HI-+ADU1X]VMZ"O^HU6'I]K MM<_Q^W7(P>0">=\)EO[A@G!_Y99^7YN,'!XVM0!PFN?$'5_!7B64 M^&M;CU&QO+.#RIKJ$/*D:%PL;D\[E+,#GGIGFJ?_``OWQU_S\6/_`("BLGXM M+=CQS)_:.FP65^8$-R;:X:@#Z;^#/Q'\0^-M:U*UUF M6W>*WMUD3RH0AR6Q7LE?-W[-?_(RZW_UYI_Z'7TC0`4444`>%ZM_R&;[_KXD M_P#0C11JW_(9OO\`KXD_]"-%`'L'AO\`Y%K3?^O=/Y5GZAXCN='U1X;^V@-J M;:XND:"0M(B1`$EP0!SGC'?BM#PW_P`BUIO_`%[I_*J*>%W;4-3N+O4#6HM(0;F'(C7_EH/2I+V-'LYBZ*V(VQD9QQ3;6 MW@-G`3#'_JU_A'I0`_[;:_\`/S#_`-_!1]MM?^?F'_OX*=]F@_YXQ_\`?(H^ MS0?\\8_^^10`W[;:_P#/S#_W\%'VVU_Y^8?^_@IWV:#_`)XQ_P#?(H^S0?\` M/&/_`+Y%`#?MMK_S\P_]_!1]MM?^?F'_`+^"G?9H/^>,?_?(H^S0?\\8_P#O MD4`-^VVO_/S#_P!_!1]MM?\`GYA_[^"G?9H/^>,?_?(K)FUS1(+IX'QB.40R M3"W8Q1R'&%:0#:#R.I[B@#4^VVO_`#\P_P#?P4?;;7_GYA_[^"J,?_?(H`;]MM?\`GYA_[^"C[;:_ M\_,/_?P4[[-!_P`\8_\`OD4?9H/^>,?_`'R*`&_;;7_GYA_[^"C[;:_\_,/_ M`'\%.^S0?\\8_P#OD4?9H/\`GC'_`-\B@!OVVU_Y^8?^_@H^VVO_`#\P_P#? MP4[[-!_SQC_[Y%'V:#_GC'_WR*`..\0^,]2LO$B:/HMA8WC"R%W)+<731@`N M4P-JMD\9JB/&'C$X_P")'HG/_41D_P#C50>(42/XI,$55']@J?E&/^7@\U,. MJ]N/\*`*-IJWB#5?B'IDE[9Z;9.FF785XKEI0%WP[B=R+R,`#MR3VP>W+:P, M[KNQ'7<`>G0D6_5)1<7(1K-RC?Z MH[CN!R`#\N/0<\G`P_[2U7_H,ZK_`.!TO_Q5:7Q"6V74/#7V;3YK8?:)PQE& M"/W)VJ,\]/F/N>>[1)%FO'9&4@Y!#'%>R?;; M7_GYA_[^"O$M&`;Q+HH8`@WT>0?H:]O^S0?\\8_^^10!1U?7+32=&OM1,D

2YQ7C_`/PTMIO_`$+EW_X$+_A7J7C2WA7P)X@(AC!&FW&# MM'_/-J^(:`/HS_AI;3?^A),X*E<;@0>H(X[T`:_VVU_ MY^8?^_@H^VVO_/S#_P!_!3OLT'_/&/\`[Y%'V:#_`)XQ_P#?(H`;]MM?^?F' M_OX*/MMK_P`_,/\`W\%.^S0?\\8_^^11]F@_YXQ_]\B@"GJ*:;JNG3V-U/$T M,R[6Q*`1[@]B#R#6))H<5QJ$5Q?:S%J4/D/;2P7BQ[3&Q!)7;CYB5&2,?_?(H^S0?\\8_P#OD4`9&D:7HNAW%]-8R0QF\D$CCS!@84*`/;C/ MXFM7[;:_\_,/_?P4[[-!_P`\8_\`OD4?9H/^>,?_`'R*`&_;;7_GYA_[^"C[ M;:_\_,/_`'\%.^S0?\\8_P#OD4?9H/\`GC'_`-\B@!OVVU_Y^8?^_@H^VVO_ M`#\P_P#?P4[[-!_SQC_[Y%'V:#_GC'_WR*`&_;;7_GYA_P"_@H^VVO\`S\P_ M]_!3OLT'_/&/_OD4?9H/^>,?_?(H`;]MM?\`GYA_[^"C[;:_\_,/_?P4[[-! M_P`\8_\`OD4?9H/^>,?_`'R*`.$\(O>LWB-K2XM8X3KEVG0GJ.W"\^NX]EKD?#*6?VCQ&)+">X<:Y<@%,[5.057T MQU8]OE!/.!6\$TT8*Z3>CIM8[A[@G/MF0YZ'!/S8%`%;P?/Y7B3Q@MW=0-.= M1BW%2%&?LT7`&>@Z>O'-==]LM?\`GYA_[[%>8P1@+XO\FSDMK8:O9B=`O[Q+ M;R8/,/'(RN2>_)SSFM-!X>&O:C;Z:VEII0TY#=(`IMQ,9,1D@$#ID-CMC/:@ M#NS>6N.;F'G_`&Q4.[3/M0N@UJ+A4\L2!EW;W@",1#'D#^X*\\TZXU#_A`XM>4Z@UU:Q)>3"ZD1H[M%!,B*,G:"N< M<#D+0!Z%]MM?^?F'_OX*/MMK_P`_,/\`W\%9^@6LO]BV\NH%)KJ<&9SM&$W' M<$7V4$`?2M+[-!_SQC_[Y%`#?MMK_P`_,/\`W\%'VVU_Y^8?^_@IWV:#_GC' M_P!\BC[-!_SQC_[Y%`#?MMK_`,_,/_?P4?;;7_GYA_[^"G?9H/\`GC'_`-\B MC[-!_P`\8_\`OD4`-^VVO_/S#_W\%'VVU_Y^8?\`OX*=]F@_YXQ_]\BD:V@V MG]S'T_N"@#D+/XB'4;..]L?"FO7%I*N^.95MP'7UYE!`^HJQ_P`)K>9Q_P`( M9XA_*V_^/5S_`(#2S_X0+0_,TFXDD^RIRGW2>2.^.3ES_N@MS@5T2)IH92FD MWHY&UFW#W!.?;,ASWP3\Q`H`\I:^74[W4+Y898!->SMY4P`=")""&P2,@@]" M:6J.D[/LUQY8<)]MNMN_.['G/C.><_7FKU`#=$QY6O-J41;1$U"-GO+4D76E MSB%-ER,?P=CZ8Y!&:Z7&H?VM(#':2^(9+?\`?0<"S\2V@'WE_A64`_AGNIXY MKPG\OB+5C82FUUUKD+:FX!^RZBGDH7M7/3=_$.XSD9Y%;)&GKI$@:*Z@\/PW M&9H0<7GAJ[_OICGR,?$AK`^)HUTN[NIK)+9%C@N\^;9X+9M MVSS\AR,'H,=1@UR%=W\6_P"T?^$USJBVCW1M(O\`2[3&R\7G;-@="PQD<].. M,5PE`'M?[-\L<7B36C)(B`V:X+,!_'7T;]MM?^?F'_OX*^<_V;HTD\2:T'16 M'V->HS_'7T=]F@_YXQ_]\B@!OVVU_P"?F'_OX*/MMK_S\P_]_!3OLT'_`#QC M_P"^11]F@_YXQ_\`?(H`\/U4[M7O2.09Y,$=_F-%+JO&L7H'`%Q)P/\`>-%` M'L'AO_D6M-_Z]T_E6I67X;_Y%K3?^O=/Y5J4`%%%%`$-W_QYS_\`7-OY46G_ M`!YP?]<'_7-?Y4`34444`%%%%`!1110`5PFI M:7K%MX;U;1(M,>ZBN;B607,HW18 M6]I"\\I49(502<#OP*XU?BKIKM=JN@^(BUF@DN5%B,Q(1D,PW9P1SF@"Y'X? MU/\`X2FQU>.[BEMGFEGE\RV*2(C1A43ENPXZ#')/6NPK@O\`A:^E[;)O[#\0 M;;Y2UJPLABF:A;ZMI5IJ5J6-O=PI/$6&#M8`C([<&@"U111 M0`4444`%%%%`'FWB3_DJ;?\`8!7_`-*&J0=5^E1^)/\`DJ;?]@%?_2AJD'5> M_'^%`%"V,H\=:68[E+91IMV9)7_A7S(.G8'.!D^_?%=F7NP6W:];9&=P``Z, M`0/3Y\)[#/5CD<5`%;Q]HV;1KIQ879C0=%;?#\Q/8`9]><8YQ78!$`&WPXR@ M8VG."H"X'3T3/3HQP,DD@`X3XDM(=2\,"74DNV^T7.T(`.!$P9B!_M94>@&. M3DU@5O?$52M_X;"Z8+%?M,VX9')$!"@`=@N/8'(&>36#0!=T7_D9]%_Z_H_Y M&O1LVT9)Z@`#N22!^->QVNNNVH1V.H6$EA--$TT/ MF2*ZNJXW#(/##(R/?J:`(_&W_(A^(?\`L&W'_HMJ^':^RM7\00^(/A_XLE@M MYHH[>TN8E,N!YB^3N#@>A#`C/-?&M`!7WII7_((LO^N$?_H(KX+K[TTK_D$6 M7_7"/_T$4`6Z***`"BBB@##U2SO8]?L=7M+;[6L,$MO)`)%5@'*,&7=@'!3! M!(X/M7-SZ?J]WX9UZT32)AJ-]?F9H2Z!$4E-I#DX;Y4&<="2,=ZTM2^(>GZ= MK-YI::7K%[/9LB3O:6F]%9E#`9)'8CZ56'Q,M#C'AOQ+SC'^@#O_`,"H`[2% MWDA1Y(FB=@"8V()4^A(R/RI]8'AOQ;9>)I;N&WM+^TFM!&TD5[!Y;;7W;2!D M\':?RK?H`**RO$&IS:5IJ26Z(UQ-/%;0^9G:&D<*"V.<#.?PK._M#5;34[G2 M;BZCGD-D;N&YCM3N7#!64Q@_,>01CWH`J^/O&-[X2@T\V&EK?S7=87(U*3R+SC)2-_*^_CG!Q[5E M:]JNJ:EJ'AMAJEM8:C!JUU!;W$\6P%A#\B2QDY7?D*0.<,".3BJY%M]CU&.3 M2YDTU)`VMZ$A_?:7-G(N[4CDH3\WR_4?Q+0!NZ/\0]=O+S3EO]&T^WBN;_\` ML^YBCNW-Q:2E68!T9`.0I(()!'(KTFO%9\MXN\(R7V+R]>^C^R:U;_ZK4K7R MWQYF./-3(Z^I(ZD5[50`4444`%%%%`!1110`4444`>>>%VF67Q'C4XK2/^V[ ML[6QDJ"NYN>^=H'89/4XKHB]V"V[7K;(SN``&,,`P'I\Q"#K@9ZLQQC)-;XC0!=OAQE48VG."N!@=.F$R>.C'` MR22`"EX).?$'C$FY%RW]I1!IAC#,+:+(&.@!R,>U=:UG;/<1W#01F:($)(5& MY0>H!]#7A.IM,GC7Q&`)[(">`"""X9`B_9X\`["!G&,^G3)IOFW'_/[??^!D MO_Q5`':^.O$7B73O%,5EH\ZP:9;V"WE\\=H)YD0R,F]4)&X+@$@TMY'YVBW!L$^S:@N,[-^[Y).OR\^HSS7)Z4Y'CY"FLSV&J&R1 M=/N;B1Y(6E,C?N9B(M_L>HQR:7,FG)(&UO04.9M,FZB[M2. M2A/S?+]1SD4`;?@[Q/K5]XJM=.U#5TNUFM+AKFSELEMY[.>)HQM8!CD$2<'H M1R*]"73[-=/_`+/6VB%GY9B\@(-FPC&W'3&*^:_B7KVO^']0T34+.]4W4EM+ M'#K]F5!U&V)0IOQT=<<]CD$=<5QG_"T_'/\`T,U__P!]#_"@#[/1%C1410JJ M,`#H!2U\T?"'QYXJUSXD:?I^IZY=W5I(DQ>*1@5;$;$=O4"OI>@`HHHH`*** M*`"D;[I^E(M1^S:MJ5G;VK6&ER21R1R%O-F\L9D*D<+W`!!SCMFK0UN\ M?Q1;:?\`9H1I]S9/<13;R9&*E.JXP!\_J3Q0!R_P_>4?#W0]FMQ0QBT&5;;E M0/O?E\JCTR2GS$(.N`3U8\.C'`R22`#Q MC3@XCNQ*5,@OKK<5&`3Y[YP.U7*HZ2$6VN!'$8D%[=!8R,%!YSX&/:KU`#=` M#LGB8740U#1%NHFO[.$?Z5:?NDVW<1'/RD'('/RY'0@]*K7O]I6U%XF;2]5-\J:=K##,$DIA3-I M-_LN`",]^G(YWB+?[)J,=CMVWXX...*X6@#V[]FO_D9=;_Z\T_\`0Z^D:^;OV:_^1EUO M_KS3_P!#KZ1H`****`/"]6_Y#-]_U\2?^A&BC5O^0S??]?$G_H1HH`]@\-_\ MBUIO_7NG\JH3^)IK/6=6MKVQ6*TL;'[:DHEW-*H+`_+C"_=XY_*K_AO_`)%K M3?\`KW3^55+CPTUYK5W?7-^TEO=6ALY+81`#RCN.-W7.6/-`&-?^-=3TV>&U MN=,M_M%Q;BZB*2,R!,'*,=N=^0JCL2U='HVM)K+7#Q*BP1E53]X"[>K%>RYX M![X)Z8JA%X3.'-SJEQ/*T"6@EVJC"`')3CNW=NOIBK.F>&[?2]7N+Z&4[9%9 M4B$:J(PQ!(R!DC*C&>@X%`&E?3116DHDD1"T;8W,!GBH[6]M1:0@W,.1&O\` MRT'I4M[&CV#_GC'_P!\BC[/!_SQC_[Y%`#/MMI_S]0_]_!1]MM/^?J' M_OX*?]G@_P">,?\`WR*/L\'_`#QC_P"^10`S[;:?\_4/_?P4?;;3_GZA_P"_ M@I_V>#_GC'_WR*/L\'_/&/\`[Y%`'/>-[NV?P#XB5;B%F.F7("AQS^[;BO/; M-IS%HD@U:,W;1*N@^(L9CN`1S9W8'4Y!`SUQD88$'T3QS!"O@#Q&?*08TRYY M"CC]VU>&@I+:SX?',VESX)%S;8ZQD_-\O&,D?Q+7HO@:[MD\`>'5>YA##3+<$;QU\ MM:\]N7+6UG,-8W.T#KH/B0C(N(R#FSN_5N"!GJ1D88$'T3P+!"WP_P##A,*< MZ9;=5'_/-:`-W[;:?\_4/_?P4?;;3_GZA_[^"G_9X/\`GC'_`-\BC[/!_P`\ M8_\`OD4`,^VVG_/U#_W\%'VVT_Y^H?\`OX*?]G@_YXQ_]\BC[/!_SQC_`.^1 M0`S[;:?\_4/_`'\%'VVT_P"?J'_OX*?]G@_YXQ_]\BC[/!_SQC_[Y%`'F_B" M6.;XHNT.M*+W9MH_[.N][J/F;]Y!\H[Y)QTY[#KFNNWP$X_X2*9V)YP#\QW8 MXQZOTQ_""%_B-$%CGVR..N>PR:[79J&,?V M)9J/3Y3@;<8]\)\GN3CA1D@'G7Q%>%M2\,^7J4EZWGW!!;H%\ILGTR6R0?3& M.!6'71?$H78U#PU]HLX+53\?(02RGGW`KTR]T^\U;4X6U:[L)+0VTMJWV*#_`)XQ_P#?(H`X;5]-@TCP=XR?^US= M"\LYG19)5)0"WV8XQS\OY8':OCVOM[QI!"/`GB`B)`1IMQT4?\\VKXAH`*^[ M=+O;4:39`W,(/D)_RT']T5\)5]X:7;PG2+(F&/\`U"?PC^Z*`+'VVT_Y^H?^ M_@H^VVG_`#]0_P#?P4_[/!_SQC_[Y%'V>#_GC'_WR*`&?;;3_GZA_P"_@H^V MVG_/U#_W\%/^SP?\\8_^^11]G@_YXQ_]\B@#RV%UD\:^,61E93>08*G.?]&C MK1'WE^G^%9T2A?&WC(*`H%Y!T'_3M'6B/O+VX_+I0`_P5/##XQ\1^;*B9M;' M&Y@,_P"NKN_MMI_S]0_]_!7FWAC4(;3QOKT!LI[RXEL[-TBAC5B%7SLDEB`! MD@=*`-#4%TS5+*2 MTNIXFB?!XF"D$'(((.000"#[5D)H=G'?RW::_165XXUZ^T>_T^WTS[)&D\,DKM);B0G!0#'(Q]XUR__"9>(?\`GXL/_`$? M_%4`7?'=AIUI>Z!%'8/KL<]S=2WL'FAYIU,!#./5E4`J!C[H`P:JH[F32I8M M85IV&WP]XC;E9U/_`"YW@[GC&3@DC(PP(.'JFOZAJ7B/PZNHZY!I96>7[/>P MVXC$4QCPF_DY0DA2#@8/45N.DC2ZK#+HZO.R[O$'AM>5N5/_`"^6GJ3C/')( MP<,`2`58V2/Q#H@@(TR)-4XW'T)P1@Y%>R_;;3_G MZA_[^"O&R!-KW@R23&KVIU!1IFO`9=[?8^ZWG_Z:*0,$CG!Z$-GO/[8NKG7- M8TZT_L=9K-O+M[:8'S9V,2N#]X8&6QT/`H`ZC[;:?\_4/_?P4?;;3_GZA_[^ M"L+PUK2^(_/N(]/CALX@L677Y_/Q^]3'HAPOU!]*Z#[/!_SQC_[Y%`#/MMI_ MS]0_]_!1]MM/^?J'_OX*?]G@_P">,?\`WR*/L\'_`#QC_P"^10`S[;:?\_4/ M_?P4?;;3_GZA_P"_@I_V>#_GC'_WR*/L\'_/&/\`[Y%`&+=^)`NHS6.G00W< MT$2RS%[E8E7=G:H)!RQVD]@.,GFJQ\;6;_V+);V[RVVIR",S-(BB`X8X89R3 ME2,#CWJQ=:!<)JMSJ&E7%K;R7421S+/;>8N5SM=<$8(#$8/!XK+A\*:@-*T6 MT5["W.F3"5B8FE\]@&&[.5P&W$D8.#0!E^&)(3-XB+ZL]NK:W=%4BS\R[E!Y M'^[`P,FNCV7^`/[$LU7T^4[1MQ^.$^7W)QPHR0#Q_4&C M;QGXD,5P]RAN8OWSG)<^0F3],YQCC&,<4E2ZOYW_``G'B7[1''')]H@S'&#J3QCG!)&1A@0>5L/LB^-=]Q=SZ=<+9 MQBSU2,$I:3&5@OF]MC_<(/!SCCK75.DAFU6&71U>X9=WB#PXO*72G_E\M/4G M&>.21@X8`D`\K^+9M!<:?'!%/IURKSF\T5SE+.8["SQ?],Y.&&.#@G@Y%>;5 MZA\7FN)+7PZ_VR+5--,4W]GZIG]]-%E?W>&-HV1G(&3R,@-@;@",\],U.+!)-7L]5GUJ M-9K>`P^1"(Q$0VW#_GC'_WR*0V\.T_N8^G]T4`><^`9+;_ M`(5_H>=:GA'V09B&X]\,!]6VJ,>A"\DFNE5X"X!\0S.V>0`<,=V.,>KX`Q_" M"!_$:P_A^M^?A_H133K24?9$VRMC/0A2>_"YS[M@<9-=(J7_``/[%LU7_@)V MC&/QPGR^Y..%&2`>(:9GR;K,@E/VZZS(,8;]\_/''/M5VJ6E_P"HN?W7E?Z= M=?N\@[/WS\<<<>U7:`$\-"22X\3Q($U6U,J?VCH+8\R6W\I/W\/?S%.>!UP. MAVUOH[%]*EAU@&5AM\/>)'Y$RG_ERO!U)XQS@DC(PX(/.Z!Y:WVIR70;3@NI M(+'7XL'['(/#B\I=(?^7RT M]6.,^I(P<,`2`>*?$]($\9RB/2)-(F\I3=63?@KC:[7 MXGOO\3V[1ZQ_:]H;*+[)=,/WAARVU9/5UY!)P>.>#_GC'_WR*`/ M#M5(;5[TCD&>0@CO\QHI=5XUB]`X'VB3I_O&B@#V#PW_`,BUIO\`U[I_*M2L MOPW_`,BUIO\`U[I_*M2@`HHHH`AN_P#CSG_ZYM_*BT_X\X/^N:_RHN_^/.?_ M`*YM_*BT_P"/.#_KFO\`*@":BBB@`HHHH`****`,#QSG_A`/$>.O]F7/7_KF MU>9VCPMH^D2_VO)]@4A=&\0'F73)\`&UN<]8R?E^;CH#_":]+\=8_P"%?^(\ M]/[,NO8\8-`#;M9 MC%K<1TB,W31%M>\.9RDX(XO+0GJ<@$XZXP<,`3Z-X$_Y)]X97;6G]B6\G]I3KI2!UT;7#_`,?&F2X(-IP/.TUZ;X$_P"2?>'. M,?\`$LMN/3]VM`'04444`%%%%`!1110!YMXD_P"2IM_V`5_]*&J0?>7Z5'XD M_P"2IM_V`5_]*&J0=5[\?X4`9B&`>.=)%Q/)%&=/NQMC^]*=\.$]3ZG'ISQF MNK#Z2>FH7SD]"3D/DYSTYW$;_<+_`'!BN:M/M'_"?:3]F6(R'3;S+2]$&^'+ M8[GMCWKMC_;/.Y;`#G(';H3UZX&$_')XP*`/-/B";)M1\-&TFN9R)Y\O-D[0 M8B<<]V/S^I!!X&!6-71_$W[=_:/AG[8UO_Q\W&!"/O'R3D\]A]WWQD]<#G*` M,_5\^1:`6TMUF^M@;>%RCS`R`%%8$$%AQG/>M4^'M#:S=EO[V/2M0EVV.LM= M3;]/GS_Q[72%\!<_+DX/8G.&K)UEE6WM&>]-BHO[8F[&/W`\U?WG/'R]?PKM M&6]_M.[1[*VEUN2#.HZ8,"UU^VQCSX<\"4#_``/�!QWB[0DBT#5I8+>2QU M?3[79J.ERWT[1E"0!=6S%OF4]"#D]^-/L;?#R=R;G4-(2-ETC4? MF^TV$F0&M+COM[`MZ`'^$UX)0`5]Z:5_R"++_KA'_P"@BO@NOO32O^019?\` M7"/_`-!%`%NBBB@`HHHH`\J3_D=_&7_7Y!_Z31UH#[R_3_"L]/\`D=_&7_7Y M!_Z31UH#[R]^/SZ4`5/"R:DGC[7+FPAMIE6QM(Y(YI3&>3*00P4],'(QWZ\5 MJ1:)KTVDQ:;-9V_D&ZFGU&,W!07+,Y<*A"M^Z)/.<-QCN:;X&_Y''Q)_UZV/ M_M>N^H`\P^)>?[:TGLW_H<=<90!6" MW#>)M&6VTV+4V/VD264IP)XO).]1VW%(-#:_O;BQ@668B\M\[K=_+^20X_A#8)SQ MC.>*[-EO?[3NT>RMI=;D@SJ.F#`M=?ML8\Z'/`E`_P`#Q@T`9\TL5MXOT9KM MTT?4!K$3ZKI18?9Y9/+D"W<+'HK`$''<@-R,GU"RGT*QO;^ZCU:U:2]F$TFZ MX3"D(J8'MA17@?Q.^;P#8M:C^TM&6Z"Z??3?\?5APV^TFS\W!`P>ORX/0$^, MT`?*VJ^'?!7_(]^'O^PE;?^C%K M[BH`****`"BBB@#S6#Q[XGU#[1-8:+I/V:.XFA0SWLBN1&[)D@1D#)4]ZF_X M2_QD3@:-H7J/]/E_^-5A^%O^01<\?\OUY_Z425MK]X=^/\*`*/@R>&XMM9EU M2:2*[DU>X9X+1BT:[MOR`X!.X\\X)"GHN:Z8/I)/&H7SD]"3D/DYSTP=Q&_W M5?[@Q6+X$^WFRUK[+]F6/^U[C+2\DG"Y;\!QCOGL!SU9_MGG MO7`PGOG)P`!0!XW?^3_PF/B,VYE,1N82K2YW/^X3+'//)Y_&BI=7\_\`X3GQ M-]I>-YOM,.\QC"@^1'P/ITSWQVJ*@!FC"];QA>)916U[NTH"XTJ<#_3X?,;> MB$]'`Y'8]#UKJ9^7YOH?X6KF;7[" M/%DSZC'<0VZ6,;#5+?&_3)/-;9-Z[<\-VP>>*[`K??VG=(]G;2ZY)!G4--&! M:Z_:XQYT6>!*!_@>,&@#RCXPB-=3LEGL9--U@F5M1LT)-LSG;B>'MB0`Y[Y7 M!Y!)\TKTWXL$G3_#WV34/MNB`7"V!G!^TVV"@>WESS\AP!GG!P.1;"4JZ,05.T\@CI725S'Q&_Y)QXB_Z\)?_030!PH\(:*`?W-U MP`1F_G^O]^E7PAHNY1Y%T>!UOY_U^?\`SQ6UV;O\H_E3E^^._'YT`5?`G]F+ MX#T19)KV-_LB@QKNPOS$?B$XPN:Z)7TDN-NH7SDG@DY#Y.?3G<1O]U7^ MX*R_``U3_A7^B"%[/R_LJX9UY`P>WL./]7*`$\*%VU?Q%%8R+>7C2#[3H=P?W6HVOE)N"9X$JG./8@'@YK:!M18 MZ>Z:E-'I:2E=%UQQ^_TB?H;6Z!ZIGY?F^A_A:L/1,`:V^HQF+2$U&-EU2V)^ MT:7<^2FV8_\`3,C`/TYX/'3%;[^T[I&L[:77)(,ZAIHP+7Q!:XQYT6>!*!_@ M>"#0!XI\5UF7QQ-]KTB/3+XPH;I(3F*:7G,L9_NMP?7.<\YKB*[#XDM9MXFB M_L[4KB]L5M46!;G_`%MLH+#R'SSE#D<\XP.>M:?^AU] M(U\W?LU_\C+K?_7FG_H=?2-`!1110!X7JW_(9OO^OB3_`-"-%&K?\AF^_P"O MB3_T(T4`>P>&_P#D6M-_Z]T_E5O4;V/3=-NKZ8$Q6T+RN!U(4$G^55/#?_(M M:;_U[I_*KUY:17]E/9W"EH9XVBD`.,JPP?T-`')W/B_4;'$-W8VR3RP1W$3J M[M'&C-M/F8&?E..0,'<.E:^A^(/[;E8+$D2)$A96D^?S#]X!?[JGY=W^30!J7\T45I*))40M&V-S`9XJ.UO;06D(-U""(U_Y:#TJ6 M]1'LYMRJV(VQD9[4VU@A-G`?*3_5K_"/2@!_VZT_Y^H/^_@H^W6G_/U!_P!_ M!3_(A_YY1_\`?(H\B'_GE'_WR*`&?;K3_GZ@_P"_@H^W6G_/U!_W\%/\B'_G ME'_WR*/(A_YY1_\`?(H`9]NM/^?J#_OX*/MUI_S]0?\`?P4_R(?^>4?_`'R* M/(A_YY1_]\B@#GO&MU;R^!/$,<5Q$TC:;56>K:`ND:5:_VG M*ND2E6LI22+W0KG&.AY:$D$=P`<'*D$>[""$'(B3/^Z*=L7^Z/RH`\-N=?MW M359UN--;5A$8M4LQ(!9ZU$5($L9/"R@=CSG@YIW@BZMXO`7AZ.2XB5UTV MW#*S@$'RUX([&NDV+_='Y4TP0DY,29_W10`S[=:?\_4'_?P4?;K3_GZ@_P"_ M@I_D0_\`/*/_`+Y%'D0_\\H_^^10`S[=:?\`/U!_W\%'VZT_Y^H/^_@I_D0_ M\\H_^^11Y$/_`#RC_P"^10`S[=:?\_4'_?P4?;K3_GZ@_P"_@IMQ90SP^7L1 M?F4YV#L0?Z5+Y$/_`#RC_P"^10!YAXKU*QMOB9Y\]W%'"^B+&LA;Y2WGL=N? M7'-1+XDT0E?^)K:\C^_Z_P#ZJ]5$4:C`11]!2[$_NK^5`'C":]H)\8Z9<7-_ M&]K'8W*MY;X!=GA**QZ8."<'CY>>E=*/$_@DD!;XDG&&,W7G@G)[G,ASW`)Y MVBO0MB_W1^5&Q/[J_E0!X=XRU70M3U/P\-$J+^5)Y4?_/-?RH`^<=9D:&UMIEMH[DQ7MN_DRD!)`)%)5B>`IZ$ MG@"MQ=8\/-96-NFH2Q:+/+OL6W8O=`N?0#JT.>.X`XY4@CW,1QCHB_E1L7^Z M/RH`^>?%>K1WWA[7_L^HV<&MM"L.H16^6M=63(VS18^[*.XZCD'(P:\0^PWG M_/K/_P!^S7WKL7^Z/RI=B_W1^5`'P3]AO/\`GUG_`._9K[ETR]M5TFS!N801 M`@(,@_NBM'8O]T?E3/(A_P">2?\`?(H`9]NM/^?J#_OX*/MUI_S]0?\`?P4_ MR(?^>4?_`'R*/(A_YY1_]\B@!GVZT_Y^H/\`OX*/MUI_S]0?]_!39;*&22%] MB#RW+8V#GY2/ZU+Y$/\`SRC_`.^10!Y%-JVGV?CCQ:+J]AA\V[@:/7>#O$VB6?B MG7I[C5;6*&>VLQ$[R8#E?.W`$^FX?3(KM?\`A-O"_P#T'M/_`._XK!A,H^)' MB98;Z&U`M+(L)=N-N)CZ:LQ^*DZW, M\-QC1$P\8PN?M#@\=!@Y'T`R2Z!<^@'5H<\=P!QR MI&/2WE5%U M&W+,R$`#S%Y)K[5^W6G_`#]0?]_!4I1",%1CZ4WR(?\`GE'_`-\B@!GVZT_Y M^H/^_@H^W6G_`#]0?]_!3_(A_P">4?\`WR*/(A_YY1_]\B@!GVZT_P"?J#_O MX*/MUI_S]0?]_!338PF[6?8G"%-NP=R#G]*E\B'_`)Y1_P#?(H`\6T#6--LM M/N;>ZOH(9OMUT=CM@X:>0C\Q@UJKXDT0LO\`Q-;7D?W_`%__`%5ZML3^ZOY4 M;$_NK^5`'COA37_#%O!JO]H78:674II(QOPI0[0H&<<,>3V^7)X`KH!XG\$D M@+?$DXPQF^]\W!.3W.9#GN`6YVBO0MB_W1^5&Q/[J_E0!\^2W-G>>)]?NM.4 MBRDN(C"W]X"%`6SW)().>M/NIK#Q= M/=P7]O;2IIH"VU[Q;WR^8V^%V(P"0<@]CZC-:::QX>:QL8$OY8M%GEWV1W8O M=`N?0#JT.>.X`XY4\>YB-!T1?RHV+_='Y4`?)7Q3N8M7U&TDCM8I-7CWI?W= MAEK>[X7RY5QT8C(8'D$`<@"O/_L-Y_SZS_\`?LU][;%_NC\J-B_W1^5`'R5\ M$X9;7XJ:9+<1/%&(Y\O(I4#]TW4 M?_?(H`9]NM/^?J#_`+^"C[=:?\_4'_?P4_R(?^>4?_?(H\B'_GE'_P!\B@!G MVZT_Y^H/^_@KFOB%=6\WP\\01Q3Q.[6$H55<$D[3T%=''8PQW$TNQ#YF.-@X MP,5*((@5#Q'HA!_P")K:\@?Q_A2IXDT0NO_$UM>0/X_7_]5>K; M%_NC\J-B?W1^5`'D/@WQ!X4M?!FD6]]*([J.W59(BX7YMQX(SQN;YCG^Z"V! MBMU/%'@G>NV^))(PS3?>^;@G)[G,ASW`+<[17H.Q?[H_*C8G]T?E0!\Y:0T; MV)::NLBN(;TE;34;;RU#0.3\H;.2&[9[C.-5-8\/-8V,"W\L6BSR[[+Y ML7N@7/MW:'/'<`''*GCW/8@&-B_E1L7^Z/RH`^.?B7)>:KXPDN'M[6:<0HDU MUIXW173#/[T8'!(QD'D$5R'V&\_Y]9_^_9K[VV+_`'1^5&Q?[H_*@#YP_9T5 MK/Q'K+72F!6M%`,HV@G?[U]$_;K3_GZ@_P"_@J5HHV^\BGZBF^1#_P`\H_\` MOD4`,^W6G_/U!_W\%'VZT_Y^H/\`OX*?Y$/_`#RC_P"^11Y$/_/*/_OD4`>' M:J0VKWI'(,\A!'?YC12ZKQK%Z!P/M$G_`*$:*`/8/#?_`"+6F_\`7NG\JU*R M_#?_`"+6F_\`7NG\JU*`"BBB@"&[_P"/.?\`ZYM_*BT_X\X/^N:_RHN_^/.? M_KFW\J+3_CS@_P"N:_RH`FHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`.!0*?B5X MDW:G4#&TDL",#Y0%ZG<`<8/= M\*,=@0.*=$3$N`/^7A\]/?.,<8P!7=4`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110!X7JW_`"&;[_KXD_\`0C11JW_(9OO^OB3_`-"-%`'K_AP@ M>&M-R0/]'3^59>H>++C2]4U6"[T]5M[.S2Y@99LO,6+M4TN6>RN+"W>]BV/OB9S$497('3(8M&4';)!]JW=&UM-9>Y>( M1K#&5"?O`7;CEBO9<\`]\$],573PT62\:ZU&>:YO!''/.%5"8DS\@`^Z#ELD M<_,?;$FF>&[?2]7N+Z&4XD5E2+8H$88@D9`R1E1C/0<"@#1OYHHK2422HA:- ML;F`SQ4=K?6@M(0;J`$1K_RT'I4UZBM9S;E4XC;&1GM3;6&(V<'[I/\`5K_" M/2@!?MUG_P`_4'_?P4?;K/\`Y^H/^_@J3R(O^>2?]\BCR(O^>2?]\B@"/[=9 M_P#/U!_W\%'VZS_Y^H/^_@J3R(O^>2?]\BCR(O\`GDG_`'R*`(_MUG_S]0?] M_!1]NL_^?J#_`+^"N%D^(#I!)JX\/*?#<=[]C>^\]?-R)/+,@BV\IOX^]GOB MNEUKQ+X<\/3Q0ZM>V]K)*N]%=#R,XSP*`-7[=9_\_4'_`'\%'VZS_P"?J#_O MX*PO$/B!-*_LNVT_34U#4-5D,=I"7$:$!=[.SX.%"^Q/M571O&-E>73Z;JMB MNGZM'??86MU/G(TAC,JE7`'RE`3D@=,4`=/]NL_^?J#_`+^"C[=9_P#/U!_W M\%&8]8M]*DN`EW/Y8"M;N`C.,HCMMPC'(^4D'D51%_SR3_OD4>1% M_P`\D_[Y%`$?VZS_`.?J#_OX*/MUG_S]0?\`?P5)Y$7_`#R3_OD4>1%_SR3_ M`+Y%`$?VZS_Y^H/^_@H^W6?_`#]0?]_!4GD1?\\D_P"^11Y$7_/)/^^10!'] MNL_^?J#_`+^"C[=9_P#/U!_W\%2>1%_SR3_OD4>1%_SR3_OD4`1_;K/_`)^H M/^_@H^W6?_/U!_W\%2>1%_SR3_OD4>1%_P`\D_[Y%`$?VZS_`.?J#_OX*/MU MG_S]0?\`?P5)Y$7_`#R3_OD4>1%_SR3_`+Y%`$?VZS_Y^H/^_@H^W6?_`#]0 M?]_!4GD1?\\D_P"^11Y$7_/)/^^10!']NL_^?J#_`+^"C[=9_P#/U!_W\%2> M1%_SR3_OD4>1%_SR3_OD4`1_;K/_`)^H/^_@H^W6?_/U!_W\%2>1%_SR3_OD M4>1%_P`\D_[Y%`$?VZS_`.?J#_OX*/MUG_S]0?\`?P5)Y$7_`#R3_OD4>1%_ MSR3_`+Y%`$?VZS_Y^H/^_@H^W6?_`#]0?]_!4GD1?\\D_P"^11Y$7_/)/^^1 M0!PMM(\WQ&\2M:VL%ZGV:QY+`[&VS8/TP6]^@[Y&YLN,<>'X%7`QRORC;@=/ M1,KQW.!QDUSP%HGQ(\2":XFMP;6Q`$(.'!\WY>.Y.WWP#CC-;`?3R>-:NW)[ M\D/D^PYW,-W'55XPH-`&;ITBP?%6X-S;0V#'1(\KN4!OWS8P>^!@?AQQ7:_; MK/\`Y^H/^_@KB-%%M+\49_)N7NXO[$0AI>6'[]_Y\M]",<8KN_(B_P">2?\` M?(H`C^W6?_/U!_W\%'VZS_Y^H/\`OX*D\B+_`)Y)_P!\BCR(O^>2?]\B@"/[ M=9_\_4'_`'\%'VZS_P"?J#_OX*D\B+_GDG_?(H\B+_GDG_?(H`C^W6?_`#]0 M?]_!1]NL_P#GZ@_[^"I/(B_YY)_WR*/(B_YY)_WR*`(_MUG_`,_4'_?P4?;K M/_GZ@_[^"I/(B_YY)_WR*/(B_P">2?\`?(H`C^W6?_/U!_W\%'VZS_Y^H/\` MOX*D\B+_`)Y)_P!\BCR(O^>2?]\B@"/[=9_\_4'_`'\%'VZS_P"?J#_OX*D\ MB+_GDG_?(H\B+_GDG_?(H`C^W6?_`#]0?]_!1]NL_P#GZ@_[^"I/(B_YY)_W MR*/(B_YY)_WR*`(_MUG_`,_4'_?P4?;K/_GZ@_[^"I/(B_YY)_WR*/(B_P"> M2?\`?(H`C^W6?_/U!_W\%'VZS_Y^H/\`OX*D\B+_`)Y)_P!\BCR(O^>2?]\B M@"/[=9_\_4'_`'\%'VZS_P"?J#_OX*D\B+_GDG_?(H\B+_GDG_?(H`C^W6?_ M`#]0?]_!1]NL_P#GZ@_[^"I/(B_YY)_WR*/(B_YY)_WR*`(_MUG_`,_4'_?P M4?;K/_GZ@_[^"I/(B_YY)_WR*/(B_P">2?\`?(H`C^W6?_/U!_W\%'VZS_Y^ MH/\`OX*D\B+_`)Y)_P!\BCR(O^>2?]\B@"/[=9_\_4'_`'\%'VZS_P"?J#_O MX*D\B+_GDG_?(H\B+_GDG_?(H`C^W6?_`#]0?]_!1]NL_P#GZ@_[^"I/(B_Y MY)_WR*/(B_YY)_WR*`(_MUG_`,_4'_?P4?;K/_GZ@_[^"I/(B_YY)_WR*/(B M_P">2?\`?(H`C^W6?_/U!_W\%'VZS_Y^H/\`OX*D\B+_`)Y)_P!\BCR(O^>2 M?]\B@"/[=9_\_4'_`'\%'VZS_P"?J#_OX*D\B+_GDG_?(H\B+_GDG_?(H`C^ MW6?_`#]0?]_!1]NL_P#GZ@_[^"I/(B_YY)_WR*/(B_YY)_WR*`(_MUG_`,_4 M'_?P4?;K/_GZ@_[^"I/(B_YY)_WR*/(B_P">2?\`?(H`\/U7YM7O2O(,[D$= M_F-%&J\:Q>@<#[1)_P"A&B@#V#PW_P`BUIO_`%[I_*M2LOPW_P`BUIO_`%[I M_*M2@`HHHH`AN_\`CSG_`.N;?RHM/^/.#_KFO\J+O_CSG_ZYM_*BT_X\X/\` MKFO\J`)J***`"BBB@#SK4_AM?M8S6.EZ^5TLWGVY-+NH`T3/O\PHTBX<(6YQ MV]ZZK5?#J:VT$MSJ&J6DJ1[633[^6!">IR%(S]37$Z3XJ\5:ZOB`V-Y`;RRE MN4M;-M*D$;>7)A1Y^[:S$#&!R"<]JZ/PCXGOO$>EZAX@DMGCTIC_`,2^V$>) MF5%^\0>%_P"VETV:VU">QU#39#):W:J)"I*[6#*W#`CK M7-6WP[U5+JXGGUY&O#J"ZE#J:6X\XR^68V1XSE-@0X7'3/3UZ?2O$IU>&[9= M)U&Q,$>X&]C10_7IM9O2N.\'^/\`4+O1;+4M8F:Z:_NK>T6&+37ME@>5F&1( M[$2KQ_#T_&@!UU\'+6YMM/@.M3D6D7E;I;:.1CB8R[E)^XQ)P2O45T%UX&BN M-!U33%U&:-K[4FU))Q&"89/,60#!X8`J.O6L/6?'-]-=J=,9[6*.WU9)$D16 M+2VRC:_?C.3C\ZMZSXMU?0/#&@>(7B%[936J+?1I'^\,LD8,;+@@`&3"D8_B M'I0!*WPVMF\6#7WO(I)9)(9[A9;&)V>6-0-R.06C!V@D#WQBNC\-Z&GAW1DT MY+AIU6663>R@'YW9\8]MV*X^X^)J^&[K3]%UZW>YU]6)/BKIL6L:QIS6,Y?3;>XN-T'!^4^F?TH`[ZBJ&BZC-JVE M07TUA-8F8;EAF968*?ND[20,C!QVJ_0`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`<-;+>'XD^)OLD<#C[+8AO-&=O$WS#GTW#'? M(Y`S6Z5UZI7G@`4` M:&F_:?\`A;%S]KBBCE_L.,GRCE6_?M_+IGOC/'2NWKSSPK-#?_$.[O;"TU2* MQ72E@WWUK)%^\$S$@;P,Y!W>N6.:]#H`****`"BBB@`HHHH`****`"BBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB MB@`HHHH`****`"BBB@#PO5O^0S??]?$G_H1HHU;_`)#-]_U\2?\`H1HH`]@\ M-_\`(M:;_P!>Z?RJAJ?BEM%O&CU&P*0M#-+#)%,'9_+V\%<#;G<,S&RA<ZU%6O+U8H9)88=@2),\("Q MPQW-\V3C/`XIVC^&(]'UBYO(94\F12D<21;2`2#AFS\P7&%X&`3US0!LW9`L MY\G_`)9M_*DM&7['!R/]6O?VIE_;PS6DIEACD*QMM+J#CCM4=KI]D;2$FSMR M3&O_`"R'I]*`+NY?[P_.CH M.XU:_LZR_P"?.W_[]+_A1_9UE_SYV_\`WZ7_``H`I:=X^T<]355_!^BOX7MO#VR5;&U*&`I.RR1,ARK*X.00>]:_]G67_/G; M_P#?I?\`"C^SK+_GSM_^_2_X4`8$/@+P];VZ01PS;$2Y0;KAV.+@`2Y).23C MJ>E:-[X=TR_\/PZ)<(QL81$$42$$>45*<]>JBKW]G67_`#YV_P#WZ7_"C^SK M+_GSM_\`OTO^%`&3J'A+2=1UD:K(UU#=%467[-=R1+.JG*B15(#@9/7UJB?A MUX;-S=S&.Y_TJ.XB:,W;E$6?F4(N<+N//'>ND_LZR_Y\[?\`[]+_`(4?V=9? M\^=O_P!^E_PH`DMXHK:VB@B.(XD"*"<\`8%2;E_O#\ZK_P!G67_/G;_]^E_P MH_LZR_Y\[?\`[]+_`(4`6-R_WA^=&Y?[P_.J_P#9UE_SYV__`'Z7_"C^SK+_ M`)\[?_OTO^%`%C'YT;E_O#\ZK_V M=9?\^=O_`-^E_P`*/[.LO^?.W_[]+_A0!8W+_>'YT;E_O#\ZK_V=9?\`/G;_ M`/?I?\*/[.LO^?.W_P"_2_X4`6-R_P!X?G1N7^\/SJO_`&=9?\^=O_WZ7_"C M^SK+_GSM_P#OTO\`A0!8W+_>'YT;E_O#\ZK_`-G67_/G;_\`?I?\*/[.LO\` MGSM_^_2_X4`6-R_WA^=&Y?[P_.J_]G67_/G;_P#?I?\`"C^SK+_GSM_^_2_X M4`6-R_WA^=&Y?[P_.J_]G67_`#YV_P#WZ7_"C^SK+_GSM_\`OTO^%`%C'YT;E_O#\ZK_P!G67_/G;_]^E_PH_LZR_Y\[?\`[]+_`(4`6-R_WA^=&Y?[ MP_.J_P#9UE_SYV__`'Z7_"C^SK+_`)\[?_OTO^%`%C'YT;E_O#\ZK_V=9?\^=O_`-^E_P`*/[.LO^?.W_[]+_A0 M!8W+_>'YT;E_O#\ZK_V=9?\`/G;_`/?I?\*/[.LO^?.W_P"_2_X4`6-R_P!X M?G1N7^\/SJO_`&=9?\^=O_WZ7_"C^SK+_GSM_P#OTO\`A0!8W+_>'YT;E_O# M\ZK_`-G67_/G;_\`?I?\*/[.LO\`GSM_^_2_X4`6-R_WA^=&Y?[P_.J_]G67 M_/G;_P#?I?\`"C^SK+_GSM_^_2_X4`6-R_WA^=&Y?[P_.J_]G67_`#YV_P#W MZ7_"C^SK+_GSM_\`OTO^%`%C'YT;E_O#\ZK_P!G67_/G;_]^E_PH_LZ MR_Y\[?\`[]+_`(4`6-R_WA^=&Y?[P_.J_P#9UE_SYV__`'Z7_"C^SK+_`)\[ M?_OTO^%`%C'YT;E_O#\ZK_V=9?\ M^=O_`-^E_P`*/[.LO^?.W_[]+_A0!8W+_>'YT;E_O#\ZK_V=9?\`/G;_`/?I M?\*/[.LO^?.W_P"_2_X4`6-R_P!X?G1N7^\/SJO_`&=9?\^=O_WZ7_"C^SK+ M_GSM_P#OTO\`A0!XIJW_`"&+[_KXD_\`0C12:H`NKWJJ,`3N`!V^8T4`>P^& M_P#D6M-_Z]T_E6I67X;_`.1:TW_KW3^5:E`!1110!#=_\><__7-OY46G_'G! M_P!<'_7-?Y4`34444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110!X7JW_(9OO\`KXD_]"-%&K?\AF^_Z^)/_0C10![!X;_Y%K3?^O=/Y5EZ MAXQ32]1GM[FUC=(XI9]4A1U M&XC!Q[&J>L>$)-?E_P!/OHQ''YAA-O;[)`6&!O8L=P7CC`R0">E`$5_XUDTQ MYK:\TQ8[V+:WEBYS&R,CL"'V_>S&RA<@/&>Y!]*SE\.W4IOI[K45:\O5BADEAAV!(DS\J`L<,=S?-DXSP.*=H_A MB/1]8N;R&5/*D4HD21;2H)!PS9^8+C"\#`)ZYH`V+P@6<^2!^[;^5%HZ_8X/ MF'^K7O[4Z6W@N,>=#')CIO4''YU'_9UE_P`^=O\`]^E_PH`L;U_O#\Z-Z_WA M^=5_[/LO^?.W_P"_2_X4?V?9?\^=O_WZ7_"@"QO7^\/SHWK_`'A^=5_[/LO^ M?.W_`._2_P"%']GV7_/G;_\`?I?\*`+&]?[P_.C>O]X?G5?^S[+_`)\[?_OT MO^%']GV7_/G;_P#?I?\`"@"QO7^\/SHWK_>'YU7_`+/LO^?.W_[]+_A1_9]E M_P`^=O\`]^E_PH`L;U_O#\Z-Z_WA^=5_[/LO^?.W_P"_2_X4?V?9?\^=O_WZ M7_"@"QO7^\/SHWK_`'A^=5_[/LO^?.W_`._2_P"%']GV7_/G;_\`?I?\*`+& M]?[P_.C>O]X?G5?^S[+_`)\[?_OTO^%']GV7_/G;_P#?I?\`"@"QO7^\/SHW MK_>'YU7_`+/LO^?.W_[]+_A1_9]E_P`^=O\`]^E_PH`L;U_O#\Z-Z_WA^=5_ M[/LO^?.W_P"_2_X4?V?9?\^=O_WZ7_"@"QO7^\/SHWK_`'A^=5_[/LO^?.W_ M`._2_P"%']GV7_/G;_\`?I?\*`+&]?[P_.C>O]X?G5?^S[+_`)\[?_OTO^%' M]GV7_/G;_P#?I?\`"@"QO7^\/SHWK_>'YU7_`+/LO^?.W_[]+_A1_9]E_P`^ M=O\`]^E_PH`L;U_O#\Z-Z_WA^=5_[/LO^?.W_P"_2_X4?V?9?\^=O_WZ7_"@ M"QO7^\/SHWK_`'A^=5_[/LO^?.W_`._2_P"%']GV7_/G;_\`?I?\*`+&]?[P M_.C>O]X?G5?^S[+_`)\[?_OTO^%']GV7_/G;_P#?I?\`"@"QO7^\/SHWK_>' MYU7_`+/LO^?.W_[]+_A1_9]E_P`^=O\`]^E_PH`L;U_O#\Z-Z_WA^=5_[/LO M^?.W_P"_2_X4?V?9?\^=O_WZ7_"@"QO7^\/SHWK_`'A^=5_[/LO^?.W_`._2 M_P"%']GV7_/G;_\`?I?\*`+&]?[P_.C>O]X?G5?^S[+_`)\[?_OTO^%']GV7 M_/G;_P#?I?\`"@"QO7^\/SHWK_>'YU7_`+/LO^?.W_[]+_A1_9]E_P`^=O\` M]^E_PH`L;U_O#\Z-Z_WA^=5_[/LO^?.W_P"_2_X4?V?9?\^=O_WZ7_"@"QO7 M^\/SHWK_`'A^=5_[/LO^?.W_`._2_P"%']GV7_/G;_\`?I?\*`+&]?[P_.C> MO]X?G5?^S[+_`)\[?_OTO^%']GV7_/G;_P#?I?\`"@"QO7^\/SHWK_>'YU7_ M`+/LO^?.W_[]+_A1_9]E_P`^=O\`]^E_PH`L;U_O#\Z-Z_WA^=5_[/LO^?.W M_P"_2_X4?V?9?\^=O_WZ7_"@"QO7^\/SHWK_`'A^=5_[/LO^?.W_`._2_P"% M']GV7_/G;_\`?I?\*`+&]?[P_.C>O]X?G5?^S[+_`)\[?_OTO^%']GV7_/G; M_P#?I?\`"@"QO7^\/SHWK_>'YU7_`+/LO^?.W_[]+_A1_9]E_P`^=O\`]^E_ MPH`L;U_O#\Z-Z_WA^=5_[/LO^?.W_P"_2_X4?V?9?\^=O_WZ7_"@"QO7^\/S MHWK_`'A^=5_[/LO^?.W_`._2_P"%']GV7_/G;_\`?I?\*`+&]?[P_.C>O]X? MG5?^S[+_`)\[?_OTO^%']GV7_/G;_P#?I?\`"@"QO7^\/SHWK_>'YU7_`+/L MO^?.W_[]+_A1_9]E_P`^=O\`]^E_PH`L;U_O#\Z-Z_WA^=5_[/LO^?.W_P"_ M2_X4?V?9?\^=O_WZ7_"@"QO7^\/SHWK_`'A^=5_[/LO^?.W_`._2_P"%']GV M7_/G;_\`?I?\*`+&]?[P_.C>O]X?G5?^S[+_`)\[?_OTO^%']GV7_/G;_P#? MI?\`"@"QO7^\/SHWK_>'YU7_`+/LO^?.W_[]+_A1_9]E_P`^=O\`]^E_PH`L M;U_O#\Z-Z_WA^=5_[/LO^?.W_P"_2_X4?V?9?\^=O_WZ7_"@"QO7^\/SHWK_ M`'A^=5_[/LO^?.W_`._2_P"%']GV7_/G;_\`?I?\*`+&]?[P_.C>O]X?G5?^ MS[+_`)\[?_OTO^%']GV7_/G;_P#?I?\`"@#Q35O^0Q??]?$G_H1HI-4`75[U M5&`)W``[?,:*`/8?#?\`R+6F_P#7NG\JU*Q_#DT2^&].#2H"+=,@L/2M3[1# M_P`]H_\`OH4`245']HA_Y[1_]]"C[1#_`,]H_P#OH4`245']HA_Y[1_]]"C[ M1#_SVC_[Z%`$E%1_:(?^>T?_`'T*/M$/_/:/_OH4`25RM[XIO-'O+^'4+:WD M$-F;N/[-(^T^*.X)29DB,3[N>03D%&& M.^0>*N:QXDN[*;4/L5M!+%I=LES=^:Y#,K;CM3'?:I.3Z@5%=^&([ZQU"&?7 M)&N=018KBYV1[C&H("*N,#EB M1HC*5PC.IVL`?4$=P/;-5=0T;3]0U'3KQKKRC9'_`%<;+ME7(*JWL&56&.XI MMCHUI9Z[>9"S>28<#!Q][ M.X[<>V?:I(/"T"V%_9W6LR7*7K>;)*RHLOF;@RON`Y*X``Z``#%+_P`(Q"+\ MZJFMRKJ[95[P"/YH\`;-F-N!@$>_/>@#+D^(Q^S?;!;VT,$4,$LL,\N)9?,8 MJWE=CM(//?':N^KFF\-6#6=IIPOL:7;*@^R_(3)M.[YG^]R<$@8S^-=#]HA_ MY[1_]]"@"2BH_M$/_/:/_OH4?:(?^>T?_?0H`DHJ/[1#_P`]H_\`OH4?:(?^ M>T?_`'T*`)**C^T0_P#/:/\`[Z%'VB'_`)[1_P#?0H`=(9!$YB"F3!VAC@$] MLFN4'BC4(Y;FPEMK5[Y+V*RBDB=O)9W3>TB;3X"PU7^S;N03$*I.,,@QDY#`\XQR.:U6UB\3QA%I#V<2VDMK).D_F MY=F5D!&W'`^?USQ6=/X7BD@@2+6WCD2\^WRR;(V,L^>&.1@`8Q@=@*O3:9YO MB.WU?^U]OD1-"(`B;2K%2V3UR2@^G-`$TGB.PBD>-_.$B7?V1E\LY#[/,S_N M[/FSZ5+I^KC6=+-YI\+@.NZ`W`VK(",JV1GY3^?M59]'L7\0G6!>,DIA\ORU M9=H?&/,_WMOR^F.U0:=H-OIEIJ26VIF.XO\`EIHEC01MMVAE0#:&[DXY/6@" MK'XGOV>2P\BT>_&H?88Y$=O)8^5YK-Z_*,@CU[TV+Q9J#SZ;$VGP`2:C)IUY M()CA)%#M))X8A\NR6#6GB:WNFO7E`#AXHN3>Q2_9H?[,EU M%M.5@Q\W>"5W^FWT?_?0H`DHJ/[1#_P`]H_\`OH4?:(?^>T?_`'T*`)**C^T0_P#/ M:/\`[Z%'VB'_`)[1_P#?0H`DHJ/[1#_SVC_[Z%'VB'_GM'_WT*`(K]KQ;8FR M^SB7(RUP3L5>YXZ_I7+V_B[4-1L;9K&QMQ7(-9>&X%LUI++" ML:B2$G.W;C"D=B.F30`NE>);G5-;AMA91Q65SIJWUO(9*<-,R3013IB/J)'V(I)X#%LC!]#5^[NKQ],6YLD@@_V[<@C7!)R!W_ M`!QWK*@\-V-K9ZA;P7_%Y+OQ*L>>M-N/#5K)X9M="@U62 M&V@8%^4?SE!)V,#QL)/W1C@`=.*`*J^+[^[TY+FRL(%>/35U*XCFD/W6W81" M!U(1B"?;CFM#3/$5SJ'B"2R-DD=HUC'>6TGF9>16)'(QA>GJ:CO/#\5XQ=M8 M>.66U^R731!%\^+).,8^4C,!58$G`Y^;FMFL/1-,&D37TDFK?: MOMDQG<.J+M<@`D;>V%%;'VB'_GM'_P!]"@"2BH_M$/\`SVC_`.^A1]HA_P"> MT?\`WT*`)**C^T0_\]H_^^A1]HA_Y[1_]]"@"2BH_M$/_/:/_OH4?:(?^>T? M_?0H`R_$>HWVDZ5/J%JMHT=M$\LHN'9=P`R%7`ZGID]\<&LN]\5W=N;NZCLX MQ8Z>T"7:R,?-S(%)V@ M:TM[:33F7RMTI8,K)N#.0./7`S]:CTOQ4)M$U'4KY(S#8SF-I;4,RR*`I+A3 M\PQN.<_W21Q3[;1GMK_4[Q=>?S;_`&DXCC_=E0`I''.`,8/6I[+2+.WCU'[3 M>"[FU$_Z5(Y50XV;``HX`VC%`!<^*=/MKQK0+<37`G\A4BCSO?8)"%R0#A2" M?KWH\2:K?:/I9*D[,KOR,(N!PQZ#/<@8K/D\*64GAU-&?4S)' MN9II9DC=Y2W&[D?*P'0C&*M:IHJ:A+IS1ZNT*6/*1,$E5WQA7;=U8=CZG/7% M`$%YXHNH+BYN([6%M-L[N*SN"SGS2S[,LHZ84R+P>N#[58TO6-5U(ZS`UE:V M]W97`AB5IBZD%%8%B!U^;H/S[U'-X=LY[R61]2?[+//'Q!K6K+T>UBTG3H[+[9%)'$-L85%C"KV&!_.M#[1 M#_SVC_[Z%`$E%1_:(?\`GM'_`-]"C[1#_P`]H_\`OH4`245']HA_Y[1_]]"C M[1#_`,]H_P#OH4`245']HA_Y[1_]]"C[1#_SVC_[Z%`&1K>JW^DW%I*D5K): M37$5N4+L)G9VVY7C'`.<=P#TQ5!/%%XUQ;W`LX7TZZO);*#;(1*9$W@,<\;6 M,;#VR#ZU;OM)^UZ_;ZJNL>68(]D<#(CHF3\S+GD,1QGTX'4YAC\.6D5TKKJ; M_9H9Y+JWMB4*PS/NRV>I`+,0#P,_2@`T_P`37$WAR?4+VSCCO$NI;5+6&0N' MD60HJAB!G)`YQQR>@J?2_$?GZ%I-]J,0@FOI!`5BRR)(20!GT)7`)[D>M5[+ MPUI\5G):ZA=IJ*&Z>[3S0J&.1RQ8C;C^\?H*?%X;TRW\*?V!;WC11#YDG#@R M(^[<'&>,@X/X4`6+?Q5I]Y>0VMLEQ+)+N;Y8_NHKF/><\[2P.",^O2DU?5;_ M`$O4;$"&VDL[JYCM@N]O.);.6`QC"XR1Z`G(JM<^&M/N%TR(WH6"P\LQJ%3? ME"""'QN7)`W8/-37.DB?Q''K`U@J8XQ''`R(RQKGYMN>06Z$]<`"@"E;^*KV M>6SG6RA>RU&2:&T"R$2;T#%=V>,-L;ITXZU):^([VY\)QZK,ME9S^=)'*)&= MXTV2,G&!EL[1Z=:=;^&[6UGB:+5'\FU>62SA;85MWDSD^K8W-@'H#]*=IVC3 M:9I8LK;Q`X*S/*)#%$?OLS,I&,$98G\J`-/0=1DU?0;+4)H5ADN(@[1J^X*3 MZ&M&LW2+.RT;2X;"WN`T<>X[G<99F8LQ...22>.*O?:(?^>T?_?0H`DHJ/[1 M#_SVC_[Z%'VB'_GM'_WT*`/#]6_Y#-]_U\2?^A&BC5>=8O2.1]HDY'^\:*`* MTO\`KG^IIE%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`7%^X/I11 %10!__]D_ ` end GRAPHIC 13 image2.jpg GRAPHIC begin 644 image2.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#UK0M"TJZT M&QGGT^WDEDA5G=D!+$CJ:T?^$;T3_H%VO_?L4>&_^1:TW_KW3^5:E`'&V*:1 MJ&N7NGPZ!IXCLYS#)(TJASA%;<(\9Q\P'6LJ\UO0;73XM0/AB'[%=F1+*<[< M2LN<;ACY%(#$'G@B?]`NU_[]BC_A&]$_Z!=K_W[%6O[,L?^?2'_O@4?V98_P#/I#_WP*`* MO_"-Z)_T"[7_`+]BC_A&]$_Z!=K_`-^Q5K^S+'_GTA_[X%']F6/_`#Z0_P#? M`H`J_P#"-Z)_T"[7_OV*/^$;T3_H%VO_`'[%6O[,L?\`GTA_[X%']F6/_/I# M_P!\"@"K_P`(WHG_`$"[7_OV*/\`A&]$_P"@7:_]^Q5K^S+'_GTA_P"^!1_9 MEC_SZ0_]\"@"K_PC>B?]`NU_[]BC_A&]$_Z!=K_W[%6O[,L?^?2'_O@4?V98 M_P#/I#_WP*`*O_"-Z)_T"[7_`+]BC_A&]$_Z!=K_`-^Q5K^S+'_GTA_[X%'] MF6/_`#Z0_P#?`H`J_P#"-Z)_T"[7_OV*/^$;T3_H%VO_`'[%6O[,L?\`GTA_ M[X%']F6/_/I#_P!\"@"K_P`(WHG_`$"[7_OV*/\`A&]$_P"@7:_]^Q5K^S+' M_GTA_P"^!1_9EC_SZ0_]\"@"K_PC>B?]`NU_[]BC_A&]$_Z!=K_W[%<#?>*[ MFW\7S6T>GZ5_9=OJ]OI3P-$?M#F5-QE#9P`,],'(!Y%='X:O%\27U_>P6%HG MA^-O)LI3%^\NG4D/*#T\O/"\\:Z_9>%UL+2ST6/4=8U.4PV5HN%#$=68]E&1_GFN7\6>(/$^A>"=5O+W MP]8:7J%L\!@N82MQ#(KR!6&&'##W]:`/2?\`A&]$_P"@7:_]^Q1_PC>B?]`N MU_[]BL30/%/@SQ'>26&F7MC=7D$>^5$C(X'4J2`&&>XS4.E^-O`.M:RNDZ?J M%E/>N2$00L`Y'4*Q4*WX'F@#H?\`A&]$_P"@7:_]^Q1_PC>B?]`NU_[]BN9N M_'_P\L+F2WNM3LHIH[AK9T,+91U.#GY>!D_>Z>]7O$'BCP7X7%O_`&Q=V=N; ME=\2B(R%U_O84$X]^E`&Q_PC>B?]`NU_[]BC_A&]$_Z!=K_W[%83>,/`J>'( M]?>]LTTR60Q1S-"P+L#@A5*[B?H*T]"O_#7B;3_MVC/:7=ONVED3!5O0@@$' MV(H`M?\`"-Z)_P!`NU_[]BC_`(1O1/\`H%VO_?L5@ZYXR\">&]2&GZM?65O= MX!,0A9RF>F[:IV]>^*Y/XD>.M.T:YT33M&U#3[-K\B::^:S^T+%;D?*Z@##9 M.>F3Q0!Z5_PC>B?]`NU_[]BC_A&]$_Z!=K_W[%1AG>$_B_N[<;MW^SC-7M!OO#?B?3!J.C?9KJU+E-ZQ%<,.H((!!Z=1WH`M?\` M"-Z)_P!`NU_[]BC_`(1O1/\`H%VO_?L5Y_-XE\0WOBG7]*T#PII%Y%H\B*YF MG\MY-R[A@8QG@UM:)XS\+:GX1E\0WT$&EQ6TK07<5R!NAE7JG`^8],8&3Z4` M=-_PC>B?]`NU_P"_8H_X1O1/^@7:_P#?L5S*>+?"NN^'-:O/#=U9W-U8VDDN MTP%60A"5)5P"1GVQ7,:%XFU"_P!6^']O<+:-'K-E/->@6R#>RJ2"./EZ=J`/ M3?\`A&]$_P"@7:_]^Q1_PC>B?]`NU_[]BN>T_P`;>`=4UM='LM1LI;YV*(@A M8*[#LK%=I/T/-2IXN\#R:T='6]L_[0$TD#0&(@JZ#+9XP``#R>#C@T`;G_"- MZ)_T"[7_`+]BC_A&]$_Z!=K_`-^Q6-H'BCP7XHU">QT:ZM+NY@4NZ+"R_+G& M02`&&<-/$=MX6\=>&[2YDLK31;J*XDO6EA4YV*-N#C(Y/0=B?]`NU_[]BC_A&]$_Z!=K_P!^Q6!!XR\"7.CQZM#>VCV3W*VGF"!OEE;H MK#;E<^I`%:[W?AZ/Q!'H+"W_`+3D@-PL`B)/E@XW$XP.?4T`6/\`A&]$_P"@ M7:_]^Q1_PC>B?]`NU_[]BO/M<\5ZO!XOUO1=#\+Z7>1Z3;).O!S>#=.\2ZE]GTZWO@0D4J;WW`[6`"@EL$=0/RH`ZC_A&]$_Z!=K M_P!^Q1_PC>B?]`NU_P"_8K&/BGP2-!M]<^VV/]F3S"!+CRSM$A_A;C*GUSC' M>LB/7]+UKQ7X?&B:OIATJ\6X#VK63&2Y:,')1BOR@'U(SVS0!V'_``C>B?\` M0+M?^_8H_P"$;T3_`*!=K_W[%W M6K/B'Q1X,\,W<=CJMY8VMY,FZ.-HRV!T!;`.T9[G%`&U_P`(WHG_`$"[7_OV M*/\`A&]$_P"@7:_]^Q7+_"Z^?Q1X&MM4U6&VFNWFE1G2%4!"N0.`,=!79?V9 M8_\`/I#_`-\"@"K_`,(WHG_0+M?^_8H_X1O1/^@7:_\`?L5:_LRQ_P"?2'_O M@4?V98_\^D/_`'P*`*O_``C>B?\`0+M?^_8H_P"$;T3_`*!=K_W[%6O[,L?^ M?2'_`+X%']F6/_/I#_WP*`*O_"-Z)_T"[7_OV*/^$;T3_H%VO_?L5:_LRQ_Y M](?^^!1_9EC_`,^D/_?`H`J_\(WHG_0+M?\`OV*/^$;T3_H%VO\`W[%6O[,L M?^?2'_O@4?V98_\`/I#_`-\"@"K_`,(WHG_0+M?^_8H_X1O1/^@7:_\`?L5: M_LRQ_P"?2'_O@4?V98_\^D/_`'P*`*O_``C>B?\`0+M?^_8H_P"$;T3_`*!= MK_W[%6O[,L?^?2'_`+X%']F6/_/I#_WP*`*O_"-Z)_T"[7_OV*/^$;T3_H%V MO_?L5:_LRQ_Y](?^^!1_9EC_`,^D/_?`H`J_\(WHG_0+M?\`OV*/^$;T3_H% MVO\`W[%6UTZR1@RVL(8'((0<59H`R_\`A&]$_P"@7:_]^Q7$>/;*VTN>Q6P@ M2V$BN7$0V[L$8S7I=>=_$S_CYT[_`''_`)B@#L/#?_(M:;_U[I_*M2LOPW_R M+6F_]>Z?RK4H`****`"BBB@"F?\`D,+_`->Y_P#0A5RJ9_Y#"_\`7N?_`$(5 M1@YKUZB@#S?XDZ1JL/B+PUXOTK3Y=2.CR2"X MLX?]8T;C!*CN1SQ[BLCQ]K5_XY^'6KVFG^%=?MS');E5O+,H\I\T$A4!)(`& M2>E>OT4`>::IH][#\4/#UWINF%8H-%GA$BPXB1]IV(Q`P.>UI9O1KZ//]JO M+^X:V#6QWSIU4IQEAG)&*P?$$VKV7B.P@TRWNOM7_"+6]I?)!8&\DC4CD-'Q MY9'N>:^BJY;Q!\._#7B;4?[0U&RD^UE/+:6"=XBZCH&VD9Q[T`>5ZMI0U+PW MX%UCPQ+K5YHNE1R6\SZ<@%[&QPN\(<\Y!!QGZ]Z[OX6:5%9PZQ?QP>(8VOIU M=WUU%265@#E@JC(ZXR>N*[;2M*L=$TV'3M-M8[:TA&(XHQP._P#.KE`'C$AU M'PKKOC2UN_"6IZN==F:2SN;2W$L;HRD!)&_@`SW]Z?;>%-8TFW^%UC<6DTTN MGW$K7;1H76`,,@,1P`,X].*]DHH`Y?QY/9Q:`(=1\-WFO6$\@CGM[.'S7C&" M0X7(/4`9!!&:\NTG2O%6G>&/%LGA;3=5M-)=(O[+T_54#S*P8>:R1MG&!NP# MUXZD5[S10!X#X)I8;CPW/`D^LP8EDEX^08[9Z`\U%=^&M= MMM$\":HUIKT<%A8207*Z5&/MEL[$X(1AWR`?85]!T4`>&Q^';"'P/<7$NC>- MIA<:PMVLC1I]NBE"<3B,=LY'//>N]^&,WB&?P[(89DD:ZC=O7C\:[6B@#QVRUJ_\(_$7QG<2>%]?OTU">(VKV=D7C?:F.7Z`9(YY M[UE2^"O$=CX1M-8N](-W=MXB_MJ^TF$AV\LC&T#HQ'ISU^M>[T4`>.-::EXK M\4Z[XFMO#^HZ99+X?FL$2\@\J>[E8$C"9S@<#/L/PK>']$UF#5?AI(=,ND-G MIETDS20L%AH^(/#,FJV/B5[RSUA'O$EM52QM MUW\&$*.F!R>GYUWGA+19;=_B+-?:+<2?:[^?RXS'L>ZB*G"HQQD')`/3)KU& MB@#R+X9KK5OXF^QVMEKD?A>"T*QC7;1(IK:3(Q'&PY9<#ZK6FGQW$DZ6\6\KP,$9XW#J!U...:]2HH`\5TSP??>*M'^(%[<:5<: M7!KG^&]'@TK2X/(LX`=B;BQY M))))Y)R30!YA>>"+WQ'\7?$S7%WK&F:;-9P)YUH?+2Z&U0R%B"".O`JOX[\' M7&B:QX9N=&MM:71--M)+4_V)A[J!B<[@&Z[L\GZU[110!X'>>%9)/A]ML-*\ M0S?;?$4-S-%JL*F>1<8:0H@^53SG/I7<>)-*O9OBWX4N;6TF%I#97<;SQQGR MX2R$+DC@=L5Z)10!\^1Z?K*_#6;X=-X-U%]9>Y*_;C`/LI_>;O.,OKCC_.*Z M*XM-3\*_$35KJY\-W^NV^JZ9!:VTMK$)%#(@1DD)X16(R2?UKV&B@#@O@YIU M[I7PYM+/4+.:TN$GGW0RH5(!D..#VKO:**`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`*\[^)G_'SIW^X_\Q7HE>=_$S_CYT[_`''_`)B@#L/# M?_(M:;_U[I_*M2LOPW_R+6F_]>Z?RK4H`YV\\3M!XNL=$@M1-%*S)J7LWB(Z+IWD1/%;+,=\\4H=>U&\T"[O%>PLKC3Y9X;PS*TD>Z+NN"I"D8//(SCFK-]X5M MYM374K%XK2Z\KR),VZR)(F`N`<#(XQ0!U^CWLNI:+8WT]N;>6X@25X6.3&64$K^&:NU1@T MJV2!%G@MY90/F<0A0Q]<=JD_LRQ_Y\X/^_8H`M455_LRQ_Y\X/\`OV*/[,L? M^?.#_OV*`+5%5?[,L?\`GS@_[]BC^S+'_GS@_P"_8H`M455_LRQ_Y\X/^_8H M_LRQ_P"?.#_OV*`+5%5?[,L?^?.#_OV*/[,L?^?.#_OV*`+5%5?[,L?^?.#_ M`+]BC^S+'_GS@_[]B@"U157^S+'_`)\X/^_8H_LRQ_Y\X/\`OV*`+5%5?[,L M?^?.#_OV*/[,L?\`GS@_[]B@"U157^S+'_GS@_[]BC^S+'_GS@_[]B@"U157 M^S+'_GS@_P"_8H_LRQ_Y\X/^_8H`M455_LRQ_P"?.#_OV*/[,L?^?.#_`+]B M@"U157^S+'_GS@_[]BC^S+'_`)\X/^_8H`M455_LRQ_Y\X/^_8H_LRQ_Y\X/ M^_8H`M455_LRQ_Y\X/\`OV*/[,L?^?.#_OV*`+5%5?[,L?\`GS@_[]BC^S+' M_GS@_P"_8H`M455_LRQ_Y\X/^_8H_LRQ_P"?.#_OV*`+5%5?[,L?^?.#_OV* M/[,L?^?.#_OV*`+5%5?[,L?^?.#_`+]BC^S+'_GS@_[]B@"U157^S+'_`)\X M/^_8H_LRQ_Y\X/\`OV*`+5%5?[,L?^?.#_OV*/[,L?\`GS@_[]B@"U157^S+ M'_GS@_[]BC^S+'_GS@_[]B@"U157^S+'_GS@_P"_8H_LRQ_Y\X/^_8H`M455 M_LRQ_P"?.#_OV*/[,L?^?.#_`+]B@"U159=.LD8,MK"&!R"$'%6:`"O._B9_ MQ\Z=_N/_`#%>B5YW\3/^/G3O]Q_YB@#L/#?_`"+6F_\`7NG\JU*R_#?_`"+6 MF_\`7NG\JU*`"BBB@`HHHH`IG_D,+_U[G_T(5C) MJ-YJ?BN2:::;`,UJ?\`"./_`,__`(R)]M5DZ]., M^K<#V!8X&,L\!LP\(6@&MK;'SKC$9`^0^=*?_0=S<^Q/`P>CWMC_`)&-5&,\ M@<#;GOZ)\W/\1R>,"@#"\/)"ZQHUR"V#\A\Z#Y?P&WWSDGKQW5`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%>=_$S_CY MT[_&_P#D6M-_Z]T_E6I67X;_`.1:TW_K MW3^5:E`'/7>OW-EXBL]/DBM)8[N8Q*D,Y:>,!"WF,N,!>,'GC(ZUC7?CJ_@T MJUU--,B:TU`R)9X=F=2H)5I%`Z%59L`Y&`*VKS0+O4-7M[FXN;5(;:Y%Q&T- MN5G;'1&?<1MYP>.0,55L/"5S9#3H&OXI+32FD>Q4PD-N8,J^8=W(4,1QC-`! MHWBBXU2\@M`+8,DDGVB?!574$B/RP3GTE6 M^W.N&N9)(MSR2"19"ZG/RL2NWO\`+@#H*ZXC(P>E`&<;NV_M=6^T0X\@C.\? MWA5K[9:_\_,/_?8JL;>#^UU'DQX\@G&P?WA5O[-!_P`\(_\`O@4`-^V6O_/S M#_WV*/MEK_S\P_\`?8IWV:#_`)X1_P#?`H^S0?\`/"/_`+X%`#?MEK_S\P_] M]BC[9:_\_,/_`'V*=]F@_P">$?\`WP*/LT'_`#PC_P"^!0`W[9:_\_,/_?8H M^V6O_/S#_P!]BG?9H/\`GA'_`-\"C[-!_P`\(_\`O@4`-^V6O_/S#_WV*/ME MK_S\P_\`?8IWV:#_`)X1_P#?`H^S0?\`/"/_`+X%`#?MEK_S\P_]]BC[9:_\ M_,/_`'V*=]F@_P">$?\`WP*/LT'_`#PC_P"^!0`W[9:_\_,/_?8H^V6O_/S# M_P!]BG?9H/\`GA'_`-\"C[-!_P`\(_\`O@4`-^V6O_/S#_WV*/MEK_S\P_\` M?8IWV:#_`)X1_P#?`H^S0?\`/"/_`+X%`#?MEK_S\P_]]BC[9:_\_,/_`'V* M=]F@_P">$?\`WP*/LT'_`#PC_P"^!0`W[9:_\_,/_?8H^V6O_/S#_P!]BG?9 MH/\`GA'_`-\"C[-!_P`\(_\`O@4`-^V6O_/S#_WV*/MEK_S\P_\`?8IWV:#_ M`)X1_P#?`H^S0?\`/"/_`+X%`'GO@-9&\'6A718[E#+<8D+#YQ]H<_JVW\%) M/8'I-D__`$+T3'_>`R=V>_J_S?09/.!7*^!7LU\(VWF:O/;L)KCWGL9H8_\`621NC*G&>2.!0!8^V6O_`#\P M_P#?8H^V6O\`S\P_]]BHK5]-OHC+:-:W$8.W?"5<9],BI_LT'_/"/_O@4`-^ MV6O_`#\P_P#?8H^V6O\`S\P_]]BG?9H/^>$?_?`H^S0?\\(_^^!0`W[9:_\` M/S#_`-]BC[9:_P#/S#_WV*=]F@_YX1_]\"C[-!_SPC_[X%`#?MEK_P`_,/\` MWV*/MEK_`,_,/_?8IWV:#_GA'_WP*/LT'_/"/_O@4`-^V6O_`#\P_P#?8H^V M6O\`S\P_]]BG?9H/^>$?_?`H^S0?\\(_^^!0`W[9:_\`/S#_`-]BC[9:_P#/ MS#_WV*=]F@_YX1_]\"C[-!_SPC_[X%`#?MEK_P`_,/\`WV*/MEK_`,_,/_?8 MIWV:#_GA'_WP*/LT'_/"/_O@4`-^V6O_`#\P_P#?8H^V6O\`S\P_]]BG?9H/ M^>$?_?`H^S0?\\(_^^!0`W[9:_\`/S#_`-]BC[9:_P#/S#_WV*=]F@_YX1_] M\"C[-!_SPC_[X%`#?MEK_P`_,/\`WV*/MEK_`,_,/_?8IWV:#_GA'_WP*/LT M'_/"/_O@4`-^V6O_`#\P_P#?8H^V6O\`S\P_]]BG?9H/^>$?_?`H^S0?\\(_ M^^!0`W[9:_\`/S#_`-]BC[9:_P#/S#_WV*=]F@_YX1_]\"C[-!_SPC_[X%`# M?MEK_P`_,/\`WV*/MEK_`,_,/_?8IWV:#_GA'_WP*/LT'_/"/_O@4`-^V6O_ M`#\P_P#?8H^V6O\`S\P_]]BG?9H/^>$?_?`H^S0?\\(_^^!0`W[9:_\`/S#_ M`-]BC[9:_P#/S#_WV*=]F@_YX1_]\"C[-!_SPC_[X%`#?MEK_P`_,/\`WV*R M]8\0QV,]C9VA@GO;V1DB#RA40*I9F8\\`#H.22*UOLT'_/"/_O@5E:QH"7]Q M8WEJT,%Y8R,\3/%N1@RE65AQP0>QX(%`%6T\1W-U-J&G&.Q34K,QG)N/W,B. M"0X.,]F!&.HZX-6=`\0Q:O82RSF"":&XEMG"S!D8HQ4LI.,J<>E8X+$/NR"3QTKH]'TE-.TR&S>WLE6$;(UMXBJJ MHZ#YB3GWS0!=^V6O_/S#_P!]BC[9:_\`/S#_`-]BG?9H/^>$?_?`H^S0?\\( M_P#O@4`-^V6O_/S#_P!]BC[9:_\`/S#_`-]BG?9H/^>$?_?`H^S0?\\(_P#O M@4`-^V6O_/S#_P!]BC[9:_\`/S#_`-]BG?9H/^>$?_?`H^S0?\\(_P#O@4`- M^V6O_/S#_P!]BC[9:_\`/S#_`-]BG?9H/^>$?_?`H^S0?\\(_P#O@4`-^V6O M_/S#_P!]BC[9:_\`/S#_`-]BG?9H/^>$?_?`H^S0?\\(_P#O@4`(+NV9@JW$ M1)X`#CFIJC%O`""(8P1T(45)0`5YW\3/^/G3O]Q_YBO1*\[^)G_'SIW^X_\` M,4`=AX;_`.1:TW_KW3^5:E9?AO\`Y%K3?^O=/Y5J4`%%%%`!1110!3/_`"&% M_P"O<_\`H0JY5,_\AA?^O<_^A"KE`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`'#/X@UB3PK<^+(;B);>%Y'2P,0(:%'*D%_O;R`3QP#@ M8-:DNJ:K'X[L+!FMETNZM9I$15)D+)Y?S,3P/OD8'IG/8)?^"[>[TZYL+?4K MVTM9I#,+>,HT2R%MW1E)*EN2F<')XYJT/#TDVJV&JW>J7+WMI$8\1*B1-N"[ M_E*D@,4!^\2.QH`YKP`-1/@VS,%E:2QB:XVM(><"X?@GM\W/?`7N3QTH35QT MTZPR,8)XY!X/7CYB7]AP,DDCC/!!TS_A%+4W#WJR^=<%C%G`_?R#([\`[1CN M_'S$XZ#_`(DN.3J`[$+^1`Q_WZ&/<+SN-`'*^++>\D\<:9YUDH@CL-]S%`F= M]JMU"74@9)_O%1Q@D<\UN3:OHLWCH36UU;"$:3(MPVS*R_.I0!?X]HWDXS@- MSC--T[[+_P`+4L_LK2E?[%N=WF8R3Y\(R,=N-H[?)QQ7=2VT$TL4LL,U^<2)=I.T+_;8(S'"Y"$;%7)Y7`).3G<.F,5 MU]%%`!6#XNU.YTK28)K:00/(L7FLJ.X#87!R<'T-;U4]1TV#4XX$G+@ M0W$=PNPX^9&W#/MD4`VA#VIBD^UD_NMPP,*W*GC MC`/>NOLDN8[&!+R59KE8U$LB+M#/CD@=AFHM0TV#4UMUG+@6]Q'<)L./F0Y& M?:KE`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!7+77C7RM6OM/LO#NLZBUE(L4TMK'%L#E%?;EY%)X9>W>NIKSG3 MOL'_``EOB_[5]J+_`-I1@"+.TC[-#A>>.2,GV3YOE'(!M?\`"97_`/T)/B3_ M`+XM_P#X]4ECXS%SK=GI5YH&L:;->!_(>[2+8Y1=S#*2,&_\`D6M-_P"O=/Y5J5E^&_\`D6M-_P"O=/Y5J4`<_J&J M:CIVOZ9;%K2:WO[AHA`J,)8T5"QDW;L$`@`C`^\.?7`NO%^NC1]/U*VMK>2/ M5FDCM8(XV,L.`S(QYPYVHQ*@#G`&:Z&'P_,D]>@Q!8^$%L6M434)GMK`R-8PLB_N&<$9)_BVAB!GL>2(D5#C#%2K-QQE1CYN.R)`!).`.]% M6_MMK_S\P_\`?P56-O#_`&NH\F/'D'C:/[PJW]F@_P">,?\`WR*`&_;;7_GY MA_[^"C[;:_\`/S#_`-_!3OLT'_/&/_OD4?9H/^>,?_?(H`;]MM?^?F'_`+^" MC[;:_P#/S#_W\%.^S0?\\8_^^11]F@_YXQ_]\B@!OVVU_P"?F'_OX*/MMK_S M\P_]_!3OLT'_`#QC_P"^11]F@_YXQ_\`?(H`;]MM?^?F'_OX*/MMK_S\P_\` M?P4[[-!_SQC_`.^165JM_'97UEI]K8Q7%]>[S&C$(BH@!9V;!(`RHX!))%`& MG]MM?^?F'_OX*/MMK_S\P_\`?P5@Q^(+2.VU3[?8)!=Z:ZQRPIAQ(7`,>PX& M=V0`"`<\5<\.7R:[H-MJ,NGQVLLNX/!D/L96*D;L#/(]*`-+[;:_\_,/_?P4 M?;;7_GYA_P"_@IWV:#_GC'_WR*/LT'_/&/\`[Y%`#?MMK_S\P_\`?P4?;;7_ M`)^8?^_@IWV:#_GC'_WR*/LT'_/&/_OD4`-^VVO_`#\P_P#?P4?;;7_GYA_[ M^"G?9H/^>,?_`'R*/LT'_/&/_OD4`-^VVO\`S\P_]_!6)XM\4KX=\.S:C:)! M>7"R111PF8*&9Y%09(S@#=GIVK=^S0?\\8_^^17&_%*&)/`TI2)`?MMGT4#_ M`)>8Z`*9\7^,0Q7^P]$R/^HC)_\`&J%\7^,695&AZ)\W3_B8R?\`QJD;_7'O M_7FB'_6P]^:`$^'$FJR>!=.>*>RC#O,PC;)P3-)QZGG<>V=H`QDFNI#:P<;; MVQ.0,$\YXX/'ME_?H,`$GB?A\EB?`VG^=IEU,Q,VZ2,'#?O6!(Y[_*GOEATW M&NF*::<[M&O&SU`R[`)Z%1_<%`''>-Y;Z+Q38SF\:.<6+A9;.P?\-+:; M_P!"Y=_^!*_X5UW@#XMV'CO4+NT33I+`V\0EWS3*0V3C'05\BU[7^S?&DGB; M60Z*P^QKU&?XQ0!]&_;;7_GYA_[^"C[;:_\`/S#_`-_!3OLT'_/&/_OD4?9H M/^>,?_?(H`;]MM?^?F'_`+^"C[;:_P#/S#_W\%.^S0?\\8_^^11]F@_YXQ_] M\B@!OVVU_P"?F'_OX*/MMK_S\P_]_!3OLT'_`#QC_P"^16;K5];:1;0,+-)[ MBYG2VMX0`N^1LXR>P`!)/H#UH`T/MMK_`,_,/_?P4?;;7_GYA_[^"L.+5S%? MW>G7VD*+V"V%U&EJ1*)T)*X7(4[@W!!`Z@Y]+'AO48]?T2/4)=.CM)&EEC:$ ME7VE)&0_,!@_=H`U/MMK_P`_,/\`W\%'VVU_Y^8?^_@IWV:#_GC'_P!\BC[- M!_SQC_[Y%`#?MMK_`,_,/_?P4?;;7_GYA_[^"G?9H/\`GC'_`-\BC[-!_P`\ M8_\`OD4`8OB/7QIMC;BRFMS=7=U%:QL[`K&7."Y&><#)QW.*H'Q&VAZS-::I MJ<-W9?8'O%N,*KH48*R$+P<[EQQG.1S6]J6B6&JV1M;B$!=RNKQ_*Z.IRK*> MQ!`-9#>#HGUI;^:\-[$\/D7-O?6\4BR(#N4+A5"$-R>#GOT!``SPGKM]?-JJ MZS<6J2PW0$42$#RD:-'"$Y^8C=@GUS71_;;7_GYA_P"_@K.TOPMHVC75[<6- MA!"]VX>0+$H`PH4`8'`XSCU)K3^S0?\`/&/_`+Y%`#?MMK_S\P_]_!1]MM?^ M?F'_`+^"G?9H/^>,?_?(H^S0?\\8_P#OD4`-^VVO_/S#_P!_!1]MM?\`GYA_ M[^"G?9H/^>,?_?(H^S0?\\8_^^10`W[;:_\`/S#_`-_!1]MM?^?F'_OX*=]F M@_YXQ_\`?(H^S0?\\8_^^10`W[;:_P#/S#_W\%'VVU_Y^8?^_@IWV:#_`)XQ M_P#?(H^S0?\`/&/_`+Y%`#?MMK_S\P_]_!7%:$]XWB7Q@]G=6J0G4DR7Y/\` MQZP[F!Z<<#_@1)Z`'M_LT'_/&/\`[Y%>?Z5'9KXJ\7>9ITTS#4XMKQC"Y^S1 M$+].K'L,`GG;0!U);6!G==V`ZY`_`DU:6YB\?>$'U"[M2%> M]QY?`_U)R3GI@_+CVY.3QH[--&-ND7JXQ@G<,<9!//IF0YZ''\1Q7+>*=.CU M/6]&T_3[&2TEN;?4(5,_&UC;$*O/0VGBO0KZY6WM]3A:1PS1 MYRHD`ZE&(`;'L33K/Q-HM_>%'S>H`^.X37/$NN6USJG)KD=8\;W$_@NS@DUI;*_%H;J>Y201O,% MD7_AK1M4E$MYIT,D@0QEL;2R_P!TXQD>QXIEGX9TRST>32/*:>PE`%V+4["6W2>.]MVB90P<2C!'KFB/5=.E.([^U<]/EF4_UK-\6V M\/\`PAVMX@C)^PS8^0?W#6!K6DSQ^!6U`QZ>NH:;&M]9O!;E0&1,[6&22&&Y M3[&@#M!?6;9Q=0'!P<2#@TOVVU_Y^8?^_@K.\/:+;:7H=K;!$DD*^9-*R#,D MC'<['ZL36G]F@_YXQ_\`?(H`;]MM?^?F'_OX*/MMK_S\P_\`?P4[[-!_SQC_ M`.^11]F@_P">,?\`WR*`$%W;,P5;B(D\`!QS4U1BWA!!$,8(Z$**DH`*\[^) MG_'SIW^X_P#,5Z)7G?Q,_P"/G3O]Q_YB@#L/#?\`R+6F_P#7NG\JU*R_#?\` MR+6F_P#7NG\JU*`"BBB@`HHHH`IG_D,+_P!>Y_\`0A5RJ9_Y#"_]>Y_]"%7* M`"BBB@`HHHH`****`"L?5](N+K4K#5+&:..]LA(BK,I*2))C5=W-O:AXHVP#R=V>XYQ0`MOX6U"[UF^FUAE' MFW$=Y#=V,Q3:R)L6,HP.=HR0>GR7(OM4\1FAB^Q+F1!U9?GP1R.E6O#OQ$TKQ+J4 M=C:V>I6\D@EV-=6_EJS1$"1>I(9=PR"!UH`ZZBBB@`HHHH`****`"N+^*G_( MB2_]?MG_`.E,==I7%_%3_D19>^!T`.>H#W)QCQ M!;@8X)"G`VYS^"?/[DYX48KE/AVBGP)IN=#^T@F;]X"/G'G-GVY(4<]@2<`# M/4;`IQZ5\9?$_\`Y*=XB_Z_ M7H`Y*O;?V;/^1GUK_KR7_P!#%>)5[;^S9_R,^M?]>2_^AB@#Z2HHHH`****` M"LK7M(?5K>V,,PANK.Y2ZMW9=R[UR,,.X(8@X]:U:Y76O'FGZ+K4FE'3M5O; MJ*))9!96WF*BN2%RR6TA\^65&@##_62,Y!SZ;L?A6)_PLRT_Z%OQ+UQ_ MQX#UQ_>]?\>E2V7Q'TZ[U.SL9-)UJS>\E$,4EU:;$+D$@$[C_=-`'94444`% M%-K;PW86-@3-;I*+J^N'B MC,CLX6/*HV&.PXSC.,5DGXA^+ELM0G;PWIHGTV4)?6?VV0SVZ?\`/4J(_FCQ M\V5)R/H:IZY+-?>+KR:.VCUG2Y]`LWOM/9,3W,!>4^;$.SH<';_M<$'%1H[M M)I4T6L*T[#;X?\2-RMPI_P"7.[]SC'/)(R,,""`:P^(NNVNOZ-9:AH^FFRU: M6)+:]L[QY8Y@YP2A,8&5X)!QP>,UZ97B3;EU/2TLT&GQ+K]H=3T.;DV5R7R) M(#T\J3GV/48.17MM`!1110`4444`%%%%`!1110`5P&D-*OBGQ@4U..T7^T4) M1@,D?9H,MD^^T>V3U)&._KS_`$A<^*_%Y&E?:C_:D1$N0,,+6+'3G`!8Y]2, M9)X`-\O=@G.O6Y(SD``<[@"/;Y\)[#CECD85\TA^(7@\2ZDEV=U[M"`#CRB" MQ`_VL@=@!CDY-;`C0`8\.,H`&.>5&W`Z>B9Z?Q'`RR57U"=[73;JXC`+Q0NZ@],@$UX!]BM?^?> M/_OFH;JRMA9W!$$8(B?G;T^4T`=-IWB#Q_?6MLLOB"QM]0U&T2[TI6L$^SW@ M*!C%YFV_?8WW^/4D?Q+6Z#??VI;.M MW:RZ[)!BQU`X%IXAM<9\F7'`E`_+J,@D``ZGP#JNOWMSKMAX@N[2[GL+F-89 M[5`J21/&'5N/4$'\:[2OC7QAK-QI'BZ_A\.W.K:-:MLWV1N)(V@D"@-'@'HI MR!VQC'%8G_"8>)_^ACU?_P`#I?\`XJ@#[EHKY4^#WB37;_XHZ1;7FM:C<6[^ M=OBFNG=6Q$Y&03CJ!7U70`4444`%%%%`!7G?Q,_X^=._W'_F*]$KSOXF?\?. MG?[C_P`Q0!V'AO\`Y%K3?^O=/Y5J5E^&_P#D6M-_Z]T_E6I0!SS:UJ2>.(M( MEM;>/3Y;26:.3>6E=D,8SCHJ_.1CD\=JP+KQ?KO]CZ?J5M;6\B:LTD=M!'$Q MEAP&9&/.'.U&)7`YP!FNDGT&XG\46^M?VD5$$3PK;^0I!1RI8%NNW-5K M'P@EBUJB:A,UM8&1K&%D7]PS@C)/\6T,0,]CSF@"CI/B:ZNM1M["[NHH/*FD M626=!&]SR1$@4XPQ4JS<<948^;CLB0JDDX`Y)KFG\%VA:T\NZG18E43@X8W! M$@EW,3T8N,DCKG'I734`9)U*R_M96^TQ[?((SG_:%6_[4L?^?J/\Z#_R&%_Z M]S_Z$*MT`5/[4L?^?J/\Z/[4L?\`GZC_`#JW10!4_M2Q_P"?J/\`.C^U+'_G MZC_.K=%`%3^U+'_GZC_.C^U+'_GZC_.K=%`%3^U+'_GZC_.O'K)U;QIX@DTM MA!K4NI3"V-Q_QZZM$$3?:N?[R]0>HW<9&:]LKQ2;YM2\7B\']H:*NKLU_9P< M76GG8ACO(L?-U!SW&W(S@@@#_P#B7KI)XNX/#T-QR.EYX:NQW]?)R?<`'NIX MMZ3)]G^*^F3:K:10:JUAEM?*NDW`_>Z9-F M'S(B?[GW2HZ=<<8H`]3_`+4L?^?J/\Z/[4L?^?J/\ZMT4`5/[4L?^?J/\Z/[ M4L?^?J/\ZMT4`5/[4L?^?J/\Z/[4L?\`GZC_`#JW10!4_M2Q_P"?J/\`.N.^ M)]_:S^"9(XIXVW^N/^>]$ M/^MA^HH;_7'O_7FB'_6P_6@"I\.Y(!X%T[=K"-H"Y/7N$P.>C-DY)`'/_#@7I\!:88M,MKA`9MKNPW,/ M/<_A\V#[!<\G`KJ0NHCIHUD2.AR!SG(/M\^7]AZL>`#SWQJ5/B&UVWC7(%HX M9F4C:V]?E&>P&!CJ"#DDDU@5T/CE95\167G6D=L?L3!1&`,KY@ZX/7.3CMNZ MDYKGJ`(YR%B#-]T.A/TW"NQOM1TNV\#>([*_9?[4EN;IOF0[G=I"89`6Q>3[V06;J<8PJ\\U\^_$QUD^)?B%T8,IO'(([U]H0P16T*0P1)% M$@PB1J%51Z`#I7QC\3_^2G>(O^OUZ`.2KVC]G*XAMO$NLM-(J`V:@%C_`+8K MQ>O;?V;/^1GUK_KS7_T,4`?0_P#:EC_S]1_G1_:EC_S]1_G5NB@"I_:EC_S] M1_G1_:EC_P`_4?YU;HH`J?VI8_\`/U'^=><7DT<_Q+UQXG5T^QV8R/\`MM7J M5>8:E_R4[7/^O*S_`/:U`%GLW^]67JCK'KGAEW8*HUB+)/;]W+6IV;_>_K_D MUE:JI?6O#:*Q1FU:-0P[$Q2\T`=_'XQ\/RW:VR:G$7=RB.581NW]U7(VL?8' M/!I\?BK1)=0-BM^HN.<*Z,H?'7:Q&&Q[$UQU[-+8>!=(TB\TV]MI+"6T6ZN5 M@9HH%B=2TH906MAYD5ANMVVRLPPTQ?&`" M/E4>A)/4``&I?1>'M3D22^CM+AT!56D4$X/;Z>U4;?0_"=O"L/E6\L2,3&DS M&01@G.Q<]$SR%Z#)P*\[B\9>)YHQ(=;E4L2=JP0X')Z?)3_^$M\3?]!V?_OQ M#_\`$4`6/%4VG2_$Z28W,MA,FGVBV6LPC,=E.9)@JR]O+D^Z0>#@#C@A'20R MZK%+HZM.PW>(/#B\K<*?^7RS/<\9P.21@X8`G(TW4-9U3QCJKO=0ZM.=-A2; M2+I(U_M"WW2;U3``#KG(X_B(/7C3!MOL6G21ZG,FFI*5T377'[_2YNAM+H'D MH3\OS?0_PM0!5O7C^W^$KBXOB+34;;I>HG6[-M6T<M;]`%3^U+'_GZC_.C^U+'_`)^H_P`ZMT4`5/[4 ML?\`GZC_`#H_M2Q_Y^H_SJW10!4_M2Q_Y^H_SKEUU1];U;6HUUM]/BL)5M[8 M0;>6\M7,C[@=PRP`'`PI]:[.LF^\.:?J%Q-/(+B)[A!'/]GN'B\Y0,`/M(S@ M$C/7!H`X^3Q7J-YI'A34UU*"V2ZN;>.\@CC!,I8D-R<[4XS@<\]:71I[:7Q1 MXN;^UW@!U&/Y(^=P^SPCMSDM@>O!"X))KH4\&VC:?9V5W?:A<1V3AK8^>8S' MM/R?K^G\((&!N-<#\1'A;5?#/EZE)>GS;D@MT5?+//H23D M@^F,<"O1MFH$8.B68&.GRG`VXQ[X3Y/3U^@&%R>21V&*`.>J&[_`./*XXS^Z?C_`(":FJ&[_P"/*XYQ^Z?_`-!- M`&MH1O!I'AEY+ZW@U(V<::)K:#]S.-HW6-R!W!!4>N,C#`@V2+06%^CZ;/'I M,COI#?*9;)NDB_]MO\`T2]?7]`%3^U+'_GZC_.C^U+'_GZC_.K= M%`%5=2LG<*MS&6)P`#UJU110`5YW\3/^/G3O]Q_YBO1*\[^)G_'SIW^X_P#, M4`=AX;_Y%K3?^O=/Y5J5E^&_^1:TW_KW3^5:E`!1110`4444`4S_`,AA?^O< M_P#H0JY5,_\`(87_`*]S_P"A"KE`!1110`4444`%%%%`!7BD?R^,M::`_P!F M:J=9F73-5?F"XDV1E[2<#^%@`5SW)*\C!]KKQ0?O-<\9Q`?VM:?VBYU303S) MY&U-MQ!_MJ0<@'G`Z$#(!(PM!87Z/IL\>DQRAM8T5#_I&C3]1=6Q'6/^+Y?< MC^):OZ$+H_$[0Y+V."ZF;3;GRM;MP-NI0?NO++8Z.N3N'3D$<'`K*\IN-*FB MU='NW7;X?\1MS'>H>?L=W_M'&,]21D88$%?"WV1?B;IL=LLVGR+;WINM#EP1 M83DQ%FC/_/.3AACY3@D8R0`#V"BBB@`HHHH`****`"N+^*G_`"(DO_7[9_\` MI3'7:5Q?Q4_Y$67G'^FV?/\`V\QT`4&_UQ_SWI(?];#]:5O]<>W].:2'_6P_ M6@"A\/FTX>"-/\^\NXI09MWEDX7$K\CCL#CCH9./F(QTN[2!UOK]<#D#(QQ@ MC@=AB,8[D@?-DUC_``V_M3_A`=,^SBS\O,NT29S_`*Y\`_CD_1<#DY'5#^V> M-OV#MC/?J`>/Q?\`)1W:@#S?QC]G_P"$@M/LTLLB_9'W&3&<^8!Q[#[O''R< M=ZPZZ+QW]I_X2*R^TB'=]B;;Y6.%WC`/OW]/FP.F3SM`&7XC*#0KCS97BB+1 MB21#@HAD4,1]!FMT>%;8-::OS, M77?,_LIO)56E\^#8K_=+>:F`?;-=4XL_L%^CV%PFC1S[M6TA#_I.B7.,?,/XEH`S6T/06AN[YO[3AT>=_(N)#=S"ZT&YZ8D7=AHL]R#C.DM\6=Z< M"T\1V@&?+DQP)0/RZC*D@?-FN!5U_4E2T-F@NI0ML>L(W'Y/PZ?A0!0KVW]F MS_D9]:_Z\E_]#%>)5[;^S9_R,^M?]>2_^AB@#Z2HHHH`****`"O,-2_Y*?KO M_7E9_P#M:O3Z\PU+_DIVN?\`7E9_^UJ`+/9O][^M9FH_\A_PO_V&8O\`T7+6 MGV;_`'O\_P"%9FH_\A_PO_V&8O\`T7+0!ZS1110!\\VG_'JGX_S-35#:?\>J M?C_,U-0!5T_[(/$>HR:A!/#:);VI&L6Y'F:9+OE\N3UV$Y#'ITSP>.M9;W^T M[M'LK:36Y(,ZEI@P+77K;&/.ASP)0/\``\8-X'CB]33K^)-4:PB\G3; MD@0:E'ND\R%L]&Q@J>W/!&:VP=/72$(>Z@\/PW&(I2,7GAJ['\+=_*R>_`!Q MRI!`!3OKFVM4\,7AD6\T"VU:!K+5+DA9M,4-^\M;@GD`8P"?3!Z`UZA_PL+P M;_T-.C_^!D?^->(_%3M;JWOK6*ZM)XY[>50\&SD9XL>1$`H)`R6P">G"'/R@YT!_!WX_PJ'P/]O\`MWBG[,;81?VF,^;G M(/V>++>G3C'^USP.0#=WZ2<8U"^;/0DYW9YSR.Y'F>X7)^4`5POQ`-DVJ>&C M:37,W[VXRTV3M!BSCGNWW^>3D'I@5Z8?[9YW+8=\@?@2.?3A/QR>RUY[\3/M MW]J>&?MC6_\`K[G`A'WCY7)^@^[^&3UP`#G:BNO^/*XXS^Z?_P!!-2U#=_\` M'C3_\`H)H`TM#8MX6\.2SZN/*6&-=)\0Q@%M/N"H#6MP.AC)^49X(P M#@X-:+H2^JQ2Z."[#=XA\-H,X&"2.S@$T?#BRG1[2.'2HUU M&33(3?Z+(08=:M/+4+-$3QYH7&>^>#V-7`T'V739(]5E6P63;H>ON,S:=+G! MM+H'DH3\OS?0\X-`'B'Q%97\8SO%K!U>`PPF"\8#>\?EKM#^K`84D\D@Y`-< MI77_`!-6X7Q]J/VS2XM,NSL-Q!"08S)M&YU(_A<_,,\_-SS7(4`>@?!/_DK6 MB_\`;;_T2]?7]?('P3_Y*UHO_;;_`-$O7U_0`4444`%%%%`!7G?Q,_X^=._W M'_F*]$KSOXF?\?.G?[C_`,Q0!V'AO_D6M-_Z]T_E6I67X;_Y%K3?^O=/Y5J4 M`(3@$^E(ANIQL`.>#GMBO0*P[#P MK8:=<6\D4ERT5JTC6MN[@QVY?.XJ,9Z$@9)P"0,4`(KR"ZCL=2O;FU@A MN/,DFN%5IBFU2(GV`@?,2S-QA2@R-U>@$X!)Z#G@5@3^#]-N+6"`O01_J'_O#VJW_:$']V?_`,!Y M/_B::?\`D,+_`->Y_P#0A5R@"K_:$']V?_P'D_\`B:/[0@_NS_\`@/)_\35J MB@"K_:$']V?_`,!Y/_B:/[0@_NS_`/@/)_\`$U:HH`J_VA!_=G_\!Y/_`(FC M^T(/[L__`(#R?_$U:HH`J_VA!_=G_P#`>3_XFO&IITC\6:U#=>9IMQ_:4UYI M>KQQ,SV[E$!25,P>TN;B6Q4VU](8]:T)4\%ZKX>T_PE96FJ+=QW:&3S0$?C<[MGC_9PO']\@=3 M6\?$7@\@[OM?3D!'_NY(X]L1_3@<9KT.B@#QK6_(U[7X3H-O=7"QVK"7$9.6 M+J<]/?'I\H`X%5O^$=UK_H$WG_?HU[=10!\^^(O#NK?V'/YVE7HA#Q&0K&00 M@D4M@^N,ULG4E74!LU?.J:?'_P`2W6WA/1M0E#W.E*&$VDW.?^/BV<#&S/.!C&<@,-2U2^ MO+/2+_4;>:YE9+SRP//&\_/CWZU]D44`?%__``JWQS_T+-__`-\#_&O5/@;X M7U[PKK^J7&N:1>6<4UJJ1L\1.YMP..,]J]\HH`J_VA!_=G_\!Y/_`(FC^T(/ M[L__`(#R?_$U:HH`J_VA!_=G_P#`>3_XFD;4K92H;S@6.%!@?D]?3VJW4)B2#&^\8[\$?UH`A_M"#^[/_X#R?\`Q->9ZU>0VGQ#U:ZN#)%#/:6JQ,\3 MC<5\W=QC/&1^8KU:B@#RC^WM,VG_`$D]<_ZI_K_=_P`FL[4=;TW^V?#TWVH" M.#58Y)&*,,*(Y`3R.>HX'/7T->T5QWC_`'[O#'ERK$W]N1?O&&0@\J7)Q],T M`7_^$Z\-_P#02'_?F3_XF@^._#0!)U,`#J3#)_\`$T\O?X);6K-%YR1M.W@$ M]>N%P>>[9/`"U!J#WXTZ\\[6;2,"&0OLVY0!?]^C7IG@'_DG?AO_`+!E MM_Z+6NBH`^?5M9-,\275MKVDSC3;Z"W0S(&2YMI%:0I/%@?P$\]^1C/(K7_M MEEN;F\^UP2:W:H(GN3`RVNNVV/N2KM^24#C.,`^JG`]KHH`^;_&<,FK>%;?1 M/#UI+?6ES,DUI93(?M.EOSNB!(PT9Z#!XZ?_`/"K?'/_`$+-_P#]\#_& MOM"B@#XO_P"%6^.?^A9O_P#O@?XU]3>!O,TKP+HEA?6]S#=6]G''+&8')5@. M1P,5U5%`%7^T(/[L_P#X#R?_`!-']H0?W9__``'D_P#B:M44`5?[0@_NS_\` M@/)_\335U.V:]CHH`\I M_M[3!C-T>`()=26X)N+X2P,L;X=!%&H]L;@3[[`3 MP!7L=%`'GO\`PD7A`$@/><'@['Y^;`/(]QU_6-`C\.VEU< M-"\[R_NV)12A51SSR37M5%`'B/_".ZU_T";S_OT:BNO#NMFSG`TF\R M8F`_='T->YT4`>"Z3-:6^BZ+I-Y?W;VPA22WNQ&WVO1;L(-V"1\\).1CG`.# MD8(N-K<12]OY(()+U_W&K:>L3?9=9BQ_K8LCY)<>N.>#V->W44`?)'BOP/KF MN^);FY\.66J:KIBI$L,TR9>-=@Q&Q/)*?=R?3J:QO^%6^.?^A9O_`/O@?XU] MH44`?,'PK\"^*=`^(VE:GJFA7MM9P^;YDK1Y"YB8#ID]2!7TK_:$']V?_P`! MY/\`XFK5%`%7^T(/[L__`(#R?_$T?VA!_=G_`/`>3_XFK5%`%0ZC;+@MYJC( M&6@<#GW(JW45Q`+F!HF)`..1['-2T`%>=_$S_CYT[_&_^1:TW_KW3^5:E9?AO_D6M-_Z]T_E6I0`4444`%%%%`%,_P#( M87_KW/\`Z$*N53/_`"&%_P"O<_\`H0JY0`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`5QGQ"`;_A&`UO]H']NP_NN/G/ERX'/'6NSKC/B$0!X9+3_`&=1 MKD):7CY!Y4N3SQ0!<"09!3P],S<;=Q.&^;(SGU;+'/903SM%07:0"PG\GP_, M"(F\LR$@9PQ7=GI_$QST."&_\`D6M-_P"O=/Y5>N;JWLXO-NKB*"/.-TKA M1GTR:H^&_P#D6M-_Z]T_E6C)%',NV6-77KAAD4`%;#3KB" M2&2X:*V:1K6W=P8["X\R2:X5 M6F*;5(B?8"!\Q+,W92@R-U>@$X!)Z#T%8,_@_3;BU@MR]RHC\S>ZR?-.)"#( M)#CG<0,]#QQBM^@#*-]#_:RMMGQY!'^H?/WA[5;_`+0A_NW'_@/)_A33_P`A MA?\`KW/_`*$*N4`5?[0A_NW'_@/)_A3)=5M((FEF:6*-!EGDA=54>I)&!5VN M(^(MI).-!GGL9[_2+;4!+J%M#$92R;&"L8QRZABI(P?I0!U,.KV=S"LUO(\T M3?=DBB=E/T(&*D_M"'^[`I[9]8\8II$3V-J\LOB875S_;W]J>7L'E_;6LR,YYQY`SGZ\4`;W]MZ<+ MO[)]H_THC/D;&\S'KMQFIO[0A_NW'_@/)_A7B%_%;Z9H36^HZ7%QGVQ70+K?B<:DMHD&LSR6]SJ^./[)FUJ6_D,$EL\JM* MCP$1B21"%P9%&X`#YL#@&@#UC^T(?[MQ_P"`\G^%']H0_P!VX_\``>3_``KR M[2%\57UMH=G/K&KFWGU*99;J*"2&00"'<`QE0-C>"`Q`]!7K8X&*`*O]H0_W M;C_P'D_PH_M"'^[3_``H_M"'^[3_``H_ MM"'^[3_``H_M"'^[3_``H_M"'^[3_``H_M"'^[3_``H_M"'^[3_``KD MO'5T)I?"ZPP/)(-&3-*\4?\`;D.Y MT.&`\N7ICG)Z<<\\@VZL,;&8@`8)VY],$LQ],C&23BO=)=+I\ M_DZ%;PXB/EEB!L(5@I./[HW9QTW`#/)II?3>0VK7C#G@.,>ORH,>A`Y MR:KWSZ<=/NMVK7DY,+[@N[]YP00,?WB`!CLA"_Q&@"QX#OH4^'WAQ2L^1IEN M.('(_P!6O<"NA_M"'^[3_"C^T(?[MQ_P"`\G^% M6J*`*O\`:$/]VX_\!Y/\*/[0A_NW'_@/)_A5JB@"K_:$/]VX_P#`>3_"C^T( M?[MQ_P"`\G^%6J*`*O\`:$/]VX_\!Y/\*/[0A_NW'_@/)_A5JB@"K_:$/]VX M_P#`>3_"C^T(?[MQ_P"`\G^%6J*`*O\`:$/]VX_\!Y/\*/[0A_NW'_@/)_A5 MJB@"K_:$/]VX_P#`>3_"C^T(?[MQ_P"`\G^%6J*`*O\`:$/]VX_\!Y/\*/[0 MA_NW'_@/)_A5JB@"K_:$/]VX_P#`>3_"C^T(?[MQ_P"`\G^%6J*`*O\`:$/] MVX_\!Y/\*/[0A_NW'_@/)_A5JB@"K_:$/]VX_P#`>3_"C^T(?[MQ_P"`\G^% M6J*`*O\`:$/]VX_\!Y/\*/[0A_NW'_@/)_A5JB@"LM]"S!0L^2<N>(M*\.6T5QJUU]GCFD$4>(VU:E"81R11['!92>^2.GK0!=_X3'PUY-U?-?(@M8H6F=X75U24_N^"N MX[CT`'7WKH0<@'UKAM9\%F\\7^%;]8Y;JWL5=+V::8;I`B[H2XXWD2<].":G M\8^&-4UV^MYK`V@2./:WGWMW"E<7XB\*7^L^*_#EQ'<75K:6=M< M)<7-G<".168)M`)R2#M.?UK+/AOQ%'XKV+8!]._X2`:K]M^U+_JS#L*;/O9! MZ]O2@#K=(\8:1KMG?I,VH1R M26H56RZH<.>GRX/'..>*Y/P-X6UC1=2TJ:_MEBCM]$:TD(E5L2FX+XX//RG. M>E5Y/`FI0W'CJ;3$%I/J,832YO.X0,NZ4+C[@:0DGCKS0!Z917B2_#[Q!'X4 MDL(=,N?*FOHY9;.>>V9E58V!>,`>4,L5SG)(!.,XKI/!W@S4K76-)OM>M=\E MCHT-NDCW&_9<*\F>`>3L8#=Z'%`'I-%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7'^/?-\SPMY`0R_V[#MWD M[<^5+UQ785R_CC1=0UFQTPZ;#!/-9:A'=-#-.T*R*JNI7>`2/O#MTS0!<5=7 M^7;:6*=-K$?=[#.#V&3Q_>`'=JKWJZO_`&=2V#U\OY"!TZ[1Q[EL# M`&3A?8/%9^]X8TU@?O`ZX^&SUS^X[@`'V`'`R"R;3/%&M-;S$96+ZV M[!LCG/[CG)P3Z[0.@Q0!T7@'_DG?AO\`[!EM_P"BUKHJR?"^FSZ-X3TC3+DH M9[.SA@D*'*EE0`X]LBM:@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"O._B9_Q\Z=_N/\`S%>B5YW\ M3/\`CYT[_?=S+%'G;N;UJGX;_Y% MK3?^O=/Y5J4`Q`]()PI."<#.!WK M(F\+Z1/:VUL]J?*M]VP+(P)#'+AB#E@Q`)!SGO6Q0!DF];^U5;['=?Z@C&P? MWA[U:^W-_P`^5U_WP/\`&@_\AA?^O<_^A"KE`%/[6]M<7BQ MRW#W+/')N0A8O)S\N6Q\V!C'O6):R:C?:3X>N[?4[I;_`%MKB&Y8S,R+NBD( M(3.%V,J@8`(Q[UW:Z%I::B;];*+[5O+^81G#'JP'0'WZTMMH>EV=X]W;V,,< M[[LNJ_WCEL>F3R<=:`//[.\;2[CR;N-GTVTN)+GR;.0L@:,(KD,VTLD9.2`. M7<]=O/IY.%)P3QG`[UGRZ#I,]O:V\NGV[16IS"A3A/I_7UK1H`S#<2_V@)_L M-UL$13[J]<@^M6/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=? M]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE? M\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J M?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=? M]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE? M\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J M?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=? M]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE? M\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J M?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=? M]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE? M\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J M?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=? M]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE? M\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J M?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=? M]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE? M\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J M?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=? M]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE? M\:/MS?\`/E=?]\K_`(U;HH`J?;F_Y\KK_OE?\:/MS?\`/E=?]\K_`(U;HH`J MK>LSA?L=RN3C)48'ZU:HHH`*\[^)G_'SIW^X_P#,5Z)7G?Q,_P"/G3O]Q_YB M@#L/#?\`R+6F_P#7NG\JU*Q_#DT2^&].#2H"+=,@L/2M3[1#_P`]H_\`OH4` M245']HA_Y[1_]]"C[1#_`,]H_P#OH4`245']HA_Y[1_]]"C[1#_SVC_[Z%`$ ME%1_:(?^>T?_`'T*/M$/_/:/_OH4`245']HA_P">T?\`WT*/M$/_`#VC_P"^ MA0`\YP<'![&N&U'Q%JFBSZX([M=1AL;%':22)5$-R[85/EQD;2&(/(&.>:[5 MIX2I'GH,CJ&'%<_9>%M*L]+N=,>^N+JRN5<30W$J-O+G+,6`#%B>Y-`%&ZU# M7["^U+28=0AN9TTY+V*ZN(`/*.YE<;4P&^Z"`>^V223FF1^&M-ALM.MXM2NDDTY#%;7(F7S$C*A2F<8(P%Z@]`>M`$&F^*+G_A M%K#4KZW$KO>?8[F2/Y0F)6B\W'ID*2.V?:A?&BOJ\-D;)8HYYY8H+B>X")-Y M;A"$.,%\[CM)'"YS6G_9.D_\(^VB*56R:(QX$GS<]6W==V3G/KS55_#>E/86 M=@;N;[%:B,>1YPVRE&#!GXR3N&201GO0!-XIN)['1;B^BU-K$6\3,-L2N9'Z M(N&!SDX&!R21S6'<:SKMRFHA9TT^XTO2X;J6)8E<23NK,5.[&]'A MO!-',ZP+OOC.,\XS5JWTRSBU$7\U]+=W"*RQ-/*I$0;[V MT``#.!SR<#K0!KT5']HA_P">T?\`WT*/M$/_`#VC_P"^A0!)14?VB'_GM'_W MT*/M$/\`SVC_`.^A0!)14?VB'_GM'_WT*/M$/_/:/_OH4`245']HA_Y[1_\` M?0H^T0_\]H_^^A0!C^*KF>PT6XOX=3:R\B)BH6)7,DAX1<,#G)P,#!)/6L.Z MUK79X]49)X["?2=,BNI85B5Q).R,[*Q/(0;-O&#R3FMW6-'LM9NK*XEU">%[ M)S)"(95V[R,;BK`@D#.#VR:AO/#NF7TSRRWUP'F@6WNC'.%^U1C.!)@>[#(P M<,10!3TW6M6N_%]G#.\":=>:4UW%;HF75@T7+,>_SL,#C@=:L:+J&K2^+M;T M_49K=H8(H);>.%,",.9!@L>6)"`GH/2K']B67]O0ZNNI7"RPQ&".%9$$2QDJ M2N-O3*COGBG6>CVEGKMSJZZGQK"@)QLCF\PH<:XNW# MSSS2*7U+Q#J6B7>M!;L:C#8Z:;B0O$JB&X+?(F5QP5R2#D M@`<\U-)?:_::IYEB6`W3SJTJQKT0$ MC`')SQDYY-`&5I^N:IJFG^$[?[6(;C5+(W5SHJ/[1# M_P`]H_\`OH4?:(?^>T?_`'T*`)**C^T0_P#/:/\`[Z%'VB'_`)[1_P#?0H`D MHJ/[1#_SVC_[Z%'VB'_GM'_WT*`)**C^T0_\]H_^^A1]HA_Y[1_]]"@#D]0U MG4=(UVXC6\_M""#3[B]NH6C5?L^WF(!@,_-\PP23\I-1VNIZ_'>:;:F\@NIM M4TY[E/.B")!*IC/&WDIB0\')^4<\FM.Q\/:=837C#4;B:.]=Y+F*>1&64L,' M)V[L`<`9X``I;+P]IU@`8=1N3)'!]F@D>=6:WBR#M3(QV')!)P.:`*OA_4+[ M5?`UIJ-]JHMIP)&N+I(D4;4=@3A@548`[&G6/B"_M_`<6N:A:M/*J^9(%'EL MT._`DV]CY>'*_4<4T>$-*'AZ/0SJ=X;*.83*#.A)();:?EPR[CG!!K&Z1U9':=UW,#U!P`.A]*`,*]\:I::FUJ+-!!]I^S+>33^7"SA%8KNP< M-E@H!X)!Y&*V]89H].>X.I'3H85,DLX16PH'^T"!^59(\*Z0N@QZ*M]KFM:18:Y:VUM/>2116\JS*L,J@,R_=W`@A@#@X/< M"@#"TW5]?UAM,T^:X&FWHW_A* M>1[6*QU2&3SH40EVD6)F)R?NKD<`>O)K'[5',JR/&Q MR5;`QC(!&`",<&HY/#>F-=Z9/#?SVRZ:NVUAAE0(@V[3P02T/B)=;.IW/VA8S"(_- M3R_+)!*XVYQD`]<^];'VB'_GM'_WT*`)**C^T0_\]H_^^A1]HA_Y[1_]]"@" M2BH_M$/_`#VC_P"^A1]HA_Y[1_\`?0H`DHJ/[1#_`,]H_P#OH4?:(?\`GM'_ M`-]"@"2JNH+(UFQ2^^Q!/G><*IVJ.3][('U(J;[1#_SVC_[Z%9NN:;8Z_IIL M+J[>.!G5V$,H7?M.=K9R"N>H/6@#G=+US6-571+)KK[.]XEU<-=+"H>2&-PL M;!6!"EPZL>/IC/$-MXCU^XC\-W#S6J6]QJ#V-V%B.^9E,R[AGA!^[!XRXE@2&9<>9\WSL6!))WMG)YS0!#K.J7^F^(=.CBNY6BN;M(I(I;8+;I&5/27 M'W\C@;CDG&*MZMXG72+J^MY;-W:"S6Y@PX_T@EMFP<<'<4'?[XJ2XT:QO+M9 M;K4+B:%9EG6U><&(.N"IQC/!`.,XSVJ34])TO5KW3[NZE_>6,OFQ;)<`GCAA MW&0IQZJ*`(M$\0_VQ>WMLUNEO):N4>)ILRJ0<99,#"GJI!((].E5M0O=0LO% M.F6L%_\`:%NY)&FLS$N(K=4/[S34S>23W+1F%& MFE#>7&6W%5]LXZY/`J"WT2SM=GZ_K4L.@:@;B*9=:>5!:O&%2$^6[QX8#=QLPV6^H3V_VB&$*%5&_A4Y'3C)S[U/9^&]*L98F@NY@EN)/LL1F!2V+YW%!C MKR0,YP#@<5`OA331I&HZ8=6OF@U"5I9R;A`VYCE\$*,!NA'3'%`%KPGJ-WJ> MESSW,HN(A=2I:W.P*9X0<*Y`XY.1D8!`![UO50TZ[46XOFG1>%\UD^4`8 M"C:`,?A5O[1#_P`]H_\`OH4`245']HA_Y[1_]]"C[1#_`,]H_P#OH4`245'] MHA_Y[1_]]"C[1#_SVC_[Z%`$E>=_$S_CYT[_`''_`)BO0/M$/_/:/_OH5Y[\ M2722XT_8RMA'SM.>XH`XB7_7/]33***`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*GM^C &444`?__9 ` end XML 14 R39.htm IDEA: XBRL DOCUMENT v2.4.1.9
Unaudited Quarterly Financial Data Unaudited (Tables)
 12 Months Ended
Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Information [Table Text Block]

  Three Months Ended 
  March 31  June 30  September 30  December 31 
Fiscal 2014:            
Product sales $2,081,752  $1,539,719  $1,770,129  $2,205,275 
Gross margin  1,149,895   878,523   1,077,896   1,342,722 
Product development expenses  594,209   760,672   361,232   462,965 
Net operating income (loss)  12,561   (458,667)  40,853   198,856 
Net (loss) income  (13,335)  (294,781)  10,330   130,626 
Net (loss) income per common share:                
Basic ($0.00) ($0.10) $0.00  $0.04 
Diluted ($0.00) ($0.10) $0.00  $0.04 
                 
Fiscal 2013:                
Product sales $1,846,734  $1,366,493  $1,234,701  $1,559,248 
Gross margin  1,053,567   783,677   615,717   607,644 
Product development expenses  266,479   271,858   290,853   325,010 
Net operating income (loss)  326,666   23,722   (159,967)  (209,975)
Net income (loss)  204,310   6,452   57,336   (150,703)
Net income (loss) per common share:                
Basic $0.07  $0.00  $0.02  ($0.05)
Diluted $0.07  $0.00  $0.02  ($0.05)
                 
Fiscal 2012:                
Product sales $1,717,109  $1,175,126  $1,076,749  $1,420,951 
Gross margin  1,012,568   670,518   620,958   750,215 
Product development expenses  247,807   211,706   223,771   234,316 
Net operating income (loss)  281,233   37,397   (86,126)  12,497 
Net income (loss)  154,761   15,187   (63,574)  (16,862)
Net income (loss) per common share:                
Basic $0.05  $0.01  ($0.02) ($0.01)
Diluted $0.05  $0.01  ($0.02) ($0.01)

 

XML 15 R54.htm IDEA: XBRL DOCUMENT v2.4.1.9
Income Taxes (Details 2) (USD $)
Dec. 31, 2014
Dec. 31, 2013
Income Taxes [Abstract]    
Product rights $ 130,036iccc_DeferredTaxAssetsTaxDeferredExpenseProductRights $ 165,527iccc_DeferredTaxAssetsTaxDeferredExpenseProductRights
Property, plant and equipment 225,229us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment 52,094us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment
Research and development tax credit 266,078us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment 235,567us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment
Federal net operating loss carryforward 464,998us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic 525,012us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic
State net operating loss carryforward 165,901us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal 201,698us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
Interest rate swap 15,486iccc_DeferredTaxAssetsTaxDeferredExpenseInterestRateSwap 13,166iccc_DeferredTaxAssetsTaxDeferredExpenseInterestRateSwap
Prepaid expenses and other (6,925)us-gaap_DeferredTaxAssetsOther (23,171)us-gaap_DeferredTaxAssetsOther
Deferred tax asset $ 1,260,803us-gaap_DeferredTaxAssetsGross $ 1,169,893us-gaap_DeferredTaxAssetsGross
XML 16 R48.htm IDEA: XBRL DOCUMENT v2.4.1.9
Bank Debt (Details) (USD $)
Dec. 31, 2014
Debt Instrument [Line Items]  
Year ending December 31, 2015 $ 150,382us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
Year ending December 31, 2016 57,384us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
Year ending December 31, 2017 61,056us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
Year ending December 31, 2018 64,876us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
Year ending December 31, 2019 68,908us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive
After December 31, 2019 493,696us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive
Total 896,302iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion
$1,000,000 mortgage [Member]  
Debt Instrument [Line Items]  
Year ending December 31, 2015 54,044us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
/ us-gaap_DebtInstrumentAxis
= us-gaap_MortgagesMember
Year ending December 31, 2016 57,384us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
/ us-gaap_DebtInstrumentAxis
= us-gaap_MortgagesMember
Year ending December 31, 2017 61,056us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
/ us-gaap_DebtInstrumentAxis
= us-gaap_MortgagesMember
Year ending December 31, 2018 64,876us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
/ us-gaap_DebtInstrumentAxis
= us-gaap_MortgagesMember
Year ending December 31, 2019 68,908us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive
/ us-gaap_DebtInstrumentAxis
= us-gaap_MortgagesMember
After December 31, 2019 493,696us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive
/ us-gaap_DebtInstrumentAxis
= us-gaap_MortgagesMember
Total 799,964iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion
/ us-gaap_DebtInstrumentAxis
= us-gaap_MortgagesMember
600,000 note [Member]  
Debt Instrument [Line Items]  
Year ending December 31, 2015 96,338us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
/ us-gaap_DebtInstrumentAxis
= us-gaap_NotesPayableToBanksMember
Year ending December 31, 2016 0us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
/ us-gaap_DebtInstrumentAxis
= us-gaap_NotesPayableToBanksMember
Year ending December 31, 2017 0us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
/ us-gaap_DebtInstrumentAxis
= us-gaap_NotesPayableToBanksMember
Year ending December 31, 2018 0us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
/ us-gaap_DebtInstrumentAxis
= us-gaap_NotesPayableToBanksMember
Year ending December 31, 2019 0us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive
/ us-gaap_DebtInstrumentAxis
= us-gaap_NotesPayableToBanksMember
After December 31, 2019 0us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive
/ us-gaap_DebtInstrumentAxis
= us-gaap_NotesPayableToBanksMember
Total $ 96,338iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion
/ us-gaap_DebtInstrumentAxis
= us-gaap_NotesPayableToBanksMember
EXCEL 17 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#6K6?=3@(``$@G```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,VLUNVD`4!>!]I;Z#Y6V% MA_FQFU:8+-)VV49J^@!3^X(M[!EK9I+"VW=L$E1%%(2*U+/!`MOW'BST;3B+ MVVW?)4_D?&M-F?)LGB9D*ENW9EVF/QZ^S&[2Q`=M:MU90V6Z(Y_>+M^^63SL M!O))O-OX,FU"&#XRYJN&>NTS.Y")9U;6]3K$MV[-!EUM])J8F,\+5ED3R(19 M&&>DR\4G6NG'+B2?M_'C?1)'G4^3N_V%XZXRU M$+'I]=]_IM.8,T45'W8=^2O_N;P?>FYSHQW5WX.+C:JK M!_AS]IDZJNR96BZ[\$`YS3^V/?:=[9P;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E M0V8+J<_;J)I"RTF#%?.&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0! M**```0`````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````"\FLUJVT`4A?>% MOH.8?2W?^4M2(F?14LBV31]@D,>6B2T9S?3';]_!M'(#S:D7XFP,&N'18>ZY MY[O(OG_X>=A7W^.8=D/?*%DL517[=ECO^FVCOCY]>G>KJI1#OP[[H8^-.L6D M'E9OW]Q_CON0RY=2MSNFJNS2IT9U.1_?UW5JNW@(:3$<8U_N;(;Q$'*Y'+?U M,;3/81MKO5SZ>OQ[#[5ZL6?UN&[4^+C67E5/IV-Y]/\W'S:;71L_#NVW0^SS M/YY1_QC&Y]3%F,NF8=S&W*AI*=7G.]HOBF95OR)'V'($R;&:+,=J*.>&+><& MR?&&+,<;**?TTGQ63ET8X_I+'DNKIK+Q;SN_6$9JV*6"E6+;&+I8V)$C.'+N MYK3-%'<7RTQ+?Q+P#OE&V`DH,`&U99^.1:=CV$XVT,J&W>4&MKDMX\5\"3CY M]G4KVR4JEG5L.0[)<6Q<.8@K-RNNKBB6NT6GXV=-Y5PFU'CQS?FR/G_"M&$; M!OK%LY/8P[,1-J<$XAP>(A@4\%C*I!?V\!2 ML5,&AHRP`2404)H-*`T!I=F`TA!0AFT=`[UCV8"R$%!N5D!=PTLX^@F;5P)Y M9=B\,C`$+9M7%O+*L7GE(*\\VSL>>L>S(>$A).C606,I.P-A!`H;GP+Q*6Q\ M"L8GNU8&%LNP?6QP!+(SQ\',<>S,<5/FU"_^JK;Z!0``__\#`%!+`P04``8` M"````"$`*7F=%A$%```L$P``#P```'AL+W=O"D6F;B$2Z))78_[XC>2T?B:Z0OC0= MV3R<&7YS).ORX[;(!Z_"6*G553#^,`H&0F5Z(=7J*O@V__3/>3"PCJL%S[42 M5\%.V.#C]=]_7;YI\_*L]W&"+ZP:R%.B*AQL?TBUT&_55ZFU MNR:**(&W^J,?4=.L)NU((] M*"?=CCVJ??>EIB.LNOY(E8V#@;F0]!_SN!A7B:/*+<^YR@2;5=^VL"J$56'_ M*C;EAHYF+9S,.#6]V3D"C;JYN//,<4>-5[JHDSN5*2IH4KQVZR3)?*8068 MPJ0K4R==_T-URU>>UR/+>VQG$8>PSN:V[:\"3H'$KJQQ?1$L%I&'L@/M*-H!!LSK=D^L=!/D," MQSZ"G;$A*\+%R-W8!T\7A71[(ZC.[DZ3EZD5M9U]EAQU$#RRUHZ3S<2J$JE/ M#@?AKK1.%ZB#-(8>C4_5O85.BTR-:)@;KBS/ZIL-:)PCE*$'Y4.QR?5."'8K ME%A*LKC#%=1`($,/R&^*E_6=B_U74BK"Y#OV22IR:\ESACJ(9.@A.2N?K?A9 M5JUYJ$83S_4<*0P]"ONMA=)OG/XL@V-D6LTYRVFH*\AAZOS8@?W>J$!K(:>:SVFU:K#(0U\F#MS)!3B./TQ[_(BTL!:&EAZJ.#Z"%G4@"08T\ M$^T^`%0/51X@$V0T\ACM-Z)6+Y'1R&.TWP%:0HALY"';/\?4SF;\8L2$@DYO M^X6HM4,RQT&.$10*.DL;YF&03X@@,+%' M;?\DMPI!:F(/V]Y)OL?.(C2Q1W!3UQL=)/M$4M+?8`]=;RN9B MZ\K6;X,8C8V"SN'TN<&]@'8D2"P%?Z2#,Y0@L11TA%JVXG,=JUMH= M64T\5D_MSO`P$\24@O?L[Q]*@HQ2T%$YY8XG6H&`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` M;(]:F27D`R+!2':-A/&((+'^+6(5#,EA:`NMF5.-!*,_6WL@,P:0$EC>^6%3 M\-H%-\5"-AO]P13\(X"C"Q-8F0D(A&(28RD^!^G"0^'PDD'O;) M?/$*ML1;R99J).K%^S2(8M]*V*U)L"0(8;^.TG1^(L+W>6BXA\2'MXA7L"7> M2M!4(UI\$`0)N1)O$CX)U9\E'A,\8'S*-"0^ND6\@BWQ/IXXU8@6SVB4D&B: MN(_KUB0H!6G$CKQ)))!5!H"TJP9L5+>O*X6"+>U60J<:T=JI3R/*K*79FD02 M0T;8<4=`Y$,$QO@@Z"E@[,D/$AYX%1)W32(,0G,:%\JLAZOR*$Q21A!H(] M4*UG=N)0W:A0L9Q658=_8+0'=XR$?F+)VV*$)IS;"X`(%G!"/EL!U9_FZ]?= M#.FWQ*54,X-^*#GI57YNO7G=!I-X*;:J>E:$^Z4>%.QI&4'_&JC=$ MWT0HC?SD2K])Q`DWT@O+5YW-D*\>:7VH2%\7?ZK[(:SP^,`36_F;#HSQ['4U MDIDC6);J68:LG\C1'0Y%U=IP*36[H$]89):#(:H8H4E`K,*4658HI-94?;$' MJG7-]T`W.N2!U7%2:C;#3SS`2,Q)8)6F#%NA)`[HE%W8`]7!YGN@^QU*"2LI M4ZH9,R7LDS!)%A%4K$:_+=`7G3SW M)^Y'V<$IO_]ZA+^-[HLW_````__\#`%!+`P04``8` M"````"$`*EM48LL#``"D#P``&0```'AL+W=O]?#Q]2Y'%! MVI+4K*4Y>J48[V0G1+W^?%GC:$SUA'6VC9LKXA M`A[[G<^[GI)2=6IJ/PR"Q&](U2(=8=G?$H-MMU5![UGQU-!6Z"`]K8F`\?-] MU?&W:$UQ2[B&](]/W8>"-1V$V%1U)5Y54.0UQ?+KKF4]V=20]PN.2/$66SU, MPC=5T3/.MF(&X7P]T&G.F9_Y$&F]*BO(0);=Z^DV1Y_P\BY<('^]4@7Z4]$# M/_GM\3T[?.ZK\EO54J@VS).<@0UCCU+ZM91_06=_TOM!S<"/WBOIECS5XB<[ M?*'5;B]@NF/(2":V+%_O*2^@HA!F%L8R4L%J&`!\>DTEEP94A+RH[T-5BGV. MP@QY&\K%0R5#(:]XXH(U?W4C-B%TY]!TAF_3&8>S,(UQG`#L/U%\/1*5V#T1 M9+WJV<&#U0),WA&Y]O`2(I_/!%*0VD]2K+K`8#F4_WD=1XN5_PPE*XSF;JH) MCPH?H$HH^9JC>%&Z>("=^'"E6*;.S_FH[E:8[AI%@PK;92OM/6; M]XX4V]QA_C17:S0WRN9)=B%A,(W;P5(\!F>QE:^6:&Z:)?-@F(A1PA@<\W:P M4H_)<63O)2.:[EKLYDS:=JX;A`J9HS,L)R_"VFBN>X01Z9K&41`-S&6:V41B11E]Q"OG2=%A(YSQJ6*)Z[ZB0.3+H MRV:!G5Q*J>VL;;LP(H.^[!?8R:B4VD8/J\AD?6I5URP#.YF54H_9$],P&IWU M(LNR9!C<>(D[V16>^E4HYD,G?DXX[WZ_4_````__\#`%!+`P04``8`"````"$`CF6! MA44&```>&P``&0```'AL+W=O-XT\]9Y*=TW*7GP\;Y^^_U,/2F=1-U\>OKYI\>WLOI2'[.LF4"$<[UQCDUS6;MNG1ZS(JFGY24[PY5] M615)`S^K@UM?JBS9M8V*DQMX7N0627YV,,*ZNB=&N=_G:2;*]+7(S@T&J;)3 MTD#^]3&_U'VT(KTG7)%47UXO#VE97"#$2W[*F^]M4&=2I.O/AW-9)2\GT/W- MGR=I'[O]884O\K0JZW+?3"&=AJ"Q:[56;07^ MJ":[;)^\GIH_R[=?L_QP;*#<(2C2PM:[[R*K4QA1"#,-0ATI+4^0`'Q.BEQ/ M#1B1Y%O[_9;OFN/&F473<.'-?*!/7K*Z4;D.Z4S2U[HIBW^1Y'>A,$C0!8'O M+H@?3N=!N%A^),JLBP+?/Y[*O`L"R?>I!--@&?IA]`%!41<%OOM4PNG"]U:S MQ'JOR;0*K`,:POB1Z3?EK"-Q7"L=UJ-W_E0YJIH,\ZR@; M!Y8O5*6&^?;U*0S]1_H2>-[EIR0"$`GU?[ M<4'W(!ZF!A5_?7KV&C59:^Q[CA$P.YHQ03:'2197&"LSB+0IT=*D*)L2AO.! M8XB&F7R_:$V&U4<'<\[ZCI$S'P9FRP'!`KR1L'AH)4/AP& MH9TN,7)(LAP0')`<4`A$[3P/?$__#;T8V<.RO#][3>;91T-BEV7YO65QQ:A(AT:"A<_HE`WX@KYBD`.48@`*GR8S5=L5@IZ?>8%RW'I MXB9'KS^L9A[K4)$.#87Z0,5V=^T5[]=0-^(*V984(XJVQXT;,X.*.1'/'9DN_W<=FT[FWHG]+ M^9*4H[*A%UW_;MHP^;XEBB<4>BXGK[IJN?[W%6 M,VDABB*F'.VY1,Z-&J%#FS*8:\0^]_6MA0@+D1:B*&+FK)WU_IS1AV$DQ].+ M==32-U&PM]&AYXBP.-)"%$7,G+57WI\S.JLQSB&K>^P3^\5#BH4("Y$6HCKD MGKFO[9"(N'/NHXD:8B)^=O&)TW9B."(LCK00-2"DVN10;]9$NR*3,X>RWU@# MZ*6F'&[C/C'<3@Y'A,61%J(Z!&LS#_WEU<*KCDS/V!TI#'Y[8#0Q%@S,9"&^PL+410QY6@?)=6Y,R5S!]X&'!$6(BU$=0@^UPG-IRNFABN&'-U\-!)<,V1^ONA(XVAO M!X1.?7:6%0-IG/K/(=$E`U\"/4+EL%$05C-I(?K] MQ1`:Y>#K"'RZ7635(=MFIU,]2@SP'^K$EP[?^&AXK`^X. M%^#MQ"4Y9+\GU2$_UY-3MH>0WE0_3*GP_0;^:,I+^TS]I6S@O43[[Q'>0V7P MI-J;`GE?EDW_0W&ULK%=;C^HV$'ZOU/\0 MY1UR@22`@*/-M4=JI:KJY3D$`]$F,8JSR^Z_[SB.P9Y0#BMU'S9D/-]G?S/C M>+S^]E%7QCMI64F;C>E,;=,@34'W97/Q4GIEDJXMGZ.J\ M?7T[3PI:GX%B5U9E]]F3FD9=K+X?&]KFNPIT?SCSO)#<_@E:\O] MKV5#(-J0)YZ!':6OW/7[GIL`;(W0:9^!WUMC3P[Y6]7]02^_D/)XZB#='BCB MPE;[SYBP`B(*-%/7XTP%K6`!\-^H2UX:$)'\HW]>RGUWVI@S?^H%]LP!=V-' M6)>6G-(TBC?6T?H?X>0,5(+$'4C@>8?D`7`V`.$Y`!WX^0`P'P#P_-I,(*;7 M"<_G9O('`#R_-E,P`.'Y<"9+9*)/;)QW^7;=THL!NP5BS3+H`1A,.)8Z%SV#CW]^R,I\[]/5%AL)G?HU%A`TQ-B38D&)# MIA@T%;`%L0HGX!^9'PCAN(T)L5$*$T4[%#Y^7[:V+C(28YY&X*)(Q"J!Z]GP MI[,DS["D*@LBR'Y`H(4*8J*&ZG&BN;,>GQE>?2A\YG?C(\=DI<;"$/3.$^!" M2A(,2%6`XSD^"FZF`#29\*E\7B9WQC+11@V%CUBYXWD>&H_$^*W>8PW@SI8(!*0+@&3(%H$E=?D4J=\92419"X2-WWQ)76"3&%:DJ8#8?`1(,2%7`)+!] M%.Q,`6A2'3ASGD]K[ZV+'?<3G'%CBN_V!-;NH3*/!A9%[F`1&->=+QRT!Y,1 M)M4P$\]=S%'4,Q6CB^;=R-.U[(C>133P?0,4CDW1V!2/3!?[0M%5_+P^`Q!,$\D;\9OI_0"'1S1S>MZUHQ-R=B4CDW\CC3, M>.V6Q)U'M,8U:8\D(E7%C(*^\?L,WU%7J[AKP;+E90N-P"WLI;^$(7O(;V>\ M7<)V=Q7=\X_=%72"8_\4)KYG?W'X!/T,UG4*N'Z=\R/Y+6^/9<.,BAQ`CCT- MX%AMQ05.O'3TW%\&=K2#BU?_\P07;0)MN#T%YP.EG7SA0;M>W;?_`@``__\# M`%!+`P04``8`"````"$`\21F@:0"``"0!@``&0```'AL+W=OUR$0P^O'G.>^!D>?DD._3(M1&J+W&6I!CQGJE*]$V) M?WR_/9MC9"SM*]JIGI?XF1M\N?KX8;E3^L&TG%L$"KTI<6OML"#$L)9+:A(U M\![>U$I+:F&J&V(&S6GE-\F.Y&DZ(Y**'@>%A7Z+AJIKP?B-8EO)>QM$-.^H M!7[3BL$^`%\UJGA-MYW]IG:?N6A: M"]4N("&7UZ)ZON&&@:$@D^0>@ZD.`.`;2>%.!AA"G_RX$Y5M2SR9)<5Y.LD@ M'&VXL;?"26+$ML8J^2L$90XJBN1[$1CW(EF>Y/,B*V;O4)GL56",*O]"("$= M[\X-M72UU&J'X,0!L!FH.[_9`@0/MH0DHE%_\@ERSJ!\X0\PT@J]'"T<$T_\A<)M* M#'F.7)B>$(28$4%8F/F2YD4*G[CCB`CNP/L]<9M.B8JH'SP),0%@>CY+3XBA M93@-3QR`0@<(9UQRW?`U[SJ#F-JZVYU#)G$U-IZKW'E^LGX-#4J0"+P,``/\(```9````>&PO M=V]R:W-H965T'3#!*F!D.TW[[W>-$P*DW=(7P+Z'<\_]P)?5W7-=64]42,:;Q/8< MU[9HD_&<-?O$_O7S889M2RK2Y*3B#4WL%RKMN_7'#ZLC%X^RI%19P-#(Q"Z5 M:I<(R:RD-9$.;VD#EH*+FBA8BCV2K:`D[UZJ*^2[;HAJPAK;,"S%+1R\*%A& M4YX=:MHH0R)H113HER5KY9FMSFZAJXEX/+2SC-+*_J:98)+7B@'Z)`1>AUSC&($3.M5SB`"G79+T"*Q[[UE MBFVT7G7Y^+5GRXR?!\J^LH9!L*),NP([S1PW]DNLM>!E=O?W0%>"[ ML'):D$.E?O#C9\KVI8)J!Q"0CFN9OZ149I!0H''\0#-EO`(!<+5JICL#$D*> MN_N1Y:I,;!\[0>3./8!;.RK5`].4MI4=I.+U'P/R3E2&Q#^1+$#]R>X[/@Z\ M(/P_"S**N@!3HLAZ)?C1@J8!G[(EN@6])3"?(S,Z^EC?"A5BU"3WFB6QH=LA M"@GE>5H'.%RA)\AI=L)LKC'>&+$](W0"-6TZV$"@MQ<-J1B*?KT,9VT:K+6= M63=F`[A[L?Y$R"N(>`Q)KR$A[B$CL?/WB-7@Q(9KKVWNS7O>+BL;@UGT`6VG M&^E@8R0%"GQ[WC08&G4D95I3@PF[BOO!-(U#Z]R=5#L=6B/WC>3!YW&[8@V> M*HXFR3.8J%,\BZ)XVJ;;(2!:1-/LIT,[CB/\AO#P/<(U>"I\TG`;@SD)]]P@ MN#CNVF([!'CZ7!A'GH[MWF+1VT<]$KU'N`9/A/L3OQN#.0G'.!@X-L*'`!P% MX468.06&=L_UXOFEST;*];`='&7_/A4T>*P\#OJ$F._,0$QSSS#VXXM?(WP( MP!$.)P0PD;0/0^"Y?KAP>P]&N!DXYCRNJ=C3+:TJ:67\H(>)#TW:[_9S[M[7 M'_YD?P/SKYL6J#?`_&G)GGXC8L\::56T`$K7B:!_A9E@9J%XVTV!'5

;K' M$GXT*)R_K@/@@G-U7H!CU/^ZK/\"``#__P,`4$L#!!0`!@`(````(0`@]/D< M6P,``,L)```9````>&PO=V]R:W-H965T-`P.FZ]B4!W^/#N>=> M(6[7$'D8JR%@FX90>;]PRCFO5D/_OPF^,1GUP:OZ>D3(^57TF$P&\HD"["G M]$%"OY1R"3;;5[OOAP)\9T:)*W1LQ`]Z^HS)H190[1`2DGFMRN<<\P(,!1K+ M"R5301L0`+]&2V1G@"'H:?@_D5+4F>E'5A@[O@MP8X^YN">2TC2*(Q>T_:-` M[IE*D7AGD@#4G^.>Y26A&T;_9[&5HB'!'`FT63-Z,J!IX)F\1[(%W14PCYDI M'5.N_TH50_!H2)1-D(=9_CU@)ANZ8 M:?-=?^(=7-DJ3#`EM-,7\MG"0@H4>.Z;++8/A^%U_^2FS(1\)[M\+]`D*4PT M5/XFB9)0T[R;`Z(T3BY>J4HOXJ'O7RJR2`!.R_L3D)OT!$(M`86)50)1.JOE MH&\WCR=!#LJW"G!T/8E_O\WG<<]+P8JEJE'G<=_S`F2JRT)V^1[<$ MZ[HU75N%&0]HXJ5:!^_F@"1.(JTD,%WE0Q0!M%ITI5P-3S5;6LP.>(>;AAL% M/8MKZ%63Y,/GL*P"SMT0%_0^Q`.FXTN`)*QXKAV#$U MC=6-H/TPT?94P!0=+FOX:,(P2QP+P!6E8KR!!]O39]CF+P```/__`P!02P,$ M%``&``@````A`/=!M/,-!```C@T``!D```!X;"]W;W)K&ULE)?;CJ,X$(;O1]IW0-QWP&!SB)*,&EJ],]*LM%KMX9H0)T$-.,*D MT_WV4Z8(P0Z336Z2@']^?ZZRB\KBZT=56N^\D86HES:9N;;%ZUQLBGJWM/_Y M^_4ILBW99O4F*T7-E_8GE_;7U6]?%B?1O,D]YZT%#K5)U MBR8-+[,6^.6^.,BS6Y7?8U=ES=OQ\)2+Z@`6ZZ(LVL_.U+:J?/Y]5XLF6Y>P M[@]"L_SLW5U#%:F%S3>?+USF$%&PF7E,.>6B!`#XM*I";0V( M2/;1?9^*3;M?VGXP8Z'K$Y!;:R[;UT)9VE9^E*VH_D,1Z:W0Q.M-X+LW(<&, M>BR,'G'Q>Q?X/KMX,R]BA`7_S^+@NKHPO61MMEHTXF3!W@-R>E9H1(* M>`,CQ&W,.)V[,XH2*Q252\66X(WQO)XQ[X0B'B0:"41H3**BY<.>O$VD'@+= M:.%>Z`[^"(D:.E"GHQL:`=4);L^LQ$L;EC>$G/F1,3-J@BYI'B-^Y.N"5!/X M-`Z&<0T,CL,X-+?!E-@$NX0<0X*:$,%<&A$C9NE80.(X)+\@"QXA4V*=S`O9 ML&(D0PV2$)FX$Z1C0HH!V,;V$ M4X-2;[Y10;B=1R4VHF^M%-^_$))E5P1TRW]SW!\JRS&*^5I!F5DDDU[4PT##?KV+T&:"QBCI=X;HNK8S:FR6!+ID%2)\45,WH-1XDZL^ M6BE&5-@68[]7\6;'4UZ6TLK%4;6\!%X#P]VA'7_V5!/B#`/0#1^R'?\C:W9% M+:V2;^%1=Q9"QAKLI_&B%8>NFUR+%OK@[N<>_O=P:,'<&8BW0K3G"S7!\$]J M]1,``/__`P!02P,$%``&``@````A`*Q6RG59!@``R!H``!D```!X;"]W;W)K M&ULK%G;CIM($'U?:?\!\3XV-#?;&D\T7+(;:5=: MK?;RS&!LHQAC`9-)_GZKJ<945T]\B38/\?CX5'&JN[H/-(\?OM8'ZTO9=E5S M7-ONS+&M\E@TF^JX6]M___7Q86%;79\?-_FA.99K^UO9V1^>?O[I\:UI/W?[ MLNPMR'#LUO:^[T^K^;PK]F6==[/F5![AEVW3UGD/7]O=O#NU9;X9@NK#7#A. M.*_SZFACAE5[2XYFNZV*,FV*U[H\]IBD+0]Y#_J[?77JQFQU<4NZ.F\_OYX> MBJ8^08J7ZE#UWX:DME47JT^[8]/F+P>H^ZOKY\68>_ABI*^KHFVZ9MO/(-T< MA9HU+^?+.61Z>MQ44($<=JLMMVO[V5UEGFO/GQZ'`?JG*M\Z\K?5[9NW7]IJ M\UMU+&&T89[D#+PTS6=)_;21$`3/C>B/PPS\T5J;R-6!$\J_#YUNUZ?=KVPMG0>1X M+M"ME[+K/U8RI6T5KUW?U/\B::CHG$2H)/#Y3I(+@9X*A$\5Z(J9+X)H,5S^ M0J2O(N'SODM"54/!\#E>TIFYOA/*>LT+SG&\AN%/\SY_>FR;-PMZ&D:D.^5R MA;@KB!S''3.<9^)[$P$S(),\RRQK&Q8CC'$'W?/E*1#>X_P+S'BA.+')<75& M,C+D],JT*0&6-(.@(D9*G'9",% M8K0BH'MX$1XLI/>7P#CR,@B:71MY7[]@C!S_7%?"@90#&0$TC="G]VN406L; MRCYW!RP-IA$YX=`[7B"$'P8Z(T'&5$6JA;@+$2Y"/20C(5H5T.BTBLLC+,E< M_4*_4(R<:%`OEN%RL>2]C0RB7@_Q'>'Q/B$AFOKP'O62S-6S"\7(0?5^Y(0. MFYP$"40\C?`"7_ALL6Z=J'[2:26_J5-I=Q>AF!8`T2(P?+<`74$?'5 MBHR`=F(@6-.D-,TR=!Q]JK,K.;1JY=T)V5PO]YDDZR6*D'51C!PL,7#@GRXN MP=_)1%T)R$B`IGQYCW))YLK9T,?(0>4+L?!"CTU?@@RBG8:$@1=&(5MV&0G1 MU+NP;=X^\`-;UQ\(M@1B1<("'GS?#Y8+)B=1'%*"%N4[+MQ5\I5"@_0BI-G= MW#TN6B-M;1$:12`)B_`67A3ZC)*H/+0&&B0"X4=\:\YHD%Z#]#I2@USOUSW- ME5%\0MA@QXJ$M;B1#[N_40OFH;5P)%-I!HXN75K@_=+1..$R9Z\+!-]O722- MO>1YRP5?#(I"I1-+'NZ.,LK1I4O?NU\ZNJ4FW6,;3.PB28TZW%TO%FRE)XI" MI1,?5M()HDN7IG>_=+1*73K?.^7C!'35I"LQD-1`,HKH2J7%W:\4C1'FDO0' MOU]SB7L.XY482&H@&45TI=*R[E>*1J>-J3`6(35+Z.,H8KV>N,B81CTUD(PB MNG)I3T3Y90-UTD(QR=.72.8CRRUN"0)_1%'M,3ZQ(T]43 M`TD-)*.(KO"'+$P^`EWO`L/"5-BD/360C"*ZTA^R,('NI(VIV05(4ET`#S*. M\3"F\EQY&E.LJ<",(GHYS.>NM,8[_L:?26+!W2LQD-1`,HKH"IF?W;B5H:]= M=@N!I&F<$@-)#22CB*Y4&@M99C=G^9"&YHJ8%D%-%$RR<+ M*OIR`PQL./84YW.QV(02$TI-*-,@7=-WW.O.`U8X>SER7[:Y,RL.ALXKF51[,RZ5^1O&E`0@: MWQJP7^!UPO,P[@R/W54RG,DS/(5$[^&Q6"7OY4G%"HY903G+\^PYH`A?19Q_ M@O<(IWQ7_IZWN^K868=R"^4XLP@VVQ;?1."7OCD-Y^4O30]O$(8_]_#&J(23 M:F<&Y&W3].,7.6CG=U!/_P$``/__`P!02P,$%``&``@````A`(NQ;\HO!``` MO0X``!D```!X;"]W;W)K&ULG%??CZHX&'W?9/\' MPKMB"^6'46]&)[-[D]UDL]E[]QFQ*AF@AN(X\]_O5[Z"4!A']T6%GAY.S_=Q M;!??WO/,>N.E3$6QM,ET9EN\2,0N+0Y+^\<_+Y/0MF05%[LX$P5?VA]XX,CGR/)93<>(%C.Q%F<<57)8'1YY*'N_J M27GFT-G,=_(X+6QDF)?W<(C]/DWXLTC..2\J)"EY%E>@7Q[3DVS8\N0>NCPN M7\^G22+R$U!LTRRM/FI2V\J3^?=#()50;_OU"V8[`QFO]05^*NT=GP?G[/J;W'YG:>'8P7E9K`B MM;#Y[N.9RP0_U]27?5<6F[_I0%,Y<`W-IR M6;VDBM*VDK.L1/XO@HBF0A*J2>!;DQ!_ZE$6A(^PN)H%OAL6.J4A(\S_6HN# MZZIM>HZK>+4HQ<6"W@/E\A2K3B9S8&[\P=6TCGUF&#BE2)X4R]*&EP:\D%#E MMQ7(6CAO4)E$8]:(@<\60_J(38-0!05YK4;PK:MQO':-%`564E0ME;8UWN@^ MEQK/'4%$+:2G!!SJ*E%NN="3MQ6I28#K+)QZQM+7B/%:U9O.C9X"KZ_@]I,5 M>&G#\EK+7;,J"/'KFA'7)>2Z\MJ^30_`(D*"<6O@=>A:%4<]K>;%N MB`E0&:/AK#^^P7&O'K^.]Z$:F6SW`#;>"1Y0IL*GL M6@5T"S&HC/I>:`K[?+SGF/K?,^+@ZP97DTQ]8;]::\2@O@GQO<`4V`>X_LQM M&7H*H[["VWVFP*8RL\\0@\K"B%Y;"?L?A['-`G8=[8DB$`)=WVZKJM&&+&:$ MTEJ#=*^%D7M]-`KK`US?]<<-(RI6.S7]0AN&<#M9?0,9N2X?WP@-TBU'6109/;G1B#IU^^54Z?NX*LSL MKG6LDY9:%8*T=R.Q1CY+?O)0]-=HTR+#@+4&:8O(+"`&8J,1(Q8]E/=JRV6\ MB,S\IUEKD)GHNMN;N#UD&.Z,FKL7#<(^8C0R(G:CQT^X5DFK427IZH MVK,Y[0`<'D[Q@?\9EX>TD%;&]S!U-@V@?4L\?N!%)4[UYGLK*C@VU#^/<$SD ML&.=30&\%Z)J+M0#VH/GZC\```#__P,`4$L#!!0`!@`(````(0`?P>813P0` M`%H/```8````>&PO=V]R:W-H965T&ULE)?;CJ,X$(;O5YIW M0-PG8'*.DHPZH-X=:4<:[?&:$).@!IS!3J?[[:<*8\L'KKDW'H>[3.V+&H3UO_[[^>1TO?XR*MCVG):KKUWRGW/^\^ M_;*YL>:%GRD5'F2H^=8_"W%9!P'/SK1*^9A=:`W_Y*RI4@&7S2G@EX:FQ_:F MJ@RB,)P'55K4OLRP;H;D8'E>9#1AV;6BM9!)&EJF`OCYN;APE:W*AJ2KTN;E M>AEEK+I`BD-1%N*]3>I[5;;^]-)71=8PSG(QAG2! M!.W/>16L`LBTVQP+F`':[C4TW_I/9)V0I1_L-JU!_Q3TQHW?'C^SVZ]-LDTL.?M*29H$=8.=_#%3DP]H*W?H%0"(/P5H"#\.]JF*<(1PGT,.9O M->1SNVS?&N](\_1:BC_8[3=:G,X"1IJ!#>C&^OB>4)[!,L!8XVB&63-60@KX M]*H"]Q/8F+Y)NN(HSEM_,A_/%N&$@-P[4"Z>"TSI>]F5"U;]*T6D2R631%T2 M^+[)_Z/YF$S#^0,Y)ET.^.YRD.AAD&F7!+YUDO^;12`=:;#5 M8<[\DF+AD#4D5,Y*'[37_V4U>(Q)GC#+UH<:!1RM,WNIF.I)Q6X@,0(6$"RQ"?0Q"(JW/DQ6 MK]G<`9$*^-2*A:V(E4+YGQ@!BPP*<3@9BFVRI3WN7BJF[5Y<$C*?NMM-"328 M$;#`YH^`H=@&6SE@4H%@^6XT(M%H`F0YELR(.-I8:36C$;`8%X\PHMAF)&ZU M2HFYKL3U3TDTFQ&PV/#);728C[<REX4I)1:;4[NQDF@V(V"Q$6@4PXUKU0Z=6ZV=1N(=?M:F8RW1>&;$YL/^ M/'AAB>SF9C,A3J_8=YI92S:%%S/'WK@3W!M?8D9L.NS1P^ED1[?HW(Y"I,9: M7+=@M>9NG[H+(C8@MNCA@+*AFX"16[1$-7UL)E%(>NZI_^]P1L2&@UD^`(=J M>^]%3KO8$ZDQW8NQ50\'E(W=`G26;T]4\[\_;".WN6C-'5#=U7,0^_5P0-G=+>S&>`&T[ MC(D;2;K(O"WQU6P)17[?QK:!V+,-OF'O3G!TZ6W%7ILQG@8=IXPL6JI)&"W# MB>,^GHGD]M`^RI.+?)FN:'.B,2U+[F7LBB<1`KET5!^MNC./_@,.*9?T1+^F MS:FHN5?2'&X-QPO858T\YL@+P2[MJ_J!"3B>M#_/<(:E\)H&ULE%9=;YLP%'V?M/^`>"^8;XA"JB:H6Z55 MFJ9]/#M@@E7`R'::]M_O&B<$2)>U+TEL'Q^?;MZO.GY8'Q)U$1(@U@:$5J5E)V M"]L6>44:+"S6D1962L8;+&'(=[;H.,%%OZFI;1>AT&XP;4W-L.#OX6!E27.2 ML7S?D%9J$DYJ+$&_J&@G3FQ-_AZZ!O.G?7>3LZ8#BBVMJ7SM24VCR1A#H:9@LWVQ^[XOP'=N M%*3$^UK^8(>OA.XJ"=4.P)#RM2A>,R)R"!1H+#=03#FK00!\&@U5-P,"P2_] M]X$6LDI-+[2""'D.P(TM$?*>*DK3R/="LN:/!CE'*DWB'DE\4']<=RTW#IP@ M_#^+K17U!C,L\6K)V<&`2P-GB@ZK*^@L@/GD3.L8O/[+*GA4)'>*)37AMH,+ M`>5Y7OE1LK2?(=/\B%E?8IPI8G-"J``5;3::L$'O(!JB&(M^NPPG;0JLM)U8 MUWH"N`>Q[DS(&XB9F^P2$L8#RT2L]Q&Q"@RW8Z3-B6='KS7&'PQMYA/9:&(B M!0H\SDT5VX.'X7I^:E-J@M\A+B>9!;;6F*BOO(?<"*%Y;:<()_%1-,2EBSU# MQ&X2#HB)"WADQBZNJU?@N7IOX.U/7FN,WZM'T[6-7M/.PB#T9[ZR\7J"'/?, M/=$3 M5YOF+H*9"XW1+MS`0V@>_Q@0>G$T(X"FKPXYQI!$P7F_-J!;NNYX#>$[LB%U M+8R<[56[=J'DP^SP)KESU:,UFU_#&Z;OQ_:P`!V^PSORB/F.ML*H20F4R(H@ M&:[?$7H@6=?WV2V3T-O[GQ6\R@ET.&0!N&1,G@9PL#W\.5C]!0``__\#`%!+ M`P04``8`"````"$`5Y7[CL,$``"P$@``&0```'AL+W=O(D:`%' MP&YV_WW'#`&/.216^^BJC-9;FPV.4Z= MGD21U#-Y%B6,'&15)`U\K8Y.?:Y$LF\G%;GCN6[H%$E6VNAA54WQ(0^'+!5< MIF^%*!MT4HD\:8"_/F7G^NJM2*>X*Y+J]>W\)97%&5R\9'G6?+9.;:M(5]^. MI:R2EQS6_<'\)+WZ;K^,W!=96LE:'IH9N',0=+SFR(D<\+1=[S-8@0J[58G# MQGYB*^[YMK-=MP'Z)Q.76OMLU2=Y^:7*]K]EI8!H0YY4!EZD?%72;WME@LG. M:/9SFX$_*FLO#LE;WOPI+[^*['AJ(-T!K$@M;+7_Y*).(:+@9N8%RE,JSH*%.V<@MUY$W3QGRJ5MI6]U(XM_4<0Z5^C$ MZYSX0-^->S-O&;`@O._%0:)V@3QIDNVZDA<+J@9^LSXGJ@;9"CQ?5X8<_5I_ MM%18HW+RI+QL;"AW6$4-^7G?^DMW[;Q#3--.LQMK&%7$5X4*H'++-8,#O#TT MA$*'_GX:KFQ*K-BN7G=H`-\]K&>`?$<140D?2\)E+R&PVK#M4!.VT'/7=?T^CQA6,L[F@5D*9#R( MED$_GW"'CW`K,>7VE_/>+W*C9M%RAR&+C/%8'V`*$W"&,4#"7.-0-!5">MUL9N%X424S3/7QC!14V' M%OI+(^DQCFMDFH&018^0*3$E\[5RPJ"A!LLU"!?CH.D"ME`"(ZP<%2T\8670 MEZ:'L56;M*$1QTXT!"H>6;ANH3SJ`-#2.JWR&!X;MYMG)]*Y<-I@X;J&&!31*/U=)QH" M%8\L7+=0'M7D-9Z)*<6CX4Y*4:1SF1;.-`OE4EW\<2[L_31>HY2B"'YY2&ED M;,E8/4["UA_@N6ZAJ*IO/XZ*W9Z@1L8!O6,H&BCBD87K%LJEFO/C7-C2[Z16 MZ_MX*#/3PG4+Y5*M^7$N;.@D7LM1:J]=_V9JKZ)AMVH6BJHZLX9Z9[=B'R>( MD?E(QK1FWX7.M'!=0W@\XT"8MEO;6?>>7CN15FHC"]=G@2KU%* M.Q'=K>:C52_J4ZI;*"K\W/24>DIMG*F1^=C4B?30X;3!PG4-Y3$.A(DIQ8/A M]B[U4#10Q",+URV42W5FK?0G_CUX$N^M_<7$DZ?>/`W[#BXLVK=[IQ^`^X)S..`7QIY;M_:7V0#-P7MQQ/<#`EX7W9G(#Y(V5R_P`\[ M_5W3]C\```#__P,`4$L#!!0`!@`(````(0#DW7Y-$`0``$@-```9````>&PO M=V]R:W-H965T`7-)($HR:@*] M.]*LM%KMY9F`DZ`&C##I=/_]EBD@MLGT9%ZZ0^7X<$Y5V:YLOKQ7I?%&6UZP M>FN2A6T:M,Y87M2GK?G/WR]/@6GP+JWSM&0UW9H?E)M?=K_^LKFR]I6?*>T, M8*CYUCQW7;.V+)Z=:97R!6MH#=\<65NE'3RV)XLW+4WS?E%56HYM+ZTJ+6H3 M&=;M(QSL>"PR&K/L4M&Z0Y*6EFD'^OFY:/C(5F6/T%5I^WIIGC)6-4!Q*,JB M^^A)3:/*UE]/-6O30PF^WXF79B-W_S"CKXJL99P=NP7062AT[CFT0@N8=IN\ M``!G=OVM+?)O14TAVU`G48$#8Z\" M^C47(5ALS5:_]!7XLS5R>DPO9?<7N_Y.B].Y@W+[X$@86^499!1H%HXO MF#)6@@#X:U2%:`W(2/K>_[\6>7?>FNYRX:]LEP#<.%#>O12"TC2R"^]8]1^" MR$"%),Y``BL&$N(LG,`G_O+'+!8JZ@W&:9?N-BV[&M`U\$[>I*('R1J81V>H M8_+Z/:O@49`\"Y:M">T.+CC4YVWGA!C@.;)]`@'7U6M]$B$'U<"[-$KM' M@-<71T_Z^-UX6B120)$M+GOI)/U\.PBP*CO4>CE"R)#SP/7G.9<1]W..""GG M4D`1'ZKB'SMOQ"+5A!?JN4<,NG@BGF.[_NW(ZYMKKT`\&_K+4[=&+"-($#K` MHB(21/1&%5\$#DVY*H\9ZU?ISK23)!I`@[6[?35`;OF/9Y%$CJC2Q64G-920 M[L&._[RQ"%Z1\D$+)XF:K6@`C54)R7)>E0$C:T?J6R21,:IV<=5IVG]\?Q&\ M(%7M^BTQ@%#[_:PCS4UG/*RY11(YHBH7MYVF_(&LXQVI*M>O`)A0Q7[!"^X[ M>V'`W)3&LXB8=`5/CT'M.+CB7%?1]D3WM"RYD;&+&$H=.->FZ#0P/SMB!M#B M$5G#T`5Q:_H"YM@F/=$_TO94U-PHZ1$H[<4*.K'%21@?.M;TT^2!=3#!]A_/ M\(N%PAQG+P!\9*P;'\0+IM]`N_\!``#__P,`4$L#!!0`!@`(````(0#OMSAW MA`,``,4*```9````>&PO=V]R:W-H965T9CU`P.[2[:8-Y_?)\ M!Q\V[Q[KRGJ@0C+>;&UOX=H6;0I>LN:XM;]_N[M9VI94I"E)Q1NZM9^HM-_M MWK[97+BXER=*E04.C=S:)Z7:M>/(XD1K(A>\I0V\.7!1$P6/XNC(5E!2=I/J MRO%=-W9JPAH;'=;B)1[\<&`%S7EQKFFCT$30BBC@ER?6RJM;7;S$KB;B_MS> M%+QNP6+/*J:>.E/;JHOUQV/#!=E7$/>C%Y+BZMT]S.QK5@@N^4$MP,Y!T'G, M*V?E@--N4S*(0*?=$O2PM6^]=>YYMK/;=`GZP>A%CGY;\L0O[P4K/[&&0K:A M3KH">\[OM?1CJ8=@LC.;?==5X(NP2GH@YTI]Y91(D;>""W]E2J.Z8M;:LX M2\7KGRCJ(AI,_-XD!/K^O;_PEY$7Q?]V<9"H"S`GBNPV@E\LZ!KXIFR)[D%O M#<[7R)!CB/5/H4*,VN16NVQM:'>(0D)]'G:1&VR.#&81@. M.>@JF(T%/C1\%$T%.0JZ8":HL"Y>CJK%)JK9?JA)$#6*DM`@R<:"9`G1N`8J M"N:H\6M0M=A$-4A2U""JOPRB.)Z29&.!%P7NR@@V1\$<-7D-JA9/45;"SP?#>.W.=5@FL<%7-4?78:&U,`&_??U[J>-$6.7*,E4]3TC1"[ M2V-Y9?B^`T+"T<"D15?_0Z@GF81F5E&#A#>AGP2>HQ%B>H$;)D879KUBA#D>F7+JK7Y4[K^7&<[Z>1:3Z2))>Q%N3C=^ M[";1#!!]>DD8^N'*Z!9]K="?ZB5>$L;/)A@!WAKP4*VI.-*,5I6T"G[6-P(? M-IQA=+BMW/IZ]S;&4WV+T>/.\`(N$2TYTL]$'%DCK8H>P-)=)+`5";R&X(/B M;7>4[[F"ZT/W\P3710J'J+L`\8%S=7W0'Q@NH+M?````__\#`%!+`P04``8` M"````"$`7SA]$@@$``!T#0``&0```'AL+W=O1&: M!N_R9I]7K*&Q^4ZY^67[ZR^;*VM?^(G2S@`+#8_-4]>=UY;%BQ.M<[YD9]K` MS(&U==[!8WNT^+FE^;Y?5%>68]N!5>=E8Z*%=7N/#78XE`7-6'&I:=.AD996 M>0?\_%2>^6BM+NXQ5^?MR^6\*%A]!A.[LBJ[]]ZH:=3%^NNQ86V^J\#O-^+E MQ6B[?YB9K\NB99P=NB68LQ!T[G-D1198VF[V)7@@PFZT]!";3V2=$=^TMIL^ M0-]+>N72;X.?V/6WMMS_4384H@W[)'9@Q]B+D'[=BR%8;,U6/_<[\&=K[.DA MOU3=7^SZ.RV/IPZVVP>/A&/K_7M&>0$1!3-+I\H2Y$:$)'\K?]_ M+??=*3;=8.FO;)>`W-A1WCV7PJ1I%!?>L?H'BHB`FHPX@Q$/Z(=Y9^F$/O&# M_[9B(5'O8)9W^7;3LJL!60/OY.= M<-B?UZUOAQOK%6):#)IDKB&J(AT5PFMA-I,&+."=H"$4,O3M;1C9A%BPC583 M'`#;$ZRC@=Q01*HDFTN"#X<56/<16"&&[)#9G)7ZZ@0UWN10J@]DTH""`AM\ M?]R$.#;!SX\PN;:&@IJ@WW%BVUX4:8I45@1V%+@?4<(]1D'OC<(*!T-F%8GI MPL']?*_%(IU9R[($-:N>>4$"$GFJ4ZDJ<"-?2X\,!7/D0$7^'%6(=51?)4E0 M@ZA1&*ZB0!6DLL"/_"#4!!D*YJBK1U"%6$?57I2@!E%)X,U(Y7G7#U;:^@SG MYZ"BA$KWT^O_UZLLISGK8P&R=%H9`OH^@10B%6"5TM_1*4 M#)&T;=^)M/Q+947@$H]H?F0HF`>3P`&2HWG?H>I7J="^K=V'R2!";#@SKGYJ MTD'14PW7N\")S1NE$EO6J2:Z$T6^ME.I^FQ26XB[[O?T!B MS5`A]9/?FXY-+*?NR@U#+=RIHH"/`%^_1E6!L_+]CVL,W<`F%WO`FK9'FM*J MXD;!+J*!=2!`T^C47#\YHMG0QA/1=(MQ:YJ`GO><'^FWO#V6#3@"3]G(% MSK?8->-#Q\Y]Y[EC'72[_<\3?-U0Z/GL)8@/C'7C@WC!]+VT_1<``/__`P!0 M2P,$%``&``@````A`":X8!86`P``$0D``!D```!X;"]W;W)K&ULE)9=;YLP%(;O)^T_(.X+ML$D1$FJAJK;I$V:IGU<.V""5<#( M=IOVW^\8TR203DMN$L"/7[_G`YOE[4M3>\]<:2';E8\#Y'N\S64AVMW*__7S MX6;N>]JPMF"U;/G*?^7:OUU__+#<2_6H*\Z-!PJM7OF5,=TB#'5>\8;I0':\ MA9%2JH89N%6[4'>*LZ*?U-0A02@)&R9:WRDLU"4:LBQ%SN]E_M3PUC@1Q6MF MP+^N1*??U)K\$KF&J<>G[B:730<26U$+\]J+^EZ3+[[L6JG8MH:X7W#,\C?M M_N9,OA&YDEJ6)@"YT!D]CSD-TQ"4ULM"0`0V[9[BYPCF!R>S7[H*_!=>04OV5-M?LC] M9RYVE8%R4XC(!K8H7N^YSB&C(!,0:I5R68,!^/4:85L#,L)>^O^]*$RU\J,D MH#,48<"]+=?F05A)W\N?M)'-'P?A0NEDGL/N@;6U!VS/8@7H/Q^1!"*9>\LW$\!LQK*\+RF\_DR?(;4Y0.S.6?( MF,C>(=(#$H*O@SD(^7)S%H;$^M[!7(2C@VX?P,8Q<9]7&U%V\F"T,LA.Z&1EQR1]TG"$4)2,@6P$))22V0$8.8NO<6;AJ;/)PAO'S'IGA%!" MCL7HDY:=`I2@-'[?&'3RY2FS\,08F7:28P9C28)F$R`;`1&ER3]2EESCS,(3 M9]%1U[618YRS.(G3=.KL%*"$(GQ\!T;%G%WCS,)39Y.%-XYQSG!"4X0/Q7+% M/`4(PLF)]9$S>W1=O"]8>.R,HO&Z&X<,QF@\GW1A-AJ/<'(<']E*K[%EX;&M M*)HT]\8QSM=-DI+)>YN-QDF$9\>$CHS!\7-%PGIZ8BT^]HCKL@$:]@R2H#F: M[&?VT+,A#HBM9GI$G#]WJ+D]OV,[_HVIG6BU5_,2MBL4S.`M4NY( MOY4&CJ+^LH)/#P[;)0H`+J4T;S?VT#Q\S*S_`@``__\#`%!+`P04``8`"``` M`"$`[*,C#H<'``"Z(@``&0```'AL+W=O]@?!\%%`0SSLEP:2[933:;O3PSBB,Y*@:8,^=\^ZVF&^FN MFN-(LO.@X\^JHNM/=7<)/'[Y?CI.OA5U4U;GS=2<&=-)<=Y6N_+\NIG^_1=[ M<*>3ILW/N_Q8G8O-]$?13+\\_?K+XWM5?VT.1=%.(,*YV4P/;7M9S^?-]E"< M\F9678HS?+.OZE/>PL?Z==Y2S;'UW0Z>2T M7:>OYZK.7XZ0]W=SF6_[V-T'$OY4;NNJJ?;M#,+-Q4!ISM[K(K]OG;L?VS>D^*\O70PNFV(2.>V'KW(RR:+2@*86:6 MS2-MJR,,`%XGIY*7!BB2?^_>W\M=>]A,%\[,7AD+$\PG+T73LI*'G$ZV;TU; MG?X51J8,)8)8,L@"1D^#W'!<2D=XEX[.;&4:WF(%![_A!]]VHX9WZ6L*[]%S-EI:] M5>?BU':5$N9M_O185^\3F'YP\II+SB>SN>;1^AH1V5ZKYF=%`]7"HSSS,)LI MI`'UT$"E?WNR7>]Q_@VJDV`8UCZA9A;\'+E1\ZPH!A$&.0 M8)`*`*_#T#Q#/W#V@8TR_#GH>145:O[_$)6'X:+VJ?H"J,.TD,A![S-D@B0. M>XL^:M0#Q05%9;U)[Q/W8/!Q7%VOI#?I?5(!M-'K+AFUL+WA_&L2PW*B2?SQ MFM:7)[>&U4L[OT@77]@LKVH'&(081!@P#&(,$@Q2##(%:!G#.C@B8VZ]F8*@ MUXIV44'[PD1)6`"GF[X/KFMY2*(0>T2JA[MR'5L_H0P[Q*J#:5C.$@TJP1XI M!ID"-'U@O1^A#[?6];&]A3YZ7]@H`@G@FIU"QFR!T@VQ0X001-HH\`@SR((<0.T08,`QB#!(,4@PR!6@" MP.8\0@!NK0NP6*`5SAU\08)!BD:LR/1I$I'IIB_'>`VAO<7F.Y-59LA4I&V`C%;,LV3+3"!*K!TEEZ M6-)0&"B*J1X?A638(\8@P2!58WXTBDSQT!2#ODQ3K.NF5KR[_DG3W6]0W%$7 MS_;0ZN(+FR'UH`>\W4+K:"B^L]4-P+8<_71$PDBH1*!%P!OEV;GAN5%8OC22-'W2H9-U/9028=7HW[P$2&, MD)B0A)"4D$PENBZ\.;U_JIJBE]6*`\\T7QJ)ZG!X<>BU$4B#0;"0D(@01DA, M2$)(*HD8C`O7$?!H,M5'UX9WE2.TX>:X5E`_[)O":$@]("0D)"*$$1(3DA"2 M$I*I1$^>=Y,CDA?-)[Q>VT8;=X&^J72HW386$!(2$A'""(D)20A)"!$VE?93)H])2&PB0A@A,2$)(2DAF21B8GCZ--7%X(WA"#%$ M'ZF*X>`YY_.+23!7U&F`24AL(D(8(3$A"2$I(9E*].1Y4S@B>=%#?C(-E$93 M5@(FH8E)1`@C)"8D(20E)%.)GCSO[T8D+]I!]D:9O""B$%4Q"$Y.($$9(3$A"2$I( MIA(M>0LWD[>;R,Y<;PSH3T)II*R(DLC:=&V7U&9(G")"&"$Q(0DAJ20W#IZI M3KH\XWI*B_:4CH%^WOG22)5'N,$>>NTX'`-=]0B)6T0((R0F)"$D)213B:X' MS/D1<\7BYGJY.`:Z(N)+(U4/X3:0D-A$A#!"8D(20E)",I7HR?.>[_Z%PA(M MXNV%0AH-J0:$A(1$A#!"8D(20E)",I7HR?,.;T3RHB%4MXC%`OUL]"W<-0:2 MB,NOYL+Y:*'`3A$)PPB)"4D(226Y](TH%]$CPD^X?M"^15!`44A11!&C M**8HH2BE*-.0GC/O[=2<^96O)9S$D?<1X78X+@YRVB?BV"XGAL)MOJC=^* MYUOUE8K'!"#?_CD!]`T\0/#YQP1,RM-=S^HSRRUG"+C_+86L-M M/,J?+0=&Y/!OYM=#P),#E_RU^#VO7\MS,SD6>TC'F/%[[K5X]D!\:*M+=]OY MI6KAF8'NWP,\(U+`O5QC!L;[JFK[#_P`UZ=.GOX#``#__P,`4$L#!!0`!@`( M````(0#G,QM@OP4``,$8```9````>&PO=V]R:W-H965TK_TQ23T/;4OZE6YWRS]?_[^ M?'?O>VV7[U?YKMZKI?]3M?ZGIU]_>7RKFV_M5JG.`P_[=NEON^[P$`1ML555 MWD[J@]J#95TW5=[!QV83M(=&Y:M^4[4+HC!,@BHO]SYZ>&C&^*C7Z[)0LBY> M*[7OT$FC=GD'_-MM>6B/WJIBC+LJ;[Z]'NZ*NCJ`BY=R5W8_>Z>^5Q4/7S;[ MNLE?=A#W#S'-BZ/O_H/COBJ+IF[K=3!(L`/#T]KDJ(0*?=:]1Z MZ3^+!QD+/WAZ[!/T;ZG>6NMWK]W6;[\UY>J/ZOJ;AGY9Z278 M'#B[/_5NC0@(_F/_O^W`D,DZFP-[8HTET/Q.SY+:7`!GU`F_K-@ZJ![VP/N:Y!\0">CY$A MCR'62Z%"C-K)L_:R]*'<(8H6SN?[4Q(FC\%WR&EA,*F+$121'1$Z@=JMM!8" MX#N0AE38I,\?PY&;!FMN1Z\I+H#O@6S$B)Q!+"A$NI#D?H`0LC$EJS,\O5@[ M1])Z$U2)Q3$)YX/_/CLI8J9#8!E?D-8"H00'/3Y_&KST(=XA74EX"A6I(&;> MGWPT"\.04LV(/7'LDMAM,Z$-6;-IZTS&T,O7CU]OXO398::(6?3TXTG,R%.K M8&;)S"??A'OR$>YZ$^,N6&I3Q"#WZ2190/9._Z8L%`9F%25M\VRR.$5*0IE_ M)!2]B8?"^C]%#(8RF\QGC+QMCB>"F:5MGMJ["7DMR6S>W:XAO8F39S,C1;V)D0]/_K%_$7,D/V6Q9=1\*@NKC^FP1*%!D-@K6 M-_H(A8?FR>&#(*Q#,9M#F_`^(H@D=A!2$,1]8B,H?ZTFX_FC]A#^?`JE`D'3 M?@XXU*\8Y86=E+!6D/&$46]LPG'"-"D5"+I`^(I1FIUX5'?W=L=1TEHZQI-& MH;%)"_/YBK&Z]N`KM3W382D"-H! ME/^[="XZIW/\'<"`KO%'-];\,'OZ%"/7P9T2DSFK$A[A?)ADC1.`B+4F.L28$`V+T>: M;`SEQ:3I1HN@MM`\.2V"("RQN3O?,WT1`H6`@.G"'N\H[%<`E+P6BO&'C+)" MR#OS/[*UY]Q+,@6L>1`@/"O-[![2/7+PH0#D!2`/%` M$_\N'8M<'7,EP8`,>9=;=@L@#8"/#DI<2\?XBD&A(14CG'*WU6@QN]2*[@)OJT& M!H3THO`MS!Y+K?#&&"]4*]5L5*9VN]8KZE=]&QS!H]ZP.MQ4/T?ZQHZM MIW"#W5_W!H,!+I`/^49]S9M-N6^]G5J#RQ`N-GROP2MH_-#5A_X:]Z7NX.JX M_W4+?RI0<($:3@"\KNON^`&^.!C^^/#T/P```/__`P!02P,$%``&``@````A M`*BB`&01!P``H1P``!D```!X;"]W;W)K&ULE)G; M;N+*$H;OE[3>`7$/=-MNMQV%+`WG,VAK':X=?E?;'+I^,U'( M2`-4?RY7=?U5&/OQKY^[;>U'?,R2=-^NRZ:HU^+].MTD^]=V_9^_!XV@7LOR M:+^)MND^;M=_Q5G]KZ<__WC\2(_?L[T\I(>=U%.'X^OK>QPC*--<=!NVW*$\%N[*-G72P\/QZ_X2%]>DG7<2]?O MNWB?ETZ.\3;**?[L+3ED9V^[]5?<[:+C]_=#8YWN#N3B.=DF^:_":;VV6S^, M7_?I,7K>4MX_I1>MS[Z+#Q7WNV1]3+/T)6^2NU89:#7GL!6VR-/3XR:A#,RV MUX[Q2[O^33ZLI*RWGAZ+#?HWB3\RZWTM>TL_AL=D,TOV,>TVUM;3N56E)%)[&'SJQ=G:]I1Y:G MN_]*J,CHXL0Y.7$I^M.ZTW0")95_AQ?OY(5>+UZ^'`(%6^1!KY>#[\[#/SG1 MMI.[\Z#6*D*AUTLH7\XC/!U,KY>#[\Y#DHS*JE+=KF[NSD2>"VO>7/Q\.1=) M>BC#8,*X5UWR+`Q)];E$\65]M4K%%PW4B_+HZ?&8?M1H*M'>9(?(S#CY8%R? M6Z<4^J69?M=+U$3&RS?CIEVG8E.;9#0`?CSY@7IL_:"F79^83I51RN%,]\R8 M'C6.>VCHHV&`AB$:1F@8HV&"ABD:9FB8HV%Q-ERW0/+DEF?BG-S*,K2H'I>B MD-!846[/L?/>&]KL_=EMIS20\TLQ<)NKA!_X/-I>E?$XT:\2?J`Y,Z@R3LB1 M8151`00\NL6XW,^XROA!P)G)+88CTUL(A#R[P82"^YG?8D`1BRH#B2]O$!#, MJHKXU[29KF@",5V99G=I3'ZN+W,4<9:<_!#"[)2,=]%@%PT]-/31,$##$`TC M-(S1,$'#%`TS-,S1L$##$@TKR\#VEV8TV]_/]]70[3I5[]*F&C34*1&_&*B. M(Y2C8:AV;4)J+22V5X\1R@VU!`'U;<(1@=0XE@^JL&).#QGAN!Y% MPOMAQ`C7][T0&Y@1@>=K%R;.A!&>(T(%9YDR0FA?>Y#MC!&4JW1@\LT9H:66 M`GPL;$*KD,8>1+JT"5\(\@)G6=F$TRLD,[`)GTKEP1X.&2`5[2%( MR@9TX/H:@+$-2*%5XH7`AS:1.N\,T_OA[X0^ M;&'7!EQ?.B[(K6<#FE+3`/1M0(6F\7GV`QMP'24D3-*A#3BA"!1D,6*`E@'6 M>`IP,!.EDP0.I08)1+FY"2 M=")@JU8V$=+(>0#,V%Y#G0*9V2.0VF,`@4[!KQJ$7OV>L-3 M@8_]WK<)TXI0@H&]WB"=A?B-.V2$5&&(YQC9!)49I^O87G<=G_ZXFB[WAA-1H M(),^(Z3K6M_=Y9<;!Y2@FTF\!D.;4-IUH88C>]WW\))L;"\[@J8-)#&Q@8:D MWWQF9:V`"%H*E;^"8L;8(&GHL7"2L;H$L( M>4V"B8CN%-TA(D/C+QHH3Z=DK%\T:.BAH8^&`1J&:!BA88R&"1JF:)BA88Z& M!1J6:%A9!K:OYB;:'1M;X+P]_1`NZSHG*"RN/T53P'KWM%[V+ZBZQPYNB"8V MYF<'#_!@`5U%5T]^LS[F!VLFX+_Z7X#O$W8`92+-2&+TTTK`'B8 M,:#J8([KD.^"K9L(8`@M&4#K4*L5KE^[B,O(W.GZ^I"G9P4XY7V<#)T3]'L9 ME4Y^(Z-RL3SXEHP^.7C`SFQV#;9UR`!:A[*-3NLW0QNS@[\D(\BE*B,$()X9 M.R7%"TTUQW7(=\'6;\K(CN"6C&`=950^^2EO7._BXVO>+TS3%WH\#>D0]TY[9J7Y@G5,;>NAQ`#X@.T6L\CXZOR3ZK;>,7.I5H M:OJA=2P?,94?\O10W$9_3G-Z-%2\?:-'@3'=O19-@E_2-#]_,">X/%Q\^C\` M``#__P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O M=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF998 M4Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5 MAT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX M3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV< M%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA M7=_\TG7I@O%TS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'# M'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LO MG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH- M<$/S*EAX.(N#UO5D"53,+2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W M%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9B1)? M7B?-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#. MM!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH; M!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO14=MK M-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'M MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4OR!5 MBF'\/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U! M!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH M@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMS MX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[ MUQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[ MA28&80-1?F#R`Y+<%B MB=+.?//-8U]\7'__Z#K*9RLXV+ZW4$>OAZIB>1M_:WOW"_5O=\;%3%4.H>EM M3VHDX#3<7^Q\=V] M&=IKV['#)R9+5=S-U;M[SP_,M0-0'T>ZN4EDLP\Y\:Z]"?R#OPM?@[B!O]O9 M&RN/?//^+9^!W$`Q@'O[LYOKPB_+9=.#(".%M?,(`%1OP[UP8WX<%!I.&\>M:()K%I MAC`XF\9XA-KD@DDF'BRWR?SYA$V5V=:8K'QCLWME1=;%9?A<&8`)URV+-J1N27Y/#7R=(T[.W*'UXS$FE2OZ M+/6ZJHU<%/:LBPN,GG7!`#A\X]CW7C1<.1SW,"+>!/8^Q,A+P_-EH"#%M(^8 M11\+\M$S$G'>[VS7.B@?K"_*C[YK>N@T.E1C.+F19KU`;B1>D,/*F*JM7)KB M>AE;VZX:@5E):M-Y"@NB`T27[3CI/'`\P9D2'+FYABEI:`6>`1^4^/W=TQ[F M21[,GC$L!]'O*GY]'YA/(XW-%L0:''S'WB**^Q6;G<6CX]7EK;&Z97H),E$4 M!4(-8S7M0>CMOI?#Z?C2YGL]E<'X]TG9&\CB/:]K;6HX4++)W1E$E$E>U5@D"25PD"25YE$_I!!Y4_ MSA18VY2Y4@D.15@D"25]DR=(>Y"GL&DG.5()#D M58)`DE<[&WS&%7@NW:L$@22O$@3G]FHRK5K=WAIL43(_,NML?!SKPD%\?5UL MU@CSU+4?;&$I*]FQ'.DP1XR.W5P[UBZ$&6E@WS_@W]#?P[]K/PQA*_3F>FN; M][YG.O!VD+1(_I:TA,UBV!=>J.&#O?D$RKBUR(B;2$5?&M*JI^-L0I_JPZD^ MT2ZC"5M'JEUK:Q_=O'6I[I-Q"30BM]6&$PZ]5$D<#MEZ^`"]$+M/L`5S-?.T M8`.(B20D!%MT86.V-R1J(VDA9B-I(&@C:2%J(Z3.J>1*F-SZ1SA/X;F##6,V M'$8+EJ)ZR@42X"+EU@>3Z!Y!G?W,^;P0!%44."AU3XN#SA[F"T/RA< M[7AK6=*5'E$K3G`+CNC!\`:`@*M3O73<74/OO[$D2`:PN)`C` M"3(0X!F$,0<0GC(0P*PM00`!FB$`."51T28/1J2:00QD*D%_7RJAQB165I.:"S@Q`.2/+#LF$:#I"Z80N#ZX#/F!/4$UT-*P@!XI&1%-DX8<3W&&6D@$&15 M2!(-FJP223'(JI&9*S19)9)`D%4AJ2=DE4B*05:-)*Z052()!&!$2H6DGI!5 M(BD&634RIB?%%02"K`I)/#'NN40.Z+)IM(A*UD]GS=9/E<==Y4+JJ&C2 M!'Y/FD>SIVCF"+Y@^!.;^SGJ$J6BT[?2X*U[K!23)^L;S8.01%F+*],/2NJK44=XY/RVPM">B MTG(VJ:]89&-`?\<8.@_#CM(4.LD$HG!T=ATN ME";H,,5JA0'$8O&I4M\I5,$%UE)A%JA-U36$7/ MJZU%G<39K32>1WV&X,_'0VCOGMI%8=<`Z\1%YZXY5<=J`>J:C=:`2/".G\^* MRZJ$P=:Q&U2T6G3UC*X2"^F7:2Q5,'6ZR^&K;`/^V/D[-<>3E,#G"PXOR[T] MH*MT+^FP./=R6'!G0YRJ9;R]&^ M02\D2(I(KX#[E9#.A4ZMQ"P<:-(N-!WQ5):.(IK+`=9G60AVDU`N&HE4E;M& MN98LS5322I.M$"&LCI459/D(*P*ST*=M9B%%;#7%4LM59)@!^M:L#XQ/L2SS M5"$1-">CB7!3.!5#M=:#LCPZ!:_CCJ;[<$KIH&RMD1MT<`6ZPFMG&CUV'5/4 MK8U*0I]Q)E[[P3F[9*6,(.H[U-H#+.^<6N="DVZHD+^J?HA/@48U/Y^[)Q.V MJ*OG$C8/MWY?W\B(MJ3W'!-YCIO61P[HRQ]O5\#]2J*C(L;+2D:OT2R4D[E. MM#[IA2.4RO%($4(N+J0B)-V8!M/7W5GW"LBNF_@:MHC_FGN,\@%3C//R091W MOOM6&:M$.9Z=)@:#>YZ1=1D@-XYH%JA MVZ=_\N.8DV-%FDE]PGD9X=+4.WW,E%X2%IK8@H%#A@LTB2J8$ND0C?H[=0WF M%#5`EPT:"WMO2FE;>.5#L-;P\AZO,>7A>.P!:.,TZ0$+]6F>M#KU==PS.M&( M*\KBY\,(533Z1"\[I22S>^3_8.B M+1:\D)3G4"1PS\8LW;GB?0_IQ^/FRV\CA*+!B<5T%S.+;X56M$[S6C@0/36` M8M=3P!44Y'XT_-UHTNLM%'Q.!3Q7:_A[Y4)YL\&@3L\* MU\)LX`Q,WUU&!^.K%\IDI4&C814DLF``4E=6ZD@-KX\BLF#+IJXL4!\%Q1BL M);+@5CVU94%.Q[+PZK4,EPY+BG5Q09-8%L_]1)![_90?V76>&2XT6007E97Y M$4>.1!:87%=6YD=P')4%)M>5E?D1$!)9.BBI*ROS(WB!RH)PJRLK]:,.CB.R M)H+<7Y[T(Q^K>%&6""XJ*_,C'ZMCP5BELC(_\K&*)M?%E?D1I!*^=/BBKJS, MCWR=T`7K!+4Q\R//_420^^<5E8]X33#B(RF9[^`=X0C'PR(<15(RK_%1/A:, M\DA*YB\^OG7!^(ZD9)X"><0B';X0MRCUT9AG5Q=D=VENDZK+!PSV,R(PX,DF MFZ,#3\;T\;F:[*)#'.83@W`30TC2@[7YI*S@'G*I(#X?L!L5$73[N'=,SPS] MX$G!"PU3<;S3)X+B_N3[*4>\!`T^B@#Z,SR%%!YPJ@`O$4-\#.,0M(Z8-!=X M>O"N(W7$0.L(#1]_.)BL(P9:1V+XHHKC)Q$Q[[S],?407TNQZQ81\=[V/EE; M/G)XAG%**B+I@W4,`S.-/SZE-$%B/N"=!U,9?(F('A24W"8Q'G]^@!L-)B3B M19@D=W`,+0+\K\>0T(BMB!#<3Q81'<'_8)(DY$0A+2(0/%_^F(IY5%$$9 M?S<##[.%2]UG,5I@478I-8S^MX_972@9[R$^IY?=GS*=#P!16VMG'IWP+OUR MH6;O_\+NO`S!%/_J!_NS'S(1"S5[_QYO:0U9#`M/4&[>'^`VR?!7.0;V0OWU M=CF=O[TUM(O9<#F[T,?6Y&(^6;Z]F.BKY=NWQGRH#5?_!QL3'XC]FQA4H^1/#9?6P!-IPEF1@Q.*0/7;[Y'P`` M`/__`P!02P,$%``&``@````A`"=RF[2$60``B3`!`!0```!X;"]S:&%R9613 M=')I;F=S+GAM;.R=VVXCR;6F[P>8=T@4U#`%4"I19QGMWE!)5+>V59)&9'7O MQF`N4F1*HHLB:1Y*+5_Y8MY@K@:8#1C[`?9#]*/X2>;[5T3DF93ZX.K!P(`/ MJF1F9,2*=?S7BI5?_LL/C\/H4S*=#<:C/[QI;6Z]B9)1;]P?C.[_\.9#]VSC M\$TTF\>C?CP/H8S_GG]/[M;#)-XO[L(4GFC\.WVUM;^V\?X\'H3=0;+T9S MWGNTN_,F6HP&?UXD)^[2_M'^FZ^^G`V^^G+^U>FXMWA,1O/H>-2/VJ/Y8/X< MG8_<"YAWU/C0.8W6UK]\.__JR[=ZQ#W6VH[>CT?SAQG/])-^^>?3I+<9[;2: MT?96:[?\X_MXNAFU#NW'O?*/_[H8\>16_9,O3?:_']_.YM.X-_\?Y6']RFZ2 M^X'N8+V7\6-2ONO\_?L/)^V+B^CDZN8Z>GO:?EN^PX]S`L6F\1!*]9,?HC\F MS^7[3A;3*?=$9X-9C_N^3^*I*!6=QO/*6_V89X-A,HU.N.%^/*T,V'F,A_K] M)IF,IW-8*#H9/T[B4>7&[C06AT6=Y\?;\;`\K_.3DY/RM92JW>=)97*MK8T_ MEA\XAF'ZQC1GP_B^_&LZW'4R'8S%5/7+3N_S-/*WG\&0L_*89]^7KY2?-@K7 M/NO)^UTR'&Y\'(V?1E$GB6=(7#\ZG\T6R;0\].6X?,4/\>UXN!C-X^DSV\I> M5&;I;PM[GVU59Q[/JXOZ/EDVPO7B=CCH16?#<3Q?,A=V_Q'Q[,S'O8_-J/,0 M3Y-9=+68FT)A_\N/O8N'\:B7<">*8K9,K/-RNU,>XN3#S4W[LAL==SKM;N?W ME9_CV4.$-HMZ^B/Y\V+P*1XFHWEED9T'.'ACGDP?H\'H4S*;BY4J=YWSTVA> M(PG'/=-LLVB:]!+><3M,FM$HJ1#J>II,XD$_2GY`:+J\NN-;OOF?71]==,]O[J,KLZBT_99FQTXC;K' M_^8VH3R9[+'SRV_;G:[&[Y1ONNI^T[[QFUC[\NY5]_C"WU!^./#`Q?GQN_.+ M\^YYN\H(Z09-XF?MCA$^[O6F"P@9=J,R<)7XM_'H(SMP6]G9T[`KTP0>651T M5G%/AH/X=C`:Q.]^KDC]]<79RV;SJ_,Z;J?E^53*_:C>!ZA-I+'6\8))M^V'-N_4Y[O23P92&`&(SBAE\QFDK)T+N6[X:3%XV(( M(?L2Q4%O4.&%+M[/;(%*]JMC-KWQ;([_L+/;;+5VW4QV]NQO6R:K6C7C)GIE M-DEZ\\&G9%BQKOD9.5W2PPQ/DP=4#`]$P_&LHE?YY71 M*]MMJJ)NC\N4*JOW:_83]RR9#W`_UI>I>]FEQ`SYU1TV;82%&+`YU^,9XH(& M7.Y/>?/CB1[HFG)+>7K%V]/]CAKP07\\',;36<:'ZZN?]B]SW%>^MFZC?VND(!8ZWV56=PN#W:.3_^(84UIN9QJU]-Q?]&;1S,,8X5-3F!;2-R?13,XI?RFKZ=P5_083^\'H_)O8>@^*G$XGMBF+M.U';W>!(.Q/L(CN(O+ M[CWN/PY&YC-+();>YFFX8J#+=C>2&3SNGE]^'34NKCJ=]>C\\N3J?;N\EBLS MTHTPI74DTO3\K-9<%8:*WK7/KF[:?F!9RG;%`/H-DTEOW"8C],I\/2RL/!7- MNO""\@W?)8/[!^FGF$@OOD_0/N:8>2X=9QY912V_BV>#7GF\T\%PP7#ERY5Y M1)`RZGQS?-.NC)MRHG$WHI?33XT+6`BZ.YY=$MRE`T2H!;<9Q5'\X\L9_3*9 M1PWIPG4TO<2CO!XW*K_DYY9_H+*JJEUM1K<)@6HBYZPJ3KE=CB<3W&ES1>9C M)O22@7YQW,BRF,$T^:L=@HK MM);=)YOBI&_=6_KESXA/'8-Z=BT/6L<*A0=6LT+[AV3:&\P2\8K9RF@\,4M3 M?L_2&T-L5WZ@B_;RRDN1D/.1X.Z5;[$]VKB-9^@KR1Y.BQF^\N!+2%XQ?>&^ M%21?^DQI.W>6S6'%V$N?*8V]^S/&KCQ3%-(3Q;C$YT]+?8:3X\XWT=G%U7>= MZ.SFZGW.]AV?=,^_71(Z]?^T\/%PQ&82X8YQR0BAB&^+"E4_ZZ(%VY/I^-,` M&"ZZ?8;!S)O!$H.##3Y9W%-1IJ<)>A=?3[Q8)L[QHP"FO]3^ED9>7@9J]9], M3(3WV!_,)F-<'3'_W>`'VI"'^K#Q-B>ZK%E]^L+PQ M+E264Y)M3%29R?5BVGM`<+08R`V1Y\_-:`*H,C=/2GB'>5WEU[T'^IG:+I@2 M>!7V$5YF]F#VTQ_)8LL5`$M*P,9"^@!+NJZ5I8SD'I5OF#%2>7%E6IZ=7QY? MGA1I62'E*2$];X*%!A.X0S#--.VWQ3^PM?,K)U"K:Q/X3=?'M\T:X!5]ZUOSZ_O!0!7OU(^_+T M)]WO?&;GVD;7Q^>GY4TYOP0Y`OV)VO]VW;[LM&MONKRZW'!37*Z-0K!NCGA_ M`!^;E/:&"^D:S"R@CC(*Q&X_`>FQ[3&1UQ!W\2``$4C6R[[9N\5L,!)ND$5M MY?6GMWA5J,!NN:OZ[D/G_++=Z00%?779*0]X_OBX.`$^!G*?`@&99HP:!"D! M@\?+)9Z*[J?C)Y.7T0"T/GI(XN'\P0PM.'WT]#!&?4P6#,'_\P`:O`=Z(92H M-R!:'^!@`?(_;T@*$Z@+7CE1-D.7)9J*'7GL`?/&3BR&\EUX[:,A(.;>REZ, M'X&.!^0&"#31PG%A,FY,&TFVX5DC:"%]MN'9WGB;)-J'/G9H"F2V&76S=49/ M,2II.B#^U$2YK>'VS;:-"G?#/]+5_NS$")OHI3,)M7-SOLW>"H\GGD6T;S)JV`8^*_G,3P[:AEK76 M=$\5'FENV7[Y;7HNDH"9S1:W?P+",A;#4K$MT70P^PB3SF9CV7UHD]+9IJXW MY;$#M@TQUR+Z"7YBG\PELQE%'Q-M>Q_FZ2_B(9,W/U(+X4?3TV/F-XV`=.[Y M/_T*!R9^E;-%3Z#?W6)H&(@M[P?0!;TGW2OQJ*TQ!V7H6MS#QGIDBME"27LK M'")VD'$PIOP$WLL>I!09G>$[,&JDY#Q;=,N M0,JGAT&/M!&DUY9&(V6VY1,HHZ+G1G*?@*9-ZW&;J8OQ8HJ?BWX8CQ1_B:6T M,W#Y>`J^*K8GM.$Y]YB8J79^>NUH/(\>![,A273>MQFQY#L0R?%3L&Z:!6LB M33_%%2%Q)"];0V:`:8X'.NF=[\8\$#7.CCOOUIV`ZD\-,(ON@9VFQJT0,YF( M@**JYR/O&PFD:WQ]?'R][I;QE,XL6Q_7T)ULYIQ=1".S3WCOD0B4K9@[G*@8 MMHW=L*W/K&,S(CT]8ITY$-:TM_G7=XIR-J,;)5VD!4P':5I>_Z&E[L;C.73D M)U'4JRBMUK$BK*3_7/,_@[=4$/Q%F0\*_>>#AFQZAOH`2BI2O3,RH+ MW"TG\7!P.QWHZEW\.&"!]N2V+EA-1.(N@%&.I[KXUMXR_^K'O]7NR0G5%[*R M6=R3F]OGF-??_^=_1(W\+&"-$Z^AV78H\:Q2`<\,,R=]F&3T=](;HKV9/LP" MB=E456DX-2YV5*E%;M-3,93PIC+NM1JKSA5S-&XK"D+Q;9-B!*)<(5!0'?YR MF+%+WW:5OE6.=DGZ%C$RQI0X2O8?@$G9OB%E*.1DL["$/W$TK`3%NS94MDAR MI;;-P$Z3),+8J]8$%<%*<1CQHEPTUD?7&$/>\KY2WAG*EJX8>WKI,NES\X"@ MO&DFG8-%8;S;N/>1BU[./VQV-D'EP7='"E.R#;,7WKK$NGD#64KK+&'A*#(" M;253H!3JR!+P!1_R[/3\9!VB/,K?875KVWLN_Z:D7";`HA'NM]E8_8))UJAP MB^1-Y3XR\6X9D`H3[8#]C(]P&6N'\S37,+9^)?J@Q22>XAKY]7H22TUK!4+<(RJ$&MFQK^.;L1Q??W&'3S:-;V M]@\L>REO8:W5/#APQ'1PT)(,93'?MQG55R<8H7,"B)?YD`Q-$(U?Y3::CP(A M91WQMMB./*NQNST$W:D?>(Q_^VUTVMVS/<0'?S'#)<\\Q_SF7-6ROUYL9BQ[ M\"D98K:]V(0G(;DK`K%J,7Q;_-8P:5L-A$(_FIY_F5]@2N0TE1)M+UY4D-KJ M?M?R'_1&O"]AIFBGXG$U>A6])`:TJA"XU.)0G(SX"7:?$QLX/VX\_;@Q&"F( MDE]@"^35`];<][DUK1GW!XTJ=P'3BZ.,`L7.P9;:)TL@P]JZ>C>8SN8,V/1_ MD=$AXB(MCJ0@"%[0&B/\`H*Y(<"9O$\4YB)!MW_W\FS$]5J2%(]?5'X]PYA` MQ%;Q&(\6=T1U:"E<$NDC(LQ^CH*[50KV*Q14?5B"-0^U,Q5@S=T`<7QQC3/J MO1A_+*-5"`*9\:?Q@-`@-L&/\%E$\@BS0`S,KC[J;1@JTKR+V[DQR/")DM6]A.V$#LN=0[94<_C)U.8A8=3P\CN$/G*+&!50+393]05T9WB MZ&<1:#[EC4--.:`4VG=N$H)PCT$B>IQ::"U\@\4IPC'_GV#,, M@1]GY"M3YPG#@0<&\\BCY8]^PJKZE%V&U3(3^5`];9MV&C:;5X;"4G\:C!Y&:2P`;'E0'%Y,$(NS7=XLH3=D9]ZCX&^-O`$O(7 MI<8U(>B>K2S5%HH4LC2F;6:FHG:VT"//^(=I?DXOI9SDGC+)E^DE!Y3YKP.PP3Y`K6FB62IB%9><=-$AK#UUVP$5ZN4.!V,1@J MNHD:+MP2C&/1M/0W*VD='>VLFX[1U*@A;MD_^.,@#;--+*>)!(,)WX+K@ M2>WMZQ*`IDG&AX(B60;H4>TBO2"84@GJMH8_H\^<%;HE3T3B[>Z8"H_D3(O^\<:?J!/G.L.*-3X>E;P$-$Z1F(+--/YV0 MF!2)C"2\YGE+$U!_L1E=B(6-#,S#='H^A[%D%'-."SN3.CA9R)?M(<1$(L.[ M>:E+-Q9?Q.:+)E0%3*ULR/C]UWR_D4ZZT;D;1L2*5Q2L]$%55.\JHHHN(*4S MD"$\KDWY()Y(C]),P@'3F[V0_/\GD.<&<8)4F*HU1$K.($Z[(&""4+Z%CL^[9M/8!340\*Y!U-S("3BP(-" M^[%E^1@[Z@(6]:*=_:WFCW_[S2")XPS@D4NCV9]GL^?*:2Y?:C6G%^BT?D&" M/C-:@567DY"GLCP4,&V,/.F!>R!>18RP8"*/5[I>ZY*S:#Z8N<':#LM(RE;A MCIE&D&4-+I^L`MY(;B\3@<**PQ5%H0XRE;D`RIH94L8O=PN<81_X&TSEE;EQ MD\)BC9RJXSO#_/P7I/(,RS:$V3>TF[.UN=1G9PT::^K6F-XE*!*>*32`+ M=-0OV5(JLW>9`)N<'@TN8%]G%IB2,(+93)T5<.T=1&.M/<)*3XJ'_*>.Z MKU@IY*U'3D4>B9[?6D6T_I46PX+=G@71"3;WMHD2[4@VWF5M\?NK&3!,B=;2WZ>XTR017G[B,@`<^HZ8VL;9``EK@:(8BZ,K2)4=< MA%T*F(=C>?=NBXUR&6V7F?5^9XT%JS%2A]N_J9'*2<%[2RL'IQFB9?+B,8// M;(V"!Z.3`((),D*3P`#NYLP4(`^1#5$6A_N>@%YJ]>2TQG96T`A,$>EE]PF+FLMK5]0+-`2Z?D4@]$9$-(M MWV`'963T-*+'F3+"9[YE%)S*HG:O*.6\RC%GD6W6H0[1H$95ZLUYK62(/'+. MW:F?;K:0PQNZ2"T'F1>A6](M"TZ=*MJ%?2AW,W+*`%*N@5>+TC,'B>@8KYAWZ"DW._\N`SV!9`56J?1X.2)`[&Z\G MZI:5)P->O3-VK-6OS^M'V6%I)_Y30-U291^"%%4@*)5_BUAD^)G0*I\G%@J= MH6G]8D$#%"'0<6-`GB%^D5'8K%"H*$@7+G"5@IK%Q)F0E!PV46`KH(!!CSS^ M%$ZS8A6L*4\DX_MI/"'2$]1G5OSG+IX^$M_K:54)`%4:(X7< M30[TUW,S7@/SP`LVP>=T,G)7N4$I%O/IH$9^1IO1-X#8!&SF2LI@B6_,\)KY M9I_PG1^!Z,E5%)%(^!N`6E)#3,7&8!SXG MJM-QW`M_9'-W4DJ>X3Z--)S*2T-:<_-PZS*@23*UL&DR-0K)E]-N6H MD6S>;SHTW(4("#]5%A1J.<"/^#%.;<\&CKL/`"66X>PE+._9SN8+Y4))A)(X MEL'0`7QB5M\O052'IK9UBH(>!A.V!3"2G7F9-BB;]&E&,I:!:ZF;P1;S.@NA ME-ZW=RHBG$GM`L^X9!5BO8JU__[7_VU9`BI+I+:DV^S_^-_[L=C!$B;RITAD M)0Z+R#B,P>M8B=R&J*K'Y>\?3E/*=A+Z')X82C(T/23[`3.R_%NR7Z?*53BF:3@`;"^G"`97;S'-! M&@RQ)_+N6S++A?_09TKI@4^S.62%)#_/]'$AL!7/6`.,+&=M#4-$*GS^H5A^ M0@T@JE5/\JBX=T9);#(U7L-WPES!.!ZZAN&">C+3*`X;;O"KJ*C#=9OT5GL+$:WX8'=L MHORT=$I"8'[&JD,&*&Q_?O6.]BY#!,G9>6D*"%>6E\:?*E+6=LT05DG9<1^> MF(.D2M`-1)9J])@P9:-*;P;`.<@)T\CR&SG(VA*T$@N'/6OFL1_>E+/YW2KO M57:>%&;NU?Z%^`.669:^'4=K^_O-UM%.D^J.O59SZW#+=FZM=;#;W&GMYL%R MRV+@#RB_7SF>;MUE=NQ9/(#MI[69#0E"+*3D4-^.M02FP6K MK@P8]6Q&RNH6?:QLT;D[F\D!K_*A1L.59!UR:`.O5B[8#N*(T&5=6`,Q'.S^ MIA!#=7V?&T=PK2JR\^G,4'3KA*QJ=I[PM);3T[3?@HYQ/A/IT:+04 M:>X6S&$`'OB!*E]0^53/Q\C,79)V3:.!ETB9E.R7EY<5G,?; M\?BC%(JD6F,4AT5'FK.#L_2$5DA0[`O['PGT*;[('"!7:9#Z`XKM;!YYZ"0X6JI" ML1]Q!P%R81RB7?PWF?5;?W`H1,92TZ#XG(`-:0R(S4$;80J:)QMN)P*T9D)D M#ZTQ57`E\6U%X=:!ML6#9\"Y&.?NQ`JH7IYQ\3)#Y0T$T?:RR"= MWF2!,X=KHN"7=GPIB%C!96!&(RL:!4X$4.+#@ MC@.EQE=L"PC@R(4<]KSW7(RY<3E&XVR)A6TB$:4,G0)>2%NQKW`I)Y^L'`0. M#8)GVRU?-\B]LY6I!PBHI>HV%@^#6)6ZPRJ<\*>E,VQG.D`.&&RUO'$M(H.- M8<7`=G3`?H,C$"SS!#RE_A1TG;$%DN-)EY6$!](G7VMX:7KW&R:@\VO=,"+4 M+#]G%3^':0H.9.8]IF9J88H]%7R8<;1AT6:!\MX-#F#)@"1QM&4>;;?]@7V@2)WT3<&7P($I/F7@$4^Z^[*7OAM2 M2[[1Z:'P4*#N]#]*$J0-!?DX)IZP,(1H"1@1AD2[7:H:MK7-L9VJMAQ1WB$-L4:CHZ/#/2VAEDK$"H)Z]6Z\Z67L'#;%B:&;E*PZ M:+).0"OBLK_6-5MO`#R@XZ/6@E5@,I98=ND)["T=J*@P8RZN3\.OY;;76;#6 M(Q,DK!EA7@H]%G\"8(HOI;6$6UG$;+%3QC6T0YP)KZA7Q]0XMS+@ M*Z:ZJ@^)X'"%'IKIH8R;Q2OJ.J-%OB*`V-Z77_!;JK)V.*\D0A@%-FL4Z^=0 M8%T42X[4KZ`QEMZ2'2:$Q:>]$_!4[BDT6EAW-2?5Z?[!B;FRW%S4S22H842* M*<97!O.>TYKB.YP:D"%?N8#\YQ_/*SL!S+E$'D5*),Z>+&^`_ZM,UT9?;8H` MCYSR%)S8,S*<.\=59%C&8_GUBW+^D5]E[0X.8?&;9*NMD=(_?%:VS!>V@CX1 M*!^!`LM);EE*XI"TS8'#U,QI8EE66,\_G'\;FDUY5-[="GO(S`41ES',JU;' M%6$@#CZF3.678*_*I8R$FN:X-F]/!,)M'W MHG-&)QC"L-B05"KZ;M^#P;O^P@47LZCLE-,KM>"JK"Q']?+#;4LSR&`&EB[, ML'(Z(K#53WG'54Y,BW(V(F[#5J8-%6S_LABD((7-A&.%] M6MIF(D#R`)MNLN2*SS",H=:?J7HX0.Y6P#9"`CDCL_/`T)3@[NH0XVH>*\^X MMP3?4;M?2P@]IQ_KIN,18K>6%#2M6`.YDA9;A974Q59J3)$2IXI5CBL[?4DI MJ``)Y>]@J.LI[2<4%)OK7>24-)[JPUE0-/<8F1)_NOK#Q&C1..Y\<&D:X-G6 MQM;>;^EK7.,7LHW7LX]TM^7O\/#W,:=G0Z]6T&^Q%U``#K'O>QK:(!A>HT,97IHPJQ^4!HK8 M'^7.;6M2$$H#K&[A]),=7^1A% M&OPDA,"+0O%&AXRL&#U*T!Y,7`XN52F@9WJ7N';!>2M4OH>00N2T9))*&3/$ M_$EG=":QY9)5#"/7BE.REG5/QW*X2N(#A#Q)7OMX%XIDPVEN+R\T[6="H.4; M&8BPI6'@!P\\B:#>!-E>_53"ZOF8:%)=?04(OCA#]E`5#DZ?YY]IU9KPRY34^8ASB<_B;\)K/7RFO@V^ MV_$JM:6\LI[:V#KZ+156@`XMBCV!R=5#2/@U]O-D@0.BLK+?*%R29@\T6L]P MAE"'B?N+3&+LD98,^=$>.+.EG0\I46YQB0T`?=D]VWXKJK$Q!*:('_6PX;SD M)/0X[BGM/OC1]=GECC3;S8@AUXOLYF8*[2RAQ^G!GDY5@WP:_BE-&Z;CIVO\ M>4^/`SNG@JZP[@%?JUV&RYPJLP^G`P:EA3K%=^%@I[^D*SA!+ZK@'>;_5XX! M"]IV7]"VRH+O&/?53&_U.B%6L+;OW3, M?4ECC5\RUHKV0NH%1\,/-:W,M;=CBM]::]`5L!>^+Z9VA9/,KS0J/#>_+ M9SB*;BVU3/SHX-#R+_B&]D/Y^EKY0J-RI>)I-W:/]M7;HOQHAU/ULKWEZXU6 M\ZBU#S)\4/[%N&Q>.D!2ODD,J*8$SRM81GMXV;VZ^7[YP_*+7DGHFWP;A_*( MI38*Y9\;N]L'%(#LE:^?%?H^E'_UIGQ&KBWT.GC%+_//05,JFZ@D"C"H+0:!TU M6X<58?#!&*`^YC5[O#Q\8_>P?.E:<`2EN&U7'^6B:3>-8XO=?_(#*P3G^J9] M3=_.T)^S8QHP_UF692]+PWOMFG.T/;+P$P3-M_,!A79=A"K$/?&U(*2OEZB6 MK>9!JT)":^N:.WM<7@3BEC&C._R=QM3E<\OE9\6"NP='U;A MP7[Y:J;WEBT,^`+?*.LP<0R5VQ@:*S0L#U>^65N2WKQR\U=\#&CY2^H:5RS? M=&(L5W%6L6<7:B?CFQ\RXV)/&5G5VL6^"PTDM$IBK;2;0GG"5SI$@#VEK,#Z MQ9H17C*L!5LG6`A.1[KS%;C+#$WU??B(2@Y*45'B\9#">Y6V_.&-J\RETF0R MMV9PGZ&G7*/EK3*SRG5/NX`F93)DS%&S;Z]0UFE_"GSL\MB-W>;NKM*\%0GD M%U4S;M5(Q.X.ROJP8B!?F&=%-=N608??*'JL.F,^2I'BS0>^$N:[/W>6OC24 M\$FFX]+GN8J$>\%%=E%05A/X][_^+Y+<$WWHZ<67ZU["\WXIA3W_*M".64ZI M&J\9R$C;HUN/-7&:S:FL*E?,YH:9CN]0*\B3<*JD>F/CL$GSO66O,6-;_K'! M6=VMJF/T3F>L90W+]Z<_K-C2=\>7?^1+;^^ZQ8=-\$[SV.ZR7B!VCH-T`?7I M^/@6O?@BM7"*+]=JQ#"A[FFDF36CR\WCS:@1`U1`<+"&)[44Q%B2-1X(<2!8 MXEZ<:K`-'7;D>T2+20!QE!>,^%@7D*J9=7Z_%2'L%:7ZCZ/=W8AOL@V%(*#S M<]D1:\:SO4WAH/N5[56,1]9K2L'@$^GK];3CG]"7Q40K+0V_W6RYSYB%N:G8 MP;@C)N;G7MX#X?N,(4TS9NO^LVMW@3KV*A'@X7'ZD6A\3P&AMS]]D_:<8 MW+T_K`'Z?)UMJY_RJ92+J5L:VY&Z41H;&?UOH0+;&DA1U##1YOP@Q`R M=B>.6GMN40!PZM?C7#;U7NTO].%%=*HB"VXE">T[^OO:*U%U;9".`J'%Q M_N[J9EV+W]G<;7T!=^OO/()@1LLD5-"#?1G#,@G*XQ>? MB>SRANQD5UJ^%@[GL&;$AZ*.N@-?V@610FLNG1W4)1TRHM=>\?R@\7+N->E) M2:A`E;D0,.M18CLLNI0'1QWHDN>`=!<\2X']G=0<3L0CY.28'RU]QFBJ#S#F M*"`))C!T-72\RP51*S(/Q>_[N#Q$VOP0Z74&)4.GC3+A]&O=#)AE3D*]5!&N M2@]B2//GV#160>S\"@M,[Z;T^IDHG;=V<'34/-K?7<:;J)50/ADR?^$89@UU M+4B$D]:V4;P$:ORQ@UW<-U[0WT=;.WF=\XN.YCC8VI7J:<>E(ZA,M,9/XF7' M6*8;BE/-#N*'[?^)>V^-%9.S/7W0P`+[6T!&@9U(@IBD6KBYAOT:H5'C&?`K/J&/K5XV4DVWY%W0T M4"M"J8GQK1(I9IY<69*OLAV,J"U$!TZI)<_=XR^[B@NSJ]/IV&)31L1(^]*F M?CR/T8M"LL*N[VRG>`3?56V3'6:EG4'(! M;$+,Q"T+)6HO=MIWB>NFP@>&?$U([A;.B*5(SNUI*NA@:9RS_X[NGMV M*Z-4/3\MDN2"SINZ.12]1NMJ MT#4;E)XN6PAA:C$X/7:DE+=Z,*\(/UU;L>^7;^<%4"IS,0)4$XK#YU\%]Z'\ MC#B[?.U[E6#Z;&?9A:V@2:MNKL"QJVZNY*Q6W5R!P5;=7(&0C^W$=GEIE=NN M)&Y1(P`YZY$OLB#[2`USF6JK[UX1_;LD0"-`-[RF38[M0[O#:]HE2&#^E7]- MR`J4OI.K3_.\,OMFZ,(%P"U53*&$"XS$+8L?]1]]O>/_60SV9OS,M[8H`[(J ML?)V-'!'JYG3U-34/Y3^[,E;&73OH'FX7>'4!B?4]P\K_-,XV&MN'^R6!TES M)J:B\KY^^4[2:H=5J,EQ@*EH5RB7S#Q&G8D[JS_:JB3D&GPI8;\T>V.#/,H= M]CT]2&'?9Z&=@3.RO_(76W+P%F`-07:IU^T.GG`.Q0!6"5_+X&`.!?:J4/$% M8C"O.\03R[M+RQJIV)OSX9VTJB9_N%]&V?F!;TI&GCVO]579T*BX1]( MBO=JT4[1N..!T@1>*8/_P.G]^)^5B7T.JL@WP!4*X)(K2_61/'8W/;(="K(6 M$UPV2P)/YAP'68V=PEL6,]9QB\)+.6@C2JJ(,#FS0*4GGBC^D-.8KNN'CO7* M'0&YP4'@-,&`TN\>)V0JP4MEJF$MON75"_@<#MNQ<\AFM#F,U'>5`'3W@%3H MKCD]#GJW,^K!-LA!SIW\DY^19_[Q/]E]:9#SXW_6J(+/P?`6.X4FP'1?JLT[ MG;L#5UTK>5A>FY+_:&C9M%PM!+/B*L-+G'ELW`(SWPWFZU95*8\@]XF=QMHA M>9*C;4$>AQC`?1>BK+6VMIO[NUMD#ZQ;B\&&XVAG[XMFM+OSA84:>_R_![`* M-=W`C]1I6C,C/P6U&"0(],7H0S"+4,CYC#M*>>3/ZNK2A>=SR[2H7_F@U[M) M%/*YTH@R!?W7GLJ7&P<')%TKGF]'Q>:5>SE0N;=7\65/?2N-RNULP]YNQ9_0 M&BGVU1GZW%*K.^J.U/L/ZTH92$_8.59Q@*(F.PY*1*)HR7U.A;NLEO7.?]H* MU:ON'*J)Y)D`8._L?B$EZ=]>V5H%6B[NF55*$T[":PN3J4R^3`HC9W@A4Q'W MZ.``O!:F^N(8C7W@T`KQ.SHE6W/^O/'+7*O%7[7[E"7:V\.51]B$[@^$`5A(< MK,-VVO##GR(TUZZ!9D2_^(=YI=J(7WW134VI1'FJ7M#<_O*8R]58QZY\2YCR M8XY%C"E>_]"U+PE+3:AV=XRP3,O#BWNV:_9RI]DZ:)5O#A*=T;)X!^[>//KA M%/`\[?X/%PJ,6UN_&R#`&4TX069,N\*GB!LK4SV=E? M.I.CU\_$XV]'^WNV+.>1R?H$-]$62MA@WZ'*.5;*P7(>HO`U#=PG>6)TXH6\ MAIO%EDL,WS)QG*^EXX>ZOC0A?P-GX)B3+'7?H.%C80J1I!>MQ4KX[#-('*=5 M\-\FF)^L'T*+O(GJ=K9$*0E<5JPL9-=9!`\M9<(=0M*=J[`0X>5XX[BN$V'TY37\5N4*)!_%$ M8\US]POLV]HQL5P[V'/"D+M=?M,RMVG=*8.0H/>%.Q8].'N&!O*?C#8>E_)1 M?T42)P8]RJ"OX/64*W,E&$9&>XNZ7#MQ<)\`Z;MC@\1VJG\4`CLBH9C9L7UT6[0<>!?KQ2+_9;# M5GHO-PWSI`>"U53S909@.+J#HTCL0))0;?W#.>&L5HJ7CU^HP;?*-9C9V%(@ M.JM(/8JZ6W+L8<$I3O358G07?\(3,PQ9N3@U*1%^8D=TQ'++7Y*Y6E8&$-YI M2(OK^$#T:X<8X)*ZOFB:F7[Q7!S4;>CYU$.#VG)=SS0?PF3@%.`IF,U20\XJ M714,?Z3FUUG.N>OSB<82Y^12`\3_^D*-;J=89&8;FWT=)*#L!N_5--I21RE7 MC+K#)^S]3E9N)DWHS@#%\>LO6[H]7NL)B24K$^T\9)+*N=D0DPBGFF M=*SDRFIXW0NFE-6R+D\3&,9&4HM8\W>IL$CSPJK>FJHM,90S=$2IV@K]NVR= M_&YE?=07S'I9ADC0GP<(KREX_W\"3YGU!XY4FM.,6>B+M\XWR?\,!WZGLX=W M[(I:Z+C/R+AL6WBW\;QUOL:*YC;3BX0DJ-(N35*5-4$S+>3B0^^IZ("RE1/Y MSH4HE'`PK#(>E&07K?+8'K$&S/YN#M+I:$"NG0*/*\H8I,E*NKJ3?*+V3>S( M?Y!O]1(R_BE/G1PJ7:334].B_&*DFA2/_FAN/@1WJE5W>$8,&LQOO`I&;._D M\62I,-L".X)?V>^.NH*H^1Z\\3NK5Y\_.PV=R63^'G_+BI1%IWMU\L=OKBY. MVS<=.SK6_;XR8.X6V@4ON\L:EERY$[[7?.*Q$BJ<<_AQ07=\ODO(=\]D4SG, MFB['F4\I3.DCW1/92B(_I)@4XZNB)8!BO2!JZ$YZ.=O-ND*G9EHITS)PH6Y? M7K7EQ'NE/N#'%N&^NIDK.>BL"RTLA^-GZDV=X#H4+APY=9I#>Q$,B[4/8PD. MQ\87Q?L+W[J>*1RU7*ZF[27'VB_#!=85R"B(8T^#9EKW92UCK.S!%U3X6BFG M.?J*(YBWZUKFN8HJ+;N(['EB&9G3.8F0Z@%=>,4A:5P&^GEO4FLW//&AJR8K MO&TS^E8=*>!O7XGDNKI)Y^>*V'SJ5#0)W?R,W@4&X%<[#FN+$PG?C6F$HEF? M$@;U9%2EFZU,S;*Q1@CU-D*#71&]"MQ5`4I(.V0;4M@`7_-@49MS_W0JQC(\ MCC-2_A3+N0C&UNSE,@B[5B/9-[=0?`W'LB?.&MM>26NZ+C[P22@?];/BAB`L M:$$5%`:>"CQ6,QD?$MK6PAHJI>"E%+:ZL";MP>@^7QH8QRTA%2(_B/R9Z"RY MG2Y4.XPR1F8=4N[]+HMAQSHK`D&HY7!V`<_%^T@KYIGSN_+I]S!$W4CZT32WPWDKEP\W_5#[&T#A5_U0^:%_T M65[Y6+H'O>Y2/3N^3OR7J1_/="^K!G_CSU0-93$ZQF/\I`X/F8R:[O/B3\46 MAA_5;DV$I?-N"3HMN,:O6H8:WW"0<_DRE5I#@& M^I1!^?;C>US#>RDL0@$J@M3N[EL5'9=O)&N+]^6[`\PK5=\5-/#KJ4J6RJ-T MK;+2A0OEWSBG@FM3N6KP4?EJ6%3E!8V6003E^U^8?;6(P`X_E$>'^2NK#K]6B8$2E7-%3N5^@/;"J,]`^%C.+4R'6:98Z7H6C8!3P38._ MA[@XAB(R,K*JE)#\OCPF:=_P#VFWB&KY^'=GA")2!A$M%\.AT6 M4'RWM]IM,D?)@7=S]UQ8-TY->:68A4OYM37WB+PFWF M5MD!9S(F"$<*LQNO.X1`[AA=D-7+9S1_<.)'1%[J([EZJEY63.&D4T6&G07[ M.=-R%`LR2'"()4KCO3H*+7L)1D7GIZP!U%IK\X!\#]]..=B$#T`0'"^XEVT[ MJ+BXM<'Q]@`R.[H+ZWW"OVM:#2,C*U!^[C?8#TX%'8G;!Y MZ2$[$:_TN9D\SL]RW`%"RBEL";9"MRO%(HBB.&V$'JRV2!>.98<;C&G"E*ID MJ$S(S,W:]N:V'=[9W-YQ5-C>/-S/J%">SG&]X('KF5DJ8%K&7S69=.S9$*\* MR&9,S#G:4-6(#`P+H$9"@=<&I!!#$^*Z:2SVV%IP. MLMCX4B=3M_E\`KD`H;<:-*M8#[HRY4/R&Z&+:J6PXX8O:VW<\4U%B$5PK>,= MVHFRQ_=%^<(ID0(+[$?/@V38+__:#B4KG\;PD'UB<>DM,C7E'_<=IE&YO.ES MN.4?NF*9^I58/IC`%3#)-WSK"J59@'O8U#V."\@WQYV M!D+8R2^EI?C="@\P=BF5W:$`,G#FP]+4+K1E=L*/6T>U))B6'8X'YZM^"_7' MOX7"M@S[%4;&&CJF2&^L8*,V?@(-Z:C]KO4E;QTAE@:)U"!JUK01RL1IP_KR MV%%#I,V];-W4#XDG/CQC3_8#(R`^]%DZ+_@F]<.^'1"SL`J"9B> MBDR*_^7O7-=BBM)[OBKG'!H;+0!LKA(8NRP(EJ`M*RY:`#M MQ,2$/P#=DMH##:;I8;1/L\^R3^;?/[.J3O6I MT^Q:D;D%<)OO#!\<4(+&D>E.XT7T4A/4^,SKI/$(FJ]''4FP*V(+)9Y&8^*$ MJG\^O;S^]^KD9@*=;UT],?]36*ZG:LB%:>V$B<,'2X@T!+4JP.\Q7A!N0Z1A M2HEK=CI'6,C_H)CNVB[)@-H2;A'`VC7>;^H(6+H8=FM,`OW33]&:(`(D2EQ- MZ,X!?EV_F)NUYX-'80Q)@$;6CKA:ZJ7FN&_MI\=(%7B#Q"7!*T,(+DPJ&_D7 MXL\!\[:\WJP6K`W..K`Y[LFI5*KKD5`U"4S#E^>>QO] M+P*T3CRYA,TIKI)!;NEU1[*KKL*Q>K-ZR_3J3@%XP1.8$R>[88.F'!LQ1H=8 M&6MXQ/ZV(5-K#ZG];?/-XP(9WUWSD\Y2?.L>RT#@;-*XBMT/L@LPLG(9G$B# MFSA2EVT/C,-$GD3@4U?B0@MOL6I+BI-HPD5X0DIAQ.-)[24X"9.(;WX\O8"! M.E,+[J#$6H@J,W;*SU.["=`P3U'KR9Q*Y=\J3JW0@VCTGP'2K>#HH"N83/]" M(GIDVXI"X\$-]CDO(R)/*!,IEL7*Q!I;`SIQ!A-D=1E:C??W5QX.R(T#B8'S M1M$8FY`+_3HUI.-ST[[Q[8K%!+"%8:7;S99V@NCGU"%A*MRAE2"!M;M29V[= M[##:G39G9&M^EV>BXZG=VK(62L(KKW>-,EN<[YJFWS@<>8!HWWS17\Y1TXDO M8!TMAFGJ:N[?_(GBCAQDSFWDHV5CM%L*E>`2GAJV\'5T.[$[PQJ3.03$NG%X M@'D)*+SJSG.G')*V`?V#(+0::6_O4('MNFQG-EE4L5P++>BWIR<4(M0\[FXJ M.42.K[%H2>+$K-%YBG3*P&I!!%]D$]:R[RU>WO&J+[P\L MN80W`-!ZY0\-JK.+0+BC?[T-8-"T"!DN(4+3*PB+#4W!U!%6AV MS->6S(2:-304\`=3KBG-55L8KJ$%85%`]$7FE)ZX2JL'4JYLJ-%1< M#+CU-2[&^&Q]C'A.NZ_>Y(-T!_`;&PJ1Z/)1M!!I&Y9'%$\/4D*3(#_KY)^% MXYJ@B>+P,9-$?J?[VK3[0JJ/]Q4`]'T$T+>^,"-LA46XM7.!^\JY$H"=@RNA M'2'08BZ)7,F>BUEOP8HG]#B,Z>^98"/2Q'L/`-UJWI7%RW2D5N4*"(C-/I@ M>"D1#Y!-=&]-/5#$B^R>K"C(@P0%,_Z"-=0"(;PB)F`+3RW]V!4Q,.?J^AI3 MTF2$HHT]Y6SR2<&-'M*E)L0(#K\2\:"("Q-V&8'5&04K-/W0CGC.;IC4S0[: MCKD#7&L96S2[I6J;NL,&/F),A6ZT@]K$@,R??)AZ90RG/;L),6-B"N;Y4%)2 M+MZC.+-Y"<,F8=]A4^]\?2@Q<%%32Q3-%<<5CCL881U!>\EVKS)*!//#K"RF MM*\'.^M/9K+-:/"!JG+(W/RF"E:*3@G$#7%E211HHH0S"D[2O?LHM.C$WFYL M;WA*>4W3-)LBY'RC9L3[;AWN[^^>[.\J]V]W9/ M=G>.IY<5-WHIQG/VZ>+T#EL9*!6L?*:#N,$B`$7ZGK.@6D=74X\AUJ?+T?`] M53Y43LP*38-;.GH_Q6\&QGE)CVSU';>7GOAMQ=.H$8I`OXW+Z4YV3_Y/Z3A) MEC7!QQK$C8G6Q_8&L/Q9CA@$/QE9 M[H$P'4CQ,^6[8UH$4T79D3H%/XH9((GSOQJBL@5H8(2W_CL5D^.4&%F$Y>:J MP#BN*$O';5G%AY=G$]JO&RV'FP'_KJ7626Y-]8W"FV<6$.Q-9X-@J.(/[=>, M06(J1#OB1H2V;4'*'_Q">-?\_0IK+^%<^L#-)G*2]M^?`CH9\1VTXD7U1.)7 M+=7A-IZ'6*SLY1OF=4*^:.[9R^7J#>&T<-!4P3A;]W?*]4-2RLOO(2&9M`+N M>AE-Q8$'AN/W:CB9@QAR!WI%C`:Y-LC]O`1V0S&?G$LQ2K1%%';`_%?GA#_) M9AN17RC4O-1$..B]_,R*FCAAD!2EQ">$?OI(;KJK42M_=?&PV+2T(^U*;Z3S M%/:$R1*OA#I0B5:2N4SPL>RIS@VO$+E2^NQDI- ME7L'D9167)#&($1T4POU$U79&\YC^+N6A. M3L$7@`C`L0)V^-;B10;CVO3\IK(*JC%K3]7FE`SIJ/:P\#3['&X\NZH_!T7'F0F?UY" MTAN#'87]@8I,**,`MP@!JK'D:87VBDW+YYY]9,SS3,]?*_\V!FU$(7&.._;T M4IPM()>K1*K?93(3Z0\1/-/` M\@L`BZXN\$$;B&+:7WK!IT,??`\)R&R5Q!=$U\E@B#$ M.!SI]9`U*NE+-5_$EST$(5-Z*ACK):=#?<4)^`O92:H$`1`.C,V@%#J',E^G M%32URZCG32^P:)RF&)*^G>\A]/@+5Y#W\>"#/. MJMV#UX='^[V3W<.#Z2V8+`FD]MIOD5IU=C-L9O2O6><42KG#D]!,_N.? MB@*O1M09=.5$]$9YAI!-0,N>#NIZ:02(/5=)$?KE-W='2DYRLDT3\D4S-]%: M(BR;*;2:L5L-Y*>/XSMFB00,.K^ZUI:%WE(BCJ(<^=;E[7)6:M(7UP\TEEX7N*F_0G*:ZDHPVAB>AD* M*1$&P?=G"FS$3DU:8NA:JU!R"%<&\V%/O$R!7.NC7Y[^-P$_J"OA10K[,N". MJZ7-]>^6*_YAP-E\^IUQ48',@V('=OY"X#'+V+J-P41&L#5:=E::*8!$TUB" M<+\;_&^#H4)W;5H4XH6@'XJHI_.`=1\1.P"+I>$&JNZ<&,R*Z1G]:E5G7-WP M,ZX^_RZ"PH,2IP&B1^3SCH\$&\^2WWHZB=.#BPDNZZP"=I9-L1DQA-\L.`X8 MQP<]*PP)AZ\C[ZQ6;!%BU_,GZH_^1.WF<%V&G9\WW@!CHOL_[I)<*>G!!+=C MD!J1,2AH!;OY8J:UK8$4PV,K<^(_0''O+A53]&LSC[3:G\ MG#_!PKK=B-WDS>^L?(0)T>T8FB-G6$UIOUB=7.PS!+4./9S&F-G4[.P;$\)" MN#H'WM4!B4=79PA*U9^>T)/YEOW!Z*]@^/> ME@2;-BO9-N6\MXF00+KB-;FZ5*>5:FGK(UPULK+2%?98@C1YR])":=UC8JO* M/VC$'C7'$>MXN,4&JB5)=@-9@H]O%3XRSEG`X820QEMG&#C'"9U&'#1#+@J% M!T[!NX3(EY>3K0%&N?CR54L%PYBJEGJ_%>3!;.'U\`9GH4K*H/VT[N+;LZ[/ M?&X1V]\1:UJK>GXMV&R;C"0(!0Z3W<\"1KR' MXT4KF7R-E5L0\FLLBS;P#8^\M7]2K/XU3OW8A';8]9]6;JL=R82H#K(0\:?] MP06%L;';ZU6`U2O@2YJFVDG\4:\)AG>L##(>8NF\Q@3"N&C85!(6MLMUB@EB MQ23X_^G&FJUE)LUG"#ZLD)X&$S[2BQ&2RB1J/%SMP#&`JF\F/AX]+%3*5XQY M*F96"RVY,(IXL%SV@-GYHXO'`V."\Z,?W:&\H"O1*IN\%)SIT8OE=04P/<)P M2\BTE$S/WPH65BQL"7`9W+[(F=V3T2:#Y6%OEGVNLB;:F^LATA63;5PP4V,B M3$V*!>(:\CWGEYTI58]6-Y=?Q(9.U(:D_VAGWJ76E>P[K2>V*K,[H39.]Z*QU.?:5-Q[KB:Y;6,JY]/;U[TA#8S%!N%MG3:N/IZM(OC]&T%=P*I<@/ M;)'I\@@CGRG0I,:6[$[BOG"FV'1:UKL. M>2'J^CR\$":^@E!XHNTR@K"\T>"7_6.G8\WY1/JG?FS#6SD.U; M&"$8F0'.RH^I".1SNOC2)Q+FLQZZJ]%=<15B-#]-@NL7L<*>'=Z)3VJGH- M?L`M!>=%@5!\J#<"W2:]C".$3YICVT9D%F8E6ISCPI$;IIN<[YMD%AF_.^B] MV]Z5"O;#.W2PG:.]GZK7NP>]@ZW=WEZUW3OI-;=\(EQ!D[JZTT68R45E_N"5 M/#."LYQS#H5A;2O_`O:TPK!S0O#*H-I'L_L(>Y2%KKG7%(SXM[^N%W5!HC6/ MWXK:(Z^!.WXCZ'BC6':Z+B/.)OFMO&Q[<_VE#<2`Y\U>(BI:O47F\5NM.)T77CL'B)VBT02_R\V61]@O?B-"B=J<5B6TEY[RM]?E-M:Q7WZ MHNR(`N1B#%2+ MI!?K7\*V6WPIF\^>K:P^77GV=&6U325=,%[BP6I/`1;'S:^M?`5)P*"&W;_Z M,"'727$0O*U86_"L#,!9/ MO*0_YN%(80OFN8[9&QX0Y3(/.2$17\/V+'9OH&@XTS`P(M[)FL3_:Y_NMY1# M2(>\HT6C'<3J2??"-]ZO;%RYYY25.\GV.=IJ2F1I745=X>%UT.[GDTA$;0`OTZRJ,_( M:2@A+HW-Z)!X3J5Y]C$8:NM.IOBB$1<)"56@!QZC>EO(-#SC%F+CP9(&G%"! M%TU*J6.64\9S!Y\;>TH@#"]V[AW+<6JYL@8T:867^*$2S/"--2\[1L<9U^"^ M_3;K/76@6Z\MZ&C6U>3K6'2J78A;0T>8CVGV6:G"!0_>,\_\<8P*S,W1G,V! M4CVOVNO.5T'Q-593DF17_K-5D3E6SBN2(POF/G&=8.+.O[?1^;<4_ZWHTS4H M_K+(M"=RR);-OXY#HVYM3:6%9[^PS;=ZRVI.Z9]6!Q9ZY=+!D>./6`I63M`E M#0UIB/W!_VN7D*)QB$E=FF-+[0O8I+Z&='QTDC1K_0CAX(ATM?.5Y$CLSE_MMU6 M,W3/MSAZ5':8_"L9MGVN0VCHAL0%V`W^W#E.'&>I/=CLR"TBGD;:!,#;U(Y# MNLXME,`6\-M?6\3(/$ORKL$Z;F%14F!@P\R`M.(S-)>+<%/#:0.VON:/-[PX M]='G6?8T.J'-:2O_9W72UB)QK M(;^8I;CKNJ'C]/Y-)LN]H9)@U)_Q:Q@5__;7;0^3$CO_.^C3]SOZ$+Y.$XP' MB[O?R.D4I+)H<8R][0B%Q2AI]2T&UA?C'WWZ?H\^??^?T?T;.9=,F5FH3U_G MHU/+D;(,8_#]%X5]6#L^TX6")<+Z#TR_";?^*6 M26(J3!JO%0`AA3$D5`5G0*B6I80>-.18ZL[+H+660'.=4U"YI(?'17&>!4)C MN\^9@1`#,+*;8G.S0-L4'U8LGXU,`@VW&471Y+>9:[9DD9W#:#O78>XWPIKD M-4.JS9#T7DUIV^**6G2:&HWFG<,$;0KA/*Z6WAUO5X]*52N[G2"3RO(;E;4X M?H8=#4NK0K51%R!2^S?S^DS;#H.I9189]_H*5U%3KP\Q[K2)):\#(5,!\(IX M6NR3&,_-LI/ET'BZ0D%'%J/Y03401R;19UX^=P@U%WLU&5Z0VO&AZ@5K1/7S MOD6X%=ZR6G5H$?SIBC$>O)^H$TY9BH]BF^8+[EQ[]U+6LF"3ZEH?AVSK+/6^ M7*41ETDJS7+E.M7))X(Q.H\F]QM>M)MZ7.>GZ^V;F-+-3R2 M41?J@[A/*C7\PRY26.5W8[^)I8C?AM7G,@D8M]:_2+L+MH'F#6;#TE28S+#3 M84`PY7[8K=QW#.Y_@70FPV:&`\='IG7RS!(\216VPD*$$@UWSCCK&_WAU\\O*<+0"Y9VK MHYB@N=@,6#ZP9"/V?[A2_.KB$\P8$9CTM*'F(9#:'2GBD\B/EO=V627_QG,! MC&GV@-*_N3_=F+&,UV?$^/9E9]#%`TD+\PY]M>:YA]F[PZ(WYR3.?FI)8MXS M@1OR_)G`B6$Z"B)SKIHNJ1YIO7F;PZ.5:H:MZ[ZKS7`_X3-$$&>.)A6[!S>S MM-N_.N:A*1Q6#Z*#PYM;P*]C7#`SRBIN&0C-DW<,,].4&:1Q-8Y+!U_',.`] MN9Q<0/2HVJ08W`[_DC0`P\+%IS3;KC'J!8]P+^27"6^^/2TD\.9KWRKZOHMW:UR(+UNX/VYO*'(AY0#4@5K)V2^I_^?58FB@_`SZ MH`DX[_I7\\[K+;;*2<9RV$`4)_M!L"QDUMFK9G+H@AN0GR`NWQRZ1S\6M$9U M_Q1DIQ,GDY6W4SA*PJ0&A^0NB:'=DM>A%0!0DRB*XBI$1"/O7ZAYF<#<+K-S M9WN:MTLNZYF7#`G(4SN"L$09==3L5IRQ'Q25B+%=I5//HA`=77KN`Y-M3(H^ M(6!\F44)>IQ2"#+1%/)9%7D+B;W.-I[?QSK3--%ROH*[[WK80ILM7UIF2!-+ M$@=>2L@KBCIMFN@[%YI_@@77-[\"YU2:Q#R[YOUEUS;J'$\B>;+RR!,*-4N, M:A[:%[VY>@\W@;DP!6F^Q0O2?68;;X_6/%MN`[20.YXCY@ZW'"%SB]R'-/9" M[1KVFQXYB[.&%@GQE#A7.X M6PFXYUY+-3V@!.-HY^K^>DV8OJOO-4H+!Z" MB1L5"1X8'-^=7FN4L#"A*.59G2_#(@K7VD%Q)XE$`T^'[ZN3T MM^9@>POA+3PTQ`2HK[`5F5@.R:A6.+PYYE2IF31!#-6.Y>P?]H?!]WVR'9V= MH/@;(D"NEVXN[JA;/#=L%\8,RV:=1J473A5"SJZRN7J+47'F5VX^HJ8 M"%E`7@]_XZ;CG%.?Z*J:L*KOU+S"3OD]RTDK/T5%J*EI&712`S2[`K'_/[,! M,ZT92KRB%DK!/MA_'\'%=F>PY>6D'$'?L6AI;_?5X=%CS;7^9&/UN^8&]@-= M=C_$#8)?5CZ>B\3;G'UJQ\W)"X:'"6L_LC\E>K'0L(,?"2]T@5 ML8#]T#C!Z\O5*X4L\W'\,\;5,VKCFG)2AD<^:)'F3F/9!ME?X:^RIA,G0I3] MU!.]5G"'`W$Q]FEWUX5Y[X?O;S^M6'6'FD2:$H"IDX4H34 MTX_T/,!$Q16K'\]W%L"C]M.72CC6E@T'\,I/QB`!-K<""XPC'!+"YQRA:\,G MS/4HMAOE51QHSI#Q*OR;AJ/AQYS=Z(YE0 M$OQTUR['0-RR)'%PV'A^0-$^D72_6$I,QLV23-84$>0@!" MML)POE[<(0=):\2Y36BOT=NSA^91,O_.;=SIM[_?[ MADTJT'7!81)0@X:S^."XHP>/E+"T\):GH-2+=72D1J#R=+8Y#GOU%><>5;?Q M[,+&;#?-Z\R6;/[$8^M=GF>09UN82D!BN'MSQM`;KGKN*9F%LC63*.*+VLW- M9S+S[$4M^SS;6[SZ?;NSEBS()Q7I3:V>W'S:PLV;_;A:*#'39@RGO4-33VAP# MO2YP8]FV>IH,D#LF>6"C:I-#`+`]KW"Z%S"#M%T2."F9DA^X0-#UVCC M(*3!_BCTP=)!Z,XP(FE\?0NG!#>1;@P'BN-1)FC M0T%=M8B(*P9?@$K44T"3=[@YW8:+A]7W'2P]+A=X@%D>/G^YYBYB$!6;S%$[ MP.DA8!*\[R\#?[_B,_Z?][?-W5(BTZ@]JU)+38G6Q)FV3UL]WCU,.(Z);FYN MKAD+7_90!?/POJT)S+%1G+0^53&+A5V&&@9N!.^BKO31OJHGUD509WDT<"^* M"O&$RDI]1+W7W!K2PY'MUP8,2Y6"QL=QVY;CBVEX]KWN[#SEAK_,?=J%K(I6]#Z<^^%9"2M:11 MX[3S,"0P(IGP7BP\TLR:U]&" M*K(D>%",E4LI7:]QF_H9,W.](.FP,?W.R^74/X5BZ/G,Q5Z:)6?J`C8/<1*'XO5Q/V-Y!9%(D,(66"B*3R$I-U^%J124&^KI MI#6[)L]AB9K])J389\5(FB,_N[`,"1RD`'S!LC)S3UA(9O$N>E-(0, M7F0V,_.9)YX,XM.@`\\2%'9B-KWPU!66[AHW\NN>*VZ+NIL7X$R=@E\\!-O# M"^+1^_=]_*_C\>W+_Q4```#__P,`4$L#!!0`!@`(````(0"5"[5*C0(``*\& M```8````>&PO=V]R:W-H965T&ULE)5+C]HP%(7WE?H?+.\G MSH.$APBC@=&T([525?6Q-HE#+.(XLLTP_/M>V\`0F%+*`F)R?/S=O\J M&O3"E.:RS7$4A!BQMI`E;UR8RWM5'390-VOT8`6!V\WN+`7O%!2R\H$8$<\Z&7-8S(FX#2;EAPJL+$C MQ:HRIO$>Y,$Z/?W MXR`>I5&:_=N%>")7X",U=#95)EET92\0'+%7C*_E,1]Q>(=Q?@H(8!U9(.*3]ELZ@GT[CJCG00ZC-X8SPCF M7C)PZ=JZ%B=_]`#`Y13@^L)6G&.P>ELX.=;E\IM[R=`E-PK=IZ]87%/TT`9] MM-NRL9/.$`=]@+F7C!UB&)QU=_&WNSTTV-*WIV;%9TCI&9*7^-22.(NBP:BO M6%Q3]-"R_T&SXC.TK+_PW$L\6IP,`*TO@$/)>AP$Z:G`@_DSQS^2'5VQKU2M M>*M1PRK81V$PA-J4/W'\P,C./8)+:>"D<)?S.;[Y]M(<@Z>JZ^OVM`[Q"H5! M=2K;;7W:K\-__KZ[2L*@'XK3MCBVIVH=OE9]^&WSZR\WSVWWT!^J:@B`X=2O MP\,PG*^CJ"\/55/TJ_9";7=LUQ0`?NWW4G[NJV(XO-<>(("2BIJA/H6*X M[B[A:'>[NJQNV_*QJ4Z#(NFJ8S&`_OY0G_LWMJ:\A*XINH?'\U79-F>@N*^/ M]?`ZDH9!4U[_V)_:KK@_PKQ?,"O*-^[QPXR^JY M`O=M^R"A/[;R$;P1OX-()T@$LB9M M,./+M4DP^!H&DS:*)MI1?J8@;'15SB>W'C@#`\OE`TOP.@0J,S#V!E80,3J6 M<(1\UW(;0`@41L(G"D<96Z),@CUE9*)5EBA(K-:2)2E"GFFY@TBE>H-PI$$E M7VZ:!'O2J"=-092TE/&8&TM&[;D-P`0)CDPQ.LK$$F42["ECGC(%4OB6)!@ M3YB8:%6=*8@21A$3WF+G]O>8$VP,=62E2V1)L"?+S%;)4A`EBS.1I-1#Y#8B M)B(6]`-I&+J*;9GL$12>?9&H\BU/I*EB)7)D7H?:O(3&@ODJ'0CAA,7"E(;C M(/8"_T*9*K2=D/-**QN9WV1B0A%EINI5];D0+!TW4>G*E-%\<0%B%>2V/'_L M3&.4BRP5=HYI=8J%C6%HI+NZ%K4&/.\-S$Q8KZ["*%T8*M",K&4Y`"JHV5NN MM$6]`<^;`S.5K:79V8\QXCCA7A;FFD?+1^!KC`W&%;BH0\CS%>P,F/S45YF7 M&IG&6!W=?N(.[C6!"^M^W@V8F9UVR0Y[.(Z)>+8[;01CG!"S=UR1B_H!GC<$ M9G:]%N<&/APLO$7.-8M>P!31U!2@*VY13\#SIL!,X6IQ=NH+80T\?I]KCL\W MY**6@.<]P<_23&/>*AHE,3/+I87974%0+K!!.)X1KRE\W@Q&M%?R?C/0&*OD M[2?NX%[4?S'X/.+]>6=$890U,>,I,;6BG'$022H(,=O%%;HN(9N*>S%.>FUF/MF0:H\3A.*4L,6-KYYQ&P`5+K*!QY2W*>/F[U\QM@%K]X:G[B#OY/QXLLC&)EGO-_E,HW1I4,$QE[0YI\A7)&+,I[,,][_ M'91IC%Y`A!BS'.>>^63:8P2>,4A.(3?(ET(0S'[ MZ,<<\0)?-G(&%?%%NLV#GWL:LI'Y[0![Q3&!`^J4$'HCV,$/$$:M\YRSS/+H M;X?(9>>-\2WWYP#W.X#&:#<)I=2+F]Q%X#3YZ,A(%W6($>V),S6DPD1CE+B4 M&ZD+M M7.RKGT6WKT]]<*QV4)9H%4-A=NJ^4'T8VO-X@7;?#G#/-_YY@'O="FZCT`K` MN[8=WC[(&\GIIGCS/P```/__`P!02P,$%``&``@````A`/)(/+$=`P``KP@` M`!D```!X;"]W;W)K&ULG)9=;YLP%(;O)^T_6+XO M7PDDC4*J)JC;I$V:IGU<.V""5<#(=IKVW^\8%VJ<-JMV$X7CUZ^?7>UQ$@JTA:DYBU-\1.5^&;S\)*J6[E^S*O:$.DQSO:PDC)14,4/(J#+SM!2=%/:FH_"H+$;PAK ML7%8B?=X\+)D.=&"Q9S53 M3[TI1DV^^G)HN2#[&O)^#.\[5_[8/39ETP MR$"7'0E:IO@V7&5+[&_6?7U^,WJ2UG\D*W[Z)%CQE;44B@UMT@W84QQ!`NS0E4IGB5>O`AF($8P&A2Z@MLVL@`^\(S34 MT89^O0T#FQ9KML%U:P+@/<)&#L@KBNNI)#N7),M1,H&%OMFPNL(SV(&7H?4D MT%F,R6(Q^O?5V1K-?$QLYP8R*S!!@D;;2)=1M+C?NF.YDL5+J@;%:.#7TC@5 MVPV:H0^9%9C0P2MAT^F"S=]\V88NZTD.Y3)P"F8TR[#?H($73X=W9OBEGID5 MF``F_P.H)[F`S@NP-9H1,)@[A&;<(K0"$\+%.>$"LKG<:#W))73>C*W13!J] MG#F4@V9LM!684.K;T3I[+M-IL4OGU&=K-(DY@.)DYI+9XW$2S)PC"JX0O8:9 M'X?A_&6'&&YS09CSLZ'B0'>TKB7*^5$?_A&L.T;'>^DVTB^H$]_"?=6?[OXX M`/=%1P[T&Q$'UDI4TQ(L`T^W39@;QSPHWO6G]IXKN"GZOQ5\&%`X+V%+8U1R MKH8'6-@?/S4V?P$``/__`P!02P,$%``&``@````A`!351`WK`@``D0<``!D` M``!X;"]W;W)K&ULE%5=;YLP%'V?M/^`_%[,-TT4 M4C5!W2IMTC3MX]D!$ZP"1K;3M/]^UW9"@71=]Y($W^/C<\XU-ZN;I[9Q'JF0 MC'<9\ET/.;0K>,FZ?89^_KB[ND:.5*0K2<,[FJ%G*M'-^N.'U9&+!UE3JAQ@ MZ&2&:J7Z)<:RJ&E+I,M[VD&EXJ(E"A[%'LM>4%*:36V#`\]+<$M8ARS#4KR' M@U<5*VC.BT-+.V5)!&V(`OVR9KT\L[7%>^A:(AX._57!VQXH=JQAZMF0(J8&!:KTH&#G3LCJ!5 MAF[]99X@O%Z9?'XQ>I2CWXZL^?&38.47UE$(&]JD&[#C_$%#[TN]!)OQQ>X[ MTX!OPBEI10Z-^LZ/GRG;UPJZ'8,A[6M9/N=4%A`HT+A!K)D*WH``^'1:IF\& M!$*>S/>1E:K.4)BX<>J%/L"='97JCFE*Y!0'J7C[VX+\$Y4E"4XD$:@_U0,W MN([]./DW"[:*C,&<*+)>"7YTX-+`F;(G^@KZ2V`^.[,Z!J]_LPH>-'_B-5@N!TC;4DZ4[>QF&@PM)TO MY*.%B11H\#@WW>P07H:W\].;,@1^A[B2-!RLFD9M+"8QG8^")(Q?LC"`[1@0 M+F(OFIG*)X`@B?V7(R86X'T96WA;N@;/I4_+6F^:"YX=N+$8FW4:AMY4SW9<3CQ_5H8IJ4^PNWW/>RE; M\78$V@G14K&G6]HTTBGX08^W`%(:5H?)>QOHJSA;W\!$-O,+#P68B#W9TZ]$ M[%DGG8960.FY*20H[$RU#XKW9B[MN()9:'[6\-='82)X+H`KSM7Y`0[&PY_I M^@\```#__P,`4$L#!!0`!@`(````(0"]\*UK(`,``,$)```9````>&PO=V]R M:W-H965TG%#L=$G;AS1<'Q_./<=PL[Q]KBOGB0K)>).XH1>X M#FTRGK-FE[B_?]W?S%Q'*M+DI.(-3=P7*MW;U>=/RP,7C[*D5#G`T,C$+95J M%[XOLY+61'J\I0VL%%S41,&EV/FR%93DW::Z\J,@B/V:L,;5#`OQ'@Y>%"RC M*<_V-6V4)A&T(@KTRY*U\L169^^AJXEXW+T/E:Z'G/$/N18@LW^V>[[+H$? MPLEI0?:5^LD/7RG;E0KBGD!'V-@B?TFIS,!1H/&B"3)EO`(!\.G4#(\&.$*> MN_\'EJLR<4>Q-YD&HQ#@SI9*=<^0TG6RO52\_JM!X9%*DT1'DC&H/ZY'7C2; MA)/X.HNO%74-ID21U5+P@P.G!NXI6X)G,%P`,W8V`G^TCK[7_[4*/2+)';(D M+AQWV"XAGZ=5',^6_A-XFATQZW-,:"(V)P0:B+3IH."#WEXT6#$4_78,)VT( M1FTGUK4N`'#E8 MW&0+M+W2F%<%&[N0#@J&I-B4=%D*@J_%IC$#*78A'10,*=./2$&P[8H=F\;T ML&G$H4!$G@`+CA7IPN\0?_C M:_4/``#__P,`4$L#!!0`!@`(````(0`.;@HH`P,``*L(```9````>&PO=V]R M:W-H965T#"0A)`JIFM!NE39I MFO;Q[(`!JX"1[33MO]\U#B20=J4\0/`]/C[GWAN;]' MDE;*D`A:$`7Z95D#Q9X53+TTI,@JX]5#5G%!]@7X M?G9G)&ZYFY*AOHL!%Z[7F)EQB8-NN$@0.==DO0-$2W[BI:(+Q9 M-_GYP^A17ORV9,Z/7P1+OK&*0K*A3+H`>\X?-?0AT4,P&5_-OF\*\$-8"4W) MH5`_^?$K95FNH-IS,*1]K9*7B,H8$@HTMC?73#$O0`#62) MRD/D+9&UIU+=,TV%K/@@%2__FJ![HC"3O=/D*:@^Q3W;"^;NW(?%QK+,3BSP M;%GF=C"?S_Q@\2X+-GZ:]$1$D-;V;3+LE>U:@X\=;T>"A%;_C-58,IK72#^[^%XS>"/;D^A^1 MJ\%#N8N^HJW!M'+MV:`_=^_$HV$\\)>]JUNN9V/Q$1L:/+0Q[&6#@28X]_MB M:&4$!HX.O=8EC^^=MQ?CP1P.9OAW(C)62:N@*5`ZMMZ8A3EMS(OB=;/G[KF"TZ+YF<-' M`87=SK$!G'*NVA=8&'>?&9M_````__\#`%!+`P04``8`"````"$`++O=MT(* M``!J-@``&0```'AL+W=O2P@PP&)PS\^PZ2F(TM@+;;=I_?TB1DO;>2[7=]*%) M/BXRXM(FM:18=W_\V+X.OI?[PZ;:W0^CT60X*'?KZG&S>[X?_O5G_NEZ.#@< M5[O'U6NU*^^'/\O#\(^'?_[C[KW:?SV\E.5Q8$?8'>Z'+\?CV^UX?%B_E-O5 M852]E3O;\E3MMZNC_7'_/#Z\[+O:[(9^A-O])6-43T^; M=9E6ZV_;5X?JZ3BRPXW]@>*<;\8W M8SO2P]WCQL[`V3[8ET_WP\_1;3&;#\#P4KVK_>;Q7YM= M:=VVY\F=@2]5]=5)S:-#MO,8>N?U&?C/?O!8/JV^O1[_6[WKVYG MY"9V^_@S+0]KZZ@=9A37A[&N7NT!V/\'VXTK#>O(ZD?]]7WS>'RY'TX7H_G5 M9!I9^>!+>3CF&S?D<+#^=CA6V_][4>0.JATD#H/8KV&0:#ZZGL]GB^NKRT>9 MAE%FW2CQ*+Z>1_/%;QR+_7WUA.S7CT]H$0:Y:@>)/G`H=HW5AV*_-K;$HUD\ MO[K^'7-OPBB1JXW@OC7Z]*D9^]-<5TVZ.JX>[O;5^\`N17LB#V\KM["C6S=B M4R_^[+85]*L"LB?=C?+9#7,_M!.SM7&P5?_]81''=^/OME+70;-$3<052:-P MM>2&327(/+#_D]\SY:/DC:8914F@)3`2%`2,K5.M7=9H9E?_LFI<<6KG2G,D M2P_LX.WA"Y.2'L4-GU^*DL4UEV0]DGC&-3EJ9C=77*-08Y<>U^@^S8)K3)]& M_*ZB3]/-BYT%NS.PL^"*UFZJO]CDFK/A>MGMC)B_F(B#6'K-K#UCB02I!)D$ MN01*`BV!D:`@@,W<[H5LYJ?KSZGOA];8MMP6L:BFI=1Z(MHSW]X9FDN@)-`2&`D*`I@[M@28.ZXNIG93.^V2ZR5^F5@D].*4**G7$A@)"@*88?:ZQ@P[;913 M"Z,FW0JM=^REUUS51L7SB:R'A+4OH#UE[="<^6;BE01*`BV!D:`@@+ECK_;, MGCA?A5F6\FCDF@)-`2 M&`D*`IAC[BY"IHGS"]#UDHZ)%;;TFL8Q474);UW<=&[9[Z1A5+P`\S/?3`R3 M0$F@)3`2%`0PPVR88X:=7H!.+8T2N\G2:_P"C.SL16G19KM;B^:4-OW7 M(O]DH9WX!D0!T4`,D((2;IZ+L'(MG@])D4^^+#-,Q?ZT#")?9#?S^4*441($ MW7Q3(!F0'(@"HH$8(`4EW!.7,:DGIY=;Y",I]T*XNH*:L>/0KV0 M)`N#=)H=!W5N<@^>A&[S%K+5$[#%):*>6D!1;UTT&FAR( M`J*!&"`%)=P2%Q:E)8NS]QB1SYC,DIE8&,L@\M>D^8B%F,DDRCZ)RTX2.E"/ M2)8-'DF20R\%1`,Q0`I*N$WU/Q3?A+`BZU90#44`T M$`.DH(3Y%,N$>]JG6BZ2+3S0":)?/M%A[7V/=)B@[YE.$!"C@"@@&H@!4E#" MC9)I]HQ1/2E6/K19QE[432,!D@+)@.1`%!`-Q``I*.&3MPN#K:;+MI38=3OW MP#.(J`F^6T=2T&1`J,)"EH,B`Y$`5$`S%`"DKX MY/MRZOD8$ONT>#J&!!$U08;,%#09D!R(`J*!&"`%)=P$&40OW#-Z`BGN&5[D MPWHT$K?`22SS:@HD`Y(#44`T$`.DH(0[TI=.SS^AC7W,Y+NH6+K+(*)E`>D4 M-!F0'(@*I-LUQ,VB!H$X-@-C%I1PBWXON\:871>1S*Y!1*WQW3J2@B8#D@-1 M0#00`Z2@A$W>E0)<9<]O&W6W%,+(*\%34?-U!`-!`#I*"$^^*2X>]'L*D/ ME&SSF,D5$D34%]^M(REHLD#"P]?Z[V0\O>701P'10`P;U__YC8];T#[<))E3 M3Z>.*>93O/4-HIE_>LB/)`F-WH-//7]2Y8*^.]]V_*9R3*.<$:1#TIIZL;6S*)`>B@&@@!DA!"7?)!=+?C[\SGV/9 MI6@N_[P51*&4)NZC-R+F!04M)3]P1S+0Y$`4$`W$`"DHX:;(N'M97IEA[%U` MC@LBEE<@Q[6BIA!2(!F0'(@"HH$8(`4EW!<75#]0+*Z;W'?DE7GF1G(MY#AWK;>F-?LPW>;\7TFYH.<6 MB0M@@"RT=TLM!Z*`:"`&B'L7J'V@[(WRK_;XES2VY?ZY3,K7U\-@77USK^W$ M]AZPI>TK19]C]XEUP9?1;5J_ES-N&^R;/F^KY_+?J_WS9G<8O)9/=LC)R+V4 ML_?O"OD?CM5;_6K(E^IHW_&IOWVQ[W25]IV,R&PO=V]R:W-H M965TFY=PB8.A-B5MKASDAAK5< M4A.I@??PIU9:4@M+W1`S:$XK'R0[DL9Q0205/0X,<_T6#E77@O$[Q;:2]S:0 M:-Y1"_F;5@SFP";96^@DU9OM<,64'(!B+3IAGSTI1I+-'YI>:;KNP/=3,J'L MP.T7%_12,*V,JFT$="0D>NEY1F8$F):+2H`#5W:D>5WBVV2^*C!9+GQ]?@J^ M,T??R+1J]U&+ZK/H.10;CLD=P%JIC8,^5&X+@LE%]+T_@*\:5;RFV\Y^4[M/ M7#2MA=/.P9#S-:^>[[AA4%"@B=+<,3'500+P1%*XSH""T"?_WHG*MB7.BBB? MQED"<+3FQMX+1XD1VQJKY*\`2O94@23=D\![3Y*D47J=)WGQ;Q82,O(&[ZBE MRX56.P1-`YIFH*X%DSDP'YR%/$:O+UD%CX[DUK&4&+H=7!@XGL=ED:<+\@@U M97O,*F#@.6+^(`AD,Z8$:1RG]/%58.?G[6R,+/^LX4KFD,7QA&`:Z7L8>%NE_'27_X&``#__P,`4$L# M!!0`!@`(````(0"%NZ<%200``!00```9````>&PO=V]R:W-H965T"WCVC0PZ'(243SP$1\<#\_4=$6`XS"C(S=\&51GUM'J;T%R!BDAX@XB\!Q$W.?9 MTK%7\R6(W#"<#X;P'`P=>^8\V1X?_(;=TV`'S\\-"+)]N/#\U(#>8`?/SPVX M'`SA^\0\*YR`M7 MV9BP]B&E#(KU;>LMEFOK#0HL'SB!SG%41C@R>#5QV0@#,082#*028$&(4YQ0 M0O]#G%R%QSEZ&(S`-7`7!34R1I-H!"23E6H3CY31)AF!JXWWK-JD(P5LE,!A M"T4"!X#Q-TZ&?4;Q M'DUM(#B2]QB(,!!C(,%`*@&*][`;/.X])Z.Y]VPUR8'@/#O]$H,=3?TN!&."3D=",[5Z1`#$09B#"082"5` MB0*V.#F*V]YS\KUZ$AS)>PQ$&(@QD&`@E0#%>WZYDC;KV]YS,IY[7$^",]73 M'*WU4'R_1A?=,8BQ08(-%FK)II*!$NI*#?6Q":'O:0)J*T)VK)1(.A(4LLW`]E15I,BCQ\4,RB2:C#I/>4U$GCA_* MTL3=7K`.9\,]S)V.UD"'0AV*="C6H42'4@52/><'LN3Y?[T7BG/]9N8":&/Z MN)6#V].J8&*-MZ+H:CA"L0XE.L0;IV'$Z;8D&B%Q-:Y(>R0A*4MFY/3,FYPE M'+@3*AHP<'OLP-`7:,U>^APB/.`M&\\MQET__!$_K\Q/7AMJ?C+PY\ M@)3RF*8AH"=KLB/Y-6N/1ABASG0,` M`)@+```9````>&PO=V]R:W-H965TB)/`9J,DU0:T=Y5ZTJEJ>\\..(FU@)'M;';__%RP7Q:EFC;8DDE54@WYUY*VZL-7%>^AJ*I]. M[<="U"U0['C%]:LA#8.Z6'X^-$+2705QOY`Y+2[.E&%0 MG)06];\61#HJ2S+M2.#9D2RB19+,T\4=D-QPG'6.\+Q\/2+S28K?ON$V[]S@ MV;F1:31=)"0QGK=5QS8#)J$YU72SDN("WRJGQ8RD^(9\9'"D$&A4OY\>X^7GQRO8 MM@/!J>M;W&SAM;BL`R7C1ICX1SGO4/WF&$Z6&PSV[%&M;R>6=!W>S`JVI5R; MLFM3[IA<`=B/1P+^[XUFV_K-G&QAQL&-09R^G=ZY/2<;4,/%UCOBF&,N,COL MV+NY9O+`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`_1V=,A8:I$CRO?Y\ MSW;5X6D\OYLL[[6Y3N:C+VE9V1ES.1YMW\HJ/_W;&.FMJ\;)K'5"G]R)-KG7 MM=7\GIQ-7WR`2?Z0KMC<[[2[:[M1I]MM]ED]K#4 ME[_J>-]VI*NF[?BQ>:[:?O1YRSQU"H-F5U@\-(I_<*:ZV-!N,SXV5YUO!OOG MIMG2[C6S[;;Q^FRG31#6,6TF5?+\6.3O(SHH:/+E)6''CF[HY(U'<[.G(KY_ M%MX4U\S+"W/S-*;-HL@MZ9K\]KRX7SQ.O]%UM&UMUFBCRQ8;;L$N&N;65(&E M`EL%C@I<%7@J\%40J"!40:2"N`>F)*W0EV+B_]"7N6'Z'INL%QVRO=B< MKQYDL=:-C5[?-NK0VP`Q@5A`;"`.$!>(!\0'$@`)@41`XCZ1I*1+79+RNH3, MFDX(\M:[OI>*AJU1NC80!X@+Q`/B M`PF`A$`B('%#]'IADJQT-[Q!5F9=R\H7NFY)3\.6]#1L"&G(CMF9IBOGK"7: MN5<;?#A`7-&K]3J7=]<3[=RK#SX"(*'HU7I5#JE(M'.O<=^')"VE$#=(RZQE M:1LRH^-"A-Y"4^:S$49\/B802Q"VIKERDMBBM1N&(/4P2E#YHO7*,($PXL.$ M0")!ZF$T.:ABT3H\C+17K!CMIWW7-XA9RQO4DM[]$H@)Q`)B`W&`N$`\(#Z0 M`$@()`(2]XDD&-43-PC&K&7!6K(0M\(-$!.(!<0&X@!Q@7A`?"`!D!!(!"3N M$TDP5E'=H%AM+DO&42_($)F(+$0V(@>1B\A#Y",*$(6((D2QA&3]6$71OT0_ M?)RR@E2)OA8MY9N?DCAL.BM^!IF(+$0V(@>1B\A#Y",*$(6((D2QA&1U68G1 M5_?Z`4B%`4C:HGYT`C)YQ\[*0F0C7_7+42W];)-40,VTE^[(Z*Q[+-B('D8O(0^2W:*`" M8#^BW*),6TK,Q8UA77M09.@7'.U/(PWZ>1G0NB@%PX_#!.H'=KF.39NA* MVN1U!MRS+[F1(X4E]#=$2IO_]_5HT"\R=_83+`4/6?%)F8BL#K&U+91TU^Z: MAW.H)B/LK/A0+B*O0VRHN1*@?M<\/)0L(LO#;Q"Q2=LI2/D$UQ2IM3S2%:@I M5^"FL^(=3416A^H`49S87?/PREH1Q83X4&[7D2.O0T-#^5WS\%"RB"Q!OD'$ M)I^61&Q3;/DV>B\?/1M=6/%EF(BL#G537VAJ-=E9<5\.(A>1UR$FG*[4"G[7 MW(W>+U-EX5A6?(-P;1+=C[Y^7EWO_T8'9"*R$-F('$0N(@^1CRA`%"**$,42 MDO5C2?(-^K4Y=5^_!O7.\HT.R$1D(;(1.8A<1!XB'U&`*$04(8HE).G'3OX; M]*O-Y5*"HRX-VR`R$5F(;$0.(A>1A\A'%"`*$46(8@G)^JFEQ/5D=X;U`T>4 M/_1^/%-N:9O.BA]6)B(+D8W(0>0B\A#YB`)$(:((42PA6=+;Z@=Z'JW6#QSU M0Q+K![2R$-F('$0N(@^1CRA`%"**$+''\/6RZS4V^C6/U9M'D*>T>$TWZ?%8 MCK;Y&WMD3K_X/3\*S)_GSXT7\D0QI;2L]0>#';M#+2MJ60VUS#1Z/:!.$E5O M,_;B0%U[0,N,OU*@M-"[!B_#,Z/A!T M_P,``/__`P!02P,$%``&``@````A`+N(Y`[J#P``!4T``!D```!X;"]W;W)K M&ULK%Q1<]I($GZ_JOL/+K^OC21`0"6Y"B`D(0E) MU-[=,[%)0JUM7$`VN__^>M"T6M,?ZS);EX=@?_[ZZQEU]\RH`7WXUQ_/3S>_ M;P_'W?[EXZUWU[N]V;X\[!]W+]\^WO[[U\4OH]N;XVGS\KAYVK]L/][^N3W> M_NO3/__QX>?^\-OQ^W9[NB&%E^/'V^^GT^OD_O[X\'W[O#G>[5^W+_27K_O# M\^9$OQZ^W1]?#]O-X]GH^>G>[_6&]\^;W-Z^ MG!J1P_9I&W'Z^_/.R?7TGBR^YI=_KS+'I[\_PP M2;^][`^;+T\T[S^\_N:!M<^_@/SS[N&P/^Z_GNY([KX9*,YY?#^^)Z5/'QYW M-`-SV6\.VZ\?;S][DW40WMY_^G"^0/_9;7\>.S_?'+_O?\:'W6.^>]G2U:8X MF0A\V>]_,]3TT4!D?`_6BW,$JL/-X_;KYL?3:;W_F6QWW[Z?*-P#FI&9V.3Q MS_GV^$!7E&3N_(%1>M@_T0#H_YOGG4D-NB*;/\ZO/W>/I^\?;X/AW2#L!1[1 M;[YLCZ?%SDC>WCS\.)[VS_]M2)Z5:D1\*T*O+-*["[W>.`C?+]*W(O1J1?RK M!T+>SK.A5ZLQNAL-!OWAZ(J!#*T(O5H1[^J!4'F=!T*O?WLR8ZM!KW]_,AYE M5!-@DUHV>%=/Q^,(FQ_:";41?B,UO(#]TP_68&@R["U3S@A/4N+Z M2'@<3O-#._1K,]P+>1KT@U7Y&ZGE<5Z8'ZS,NZ=TWY3N>268;TZ;3Q\.^Y\W MM+Q2<1Y?-V:Q]B9&F->`YMJVJ\)?+0JT&AB5ST;FXRW94[T?:27[_5,_##_< M_TZKSX/E3)'CN8P9,\Q28V3G&H@TL-!`K(%$`ZD&EAK(-)!KH-#`2@.E!BH- MU!I8=X!["D\;(ZJ;_T>,C(R)$5_=*0,2-%\%A!EL,M=`I(&%!F(-)!I(-;#4 M0*:!7`.%!E8:*#50::#6P+H#.`&AY0@"$M`:>7GCY!HQ5K1%=FO$[[D7?-IP M:*7D*SX#9`Y(!,@"D!B0!)`4D"4@&2`Y(`4@*T!*0"I`:D#67<0)"2WS$!)O M<&>V[M/WW<-OTWUS$KD0HH#6JV85,R*T$)*3SC(V4B&RI/.Y[&PVL\BP#=J\ M00(J:!'R^ZY0U)(XU@M`8D`20%)`EH!D@.2`%("L`"D!J0"I`5DW"&VB-%,G M:A0=C!J=(6W0?MV_GG>H]T?0")XCR-=TVB#!N`W.S'(ZX6J0<-QL7'YOK$/5 M$EAV`2(Q($EK==X/?6\T<#,@;0DLNP21#)"\00):G#K)I:2+EL32*Q`J`:E: MJZ[TT!UUW9)8>MT5%R61L4-JD7<^E+GC5E+XG'. M&V1TOBLZEVX$R`*L8D`2L$H!68)5!D@.5@4@*[`J`:G`J@9DW;5R8D2'4B=& M;\?"L-U86(3N--IT#-6V-FLXOESX^04KWU/'C\B:>>>Z]'LC+QPHRJ+5X2#' MX"MI.3)"\)4ZOKQ!,`Z]L9OXRU:'?67@*V\Y;_@J7%]AV/-\Y6O5ZK"O$GQ5 M+><-7[7CR_=[`S]4:\6ZU2%?3FK0>?Z*U#!L-S4:Q.^N5*$*X,QR@G9]GK=6 M//6H0>B$9192S^N/1V,UAP48Q2"<`"=UA$?A:.`'*N9@DX%N#IS"T?5Z83@: MJU5T!48E"%?`J5WAH.^'OKJ@ZZZ1$TVJT"NB:=AN-"WB%+JZ7+.&TRWTUJJ- MIN4T53T8]VF_=2_Z`FQBT$V`DSJZX;`WU+FV!)L,='/@%(YN,/3\0%WR%=B4 MH%L!IW9T^T-_/%1)O>[:.*$TG9DK8GFFN\&TD%.;?5^==6?,ZE0G0W*+$EF( MZ],?#-6-_0*-8H9$.F%(I%,+]=V=7N7+4@R[*Z$ZQ&7,$H\Y0^*QL)"=3+\W M&J@<7Z%1R9!(5PR)=.U*>^/1:*!6A;5CY8;<=`>ZG9JW]VG/T%7(+419U>[4 M(XAX0^I6,$O)$3JR$#6G1:H?J%U_(8;"\CT5EMBR.AX3,>1%([WL4>794@S? M\)BAQUP,V6/!K&:=\GJ!GM\*C4HVDI-.A:R:658ZZ`U]2(0V6#0@-Q%,5^** M1&B:&'13RS.;FD8LY89;^WI1FS%+#.<,24Y'%J("9?D%LF*&1"MA2+12U%HB M*V-(M'*&1*M`K16R2H9$JV)(M&K46CLL-SRF17%%>&Q'0T8P-?T'"D]`)W:I M4[4(S2RI4S5S"WG=^O8]91BQ>G@^3$')VN&X&E"R#:OC/'F7\U0YOX/Z?8_[ MS*ITW.>7W:M]NE#NW5/'2C0XE4OT5`E+H@-W$[7R=-=3EW`M,E#?IEMR10+9 MYDHW@1JH3R^20&H`,_/&B%D$Q&[.4/>\?B&!K'JS>$$"65E70SF/V9,X3QAR M#57VII9%RXVY%>AA`KW'?<:^Q'W.D.L>$NBMN:]$0Q+(CD<\5<*2Z%Q((-?3 MA01J9PH)9-HQ5R20[=[($*?F36!S>)`=?V:A3LW-D159J'G3^MQA62`K1JT$ M62EJ+9&5H5:.K`*U5L@J4:M"5HU::X?E[@:F[7)%+&R7IAN+!E*;M:J+F7F# M4E=S:\C9&%F6LUD#*T:MA"'9%%/46B(K8T@FE#,D6@5JK9!5,B1:%4.B5:/6 MVF&YX3&MCRO"8SLE,H*I>7.W*16I9FA_69)3/!?L8!6(V-`>%$?]81BHM70A M(^`XQVPFI]!$6#).\)>R(1],A\/^6*7:4I387\9FXB\7UAO^"C:T_OR@3[TP MO2VW5XK]E6PF_JIW^:O9T/H;#,9^7]T!K46)_+G98EHK5V1+TXFAG9X'/C7O ML)LR[>XRNDLQ8Y+8S1F2/(\LQ#?=O4$P&*H.^`+-8H9$/&%(Q%-7/!P%0_UN M_A*M,H9$.V=(M`M7>^@-0D^->X56)4.B73$DVK72[H7#OBJ7M6/EAM>T6ZX( MKZ&K.VP+=4_/H:J?F3F?FQR0Y)U;J+/?1LQJ,M6G0@Q5UV.!5C%;B7:"K)19 M5CND-Z94$2S1*F,KTH73.KT0[\0<]3Q\^U M8^5$EZ[W-=$]T]WH6L@I7FR9,4L2=TXO2.MQ+"[]JM"+)DE'BN&Q&-]V:-NE(KA M98]N)IC6ROOKW+>=&!GGE*%NG5.#R-VX9I9%8^,\GXLA0Q&S;,'T^H%.Z@5: MQ6PEV@FR4F8UVL.^?O=LB389VXARCJR"68WR(`P"E;XK-"K92*0K9-464KU% M);\6P_=$G/;;:R)NZ*KV&\BM_4#M6S/S9[.T2ZK,&9*4CBS4/84C*V9(M!*& M1"M%K26R,H9$*V=(M`K46B&K9$BT*H9$JT:MM<-R"])T?:XH2-LDDA%,Z8J; M"_]VR\R2G'J\V&]2=_T1JS4]<[I!!XREA6/.4,O>FI4)XNI!`X*UE9G%4,NK-&9*ZBRSD;-BMO%0G:"6HE:+6$ED90S*NG"$95X%:*V25#(E6Q9!H MU:BU=EAN>$Q+YHKPV`Z.C&#JMTT="0^TS2RIDZ3S2W875MM&G"VTS)DF6S1F2/(\LU+;-Z*MJ0[4J+-`L9DC$$X9$/'7%AV%OX"GM)5IE M#(EVSI!H%TK;A$!IK]"J9$BT*X9$NW:UPT'/]V`K;3N7$%[3SKEB,;#='QG1 MU&\;0IWPJLU^9DG.8M#:<8I'S&HRU>^'HYZZ25N(-[:*V4H*(T%6RBRK[7EA M3]V5+M$J8RO1SI%5,,MJ4],F5`6V0JN2K42[0E;-+*L=4(=!C7OM6#G%2X5R M373/=/?6V4).\6+;C%F2%G.&)%$C"]&+6=C]$7T63^7)`JUBAD0[84BT4PO1 MB]$.0OH$L+ME+-$H8TBDL-^B%\NA"M M8K:2RDB0E3*+M;T1A-Q.3H[A&1N)=([2A87<+E9?W7JMQ%`NU(60-X/H7*A* M#/E"U9<]JE5D+8:7/;J90!ON%4N[^4J*SH0&$Q'9+W[[R! M;:C("*86>KMO9DF=])NS5+?`X5@9BF,!SB"/VIG)A;VP05B6 M^*_>Y;\&_VJRZ\LR$EDWCTR#ZHH\LHTP&?4TL)"LB#.$Y@A%""T0BA%*$$H1 M6B*4(90C5""T0JA$J$*H1FCM0&XL3#?JBE@TS2NGIAN(,H#S?&;V"?,VBT!S MA"*$%@C%""4(I0@M$(?:!DDB_,3EY3)-!C27\[?7(>_A/272VKS_J0^ M%ZRRF`\FT24?R6!"7TS'4>6#"7VK'/%J,*DOX?/AA+Y>C?QD.*&O2R.>#R?T M]6?$J^&D/N/W[03H(52OFV_;8G/XMGLYWCQMOU((Z:E1M'L-[:E1\OTS$,&ON[W)_Z%'-^W#S#[]#\```#__P,`4$L# M!!0`!@`(````(0#`0/8Z.0P``-@Y```9````>&PO=V]R:W-H965T8=S!\?V*MWI#D(-:^&8/!F9EKMZ,D1L=18+NW MMY^BR!+%*L6).^>FG?Y<]9,LKD59UW_^W#^/OM>'XZYYN1G;5]9X5+]LF_O= MR^/-^#]_Q7_,QZ/C:?-ROWEN7NJ;\:_Z./[S]I__N/[1'+X>G^KZ-`*%E^/- M^.ET>EU.)L?M4[W?'*^:U_H%OGEH#OO-"?Y[>)P<7P_UYKYUVC]/',N:3O:; MW46V__8CE7*SH>[;?+[/&E.6R^/$.[?]K>9HO:[7^8_'ZW/33'YN%T M!7(365'>YL5D,0&EV^O[';1`A'UTJ!]NQG?VWZ/C M4_,C.>SNR]U+#=&&?A(]\*5IO@K3[%X@<)XP[[CM@7\=1O?UP^;;\^G?S8^T MWCT^G:"[?6B1:-CR_E=8'[<049"Y-;%&I3L13(O"I1)R+-:"T MMB+PJ33F5W/?]Z;SV<;84./2A7=M?#7!WO4=M$;_E!UF%UYCC^;7S(P;!P9XH]+FS*10[4= M^>'FM+F]/C0_1K"3E"NUGPUB2`@2M4[H3,S1BZ&<;W M$6;N]UMO.KN>?(?9ME4V*VYCFQ8!6HCY(&1#"B(*8@H2"E(*,@IR"@H*2@HJ M"M8],('0=O&%8?)WQ%?(B/AB9%8(=,`=$DRT0)>0@HB"F(*$@I2"C(*<@H*" MDH**@G4/&,&$^6,$D^)Z%51G)W$[,Y4&3:!3N4Q(7)TPG9"[(J1)T1]E',2,)(RDC&2,Y( MP4C)2,7(6A*[;9@1;8@JCS:<"52P_VI>VQ7XXY$7@FWD,18K2=Q%%]1`V?3" MK&R<=F%V+-LSNRKJOD?5F&DDC*2=EUCN097,K:S['E5SIE$P4G9>2I4L:U7W M/:JN^QI&].'DPJ/OZ[&.X1\8ZW!@P\$N5,R02^+!B:(;M:X]-6,:2".G/7'* MS4P)P7FF1L#;[2!*G-RT4<;N)$BJB%_]($D^O M63&S29A.RFPRII,SFX+IE,RF8CKKOHT1,)&$]@]RYP,FK,V`24(&-3G"!=*H M/ZB5D(YS)`F,8#TL7)OT>]RY:2.'+DL)*RWMW'!89LK&;N?+S)O152AG+@63 M+9E-9/>PTE)66J;(M.T>VYG[=*'I2L(>+9ALR60K M(FM[9$=;]V6-[A%Y(.^?SVS)K:+960J9D\DA30^457\VH6-O24)DS">'[@O* MRH9VG^DQ7F**\KK$#)$X[WV_A2N#*8ENKDOK>HU+EZBCI2M$4MJV[(5+6K(V MM,VN$SE6?XEKI]:GNDYF;7"0Q7:L;(F,B;;PS>D1H)'V"Q7R^O/*H8M1A%9R M/LSGSH(T/T;I\U,/K70%4I0V*T#D,[12%9C-IZ1M.4KK7BL0Z=)*U#E;6H56 M:OI;SM0C*\T:M=OBS.X662#K[HN/;^+NAJREB'03`XY"CB*.8HX2CE*.,HYR MC@J.2HXJCM8&,N,JH MX*CDJ.)H;2`S?B+;NR!^*CDTDV6R.VBKB*.8HX2CE*.,HYZC@ MJ.2HXFAM(#-^(HWJ#\G?.G3"_04+JT(Z(0K0JG>]H-`[USC:"C?;F*.$HY2C MC*.7Z;:QWLB((WM]16.D[L3JM"1]G_R0W\7-BC-[&.1R=$^=J;B M`>P;SV7QWD[$CNX275JHJ^LZY`0<*$='CX<0D9Y*D4)P5]37(K>`L7;45CR3 M1BM=8HI(EY@IY%HR+_/FI%=S[E,@TLHE(JU<$67+)B%9&SY&_\#@-_OG_&FR M-3>W;D3]U-5UZ,V3LH(/'(^A=D04H94<:;8%M])FZA9SIP2=M'3*K3*T0FG? M(7V=A0IYN=X1(7=UX,Y?N M6;HTU$FX=(HZ6CI#)*4=:^&3"9!SZ8)+EZBCI2M$4MJU7'8!84B;W4(3Y4_? M-\&60K&-E!6_2T)'6$?[!SY20.MWKYP0NG^_.<[%%KIN9&B MM%D!LB=E:/7VA1-*ZUXK$.G22M0Y6UJ%5FY0@.)D3B/L7.:_9G$ MJ%4D1P51"*!^I!3J1THB]\W$2"F#@0X2DTFP?*V<:LR M]H\]GW9XVJZ0^?S!)8>Z0%D9Z[[2ZF\8[#P?H:,Z"KF6Y9(%.\9*Z>>""7KI M;2;55OTUC"TALE*PI8JHVU/?IZ?#7`M!W,T@TX3]G0,2S\8=B8PG`BYM<(!6 M>LD*$>EA%BFDCO".XSL.F<$Q]TH0:>T4D=;.3&T?U@:2K^:&DQDED7_ULZQW MHJ32-5VAE2.1.>3X,5):&4-.:>F1$BDMU>'.=&K-R'DT5B:0E^!$2]"K/[Z8 M=H96W,U/8=WZ*_5,D-+R-,4*-+PM2:FV%2R!Q-+FE= MH*SZHPFU]+B(T*I;/A8L*>1>"7KU1A.WRM!*C2;+GM(NR`TO,TR7Y6YBYR>C M22'1$]T9T"?'BP"-=(>'B'2'1PI!;=M%UO?F=$GG3@DB+9TBTM(9D8:?2A'I MW'`R8_2WI$:PT[/0241&&%F,`^5HC##EJ!L8*2L/-HJN&UBB$6,E^IW%#]J\ MQ!3E=8D9(K-$DH3F[Y5H1OIOSW9EB%"I''Z\0Q0BMU M_'>FUMRB62J*ZV@FB'1Y*2K!L;#K4G80RM!*E2=F_X*4EZ-X6YX9\<%\X^+K M:[=+,G!G6"'2;0PX"CF*.(HY2CA*.* MV.*@4.]I+%II%'(4<11SE'"40<9-8P\\LW*]I;BB>_0-SY\T[X_ M17SN'%"#>@WXN*`&/3[T#:@-^H2@)G)8[A,Z_C*"O(Q_`QD>^`Q]`^^>W;73 MB=1Y!>^DM4]'*7>6\!H#+V'E0G4'^!TT73X#I$(V*,DGUNP;T!KT";TE_$J= M%QY"NX<:ET*KAWCI+^'WU@,Z]G0IGIL.?3-;1C(_)[6%IXK+;/`;>"H(:FU. M/^FG2'B% M"=Z@K.%]`TO\SOZA:4[X'ZCNI'LG\_;_````__\#`%!+`P04``8`"````"$` MW,V2A^X(``"\)P``&0```'AL+W=O]`\1Z#).ZRG5K0?54JM4F>,_/O[\T_U[=?E2OQ9%,P"%4_TP?&V:\VHTJG>OQ7%;WU7G MX@3?/%>7X[:!/R\OH_I\*;;[MM'Q,++'X]GHN"U/0ZZPNERC43T_E[O"K79O MQ^+4<)%+<=@V,/[ZM3S7J';<72-WW%Z^O)U_V57',T@\E8>R^=Z*#@?'W2IZ M.567[=,!GON;-=GN4+O]@\@?R]VEJJOGY@[D1GR@])F7H^4(E![O]R4\`7/[ MX%(\/PP_6:O<=H:CQ_O607^6Q7NM_']0OU;OP:7SI?W/(4,R$"GT+$NMD34%;M0.#SYH=8BK;P^>\?PH(,:D?`_O.O'\,"UW,5 MF1?VS/]I7H?P%0$B5R?MVQB MLU9,&.N%9W=703\J(*@S*^'WV%2MT)FS6UL72+ M#5JPLF2RK@D\$_@F"$P0FB`R06R"Q`2I"3(3Y`H8@6L[_T*^_!_^93+,O^B9 M-0+%X88ST0*;N";P3.";(#!!:(+(!+$)$A.D)LA,D"M`(3TA`2$A(1$A, M2$)(2DA&2*X2S6'L>*1N$SZ>+IBU[C!!8!90)A#'F",Z(ZQDEQ"/$)^0@)"0 MD(B0F)"$D)20C)!<)9H/81][@P^9M>Y#092D(\0EQ"/$)R0@)"0D(B0F)"$D M)20C)%>)YC"V9;_!8ZVY[C)$RLQ&D4N11Y%/44!12%%$44Q10E%*4491KB'= M?VQ3>GW56GP/"ZL\UM\:D9)S%+D4>13Y%`44A11%%,44)12E%&44Y1K2_-PNE59J M=T:&9-B0=V=/E\N%WEO>KR-S6`\R.V1\%.3KYCQQ5%%CS)$-\UP78WLB1]%& M=,.N:EF094,7D5S#/40S'M&IO3"F&A\MY,(5()+2(2(I'2'BIUA#-L9OI6R" M2,JFB*1LANB'(\[1HI760\*.,20D_VDFY`60-+*122M M/($F_"<+=LWJ4ZL`D=0*$4FMB&K%U"I!)+521%(KHUJY9J7[E9VR5+_^PYHC M#F5R!&M+("V,$V.FW@@K)7%T48*-I'1*K3*!G'E;IL94EVL-=-^S`YOJ>[8MMF?L][1_N(EE-<,V16H8 M.#*6!6,)VXB&VK+0-42/>L(*,ENIS`D)1==0L5+JMUV(`MICB$CF;-3;X]1P M92P;?M!C@E;2.2DBV6/6WZ.QK\MEP_X>M7A"90"#X0!2BC/1HA(B7P9Q$3WRO M""<"P0<*IZ@BA3-$8LC6W!AR+@RXLAX22&%28M9_6?)MIFB$AZ,);*)E>*;& M[GDC&JJEATCN;SQ$8G^S6#K&P_IH(1T4()(9'R*2TA$B(>W,'&-%CM%"2B>( MI'2*2$IGB+CTU%X:N9FC0:NL1XB=U\U)4"V:ZPY#;-XSPR*03.2-L%+RS<6& MTLH3".9SS$J?6@54*Z16$=6*J55"M5)JE5&M7+/2_U998&B.0P0Q3ZL+L( MK41W_ M?G`L+B_%IC@F,OY,!F[_&^P_QM(;B`7+$+.DAH\YOI"GX/Z^&S%?SL MT\/G*_AUHXRE,].!3/$,IQ>R=TX6]?\3\:<5WW5#7PUA1$ M&UXU@;?D"CA^C-F=WG-5-?@']#SJWKM[_!L``/__`P!02P,$%``&``@````A M`'XW+7V5"```ZRD``!D```!X;"]W;W)K&ULK)I9 M;^,X$L??!YCO8/A];.OT@22#CG5?6"QV=Y[=MI(8;5N!Y72ZO_T4)=(\_MY, M-)A^:#L_%HMD'12+UMWO/XZ'T??ZW.Z;T_W8FLS&H_JT;7;[T_/]^+__B7Y; MC$?M97/:;0[-J;X?_ZS;\>\/O_YR]]ZS]^N5Q>5]-INWVI MCYMVTKS6)VIY:L['S87^/#]/V]=SO=EUG8Z'J3V;^=/C9G\:]QI6Y\_H:)Z> M]MLZ:+9OQ_ITZ96NG^_$7:U79WGCZ<-<9Z'_[^KU5OH_:E^8]/N]WQ?Y4D[7) M3\P#7YOF&Q--=PQ1YRGTCCH/_.L\VM5/F[?#Y=_->U+OGU\NY&Z/5L06MMK] M#.IV2Q8E-9-^&MOF0!.@_T?'/0L-LLCF1_?YOM]=7N['CC_QYC/'(O'1U[J] M1'NFQY'WI\^\O MPJ(X[,."!21W^>!E6"(NV)?!"[%$0+`OO/=BLO`\UU_,/Q^;EH@(]F7H4J9] MMG3)%VPNFX>[<_,^HAV-\J%]W;#]T5HQQ2+M^B2Y)N+_RT/*':;E"U-S/R8W M4XJUM'E\?[`]YV[ZG1)^RV4>4<;2)=9"@J4D4QN8(#1!9(+8!(D)4A-D)LA- M4)B@-$&E@"F9]FI?"IA_PKY,#;.OL,RC`(K!#6,*"=$E,$%H@L@$L0D2$Z0F MR$R0FZ`P06F"2@&:,2E_P)@.)?;M9X2(3=:+G@9:;+JZL1Y[&4IO8:TUD`!( M""0"$@-)@*1`,B`YD`)(":12B69*2G7-E!^;D$G3#D':E/SV#!MR(:]+_[G> MN+XVWM:@S8WVQ`%S8]+=W(3K'CE1G`DD`!("B8#$0!(@*9`,2`ZD`%("J52B M&8P>T0,,QJ1U@W'BRN@'$@`)@41`8B`)D!1(!B0'4@`I@50JT0PV'V0P)JT; MC!,EPH`$0$(@$9`82`(D!9(!R8$40$H@E4HT@[$J2STF?+Q=,&G=8)S0+J!L M(+ZQ1UR%1"8'0$(@$9`82`(D!9(!R8$40$H@E4HT&])!=H`-F;1N0TZ4H`,2 M``F!1$!B(`F0%$@&)`=2`"F!5"K1#,8.[P,LUHGK)A-(V=D0!8A"1!&B&%&" M*$64(&:64$NHK39=N;G82'V!N?G!7S=TCFW9GY6%N'OC990)Y@*3$ MI`*)E(Z6K:\FY%+NHO.3X]FVZQNE1B0U">4QHD2B#\9+C?&LA>TOC)-))C6) M\7)$A40?C%<:XSG+^=Q(]4HJHN%T[[$:8(#W>,F@>J]'-F6#XKV%[H0UNWEE MWI,=`T0A1^ZR3ZFEOUPLC;T@PFXQH@11:BIW9[9C&"K#;CFB`E%I*O<](PPK MK9/N`U96#/`!KT*D*1]ID^6YH?K`6-Q:2HF@"Q"%'/%T<>$99,[YD9D1:@I1I0@2G7E2W]FS#'# M/CFB`E&I:[9LWYJ9TZZT;KHW6,FC>N,O7,`K)-4%/=(?*;ZQE:RMJY2P=X`H MY(@GA#>C?_KF%F&G&%&"*/U+U1EVRA$5B$J)V!G"F'$E6^&!P*JG`;;GQ99J M^QX9X6\$[=JZ2DG;`PJY%`__A;UP?`>>W=`M1N4)HE17[GN./_>-YU:&W7)$ M!:)25V[-Z;<9W]A'*ZV;E@$L<`=XH1/7*U6.C`PP=MNUE+IZ`5$HD?)X,7?7 MZ*:4>2B.I908,4&42J2.:'@^NREECIA+*3%B@:B42!W1.+=5-Z64$74G#BN7 M;2R7.3)2R0BCM902"PPD4E8#)V,NQ;/+63ASWS641U*34!XC2B3Z8+Q4'\_V M;'=NGL0SJ4F,ER,J)/I@O%(?SZ)?[A<+8Q^JI"8:3W??L&K=QFI=(.6&` M*$04(8H1)8A21!FB'%&!J$14:4BW'ZN/U2?)I\]4+-Y9L:T\5#CR9/6W1A0@ M"A%%B&)$":(4488H1U0@*A%5&M)-.:S&MK'&%D@-12XE48!2(:((48PH090B MRA#EB`I$):)*0[K]6/7Y]T*QKUNU4.P1A:*R]Y@'AS5[,X=B6`G8`%&(*$(4 M(TH0I8@R1#FB`E&)B+VK)1?46[=_]ZI__>-8GY_K=7TXM*-M\\;>JZ*=]>'N MBON7ON@">,4N2&FO-5MLF]X'ZV(16AQJZ?8":'&II;M>@Q:/6KJWR\P6:KC) M_17]O'=C7O,5_8IU@R]6],O,#;Y)+8'EK-C](K;0Y2%IN]5"EW^D[58+O8KWY=8HC\Q9-\9X9*ZZQ;\_/^U(X.]1.%S*PKN,_]RWK]'Y?FE9X$]*9:13TUS$'V2-Z?4US8<_`0``__\#`%!+`P04``8`"``` M`"$`8&_2OND'``"=(@``&0```'AL+W=O]`\1ZC`W&5[=2"[JM2J1S/,LA&M8`H25[O?OOT:*89S33K MF$U>C/G1_9]1=\]H6G#_Z]?C8?2E;-JJ/CV,S3MC/"I/VWI7G5X>QG_^X?^R M&(_:KCCMBD-]*A_&W\IV_.OCSS_=O]7-YW9?EMT(%$[MPWC?=>?59-)N]^6Q M:._JJV?N[N0&[")TJO>3E93D#I\7Y7P16P ML(^:\OEA_,E]P'ZJRK?VL'_HW9?OP5-M4NK4PG1ACRQ##S5]6=F M&NT8`N<)\?;[#/S6C';E<_%ZZ'ZOW\*R>MEWD&X'KHA=V&KWS2W;+4049.XL MAREMZP-,`/Z.CA4K#8A(\;5_?:MVW?YA;,_NG+EAFV`^>BK;SJ^8Y'BT?6V[ M^O@W-S*%%!>QA`B\"A'+NEG$%B+P^N,SF0H1>,69?/@JX'K[4,"K\)W?32UG MOK@E%+"N>A%XO7D"2^$+KS\^`1.3P?ZY>0HF9H']\Q\F@7DP92+,CU;$A)=H M7_%NT16/]TW]-H)M!(JP/1=L4S)73!AKG5?FI?J_5_Q0]4SE$Y-Y&$."H*Y; M6+%?'JW9\G[R!5;95MBLJ8VI6FS0@BTI)NOJP-.!KX-`!Z$.(AW$.DATD.H@ MTT$^`!,([26^4##_1WR9#(LO1F:-8!!P+9AH@2ZN#CP=^#H(=!#J(-)!K(-$ M!ZD.,AWD`Z`$$]8/":8-V_OUC1EKDWG!%CRLS;FA!FO-;6!Y8[0VA+B$>(3X MA`2$A(1$A,2$)(2DA&2$Y$.BA!*6.@FEY=Q]]RZ'P61^L%>`KESI&!X M?TDR:S5@@L`N,-A`+&V/N!CA2G8)\0CQ"0D("0F)"(D)20A)"12Y%'D4Q10%%(44113E%"44I11E"M(C1\[D0[CQ]NDNSG7J&_8(5=/A+"R>(MKF%/UQN4)'ULN$Y_*!!2%TK%O MG@W35I4C:8`ABZE,0E&*CDKQF%H#E$DKE,\5+34C[`Q/,N+(Y8`IN;(5$!F^#-`\:3@FJ.IG2L\=#1Y_AS37FC:OC`Q M92$$Z-4_->R'"Z758)[ZF>T#!W%:-9\ ML9BKP^52"(934\I:BF%*_R5UH@,9IHXC"[:O0>JT!;)ASU%9ZJ2CBTBN&4\@ MZ.WY:I@N](+UJ5>`2&J'B*1VI&J;R^7<)%FY7(K,"IEW2K4S5=LQEMKEYXJ/ MF@#6HMR0`-'1R&M=P\[<[U?JVG'4$M@(*V7M7!SQLG1#:A6A%=>>.[:>VY@Z)>@DI5-JE:$5EYXM%S-MUKGBI":`M3PW)$!T M2,,$<*2M`&T&&U-824<7D:Q23R"Q`DS;7$ZU3/K4*T`DM4-$4CL2:,JCI-T) M8NJ0()*R*2(IFPGTSI1SQ4N-/FN6;HB^Z*WDC-:F0&KY:SO@1E@IY7]QQ$+V MT(I':&I9CA8E7XZ&3@$ZR1(-J56$5ES:,1Q#DXZI4X).4CJE5IE`-A388`?6 MGK_ETG%@-3C(J&EA+=DP+3]V\&4J6C_&D;96M"/M!N["Y&XAD&SD/+2:]7>+ M^D($9=>SBQ#*Z@8+:1T@DA*IXBD=(8(;BPR6PNM M&'*T4NZJW\L65/65;/V7DW*OJ&9.(!MN&I=Y+[6]:2.,X`67AXM(J4[]R.2A MU:+/Y<(Q9W,MXKXP@RJQH7JI3.SJ4SY!*HV^7&O[S M`OZF$YWL4]W!SP+ZIG8//P,IX;&`P=K=Y[KN\`V,/+G\L.3Q'P```/__`P!0 M2P,$%``&``@````A`"D7FR3S!P``&2,``!D```!X;"]W;W)K&ULK)K;CN(X$(;O5]IW0-P/$,(I47>/!G(D!ZU6L[O7:0A-U$!0 MDIZ>>?LMQS8^5$"PVKD8Z,]5OYURV7$E/'W]>3ST?N15792GY[XQ&/5[^6E3 M;HO3VW/_K^_>ET6_5S?9:9L=RE/^W/^5U_VO+[__]O195N_U/L^;'BBC7*W*S:Y4VX^COFIH2)5?L@:&'^]+\XU5SMN[I$[9M7[Q_G+ICR>0>*U M.!3-KU:TWSMN[/#M5%;9ZP&N^ZV@#]7>2?M?2]5^_+3[\JMG%QRB': M,$]D!E[+\IV8AEN"P'F(O+UV!OZH>MM\EWT3U!B(*,H/QE"AMR@,,`/[O'0N2&A"1[&?[^5ELFSU\LP:3\72^,,"^]YK7 MC5<0S7YO\U$WY?$?9L6TJ,J8J<`G4S%G@^E\9+8B-QQ-Y@B?W'%\E^.$.<(G M>.?+EKG$.:M.T: M<+(F>WFJRL\>;"QPH?4Y(]N481,UGOUT/B_KX=IR@'5`5+X1F><^3!0D>@UK M^,?+>&$\#7_`NMLPFR6VT2Q6W((L,B+KZ,#5@:<#7P>!#D(=K'40Z2#60:*# M5`)#".TEOI`-_T=\B0R)+X_,D@,IX&JX5]R"NS@Z<'7@Z<#70:"#4`=K'40Z MB'60Z""5@!),6"!*,+NW:)Z3Q/JY#_]+.3E6@[2D-K!F>916B#B(N(AXB/B( M!(B$B*P1B1")$4D0266BA!"6^`,A)-:P,X":%$-3BR$S&K7+WE(;5Y?&;@5E M;+#I/3`V8MV.C4_=DA%I,A%Q$'$1\1#Q$0D0"1%9(Q(A$B.2()+*1`D8W%D? M"!BQ5@-&B3D1V8^(@XB+B(>(CTB`2(C(&I$(D1B1!)%4)DK`X`CR0,"(M1HP M1J0,0\1!Q$7$0\1')$`D1&2-2(1(C$B"2"H3)6"DR$''`V,R$&?$NX\(1$J- M)B.P14B[RT3;0"Y&?)D[B+B(>(CXB`2(A(BL$8D0B1%)$$EEH@08SJA*@&_? MTHBU&D-&I(Q$Q$'$1<1#Q$4G?SCB#'FSA",#7WY(C M*>I95XD>1"7N"M.]- MM7V/U)&PUJ6;LR.0[#A3'5UAQ6?,P\C'*&!H:K0'N=F(_%.U0V'"M==8*,(H MYDB^9DN[Y$08B[D:+Q<[>ACY&`4"R?(+53X45CQ@:XPBC&*. MQ#4F&*4<=02?'.MO!?][>;X6?'A:=(D^JP[DZ%,T@5U>6AQZ54&>5,"$T,>" M[%$!TX(;AW`TM'K/Y8XTQZ>3T40[;WC,PK`NT^]SI_8Y8MM;(*QN]!9R1]J; M-3--;0;70H?/8,2=1&^QL+K16\(=:6_&=&0NM,M/A1!TIRXG4F3(,]JQ;.29 M8S6)/',4C94)L+0=9$6>K)*9$XX.1^)^XC)DTIIR.C<7:)J8CG#RN8Z0#C@2 M5B%#$QHE;7AK[!!Q)&1CCH1LPM#U$:>*DQI[4J\\$'M:WL#JY#FS-"A25XV% M'J]1*V75,"V1[2[3&M,`S8S15+O#>,Q"62)(.L!6(4/FO+W#H-BCL41\+/): M0%8)M[HZXE09BQI[4OH\$'M6*VWEK0QF)1P=CD06N0RQ+)I-%G,4 M>Z8CG'RN(Z0#CH15R-"UO$>R$=<0LC%'0C9AZ/J(4\5)C3VIBAZ(/2NBQ("6 M!D5:WFL/J%;,2LE[IB7G/44\[Q?62-NL/::CY#US$@D:8*N0H6MYC\82X1'' M6#;A5BSO\8A3Q4F-/2FPY-C_M^,3*]/D*:%(6P[:]KV"&*+;`$.B+'.YU:S= M+R:6.;/0>F!>(B5][B4&%7`DM$..R&GDQPO:BY!LQ!V$;,R1D$TXNC[DE)NT M0U8F!3+T]J3<=ZQJ9=2:ER'R<3D=Z>?OE3#B-Q9'(.$W1JQ2NCPWB*,8H%N]):HO2V@NY'8W.GTT7?+]+W: M,:_>\E5^.-2]3?E!WAN/)Q"6"Z8OM9?&R"9%.@P/M<#[;B@_<0N\"/_6Y@SR M`(<.^^487IQW<=.&]P,=^A/0[QS2U(9GT-AA.;/A46L'G]OP1+&#+VQX$-;! M+1N>]V`.%:E-2LZN%A-:NBX"ZE&;%$'8!\I2F]1"N`6J4YO4/[@%ZD^(;5?+ M$EJ6G2TK:"$5(U:#`MXFY7E7BPDM73Y0N]ND9L0^4,+;I'2$EN$E(^"'">?L M+4^RZJTXU;U#OH,$A+?M<%JNZ$\;Z!\-J\]>RP9^D="6:GOX"4H.+UU'`S#> ME67#_R`=7'[4\O(O````__\#`%!+`P04``8`"````"$`1;+T;``)```T*0`` M&0```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`7UP2>"7P3!"8( M31"9(#9!8H+4!)D)\A[0Q*1$`3$=2O+AF9W'IO"B.5P;FPM=K$UK0[G+:FV! MN$`\(#Z0`$@()`(2`TF`I$`R('F?:%)2JFM27I=06-,,0=%Z^;TT-)1&\R;] MK:G^=-L]'0ZA58[>(Y^HG+!N*L=]MY&DUYM`7"`>$!](`"0$$@&)@21`4B`9 MD+Q/-,'H'?X)P82U+I@D/<&`N$`\(#Z0`$@()`(2`TF`I$`R('F?:(+1RN,3 M@@EK73!)>H(!<8%X0'P@`9`02`0D!I(`28%D0/(^T003FZ._89T@PNA*2D)3 M?F]JN34FC\Z(4]P%X@'Q@01`0B`1D!A(`B0%D@')^T03EQ:*FKC7)V-AK6LH M26\T`G&!>$!\(`&0$$@$)`:2`$F!9$#R/M$$$TO\3RC6F.N2,>IIALA%Y"'R M$06(0D01HAA1@BA%E"'*-:3K)Y:K_72^/N+$ML@83IK4R=E.>LN+P/J(`48@H0A0C2A"E MB#)$N416TT9=:;&"!:7I/$8*_4?Y1G)]2G6Y)NZKWB*G/0T2.\^M6.N*CNBK M+JWL=G\[M6;Z6\J3/HY*`!_#!(A"Y=CLG*>6HT>.E`%W98QA$D2I%RE&I8JJRO%9=)JN&&YBD$EZ1TI=A+]K/I%C\F-1S]E6F3WUVV.V=:M M.':E?K65H\M()8DGT:P5S=#+1X>`D0H;,E)A(Q562>A,C5DR5H[*RC93.V$K M56+*2)68241'$B+;K+FU,,X9M**44*/2F1HO M')]C]9,0QF[`5JJJ(2,U=J/A$HTSW%@YJGI!B0E;J1)31JK$;+A$R)A.G.$2 M]4X46ZQ/=*+A,C=UTK!Q[]<(IKZU]KXVIXEIO'?M^VR$A06&5(*^7HBG6)>(TU/UHV"P^/$;W@NA6+8QYZ^FSU MBP2%$D-V5"5&C!;-R\69KT8_S1J+254#;ES"7JJXE)%> MG-&:C*W:XN;V[?02(XX!K:5\D_3]1?Z"7-#OQ;-529MQ9Q(5CWD(O(0 M^8@"1"&B"%&,*$&4(LH0Y1K2]1/;^/ZX_(5^\B!`B;6A[4PCJ1IL6T0N(@^1 MCRA`%"**$,6($D0IH@Q1KB%=OZ%#`(?NG/!EC@]?&J#W*0S-%LWIHYM1Z=Z- M/NMMI2-9\:SG(O(0^8@"1"&B"%&,*$&4(LH0B>M03?HU#6K5;J\WM7Y,LU_7XTP&_7]-/'`%^MZ81_@%O3M3B['GI"+:1367Q"1Z)K M<;`X],19BY,Y?$+';FMQLH9/Z-B,H@T]H;MK7X9*V8B*#43:".&'.,D^&']& M\9M18(H[7]//OU352?>`[JR][5Z*;'=Y.9RKT;%XIH$Q;&ULK)S;;E_7N M?OOR]6;PG]^27V:#J\-Q]7*_>MJ];&X&?VX.@U]O__F/3S]V^V^'Q\WF>$4* M+X>;P>/Q^+H8#@_KQ\WSZG"]>]V\T)6'W?YY=:3_[K\.#Z_[S>J^=7I^&OJC MT63XO-J^#+3"8O\1C=W#PW:]B7;K[\^;EZ,6V6^>5D>Z_\/C]O7`:L_KC\@] MK_;?OK_^LMX]OY+$E^W3]OAG*SJX>EXO\J\ON_WJRQ/U^P]OO%JS=OL?D'_> MKO>[P^[A>$UR0WVCV.?Y<#XDI=M/]UOJ@0K[U7[S<#/X["V:\70PO/W4!NB_ MV\V/0^?OJ\/C[D>ZW]Y7VY<-19O&28W`E]WNFS+-[Q4BYR%X)^T(_&M_=;]Y M6'U_.OY[]R/;;+\^'FFX0^J1ZMCB_L]H;@>]?A]-1X)'YU9?-X9ALE>3@:OW]<-P]_T\;>49*B_A& MA%Z-2#"Y6"0P(O3:(W*F];%QI%?C.+.-G_&C_K5=IU?CY\^O9V$XGLRFQ,YX M3HPGO1K/\-H;CR8J9&?>92` M.A]4)NJQ_E#?O%,BT1\?ZYW'::/^N*A_'N>*^H-[>#[V'F>)^N,#'1OJ>=). MNVAU7-U^VN]^7-%:1MT[O*[4RN@ME!9/.#T:ZFMC<]=CXUHLV4+-:R4;21!+D$B02I!)D$M02%!*4$E0 M2]!TP)!">XHOY<+?$5\EH^++D;EC8`/NBV"R!;M$$L02)!*D$F02Y!(4$I02 M5!+4$C0=X`23IH<3S/ZG`N>DLKX9T+^GG`P\F9/:AF8L1VD))`(2`TF`I$`R M(#F0`D@)I`)2`VFZQ`DA3?$+0JBL:64@M4X,QVZBW6FC,-33WG.O+D]7^R6< MFZ,U[X*;4];MS?'8W6D2SNUH`HF`Q$`2("F0#$@.I`!2`JF`U$":+G$"1D_L M"P*FK-V`:3*AAV-G?$,Q@BW&4)-NT@&)@,1`$B`ID`Q(#J0`4@*I@-1`FBYQ`J9J+=PR7*M-YO%Q MN_YVMZ-DHN=AS^H&`E]A69:W.M%6[;4U',S=@C56AMMRA5/OQ[B+USI#I[3MM=/BF[U0%2)'W M;O:J_;QX*AA$V=Z-\%R.EG;T;:)%[#@^S9R8D7IJ\6E`X(],6-H;BX1J MV**5=D=+%EOM:/W,XUR=T,B1T\B=9[[H_](X.O/,.-J0Q,:*#GCMF`0^/$W, M371SI6?DM%6GQ8SE;8LY([4Q_/V6#BHG(KR%L:!9S9.S-*@C7;&.E:X9:6EO MY,T#T9/&T7:'3I5<,-%^:NB4HM@5:.1,NKFLOM3IMUHA;9I&!HWI2F?JB.U4 MS%8ZO-$PQJ< M`HXR*:+,.KYQJF$-6+E`F1)191W?.-FP!JS<.#+N8,B"6*;]Q\XV?"R4&5&N MGW8C@2^V<4MC13?(-QOU.?JRSHK9T91+DUDH%O^D7T?<0,HZ]@:R?D>YC6%' M?0,3K-<*J\-]*]G)ME99*QLG.,JIV=&T%@:P:;4ZU)H[QJIREDN;/U&?E.@[ MC.T<6?FFYNX\)0Q2+YUA%3NX)5M9QXB1W8K'!M&12%=+''\EUM%:85W!5K;% MC)%M,3,K'(ME$>>"$GC^+CC(ZOW\[LAVO++9PPC M=Z[)0Q5CY2 MG:QTA58U6VGI^70BE!O'QPV_JDB[T^.=\)LRUZ;#G6]J6G=.B..;)5M9QXB1 MS:/8(#$GQ(E+8AW/S@ES7[;%S#KRV.6]+0:B2"JLXYD62[:R+5:,;!_K_A9% MFC76L;]%=Q!5?=@=1/D<^]`)F%H1Q?:-D3.UY.*[-%;.U-):8]OOV%B-S='# M>!K`,\O<@)V/*4IGK&.E^1*E*]:QTC4C+1V,`BB@ M'6EW6'H+Z)_:ZV$M[6LTIFRWCR09VJ6QHG6`^Q^Q(P7]Y-BSTS#R;Q^8L'1W M_O<\H;1.YP:R_AL0SZ2T5K/5F0,3UFZ3Q!UO M6=C+:?C![206_+XIY>W;)TM$$:(848(H190ARA$5B$I$%:(:4>,@-ZZJZNXN M;^\\HW21WCTP\35R#TP"L1M>6BM.I`A1C"A!E"+*$.6("D0EH@I1C:AQD!M2 M581?$%)E+FI,C2BD'*RE.K,EJPZ*$,6($D0IH@Q1CJA`5"*J$-6(&@>NU6-K14/48(H190ARA$5!O4< MZ$E`GUL6<'=4-.5(/<]\("4:`MC55W#\=:-*L[&P3QQ(S9 MT90UP6@4B,U78H4X$"E[V=4CLU9GFLO9T30W"4-?5'J%%:+FW"!?5FL&6&L: MI!:&4TP"V>$E6]GM1\3(IEEL$$VC-H'\T/?%#$[0*V5DM3-&5CMWM4-:&\3# MKG"+&CMM=H)%()G$'2[:RCA$C M.^"Q02:9QI/Q?`YA,LU9KY2%K';&R%KEKG;HAR/Y8:O"\7+#I#;^%X1)UPE. M-ID2Q/F<6"!ZMPQ,@6%'/#*H4_3%;'5:/N9PP(->*7M9[0RM[+R:90'&0LV<@.>,3(#GALD$DF+QS/8$DWC5FG ME'6L=,;(6N5".O#D657A.+DQDG6`?$9^;-.%Y4&@D;M>!6(Q7AHK9[TRCK:# M,6M1@.P30AX:),9*O4]TLL*B&5O,6-ZVF#-R6Q0'2L5[+;J15COY[J3]^0V< M4A0;.(VQVK2V:149)#[J(1QCMC*EO#\9S4;RQ(G%;3131K:] MC)5H_>P,EF@O9RO3GIK]<]%>P>)M>T[$5>YAQ"_^L$4KXX;9H.X[VX@B1#&B M!%&**$.4(RH0E8@J1#6BQD%N7-5>7F;RV&O?_KGPZWSJ5%JDL$'NN<)8C/K2 M6O'^-T(4(TH0I8@R1#FB`E&)J$)4(VHQ8 MQ8@21"FB#%&.J$!4(JH0U8@:![GQDQ6*6GC]4'W9X=)LQ>*%CMY5M$6VBL)@ M::ULMIX<&<5HE2!*$66(RU=0"]M%PIX[= M=4@Y,DM$$:(848(H190ARA$5B$I$%:(:4>,@-WZJHNC&[Z]GJZY-NMM^]7C' M;)7G%M:*!R!"%"-*$*6(,D0YH@)1B:A"5"-J'.1&^[)*:HR5E$&=`]HEH@A1 MC"A!E"+*$.6("D0EH@I1C:AQD!L_5;/\/=FJJQ\G6S42:ZLHFY;J0^3N#E?KW7?U M$R5T['3[Z83U[Z?N<&7*/[HBK_CSA3JYI_5`7AF/ MR*05^BFV_-JR3WJISY( MAROD0A]\[>F--Z,K[:\?2!^??.CMM!X?GWSH72&\$@6CA3KD[[OB+6(ZN,8K M=`1./GU7Z!=Q/O?&C,+<9W]'0>ZUIQ#W1?CS>/&94@]OZ8XRJ3>1*+Y]:13- M%O155-2)YHNX+X6R^8*^DHGVU7Q!7ZI$3A]M7:@/B/9<\4>+6)\EB.&CCT\N M\MXK]/''1:VO#$].]$L_KZNOFWJU_[I].5P];1YHFHW:;S_M]6\%Z?\B;O\/``#__P,`4$L# M!!0`!@`(````(0`/5@@KT`<``!HB```9````>&PO=V]R:W-H965T8=S!\W[%E^2@D&<36^83%8F;W6K&56&C;,B2E MT_WV4Q19YJ''H74W'@[*T[;> M5:?7A^%??_I?EL-!VQ6G77&H3^7#\$?9#O]X_/VW^_>Z^=KNR[(;@,*I?1CN MN^[LC$;M=E\>B_:N/IB@S^;UU%[;LIBUSVX_8S MJT/5_>A%AX/CUHE>3W53/!]@WM^M:;%%[?X/(G^LMDW=UB_='C MU0B4'N]W%#MV_Z_>PK%[W'81[!C-B$W-V M/]RRW8)'0>9N,F-*V_H``X"?@V/%E@9XI/C>7]^K7;=_&$Z6=]/);+&TP'[P M7+:=7S'-X6#[UG;U\;_G`1/NG0%7T79YMYS-IO/EXO.^F`L1N.(T;G8%9&<_$+C>/(F5:`M7 MT79QNQ?WA@&N263\,X:>R)A>ZD];(3TA`2$A(1$A,2$)(2DA&2*X2S6'P:+[! M8XP0905 M1HA+B$>(3TA`2$A(1$A,2$)(2DA&2*X2S6&LO%*/!Q_ON,Q:=Y@@L`LH&\C* MV",N1IC)+B$>(3XA`2$A(1$A,2$)(2DA&2&Y2C0?P@'V!A\R:]V'@BB+CA"7 M$(\0GY"`D)"0B)"8D(20E)",D%PEFL/8H?T&C_7FNLL0*3L;12Y%'D4^10%% M(44113%%"44I11E%N89T_['#Z.>SUN)G5WC*8_ZM$2EKCB*7(H\BGZ*`HI"B MB**8HH2BE**,HEQ#NO_8^5/U'R^*[ECQW.VK[==U#;L9>.W*;FC#*4B41/P4 MJ[E5(/[2@54X&U91LGR?7YSO"F1#!W+3'!N;IB>M,&H^10%%(4411;%`RK@2 MBE)L"'N?'*IEE'69M,*AYIJ6[GQV="7.A[]S<$0AR&U?4MD!H( M@=1`<&1/>$$[MJ;Z@\MC!V,('AC@Q'R!%+\%%(6R85\JCRU;5XZD`2K'5":A M*,6&VN*QQKI\)JU0/M>T](BP,SR)R$RF`X;D2CK`N[=+/HA20`V#0/`DD,O' M-@:[8:\EP,N3_@6B>"]PK:$UT6?I84.KCY\U'D]7*T/<%S;\U68O'F`SV5\H MK92!FOU%V)#W-Q^OYK91*\52"!V?8"O972JM/N@NPX:\.WLULV>&!W(I!-WI M065%A1G4"9P#;\@K49>H`>5H`IN:$E!C/]BP][HLH+*ABT@^L#U$8*QH&3/T MT4KKT4S4`*UDCR$BV6.$2._12,T8K3[L,4$KV6.*2/:8(=)[-+:9'*U^UJ,> M6%;\F(&U;L]644/)\:]A3^MW.[@H`3$+?F&E9:O0ZC\?]#GFH15?NZOE4)9(_Y[CB?T@A<>L/-*D`=*1TB MDM*1+FW/Y@MCB#%ME""2TBDB*9T)--6>;[;Q6B^7#96EJNP*>EA8Y::&Y7\[ M[HGZ3PY_;0FD/]Z,1\)&6"F+VA5H*N?M(5KTT2)/L4M/,E(<*;(A:DC9"!&7 MG1ICB\5M)0<3@13=%$6D;H8(5I"R5QAGV%S**U8_#1.K%TF8?NE@*"I0-60< M3>%\<1FW;>S'&W`'>7Z)=MI&;AX0/-%P.L<#R6RR(@\T(2Z=&=#^0E3ZL+\( MK7A_<]N:FKM5C-JRNP21=$N*0A]VEZ$5[\Y>V,NE,3OV";EW7=\=ST+^29A_ ME#J6S6NY*0^'=K"MW]CG7LCDQ_L+YM^BH3R%C]']V=V\,W/@;2GD@,GG#KP4 MO,(7#KS[NL*7#KS/N<)7#KRVN,*M,8RH?W08/4,UY[#ZBK:!XLEAI1&]XUJV MPVH+>@<*!U"[=@<._J!V[0Y\N7^ZULN:.?%*'^N)`Q]@:-]KVX'/"I0_39TG M""O<&%WF#E_FS\5KF17-:W5J!X?R!4(Y[BN&AG_;YW]THIA[KCOX)-_7=7OX M'XP2*N,QJ_A>ZKK#/U@'E__J>/P;``#__P,`4$L#!!0`!@`(````(0!'@7Y! M)`<``!8>```9````>&PO=V]R:W-H965T7QYY_6'W7SUN[+LIN`PJE]4/9==[9GL[;8E\>\G=;G\@17=G5S MS#OXMWF=M>>FS+>]T_$PTU5U/COFU4D9%.SF%HUZMZN*TJF+]V-YZ@:1ICSD M'J^]&+*I-C88>OI[K)7PYPW]\U M,R^8=O\/DC]615.W]:Z;@MQLF"B^Y]5L-0.EQ_6V@CL@89\TY>Y!>=+L3%LH ML\=U'Z`_JO*C'7V?M/OZPV^J;5*=2H@VY(EDX*6NWXAIN"4(G&?(V^LS\&LS MV9:[_/W0_59_!&7UNN\@W1;<$;DQ>_O#*=L"(@HR4]TB2D5]@`G`W\FQ(J4! M$5,GDIV\ZKB)0R*=[;KC[^22]2B<%9I\[PR9S-J;ZT-&L. M@]VJ8E`5^&0JZE0SU7LT3*H!GU0#YG3C769%,@/E'4+"_7;HV&L9]]@;1749(----'BF5F0A414'1FX,O!DX,L@ MD$$H@T@&L0P2&:0RR$9@!I&]A!?*Y?\(+Y$AX661V3#`XZU+P606S,61@2L# M3P:^#`(9A#*(9!#+()%!*H-L!(1@PJH1@GE]&V8E2:P?%/A[*4E=6XE!V@PV ML*A9E)X1<1!Q$?$0\1$)$`D1B1")$4D021')QD0((:SP.T)(K&%C`#4>0UV5 M8C@8&4:_ZDWQXO/EXG4%86ZP'=\Q-V+=SXVE;D/)*)F(.(BXB'B(^(@$B(2( M1(C$B"2(I(AD8R($;'Y7P(BU&+"!&":O?D0<1%Q$/$1\1`)$0D0B1&)$$D12 M1+(Q$0*VN"M@Q%H,&"6C"D/$0<1%Q$/$1R1`)$0D0B1&)$$D120;$R%@Y"`S M[@X^WW&)M1@P2F`7&&T@\L_^Q8BM9`<1%Q$/$1^1`)$0D0B1&)$$D121;$R$ M&$+C>4<,B;480TI&18>(@XB+B(>(CTB`2(A(A$B,2()(BD@V)D+`-#BGW1&Q MWEP,&4.CG0TC!R,7(P\C'Z,`HQ"C"*,8HP2C%*-,0&+\2#-Z^ZK5AMX5?N79 M^MLP-*HYC!R,7(P\C'R,`HQ"C"*,8HP2C%*,,@&)\2/]YSA^PYEH2LZ+W;XJ MWC8U[&80M2N[(>F"Z(EHZ&*%L`[(6%TB_4S.DV2]SR_(H7`4G)E.<`S MGLMZ&(X",`X;-T#\3-CO>?GH\D&66NG]HSKZ7(!JP4\(=]0D1YAB(NQ(:+F1!T<24DB/%.*7_D#IZ`AFG;D"ZD`%=*N-G\JP4$JQS M1XV4 M(E-8:[I48AEW'&>36XF)(4>7<6+^W4_/<``2EAI%8KZD,#_#MM7GBQ>C0Y') M[]ME:#CQZTO#FL_%0O>HB;"ND';`A+AVR-"@K5F&NI***L+:,46C+2)A0EP[ M98AJ&ZJYD+0S05O,##DCHNKB1;:!=QG]A@C;VV5?6Z$D#4;"HJ)^ ML-PN?CK>#ZG5O%]G*]-:R!N41R>@\ZCY#/%I!FR:GPX7,JMA.$U7YY:Z%.LD M8N)\O)@A/E["E,3QI-RES&H83Y^K"TLR(>^*^OJ&IFL4)WDM#J^#AJ?DQ[)Y M+9_+PZ&=%/4[>=4#&H_K"Q[>0T'##"^B-/(C(E^Q;'A^&6,C6[#(V$\]L:PX4$GYD^F_019@@NSR[W# M6[ES_EJF>?-:G=K)H=Q!*M6^AVF&]WK#/QUM+U_J#M[+]9WF'MZ_EO`V0B4] MZ*ZN._8/&>#R1O?Q+P```/__`P!02P,$%``&``@````A`(M#OHQW!P``&2`` M`!D```!X;"]W;W)K&ULK)E=<^HV$(;O.]/_P'!_ M`K:!@"=))^!/;#.=SFE[[8`3/`',V,[).?^^*TN+/I:D<-J;.#Q>K>1WM;+6 MNOOM^W[7^U;435D=[OO6S;#?*P[K:E,>7N[[?WX-ODS[O:;-#YM\5QV*^_Z/ MHNG_]O#K+W?O5?W:;(NB[8&'0W/?W[;MT1T,FO6VV.?-374L#G#GN:KW>0L_ MZY=!SS\M#G'MSZ$A_5\W.Y+KQJ_;8O#BUW4A>[O(7Q M-]ORV*"W_?H2=_N\?GT[?EE7^R.X>"IW9?NC<]KO[==N_'*HZOQI!\_]W1KE M:_3=_2#N]^6ZKIKJN;T!=P,^4/K,L\%L`)X>[C8E/`&3O5<7S_?]1\M=6=/^ MX.&N$^BOLGAOE/][S;9Z#^MRDY:'`M2&.+$(/%75*S.--PQ!XP%I'701^+WN M;8KG_&W7_E&]1T7YLFTAW&-X(O9@[N:'5S1K4!3W+]G4 M`$7R[]WUO=RTV_N^,[D9WPX="\Q[3T73!B5SV>^MWYJVVO_-C2SABCNQA1.X M"B>V?3.RQ[?3:[PXP@MIDN`.I^^W!'H[N!M\@W=;"9DYM+-UB@18LMYA;SP2^"0(3A":(3!";8&F"Q`2I M"3(3K!0P`&E/^L+$^3_T96Z8OJC,'($BN"$F6F`3SP2^"0(3A":(3!";8&F" MQ`2I"3(3K!2@B0GY0\1T8)T_OT+CW&2M8"W6YN98%VO.;2#-4:T%(1XA/B$! M(2$A$2$Q(4M"$D)20C)"5BK1I(14IU).V8OM7]1D#6&Q`,=*JD\,.;F1XW0K M@:/?7`@/T)/BX?9DI`T3C+1A?AYI9MV-#:,X%T2)*R$>(3XA`2$A(1$A,2%+ M0A)"4D(R0E8JT02;7"48L]8%X\09R40@Q"/$)R0@)"0D(B0F9$E(0DA*2$;( M2B6:8+=7"<:L=<$$4688(1XA/B$!(2$A$2$Q(4M"$D)20C)"5BK1!&/ECKIC M^#PEF;4NF""P"BCI/SVE?_?B7YR,,),]0GQ"`D)"0B)"8D*6A"2$I(1DA*Q4 MHFD(N](K-&36NH:"*)..$(\0GY"`D)"0B)"8D"4A"2$I(1DA*Y5H@EGPEK]" ML=CPVM+GS3\7!H M&SN/0)A8LU/VA=A*=A=)*SE,TEV,#7EWM@W?`J=&Y;F4GE#W!)O)_E)II?9G M3)$,&_+^K)$]=,:RL.J$6IWW)*>Q'F=69WP6Y\N6/5&MJ&'FR(:E3H;9B-:" M?7QE89;M/$3R+>XCFO"4'$UGPZ&QW`1H([,R1"2=1XBD\QB1<#YC4\9POD0; MZ3Q!))VGB*3S#!$\YDD$VS(FR`JM5*EL9=W1`\;JG,\"=F%B\G()%@"4B:A=A,YD4DD)*M,5IQYV-[ M/#Z3=,1Y@LVD\Y0ZSP1RH#I25"`Y=G*O6GV48ZS2^BQDE^68J-?4B'&DY9AM M&>O=PA)6LJ&'2$Y5'Q'/@]%L0M(@0!.9!B$BZ3M")'W'B-A[X=L#R:[34^!4 M3+"!=)LBDFXS1!\/>84FW9#U/&*E&PG*?]IRB&)0#GH.AUDDI69&^B^$D991 MO)T-RBB3T%@]?6PX[61UIL[X3)*)03Y.'N MA/E1)%1#JY#/< M&L*(.A&-GJ%X<-EVGK:!O;K+=N+TCF/ MYWJ9,Q'/]#&W73@"H'W/'1<^:%/^.'(?8<[`C<'IV>%@]IB_%%E>OY2'IK&PO=V]R:W-H M965T&ULE%;;CILP$'VOU']`O"=@"+Z[?Z^&%Q8OQ)'`B1#C`T8ND>I&SGGB>* M`ZFQF+*6-+"R8[S&$F[YWA,M)[CL-M65%_A^[-68-JYFF/-;.-AN1PN2L^)8 MDT9J$DXJ+$&_.-!6]&QU<0M=C?G3L9T4K&Z!8DLK*E\[4M>IB_GCOF$<;RO( M^P7-<-%S=S=7]#4M.!-L)Z=`YVFAUSEG7N8!TVI14LA`V>YPLENZ]VB>9ZZW M6G3^_*+D)(QK1QS8Z1.GY1?:$#`;RJ0*L&7L24$?2Q6"S=[5[H>N`-^X4Y(= M/E;R.SM])G1_D%#M"!)2>1HD?(H`[6R+D`U64KE,,UA:G"'K:P@:(S8]0OFG6',CX('<03,X86K^>Q5Z:0JLI/6L:QT` M[D%K8`GY"R(;0_)K2)P.D)'8<"Q6&1Q"`[XM6FT"G*$Q30;ZSIRUALR&O#9V M(#<"(T50YMOM4^"E"^D.;J671+42#8F[LD]0G*#(^ M!NH,UY.Q^.+/;H'_H5` M&Z]'HIX8->%[LB%5)9R"'=6X"Z!?A^@PB>\#]5*RXFN8T-T\\X8%F)`MWI.O MF.]I(YR*[(#2GR9PYKB>L?I&LK:;4ULF839VEP?X%"(P(OPI@'>,R?X&'NP- M'U>K/P```/__`P!02P,$%``&``@````A`+2%1D#H!@``.!\``!@```!X;"]W M;W)KQ)LOJNV5Q<"[)5V MI=5J/YYI0AK4)$1`;^_]]SO&3L(,CDM>2N,Y,_$?_WE\:-NWMI= M678SB'!LGZQ=UYT>ELMVO2L/1;NH3^41+-NZ.10=?&Q>E^VI*8M-[W38+[EM M^\M#41TM&>&AF1*CWFZK=;FJU^^'\MC)($VY+SJ8?[NK3NTYVF$])=RA:-[> M3_-U?3A!B)=J7W4_^Z#6[+!^^/9ZK)OB90]Y_V!NL3['[C^,PA^J=5.W];9; M0+BEG.@XYV@9+2'2\^.F@@P$[;.FW#Y97]E#SGUK^?S8$_1O57ZT@_]G[:[^ MR)MJ\WMU+(%M6">Q`B]U_2:@WS9B")R7(^^L7X$_F]FFW!;O^^ZO^N.WLGK= M=;#<'F0D$GO8_%R5[1H8A3`+[HE(ZWH/$X"_LT,E2@,8*7[TSX]JT^V>+,=? M>('M,(#/7LJVRRH1TIJMW]NN/OPG04R%DD&X"@)/%839=P=Q5!!XGH.X"QYZ MS//OF(JKHL!31>'!@KGV/3$@\9X3>)YG$MT;PU&LBJYX?FSJCQET(ZQE>RI$;[,'""PJQH&ZTU<,E(KP^2J< M>E=`MU#FWY\C]W'Y'2ISK2"Q!N)A2**!^!BRTD`"#$DUD!!#,@TDPI!\#&&V M?<$L@:P+8U#70\;,3`GPDP5_+TPQFUWB]FS&$N-+'FUNNXZ#$D),$V/+&\L M,3*;,/(&M/;I)]+N]ME>B[*WK0RV]).XF<$WU]L0#[!S#7F8MG4()\H'J=58 M8B0?\\BQR=HFTJ[GPV!+#;;,8,NE332%?'$B._U[/# MP88DZT+:KVVQ&CJP(`K)=IJ>'<2.30HI&_HZ/!QU@]X7$0#GQW0"!)@20.8; M2\PUP>0\H$E@=;8)62,VB90.9')`K2/S;$IH/O!`B0E]/#@DS2LKP#0QAD]\4X-O9K#E>AOB@8$^FEX./9HR04[66($D%1&+0!B20R)!$*T(0(@H M"ASFDH9*$63N<3>TR?=D%!+Y'EF7G$!LQJ^;"69*R*K)C<.D"`.5<15+[!JY M;XU8@09[@AI19234T4@,C)S2T4B&PG"7C_7`T`>G*831]#2EC$)ITE6(F03) MI!@+G(@L0J(0^NXP&=-/8V< M.-"L".EO]P1!]/)A&`3> M?C#F.(37%$69NW8`;P$P]1F&>/"FP273S3&$1>%@!\)4"34VG2JIW3!5]%4" M.PN\<]\G:D0=*'K]0)W249@,A>&.I]$/@R@H37Z7H.S15%`2%1F8'RGMX27*!IK5`%H4"J`9A+FCY1]NO)NKJ,B),U\DF/I?>:=FKPSDS&_8<1\W"47Q041 M+7HVVB`E2+UUYQZ<082R1,61$.V1B1!P9+K??\D-7G_JKJI>Z@QO+ M_M\=W%"7\(80KB6MV;:NN_,':.;EY<[[^7\```#__P,`4$L#!!0`!@`(```` M(0"5>D4++@<``%H=```8````>&PO=V]R:W-H965T&ULG%G; M;N,V$'TOT'\P_&Y;O.D2Q%E$$K9=H`6*HI=GQ99C86W+D)3-[M]WJ*$MSLA) M[+[LQN31Z,R%3"?E856OJ\/SSJ0[F<_BC;Z:>'GW^Z?ZV;K^VV++L)6#BTR^FVZXYWBT6[VI;[HIW7 MQ_(`,YNZV1<=_&R>%^VQ*8MU_]!^MY!!$"[V1768HH6[YAH;]693KK>G\$$T_5KNI^]$:GD_WJ[LOS MH6Z*IQWX_5WH8G6RW?\8F=]7JZ9NZTTW!W,+)#KV.5DD"[#T<+^NP`,;]DE3 M;I;31W&7JW"Z>+CO`_1/5;ZVWM^3=EN__M)4Z]^J0PG1ACS9##S5]5<+_;*V M0_#P8O3TYSX#?S23=;DI7G;=G_7KKV7UO.T@W08\LH[=K7_D9;N"B(*9N336 MTJK>`0'X=[*O;&E`1(KO_?^OU;K;+JR[3Y7UN1TLGIINWK_ M+X*$,X5&I#.B@;V;EW,9&V'"CZTLD%'O8%YTQ<-]4[].H&K@G>VQL#4H[L#R MR3/D[??121&CSXYE?"#W!@@E2/3U\;/@Y13\/8#`C%DS$ M>,'D`[DW0"B%E-+[>;5@&DPA>#01$_71U#H,-(M51@!"JX`YD_L`E22A#L[> M$NK1+=0MF%-G:4X1@]1E'+&*S>ATHL^L<+G3:>]I0MJ*JM>QWH^W!3/2<@@& M5B]BD/0LCDW"`)D/B",1,K=R?S[1*AJ>)\236XA;,",>\$)!#!)701"P>&9D M7BB^*',R;Y)XJ#/"6T"WNC[B/9HQEX)F.G4@5^-&L#K*R+PR(F*`G`"$E.%; MW*V$7%TM`@6'M%TY="(L%P?R6L5H)/=':"RM;ES/!U7&[[U"*AY+!+GZ59&* M8T8Y$P0"FT?#2Y@A9&3,4&W4`RLJUWN`$N1[H$8.(`8=D&$0&8;(A(_06NI1 MZR`($>EP,$'96YVYGCVJ$F$_%)HK!\0X]D8/8>OG,^'/:Y,(WJP)8`;Y#>5@ M@Y*W$N21OVXK83>JK)5HUBE2AT$G1!2;<.AAS@VTXJK,1,E(P8D-6++>!I!Z M8=7)\^+]!BY0R_P4:%:\J<,@MS`<]6\WKWM%98[EY.%9+,T`H+2M.GFTKPP^ M:II/7\A1]'WA4P%4`$-DPD>(((E#GJ"<0)36R@L#=<3*U>V.H,C!0CQO`^'C MA;%0@OM+-A%'&;V^NP`G&)%&8C%8J@4"/ M]+>QQ!=YDV3V:"Z9[.6I`[D^`V(-@D_#GU&(CI,1)"<0#2O=AU`7;E).BUWGE*B;I.$HOH]T(*_AC$9R?X3R8G+Z06V,950HMM%* M[4$,%-`I<(D]X>&+E$)BH?GW7;KI5BF^!6-A`N@TYTC0-#!A_2`-%P25?_^F$D$7UU]&)E7"FE3N MII%V),.AY"AK*V/>"OV`-8H>79E,Y%.)H%/QV"_-(>VNL5"(2>1(I)@5H:-D M*$'J@I4SSX4KBP=%D+HRK'S79(A2"BT#99B@99)@=*"48A')"43$B00[EXO( MGJC=[DO_%.OWBF\>'`C3(B6!X9S`.7['1]S8D0R'ZD'5D6]NGI_:2B+YAZP19DZ$"YH M:8:"=O31QL7UGI-G(^\0A9)FBOL!Z4M*RSIDJGRE-;$60^TZVCX@C`+OBZD' MY,1"9,+XC6:DF,)^0/Z"LGHGA/VKT]XD'*YZI\OXV#"2^Q@:3*:LMK-\?$RK M+BBL'CQVO'SYE$:H>!15@E!Z]*'JWH/%KHTG7-2)_Z6M<`TU*F?-ZC5U(#PP M'S/,R/P,O@ACWAD)(E&CJL:K++SIV9?-?1\A?8H M;;+9>`I7:_T]U.(\`3=;Q^*Y_+UHGJM#.]F5&S`9S".(>X-W8_BCJX_]_=)3 MW<&=5O_G%NXP2[C9">8`WM1U=_H!+UZ<;T4?_@,``/__`P!02P,$%``&``@` M```A`-\D)+86`P``]@@``!@```!X;"]W;W)KB4"WV\^?-B?>1!B#2`H181*J1L0LL224$J+$S6D!J>9(Q76,(MSRW1 M<()3O:@J+=>VEU:%:8U:AI!_A(-E&4W('4N.%:EE2\))B27H%P5M1,]6)1^A MJS!_.C8W":L:H#C0DLI738J,*@D?\IIQ?"AAWR^.AY.>6]^\MM86,&TW*84=*-L-3K(([9PP7B-KN]'^_*;D)$;_#5&PTQ=.TV^T M)F`VE$D5X,#8DX(^I"H$BZVSU?>Z`-^YD9(,'TOY@YV^$IH7$JKMPX;4OL+T M]8Z(!`P%&M/U%5/"2A``OT9%56>`(?A%7T\TE46$W,#T7'\5.(`W#D3(>ZHX MD9$!-M#L3U"/F M@L"HL:#+/=-[H\`1@M^1-]XTT;[%..X@+AY')F9XU^168*CL-+D_2]Z![+9N MTX?Q\'`L_XUA(@U:]N.V*+"6-M2CBXQ,&$!R5ND!-._V]538 M^]VNP-/D761DP3C26M`>T^W!5!&>DYB4I3`2=E1'L*-:2->`5S!XF8=[HOP5\ M7Q`XZW0;98S)_D;5>/ABV?X%``#__P,`4$L#!!0`!@`(````(0"?B7[#4!\` M``K1```8````>&PO=V]R:W-H965T&ULK-U;<]O(=H;A^U3E M/ZATORU2)'5PV=YE"^=3I5([R;5&IFW56)9+TGAF_GV^)M%$KW[;LN'D9A\> M-$#ZZR:X%@D1K_[YU]WGHV_;A\?;^R^OCY7]]>?[+]O7QW]O'X__^>;?_^W5G_7+R>/-I>W?]^.+^Z_:+MGRX?[B[?M+_??AX\OCU87O]?K?3W>>3T\7B M[.3N^O;+\?X(+Q]^YACW'S[=A^OG[2\W_\=/OUT1_M M[N9G#G=W_?#['U__<7-_]U6'^.WV\^W3W[N#'A_=W;RL/WZY?[C^[;/^W7\M MU]/-P_WG]X>J'#G>R?*/_-ER>7)SK2FU?O;_4O<+$?/6P_ MO#Y^NWPY+#?KXY,WKW8)_??M]L_'X'\?/7ZZ_[-\N'W?W7[9*FY-E)N"W^[O M?W=#Z_>.M/,)]BYV4_`?#T?OMQ^N__C\])_W?U;;VX^?GC3?&_V3W+_LY?N_ ML^WCC2+585Z<;MR1;NX_ZPGH/X_N;MW:4"37?[T^7NF!;]\_?=+_.GNQ.5^L MEAI^]-OV\:FX=8<\/KKYX_'I_NY_]H.6XZ'V!UF/!]%_CP=9GCV[@PZ]>U3] MM]]A\V)]NCF_V#WL,P^EX^[VU`+V>S[_4)?C#OIOO\-//M12D[%[K.7IM._S M#[94C/M=ICR7/_MP/L7ECV(\V<_A;DEDUT_7;UX]W/]YI!>:9NGQZ[5[V2Y? MNJ/XQ;#/\[`\OKMZ6]OENOS5R??M`QOQC'O$F/L MB"L_PJTY=]@LACR&(H8RABJ&.H8FAC:&+H8^AB&`$T5[R%?KX/\C7W<8EZ]/ MYIV'*?#3*$P_PN^2Q9#'4,10QE#%4,?0Q-#&T,70QS`$8,+4*P1AKO222Y^Y M_-IT>^W.5L':O+!AO=N/T:O6IW4%R2`YI("4D`I20QI("^D@/60(Q42IESJB M/-V\^.[;@`_3[:=SA8X;I'D9I3D.6NQ.!/&Z/&Q,'\$\2ST=\RR?GV@W>O?< M_"2^&R685D@&R2$%I(14D!K20%I(!^DA0R@F,+W7S`C,C;:!C;*K/G:GX"M( M!LDA!:2$5)`:TD!:2`?I(4,H)K#S68&YT3:P48(5!LD@.:2`E)`*4D,:2`OI M(#UD",4$YMJ`L&!X_B7I1MO`1M$*GDX@FX4]@5PE!RT/@\P34I4VXPFYT?8) MC1+,("2#Y)`"4D(J2`UI("VD@_20(103F"M29R2V&VXC&VD5G"9(&2DG%:22 M5)%J4D-J21VI)PV&;'ZNUOOYE\!R7QKJ+?/PMN0I6'.DC)23"E))JD@UJ2&U MI([4DP9#-C]7WH7YN9YC=>&:S;%C_/FV8U\IFFQ'4ID1G&#B(L3U9^X\,*W@ MC)23"E))JD@UJ2&UI([4DP9#-FY7`X9Q/W_&=J5==(;T%"[7L+`<>S50SAT+ M4DFJ2#6I(;6DCM23!D,V/U>PSLAOK&_#E_M(TV*[L-8M)@R.8WKZ!>LJ+V M%)Y>QE$391R5DPI22:I(-:DAM:2.U),&0S8_5^?.6']C61RNO[!2'M1OGZ."/EI()4DBI236I(+:DC]:3!D,UZ7N=PRL[!T_0F=T7*2#FI()6D MBE23&E)+ZD@]:3!D\XL[A^??:T[9'8P4=JZDC)23"E))JD@UJ2&UI([4DP9# M-K]YK<`I6P%/X?I#W9]Q5$XJ2"6I(M6DAM22.E)/&@S9_%R)_O/O-:=C11^\ MUWA2M1><$L_B4^*X8SAJ-55I]CFYPG'&6\>'Z0V5_=0K*2#FI()6DBE23&E)+ZD@]:3!D\YM7_Y^R_O=D MRZSHV_>K:=149J%+R#FJ()6DBE23&E)+ZD@]:3!D(W6E^HPE.5;VX9)$L7]U M"LI(.:D@E:2*5),:4DOJ2#UI,&3RF;]BF>\I>$LF9:2<5)!*4D6J20VI)76DGC08LOG-*_-7 M+/,]V4^PHHL^KM*CIHL9[).:5SNO6#M["B>5M3-'Y:2"5)(J4DUJ2"VI(_6D MP9#-;U[MK`XM_O!RI+!W(V6DG%202E)%JDD-J25UI)XT&++YN?K[Y]_45F.Y M'KRI>0K7'XKZC*-R4D$J216I)C6DEM21>M)@R.87U_F__JWCBCV`)U.#G<67 M-4RC#C48*2<5I))4D6I20VI)':DG#89LW//:@A7;`D_A M#[!B#^`I7'_L`3@J)Q6DDE21:E)#:DD=J2<-ADQ^ZWD]P&ZX[0$\F1KL;+J( M:__I?WK4=+F&?5+S"NLU"VM/P:22,E).*D@EJ2+5I(;4DCI23QH,V?SF%=9K M%M:>@I,**2/EI()4DBI236I(+:DC]:3!D,UO7@^P9@_@*5Q_[`$X*B<5I))4 MD6I20VI)':DG#89L?G$/\.LUV)K]@2=;@TT?FX\GG''':05GTXZ^+,M)!:DD M5:2:U)!:4D?J28,A&_>\EF'-EL%3N%S9,G!43BI():DBU:2&U)(Z4D\:#-G\ MXI;A^:\&UFP+/$V+[8J4D7)202I)%:DF-:26U)%ZTF#(YC>O!UBS!_`4KC_V M`!R5DPI22:I(-:DAM:2.U),&0S:_>3W`FCV`)UN#35=RC:?$<4<[:KI.PSZI M>87UFH6UIW!265AS5$XJ2"6I(M6DAM22.E)/&@R9_#;S"NO=<%M8>PI.*J2, ME),*4DFJ2#6I(;6DCM23!D,VOWD]@+N2*;H(TE.P_D@9*2<5I))4D6I20VI) M':DG#89L?G$/,%U..O.*KPW;`T^V!(LO;YA&^7HK(^6D@E22*E)-:D@MJ2/U MI,&037M>Q[!AQ^`I7*WL&#@J)Q6DDE21:E)#:DD=J2<-AFQ^KEK_^4^]];,) M>+6CWK_RHZ83:$;*206I)%6DFM206E)'ZDF#(9O?O!9@PQ;`4[C^V`)P5$XJ M2"6I(M6DAM22.E)/&@S9_.(6X-<[U@W;`T_V=!E?N3&-FDZ7X[&F%9QS5$$J M216I)C6DEM21>M)@R,8]KV/8L&/P%"Y7=@P>PO7'YH:C M/:FQG0BFUX^:*"/EI()4DBI236I(+:DC]:3!D)W>N'?XP:2R03@; M*3B]D#)23BI():DBU:2&U)(Z4D\:#-G\YG4#9^P&/$V+[8J4D7)202I)%:DF M-:26U)%ZTF#(YA=W`^[TXEK=F9WK&=L$3Z84.X\OX)A&'4HQ4DXJ2"6I(M6D MAM22.E)/&@S9K.=U#F?L'#R%:Y6=`T?EI()4DBI236I(+:DC]:3!D,TO[AQ^ M<*YD=W"&(O^*E)%R4D$J216I)C6DEM21>M)@R.8WKQ4X8RO@*5Q_;`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`4;`$_38KLB M9:2<5)!*4D6J20VI)76DGC08LOG%#8`KP'[M=[DOV!QXLC58?#G'-&JJP<9C M38LZYZB"5)(J4DUJ2"VI(_6DP9"->UZ_<,%^P5.X7-DO<%1.*D@EJ2+5I(;4 MDCI23QH,F?PNXW[A^1IL-]RV!9ZFE75%RD@YJ2"5I(I4DQI22^I(/6DP9/.; MUP-N[=O2 MY*B+Z@*-R4D$J M216I)C6DEM21>M)@R.87]P"__#WD)=L#3Z8$NXBOVIA&'4HP4DXJ2"6I(M6D MAM22.E)/&@S9M.=U#)?L&#R%JW4<-5'&43FI()6DBE23&E)+ZD@]:3!D\XL[ MAA^48.P*+O<4?@Q&RD@YJ2"5I(I4DQI22^I(/6DP9/.;UP):S#=;`VFNZW!=+LU MF.ZW!M,-UT*+XIQ7:R\7++8/-E5A5PE3G..^TSC%"5.<,,4)4YPPQ0E3G##% M"5.<,,4)4YRA17'.ZQ*6"[8)!YM6G>)DHY`PQ8EQBA.F.&&*$Z8X88H3ICAA MBA.F.&&*,[0HSKAI<$7;V>J%NX!BYK6VRP4[BH/9NFVZ#&+?)P;##H5;PI3^ M^!#3`E?Z,*4/4_HPI0]3^C"E#U/Z,*4/4_JA1>G/:SF6"_8S!5]\-=QW&1ZV<`TSS#-,TSS#-,\PS3/,,TS3/,,TSS#-,\P MS7-H-L[=W7=__@ONY7BW7MW%T[_WO3O8]#YWE3#=9MG2 MW[C71'THW8/KU2ZFRRY\^H=A?M$K?9C2ARE]F-*'*7V8TH&35_'1D_,%:ESGMA8 MU)HG%A:Z?IYAFF>8YAFF>89IGF&:9YCF&:9YAFF>89IGF.89IGD.+8IS9F'O M;PALXAR+_:F04\$'4YPPQ0E3G##%"5.<,,4)4YPPQ0E3G##%"5.^]4)4YPPQ0E3G##%"5.<,,4)4YPPQ0E3G##%"5.-T!=\O_/#(TM\;.,S9F]Y3IM/3Y72!QQC]-,R?V;+#X:85GR>L2%B9L"IA M=<*:A+4)ZQ+6)VRP%D7ORO`P^A]4>_[NP2;AL)3W<<(4)TQQPA0G3''"%"=, M<<(4)TQQPA0G3''"%&=H49RNKIX3YUB'FSC#VMS'"5.<,,4)4YPPQ0E3G##% M"5.<,,4)4YPPQ0E3G*%%<;JZ>DZ<8QUNX@QKKJ,$YWGEUN=M^D/'VZO?G]W;V#XZ/$26!U_.;5 M+KVW2W^799/R6+*?'PK#J\.XBX,IY?TX=W?"X&P<722CX`_#_-E8P<,4/$S! MPQ0\3,'#%#Q,P<,4/$S![TUE@YYS%+RKP!'\V0OQ+O=_W7_=Y3YG$L:BWDS" M:&821C.3L#?=H/'-JV]O3A?+Z,LNY7\8$>2/(RE_F/(_[#L>??H6?[>`-!N' M$?[HF@T<2;,!TVP<]AV/'EU*H+DYC/!'U]R$1XKF)FZ!W(O"W5#8S$SB%:%C M3B^)1%_D;^JLNB=8ZM'3U:MDOZOJ#_]T]2H9#W=Y,$W).&ZYF[35XO1\L8A> M-WJ-8$?-$1Y`CE]X+]; M&YJI<,=HIEQ_@U?1_-/7V":95\[>W%M1,%?1PM5,V1.?SE M0F\GKTZ^Z7QV,ZYUS5!X^&B&7,N$&?J_G>?&+FR*_-W2WYO:OK*BDYAF:[^K M?66--ITB]+95];X/*:7I.8,#Z`YPP-HSJ('N-@LUM'G(YHU/(!F#0^@ M6<,#:-;L`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`;)*:V:!9T,[_$EC/MH]O%I[9H']T(/;5% M6>L6WZDMREHWI$YM4=:ZU7)JB^94-Q%.;-GH:.G*8J.C;9)'V^AHF_31-`N; MY"QL-`N;Y"QL-`N;Y"RXTB9=V:RU3[IV<:5+NG+9:!;2=8LK6])5BRO*5"\G MN5M8Z6KE;6FH5TK;+6+.ASZ=0ST"RD:QA7IJ2K%%>DI&N4 ME8Z6KE!6F@5="9%X!BO-:;IR66E^TG7+J8ZF*\\31SO5T70!=&J+CJ:K:1-; M5IKM=+WBRI5TM>(*O'1]Y\J#='7@BJUTK76JV4Y76J=ZG'2==:I9T"=6B7_/ MJ69!?SF1V++4T;Y3$6BVOU-?Z7&^4UUI%KY36VD6OE-9:1;2=96>=/(YZT&2 M,ZT#)6=S5THES[I+Y?^=.DKY)ZLH]S=J+W6A=NI,J6V;E[N_CF+2NIQ\\U+7 MCZ?F1]>";]PQ4]O>+E^^39[)W5-/S:A;."EWRS/A;]?MA]W'I.ZG%A]N/[K/5!;[/PH8_V#MM_NGI_N[ MW=^N?=I>O]\^N`$:_.'^_LG_'T5U\N?]P^^[YO;-_PH```#__P,`4$L#!!0` M!@`(````(0#5Q0-]OPP``#$Z```9````>&PO=V]R:W-H965T_ MWY:E5DO=K).9.GNQR3SI?EM2JR59F)L_?^Q?&M^VQ]/N\'K;#%J=9F/[NCD\ M[%Z?;IO_^6O\QU6S<3JO7Q_6+X?7[6WSY_;4_//NW_^Z^7XX?CD];[?G!BB\ MGFZ;S^?SV[#=/FV>M_OUJ75XV[["7QX/Q_WZ#/\\/K5/;\?M^J%RVK^TPTXG M:N_7N]>F5A@>/Z)Q>'S<;;;)8?-UOWT]:Y'C]F5]AO:?GG=O)U3;;SXBMU\? MOWQ]^V-SV+^!Q.?=R^[\LQ)M-O:;8?[T>CBN/[]`OW\$O?4&M:M_"/G];G,\ MG`Z/YQ;(M75#99^OV]=M4+J[>=A!#]2P-X[;Q]OFIV"X"J^:[;N;:H#^N]M^ M/SF_-T[/A^_I[;=/3V?(=U]Z)'JV/#A9[(];6!$0:85]I72YO`"#8#_-_8[-35@1-8_ MJI_?=P_GY]MF-VKU!YUN`.:-S]O3>;Q3DLW&YNOI?-C_3QL%1DJ+A$8$?AJ1 M<-#JA?W!U:^H0+RJ*?#3J$2M0="Y[@X^WI+(:,!/;$DKO.H'_>@7NG-M1.#G M;S=*6&I28I01=;`+]@"P(:T3K7 M'KK"+^CZ&XW';`24CIXS+^I:,,`6P"^F!4'4"GJ=*I'2LZWG=54FR?J\OKLY M'KXW8.V!F7MZ6ZN5+!@&L.IA@6@)6S+_5#%0*DKEDY*Y;8(_%,,)ROS;76\0 MW+2_06ENC,V]M&$6,5JH.E2R"0%@Q,&8@Y2#C(.<@PD' M!0`FYO)M@;2AKV#>")(*,!!D+D@J2"9(+,A&D$*049"K(3)"Y(`M!EH*L7.*E`E9@+Q5Z_6JI MQ?_\O-M\N3_H[?E"BKJP3NG52XG``@A!G.6+U<*],=);NUJ=8DWZ5%&))@-8 ME*U0M]_WKG2;/(OK1%*KUPA+]V0UMIT_W5XJ_:T"^F&$P[F6ZE4^<:`]YI$4/!. MXJ[](8BM$;HEAG1MV8X,Z55[8'`5]3L=7V4L?%*AFPF;W-/M70O9B7`IA&QI M;:B78<#F^=08J='Z=M=M!6P49E8$1V$N`BVL34V@I3'20]7M]3I\J%96!D)Y MTP`.3-XTJ$^WLO;3K4D$/RC=$4M4;(P&-KF)(53P(T.NJ\%B`F-AG@K)3-CD MF@PZE20\+C+5B?`HA&II;:A_,M'&2+>]W[KN^A-U9D5LHC4):;HO#*%]:ZE) MCY;)E6OC91&6R5_(HK+VLZC)`(Y-3A;YF5(;065C+Q)#J!/62JB9=8-X^<7H['!GUBWFFB%B%9>=&,]F=H&5.=TV"O]3LRL"#9Y MKDE8/6M76^9"D^#:#NM2DRZ5R\JU\1*O;E?D0\[$:`EIQ"2 MI;5Q6\*3;HQTM7=;7;ZL6Q&;=$W<:C>$VK[4Q*UVU\9+.EP7U";]8UNW4O&S MKHF_=4?L8!1;(^Q=8HBS"AABMNZH*_;8L?!)A6XF;')/]]+6+5P*(5M:F[H< M&R.[=;-%969%XG MW"!6YZP!,5I1Z26(J)A&B"YOX/A7JV(G=UG:$`MG!OD5C!]H],Z.;JS<+1T1:8T0Z6)@LV.,?R6'%!%U/T-$5CDB_ZS`!GR"5NX. M(C:'`JTH8HG(=Q0)U^,4V4)G>].,9'!LYP:Y>[A![B9ND+N+>U9^PM7]B)OP MWWKX5E>W;$DWB%4XW\G1BNHE,=^UX9[/0-T*@AXV\#S1BBP1;Z&.THI)-$-%N.$+T M#\<`$XD<4G0@V0P16>4&X3%`'I,FTJE`1-(EHG=*WC33'@.N(2'T'UO,9B2* M0SHWR%L`M&A(,W%IK+P%P+7R\ZSN<'XAS_K*Q\NS1N\="K255^@&T9P9J8]^ M81TQ&R>;*V/\*SFDB*C[&2*RRA&!NJW-;L1J;X)6?@6SM!1H11%+1+ZC6/&] MOO7E8SW)4,*UCW86OD5?XKI4_#]3MCY@'\/($U(CZ8`8W M_H]_2A.8^R0JO'N#_$/`@-5U3%8X\1.#!CV[GXP0Z:TSN'@(T"V(J`6IU,Y0 MB+1S1%K[NB_.%Q/4(>D"D;L2V`;00B,O=M$1#P$]-D5F:$#!YH@HV`*1.YM% ML"5:Z5-`-[IPC8\F53A_DL!4EI-$K5ULEKQS.E`R[))`(V=&Q^KU!K!R4(*( M>CTRR)GD8VF5(J(1S!"15BZU)M*J0$1:)2+2FDJMF;2:(R*M!2+26DJME6?E MYTA=Y8A"=G+TH8]883\1*3)W1/#P0+LF?VLD-H[>QJX=O>(UJ*YX33@:FE1J M9P8YVCDBK0WO;?'+K@GJD'2!B$:]1%1;3U.TPN+ML$?5&1I0L#DB"K9`5!ML MB5:F>.'%-MZW%9I4X;R)`:>&^HF!2WQ]\58R?O$:Y%1J+%&"B'H],L@M7FF5 M(J(1S!"15BZU)M*J0$1:)2+2FDJMF;2:(R*M!2+26DJME6?EYXC?R?W6:2R4 M5W4&P5;H%B_;:&*THN8G!CD%-D(47?H$9(P:-"HI(I+-4,/9=!'I2@H[%PH7 MA4B[,`B&%`\+I4%0"8BF!CE'XIFTFDNMA;1:2JV59^4G5%VUU*W&'RPZ?6.C MGL_MVML;L">6>SC\58LV#6HL42+12**Q1*E$F42Y1!.)"HE*B:82S22:2[20 M:"G1RD-^VF"@O;2]LR8J<[8F&D1S/H;UL;(BE$@TDF@L42I1)E$NT42B0J)2 MHJE$,XGF$BTD6DJT\I"?"W5945="'SK0A/K*PWU"142/;#&BR"X=B4'=P+S@ MP=\A&)$!+C=C*9-*E)&C^B0Y[`2LGG,R0.6)E"DD*LG1*+.%?DH&J#SS9/P$ MJ,N#N@1\<`TS=Q"T>-^KM]A5W1"K%YX*8^6$ M*LD10TU9J*L6&YP9^5P.YF>,7X^\DS%Y#0+?K5(+HCJ8.`LB>Z2,T8JF8H*( MIN+(("@O5TLDSD;$04E1B^0S1"2??TA^(AT+1"1?(B+YZ47Y*W95./,<=2[T M=\OTEV;VV^/3-MZ^O)P:F\-7];TQN%2_N['8?JGM4Q69\7OXLEOU7B3G(7P) M3AT0..\.5U6G&/_4&WZ")P3I\"D,X2_5O2YS@:,\Q+@8)(0H<%B2:DEO".^J M2Y[UAO"BN>1E;PAOB4N^Z`V7ESBFJ\;!\A,9WJ$O&HO_*G_W$V+X=_/ISAJWJ0._BZ$WPU M=W\#``#__P,`4$L#!!0`!@`(````(0`T'.H? MUQ(``--E```9````>&PO=V]R:W-H965T7._?GI_.CJ[.#U9/=VM/]\_?7U_^N]_)?^X M/#W9O-P^?;Y]6#^MWI_^N=J<_O/#W__V[N?Z^;?-M]7JY80L/&W>GWY[>?E^ M?7Z^N?NV>KS=G*V_KY[HRI?U\^/M"_WS^>OYYOOSZO;S5NGQX7Q\<3$_?[R] M?SJU%JZ?C[&Q_O+E_FX5K>]^/*Z>7JR1Y]7#[0OU?_/M_ON&K3W>'6/N\?;Y MMQ_?_W&W?OQ.)C[=/]R__+DU>GKR>'>=?WU:/]]^>J#[_F,TO;UCV]M_@/G' M^[OG]6;]Y>6,S)W;CN(]7YU?G9.E#^\^W],=F&$_>5Y]>7_Z<70]S&:GYQ_> M;0?H/_>KGQOO]Y/-M_7/]/G^Z MYY//JR^W/QY>AO7/;'7_]=L+N7M&=V1N[/KSG]%JS,U:$1N_]C^_'G_^>7;^]/QY=EH>C$GZ9-/J\U+NG`+]/*YK([I5._3&Z7;87IT*#:7]YX:^QB,XF/ MO#5V\DB\_,JML7='](MK9#PZ:LJ.:$+847EM9IS;2-L&;G3[GI$_QN:&%Y_G8\H2/X?/C)FC(]X=&\8B-/&@4-8@E6B$,0A2$*0AB`+01Z"(@1E M"*H0U"%H0M"&H`M!'X+!`\HAM`8IA^S?WS@VC/3[4_J_%QN7>J!OK`PMASS2 M2R`1D!A(`B0%D@')@11`2B`5D!I(`Z0%T@'I@0P^4:Z@-?T-KC#2M-*1-<\7 M5X$OK!#E2689&X4AL;OJF9A=[$RHSM&N\8;.&>EMYW@.W%@RNY)9`20"$@-) M@*1`,B`YD`)(":0"4@-I@+1`.B`]D,$G:N!IQWW#P!MI/?"6T!00)X\\)V\W MI^4>HD!S+X1`T\I21JX$U^,[DTQP^7;AZ=XAA+VBF6S"ECEM5D%JX7.R&.Z@A( M#"0!D@+)@.1`"B`ED`I(#:0!T@+I@/1`!I\H/]%)1?GI\)9JI+4O+"%?\#`O M@41`8B`)D!1(!B0'4@`I@51`:B`-D!9(!Z0',OA$#;PY^:F1-Q$RGIV]/4"V MEK17'`I"9++;+>U"*E+LO`A1C"A!E"+*$.6("D0EH@I1C:A!U"+J$/6(!H6T MY\QYP3^['8X9(-[W''#=X]%_@9CCA'D,0]%B&)$":(4 M488H1U0@*A%5B&I$#:(648>H1S0HI'T1'MELR>G,E/%>OMW?_7:SIAV(%JL] MR]F$SF2NX+0[RO&LOS'U/;/`V7JPJ1\M'9I)T2-R:$$9HY>US7236U7HA>[^U_K[7[F;LO2=OXV9(+FP:$Y+HN?)X#2_-*5;$Z526HD827C' MC*;VT'\YGUW(F7X[XQ(6$:V4D=C.&(E4SLC:GEZ!Z8(E1*ED)*8K1K3L[.YW M'-8G:I:RY8O)V2@8D(8%I+&6D336,3K86,]2]M8FT^E%.&P#BVR;TS/C;:=T M4U`/9X!%<_JQ&Y')/'#1P:6"]0I&8GEBA&=GW9WNL?W;CSL/T"ZPN]W)7&HK[MQ@I51H M.R2V8F=K3NN`9RLXIB

  • =[D'ZE+"4CDS&2%G-&NL7`%P5+'6RQ9"EIL6*D M%8,;JEG*K@-3VE[U'M2P@'2\=6@LI^C.H9'4('N')C(]!R6EYX(Y\?MS(5S^ MC]OM;=U`31%72M"Q'SAL:1YIF=5?^AHYM)`1C1GY(SJ9!P.6L"TRN9M(XU'0 M8LI2TF+&YJ7%G)%):'[_`&N"Z[6L(R6:K1CI_L`\<+;LFC`YF\!^`(VUSK): M$ZS46.ZA=U)J3?"E]#PP!8A#\^#(-,#6,=1$<*4-E0;,@XQK21,8T@"')`!B MEG)IP'P">W7"(J*5,I*QR1B)5,[H0!H`'2I924Q7C/S)NF;^7"&[%=2+HT"MI M`$M)8$:,),YB1OO3`+XJ"BDC,9LQ$JG<(4X#YC!`!2J5C,1TQ8CBS%N#PIAG M*7L3T[-Y<$!H6$!ZV#KDQSPCF0^]0W[,*RGMV;<5J,98H'+HE3S`2?EY`".) MOYB1C8A@?B9\51121G+[&2.1RAGIS3X8\(*E=!P%>T?)4M)BQ4@K@L/MT%&. MLWWUXFP4[%V-F-E%NT/D/D:=0Q2KC'J'_,U>26F'F^K4H47^J,V>]I@PT71O]HS\$9W,@S-NPK9TH`4MIBPE+69L7GR8,](MPA2QMST_ MV&*)+5:,M"),$6>>\X!1D$TW8H:=WSJDU@1KAJZP5.^DU)K@2^DI0H-P<(H< MEP=0EV".6*3+`?,@VUDZ1;56.$4)ZIBEW(8V6V`>P"*BE3*2L M8(I1L(0HE8S$=,6(>G]H*W`WQRM#F`:(%?9GRTC:ZA@=;*MG*7MGX_$$=KF! M1;:WIB=&6!9\)0W`^M_8HF"1"!;Z)4M)R$:,9#>,&?U%&N!:$H64%<1LQDBD MP5+*6C*G!+R5+28L5(*\**K^YMAA4`,;1U228$U MHY("BU12X$MIAYNBE._P7ZH`C&UIRS_X.13$>S!\2Y:2Z(D<4DF!-;_8>QY/ MV(9$C%Z.`46,Y*YCA[Q)GJ!4RDA&,&,DMG*T M5:!4R4AL58S$5HVV&I1J&8FMCI'8ZM'6H*2TCTQI"0+9\]%QISQ;H%+!ZVI6 M='B077,1G%.6XYV4!*]%*G@=.A2\SI`,38JV,X<\VSDC:YO^@B>L=A5L1TR7 MC&34*T8'XZEF*0[>B^"HVK"`--8RDL8Z1@<;ZUG*!2_]W51X;P.+;)M3$V,2 M5O+"G9Z7^,/!NS6C@]2EPYY*7$M4-> M2MR@5(NV.I3JT=:@I+1#3:GET&I\9-#9BHV_'$\L\MYO6B**$,6($D0IH@Q1 MCJA`5"*J$-6(&D0MH@Y1CVA02/N(@@)\-)]LLYHW_J'=Q)@*%D>+]$NVB^"P MN72*GC\_ZM9=$%/R6@I)(BBUEHL@CE>N61F?!2P>%J!QH MJ\2V*E'DMFK=UL795?#\J!&=_8UI3YJZ@>_)5Y8U6V90'K/(//SQ/!:,P)*< M8+8K+W&/&$FN%CM$6;KQ6%"M243!;PD\!BUEHLBCF!]LJ1"%`RV5+"4+2,5( M[JD^V%(C"OM;TLX*BR*O.`N+'Q.'='@%,VCII+Q,-Q)%'L+8(;H#XZQI\(`M M$8W]=[9]=2_%IC)1Y*;RPTT5HG&@J1*;JD21FZJ#IB[/@L%I1&=_8]ICIK3P MAO"RE0@57A8%X14<_9<3)R53,6(D4S%VB,++[SHX;M9 M+U"Q9"3F*T9BOMYK_C)8)!JEJ'PQ#:L2AZ-G*ZX3;(?\#`Y1A"A&E"!*$66( MD2#0MH78?7A%5]@F<%,8O/`CIPJV\YE6",4*9[+ M$:(848(H190ARA$5B$I$%:(:48.H1=0AZA$-"FGWA+6$5]R#-8.I1?JOV"Z# MI',I4N*>G2*C&*421"FB#%&.J$!4(JH0U8@:1"VB#E&/:%!(NRD2#0MH7^P[(O_2WW%,\)#L4K+SA$4VD.(XC1#&B!%&* M*$.4(RH0E8@J1#6B!E&+J$/4(QH4TIX+3]:OA#:>H*<6>?6]):((48PH090B MRA#EB`I$):(*48VH0=0BZA#UB`:%M"_,2=)/WDV9Z=>BR)Y)_;Q^:E$01<%A M=BE2$D4[148Q2B6(4D09HAQ1@:A$5"&J$36(6D0=HA[1H)#VW-L.RE,\*#ND MHLA*>2A"J1A1@BA%E"'*$16(2D05HAI1@ZA%U"'J$0T*:5^8X^3_)XKLP51% MD45!%(7%I^E.BD,F0A0C2A"EB#)$.:("48FH0E0C:A"UB#I$/:)!(>6YV=L. MS%MQ?6!VR`N9):((48PH090BRA#EB`I$):(*48VH0=0BZA#UB`:%M"_"`_,O M[T4S/$L[%$114/A:BM0NBA#%B!)$*:(,48ZH0%0BJA#5B!I$+:(.48]H4$A[ M[FUGZ1F>I1U2462E/!2A5(PH090BRA#EB`I$):(*48VH0=0BZA#UB`:%M"_" M@[.)(N.Z-SY\G^&)VJ$@AL(ZK4A)#%E;GBMCE$H0I8@R1#FB`E&)J$)4(VH0 MM8@Z1#VB02'MM[?5%F986W#(KRT@BA#%B!)$*:(,48ZH0%0BJA#5B!I$+:(. M48]H4$C[8F]MX?(7/B?.?*QF\`J+0T$4!4\HEB(E461MJ2@"E*!BBBA#E",J M$)6(*D0UH@91BZA#U",RG^OO"N,T.-9S]G/Z[<=]/ZZ>OZZ6JX>'S7;?%1H=JLOMNT*C0W6??5?F=&7[?DG8MQ'UP'Z,%5RA'M#' MG.VQ-B+/V2-2J#,A'7HW;8_.A'3HU:=]5^A^Z$4$;,\OV<9IC>Z<8S;"]$XSFU][I-:()01^VB"W31X9= MFP\$PRL973&?Y857Z(.ZKLW'<.$5^HRM:_,)6GB%7C"Z-N\0X15Z0>C:O`.$ M5^@%GVOS#@]=.=_YG;Y2X_OMUU5]^_SU_FES\K#Z0N%^L7W;\-E^*8?]QXO[ MY*U/ZQ?Z-@TZPM''_].7IZSHD],NS+K^9;U^X7^8!G9?Q_+A?P(```#__P,` M4$L#!!0`!@`(````(0"IUTF;O`H```,\```9````>&PO=V]R:W-H965TMVN]`\3X!VR3I4$FF&GR3;[6UM9=GFC@) MU8!30$^ZO_T>V1+2T=]#XJE]:3H_77TL*Y*"[W__N=N._J@/QTVS?QA[5]/Q MJ-ZOFZ?-_N5A_.]_Q;]]&8^.I]7^:;5M]O7#^%=]'/_^^/>_W;\WA^_'U[H^ MC:B&_?%A_'HZO7[>K.NP6?_8U?M35\FAWJY.U/_CZ^;MJ&O;K3]3 MW6YU^/[C[;=ULWNC*KYMMIO3K[;2\6BWGHN7?7-8?=O2=?_T9JNUKKO]`:K? M;=:'YM@\GZZHNDG74;SFN\G=A&IZO'_:T!7(L(\.]?/#^*LWKV;3\>3QO@W0 M?S;U^]'Z_^CXVKPGA\U3L=G7%&VZ3_(.?&N:[S*K>))$A2=0.F[OP#\.HZ?Z M>?5C>_IG\Y[6FY?7$]WN:[HB>6'SIU]A?5Q31*F:*_]:UK1NMM0!^G>TV\BA M01%9_6P_WS=/I]>'<7!S=7T[#3S*/OI6'T_Q1E8Y'JU_'$_-[K]=)D]5U57B MJTKHLZ>2"P4#59`^>PI^LO69JH0^526RZQ=:I=3VFNE3%?ARYJT>KP_-.\CFE*HS\>WE9R@O+FL2X_[[K:? MGX0_>Q#H"9"U?)75/(SIUM`8/]+3^\=C<'=[/_F#GKBURK/`/![/L=0YY.,E MJPU=B%R(74A<2%T0+F0NY"X4+I0N5!9,*+3G^-)0^'_$5U8CXZLCL]!@`NX[ MP=0Y=)'0A?P[P$B0$B4!BD`0D!1$@&4@.4H"4()4M+)3TJ$,H_>LKFLHO M!U.6H[F"ZK6>]#LGFBK3M)T(O!E/79Y3^ZM@W:3^L&Y>[IS,W79.C_F%$NN^ M@H0@$4@,DH"D(`(D`\E!"I`2I+*%!8Q^J0X(F,S-`]9),#,/`D@($H'$(`E( M"B)`,I`&]/./)W#R&2JSQ"!*"1"`Q2`*2@@B0#"0'*4!*D,H6 M%C"Y7A\0L38[#YDF:])#"I$BI!@I04J1!%*&E",52"52Q8C'3RY=[0?Z\HB3 MNQQGR&FRQAQ2B!0AQ4@)4HHDD#*D'*E`*I$J1CQ^;;FBM:/]P6A5"^#@ MO)Y9R+6K',#V:`4*,5>$%",E2"F20,J0/SDRGM`_-1"W8Z?(A.LI3QH M=.,'%&&N&"E!2I$$4H:4(Q5()5+%B,=/+L0'Q*];M]-XUC/;PE/4'9W*8Z*E MIIMSKE`1;63,6M*[_E4GN;XK?+[EIL.]7=[I]=4N3ZP?K!K7=L&]=1SZM%:Q;YXS4I7?.I2\R M1(H,M`JDTU#;E;-PK MD]S?%+MU\@EAM^[R_6JS\UV=)FN=AQ0B14@Q4H*4(@FD#"E'*I!*I(H1C]^P M79V/NSI-UCH%*42*D&*D!"E%$D@94HY4()5(%2,>/W=7]\'XPZV;K\@>?T`A MYHJ08J0$*4422!E2CE0@E4@5(QX_N:7Z2U.OG&"=`P9%U_RWIOMW!9-+3U(A M4H04(R5(*9)`RI!RI`*I1*H8\>C*#9<=W0]&I]J?6;_-?$7VZ`0*,5>$%",E M2"F20,J07?^IU='%*$%",E2"F20,J0 M?(GIFK=6HLUI>^N=<9DH$BC!7C)0@I4@"*4/*D0JD$JEBQ$,Z M;&_FX]Y,DQE_2Z00*4**D1*D%$D@94@Y4H%4(E6,>/SD;F+`D.PV'_;!C*_( M7C`"A9@K0HJ1$J0422!E2#E2@50B58Q8_.3W4`;$K\W.-RR:K/@AA4@14HR4 M(*5(`BE#RI$*I!*I8L3C-VS#$N"&19-UBJ7).L52Q`X&_:GS#9;(Y-(39XR4 M(*5(`BE3U'.8%PS;=[39G6&D-AEV&!398>CHSP_S5,V4P40`JDET^Z;FU!3L M3@$\YW1#F`RZYHQ5PX>%NX^XO-(-5(!5*)5#%B(:4WF88\TFUVOLK39,;?$BE$BI!BI`0I11)(&5*.5""5 M2/)]KW8=TEYC%[_N_:WN#99=?7BIE_5V>QRMFQ_RW2P*^./]F;L7QQ:SJ7YS MS$WQ[^9R0T>CS4T)J`QM5?I2;BBE7>U"F5M*N>TM\X52VG6:4MJ7TR"%>DVG47WM4*_I4*4OA7I-QP4]*1Y%A[Y/ MV)=";^G1-^7Z4GQ*:6^DVS>/KK0[1H`4NE+Z)DY?;72E]!T33*'7!+_VMT(% M>O(OJ%N]^:E3?='_.IM_I6&)#2^H1WT=6E#D>P-/<>\-.T6]-^@T4OH&"GW1 M92Z_+H(]"KW;N?Q*!J;0]RWF\BL5F$+?EZ#:^E+"P)O+G2R6"0-_'M$&#E-H M*TAE^E(6/@TA6@=CF85/0XC^+->7(N]56]OD/%+H%TT[;_?M1T(-FG45GL)X?KX^/CA[/2UPC/J$M;F!D2UF-!+RRG<=;AE&A)M65%_I^XM6(-*YF2-E; M..AV2W)\1_-]C1NA21BND`#]O"0M[]CJ_"UT-6*/^_8JIW4+%!M2$?&B2%VG MSM.'74,9VE2P[^?@&N4=MWH9T=%CO<\\V8>,"WG!8$=2-L= MAK<+=Q6D61"ZWG*N#/I#\($/_CN\I('"UP&;YI#.IV4T\^?>$Z0@/V+68TQ@(K(.(3,'\GJ-8-!_T"A9I$:9 M32EZW05.HD-+4(>P!8%1MJ`(:O!\]70>R4E0)X9'E@-KC=&5KT1FPXAARO58 M0QA/7JWA3H6M3 MI"/QK$]:-HP8*R7F2K*0PV0ZF<*$=Q:S9#)EZ$@"*1[4MVU+#[*K96HJN^R! M!)N+ZP@LWKF2#2.&!_)ZLC[F)/J(!9+(5*$CE@775F7T(-N"F2GLL@42;"ZN M(T,+AA'#@@"29'L0S`)YC+^W#A25*>08LFR(+1M.*-N'P#IN+QNAT)8`?48. MK3BB=,CTXLS!^;%Z@!/)SLDQ9%F1V%;HB4-Q^E+6EU"-V0YGN*JXD].]O'#A M9%K.^[#N!M:!#^V`^@!&([)14-?J:"3L6@AK!'J+E6HMK/A:4LF/S(X#T5E\ ME,+I/,:OKM.5/L%MHCB%XVL\89VD67(N/DWA4S^#OTDS=8W9_+,T4R>EUP]` MS]*B'?Z.V(XTW*GP%BSVU8G`=->C7P1MP7KH7*B`;D7]+:$[Q7!-^O).V5(J MNA<0Y/7][O(?````__\#`%!+`P04``8`"````"$`CX)"="X'``!$'0``&0`` M`'AL+W=O=OD^NSQ/VG]_7GT:M%MEE5SVR2F_I)/VU[1L_S']_;?Q M>UZ\E,=3KD[IN>D?,BOZ05^.>3%.:G@:_'<*:]%FNQK MI?.I8W>[OJDX29&>D@K&7QZS:XELY]U' MZ,Y)\?)Z_;3+SU>@>,I.6?6U)FVWSKM1^'S)B^3I!//^8KG)#KGK+X3^G.V* MO,P/U0/0=?A`Z9R'G6$'F*;C?08S8&YO%>EATGZT1EO+:W>FX]I!_V3I>ZG\ MWRJ/^;M?9/LHNZ3@;8@3B\!3GK\PT7#/(%#N$.U5'8$_B]8^/22OI^JO_#U( ML^=C!>'V8$9L8J/]UT5:[L"C0/-@U\/8Y2<8`/QMG3.6&N"1Y,ND;8/A;%\= M)VVG]^#UNXX%XJVGM*Q6&:-LMW:O996?_^5"%AM40^(*$O@4)$#W05VP4@\` M/H5N_\&UO?[@G@'T!`E\"A+K[DE`1=0#@<^[)S$4NO#Y\Y.P(/CU"-@_/ST- M"US/661([;N=83G(`O_@E#X<4PL3@OUS[TPZ/$/KA%\D53(=%_E["[H(Y&!Y M35A/LD:,&%.=)V:3_-_*?C`2F[:KI%Y,RX#98[>FA-D09`E058$\0D2$"0DR)H@&X)$ M!(D)LE41S950ZL25EO?0AQ6C.F:[EUG.%Z@;KG6@OGG5,Q)H'&!$*?N^GHT;'Y'UA7A\`D2-%IL)0!61V<-F]^1=4TX-@2)A):6)991R7$C MA-1;E4@+`6QL:`B4&L`8W*@!V,=A$3`6W>\"@7U+D\V.IWM@SF7L>A_*U[H; M6K9E-/6E4+/J<%F.8UE&E:P:&IR_3TP%C8P<(#$5ZJ:\H649E;UN:-#4AIB* M&AG5E)$.L6;*]H;#@>ZM[4T6F:I:5/L_B.J'.ALCT8/*$1N6IB:HMBN'4,=P M+H09(MRJM%@/HDK2R?J6Y,4(]'AQQ(#.4>)A5QH74*N.(*Q?ZI4#8JO8VM=R! M,S1+BDM8PR:&/N$-"&^H\]ZJ'\*[(;P1X8T%`KY7)F[LM;<-M2*D]'8M6-"G M:+#N;H.,18\01Z!B,(_G`E'*@\@L.>+RLS`[!*R(C$^0@&B%1&8M$&E]0V0B MPA.K,IK;V(%2\]OWEXE:7'<00F!"":719>="2DUBJ8BN7:(47QGLGCLPLY@J M^:@D5Z&`2H4H]4WJ-57:H)*DCJA4+""G?ZMK;34%W??LN&4>6^T>NXWYP6'` MX@8N6P+*:W$.)>Z4`@IEZ\4@Z%M.'DEC6%N^90Y0!KIT1`A7@9]&CTQ M,;D";2AQA"R2.$9(#-GJ&T/>"@&^MNDA84='$I)?6KM&"4F] M04A21PA)ZA@A3NW90R,WMRA0,^L18F=+$J&[%VYVZV>&14`RW^9"2BL1(K44 M4M#/L0)62"^Y?,H54*F0JP=9]B=L;>O&_(S>P3WII1GYHS@%I#BC^[H$9P*/W0:"_"& M=4V>TS@IGK-+V3JE!W!*M[X4+/@K&/]2B;]<_H?````__\#`%!+`P04``8`"````"$`R6_C;&`'``#-'P`` M&0```'AL+W=O9\=RW/^./V1U]/? MGG[]Y>&CK+[6;WG>3$#A7#].WYKFLI[/Z]U;?LKJ67G)S_#F4%:GK(&OU>N\ MOE1YMF^=3L>YIBC6_)05YRE76%>W:)2'0['+[7+W?LK/#1>I\F/60/WKM^)2 M"[73[A:Y4U9]?;]\V96G"TB\%,>B^=&*3B>GW3IX/9=5]G*$=G]7C6PGM-LO M1/Y4[*JR+@_-#.3FO**TS:OY:@Y*3P_[`EK`PCZI\L/C]%E=I^IB.G]Z:`/T M=Y%_U*//D_JM_/"J8A\7YQRB#?W$>N"E++\RTV#/$#C/B;?;]L#OU62?'[+W M8_-'^>'GQ>M;`]UM0HM8P];['W9>[R"B(#/33*:T*X]0`?@_.14L-2`BV??V M^5'LF[?'J6[-S(6BJV`^>Z^;\O0/-U([*2ZB=2+P_$3DBJ/> M.<*S%Y3P-7G1L\A^)N:J`*F<<3@:5@U\DW-5'M M4P@^",^;&JF*O&$?[FFF*O*&?>@<5[.E:1K6\B<=HHK481]$;:^U<\X'3#O^ M[*S)GAZJ\F,"DQJTMKYD;(I4UTQ,C#R>1?U8_*^A"&.0J3PSF<\(,PRDW--.1@;;@-C&`1K2TA-B$.(2XA M'B$^(0$A(2$1(3$A"2'IF$BAA*$NA?)Z")DUS!"@-AK?*Q3#SHC_J++AN^V( MU4?5YD2'1R^D*4C(Z8U$9[B$>(3XA`2$A)RH0X4B0N+>:U1%%( MWWMUJKK!HJ2N@O6D'=T%[.6NXL3;3P5 M:7BIL>V-1$-M0AQ.C!4?,RMKM5RA4>X2)X\0GY``"1N*IJ/HA,0I(B0F)$'" MEHG2+1V[2$%G^^3Q*N_Z;,^LY:!S@L8(:M2V-^J#3HC#23<@C(5B*6BDN<3' M(\0G))!T==/0##19A<0G(B0F))%T5=72+32UIF,?*>:P>Y%BSE?6,[:ROQY^ MYBB'GQ,YYRTT96Y[HS[\A#B<=#FO:A#_!LM-$=L!ZL^[A0Y'>H2WU3@ M3YZ;7>KD4>13%/Q4.J1.$44Q1Z.,[Q!* M>92KV\%JB#W7`D>!G,ZJR_JEMM0M'?\*4R6/(I^B0!:W3-U:6&CC&U*WB**8 MHD065Q=P,&"A^3*5W.1>8-NH.WJ![[I@D2\BMV$G&M`Q:`2@F74[6`E'FR)G M0*.%!9Y-W4^M\'+6&ZQ$B3Y%P8#&):*>#S^UPB5&@Y4H,:8H&="X1+0*2S^U M&I4H=R+;P=W1B=V&;]R)'*&AA-)HR_9VK*L'1WM`H]:0)6YGU8TN?:DO+`.) MNX.2B)Y'D3^@*^4%2J<*"^7:!Y*!R4H M3^X^MBV\H_NZ7>30"QMV*,13Y%`44A11%%,44)1:F$ MY/BQ;=\X?C>OHMCU`?Y1X'IHDC=&PO=V]R:W-H965T M/C.<[IX99O3;]\NY]RW)BS2[CC7V9&B]Y!IG^_1Z'&M_?O6_#+1>44;7?73. MKLE8^Y$4VF^37W\9O6?Y:W%*DK('"M=BK)W*\N;I>A&?DDM4/&6WY`J_'++\ M$I7P-3_JQ2U/HGT5=#GKIF'T]4N47C6AX.6/:&2'0QHG\RQ^NR374HCDR3DJ M8?[%*;T54NT2/R)WB?+7M]N7.+O<0.(E/:?ECTI4ZUUB;W6\9GGTB M[]7G>[HO3V/-ZC\YKF$QH/=>DJ+T4RZI]>*WHLPN?PL2JZ6$B%F+P&<*>4PE3&3#-X- M7':.@04&?`PL,1!@8(6!-08V&`@QL,7`K@/H8&WC+Q3,_^$OE^'^2F>F$F@- M-Y&9DB%#YAA88,#'P!(#`096&%AC8(.!$`-;#.PZ@&(F]`\QTX*5^>,U5=8F MCX+5LU.;IHMK4W#$?E"5WHP@XZPHI"0"C:0)@AZ_]_YK=JL7Y\61PP2H9G-[U+5)QI+@@1-%-\)0-5255?-[U)U330V!`GK**5*&.KD;4.2TKNN MD)*"_DSN&Y4Y$@;,E+8<.Z,M%5' M,MW!P%6'VC4R,)220Q?E\'ZN.%O-E4!,V'$ZN4)-,*M)5M-(\R9,/OI"(+`; MB9*W![@R?1*S)+H!X:P4738(VIW.&J^9X+4[8XFK'&\YHA68+;#7.2,3V*61#<@G)6BZSH63N2: MA&R(;$@X6T6V/QSTT6QWW1#%<;#J$XYSMNJX0%"-H]%G-:E3XTU8X[A`ZAIG M%AO:*&\^B5D2W8!P5@*Q12;1@KXF]`V1#`EG*Y`[4]UU8Q2[&9PH/^%W15<- MEQ`,T5E5T)HVJUG=(F\#&\\E2YACFZ:##/)IT%(&M;M+0%DKR1+2CN$82'I- M@S8RJ)4.*6M;0Q:L(AT'!FJ7[]K`#JMS!%'3PE^QZ*OJ)X^L3+RHP9E5.CRM M(=0?Z/0YDZPV<"XAN]%:2*A?;0-NG^&CCR\9U=53M?$O)=1*!Q)JI5<2$M+# MOFF@@EI+1BN]D5`K'4JHE=Y*"$Y*;;8&J!AVDJ7LE3_-%G^'NY>MQPY7_.8% MK68U!&W33G:(UJ%92Y)IGK=0&V?B0\^B9MF#*H$#A_5=9+/?"DGM)86"%KHS MW$H=SK8=TT2%MVZ%Y'`;"H4M=&>X+1K.Z-MVVY.BV\2%IK@CNB3Y,9DEYW/1 MB[,W?ED)'3L9-;"X29W;'KQ3P>00'MH>O!!1?.YXB^IM$/$#QX,7`\H/'0]. M]12'&]SGJM21SI3?['[`GYH>W"Q0G:GEP7LRQ9]M[QD,@Q_T9@2XH;U%QV0; MY]`>!^5BRA$G;07 M!+EDLYG=?:816](J!NCNF6^_IZ@JH.JHVYWL/`SZZW/^577JU.7@[/O/\TEY MS\HJ+RYS51N,5"6[I,4^O[S,U;]^N-^FJE+5R66?G(I+-E=_997Z??'[;[./ MHGRMCEE6*Z!PJ>;JL:ZOSG!8I-T M/@WUT<@:GI/\HE(%I_R,1G$XY&FV+M*W^S4AV+ MCVV9[\/\DD&T89[(##P7Q2LQ]?<$@?,0>;O-#/Q1*OOLD+R=ZC^+#R_+7XXU M3/<81D0&YNQ_K;,JA8B"S$`?$Z6T.$$'X'_EG)/4@(@D/YOG1[ZOCW/5,`;Z M=*R-+;!7GK.J=G.BJ2KI6U47YW^HE<:TJ(K.5.#)5'1KH)FCKVB83`.>7*.5 M>-`T=+(9`#R9VV0P'8]-:SH!],`15D#C"$_>WD-[F]G#D]E;@_%D9&@D3@_: MT7APR(>NI4]&5C-8L^1#.T!3'T^F3<./989TMIOD62=ULIB5Q8<"*Q*FL[HF M9'UK#J2GPM.&CJ--I'MY!`E$5)Z(S%R%"$*&5)#\[PO3TF?#=TC8E-DLL8TF M6JRX!626''0!E\*]XA;<92V#C0Q<&6QEX,G`E\%.!H$,0AE$,HA[0`@F9+X0S-M[ M&\])8@V[6"\G]:D4I"6U@07)H[1"9(W(!A$7D2TB'B(^(CM$`D1"1")$XCX1 M0@A+_`LA)-:P,X!:;UT;XJI=,J/F;&N6[0J1-2(;1%Q$MHAXB/B([!`)$`D1 MB1")^T2((6SS7X@AL6YBR%-LR4@OZ1!9([)!Q$5DBXB'B(_(#I$`D1"1")&X M3X2`65\*&+$6`T:)T3]>X&8BIN&*&75IN&Y)E[WZU!+=-JT1GQX7D2TB'B5C MK3GJK!'Y)^KZK077W2&5`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` M,'6`\48\&$[,_`#PC5YR:*D?,DOE7+*#C#9HZ:^+.E/$/1+S2J? MYZ*&7PX@'^!%,_Q4E$'I."*K_%`4-?]"&FA_?%K\"P``__\#`%!+`P04``8` M"````"$`MG&_`)4'``!-(```&0```'AL+W=O#'SJ0]/3/6<>/G\_'@;?RJ:MZM/CT+H;#P?E:5-OJ]/KX_"O+_ZG M^^&@[8K3MCC4I_)Q^*-LAY^??O_MX;UNOK;[LNP&8.'4/@[W77=>C$;M9E\> MB_:N/I+*KFV/1P<_F==2>F[+8]DK'P\@>CZ>C8U&=AM3"HKG%1KW;59MR M76_>CN6IHT::\E!T\/[MOCJWW-IQMA6T M@(1]T)2[Q^&SMZ;#<043!S M9[O$TJ8^P`O`W\&Q(JD!$2F^]Y_OU;;;/PZ=Z9T[&SL6B`]>RK;S*V)R.-B\ MM5U]_(<*6+\JB-XVLO#)W?DW!0*"W*FUR1?;FJ3 M)3H=OG!GM[7*XEU-OC#5&[O,@NR@[ZFDR6V=9O$\(5^N-7%$L[LOEG71%4\/ M3?T^@!$(&MJ>"S*>60MBA)<)[4!1.#^K&R@88N69F'D<0I="2;10[-^>)M/) MP^@;%.B&R2RQC*5+K+@$J49B=FT"SP2^"0(3A":(3!";(#%!:H+,!+D"1A!: M$5_(AO\COL0,B2^/S)(#&7#;"":7X"IK$W@F\$T0F"`T062"V`2)"5(39";( M%:`%$^H#!=.!XKX\IO/<)%HP>BNY:<^G>K"65`9JET=KA<@:$0\1'Y$`D1"1 M")$8D021%)$,D5PE6BBAU%$H+?=N!O-&MZ\V7Y4.%!$PI`U-T8'3PCQ/O(1"1`)$8D0B1%)$$D1 MR1#)*;'ZAFG1AJCB:,/$PH+]I3[W(_'MD2<&^\CS6"PI<>A2A@R>*R:CA)G) MV/T`;8\M8X3VQ'-NU4?<:HQL)(BD0HM9-8:W3#SG M5G/5AA9]6-+<$OT+J0Y+/9[KQ(@><49@72*2UI[/]<:OJ)#=KU7IG'9)S3): MYU$A9];WU%BWZ0L+O.D!\A(*&>7E3"\14[-H/KAC^*>[BH49[BI!KE(A<\55 M1H4N-R@7%L"+UG.PN-1Z[GH7$6F]BRBQ83X17>28;5PQ(4<.1T*-M]JC9$(C M903)1^(!,ADBF4B85-_-&/-BH2:%;+-L$^0M%6J\`1DE,%F2]&8N)6*A=\98@;ZE0X]ZR MB][,FA!JE[UIO48VF1_HMEY<[S>.P*LR6LWT$7G%I-12D8J\>1Y#,-Y*6[9K MC"Z^5%2DS.$EP!Y#J<@]1I<\.N-[_>UCJ7C%8X(]IE*1>\PN>41MS*7B98]Z M)Y)MG#K8T>WP!Y?%Y!C!J$F&C*(T%PM<2JE*CB9B=O(X@O6.S!/+G)2XE#KW MX<+D4M)CR)'T&'$T[6 MB63[B#KQOZRVR9F.V:$,J<4Z,[)]Q?2T6J5ZME:8YI+9XXKW?<`AWJXQ?OO\ ME53_%[J7>9/+SY";UE_`F$HC+D5?P+8G]^;B,99OP"LRX5K27J&FNYFN91,_35& M'D8^1@%&(4811C%&"48I1AE&N8;TN)(-KAK77\2/[8?E"+`D1XP04D>.`"N, MUAAY&/D8!1B%&$48Q1@E&*4891CE&M+C1[:H'X@?V]&J\6-()MN*7&J0+)5H MC9&'D8]1@%&(4811C%&"48I1AE&N(3U^9*.HQH],S^0`\*.GU6S#J0:6(A>, MB4EU8FZ25G"T0V(-4GS,6V/D8>1C%&`48A1A%&.48)1BE&&4:TB/-8S86JQ_ M4>M$W%C/,B03ZSWUG&_:7Y*KW M@OS27L!1/[:S=!9P<(WY\V3Q#`''#Y86:,"T!4]&PC= M_@4``/__`P!02P,$%``&``@````A`$39*!1P!0``N!,``!D```!X;"]W;W)K M&ULK%A;;^HX$'Y?:?]#E/=#[@$BX*C<+P&M5F=W MG]-@("K!*$D/[;\_X]@.L:=;4>V^-/!UYAMGOIFQ\>#[6WXV?I*BS.AE:#H= MVS3():7[['(R07^0, M4?$(!ST'F]?DMI?@6*Y^R< M5>\UJ6GD:;0Z7FB1/)_AO=\=96M"2'JH.T%E\H?B=^U;?`J;1 M8)_!&["T&P4Y#,TG)]KU36LTJ//S=T9N9>NS49[H;5%D^SB[$$@VR,0$>*;T MA9FN]@P"9PMYSVL!_BB,/3DDK^?J3WI;DNQXJD#M`%Z(O5>T?Y^2,H6$`DW' M#1A32L^P`/AKY!FK#$A(\E8_;]F^.@U-M]?I.G;?ZP++,RFK><8H32-]+2N: M_\.-'$'%25Q!`D]!XO@=MQ]H4H]6O`4_AV.[X;='O. M%Q8`+5&3P//+"^@+7W@*WUZG%P1^V/M"'AV92/9!+J$3=&WO*Z_A>&(M[(-< MS,.9=*0,[(/P=AY=@\6KJR[6:5(EHT%!;P8,`*B?\IJP<>)$C%B6*2^JIG#_ MK6ZA8!G+$Z,9FJ`/E&0)O?9SY`?NP/H)#9(*FS&V<52+B;1@W%IJN9%7;[&UVT2XA4VR MI\(&FJ;ZVB#:]L8R27N MVD2*`)!H+$#8D?G_0:_U4'Y<#$98BR%CCSG2SKRPN;_H5-BX]:QV;<=7U9LU M_Y>L<\2Q0,BR\6([`+!J-;%J_B]9UXAC@Y!8>"E5XMCJ@K>-D:3>M8D4"<*/ M)`CN/2`U^*`'X-`BFX"QJ'GGB`]'Q7LUN_I8YD9N?7CDFYP@@@/*WU_H!;]ZX5\J<;IZIA5&PO=V]R:W-H965TQ]H;&S,[C[3B$JTB`'T],R_WRRJ"JA,I]>>G1>1C\POJ_*J8_CY6WK1OL9Y MD637D6YVNKH67Z/LD%Q/(_VO+XM/`UTKRO!Z""_9-1[IW^-"_SS^_;?A6Y:_ M%. M/D59>@.*Y^22E-\K4EU+(W]]NF9Y^'R!>7\SG3"2W-4+H4^3*,^*[%AV@,[@ M`Z5S]@S/`*;Q\)#`#)C;M3P^CO0GT]^;IFZ,AY6#_D[BMZ+U7RO.V=LR3PY! M%V849L M8O[A^RPN(O`HT'0LES%%V04&`+]:FK#4`(^$WT:Z!8:30WD>Z7:OX_:[M@GB MVG-I:]%J46?H/%ZIF5),X@@2>@@3H'M0%*]4`X"ET!YV!ZSJ]0?_Q M`?0$"3P%B?GA24!%5`.!YX`K=?L>QW/[@(UXT(?C5"-B?GYZ&":[G M+$U('X^&:4MM^/,_IB(SPFQ2XN&(&#Q%JXR?A64X'N;9FP9M!)*PN(6L*9D^ M(Y:YSC.SSOX?)3]D/6-Y8C0C'<(,>5U`Q7X=.ZXS-+Y"E45"9D)E3%5B*B58 M23':&0;F&%A@8(F!%0;6&-A@8(N!``,[#.Q;@`&NK?T+:?(K_,MHF'^E9R82 M:!QN(6=*":DRP\`<`PL,+#&PPL`:`QL,;#$08&"'@7T+4)P)]:,X\WY#ECG) MI*'UMG+2LOJJDR9FE*D!E!Y@19$&1)D!5!U@39$&1+D(`@.X+LVXCB M0BAQQ86\WCML72C/2?0RR?C*=,>U-M0UKW9&`@T#C+3*W46N%4)\56/5/!5( MKW;VC",V%$]-9'4]E6A>"\D8+0BR),B*(&N";#AB-@/:$B006NW69IFH<>UJ M(3G$?9M("0`XF@8`M@?"_U^R6]64'P\&(ZR"(6U/!-+RO$":B\"@0U+D\TV&N>4"UG5#I0OCU[H#I[4]-(4UMB*JAE MWC&U4TS9GFN[:.+[F@9,*5'LWXFB!>#CE<,8U`ARQ(+UIQ5!5.Q3(60W;4P@ M3HW,!0(IV")"4UO$-B,Q.X;4]V\3=50/S41JUB40,D(1A,JRI0@Y\*J799",AI]LIS M"?6K(.'UJ+$D@[JDM"O)T="N)<1I'32V#>7=4MY`DC2\.PE!;VI-'6TW]PU] M2^J'86+G/GI^_NA>`FZS<"$)R&IOLFW49:>-D'3QK(':PT=+SUQ(.9[<3[B6 MAV06#9,D7U)HU4#OV%NK]GJVZ>"6M&F(I+DMA8(&>L?<3C5G]^W!H)D=KS-^ M^\?O0M(X/\73^'(IM"A[93=[D`3C80WS:\>9X\,9`@:'\,#QX0!`\9GKPS:: MXBO7AXTPQ0/7AUTLQ>&Z\ZG*8F1WPJY![\A/+!].T)1G8OMP+J3XD^,_@:89:5\80;JJ_#QOP```/__`P!02P,$%``&``@````A`%@""KN.!0`` MUQ4``!D```!X;"]W;W)K&ULK)C;DJ,V$(;O4Y5W MH+A?VM\0$#!E%!$9J9S*3Y&9G_='Z@;]; MC:3I][?\K+V0HLSH9:9;/5/7R"6E^^QRG.E__/"^C72MK)++/CG3"YGI[Z34 MO\]__67Z2HNG\D1(I8'"I9SIIZJZ3@RC3$\D3\H>O9(+7#G0(D\J^%DGJ_?4II?0>(Q.V?5>RVJ:WDZ"8X76B2/9WCO-ZN?I(UV_0/)YUE: MT)(>JA[(&?Q!\3N/C;$!2O/I/H,W8+9K!3G,]`=KLK-LW9A/:X/^S,AKV?F_ M5I[HZZ;(]E%V(>`VY(EEX)'2)Q8:[!F"P08:[=49^*W0]N20/)^KW^FK3[+C MJ8)TN_!&[,4F^_<5*5-P%&1ZMLN44GJ&!X!_M3QCI0&.)&\SW88;9_OJ--.= M0<\=FHX%X=HC*2LO8Y*ZECZ7%)54RGQ;T58,"AMJ4 MI4\+RGOC'6L=F-]\UC,1:!QPD\ZT'\MUN!!!P[9VEX+ZT[\>>>9 M8.U\X\5"D([-@G1LYL2QZP9MFU9?3M6ZO=ZH>DAC@XC?CF)M'U0=635HKS>J M(=+8(A*UHX2JTM[B]GJCNNMJ2.X/[KAO#Q7O[Q0ZK!.:2F<2LM^"P#>]4[+* M0RYYD%TO=/@7K1W6//9:Q%AU4AS3'IJF4OD>&K1!PCZ*"11A:]PWAW)J0C1H MBX0C%!.KPB-[/)"%=]U!4B[`=CP3OMIWF(B<#4YL^'!TLJ$4XE($.6TG6@G2 M;\E:$);YE[DIOY77WJ5)W@9)^D@R$&102P[<05]);XADMT@V0K*Q)#LV+5MY MW5U75LH!VR&A-=]_Z49,4,Z'(/+L4-K-D@=U9X<@MR:V%F3TP>QH[]5F!0G[ M2#A0A$>NJ2X*0B2\1<(1$HYE8N[J4(ZDP/0>I-7MV^UIS`FJONRJYCFNH<06,V2-=',8&D.W!@ M=R4_7(B&;)%LA&)B2=89#UWE:7?=(5(F+%A62JGXV/(Z7/:\03?WEABM,%IC MY&&TP8K3" M:(V1A]$&(Q^C`*,0HRU&$48Q1CL)R?ZQ/=`7_.-;)LD_@;KUA]`*MCQUL[A% MK3'R,-I@Y&,48!1BM,4HPBC&B)T_W9Z>^\?/D_@91TZ*(UF2\[G44OK,SHI@ MP'S:8GZ0!94&)UGUN0^Z8C=G7,J557\"ZW^H596[$UA%8^Z[$U@'8QZY$UC) M8@Z':P]U2A3]!7O4._$+>-"[\:04':N`VG"?!`2J!HQR3;78.E%;- M#[BUT1[)SG\"``#__P,`4$L#!!0`!@`(````(0`*(0J]&`,``/<(```9```` M>&PO=V]R:W-H965T5O>O56F\8,8) MK6/3M1S3P'5*,U+O8_/WK\>[A6EP@>H,E;3&L?F&N7F__OQI=:3LF1<8"P,0 M:AZ;A1!-9-L\+7"%N$4;7,.;G+(*"5BRODQ0_T/10X5IH$(9+)(`_+TC#.[0JO0:N0NSYT-REM&H`8D=*(MX4J&E4 M:?2TKRE#NQ+R?G4#E';8:G$&7Y&444YS80&Y[RTES8@K5<9@0RD[`;# M>6QNW"A9FO9ZI?3Y0_"1#_X;O*#'+XQDWTB-06PHDRS`CM)GZ?J421-LML]V M/ZH"_&!&AG-T*,5/>OR*R;X04.T0$I)Y1=G;`^8I"`HPEA=*I)260`!^C8K( MS@!!T*MZ'DDFBMCT`\M;A&XX`W]CA[EX)!+3--(#%[3ZJ[W<%DNC>"T*/%N4 MP`J\<+YP)<@'&_UV(SR[\#,KG#O^.QMM35^I\8`$6J\8/1K08<"/-TCVJQL! M6">##MT+\YXN((@$V4B4V(2C`1ESJ.7+.G"=E?T"!4A;G^VYCSOV2#H/63>@ MUW,$=?X#1XDB.22H64D1G!+;.D,E1T'GV2YU4Z^K^KFAA,-^K=Q)&WQ@Y/>0\LHTOR62-)Y'*FU#'(:6D:1Y&29'$4O M""S0X,;3*('&+%H+U')P0/U)I7NG:;LOQ\0^;G?I/`[>6@82#"U:`GU/ZYNI MPFR/$UR6W$CI0=[!K@.]V9O[^;!1D!/[%N:&NF2G=B]*+OK[$1PV2'GBOPFB MC9H_$_LVC!(U$*;V693,+N!LYU$ROV1?1(FZC*8XRW;NV?T+F#L-VN/OB.U) MS8T2YZ")8\VA,YB>7'HA:`-:P?"A`@:.^EO`!P:&R\Z1;913*KJ%K''_R;+^ M!P``__\#`%!+`P04``8`"````"$`=RPUG0X#``#M"```&0```'AL+W=O[*6A"4FI=8ZCO4-YJP&B@,MJ7HUI+;%^V&RL=W= MUOCSFY*3'/RW9,%/7P1-O]&*@-E0)EV``^=/&OJ0ZA"\[)Z]?6\*\%U8*5YB^WA&)P5"@<68+S81Y"0+@UV)4=P88@E[,]413 M543V?.DL5M[!-]&PB MJ$-,!8%10T&7.Z7S1H.A)T;>+,:)X@;CSWIQR3`R,B.X)K<&0V7'R9>3Y`UH M/C=U\R=/D_[IFTV!O^HI1MJ@WS_NBP8;;7U!VLC`A6%DE&EY328-'F=J(\&; MW\/(*-/JFDP:/,[41@9K&D9&F?0\F6[%U=H!#Z[4$[B,4P+<[9.X[,PN8B?A[#98,D3_#X(]V;J3.+Q(DS,&)C&EV&RO,`3 MK\)D=2F^#L'Q\[SQIIUV;I\`IDV-AJ;3L4V#7!*Z3R_'H?G'C_FWGFD497S9 MQV=Z(4/S@Q3F]]&OOPS>:/Y: M9W$)/_.C55QS$N^K0=G9C$Y0YC?PT$/AS0A4YJ\9.12:QT]G6/>[X\>) MY*Y^(/HL37):T$/9`3J+3Q2ON6_U+6`:#?8IK("%W'.*7 M<_D[?5N2]'@J(=T!K(@M+-Q_3$F10$2!IN,&C"FA9Y@`?!I9RDH#(A*_5\^W M=%^>AJ;7[00/MN>`N?%$BG*>,DK32%Z*DF9_<2-'4'$25Y#`4Y"X;L=W@X?> M5UA\P0)/R7+W#&"NU3+@*<;V.KT@\+N]A_N7`9JH2.#YY0GTQ5AX_OL).#*0 M[(NSX7AB+NR+8.E_/1V.S`?[(FB<>R=C\3*KJG8:E_%HD-,W`UH!%%)Q MC5EC<4)&+.N55U==P9\5,%0N8WED-$,3$@6U68#J7D=^8`^L5U!*(FS&V,91 M+2;2@LF"T4YU8*8#B*&=>M@3X4-B*@FA4V+A5SW9MQ]>"7O\O6>>(8X&093V*[03`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`!!L:MWEIS?M/$?I3@[/]$2;L@@;G"M`3>B!-X];';`/E!:RA_,07W'.OH; M``#__P,`4$L#!!0`!@`(````(0![$ZR]]1D``/^F```9````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`_3XZ]FAZ:%Z^7* M=?/^6`EKX)\UI__X<'9V_N[D#TW#V['-EFV6ML6U;^'FG.LVBR&/H8BAC*&* MH8ZAB:&-H8NACV$(X$31'O+5//A7Y.NZIL!749B^A=\EBR&/H8BA MC*&*H8ZAB:&-H8NACV$(P(2I5PC"/-5++GWF\G/3[;4[6QWFYO)L8\/:[MOH M5>O3NH9DD!Q20$I(!:DA#:2%=)`>,H1BHM1+W43Y>H2NMK=C M(YV@@T8+&_1ULM'4DSE&]33C&%WKW3'Z(=R.$@PJ)(/DD`)20BI(#6D@+:2# M])`A%!.8KC0S`G.M;6![.3V;7@60#))#"D@)J2`UI(&TD`[20X903&`7LP)S MK6U@HP0S#))!QJ_483\O7L=CONP@NG MVYF]7&U]*SU*,"E/;:OK=*NI+WO$KE0,7T/?.RE-E)%R4D$J216I M)C6DEM21>I+>00B>D,W/U80S\AM+R'#^A57E;J%V[4I#E]\T)3-23BI():DB MU:2&U)(Z4D\:#-G\7`D;YN?..&N]).?(CLT6JZC M-WNN4ZV"KNQ1NG)SQE&.U6DXRF'!.IZ10-D2E),*4DFJ2#6I(;6DCM23!D,V M/U=.SLAOK#[#_,*"=,P/E"U!.:D@E:2*5),:4DOJ2#UI,&3S<]7EC/S&8C3, M+ZQ/Q_Q`V1*4DPI22:I(-:DAM:2.U),&0R:_55R#OWZ6WC7?5=[^^K7U9"]\ M%]&%;VKE=\Q(.:D@E:2*5),:4DOJ2#UI,&0CG;=(6'&1X"FX\)$R4DXJ2"6I M(M6DAM22.E)/&@S9_%SY^^,O:7W^Y?K2SK^M;V47@]%;R=?I5E-? M]CA=W3SC.,M)@R.87%]AN,?AS;XBN#L6WO[IM/6D^3J7V>?R1 MRM3*[YB1M)@R.;G*O@9^8T%OZXGP?R+WI+?KL96X67Q[`S%6Z+5\GSJ MRQZGJY1G'.=86(?CC%K[>@7*2#FI()6DBE23&E)+ZD@]:3!D\G,?BL_(;]?< M5N2>IC=$KTD9*2<5I))4D6I20VI)':DG#89L?O/*[U.6WYZ"LHR4D7)202I) M%:DF-:26U)%ZTF#(YA>7WS]_63P]E.;^ZK;U9"^+T?M4UU,KOV-&RDD%J215 MI)K4D%I21^I)@R$;MROX?_QT>3JN#X+3I:=PNG(5P58YJ2"5I(I4DQI22^I( M/6DP9/-S!?^,_/;K`_,VZ?(\>IM^JQ7%K@H.+XO+\^E#P?W;1.E64U_V..=5 MZZ>LUCV%X\QJG:UR4D$J216I)C6DEM21>M)@R.875^NOOU%URHK<4WA9'%M- ME+%53BI():DBU:2&U)(Z4D\:#-G\YI7?IRR_/87SC^4W6^6D@E22*E)-:D@M MJ2/UI,&0S2\NOZ`IG*Q<1;)63"E))JD@UJ2&UI([4DP9#)K^S>8N( M77.[B/`TG1JO21DI)Q6DDE21:E)#:DD=J2<-AFQ^\Q819UQ$>`KF'RDCY:2" M5)(J4DUJ2"VI(_6DP9#-[U^WB#CC(L*3/5W&[UI,K0ZG2U).*D@EJ2+5I(;4 MDCI23QH,V;CG+2+.N(CP%$Y7+B+8*B<5I))4D6I20VI)':DG#89L?J[>#Q<1 MT\7]]3+S;%PH**K@7;;I`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`,U).*D@EJ2+5I(;4DCI2 M3QH,V:SGK2#.N8+P%,Y5KB#8*B<5I))4D6I20VI)':DG#89L?O-6$.>'%41X M38P^#=OZ5O::&'_%(-UJZLL>Y[Q*_9R5NJ=PG%FILU5.*D@EJ2+5I(;4DCI2 M3QH,V?SB2OWUVN>;)63"E))JD@UJ2&UI([4DP9#-K^X]O[Y;_J>'^IR?W7;>K*7Q?A# MSZF5WS$CY:2"5)(J4DUJ2"VI(_6DP9"->]X2XIQ+"$_A=.42@JUR4D$J216I M)C6DEM21>M)@R.1W,6\)L6N^6T($E\5-]#'8UK>RE\7I0_=]\99L%?1ECW-> MJ7[!4MU3,,ZDC)23"E))JD@UJ2&UI([4DP9#-K^X5'_]LGC!BMQ3<%DD9:2< M5)!*4D6J20VI)76DGC08LOG-*[\O6'Y["N'RMQ?W+:>S%5Q$W_<-+7R.V:DG%202E)%JDD-J25UI)XT M&+)ISUM$7'`1X2F5?7/? MD[TL3I_%[,OPJ=7ALDC*206I)%6DFM206E)'ZDF#(1OWO$7$AHL(3\%T)66D MG%202E)%JDD-J25UI)XT&++YS5M$;`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`YG=3*FG!K[GAMVTI&[:<>PY^D"HGQKXG@?3C1V,>"GB!L/]_.DN M?3\4B3FO7_0]3/K#^L0_X/9R)-7ZP72.CO1Z;*4?;:(5O8-=VO];E/G'5OUOM6A\\WJ!$$_3:MYK^`#;S-%U.OF4GJ9N*T]3M[6G\UVWY^OSLVC$&]]BZKKU-'7=>9JZ[CWMN[Y< M+%?1,Q]\BUW79DB6BWA%]_\^=^V[M*N^@]F73W1RTDW3W-'HY3K-PNQ@TXDO M/]CFE5>0;Z2;5/A77NDM>(#J8-,#U`?S#[!9+^(;Q#:^4?``K;?@`;J#30_0 M'VQ\@.5B<[:3E?W'SO3+1=<8GISOR45;Q/LI[$:^YKZUUBA?XV5 MZ?_\=',1':I&"KMII-"]1@KM-%*F^]/+BW5T](-OLC_Z:)SB%>OK5Y[E@BO3 M@TVAZI4RMIM,X<,4/JQ(F,)&.X4-4]@PI0M3NC"E"U.Z,,496A3GO$7I&'WO:'G(DY5UOXW<,S0PS3T,`T]3$,/T]##-/0P#3U,0P_3T,,T]#`-/4Q# M'UH4IULSS1GZ_1HK_/F@Y6*TZ:JI084I3ICBA"E.F.*$*4Z8XH0I3ICBA"E. MF.*$*<[0;)RXZ?1W9J>_/W1XZO<6SDZ:[N*\7R4%=];5;9QANH\S3#=RANE. MSC#=RAFF>SG#=#-GF.[F#-/MG&&ZGW-H49RNZ`YGY^Y=G-T]O&=^*W#I;QMM MDM[7].XNL\%Y+%I_71]VG>:WPC_LZB^\"A^F\&$*'Z;P80H?IO!A"A^F\&$* M'Z;P0XO"=_5W&/[WYO)8KYN$PQI^MYQ5G##%"5.<,,4)4YPPQ0E3G##%"5.< M,,4)4YPPQ1E:%*>KO^?$.=;KX456[^1&=QYQ2MKA9YL M-O46':LK;N<IJ&':>AA&GJ8AAZFH8=IZ&$:>IB& M'J:A#RV*TU6R<^(<*U\3Y]["'RA9CK=W#DQQHIWBA"E.F.*$*4Z8XH0I3ICB MA"E.F.*$*<[0HCA=)3LGSK'R-7&&U;`_,<$4)TQQPA0G3''"%"=,<<(4)TQQ MPA0G3''"%&=H49QQ]>\NLC_Q;8JEOP^UR7DL[O7B"$Y/\0IBBAREZF**'*?K0HNA=83YG)H^%O$DX+.[]3(9I)L,T MDV&*$Z8X88H3ICAABA.F.&&*$Z8X88HSM"A.5YC/B7,LY$V<87'OXX0I3ICB MA"E.F.*$*4Z8XH0I3ICBA"E.F.*$*<[0;)SZ]&)6G+OVT2<^WL(J@)8M:7G" MBH25":L25B>L25B;L"YA?<(&:U&K.G MVNA#P.OEU,R?5I5^N`K837JE#U/Z,*4/4_HPI0]3^C"E#U/Z,*4/4_JA1>F[ MRCQ,_SNK&?7=]]^?)\=/OX^U==W]T`!'[T=/?I M_?&5%A]OKUQGFG"'??;;MBJ;W^HDM+ON<]O:;5NG]SMWV\[3VR[MO*;4L_]X5[[OH@(=7GPCUW MO06>W.:>N][/Y;8KO9NJK+4,Y;:MW@=T^Z6?^\(]=[VSE=IOZ9Z[WJ9);G// M7>\B)+>YYYX\EJO-1H>9?`K;C8Y$WSU/='BIX]"WJE-;=!3ZOG!JBXY!WVY- M;3G5EMT)-![L2XV+OI&8VD>CHN_:);;HXTH78/*1]-F;VY9ZK*O-ZNV5_J(B MT>-&.^E/TU);='SZHZO4%AV?_IPHM45S1G_YDMJB5TOR"*XNSG5LR50OM(_^ MFCS1VX7FF/Y..K5%XZJ_`$YLV6A<]<>JJ2T:U^017%TLWE[I.XR)?2ZTCW[_ M);5%0Z1?-DEM4=;ZS8[4%F6MWY=(;5'6R2.X.C][>Z5?&DKL/$'++=JUCTT^Y)K:<:Q[H1TI36S2F^OG-U!:-J7XL,K5% M8YH\@JLSC4_RJ+=GRD"W]4GT=J8,=,.:U!9EH%NQI+9H?'3CD-069:!;8B2V MK)6!;O:0VJ(,M"Q/;5$&^LG]U!9EH!^3YY:K4V6@6U9QR_94&>A.J:DMRD#W M`$UM40:ZNV5JBS+0G1A36Y2![C&8V'*F#'3WO-069:#[PJ6V*`/=PBRU11DD MG^G52G-4;YPF]EGIV/3%I\264QV;OL.4VJ)CT_><4UMT;/NOVL97FE,=6_(( MKE:Z+NC[JHG>5MIGE3YJO;97R=?V2F.J=4:J-XWI*CFF*XUI\@BNEKHN_$6Y MHWW^HO#2//B+LDM9IXLN5W.E2RY7<:6/0$\G^6QT8,DT=5C)V:F#2HV_BA85 M+LDDESJFORB$-/[),FBKRGC8?Y8:SXQ=79P5=8YR=GGQ MUGWGFUOTA>ZW[CO;W*(O9*NWU):KI88_LS?Y$^VO=&I*9;_5 M$]\E?W((Z_G#NV\WO][U-T^_WG]]/OIR]TFKD,7NZX]/][^Z!?;^'R_C=^]_ M>7QY>7S8?0W_\]W-Q[LGUT#K[T^/CR_^'XKBY,_'I]]V*YT/_R<`````__\# M`%!+`P04``8`"````"$`TPY\C041``"95```&0```'AL+W=O^@T+TE8B%!,FQ/F!OV-68YTQ)M,UH2 M%2+=[G[[J2(JD:C\V1RA8_K0DC]F_@E49A50*1`?_O'[\]/-;[NWX_[P\O'6 MN1O=WNQ>'@Z/^Y=O'V__]<_-+]/;F^-I^_*X?3J\[#[>_K$[WO[CT]__]N'G MX>W7X_?=[G2C%%Z.'V^_GTZO\_O[X\/WW?/V>'=XW;VH3[X>WIZW)_7/MV_W MQ]>WW?;Q[/3\=.^.1I/[Y^W^Y;95F+^]1^/P]>O^8;B2UYX?WR#UOWW[]\?K+P^'Y54E\V3_M3W^<16]OGA_F\;>7P]OV MRY,Z[]\=?_M`VN=_@/SS_N'M<#Q\/=TIN?OV0/&<9_>S>Z7TZ?G7GCN[?WGSZOG^\]29WXV#D.-KLM>3MS<./X^GP_)_6R#%2K8AK1-1/$AG=!BINCY0-3/ MOWPR,Z.A?O[UDW%45;9%HLO3%,#@TW&H2O0OW0EU57*EO!PJ#?V+\9S=N=.Q M,SX7QS57J@B'2V)X)AQ*I_ZE._2AL\0):!C5+T;E+Y260W6A?S$R[SZE^W;Z MGU>3U?:T_?3A[?#S1BW1:H(?7[=ZP7?F6IC6D79LNY7ESQ86M:)HE<]:YN.M M\E=KQE&MAK]]\IW9A_O?U`KV8&P6:./8%DNRT,N5EEU)L)9@(T$H021!+$$B M02I!)D$N02%!*4$E02U!TP/W*CU=CM2\^7_D2,OH'-'H+@APTER1$+(@EY4$ M:PDV$H021!+$$B02I!)D$N02%!*4$E02U!(T/6`E1"U'D!!/K9&7+[XT1[27 MNLSVYX@[L@=\T=JHE9)&?`ED!60-9`,D!!(!B8$D0%(@&9`<2`&D!%(!J8$T M?6*E1"WS5DJNIT);JQ5/J?%ZY8K5:&&,1N?ES`GL3"V[3_L2/'^L@U.W%`,. M3EN?#XYJ8&%(KRJ`K("L@6R`A$`B(#&0!$@*)`.2`RF`E$`J(#60ID^L@5>7 M[0$#KZWM@3?$Y^D(9`5D#60#)`02`8F!)$!2(!F0'$@!I`12`:F!-'UB#;RZ MTQDP\-K:'GA#>A4/9`5D#60#)`02`8F!)$!2(!F0'$@!I`12`:F!-'UB#;RZ M!1LP\-K:'GA#U.K66QD]L?9U1K1"K8"L@6R`A$`B(#&0!$@*)`.2`RF`E$`J M(#60ID^L7*C-UX!<:&L[%X;T)@&0%9`UD`V0$$@$)`:2`$F!9$!R(`60$D@% MI`;2](DU\'KC.F#DS^;VT!/JK?R(5HC6B#:(0D01HAA1@BA%E"'*$16(2D05 MHAI18R$[%WI7T]]A7K\S<]I-D+HUH[5E0:@W#Q"M$*T1;1"%B")$,:($48HH M0Y0C*A"5B"I$-:+&0G8N](:FGXMVMW^G&URG[_N'7Q>'MN=W(4>>N@TV>_UV M6V2ER*"@R]I2=WOT>C;IT,H@3Z6X=W'Q[8O+FJVH`C:(0D01HAA1@BA%E"'* M$16(2D05HAI18U`[7G;6]*8'LJ:ZM29I_SR\JG$>E$&SC>I/LA9YLRY=2[T] MDAEL43!K6SSN:`;9ZRPX>Z`3HG1D4"?M3,=V8<1L0=()ZJ2(,H,\59&]NA/R M.5N1?(%:):**'?OR$_OH:[8B^<;2LE.N=Y>0\C%/5,KYA8FJVN;=3#6;U'Z> M#;+GH-S@Q2MS9=J0:B2;34?^=1V7$Y%2N# MG+Z?ZW`[PB3,.#KGZ>N.IDXP%C8;5J(Z#3%>Q%9\G!`O)LL M1/%2? M36?B5#;H%A)B\8@0B\>V^#28CEVQI4S0*R7$VADAULYM;6<4!-.96'L+="L) ML7A%B,5K(>[Y;N"*\6TL-SO!>I<^(,%F4\^'M-!_.M+K<']:!V+HEL;(6@XZ M/RKR-5FUM3J>^>KB;5^B-AR-O$+RXJD1H55,5JUV,!E-9!4FZ)62%VMG:)63 M5:OM31S7$QDHT*LD+]:NT*HFJU;;G[BSB:CYQO*RLZOW_0.R:]H$_>RVR)J^ MOCNUL[+4?Y63\[=SI$2MC17-7W<\$>WL#>EP>8>$^)@B0FP5&^3;MPRB>!)V M[*^8XO8P)2N.F!'BB+E!YF3\T70L:KY`IY(02U>$6+JVI9W9=#H6JT5C>=DI MUQV'`2G7YFKV\A$M]$R6$WH*&6^-K`G=^7'&6^2IJ=[=*OB>N%?87`KH.B(M MH;'J18S8D2+&!HF(HLX2=N3C@H@I1LS8D2+F9-5.4&?DR?,KT*DDI_[^IY$RB$OI=5"&J@AA3"V=PN!(/LN2]7MB59<06M"'%-KPU2$Y0&;H-6 M(2'6B@BQ5HQ:"5JEA%@K(\1:.6H5:%428JV*$&O5J-585G9ZU%(U8)ZZVERD MIT6>NG?J)M=4+$)+XZ>.@\9]15*JV+7<$:-*0E1JK8JC_*(E(M(MV-Q#DT M+*."V06DFU?O7^CU+)8%U")?[9J[0IB*`U@:O_ZM.:'^+?V%`C+J[>(%!=1^ M:JTML`*'%(GG743H:O#86*GEYER]6$#O"9]2+`Z?$;+#B[3F(KPLH"XX%Y!! M'*EZ5Z1:1+I00/U@=@'IGM>``C(M,C[$A2H*Y<#O(BMN(P@7BSB>9.)/Q.EEK`2Q4O)C6]&,K:Z$B\G M1W-^KN>KMIE<5;N1HG@EN7&\ZEWQ:G(T\<;CF>N+'5##2BJ>72VZFS6@6MKF M5W\+YII^6'\RRW;%DHRXRE:$N,[7!M&F>S3VQA/12M^@6TB(Q2-"+![;XL'4 MFP1".T&OE!!K9X18.[>U)\XXD,^W%>A5$F+MBA!KUT)[%$Q\,5T:R\M.KVY< M#4BOZ7/Q$2WX"2K#AB18@CUI";JT,J`33B>'C7+A=%:&BMKHG>./-%;I/:#>D?CCGQ/ M%O6&PY%7B-H16L5DU6I/?/D'MP1]4O+AJ9BA54Y6K?(X\#Q1O@4ZE>3$TA5: MU0:)3I^0;]B14]"O,2OC:IH-R?C9W.[)&"3NPL4U<4E67"HK0ES2:X/Z=^%H M%1)BK8@0:\6HE:!52HBU,D*LE:-6@58E(=:J"+%6C5J-966G9UC+3#_#(SH> M!EUOF1FC_GPD*34'N\T5W!6O2;UMF05W(_N_8/V+Z!-L6+>;L1@]8JLKT6,[ MNKC@):Q!D5*,E+'5E4BYB'0W$J=5L`P%*S%8Q5;]8&)UK"&87-,OR_#MG%U" MNAOR_C5=/XXC2ZA%UYMFQD_M]VD`5H3ZM_072LBHM^OENTJH]5`K#H4**11' MCPA=C1X;*^J:V=>IA#4H4DJ((V6$KD;*1:0+)02G59(R!ZL(V<&@A%HM.JV[ M$910%ZQ?B7]60L/:9AZVS0SR^?JV-,A:<[!M9JSZ;3.2YV?B0M2*T"I&K02M M4M3*T"I'K0*M2M2JT*I&K<:RLJ>S[DH-F,YM$ZM_L^YU?2U.O>^);3HXFGFIS M!+XXOX*5*%Y);ARO8JLK\6IR-/'TXSMCT:9K6$G%LZME6-M,W\3):_-[VF;& MS[HV=WXT!FMCI6Y&S\^:J8?TQA.Q*FQ(B:='2(A+."+$5K$M/@E&8T=H)^B5 M$F+MC!!KYT);IT!H%^A5$F+MBA!KU[9V,!ZY#EQ*^T-IIW=8VTSOZV1ZW],V M,W[68M#Y<7I;1+MI/YB.Q"9M0P?0O[(:+YX8$5K%=`3M+'#5-!^)76F"7BEY ML7:&5CE9&6W5M`G$!"O0JR0OUJ[0JB8KH^VI#H,X[L;RLK,[K&WF8=O,('OK M#$^:D147ZHH0%^K:(#-[W:EZ($_<%&[0*R3$VA$AUHYM;2]0#PS;EXP$G5)" M+)T18NG<('4#P:NL[\&*?:&_V&]IG)^C+DF>(U:$.&)M$"USKB]/IK&<[)3K MCM2`J[OI:?$!+=0W.6%UGP??%[KU@1[:ZD'(S!!RQ8D_)[8I279,4EM"+$-;TVJ'\;CE8A(=:* M"+%6C%H)6J6$6"LCQ%HY:A5H51)BK8H0:]6HU5A6=GJ&]%;^&^%!' M_R-^6T?MFP+;=WL][]Z^[9:[IZ?CS'V%84+9S1OU!>WU1#" M)^KMA>V7_\0GZK6&G\]+I>`+[7!)R9TW%^V]>7/.E-#Y[,\_JP&Y<$CC>7-^ MCZ%P6$SFS?DKQI('\^;\!)SDTWES?@66Y+-Y<]Z-"*Z^M#S77]?%(UHYWGS= MMKN$C_HNZUQ_6Q5]U%=1Y_J+IOB)^A:IBG/IDY7CJSCG%Q%`'%_%N?2)^E:D MBG/I$_4=1Q7G_,E])Z=>#/FZ_;;+MV_?]B_'FZ?=5U4RZDV.JA?SUKY:LOW' MR7S3^,OAI%X)J>XRU/OBU"M`=^I5;2/]=>2OA\.)_J%.\;Y[J>BG_PH```#_ M_P,`4$L#!!0`!@`(````(0"*TK_Z$`,``/8(```9````>&PO=V]R:W-H965T M;6XRD(G5*2E[3"+]0B>^V'S]L3EP\RH)2A8"AEA$NE&I"VY9)02LB M+=[0&IYD7%1$P:W(;=D(2E*SJ"IMSW%6=D58C5N&4+R'@V<92^@]3XX5K55+ M(FA)%.B7!6MDSU8E[Z&KB'@\-C<)KQJ@.+"2J1=#BE&5A%_RF@MR*&'?SZY/ MDI[;W%S05RP17/),64!GMT(O][RVUS8P;3 M8"T#9^%".#I0J1Z8IL0H.4K%JS]MD-M1M21>1P+7CF3$\<:Z1;<.KMVZQ>J< M_'*AW8HW7MP31;8;P4\(^@ODR8;H;G5#(.M-:!D&6_[E"MBA27::)<+P8L"& M)53R:>O[WL9^`ON3+F9_&>-.(^(^0E<-Y`T:P9S_H%&S:(VZDEKTO@?.HF>2 MXSYB+@B,&@MZO6-Z;W1PA.%WY,UBNO-]&^-Z@[AXC$S,\*_)K8.ALM/D_BQY M%^28NKFWTZ?Q\'2L_TPQT09]_WY?=+#1-A2D0T8NC)%)IM4UF73P-%.++/RS MWV-DDBFX)I,.GF;JD-&>QL@DDYXKLU?16P56`"9<^3IJIJF,#H%BCKIP.2OU M$#3O]_54V=O]KH.GR3MDY,$8:3UHC^GV:*JHR&E,RU*BA!_U$>SJYAS@83SL M#.4,W\/8,(?L'/=">*%A:W-\$<+;=HGO_'!GQL\\?AG&9A[,\548KU[AV0=A M'+R&WX:Q.8WF/.MN[-G#`Q@[#*-^`5#!^N M8."8OP5\7U`X[1P+VBCC7/4WNL;#%\OV+P```/__`P!02P,$%``&``@````A M`!R$&OZ5````J0```!````!X;"]C86QC0VAA:6XN>&UL/(Y!"@(Q$`3O@G\( MG[GI%Y4)18VL!]&4,2^ M+)&?!NZWZ^X(2IKCQ:7"9.!#`K/=;K1WR5^"BZRZ@<5`:&T](8H/E)T,927N MS:/4[%K'^D19*[E%`E'+"0_C.&'N`K#:JVK@/(&*_0.H]$NT&O\C]@L``/__ M`P!02P,$%``&``@````A`'+!3J[5`P``Y`X``!``"`%D;V-0&UL(*($`2B@``$````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````````````G%?! M;N,V$+T7Z#\8NF_D9+-!$F+$/UBVBV#RP@TX.+-@R[7@TB(L9];_ MZ;[+VE@=_Z7TJRD`K(E"-.@'N\^Q[?A;7,977SH+_#JV=!%Z)#AQC#$5M@3S MN%YQ;0G(5U_&F#L4/>(>T'X7V8W,V5):K!>[E_UN"S5&/N1PRTLN,V#)N^1. MF#"$AD0IP.+>X48-9JYP/8S$<@N.38:I-7M$2G:;?%2Z$\9S5=4:"I!&;($] MT)B/XR=69:^%*G,4#%O^:#X`:Y*]3<-Z;8Q0H(Q_PF]J2JN6Y=D(C92 MH)"00NPFRU0C+8FC6[G[0:1BB]1U54H*I6T*FG2YEULT4KHE9]\6,^P),L"` M+R5*8"CN84]6&FHND!4[/`(,&(;'!WO$;=3LQM!E>#M-6K9"BF!:CE,(NG8[ M2ZXQ8%GQU@'IUL!!W0"ZDBZW7+ZR!;S0`7M\`^0GP$HTB/T/H.WO\92L@*5\ M!W1*/W,%!4+"0AI6PO84=H6:*Q23W&#B[$%PTB6!C;/ORC1FP[PQ5E6DRQ.4 M*)3<*0J%FFHN#<_<<4B#7U9UJ5H`=@L2U@)YLQ\AHS]+WN3"Q?^SP05`ERV[ M$Q+5+GC)2)>D>3'PHW%I+!WI:!R)E_;G)R+[I')!^OBU0J\SB`5)@`RD$QAX M>M",S]PO'1J'3SLL)=,=4)'JH9<9Y./#[U$1NI%8QD+RA2;TY#7W:H1.T4]C MVL?/T,]DRGZ?2]+'SU":U0>&+L!R47Z:1T^Q/H/=Y MI'3A_7`XD6_>E;&Q\REI3-_IY^?W.?=/$?>T<5.&HG M?FH@'H1\-<]UJA;XTMAW2,>#45+@BS['WF$_?QB(OF%SI$L79%YP?`#E>YOW M$ZZ?^]XWK?'YY=GT\Q1;M=%8%+X=.-B>QO\"``#__P,`4$L#!!0`!@`(```` M(0#:AG6,,@$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0!**```0`` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````"&>PMM M=3&D98F:G5QBXHR+-X1O*[%0`FBW?R_KNCJC)X_D?7EXOH]JOM-M\@G.J\[4 M*,\(2L"(3BJSK='S:I'>H,0';B1O.P,UVH-'?@T7467%#@DT@R MG@I;HR8$2S'VH@'-?18;)H:;SFD>XM%ML>7BG6\!%X3,L(;`)0\<'X"IG8AH M1$HQ(>V':P>`%!A:T&""QWF6X^]N`*?]GQ>&Y*RI5=C;.-.H>\Z6XAA.[9U7 M4['O^ZPO!XWHG^/U\N%I7YK`K`8@=]M-R'Y9QE1L%\G;/=F^N3;QO*OP[ MJZ08[*APP`/()+Y'CW:GY*6\NU\M$"M(?IV2,BUFJ_R*$D)+\EKA4VN\SR:@ M'@7^33P!V.#]\\_9%P```/__`P!02P$"+0`4``8`"````"$`UJUGW4X"``!( M)P``$P``````````````````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M M`!0`!@`(````(0"U53`C]0```$P"```+`````````````````(<$``!?9T6$04``"P3```/`````````````````)(+``!X;"]W;W)K8F]O M:RYX;6Q02P$"+0`4``8`"````"$`U*=99A@%``!L$@``&``````````````` M``#0$```>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`"I;5&++`P``I`\``!D`````````````````'A8``'AL+W=O&P``&0`````` M```````````@&@``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/$D9H&D`@``D`8` M`!D`````````````````124``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/=!M/,-!```C@T``!D````````````` M````&"\``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`!_!YA%/!```6@\``!@`````````````````4CX``'AL+W=O M&UL M4$L!`BT`%``&``@````A`%>5^X[#!```L!(``!D`````````````````(48` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`%\X?1((!```=`T``!D`````````````````'5,``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+Z7;Y._#```NGD```T````````````````` M:G8``'AL+W-T>6QE&PO&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`/6&'5:C!0``;A8` M`!@`````````````````S=\``'AL+W=O&UL4$L!`BT`%``&``@````A`!351`WK M`@``D0<``!D`````````````````^N@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`"R[W;=""@``:C8``!D````` M````````````K?(``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`)Z&*'.=`P``F`L``!D`````````````````;00! M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`,!`]CHY#```V#D``!D`````````````````12`!`'AL+W=O;)/,'```9(P``&0````````````````#& M1@$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'FQ6OKK#@``:DH``!D````````` M````````)U@!`'AL+W=O&PO=V]R:W-H M965T```9 M`````````````````%!O`0!X;"]W;W)K&UL4$L! M`BT`%``&``@````A`(M#OHQW!P``&2```!D`````````````````JW8!`'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+2%1D#H!@``.!\``!@````````````````` MXH$!`'AL+W=OD4++@<``%H=```8``````````````````")`0!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`)^)?L-0'P``"M$``!@`````````````````L),!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`"9[*;:\!@``P1H``!D` M````````````````4/&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&]&X0;X!0``3Q<``!D````````````````` MM@L"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`'&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-,.?(T% M$0``F50``!D`````````````````2#X"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'+!3J[5`P``Y`X``!`````````````````` MCE,"`&1O8U!R;W!S+V%P<"YX;6Q02P$"+0`4``8`"````"$`VH9UC#(!``!` M`@``$0````````````````"96`(`9&]C4')O<',O8V]R92YX;6Q02P4&```` /`$L`2P!V%````EL"```` ` end XML 18 R55.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Income Taxes (Details Textual) (USD $)
    		 3 Months Ended 12 Months Ended 15 Months Ended 3 Months Ended
    Dec. 31, 2013
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Dec. 31, 2014
    Dec. 31, 2004
    Income Tax [Textual]            
    Income tax (benefit) expense   $ (88,292)us-gaap_IncomeTaxExpenseBenefit $ 87,865us-gaap_IncomeTaxExpenseBenefit $ 102,640us-gaap_IncomeTaxExpenseBenefit    
    Income tax rate percenatge   35.00%us-gaap_EffectiveIncomeTaxRateContinuingOperations 43.00%us-gaap_EffectiveIncomeTaxRateContinuingOperations 53.00%us-gaap_EffectiveIncomeTaxRateContinuingOperations    
    U.S. federal corporate tax rate   34.00%us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes        
    State net operating loss carryforward 201,698us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal 165,901us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal 201,698us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal   165,901us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal  
    Federal net operating loss carryforward 525,012us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic 464,998us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic 525,012us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic   464,998us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic  
    License costs   0us-gaap_LicenseCosts [1] (250,000)us-gaap_LicenseCosts [1] 0us-gaap_LicenseCosts [1]    
    Finite-Lived intangible assets, remaining amortization period   15 years        
    Investment 65,000iccc_InvestmentsOwnedBalancePrincipalAmount       820,000iccc_InvestmentsOwnedBalancePrincipalAmount  
    Intangible asset [Member]            
    Income Tax [Textual]            
    License costs           965,000us-gaap_LicenseCosts
    / us-gaap_FairValueByAssetClassAxis
    = us-gaap_IndefinitelivedIntangibleAssetsMember
    Investment [Member]            
    Income Tax [Textual]            
    Investment   755,000iccc_InvestmentsOwnedBalancePrincipalAmount
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_InvestmentIncomeMember    		     1,112,000iccc_InvestmentsOwnedBalancePrincipalAmount
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_InvestmentIncomeMember    		  
    State and Local Jurisdiction [Member]            
    Income Tax [Textual]            
    State net operating loss carryforward   1,858,000us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
    / us-gaap_IncomeTaxAuthorityAxis
    = us-gaap_StateAndLocalJurisdictionMember    		     1,858,000us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
    / us-gaap_IncomeTaxAuthorityAxis
    = us-gaap_StateAndLocalJurisdictionMember    		  
    Tax credit carryforward, description   2028 through 2031        
    Domestic Tax Authority [Member]            
    Income Tax [Textual]            
    Federal net operating loss carryforward   $ 1,368,000us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic
    / us-gaap_IncomeTaxAuthorityAxis
    = us-gaap_DomesticCountryMember    		     $ 1,368,000us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic
    / us-gaap_IncomeTaxAuthorityAxis
    = us-gaap_DomesticCountryMember    		  
    Tax credit carryforward, description   2029 through 2031        
    [1] During the second quarter of 2013, we received a $250,000 exclusive option fee from a prospective partner for the development and marketing of Mast Out. This payment was recorded as deferred revenue upon receipt. During the third quarter of 2013, this prospective partner decided not to execute a license after its final due diligence. Accordingly, the deferred revenue was recognized during the third quarter of 2013. At the same time, $47,604 in capitalized expenses pertaining to the development of Mast Out were written off.
    XML 19 R46.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Property, Plant And Equipment (Details) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Property, Plant and Equipment [Line Items]    
    Laboratory and manufacturing equipment $ 3,522,465us-gaap_MachineryAndEquipmentGross $ 3,182,686us-gaap_MachineryAndEquipmentGross
    Building and improvements 2,969,891us-gaap_BuildingsAndImprovementsGross 2,940,239us-gaap_BuildingsAndImprovementsGross
    Office furniture and equipment 470,607us-gaap_FurnitureAndFixturesGross 354,243us-gaap_FurnitureAndFixturesGross
    Construction in progress 1,270,672us-gaap_ConstructionInProgressGross [1] 9,600us-gaap_ConstructionInProgressGross [1]
    Land 50,000us-gaap_Land 50,000us-gaap_Land
    Property, plant and equipment, gross 8,283,635us-gaap_PropertyPlantAndEquipmentGross 6,536,768us-gaap_PropertyPlantAndEquipmentGross
    Less: accumulated depreciation (4,445,988)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment 4,012,003us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
    Property, plant and equipment, net 3,837,647us-gaap_PropertyPlantAndEquipmentNet 2,524,765us-gaap_PropertyPlantAndEquipmentNet
    Property, plant and equipment, gross increase (decrease) 1,746,867us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease  
    Less: accumulated depreciation (increase) (433,985)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease  
    Property, plant and equipment, net increase 1,312,882iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease  
    Laboratory and manufacturing equipment [Member]    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross increase (decrease) 339,779us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease
    / us-gaap_PropertyPlantAndEquipmentByTypeAxis
    = us-gaap_ManufacturingFacilityMember    		  
    Building and improvements [Member]    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross increase (decrease) 29,652us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease
    / us-gaap_PropertyPlantAndEquipmentByTypeAxis
    = us-gaap_BuildingImprovementsMember    		  
    Office furniture and equipment [Member]    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross increase (decrease) 116,364us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease
    / us-gaap_PropertyPlantAndEquipmentByTypeAxis
    = us-gaap_OfficeEquipmentMember    		  
    Construction in Progress [Member]    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross increase (decrease) 1,261,072us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease
    / us-gaap_PropertyPlantAndEquipmentByTypeAxis
    = us-gaap_ConstructionInProgressMember    		 [1]  
    Land [Member]    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment, gross increase (decrease) $ 0us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease
    / us-gaap_PropertyPlantAndEquipmentByTypeAxis
    = us-gaap_LandMember    		  
    [1] As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015.
    XML 20 R33.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Accounts Payable and Accrued Expenses (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Accounts Payable and Accrued Expenses [Abstract]  
    Schedule of accounts payable and expenses

      As of December 31,  Increase 
      2014  2013  (Decrease) 
    Accounts payable – capital $251,383  $23,496  $227,887 
    Accounts payable – trade  204,810   199,716   5,094 
    Accrued payroll  145,176   75,310   69,866 
    Accrued clinical studies  131,945   0   131,945 
    Accrued professional fees  42,250   50,500   (8,250)
    Accrued other  76,113   96,207   (20,094)
    Total $851,677  $445,229  $406,448
    XML 21 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 22 R57.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stockholders' Equity (Details 1)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Stockholders Equity [Abstract]      
    Risk-free interest rate 2.00%us-gaap_FairValueAssumptionsRiskFreeInterestRate 1.60%us-gaap_FairValueAssumptionsRiskFreeInterestRate 0.97%us-gaap_FairValueAssumptionsRiskFreeInterestRate
    Dividend yield 0.00%us-gaap_FairValueAssumptionsExpectedDividendRate 0.00%us-gaap_FairValueAssumptionsExpectedDividendRate 0.00%us-gaap_FairValueAssumptionsExpectedDividendRate
    Expected volatility 49.00%us-gaap_FairValueAssumptionsExpectedVolatilityRate 49.00%us-gaap_FairValueAssumptionsExpectedVolatilityRate 48.70%us-gaap_FairValueAssumptionsExpectedVolatilityRate
    Expected life 6 years 6 years 6 years 6 months
    XML 23 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Subsequent Events
    		 12 Months Ended
    Dec. 31, 2014
    Subsequent Events [Abstract]  
    SUBSEQUENT EVENTS
    18.SUBSEQUENT EVENTS

     

    We have adopted the disclosure provisions of Codification Topic 855-10-50-1, Subsequent Events, which provides guidance to establish general standards of accounting for and disclosures of events that occur after the balance sheet date but before financial statements are issued. Entities are required to disclose the date through which subsequent events were evaluated as well as the rationale for why that date was selected. This disclosure should alert all users of financial statements that an entity has not evaluated subsequent events after that date in the set of financial statements being presented. Codification Topic 855-10-50-1 requires additional disclosures only, and therefore did not have an impact on our financial condition, results of operations, earnings per share or cash flows. Public entities must evaluate subsequent events through the date that financial statements are issued. Accordingly, we have evaluated subsequent events through the time of filing on March 26, 2015, the date we have issued this Annual Report on Form 10-K.
    XML 24 R50.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Other (Expenses) Revenues, Net (Details) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Other (Expenses) Revenues, Net [Abstract]      
    License option fee(1) $ 0us-gaap_LicenseCosts [1] $ 250,000us-gaap_LicenseCosts [1] $ 0us-gaap_LicenseCosts [1]
    Royalty income 0us-gaap_RoyaltyIncomeNonoperating (3,000)us-gaap_RoyaltyIncomeNonoperating 15,166us-gaap_RoyaltyIncomeNonoperating
    Interest income 15,552us-gaap_InterestIncomeOther 12,493us-gaap_InterestIncomeOther 17,202us-gaap_InterestIncomeOther
    Interest expense (57,827)us-gaap_InterestExpenseOther (66,689)us-gaap_InterestExpenseOther (75,274)us-gaap_InterestExpenseOther
    Debt issuance amortization (2,876)iccc_AmortizedDebtIssuanceExpense (2,894)iccc_AmortizedDebtIssuanceExpense (2,876)iccc_AmortizedDebtIssuanceExpense
    Other gains (losses) (3,902)us-gaap_OtherNonoperatingGainsLosses 34,902us-gaap_OtherNonoperatingGainsLosses (7,067)us-gaap_OtherNonoperatingGainsLosses
    Other (expenses) revenues, net $ (49,053)us-gaap_NonoperatingIncomeExpense $ 224,812us-gaap_NonoperatingIncomeExpense $ (52,849)us-gaap_NonoperatingIncomeExpense
    [1] During the second quarter of 2013, we received a $250,000 exclusive option fee from a prospective partner for the development and marketing of Mast Out. This payment was recorded as deferred revenue upon receipt. During the third quarter of 2013, this prospective partner decided not to execute a license after its final due diligence. Accordingly, the deferred revenue was recognized during the third quarter of 2013. At the same time, $47,604 in capitalized expenses pertaining to the development of Mast Out were written off.
    XML 25 R42.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Cash, Cash Equivalents, Short-Term and Long-Term Investments (Details) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Dec. 31, 2011
    Cash, Cash Equivalents, Short-Term and Long-Term Investments [Abstract]        
    Cash and cash equivalents $ 850,028us-gaap_CashAndCashEquivalentsAtCarryingValue $ 2,270,385us-gaap_CashAndCashEquivalentsAtCarryingValue $ 2,673,719us-gaap_CashAndCashEquivalentsAtCarryingValue $ 781,516us-gaap_CashAndCashEquivalentsAtCarryingValue
    Short-term investments 2,489,000us-gaap_ShortTermInvestments 2,985,000us-gaap_ShortTermInvestments    
    Subtotal 3,339,028us-gaap_CashCashEquivalentsAndShortTermInvestments 5,255,385us-gaap_CashCashEquivalentsAndShortTermInvestments    
    Long-term investments 496,000us-gaap_LongTermInvestments 0us-gaap_LongTermInvestments    
    Total 3,835,028iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments 5,255,385iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments    
    Increase (Decrease) in cash and cash equivalents (1,420,357)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (403,334)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 1,892,203us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease  
    (Decrease) Increase in short-term investments (496,000)iccc_IncreaseDecreaseInShortTermInvestments      
    (Decrease) Increase in cash and cash equivalents and short term investments (1,916,357)iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments      
    (Decrease) Increase in long term investments 496,000iccc_IncreaseDecreaseInLongTermInvestments      
    (Decrease) Increase in cash and cash equivalents short term and long term investments $ (1,420,357)iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments      
    XML 26 R37.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stockholders' Equity (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Stockholders Equity [Abstract]  
    Summary of stock option activity and changes

      2000 Plan  2010 Plan  Weighted Average Exercise Price  Aggregate Intrinsic Value 
    Outstanding at December 31, 2011  186,500   49,500  $3.19  $344,000 
    Grants  0   2,000  $5.93     
    Terminations  (8,000)  (2,000) $4.75     
    Exercises  (15,000)  0  $3.39     
    Outstanding at December 31, 2012  163,500   49,500  $3.13  $185,000 
    Grants  0   26,000  $4.67     
    Terminations  0   (1,000) $3.15     
    Exercises  (6,000)  (1,000) $3.11     
    Outstanding at December 31, 2013  157,500   73,500  $3.30  $223,000 
    Grants  0   25,000  $4.69     
    Terminations  0   (2,000) $5.75     
    Exercises  0   (1,000) $3.15     
    Outstanding at December 31, 2014  157,500   95,500  $3.42  $364,000 
                     
    Exercisable at December 31, 2014  157,500   42,500  $3.08  $357,000 
                     
    Reserved for future grants  0   202,500         
    Fair value stock-based option awards granted using Black-Scholes option valuation model

     

      2014  2013  2012 
    Risk-free interest rate  2.0%  1.6%  0.97%
    Dividend yield  0%  0%  0%
    Expected volatility  49%  49%  48.7%
    Expected life  6 years   6 years   6.5 years 
    XML 27 R52.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Income Taxes (Details) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Income Taxes [Abstract]      
    Current $ 252us-gaap_CurrentIncomeTaxExpenseBenefit $ 301us-gaap_CurrentIncomeTaxExpenseBenefit $ 708us-gaap_CurrentIncomeTaxExpenseBenefit
    Federal (77,986)us-gaap_CurrentFederalTaxExpenseBenefit 74,713us-gaap_CurrentFederalTaxExpenseBenefit 89,788us-gaap_CurrentFederalTaxExpenseBenefit
    State (10,558)us-gaap_CurrentStateAndLocalTaxExpenseBenefit 12,851us-gaap_CurrentStateAndLocalTaxExpenseBenefit 12,144us-gaap_CurrentStateAndLocalTaxExpenseBenefit
    Deferred (88,544)us-gaap_DeferredIncomeTaxExpenseBenefit 87,564us-gaap_DeferredIncomeTaxExpenseBenefit 101,932us-gaap_DeferredIncomeTaxExpenseBenefit
    Total $ (88,292)us-gaap_IncomeTaxExpenseBenefit $ 87,865us-gaap_IncomeTaxExpenseBenefit $ 102,640us-gaap_IncomeTaxExpenseBenefit
    XML 28 R61.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Segment And Significant Customer Information (Details 1)
    Dec. 31, 2014
    Dec. 31, 2013
    MWI Veterinary Supply Company [Member]    
    Revenue, Major Customer [Line Items]    
    Accounts receivable due from significant customers 26.00%iccc_AccountsReceivableDueFromSignificantCustomers
    / us-gaap_StatementBusinessSegmentsAxis
    = iccc_MwiVeterinarySupplyCompanyMember    		 26.00%iccc_AccountsReceivableDueFromSignificantCustomers
    / us-gaap_StatementBusinessSegmentsAxis
    = iccc_MwiVeterinarySupplyCompanyMember
    Animal Health International, Inc [Member]    
    Revenue, Major Customer [Line Items]    
    Accounts receivable due from significant customers 45.00%iccc_AccountsReceivableDueFromSignificantCustomers
    / us-gaap_StatementBusinessSegmentsAxis
    = iccc_AnimalHealthInternationalIncMember    		 39.00%iccc_AccountsReceivableDueFromSignificantCustomers
    / us-gaap_StatementBusinessSegmentsAxis
    = iccc_AnimalHealthInternationalIncMember
    Robert J. Matthews Company [Member]    
    Revenue, Major Customer [Line Items]    
    Accounts receivable due from significant customers    [1] 10.00%iccc_AccountsReceivableDueFromSignificantCustomers
    / us-gaap_StatementBusinessSegmentsAxis
    = iccc_RobertJMatthewsCompanyMember
    [1] Amount is less than 10%
    XML 29 R47.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Accounts Payable and Accrued Expenses (Details) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Accounts Payable and Accrued Expenses [Abstract]    
    Accounts payable - capital $ 251,383us-gaap_AccountsPayableOtherCurrent $ 23,496us-gaap_AccountsPayableOtherCurrent
    Accounts payable - trade 204,810us-gaap_AccountsPayableTradeCurrent 199,716us-gaap_AccountsPayableTradeCurrent
    Accrued payroll 145,176us-gaap_AccruedPayrollTaxesCurrent 75,310us-gaap_AccruedPayrollTaxesCurrent
    Accrued clinical studies 131,945iccc_AccruedClinicalStudies 0iccc_AccruedClinicalStudies
    Accrued professional fees 42,250us-gaap_AccruedProfessionalFeesCurrent 50,500us-gaap_AccruedProfessionalFeesCurrent
    Accrued other 76,113us-gaap_OtherAccountsPayableAndAccruedLiabilities 96,207us-gaap_OtherAccountsPayableAndAccruedLiabilities
    Total 851,677us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent 445,229us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent
    Increase (decrease) in accounts payable - capital 227,887us-gaap_IncreaseDecreaseInOperatingCapital  
    Increase (decrease) in accounts payable - trade 5,094us-gaap_IncreaseDecreaseInAccountsPayableTrade  
    Increase (decrease) in accrued payroll 69,866us-gaap_IncreaseDecreaseInAccruedSalaries  
    Increase (decrease) In accrued clinical studies 131,945iccc_IncreaseDecreaseInAccruedClinicalStudies  
    Increase (decrease) in accrued professional fees (8,250)iccc_IncreaseDecreaseInAccruedProfessionalFees  
    Increase (decrease) in accrued other (20,094)us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities  
    Increase (decrease) in accounts payable and accrued liabilities $ 406,448iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses  
    XML 30 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Summary of Significant Accounting Policies
    		 12 Months Ended
    Dec. 31, 2014
    Summary of Significant Accounting Policies [Abstract]  
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
    2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     

    (a)Basis of presentation

     

    We have prepared the accompanying audited financial statements reflecting all adjustments, all of which are of a normal recurring nature, that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB Accounting Standards Codification™ (Codification). Certain prior year accounts have been reclassified to conform with the 2014 financial statement presentation.

     

    (b)Cash, Cash Equivalents and Short-Term Investments

     

    We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $567,000 and $1,770,000 at December 31, 2014 and 2013, respectively. Short-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than three months from their purchase dates and not more than twelve months from the balance sheet date and are held at different financial institutions that are insured by the FDIC, within the FDIC limits per financial institution. See Note 3.

     

    (c)Inventory

     

    Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or market (net realizable value). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. See Note 4.

     

    (d)Trade Receivables

     

    Trade receivables are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded as income when received. A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Interest is charged on past due trade receivables. See Note 5.

     

    (e)Property, Plant and Equipment

     

    We depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The cost of our building (which was acquired in 1993) and the 2001 and 2007 additions thereto are being depreciated through 2023. We anticipate depreciating the building addition that was completed during the first quarter of 2015 over twenty-five years. Related building improvements are depreciated over ten year periods. Large and durable fixed assets are depreciated over their useful lives that are generally estimated to be ten years. Other fixed assets and computer equipment are depreciated over their useful lives that are generally estimated to be five and three years, respectively. See Note 7.

     

    (f)Intangible Assets

     

    We amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. In connection with certain credit facilities entered into during the third quarter of 2010, we incurred debt issue costs of $26,489, which costs are being amortized to other expenses, net over the terms of the credit facilities. See Notes 6 and 9.

     

    We continually assess the realizability of these assets in accordance with the impairment provisions of Codification Topic 360, Accounting for the Impairment or Disposal of Long-Lived Assets. If an impairment review is triggered, we evaluate the carrying value of long-lived assets by determining if impairment exists based on estimated undiscounted future cash flows over the remaining useful life of the assets and comparing that value to the carrying value of the assets. If the carrying value of the asset is greater than the estimated future cash flows, the asset is written down to its estimated fair value. The cash flow estimates that are used contain our best estimates, using appropriate and customary assumptions and projections at the time. We also review the estimated useful life of intangible assets at the end of each reporting period, making any necessary adjustments.

     

    (g)Disclosure of Fair Value of Financial Instruments and Concentration of Risk

     

    Financial instruments consist mainly of cash, cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable, bank debt and an interest rate swap. Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, long-term investments and accounts receivable. We make short-term and long-term investments in financial instruments that are insured by the FDIC. We account for fair value measurements in accordance with Codification Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and requires additional disclosures about fair value measurements. The estimated fair value of cash, cash equivalents, short-term investments, long-term investments, accounts receivable and accounts payable approximate their carrying value due to their short maturities. The estimated fair value of bank debt approximates its carrying value because the interest rates are variable. The interest rate swap is carried at fair value. See Note 9.

     

    Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area.

     

    We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies.

     

    (h)Interest Rate Swap Agreement

     

    All derivatives are recognized on the balance sheet at their fair value. We entered into an interest rate swap agreement in 2010. On the date the agreement was entered into, we designated the derivative as a hedge of the variability of cash flows to be paid related to our long-term debt. The agreement has been determined to be highly effective in hedging the variability of identified cash flows, so changes in the fair market value of the interest rate swap agreement are recorded as comprehensive (loss) income, until earnings are affected by the variability of cash flows (e.g. when periodic settlements on a variable-rate asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreement and the related hedged items. We also formally assess, both at this interest rate swap agreement’s inception and on an ongoing basis, whether the agreement is highly effective in offsetting changes in cash flow of hedged items. See Note 9.

     

    (i)Revenue Recognition

     

    We recognize revenue in accordance with Staff Accounting Bulletin (SAB) No. 104, “Revenue Recognition”, which supersedes SAB No. 101, “Revenue Recognition in Financial Statements”. SAB No. 104 requires that four criteria are met before revenue is recognized. These include i) persuasive evidence that an arrangement exists, ii) delivery has occurred or services have been rendered, iii) the seller’s price is fixed and determinable and iv) collectability is reasonably assured. We recognize revenue at the time of shipment (including to distributors) for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably assured. We recognize service revenue at the time the service is performed.

     

    (j)Expense Recognition

     

    Advertising costs are expensed when incurred, which is generally during the month in which the advertisement is published. Advertising expenses amounted to $66,193, $151,080 and $174,314 during the years ended December 31, 2014, 2013 and 2012, respectively. All product development expenses are expensed as incurred, as are all related patent costs.

     

    (k)Income Taxes

     

    We account for income taxes in accordance with Codification Topic 740, Income Taxes, which requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. We believe it is more likely than not that the deferred tax assets will be realized through future taxable income and future tax effects of temporary differences between book income and taxable income. Accordingly, we have not established a valuation allowance for the deferred tax assets. Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. We have evaluated the positions taken on our filed tax returns. We have concluded that no uncertain tax positions exist as of December 31, 2014. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 11.

     

    (l)Stock-Based Compensation

     

    We account for stock-based compensation in accordance with Codification Topic 718, Compensation-Stock Compensation, which generally requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model, as detailed in Note 12(a). Accordingly, we recorded $30,004, $31,359, and $35,985 of compensation expense pertaining to stock-based compensation, which resulted in a decrease (increase) in income (loss) before income taxes of approximately $0.01 per share during the years ended December 31, 2014, 2013 and 2012, respectively. Codification Topic 718 requires us to reflect gross tax savings resulting from tax deductions in excess of expense reflected in our financial statements as a financing cash flow.

     

    (m)Net (Loss) Income Per Common Share

     

    Net (Loss) Income per common share has been computed in accordance with Codification Topic 260-10, Earnings Per Share. The Net (Loss) per common share has been computed by dividing the Net (Loss) by the weighted average number of common shares outstanding during the period, without giving consideration to outstanding stock options because the impact would be anti-dilutive. The basic Net Income per share has been computed by dividing Net Income by the weighted average number of common shares outstanding during this period. Diluted Net Income per share has been computed by dividing Net Income by the weighted average number of shares outstanding during the period plus all outstanding stock options with an exercise price that is less than the average market price of the common stock during the period less the number of shares that could have been repurchased at this average market price with the proceeds from the hypothetical stock option exercises.

     

      Year Ended December 31, 
      2014  2013  2012 
    Weighted average number of shares outstanding  3,027,001   3,019,407   3,018,296 
    Effect of dilutive stock options  0   65,641   90,123 
    Diluted number of shares outstanding  3,027,001   3,085,048   3,108,419 
    Outstanding stock options not included in the calculation because the effect would be anti-dilutive  253,000   63,875   39,750 

     

    For additional disclosures regarding the outstanding common stock options, see Note 12(a).

     

    (n)Use of Estimates

     

    The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual amounts could differ from those estimates.

     

    (o)New Accounting Pronouncements

     

    We adopted Accounting Standards Update (ASU) No. 2011-05, Presentation of Comprehensive Income (Loss) (Topic 220) during the three-month period ended March 31, 2012, and retrospective application was required. Under ASU 2011-05, we have the option to present the total of comprehensive (loss) income, the components of net (loss) income, and the components of other comprehensive (loss) income either in a single continuous statement of comprehensive (loss) income or in two separate but consecutive statements. We elected to present two separate but consecutive statements. The statements of other comprehensive (loss) income immediately follow the statements of operations and include the components of other comprehensive (loss) income and a total for other comprehensive (loss) income, along with a total for comprehensive (loss) income. The adoption of Topic 220 only impacts the presentation of the financial statements.

     

    In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. ASU 2014-09 is effective for the Company on January 1, 2017. Early application is not permitted. ASU 2014-09 permits the use of either the retrospective or cumulative effect transition method. We have evaluated the effect that ASU 2014-09 would have on our financial statements and related disclosures. We expect that ASU 2014-09 will have no significant effect on our ongoing financial reporting, but we continue to evaluate this pending accounting standard.
    XML 31 R62.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Segment And Significant Customer Information (Details Textual) (Sales Revenue, Net [Member])
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Revenue, Major Customer [Line Items]      
    Concentration Risk, Percentage 10.00%us-gaap_ConcentrationRiskPercentage1    
    Primary dairy and beef industries [Member]
    		      
    Revenue, Major Customer [Line Items]      
    Concentration Risk, Percentage 83.00%us-gaap_ConcentrationRiskPercentage1
    / us-gaap_ConcentrationRiskByBenchmarkAxis
    = us-gaap_SalesRevenueNetMember
    / us-gaap_MajorCustomersAxis
    = iccc_PrimaryCustomersMember    		 83.00%us-gaap_ConcentrationRiskPercentage1
    / us-gaap_ConcentrationRiskByBenchmarkAxis
    = us-gaap_SalesRevenueNetMember
    / us-gaap_MajorCustomersAxis
    = iccc_PrimaryCustomersMember    		 80.00%us-gaap_ConcentrationRiskPercentage1
    / us-gaap_ConcentrationRiskByBenchmarkAxis
    = us-gaap_SalesRevenueNetMember
    / us-gaap_MajorCustomersAxis
    = iccc_PrimaryCustomersMember
    Foreign dairy and beef industries [Member]
    		      
    Revenue, Major Customer [Line Items]      
    Concentration Risk, Percentage 13.00%us-gaap_ConcentrationRiskPercentage1
    / us-gaap_ConcentrationRiskByBenchmarkAxis
    = us-gaap_SalesRevenueNetMember
    / us-gaap_MajorCustomersAxis
    = iccc_ForeignCustomersMember    		 14.00%us-gaap_ConcentrationRiskPercentage1
    / us-gaap_ConcentrationRiskByBenchmarkAxis
    = us-gaap_SalesRevenueNetMember
    / us-gaap_MajorCustomersAxis
    = iccc_ForeignCustomersMember    		 16.00%us-gaap_ConcentrationRiskPercentage1
    / us-gaap_ConcentrationRiskByBenchmarkAxis
    = us-gaap_SalesRevenueNetMember
    / us-gaap_MajorCustomersAxis
    = iccc_ForeignCustomersMember
    EXCEL 32 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C,S-?8F9E.%\W,&8Q M.68X-C(Q86,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-U;6UA#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D-A#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DEN=F5N=&]R>3PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%C8V]U;G1S7U)E8V5I M=F%B;&4\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K5]0;&%N=%]!;F1?17%U M:7!M96YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E;%=O#I%>&-E M;%=O&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O3PO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG M96YT7TQI83PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-E9VUE;G1?06YD7U-I9VYI9FEC86YT7T-U#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E)E;&%T961?4&%R='E?5')A;G-A M8W1I;VYS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E!R97!A:61?17AP96YS97-?86YD M7T]T:&5R7T%S#I7;W)K5]0;&%N=%]!;F1?17%U:7!M96YT7U0\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D]T:&5R7T5X<&5N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN M8V]M95]487AE#I7;W)K#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-E9VUE;G1?06YD7U-I M9VYI9FEC86YT7T-U#I7;W)K#I%>&-E;%=O5]O M9E]3:6=N:69I8V%N=%]!8V-O=6YT,SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D)A;FM?1&5B M=%]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D]T:&5R7T5X<&5N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D]T:&5R7T5X<&5N#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O&5S7T1E=&%I M;'-?5&5X='5A;#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-T;V-K:&]L9&5R#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-T;V-K:&]L9&5R#I%>&-E M;%=O5]$971A:6QS7U1E/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E-E9VUE;G1?06YD7U-I9VYI9FEC86YT7T-U#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D5M<&QO>65E7T)E;F5F:71S7T5M<&QO>65E7T1E M=#PO>#I.86UE/@T*("`@(#QX.E=O#I7 M;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T&-E;"!84"!O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\T-#%F8V,P-E]A,60P7S1C,S-?8F9E.%\W,&8Q.68X-C(Q86,-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#0Q9F-C,#9?83%D,%\T8S,S7V)F M93A?-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA2!);F9O'0^24U-54-%3$P@0T]2 M4"`O1$4O/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@ M("`\=&0@8VQA2!&:6QE3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^4VUA;&QE3QS M<&%N/CPO6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,C`Q-#QS<&%N M/CPO2!&:6QE'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!0=6)L:6,@1FQO870\+W1D/@T*("`@("`@ M("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'!E;G-E'!E;G-E&-E3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C M,S-?8F9E.%\W,&8Q.68X-C(Q86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-#0Q9F-C,#9?83%D,%\T8S,S7V)F93A?-S!F,3EF.#8R,6%C+U=O M'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T M-#%F8V,P-E]A,60P7S1C,S-?8F9E.%\W,&8Q.68X-C(Q86,-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#0Q9F-C,#9?83%D,%\T8S,S7V)F93A? M-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M/B@U+#@Q-2D\&5S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M/B@S+#0Y-2D\7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA&-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S&5S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y+#,P."D\&5R8VES92!O9B!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XU,"PX,#`\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES92!O9B!S=&]C:R!O<'1I M;VYS+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA'1087)T7S0T,69C8S`V7V$Q9#!?-&,S,U]B9F4X7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!O M<&5R871I;F<@86-T:79I=&EE&5D(&%S6%B;&4@ M86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA2!O<&5R871I;F<@86-T:79I=&EE6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=CX\=&%B M;&4@#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[ M)SX\8CXQ+CPO8CX\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\8CY"55-)3D53 M4R!/4$52051)3TY3/"]B/CPO=&0^/"]T6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P M<'@[(&QE='1E'0M'0M M86QI9VXZ(&IU#L@=VAI=&4M2!A;F0@8F5E9B!I;F1U M2!W87,@;W)I9VEN86QL>2!I;F-O2!H87,@9&5V96QO<&5D('!R;V1U8W1S('1H870@<')O=FED92!S:6=N:69I M8V%N="P@:6UM961I871E(&EM;75N:71Y('1O(&YE=V)O2!I;F1U2X@5&AE($-O;7!A;GD@:7,@2!A<'!R;W9A;',L('=H97)E(&%P<&QI8V%B M;&4N/"]P/CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T#L@;&5T=&5R+7-P86-I;F#LG/CQB/C(N M/"]B/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F#L@=&5X="UA;&EG M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/CQB/E-534U!4ED@3T8@4TE' M3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4SPO8CX\+W1D/CPO='(^/"]T M86)L93X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG M;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG(&)O#LG/CQB/BAA*3PO M8CX\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P<'@[)SX\8CY"87-I'0M86QI9VXZ(&IU#L@;&5T=&5R+7-P86-I;F#LG/CQB M/B8C,38P.SPO8CX\+W`^/'`@'0M86QI9VXZ(&IU#L@=VAI=&4M65A'0M86QI9VXZ(&IU#L@;&5T M=&5R+7-P86-I;F#LG/B8C,38P.SPO M<#X\=&%B;&4@#L@=&5X="UT M'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'@[)SX\8CXH8BD\+V(^/"]T9#X\=&0@#L@=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@=VAI=&4M M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/E=E(&-O;G-I9&5R(&%L;"!H:6=H;'D@;&EQ=6ED M(&EN=F5S=&UE;G0@:6YS=')U;65N=',@=&AA="!M871U2!I;G9E2!T:&4@52Y3+B!G M;W9E&-E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M#L@;&5T=&5R+7-P86-I M;F#LG(&)O3L@=&5X="UI;F1E M;G0Z(#!P>#LG/CQB/BAC*3PO8CX\+W1D/CQT9"!S='EL93TS1"=P861D:6YG M.B`P<'@[('1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@[ M)SX\8CY);G9E;G1O'0M86QI9VXZ(&IU#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@ M=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E'0M#L@=&5X="UA;&EG M;CH@;&5F=#L@8V]L;W(Z#0H@(S`P,#`P,#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VED;W=S.B`Q.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)W!A9&1I;F#L@=VED=&@Z(#`N-6EN.R!T97AT M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!X.R<^/&(^*&0I/"]B/CPO M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F#L@=&5X="UA;&EG;CH@;&5F M=#L@=&5X="UI;F1E;G0Z(#!P>#LG/CQB/E1R861E(%)E8V5I=F%B;&5S/"]B M/CPO=&0^/"]T6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/E1R861E(')E8V5I=F%B;&5S(&%R92!C87)R:65D M(&%T('1H92!O6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P M86-I;F#LG/B8C,38P.SPO<#X\=&%B M;&4@#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[ M)SX\8CXH92D\+V(^/"]T9#X\=&0@'0M86QI9VXZ(&QE M9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E M'0M2!C:&%R9V5S('1O(&]P97)A=&EO;G,@:6X@ M86UO=6YT2!A&5D(&%S65A&5D(&%S6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,'!X.R!L971T97(M#L@=VED;W=S.B`Q.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6QE M/3-$)W!A9&1I;F#L@=VED=&@Z(#`N-6EN.R!T97AT+6%L:6=N.B!L M969T.R!T97AT+6EN9&5N=#H@,'!X.R<^/&(^*&8I/"]B/CPO=&0^/'1D('-T M>6QE/3-$)W!A9&1I;F#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI M;F1E;G0Z(#!P>#LG/CQB/DEN=&%N9VEB;&4@07-S971S/"]B/CPO=&0^/"]T M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M:6YD96YT.B`P<'@[(&QE='1E'0M M'0M86QI9VXZ(&IU#L@=VAI=&4MF4@:6YT86YG:6)L92!A'!E;G-E('1H92!C;W-T(&]F('1H92!A#L@=&5X="UA;&EG;CH@;&5F=#L@ M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN M9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P M86-I;F#LG/E=E(&-O;G1I;G5A;&QY M(&%S2!O9B!T:&5S92!A6EN9R!V86QU M92!O9B!T:&4@87-S970@:7,@9W)E871E2!N96-E6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P M<'@[(&QE='1E'0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@=VED;W=S M.B`Q.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)W!A9&1I M;F#L@=VED=&@Z(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!T97AT M+6EN9&5N=#H@,'!X.R<^/&(^*&6QE/3-$)W!A M9&1I;F#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P M>#LG/CQB/D1I#L@ M=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT M.B`S-G!T.R!L971T97(M#L@=VAI=&4M&EM871E('1H96ER(&-A'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#,V<'0[(&QE='1E M'0M'0M86QI9VXZ(&IU M'0M2!W92!H879E M(&YO="!E>'!E2!P87)T:6-U;&%R(&EN9'5S=')Y(&]R(&=E;V=R M87!H:6,@87)E82X\+W`^/'`@'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M#L@=VAI=&4M6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD M96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M#L@;&5T=&5R+7-P86-I;F#LG(&)O#LG M/CQB/BAH*3PO8CX\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\8CY);G1E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@ M;&5T=&5R+7-P86-I;F#LG/D%L;"!D M97)I=F%T:79E2!O9B!I9&5N=&EF:65D(&-A2!O9B!C87-H(&9L;W=S("AE+F2!A2!D;V-U;65N=&5D('1H92!R96QA=&EO;G-H:7`@8F5T=V5E;B!T M:&4@:6YT97)E#L@=&5X M="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\ M8CXH:2D\+V(^/"]T9#X\=&0@#L@=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X M.R!L971T97(M#L@ M=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F2!AF4@2!AF4@'0M86QI9VXZ(&QE9G0[(&-O;&]R M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z M(#!P>#L@;&5T=&5R+7-P86-I;F#LG M/B8C,38P.SPO<#X\=&%B;&4@#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE M='1E'0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'@[)SX\8CXH:BD\+V(^/"]T9#X\=&0@#L@=&5X="UA;&EG M;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@ M;&5T=&5R+7-P86-I;F#LG/D%D=F5R M=&ES:6YG(&-O'!E;G-E9"!W:&5N(&EN8W5R'!E;G-E9"!A'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F#LG/CQB M/B8C,38P.SPO8CX\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X M.R!L971T97(M#L@ M=VED;W=S.B`Q.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$ M)W!A9&1I;F#L@=VED=&@Z(#`N-6EN.R!T97AT+6%L:6=N.B!L969T M.R!T97AT+6EN9&5N=#H@,'!X.R<^/&(^*&LI/"]B/CPO=&0^/'1D('-T>6QE M/3-$)W!A9&1I;F#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E M;G0Z(#!P>#LG/CQB/DEN8V]M92!487AE#L@=&5X="UA;&EG;CH@ M;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T M=&5R+7-P86-I;F#LG/E=E(&%C8V]U M;G0@9F]R(&EN8V]M92!T87AE2!O2!O69O'1E;G0@=&AE>2!A&5S(&)Y M('!R97-C"!P;W-I=&EO;B!M=7-T(&UE970@8F5F;W)E(&)E:6YG(')E M8V]G;FEZ960@:6X@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S+B!);B!T:&4@ M;W)D:6YA"!O=71C;VUE(&ES('5N8V5R=&%I;BX@26X@861D:71I;VXL('=E(&%R92!S M=6)J96-T('1O('!E&EN M9R!A=71H;W)I=&EE&ES M="!A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M#L@;&5T=&5R+7-P86-I;F#LG(&)O#LG M/CQB/BAL*3PO8CX\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\8CY3=&]C:RU" M87-E9"!#;VUP96YS871I;VX\+V(^/"]T9#X\+W1R/CPO=&%B;&4^/'`@'0M86QI9VXZ(&QE9G0[(&-O M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E M;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@ M=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I M;F#LG/E=E(&%C8V]U;G0@9F]R('-T M;V-K+6)A&-E'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#,V<'0[(&QE='1E M'0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M=')A M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VED;W=S.B`Q.R!F;VYT M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)W!A9&1I;F#L@ M=VED=&@Z(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@ M,'!X.R<^/&(^*&TI/"]B/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/CQB/DYE M="`H3&]S'0M M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P M=#L@;&5T=&5R+7-P86-I;F#LG/DYE M="`H3&]S2!D:79I9&EN M9R!.970@26YC;VUE(&)Y('1H92!W96EG:'1E9"!A=F5R86=E(&YU;6)E2!D:79I9&EN9R!.970@26YC;VUE(&)Y('1H92!W96EG:'1E9"!A M=F5R86=E(&YU;6)E'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F#LG/B8C M,38P.SPO<#X\=&%B;&4@#L@=&5X="UT M'0M:6YD96YT.B`P<'@[(&QE='1E#L@8F]R9&5R+6-O;&QA M<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1EF4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@ M8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T M9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[ M/"]T9#X\+W1R/CQT6QE/3-$)W=I M9'1H.B`Q,#`S<'@[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@ M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-G!X.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T M:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O M;G0M6QE/3-$)W=I9'1H M.B`Q-7!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ M(&QE9G0[(&9O;G0MF4Z(#$P<'0[)SY%9F9E M8W0@;V8@9&EL=71I=F4@6QE/3-$ M)W!A9&1I;F6QE.B!S;VQI9#LG/C`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M6QE/3-$)W!A9&1I;F6QE.B!S;VQI9#LG/C8U M+#8T,3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[(&)OF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T M>6QE/3-$)W9E6QE.B!D;W5B M;&4[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C M:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T M>6QE.B!D;W5B;&4[)SXS+#`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`P<'@[(&QE='1E'0M'0M86QI9VXZ(&IU'0M'0M86QI9VXZ(&IU#L@;&5T=&5R+7-P86-I;F#LG/B8C M,38P.SPO<#X\=&%B;&4@#L@ M=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E M'0M6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`P<'@[)SX\8CXH;BD\+V(^/"]T9#X\=&0@#L@=&5X="UA;&EG;CH@;&5F M=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VED;W=S.B`Q.R!F;VYT+7-I>F4M861J=7-T M.B!N;VYE.R!F;VYT+7-T6QE/3-$)W!A9&1I;F#L@=VED=&@Z(#`N-6EN M.R!T97AT+6EN9&5N=#H@,'!X.R<^/&(^*&\I/"]B/CPO=&0^/'1D('-T>6QE M/3-$)W!A9&1I;F#L@=&5X="UI;F1E;G0Z(#!P>#LG/CQB/DYE=R!! M8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]B/CPO=&0^/"]T6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE M='1E'0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M2!I;7!A8W1S('1H92!P#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N M;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P M=#L@;&5T=&5R+7-P86-I;F#LG/DEN M($UA>2`R,#$T+"!T:&4@1D%30B!I2!O;B!*86YU M87)Y(#$L(#(P,37!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A#L@;&5T=&5R+7-P86-I M;F#LG(&)O#LG/CQB/C,N/"]B/CPO M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F#L@=&5X="UA;&EG;CH@:G5S M=&EF>3L@=&5X="UI;F1E;G0Z(#!P>#LG/CQB/D-!4T@L($-!4T@@15%5259! M3$5.5%,L(%-(3U)4+51%4DT@24Y615-4345.5%,@04Y$($Q/3D#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#L@=&5X="UA;&EG;CH@:G5S=&EF M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,"XU:6X[(&QE='1E'0M6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)W=I M9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M3H@ M)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[ M/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE.B!S M;VQI9#LG(&-O;'-P86X],T0R/C(P,3,\+W1D/CQT9"!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M6QE/3-$)W!A9&1I;FF4Z M(#$P<'0[)SY#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T M.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L M:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=W:61T:#H@,39P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@'0M86QI9VXZ(&QE M9G0[(&9O;G0M'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXR+#(W,"PS.#4\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X M="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N M.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXH)#PO=&0^/'1D('-T>6QE/3-$ M)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q-7!X M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\ M+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE.B!S;VQI M9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W!A9&1I;F6QE.B!S;VQI M9#LG/C(L.3@U+#`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`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`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA#L@;&5T=&5R+7-P86-I M;F#LG(&)O#LG/CQB/C0N/"]B/CPO M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F#L@=&5X="UI;F1E;G0Z(#!P M>#LG/CQB/DE.5D5.5$]263PO8CX\+W1D/CPO='(^/"]T86)L93X\<"!S='EL M93TS1"=F;VYT.B`Q,'!T+VYO#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[ M(&QE='1E'0M6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)W=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M3H@)W1I;65S(&YE=R!R;VUA;BF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W!A9&1I M;F6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1EF4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R M+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O6QE/3-$ M)W!A9&1I;F6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L M:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q-G!X M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@'0M M86QI9VXZ(&QE9G0[(&9O;G0M'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I M>F4Z(#$P<'0[)SXR-S`L,S4U/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-7!X.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X M="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('-T M>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`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`V7V$Q9#!?-&,S,U]B9F4X7S

    '0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$#L@;&5T=&5R+7-P86-I;F#LG(&)O3L@=&5X="UI;F1E;G0Z(#!P>#LG/CQB/C4N/"]B/CPO=&0^/'1D M('-T>6QE/3-$)W!A9&1I;F#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@ M=&5X="UI;F1E;G0Z(#!P>#LG/CQB/D%#0T]53E13(%)%0T5)5D%"3$4\+V(^ M/"]T9#X\+W1R/CPO=&%B;&4^/'`@'0M86QI9VXZ(&IU#L@;&5T=&5R+7-P M86-I;F#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E M'0M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M M#L@=VAI=&4MF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T#LG(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\ M=&0@F4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)OF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T M9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@ M6QE/3-$)W!A9&1I;FF4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU M<'0[(&9O;G0MF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@ MF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O6QE/3-$)W!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)W9E#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US M:7IE.B`Q,'!T.R<^5')A9&4@86-C;W5N=',@'0M M86QI9VXZ(&QE9G0[(&9O;G0M'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I M>F4Z(#$P<'0[)SXQ+#`P-"PY.3`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`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`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`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0M6QE/3-$)W9E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'@[)SX\8CXV+CPO8CX\+W1D/CQT9"!S M='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@[)SX\8CY04D5004E$($584$5.4T53($%.1"!/5$A% M4B!!4U-%5%,\+V(^/"]T9#X\+W1R/CPO=&%B;&4^/'`@'0M86QI9VXZ(&IU#L@;&5T=&5R+7-P86-I;F'0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M#LG/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&%S'0M86QI9VXZ(&IU'0M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E MF4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O M;2UW:61T:#H@,2XU<'0[(&)OF4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T M9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[ M(&)O6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/C(P,3,\+W1D/CQT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M6QE/3-$)W!A9&1I;FF4Z(#$P<'0[)SY0#L@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M'0M86QI9VXZ(')I9VAT.R!F;VYT M+7-I>F4Z(#$P<'0[)SXQ,S,L,3$Y/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@ M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D M('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q-7!X M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXH)#PO=&0^ M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@6QE/3-$)W=I M9'1H.B`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`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O M;G0MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE M.B`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`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`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@6QE.B!D;W5B;&4[)SXD/"]T9#X\=&0@6QE.B!D;W5B;&4[ M)SXD/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M6QE.B!D;W5B;&4[)SXU+#0R-#PO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X M.R!L971T97(M#L@ M=VED;W=S.B`Q.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$ M)W!A9&1I;F#L@=VED=&@Z(#`N-6EN.R!T97AT+6%L:6=N.B!J=7-T M:69Y.R!T97AT+6EN9&5N=#H@,'!X.R<^/&(^-RX\+V(^/"]T9#X\=&0@'0M86QI9VXZ(&IU#L@=VAI M=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T M97(M#L@=VAI=&4M M#LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`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`\+W1D/CQT9"!S M='EL93TS1"=F;VYT.B`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`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,'!X.R!L971T97(M#L@=VAI=&4M3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C,S-?8F9E.%\W M,&8Q.68X-C(Q86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#0Q M9F-C,#9?83%D,%\T8S,S7V)F93A?-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA6%B;&4@86YD($%C8W)U960@17AP96YS97,\8G(^ M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L#L@;&5T=&5R+7-P86-I;F'0M6QE/3-$)W9E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@[)SX\8CXX+CPO8CX\+W1D/CQT9"!S='EL M93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P<'@[)SX\8CY!0T-/54Y44R!005E!0DQ%($%.1"!!0T-2545$ M($584$5.4T53/"]B/CPO=&0^/"]T6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P M<'@[(&QE='1E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F'0M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L M971T97(M#L@=VAI M=&4M#LG/B8C,38P.SPO<#X\=&%B;&4@ M#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@ M+7=E8FMI="UT97AT+7-TF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\+W1R M/CQT6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/C(P,30\+W1D M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0MF4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D M97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@ M,2XU<'0[(&)O6QE/3-$)W!A9&1I;FF4Z(#$P<'0[)SY!8V-O=6YT6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA M;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('-T>6QE M/3-$)W=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-7!X.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X M="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('-T M>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\+W1R/CQTF4Z(#$P<'0[)SY!8V-O=6YTF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,C`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`Q,'!T.R<^-#(L,C4P/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&9O;G0M6QE/3-$ M)V9O;G0M6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P M<'0[)SXH."PR-3`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`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A M,60P7S1C,S-?8F9E.%\W,&8Q.68X-C(Q86,-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-#0Q9F-C,#9?83%D,%\T8S,S7V)F93A?-S!F,3EF.#8R M,6%C+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$F4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)W!A M9&1I;F#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P M>#LG/CQB/D)!3DL@1$5"5#PO8CX\+W1D/CPO='(^/"]T86)L93X\<"!S='EL M93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@ M9F]N="US=')E=&-H.B!N;W)M86P[)SX\8CXF(S$V,#L\+V(^/"]P/CQP('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE2`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`^/'1A8FQE('-T>6QE/3-$)W=I M9'1H.B`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`[/"]T9#X\+W1R/CQT6QE/3-$)W=I9'1H.B`Q,#`S<'@[('1E>'0M86QI9VXZ(&IU M6QE/3-$)W=I9'1H.B`Q M-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T M9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@6QE/3-$ M)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M'0M86QI9VXZ(')I M9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ-3`L,S@R/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M6QE/3-$)V9O M;G0M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXU-RPS.#0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$ M)W9E3L@9F]N M="US:7IE.B`Q,'!T.R<^665AF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US M:7IE.B`Q,'!T.R<^-C$L,#4V/"]T9#X\=&0@F4Z(#$P<'0[)SY996%R(&5N9&EN9R!$96-E;6)E6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXV-"PX-S8\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,#PO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!F;VYT+7-I>F4Z(#$P<'0[)SXV-"PX-S8\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CPO='(^/'1R('-T>6QE/3-$)W9E3L@9F]N="US:7IE.B`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`C,#`P,#`P.R!T97AT+71R M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I M;F#L@=VAI=&4M'0M:6YD96YT.B`P<'@[(&QE='1E'0M'0M:6YD96YT.B`P<'@[(&QE='1E6QE.B!D;W5B;&4[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B0\+W1D/CQT9"!S='EL93TS M1"=F;VYT.B`Q,'!T+VYO'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M M#L@8F]R9&5R+6)O M='1O;2UC;VQO'0M'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M'0M=')A M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@8F]R9&5R+6)O='1O;2UC;VQO M'0M#L@;&5T=&5R M+7-P86-I;F'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M'0M:6YD96YT.B`P<'@[(&QE='1E'0M'0M:6YD96YT.B`P<'@[(&QE='1E6QE.B!D;W5B;&4[('=H:71E+7-P86-E.B!N;W)M86P[("UW M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B0\+W1D/CQT9"!S='EL M93TS1"=F;VYT.B`Q,'!T+VYO'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@8F]R9&5R M+6)O='1O;2UC;VQO'0M3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C,S-?8F9E.%\W,&8Q M.68X-C(Q86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#0Q9F-C M,#9?83%D,%\T8S,S7V)F93A?-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$#L@;&5T=&5R+7-P86-I M;F#LG(&)O'0M:6YD96YT.B`P<'@[('=I9'1H M.B`P+C5I;CLG/CQB/C$P+CPO8CX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!J=7-T:69Y.R!P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[ M)SX\8CY/5$A%4B`H15A014Y315,I(%)%5D5.5453+"!.150\+V(^/"]T9#X\ M+W1R/CPO=&%B;&4^/'`@F4Z(#$P<'0[(&9O;G0M'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W M:61O=W,Z(#$[('=O'0M#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^ M)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-T'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R<^3W1H M97(@*&5X<&5NF4Z(#$P<'0[(&9O;G0M'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L M.R!W:61O=W,Z(#$[('=O'0M M#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[ M)SXF(S$V,#L\+W`^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`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`[/"]T9#X\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0M'0M M86QI9VXZ(&-E;G1E6QE M.B!S;VQI9#LG(&-O;'-P86X],T0R/C(P,3(\+W1D/CQT9"!S='EL93TS1"=P M861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M6QE/3-$)W9E M#L@9F]N="US:7IE.B`Q M,'!T.R!T97AT+6%L:6=N.B!L969T.R<^3&EC96YS92!O<'1I;VX@9F5E/'-U M<#XH,2D\+W-U<#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P M>#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^ M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@9F]N="US:7IE.B`Q,'!T.R!T M97AT+6%L:6=N.B!R:6=H=#LG/C(U,"PP,#`\+W1D/CQT9"!S='EL93TS1"=W M:61T:#H@,35P>#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T M.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q M-7!X.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T M9#X\=&0@F4Z(#$P<'0[ M('1E>'0M86QI9VXZ(')I9VAT.R<^,#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H M.B`Q-7!X.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E6QE/3-$ M)V9O;G0M6%L='D@ M:6YC;VUE/"]T9#X\=&0@F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[ M('1E>'0M86QI9VXZ(')I9VAT.R<^*#,L,#`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`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H=#LG M/B@W+#`V-SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;FF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE.B!D;W5B;&4[(&9O;G0MF4Z(#$P<'0[('1E>'0M M86QI9VXZ(')I9VAT.R<^-#DL,#4S/"]T9#X\=&0@6QE/3-$)V9O;G0M6QE/3-$)V)O M6QE/3-$ M)V)OF4Z(#$P M<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F6QE.B!D;W5B;&4[(&9O;G0M'0M86QI9VXZ M(')I9VAT.R<^-3(L.#0Y/"]T9#X\=&0@6QE/3-$)V-O;&]R.B`C,#`P,#`P M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ(&QE M9G0[)SX\8CXF(S$V,#L\+V(^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ M(&IU&-L=7-I=F4@;W!T:6]N(&9E92!F&5C=71E(&$@;&EC M96YS92!A9G1EF5D(&1UF5D(&5X<&5N'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/&)R/CPO'0^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\8CXQ,2X\+V(^/"]T9#X\=&0@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E#L@=&5X="UA;&EG;CH@ M;&5F=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N M;W)M86P[)SXF(S$V,#L\+W`^/'`@"`H8F5N969I="D@97AP96YS92!A9V=R96=A=&5D("@D M.#@L,CDR*2P@)#@W+#@V-2!A;F0@)#$P,BPV-#`@*&%M;W5N=&EN9R!T;R`S M-24L(#0S)2!A;F0@-3,E(&]F('1H92`H;&]S2D@9F]R('1H92!Y96%R"!P6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E#L@ M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N M="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W`^/'1A8FQE('-T>6QE/3-$ M)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%PF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6QE/3-$)W!A9&1I M;F6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE M/3-$)W!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0MF4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW M:61T:#H@,2XU<'0[(&)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/C(P,3(\+W1D M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M6QE/3-$)W9E3L@<&%D9&EN9RUL969T.B`Q,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[)SY#=7)R96YT/"]T9#X\=&0@F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M'0M86QI9VXZ M(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXR-3(\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('-T>6QE/3-$ M)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M6QE/3-$)V9O M;G0M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$ M)W9E3L@9F]N M="US:7IE.B`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`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`Q,'!T+VYO'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+7-I>F4M M861J=7-T.B!N;VYE.R!F;VYT+7-T'0M86QI9VXZ(&IU M'0M:6YD96YT.B`S-G!T.R!F;VYT+7-I>F4M861J=7-T.B!N M;VYE.R!F;VYT+7-T"`H8F5N969I="D@97AP96YS92!D:69F97)S(&9R;VT@=&AE(&5X<&5C M=&5D('1A>"!C;VUP=71E9"!B>2!A<'!L>6EN9R!T:&4@52Y3+B!F961E6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#,V<'0[ M(&9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&IUF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[ M/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)OF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@ MF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O6QE/3-$)W!A M9&1I;F'!E8W1E9"!T87@@*&)E M;F5F:70I(&5X<&5N6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^*"0\ M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@.24[('1E>'0M86QI9VXZ(')I9VAT M.R!F;VYT+7-I>F4Z(#$P<'0[)SXX-BPX-3,\+W1D/CQT9"!S='EL93TS1"=W M:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA M;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('-T>6QE M/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)3L@=&5X M="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE M9G0[(&9O;G0M'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXV M-2PS,S(\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O M;G0M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[#0H@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M6QE/3-$)V9O M;G0M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXQ,"PU,C8\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`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`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`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D M97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@ M,2XU<'0[(&)OF4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1EF4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E3L@9F]N="US:7IE.B`Q,'!T.R<^ M4')O9'5C="!R:6=H=',\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O M;G0M6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[)SXD/"]T9#X\=&0@ M6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\+W1R/CQTF4Z(#$P<'0[)SY02P@ M<&QA;G0@86YD(&5Q=6EP;65N=#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@9F]N="US:7IE.B`Q,'!T.R<^,C,U+#4V-SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M3L@9F]N="US:7IE.B`Q,'!T.R<^1F5D97)A;"!N970@ M;W!EF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T M.R<^-3(U+#`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`D,2PQ,3(L,#`P M(&]F(&]U2`D.#(P+#`P,"`H)#8U+#`P,"!D=7)I;F<@=&AE(&9O=7)T:"!Q M=6%R=&5R(&]F(#(P,3,@86YD("0W-34L,#`P(&1U65AF5D(&%N9"!D97!R96-I871E9"!O=F5R('-T871U=&]R>2!P97)I;V1S(&9O M6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z M(#,V<'0[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[(&9O M;G0M&%B;&4@:6YC;VUE M('=I;&P@8F4@879A:6QA8FQE(&EN(&9U='5R92!P97)I;V1S(&%G86ENF5D+B!(;W=E=F5R+"!T:&4@86UO=6YT(&]F M('1H92!D969E'0M86QI M9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!F;VYT+7-I>F4M861J M=7-T.B!N;VYE.R!F;VYT+7-TF%T:6]N(&]F(&YE="!O<&5R M871I;F<@;&]S69O6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E#L@=&5X="UA;&EG;CH@:G5S M=&EF>3L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N M;W)M86P[)SXF(S$V,#L\+W`^/'`@"!R971U"!A=71H;W)I=&EE65A2!H879E(&YO('1A>"!E>&%M:6YA=&EO;G,@:6X@<')O M9W)E&5S M+"!I;G1EF5D('1A M>"!B96YE9FET7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA3QB'0^/'1A8FQE('-T>6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W9E#L@<&%D9&EN9SH@,'!X.R<^/&(^4U1/0TM(3TQ$15)3)B,X M,C$W.R!%455)5%D\+V(^/"]T9#X\+W1R/CPO=&%B;&4^/'`@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E6QE/3-$)W9E#L@<&%D9&EN9SH@,'!X.R<^/&(^4W1O M8VL@3W!T:6]N(%!L86YS/"]B/CPO=&0^/"]T6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU28C.#(Q-SMS(&-O;6UO M;B!S=&]C:R!A="!I*2!N;R!L97-S('1H86X@9F%I2!C87-E(&)A2!A<'!R;W9E9"!A;B!I;F-R96%S92!I M;B!T:&ES(&YU;6)E'!I M65A2!B92!E>&5R M8VES960@:6X@86-C;W)D86YC92!W:71H('1H96ER('1E#L@=&5X="UI M;F1E;G0Z(#,V<'0[)SXF(S$V,#L\+W`^/'`@3L@9F]N=#H@,3!P="!T:6UE'0M:6YD96YT.B`S-G!T.R<^26X@ M2G5N92`R,#$P+"!O=7(@#L@=&5X="UI;F1E;G0Z(#,V<'0[)SXF(S$V M,#L\+W`^/'`@'0M:6YD96YT.B`S-G!T.R<^06-T:79I='D@=6YD97(@=&AE('-T;V-K M(&]P=&EO;B!P;&%N6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@=&5X="UI;F1E;G0Z(#,V M<'0[)SX\+W`^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M M8V]L;&%P6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE'0M86QI9VXZ(')I M9VAT.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA M;&EG;CH@;&5F=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M;&5F=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W=I9'1H.B`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`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T M9#X\=&0@6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE M6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N M+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI M9VXZ(')I9VAT.R!F;VYT.B`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`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I M9VAT.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W!A9&1I M;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[ M('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)V9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)V9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE M/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`Q,'!T M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ M(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE M'0M86QI9VXZ(&QE9G0[(&9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE'0M86QI9VXZ(&QE9G0[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W!A M9&1I;F6QE/3-$)W!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W9E6QE/3-$ M)V9O;G0M6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M M6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^ M)B,Q-C`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`[/"]T9#X\=&0@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$ M)W!A9&1I;F6QE/3-$)V9O;G0M6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;FF4Z(#$P<'0[('!A9&1I;F'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[ M('!A9&1I;F'0M86QI9VXZ(')I9VAT.R<^)B,Q M-C`[/"]T9#X\=&0@3L@ M9F]N=#H@,3!P="!T:6UE'0M:6YD96YT.B`S-G!T.R<^)B,Q-C`[/"]P/CQP('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&IU65A65E(&5X97)C:7-E9"!S=&]C:R!O<'1I;VYS M(&-O=F5R:6YG(#$L,#`P('-H87)E65E&5R8VES960@65A M65E(&5X97)C M:7-E9"`Q-2PP,#`@&EM871E;'D@9F]U65A&5R8VES92!P&EM871E9"`D,2PP,#`L("0X+#`P,"!A;F0@)#(U M+#`P,"P@2!A;B!I;F1E<&5N9&5N="!A<'!R86ES97(@=7-I;F<@=&AE($)L86-K+5-C M:&]L97,@;W!T:6]N('!R:6-I;F<@;6]D96PL(&9O6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O M;G0M'0M86QI9VXZ(&QE9G0[)SY2:7-K+69R964@:6YT97)E6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@ MF4Z(#$P<'0[('=I9'1H.B`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`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E#L@=&5X="UI;F1E;G0Z(#,V<'0[)SXF(S$V,#L\+W`^/'`@ M3L@9F]N=#H@,3!P="!T:6UE M'0M M:6YD96YT.B`S-G!T.R<^5&AE(')I6EE;&1S(&9O&EM871I;F<@=&AE(&5X<&5C=&5D(&]P=&EO;B!T97)M+"!W:&EL M92!T:&4@;W1H97(@87-S=6UP=&EO;G,@87)E(&1E#L@=&5X="UI;F1E;G0Z(#,V<'0[ M)SXF(S$V,#LF(S$V,#L\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W9E3L@=&5X="UI;F1E M;G0Z(#!P>#L@<&%D9&EN9SH@,'!X.R<^/&(^0V]M;6]N(%-T;V-K(%)I9VAT M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE M6QE/3-$ M)W1E>'0M86QI9VXZ(&IU#L@=&5X="UI;F1E;G0Z(#,V<'0[)SXF(S$V,#L\+W`^/'`@3L@9F]N=#H@,3!P="!T:6UE'0M:6YD96YT M.B`S-G!T.R<^5&AE(%)I9VAT2!A('!E#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=T97AT M+6%L:6=N.B!J=7-T:69Y.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E#L@=&5X="UI;F1E;G0Z(#`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`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E#LG/B8C,38P.SPO<#X\<"!S='EL93TS M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E#L@=&5X="UI;F1E;G0Z M(#`N-6EN.R<^070@86YY('1I;64@869T97(@82!P97)S;VX@;W(@9W)O=7`@ M8F5C;VUE2!M87D@97AC:&%N9V4@ M=&AE(%)I9VAT2!P97)S;VX@;W(@9W)O=7`@8F5C;VUE M2!T:&4@0F]A2!M87D@3L@9F]N M=#H@,3!P="!T:6UE'0M:6YD96YT.B`P+C5I;CLG/B8C,38P.SPO<#X\<"!S='EL M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT.B`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`P+C5I;CL@=&5X="UA;&EG;CH@ M;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@<&%D9&EN9SH@,'!X.R<^/&(^,3,N M/"]B/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`P<'@[('!A9&1I;F#LG/CQB/D-/34U)5$U%3E13($%. M1"!#3TY424Y'14Y4($Q)04))3$E42453/"]B/CPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU2!U;F1E2!U;FQI M;6ET960@86YD(&ES(&EM<&]S2!F;W(@2!O9B!O=7(@;V9F:6-E#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=T M97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E#L@=&5X="UI;F1E;G0Z(#`N M-6EN.R<^07,@;V8@1&5C96UB97(@,S$L(#(P,30@=V4@:&%D(&-O;6UI='1E M9"!T;R!C;VYT#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=T97AT M+6%L:6=N.B!J=7-T:69Y.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E#L@=&5X="UI;F1E;G0Z(#,V<'0[ M)SY792!E;G1E2!C;W5R2!U;FQI;6ET M960N(%=E(&AA=F4@;F]T(&EN8W5R2!O9B!T:&5S92!I;F1E;6YI9FEC871I;VX@;V)L M:6=A=&EO;G,L(&%N9"!B87-E9"!O;B!O=7(@86YA;'ES:7,@;V8@=&AE(&YA M='5R92!O9B!T:&4@#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E#L@=&5X="UI;F1E;G0Z(#,V<'0[)SY4:&4@9&5V96QO<&UE M;G0L(&UA;G5F86-T=7)I;F<@86YD(&UA2!I;G-U3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\T-#%F8V,P-E]A,60P7S1C,S-?8F9E.%\W,&8Q.68X-C(Q86,-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#0Q9F-C,#9?83%D,%\T8S,S7V)F M93A?-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VED;W=S.B`Q.R!F;VYT+7-I>F4M861J=7-T M.B!N;VYE.R!F;VYT+7-T6QE/3-$)W!A9&1I;F#L@=VED=&@Z(#`N-6EN M.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!X.R<^/&(^,30N M/"]B/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F#L@=&5X="UA;&EG M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/CQB/E-%1TU%3E0@04Y$(%-) M1TY)1DE#04Y4($-54U1/3452($E.1D]234%424]./"]B/CPO=&0^/"]T6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT M.B`S-G!T.R!L971T97(M#L@=VAI=&4M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L M971T97(M#L@=VAI M=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M2!A;F0@8F5E9B!I;F1U#L@=&5X="UA;&EG;CH@ M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q M,'!T+VYO#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@ M;&5T=&5R+7-P86-I;F#LG/CPO<#X\ M=&%B;&4@#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL M87!S93L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M6QE/3-$)W!A M9&1I;F"`P<'@@,2XU<'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M M6QE/3-$)V9O;G0Z(&)O M;&0@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B"`Q+C5P=#L@=&5X="UI;F1E;G0Z(#!P>#L@ M9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=F;VYT.B!B;VQD(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&-E;G1E#L@<&%D9&EN9RUT;W`Z(#!P>#L@<&%D9&EN9RUR:6=H=#H@,'!X.R!P M861D:6YG+6QE9G0Z(#!P>#L@8F]R9&5R+6)O='1O;2UC;VQO6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)R!C;VQS<&%N/3-$ M,3`^665A"`P<'@@,2XU<'0[('1E>'0M:6YD96YT M.B`P<'@[(&9O;G0M6QE/3-$)W!A9&1I;F"`P<'@@,2XU<'0[('1E>'0M:6YD96YT.B`P M<'@[(&9O;G0M6QE/3-$ M)V9O;G0Z(&)O;&0@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B"`Q+C5P=#L@=&5X="UI;F1E M;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=F;VYT.B!B;VQD(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O M;G0Z(&)O;&0@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B"`Q+C5P=#L@=&5X="UI;F1E;G0Z M(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=F;VYT.B!B;VQD(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&-E;G1E#L@<&%D9&EN9RUT;W`Z(#!P>#L@<&%D9&EN9RUR:6=H=#H@ M,'!X.R!P861D:6YG+6QE9G0Z(#!P>#L@8F]R9&5R+6)O='1O;2UC;VQO6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)R!C;VQS M<&%N/3-$,CXR,#$S/"]T9#X\=&0@6QE/3-$)V9O;G0Z M(&)O;&0@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B"`Q+C5P=#L@=&5X="UI;F1E;G0Z(#!P M>#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=F;VYT.B!B;VQD(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&-E;G1E#L@<&%D9&EN9RUT;W`Z(#!P>#L@<&%D9&EN9RUR:6=H=#H@,'!X M.R!P861D:6YG+6QE9G0Z(#!P>#L@8F]R9&5R+6)O='1O;2UC;VQO6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)R!C;VQS<&%N M/3-$,CXR,#$R/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O M;G0M#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H M.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T M+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=VED=&@Z(#$T M,G!X.R!T97AT+6%L:6=N.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N M="US=')E=&-H.B!N;W)M86P[)SXS.#PO=&0^/'1D('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE#L@=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'@[#0H@9F]N="US=')E=&-H.B!N;W)M86P[)SXE M/"]T9#X\=&0@#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=VED=&@Z(#$T,7!X.R!T97AT M+6%L:6=N.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H M.B!N;W)M86P[)SXS.#PO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE#L@=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'@[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=VED=&@Z(#$U<'@[('1E>'0M M:6YD96YT.B`P<'@[(&9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US M=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT M.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@'0M:6YD96YT.B`P<'@[(&9O;G0M6QE/3-$ M)W9E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=&5X="UA M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!#;VUP86YY/'-U<#XH,2D\ M+W-U<#X\+V9O;G0^/"]T9#X\=&0@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE#L@ M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E M=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q M,'!T+VYO'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@ M,'!X.R!F;VYT+7-T'0M:6YD96YT.B`P M<'@[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=&5X="UA M;&EG;CH@'0M:6YD96YT.B`P<'@[(&9O;G0M'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M M6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N M;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO M'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O M;G0M#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXR,#PO=&0^/'1D M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=&5X="UA;&EG;CH@;&5F M=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXE M/"]T9#X\+W1R/CPO=&%B;&4^/'`@'0M86QI9VXZ(&IU'0M'0M86QI9VXZ(&IU#LG/CQS=7`^*#$I)B,Q-C`[/"]S=7`^07-S=6UE2!-5TD@ M:&%D(&]C8W5R6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M'0M86QI9VXZ(&IU#L@=VAI M=&4M'0M86QI9VXZ(&IU#L@=VAI=&4M6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD M96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/CPO<#X\=&%B;&4@#L@=&5X M="UT'0M:6YD96YT.B`P<'@[(&QE='1E#L@8F]R9&5R+6-O M;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`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`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,"XU:6X[(&QE='1E'0M6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA#LG(&)O'0M:6YD96YT.B`P<'@[)SX\8CY214Q!5$5$(%!! M4E19(%1204Y304-424].4SPO8CX\+W1D/CPO='(^/"]T86)L93X\<"!S='EL M93TS1"=F;VYT.B`Q,'!T+VYO#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#L@=&5X="UA;&EG;CH@ M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E'0M6UE;G0@=&5R;7,I(&1U92!F'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/&1I=CX\=&%B;&4@#L@=&5X="UT'0M:6YD M96YT.B`P<'@[(&QE='1E'0M6QE/3-$)W9E'0M:6YD M96YT.B`P<'@[)SX\8CXQ-BX\+V(^/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R M+7-P86-I;F#LG/B8C,38P.SPO<#X\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@:G5S M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E'0M2!C;VYT7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX\=&%B;&4@#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\8CXQ-RX\+V(^ M/"]T9#X\=&0@#L@=&5X="UA;&EG;CH@;&5F=#L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I M;F#LG/E1H92!F;VQL;W=I;F<@=&%B M;&5S('!R97-E;G0@=&AE('%U87)T97)L>2!I;F9O6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)W=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE M.B!S;VQI9#LG(&-O;'-P86X],T0Q-#Y4:')E92!-;VYT:',@16YD960\+W1D M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M6QE/3-$)W9E3L@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[ M/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)OF4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW M:61T:#H@,2XU<'0[(&)OF4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M86QI M9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)R!C;VQS<&%N/3-$,CXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q M,'!T.R<@8V]L6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[(&9O;G0M'0M86QI9VXZ(&QE9G0[(&9O;G0M'0M86QI9VXZ M(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#`X,2PW-3(\+W1D/CQT9"!S M='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$ M)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O M;G0M6QE/3-$)W=I9'1H M.B`Q-7!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X M="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W M:61T:#H@,35P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M'0M86QI9VXZ(&QE9G0[(&9O;G0M M'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#(P-2PR M-S4\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@ M;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQTF4Z(#$P<'0[)SY'F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q M,'!T.R<^,2PP-S6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXW-C`L-CF4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^-#8R+#DV-3PO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-#4X+#8V-SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0MF4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^-#`L.#4S/"]T9#X\=&0@ M6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0MF4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^*#(Y-"PW.#$\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXI M/"]T9#X\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,S`L-C(V/"]T9#X\=&0@F4Z(#$P<'0[)SY.970@*&QO6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`Q,'!T.R<^)B,Q-C`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`Q,'!T.R<^ M)B,Q-C`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`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`Q M,'!T.R<^)B,Q-C`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`U/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&9O;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@F4Z(#$P<'0[)SY& M:7-C86P@,C`Q,CH\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT M+7-I>F4Z(#$P<'0[)SXQ+#`W-BPW-#D\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXD M/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I M>F4Z(#$P<'0[)SXV-S`L-3$X/"]T9#X\=&0@F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE M.B`Q,'!T.R<^-S4P+#(Q-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0MF4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@9F]N="US:7IE.B`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`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`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXP+C`R/"]T9#X\=&0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0MF4Z(#$P<'0[)SXI/"]T9#X\+W1R/CQTF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@ M6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXP+C`R/"]T M9#X\=&0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M MF4Z(#$P<'0[)SXI/"]T9#X\ M+W1R/CPO=&%B;&4^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C,S-?8F9E.%\W,&8Q.68X M-C(Q86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#0Q9F-C,#9? M83%D,%\T8S,S7V)F93A?-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@=VED;W=S M.B`Q.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)W!A9&1I M;F#L@=VED=&@Z(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!T97AT M+6EN9&5N=#H@,'!X.R<^/&(^,3@N/"]B/CPO=&0^/'1D('-T>6QE/3-$)W!A M9&1I;F#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P M>#LG/CQB/E-50E-%455%3E0@159%3E13/"]B/CPO=&0^/"]T6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T M.R!L971T97(M#L@ M=VAI=&4M2P@=V4@:&%V92!E=F%L=6%T960@7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^ M/&1I=CX\=&%B;&4@#L@=&5X M="UT'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$ M)W9E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P<'@[)SX\8CXH82D\+V(^/"]T9#X\=&0@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M M6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD M96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/E=E(&AA=F4@<')E<&%R960@=&AE(&%C8V]M<&%N>6EN9R!A=61I M=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(')E9FQE8W1I;F<@86QL(&%D:G5S M=&UE;G1S+"!A;&P@;V8@=VAI8V@@87)E(&]F(&$@;F]R;6%L(')E8W5R2!R97!O'0^ M/&1I=CX\=&%B;&4@#L@=&5X M="UT'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'@[)SX\8CXH8BD\+V(^/"]T9#X\=&0@#L@=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L M971T97(M#L@=VAI M=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F2!I;G9E2!T:&4@52Y3 M+B!G;W9E&-E#LG(&)O#LG/CQB/BAC*3PO M8CX\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P<'@[)SX\8CY);G9E;G1O'0M86QI9VXZ(&IU#L@;&5T=&5R+7-P M86-I;F#LG/B8C,38P.SPO<#X\<"!S M='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@:G5S=&EF M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,"XU:6X[(&QE='1E'0M#L@;&5T=&5R+7-P M86-I;F#LG(&)O#LG/CQB/BAD*3PO8CX\+W1D/CQT9"!S='EL93TS1"=P861D:6YG M.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\ M8CY4#L@=&5X="UA;&EG;CH@;&5F=#L@ M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN M9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE M='1E'0M2!U2!W2!P;W)T:6]N M(&]F('1H92!R96-E:79A8FQE(&)A;&%N8V4@:7,@;W5T#L@;&5T=&5R+7-P86-I;F#LG(&)O#LG/CQB/F4I/"]B/CPO=&0^ M/'1D('-T>6QE/3-$)W!A9&1I;F#L@=&5X="UA;&EG;CH@;&5F=#L@ M=&5X="UI;F1E;G0Z(#!P>#LG/CQB/E!R;W!E6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE M='1E'0M'0M86QI9VXZ M(&IU#L@=VAI=&4M2P@<&QA M;G0@86YD(&5Q=6EP;65N="!O;B!T:&4@2UF:79E('EE87)S+B!296QA=&5D(&)U:6QD M:6YG(&EM<')O=F5M96YT65A M2!E#L@;&5T=&5R+7-P86-I;F#LG(&)O#LG/CQB/BAF*3PO8CX\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[ M('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\8CY);G1A M;F=I8FQE($%S#L@=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/E=E(&%M;W)T:7IE(&EN=&%N9VEB M;&4@87-S971S(&]N('1H92!S=')A:6=H="UL:6YE(&UE=&AO9"!B>2!C:&%R M9V5S('1O(&]P97)A=&EO;G,@:6X@86UO=6YTF5D('1O(&]T:&5R(&5X<&5N'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P M86-I;F#LG/B8C,38P.SPO<#X\<"!S M='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@:G5S=&EF M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,"XU:6X[(&QE='1E'0M2!AF%B M:6QI='D@;V8@=&AE6EN9R!V86QU92!O9B!L;VYG+6QI=F5D(&%S2!D971E2!A9&IU M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VED;W=S.B`Q.R!F;VYT+7-I M>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)W!A9&1I;F#L@=VED M=&@Z(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!X M.R<^/&(^*&6QE/3-$)W!A9&1I;F#L@ M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/CQB/D1I#L@=&5X="UA;&EG;CH@ M;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T M97(M#L@=VAI=&4M M&EM871E('1H96ER(&-A'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#,V<'0[(&QE='1E'0M'0M86QI9VXZ(&IU'0M2!W92!H879E(&YO="!E>'!E2!P87)T:6-U;&%R(&EN9'5S=')Y(&]R(&=E;V=R87!H:6,@87)E82X\ M+W`^/'`@'0M86QI9VXZ M(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@ M=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L M971T97(M#L@=VAI M=&4M'0^/&1I=CX\=&%B;&4@#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E'0M M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\8CXH M:"D\+V(^/"]T9#X\=&0@#L@=&5X="UA;&EG;CH@;&5F=#L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E M'0M2!E9F9E8W1I=F4@:6X@:&5D9VEN9R!T:&4@=F%R:6%B:6QI M='D@;V8@:61E;G1I9FEE9"!C87-H(&9L;W=S+"!S;R!C:&%N9V5S(&EN('1H M92!F86ER(&UA2!E9F9E8W1I=F4@:6X@;V9F'0^/&1I=CX\=&%B;&4@#L@=&5X="UT'0M:6YD M96YT.B`P<'@[(&QE='1E'0M6QE/3-$)W9E'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\8CXH:2D\+V(^/"]T9#X\ M=&0@#L@=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD M96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/E=E(')E8V]G;FEZ92!R979E;G5E(&EN(&%C8V]R9&%N8V4@=VET M:"!3=&%F9B!!8V-O=6YT:6YG($)U;&QE=&EN("A304(I($YO+B`Q,#0L("8C M.#(R,#M2979E;G5E(%)E8V]G;FET:6]N)B,X,C(Q.RP@=VAI8V@@&ES=',L(&EI*2!D M96QI=F5R>2!H87,@;V-C=7)R960@;W(@2!AF4@2!AF4@'!E;G-E(%)E8V]G;FET M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/CQT86)L M92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@;&5T=&5R+7-P86-I;F#LG(&)O#LG M/CQB/BAJ*3PO8CX\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\8CY%>'!E;G-E M(%)E8V]G;FET:6]N/"]B/CPO=&0^/"]T6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P M<'@[(&QE='1E'0M'0M M86QI9VXZ(&IU#L@=VAI=&4M2!D M=7)I;F<@=&AE(&UO;G1H(&EN('=H:6-H('1H92!A9'9E65A M2X@06QL('!R;V1U8W0@9&5V96QO<&UE;G0@97AP96YS97,@ M87)E(&5X<&5N'0^/&1I=CX\=&%B;&4@#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\8CXH:RD\+V(^ M/"]T9#X\=&0@&5S/"]B/CPO M=&0^/"]T6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M'0M86QI9VXZ(&IU#L@=VAI=&4M&5S('!A>6%B;&4@;W(@"!A"!E9F9E8W1S(&]F('1E;7!O2!D:69F97)E;F-E"!A2!C;W5R&%M:6YA=&EO;G,@8GD@=&AE($EN=&5R;F%L(%)E=F5N=64@4V5R=FEC92!A M;F0@;W1H97(@=&%X:6YG(&%U=&AO&ES="!A#L@;&5T=&5R+7-P M86-I;F#LG(&)O#LG/CQB/BAL*3PO8CX\+W1D/CQT9"!S='EL93TS1"=P861D:6YG M.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\ M8CY3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+V(^/"]T9#X\+W1R/CPO=&%B M;&4^/'`@'0M86QI9VXZ M(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@ M=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T M+VYO#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T M=&5R+7-P86-I;F#LG/E=E(&%C8V]U M;G0@9F]R('-T;V-K+6)A&-E#L@;&5T=&5R+7-P86-I;F#LG(&)O#LG/CQB/BAM*3PO8CX\+W1D/CQT M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'@[)SX\8CY.970@*$QO6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[ M(&QE='1E'0M'0M86QI M9VXZ(&IU'0M M2!D:79I9&EN9R!T:&4@3F5T M("A,;W-S*2!B>2!T:&4@=V5I9VAT960@879E2!T:&4@=V5I M9VAT960@879E2!T:&4@=V5I9VAT960@879E&5R8VES92!P&5R M8VES97,N/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M:6YD96YT.B`P<'@[(&QE='1E'0M M6QE/3-$ M)W=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN M9&5N=#H@,'!X.R!L971T97(M3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T M9#X\=&0@F4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O;&]R M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)OF4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1EF4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@ M8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T M9#X\=&0@6QE/3-$)W9E M#L@=&5X="UA;&EG;CH@ M;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^5V5I9VAT960@879E6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30R M<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXS+#`R M-RPP,#$\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W M:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P M<'0[)SXS+#`Q.2PT,#<\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@ M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L M:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT M+7-I>F4Z(#$P<'0[)SXS+#`Q."PR.38\+W1D/CQT9"!S='EL93TS1"=W:61T M:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\+W1R/CQTF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT M+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I M>F4Z(#$P<'0[(&)OF4Z(#$P<'0[)SY$:6QU=&5D(&YU;6)E6QE/3-$)W!A9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE.B!D;W5B;&4[)SXS+#`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`P/"]T9#X\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F M;VYT+7-I>F4Z(#$P<'0[)SXS.2PW-3`\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO M='(^/"]T86)L93X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X M="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT M.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0^/&1I=CX\=&%B;&4@#L@=&5X="UT'0M:6YD M96YT.B`P<'@[(&QE='1E'0M6QE/3-$)W9E'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SX\8CXH;BD\+V(^/"]T9#X\ M=&0@#L@ M=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT M.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/E1H92!P'!E;G-E#L@;&5T M=&5R+7-P86-I;F#LG(&)O#LG/CQB M/BAO*3PO8CX\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M M:6YD96YT.B`P<'@[)SX\8CY.97<@06-C;W5N=&EN9R!0#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,S9P=#L@;&5T=&5R+7-P86-I;F#LG M/E=E(&%D;W!T960@06-C;W5N=&EN9R!3=&%N9&%R9',@57!D871E("A!4U4I M($YO+B`R,#$Q+3`U+"8C,38P.SQI/E!R97-E;G1A=&EO;B!O9B!#;VUP'0M'0M86QI M9VXZ(&IU'0M M2!T;R!R96-O9VYI>F4@=&AE(&%M;W5N="!O9B!R979E;G5E('1O('=H M:6-H(&ET(&5X<&5C=',@=&\@8F4@96YT:71L960@9F]R('1H92!T2`Q+"`R,#$W+B!%87)L>2!A<'!L M:6-A=&EO;B!I'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2!O9B!3:6=N:69I8V%N="!!8V-O M=6YT:6YG(%!O;&EC:65S("A486)L97,I/&)R/CPO6QE/3-$)W=I M9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M3H@ M)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\ M=&0@F4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)OF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1EF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W9E#L@=&5X="UA;&EG;CH@;&5F M=#L@9F]N="US:7IE.B`Q,'!T.R<^5V5I9VAT960@879E6QE M/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30R<'@[ M('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXS+#`R-RPP M,#$\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@ M;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T M:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXS+#`Q.2PT,#<\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X M="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N M.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I M>F4Z(#$P<'0[)SXS+#`Q."PR.38\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M,35P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`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`Q M,'!T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O M;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXS M+#$P."PT,3D\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P M861D:6YG+6)O='1O;3H@-'!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL M969T.B`Q,'!T.R!F;VYT+7-I>F4Z(#$P<'0[)SY/=71S=&%N9&EN9R!S=&]C M:R!O<'1I;VYS(&YO="!I;F-L=61E9"!I;B!T:&4@8V%L8W5L871I;VX@8F5C M875S92!T:&4@969F96-T('=O=6QD(&)E(&%N=&DM9&EL=71I=F4\+W1D/CQT M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N M="US:7IE.B`Q,'!T.R<^,C4S+#`P,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT M+7-I>F4Z(#$P<'0[)SXV,RPX-S4\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US M:7IE.B`Q,'!T.R<^,SDL-S4P/"]T9#X\=&0@'0M86QI9VXZ(&IU M#L@;&5T=&5R+7-P86-I;F#L@=VAI=&4M7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/&1I=CX\<"!S='EL93TS1"=F;VYT.B`Q M,'!T+VYO#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[ M(&QE='1E'0M6QE/3-$)W=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW M:61T:#H@,2XU<'0[(&)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/C(P,3,\+W1D M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M6QE/3-$ M)W!A9&1I;F6QE/3-$)W=I9'1H.B`Q-G!X M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M'0M86QI9VXZ(')I9VAT M.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#(W,"PS.#4\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H M.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXH M)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@ M6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I M>F4Z(#$P<'0[)SXI/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&9O;G0M6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W!A9&1I;F6QE.B!S;VQI9#LG/C(L.3@U+#`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`Q,'!T M.R<^-2PR-34L,S@U/"]T9#X\=&0@F4Z(#$P<'0[)SXI/"]T9#X\+W1R/CQT6QE/3-$)W!A9&1I;F6QE.B!S;VQI9#LG/C0Y M-BPP,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D M:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W!A M9&1I;F6QE.B!S;VQI9#LG/C0Y-BPP,#`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I M;CL@;&5T=&5R+7-P86-I;F#LG/CPO M<#X\=&%B;&4@#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E#L@8F]R9&5R+6-O;&QA<'-E.B!C M;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M6QE/3-$ M)W1E>'0M86QI9VXZ(&IU6QE/3-$)W!A9&1I;F6QE.B!S;VQI9#LG(&-O;'-P86X],T0V/D%S(&]F($1E8V5M8F5R M(#,Q+#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@ M8V]L6QE/3-$)W9E3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`Q,#`S<'@[('1E M>'0M86QI9VXZ(&IU'0M86QI9VXZ(&QE9G0[(&9O;G0M'0M86QI9VXZ(')I9VAT.R!F M;VYT+7-I>F4Z(#$P<'0[)SXS,#8L-#0T/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P M>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`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`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/C(P,30\+W1D/CQT9"!S M='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0MF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[ M(&)O6QE/3-$)W!A9&1I;FF4Z(#$P M<'0[)SY46QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@ M;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I M9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q-G!X.R!T M97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@'0M86QI M9VXZ(&QE9G0[(&9O;G0M'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z M(#$P<'0[)SXV,#DL-C,X/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-7!X.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA M;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('-T>6QE M/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`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`C,#`P,#`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`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z M(#!P>#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'0M86QI9VXZ(')I9VAT.R!C;VQO#LG/C,W,RPX.#(\ M+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E'0^/'1A8FQE('-T>6QE/3-$)W=I M9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M3H@ M)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W9EF4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,2XU<'0[(&9O;G0M6QE/3-$)W9EF4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M MF4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O M;2UW:61T:#H@,2XU<'0[(&)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T M9#X\+W1R/CQT6QE/3-$)W=I9'1H M.B`Q,#`S<'@[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F M=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H M.B`Q-#)P>#L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L M969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=W:61T:#H@,35P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`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`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,C8L M-#@Y/"]T9#X\=&0@F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,C8L M-#@Y/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0MF4Z(#$P<'0[)SXI/"]T9#X\=&0@ MF4Z(#$P<'0[)SXI/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&9O;G0M6QE/3-$ M)W9EF4Z(#$P<'0[)SY396-U2!D M97!O6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&9O;G0M6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W!A9&1I M;F6QE M.B!S;VQI9#LG/C@L,3

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`Q,'!T.R<^)B,Q-C`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`@("`\=&%B;&4@ M8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2P@<&QA;G0@86YD(&5Q=6EP;65N=#PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'`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`Q,'!T+VYO#L@=&5X="UA;&EG;CH@ M;&5F=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXD/"]T9#X\=&0@#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US M=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT M.B`Q,'!T+VYO#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG M;CH@;&5F=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXD/"]T9#X\=&0@#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N M="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F M;VYT.B`Q,'!T+VYO#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`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`Q,'!T+VYO6QE.B!S;VQI M9#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXP/"]T9#X\=&0@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&)O6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L#0H@)W1I;65S(&YE=R!R;VUA;B6QE.B!S M;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M M86P[)SXH-"PP,3(L,#`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`S-G!T.R!L971T M97(M#L@=VAI=&4M M#LG/CQS=7`^)B,Q-C`[/"]S=7`^/"]P M/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C,S-?8F9E M.%\W,&8Q.68X-C(Q86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M-#0Q9F-C,#9?83%D,%\T8S,S7V)F93A?-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA M6%B;&4@86YD($%C8W)U960@17AP96YS97,@ M*%1A8FQE'!E M;G-E6%B;&4@86YD M(&5X<&5N#L@=&5X="UA;&EG;CH@:G5S=&EF M>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!F;VYT+7-T#L@8F]R9&5R+6-O M;&QA<'-E.B!C;VQL87!S93LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`^/'1R('-T>6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q M-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O MF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[ M/"]T9#X\=&0@6QE/3-$ M)W!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0MF4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T M:#H@,2XU<'0[(&)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/BA$96-R96%S92D\ M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M M6QE/3-$)W9E#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^06-C M;W5N=',@<&%Y86)L92`F(S@R,3$[(&-A<&ET86P\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,39P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@'0M86QI9VXZ(&QE9G0[(&9O M;G0M'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXR-3$L M,S@S/"]T9#X\=&0@'0M86QI9VXZ M(&QE9G0[(&9O;G0M6QE M/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q M-#%P>#L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N M.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=W:61T:#H@,35P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@'0M86QI9VXZ(&QE9G0[ M(&9O;G0M'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXR M,C'0M86QI M9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXU+#`Y-#PO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0MF4Z(#$P<'0[)SY!8V-R=65D('!A M>7)O;&P\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,30U+#$W-CPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXW-2PS,3`\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^-CDL.#8V/"]T9#X\=&0@F4Z(#$P<'0[)SY!8V-R=65D(&-L:6YI M8V%L('-T=61I97,\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,3,Q+#DT-3PO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O M;G0M6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXP/"]T9#X\=&0@F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&9O;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXT,BPR-3`\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^-3`L-3`P/"]T M9#X\=&0@6QE/3-$ M)W!A9&1I;F6QE.B!S;VQI9#LG/C6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[(&)O M6QE/3-$)W!A9&1I;F6QE/3-$)W9E'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M'0M6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@;&5T=&5R+7-P86-I;F#LG M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M86QI9VXZ(&QE M9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE'0M M86QI9VXZ(')I9VAT.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E6QE.B!D;W5B;&4[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/C@U,2PV-S<\+W1D/CQT9"!S='EL M93TS1"=F;VYT.B`Q,'!T+VYO'0M:6YD96YT.B`P<'@[(&QE='1E M'0M'0M:6YD96YT.B`P<'@[(&QE='1E'0M'0M:6YD96YT.B`P<'@[(&QE='1E6QE.B!D M;W5B;&4[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O M:V4M=VED=&@Z(#!P>#LG/B0\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T M+VYO'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@8F]R9&5R+6)O='1O;2UC;VQO'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@=VAI=&4M'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M M'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@8F]R9&5R+6)O='1O;2UC;VQO'0M#L@;&5T=&5R+7-P86-I;F7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6UE;G1S(&1U93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'`@'0M86QI9VXZ M(&IU#L@=VAI=&4M#LG/B8C,38P.SPO<#X\=&%B;&4@#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE M='1E#L@8F]R M9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@+7=E8FMI="UT97AT+7-T'0M86QI M9VXZ(&-E;G1E6QE.B!S M;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)R!C;VQS<&%N/3-$,CXD,2PP M,#`L,#`P)B,Q-C`[/&)R("\^;6]R=&=A9V4\+W1D/CQT9"!S='EL93TS1"=F M;VYT.B!B;VQD(#$P<'0O;F]R;6%L("=T:6UE'0M86QI M9VXZ(&-E;G1E6QE.B!S M;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)R!C;VQS<&%N/3-$,CXD-C`P M+#`P,#QB6QE/3-$)W!A9&1I;F6QE/3-$)W=I M9'1H.B`Q-G!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#)P>#L@ M=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W M:61T:#H@,39P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M'0M86QI9VXZ(&QE9G0[(&9O;G0M M'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXY-BPS,S@\ M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F M=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`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`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`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`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`@("`\=&%B;&4@8VQA'!E;G-E M'!E;G-E6QE/3-$)W=I9'1H.B`Q-38W<'@[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI9#LG(&-O;'-P86X],T0Q,#Y996%R($5N M9&5D($1E8V5M8F5R(#,Q+#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0MF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[ M/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE.B!S M;VQI9#LG(&-O;'-P86X],T0R/C(P,3(\+W1D/CQT9"!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M6QE/3-$)W9E#L@=&5X="UA;&EG;CH@;&5F M=#L@9F]N="US:7IE.B`Q,'!T.R<^3&EC96YS92!O<'1I;VX@9F5E/'-U<#XH M,2D\+W-U<#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M'0M86QI9VXZ(')I9VAT M.R!F;VYT+7-I>F4Z(#$P<'0[)SXP/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@ M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D M('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q-7!X M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M9F]N="US:7IE.B`Q,'!T.R<^*#,L,#`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`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`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`P<'@[(&QE='1E'0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M&-L=7-I=F4@;W!T:6]N(&9E92!F&5C=71E(&$@;&EC M96YS92!A9G1EF5D(&1UF5D(&5X<&5N'1087)T7S0T M,69C8S`V7V$Q9#!?-&,S,U]B9F4X7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S("A486)L M97,I/&)R/CPO2=S(&)E;F5F:70@9F]R(&EN8V]M92!T87AE'0^/'`@'0M86QI9VXZ(&IU'0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&-E;G1E3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@F4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@ M8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O6QE/3-$ M)W!A9&1I;F6QE/3-$)W!A9&1I M;F6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1EF4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M6QE/3-$)W=I9'1H.B`Y.#DN-C=P M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUL969T.B`Q,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[)SY#=7)R96YT/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I M>F4Z(#$P<'0[)SXD/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O M;G0M6QE/3-$)W=I9'1H M.B`Q-G!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X M="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M,35P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M'0M M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXW,#@\+W1D/CQT9"!S M='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W9E3L@9F]N="US:7IE.B`Q,'!T.R<^ M1F5D97)A;#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-S6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXW-"PW,3,\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@9F]N="US:7IE.B`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`Q,'!T+VYO#L@=&5X="UA;&EG;CH@;&5F M=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F'0M2!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA M;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F'0M6QE/3-$)W=I9'1H.B`Q M-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X M.R!L971T97(M3H@)W1I;65S M(&YE=R!R;VUA;B#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`^/'1R('-T>6QE/3-$)W9E3L@9F]N="US=')E M=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,2XU<'0[(&9O;G0M3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@F4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@ M8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O6QE/3-$ M)W!A9&1I;F6QE/3-$)W!A9&1I M;F6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1EF4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M6QE/3-$)W=I9'1H.B`Q,#`S<'@[ M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M"`H8F5N969I="D@97AP96YS93PO=&0^/'1D('-T>6QE M/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@ M9F]N="US:7IE.B`Q,'!T.R<^*"0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M,30R<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXX M-BPX-3,\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D('-T>6QE/3-$ M)W=I9'1H.B`Q-G!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N M="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P M>#L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L M969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,35P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@'0M86QI9VXZ(&QE9G0[(&9O M;G0M'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXV-2PS M,S(\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@ M;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`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`S-G!T.R!L M971T97(M#L@=VAI M=&4M#LG/CPO<#X\=&%B;&4@#L@=&5X="UT'0M M:6YD96YT.B`P<'@[(&QE='1E#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@+7=E8FMI M="UT97AT+7-T6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)W!A9&1I M;F6QE M/3-$)W!A9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI M9#LG(&-O;'-P86X],T0R/C(P,30\+W1D/CQT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,2XU<'0[(&9O;G0MF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T M9#X\+W1R/CQT6QE/3-$)W=I9'1H M.B`Q,3DQ<'@[('1E>'0M86QI9VXZ(&IU6QE/3-$ M)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M,35P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M'0M M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ-C4L-3(W/"]T9#X\ M=&0@'0M86QI9VXZ(&QE9G0[(&9O M;G0M3L@9F]N="US M:7IE.B`Q,'!T.R<^4')O<&5R='DL('!L86YT(&%N9"!E<75I<&UE;G0\+W1D M/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M9F]N="US:7IE.B`Q,'!T.R<^,C(U+#(R.3PO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F M;VYT+7-I>F4Z(#$P<'0[)SXU,BPP.30\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO M='(^/'1R('-T>6QE/3-$)W9E3L@9F]N="US:7IE.B`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`Q M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[)SY$969EF4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE.B!D;W5B;&4[)SXQ+#(V,"PX,#,\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H-"B`T<'0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z M(#$P<'0[(&)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P M86-I;F'0M M3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C,S-? M8F9E.%\W,&8Q.68X-C(Q86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO-#0Q9F-C,#9?83%D,%\T8S,S7V)F93A?-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@8VAA;F=E'0^/'`@3L@ M9F]N=#H@,3!P="!T:6UE'0M:6YD96YT.B`S-G!T.R<^/"]P/CQT86)L92!S='EL M93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$ M)W9E'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE'0M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE'0M86QI9VXZ(')I9VAT.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`Q,'!T M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`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`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0Z(#$P M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE M/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F M;VYT.B`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`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`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`[/"]T9#X\=&0@6QE M/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[ M('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W!A9&1I M;F&5R8VES86)L92!A="!$96-E;6)E6QE/3-$)W!A9&1I;F6QE/3-$ M)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N M+"!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E6QE M/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W9E6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q M-C`[/"]T9#X\=&0@6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$ M)V9O;G0M'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E6QE/3-$ M)V)O'0M86QI9VXZ M(&QE9G0[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z(#$P<'0[('!A9&1I;F'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\'0^/'`@'0M86QI9VXZ(&IU'0M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T M:#H@,2XU<'0[(&)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/C(P,3,\+W1D/CQT M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0MF4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W=I9'1H.B`Q,#`S<'@[('1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L M:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=W:61T:#H@,30R<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT M+7-I>F4Z(#$P<'0[)SXR+C`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P M>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)3PO=&0^ M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M'0M86QI9VXZ M(&QE9G0[(&9O;G0M6QE M/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@#L@ M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)3PO=&0^/"]T M6EE;&0\+W1D/CQT M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N M="US:7IE.B`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`V M7V$Q9#!?-&,S,U]B9F4X7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0M86QI9VXZ(&IU'0M6QE/3-$)W=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M3H@)W1I;65S(&YE=R!R;VUA;BF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT M.B!B;VQD(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,2XU<'0[('1E>'0M:6YD96YT.B`P M<'@[(&9O;G0M'0M:6YD M96YT.B`P<'@[('!A9&1I;F#L@<&%D9&EN9RUL969T.B`P<'@[(&)OF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=F;VYT.B!B;VQD(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,2XU<'0[('1E>'0M M:6YD96YT.B`P<'@[(&9O;G0M'0M:6YD96YT.B`P<'@[('!A9&1I;F#L@<&%D9&EN9RUL969T.B`P<'@[(&)O6QE/3-$)V9O;G0Z(&)O M;&0@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B"`Q+C5P=#L@=&5X="UI;F1E;G0Z(#!P>#L@ M9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=F;VYT.B!B;VQD(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,2XU<'0[('1E>'0M:6YD M96YT.B`P<'@[(&9O;G0M'0M:6YD96YT.B`P<'@[('!A9&1I;F#L@<&%D9&EN9RUL969T.B`P<'@[(&)O6QE/3-$)V9O;G0Z(&)O;&0@ M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B"`Q+C5P=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N M="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F M;VYT.B!B;VQD(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,2XU<'0[('1E>'0M:6YD96YT M.B`P<'@[(&9O;G0M'0M M:6YD96YT.B`P<'@[('!A9&1I;F#L@<&%D9&EN9RUL969T.B`P<'@[(&)O6QE/3-$)V9O;G0Z(&)O;&0@,3!P M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B"`Q+C5P=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US M=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$ M)W9E6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE#L@=VED=&@Z(#$V<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@ M=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@'0M:6YD96YT.B`P<'@[ M(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE#L@=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'@[(&9O;G0M'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI M;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXE/"]T9#X\=&0@ M#L@=&5X M="UI;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R M:6=H=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[ M)SXS-3PO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M#L@=VED M=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[ M(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M:6YD96YT.B`P<'@[(&9O;G0M6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE#L@=&5X="UA;&EG;CH@'0M:6YD96YT M.B`P<'@[(&9O;G0M'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'@[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=&5X="UI;F1E;G0Z M(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=F;VYT.B`Q,'!T+VYO'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M#L@9F]N="US=')E=&-H M.B!N;W)M86P[)SXR,CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N M="US=')E=&-H.B!N;W)M86P[)SXE/"]T9#X\=&0@6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@ M9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@'0M:6YD96YT.B`P<'@[(&9O;G0M'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T M97(M#L@=VAI=&4M M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E'0M6QE/3-$)W=I9'1H.B`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`Q,'!T+VYO#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`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`^/'`@#L@;&5T=&5R+7-P86-I;F#LG/BI! M;6]U;G0@:7,@;&5S3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C M,S-?8F9E.%\W,&8Q.68X-C(Q86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-#0Q9F-C,#9?83%D,%\T8S,S7V)F93A?-S!F,3EF.#8R,6%C+U=O M'0O:'1M M;#L@8VAA2!&:6YA;F-I86P@ M26YF;W)M871I;VX@1&ES8VQO2!&:6YA;F-I86P@26YF;W)M871I;VX@6U1A8FQE(%1E>'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/CQP('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/CPO<#X\=&%B;&4@#L@ M=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E M#L@8F]R9&5R M+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[ M(&)O6QE/3-$)W!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P M861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/D1E8V5M8F5R)B,Q-C`[,S$\+W1D M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M6QE/3-$)W9E6QE/3-$)V9O;G0M M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)R!C;VQS<&%N/3-$,CXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T M.R<@8V]L6QE/3-$)W=I9'1H.B`X,35P>#L@=&5X="UA;&EG;CH@;&5F M=#L@9F]N="US:7IE.B`Q,'!T.R<^4')O9'5C="!S86QE6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F M=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H M.B`Q-#)P>#L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=W:61T:#H@,39P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@'0M86QI9VXZ M(&QE9G0[(&9O;G0M'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P M<'0[)SXQ+#4S.2PW,3D\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@ M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L M:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-7!X.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X M="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('-T M>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H M.B`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`Q,'!T.R<^.#6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#`W-RPX.38\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,2PS-#(L-S(R/"]T9#X\=&0@ M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O M;G0M6QE/3-$)V9O;G0M M6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXW M-C`L-C6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M6QE M/3-$)V9O;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z M(#$P<'0[)SXH-#4X+#8V-SPO=&0^/'1D#0H@6QE/3-$ M)V9O;G0M6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P M<'0[)SXT,"PX-3,\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T M.R<^,3DX+#@U-CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M6QE M/3-$)V9O;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z M(#$P<'0[)SXH,3,L,S,U/"]T9#X\=&0@6QE/3-$)V9O M;G0M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXH,CDT+#6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`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`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@F4Z(#$P<'0[)SY&:7-C86P@,C`Q M,SH\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M6QE M/3-$)V9O;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`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`Q,'!T.R<^,S(U+#`Q,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,C`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`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`Q,'!T.R<^)B,Q-C`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`Q,'!T.R<^)B,Q-C`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`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M6QE/3-$)V9O M;G0M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$ M)W9E6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#$W-2PQ M,C8\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@F4Z(#$P<'0[)SY'6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXW-3`L,C$U/"]T9#X\=&0@ M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O M;G0M6QE/3-$)V9O;G0M M6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXR M,3$L-S`V/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE M.B`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`Q,'!T.R<^)B,Q-C`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`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X M.R!L971T97(M#L@ M=VAI=&4M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^,C4@>65A'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,3`@>65A7!E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,3`@>65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^,R!Y96%R'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C,S-? M8F9E.%\W,&8Q.68X-C(Q86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO-#0Q9F-C,#9?83%D,%\T8S,S7V)F93A?-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!; M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA&5S(')E8V5I=F%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!D97!O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$F%T M:6]N(&]F(&1E8G0@:7-S=64@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA M2!D97!O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C,S-?8F9E.%\W,&8Q.68X-C(Q86,- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#0Q9F-C,#9?83%D,%\T M8S,S7V)F93A?-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2P@4&QA;G0@86YD($5Q M=6EP;65N="!;3&EN92!)=&5M2!A M;F0@;6%N=69A8W1U2P@<&QA;G0@86YD(&5Q=6EP;65N="P@9W)O'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!A;F0@;6%N=69A8W1U2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN M92!)=&5M2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2P@4&QA;G0@86YD($5Q M=6EP;65N="!;3&EN92!)=&5M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA6%B;&4@86YD($%C8W)U960@ M17AP96YS97,@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L7)O;&P\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4@+2!C87!I=&%L M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6%B;&4@+2!T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C,S-?8F9E.%\W M,&8Q.68X-C(Q86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#0Q M9F-C,#9?83%D,%\T8S,S7V)F93A?-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!O=VYE M9"!S=6)S:61I87)Y(&]F(%1$($9I;F%N8VEA;"!''0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/&1I=CY,;VYD;VX@26YT97)B86YK($]F9F5R M960@4F%T92`H3$E"3U(I(&]F(#,N-#$E/"]D:78^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S65A6UE;G0@5&5R;7,L($)A M;&QO;VX@4&%Y;65N="!T;R!B92!296-E:79E9#PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S6UE;G0@5&5R;7,\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2UF;W5R(&UO;G1H/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'1E;F1E9"!T:')O=6=H($UA>2`S,2P@,C`Q-2!A;F0@:7,@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/&1I=CY);G1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C,S-?8F9E.%\W,&8Q M.68X-C(Q86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#0Q9F-C M,#9?83%D,%\T8S,S7V)F93A?-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S2!I;F-O;64\+W1D/@T*("`@ M("`@("`\=&0@8VQAF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M/B@R+#@W-BD\&-L=7-I M=F4@;W!T:6]N(&9E92!F'!E;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-#%F M8V,P-E]A,60P7S1C,S-?8F9E.%\W,&8Q.68X-C(Q86,-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-#0Q9F-C,#9?83%D,%\T8S,S7V)F93A?-S!F M,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA'1U86QS*2`H55-$("0I/&)R/CPO M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-L=7-I M=F4@;W!T:6]N('!A>6UE;G0@'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;F1I='5R92!F;W(@9&5V96QO<&UE M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-#%F8V,P M-E]A,60P7S1C,S-?8F9E.%\W,&8Q.68X-C(Q86,-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO-#0Q9F-C,#9?83%D,%\T8S,S7V)F93A?-S!F,3EF M.#8R,6%C+U=O'0O:'1M;#L@8VAA&5S("A$971A:6QS M*2`H55-$("0I/&)R/CPO'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M&5S(%M!8G-T'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M/B0@*#@V+#@U,RD\'!E;G-E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#DV."D\'!E;G-E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M/B0@*#@X+#(Y,BD\7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2P@<&QA;G0@86YD(&5Q=6EP M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S"!C3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C,S-?8F9E.%\W,&8Q M.68X-C(Q86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#0Q9F-C M,#9?83%D,%\T8S,S7V)F93A?-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R&5S("A$971A:6QS(%1E>'1U86PI("A54T0@)"D\8G(^ M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\"!R871E('!E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'1U86Q=/"]S=')O;F<^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$"!C'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^,C`R."!T:')O=6=H(#(P,S$\"!!=71H;W)I='D@6TUE;6)E'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S"!C'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^,C`R.2!T:')O=6=H(#(P,S$\&5C=71E(&$@;&EC96YS M92!A9G1EF5D(&1UF5D(&5X<&5N'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2`H1&5T86EL6UE;G0@07=A&5R8VES92!0&5R M8VES97,L(%=E:6=H=&5D($%V97)A9V4@17AE&5R8VES86)L92P@5V5I9VAT960@079E&5R8VES92!0 M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&5R8VES86)L92P@06=G'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!O9B!S=&]C:R!O<'1I;VYS+"!3:&%R97,\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-#%F M8V,P-E]A,60P7S1C,S-?8F9E.%\W,&8Q.68X-C(Q86,-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-#0Q9F-C,#9?83%D,%\T8S,S7V)F93A?-S!F M,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XT.2XP,"4\65A'0^ M-B!Y96%R7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'1U86PI("A54T0@)"D\ M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L M6UE;G0@07=A&5R8VES960\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&EM=6T\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!3:&%R92!" M87-E9"!087EM96YT($%W87)D($]P=&EO;B!497)M:6YA=&EO;B!796EG:'1E M9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XD(#`N,#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!087EM M96YT($%W87)D(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!M971H;V0@:6YV97-T;65N="!O=VYE'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6UE;G0@07=A'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6UE;G0@07=A'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=CY.;R!L97-S('1H M86X@.#4E(&]F(&9A:7(@;6%R:V5T('9A;'5E(&]N('1H92!D871E(&]F(&=R M86YT(&EN('1H92!C87-E(&]F(&YO;BUQ=6%L:69I960@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^-"!Y96%R&5R8VES86)L92!W96EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6UE;G0@07=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=CY.;R!L97-S('1H86X@.#4E(&]F(&9A:7(@;6%R:V5T('9A;'5E M(&]N('1H92!D871E(&]F(&=R86YT(&EN('1H92!C87-E(&]F(&YO;BUQ=6%L M:69I960@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$65A'0^-"!Y96%R7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M2!#;VUP86YY(%M-96UB97)=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\2!-5TD@:&%D(&]C8W5R M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!#;VUP86YY(%M-96UB97)= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-#%F8V,P-E]A,60P7S1C,S-?8F9E M.%\W,&8Q.68X-C(Q86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M-#0Q9F-C,#9?83%D,%\T8S,S7V)F93A?-S!F,3EF.#8R,6%C+U=O'0O:'1M;#L@8VAA M65E(%-A=FEN9W,@4&QA;B!$97-C'0^3VYE(&UO;G1H/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^075G=7-T(#(P,3(@=V4@:&%V92!M871C:&5D(#$P,"4@;V8@=&AE(&9I M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M M87,M;6EC'1087)T7S0T,69C8S`V7V$Q9#!?-&,S,U]B9F4X7S XML 33 R43.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Inventory (Details) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Inventory [Abstract]      
    Raw materials $ 306,444us-gaap_InventoryRawMaterials $ 270,355us-gaap_InventoryRawMaterials  
    Work-in-process 355,745us-gaap_InventoryWorkInProcess 783,060us-gaap_InventoryWorkInProcess  
    Finished goods 283,566us-gaap_InventoryFinishedGoods 153,093us-gaap_InventoryFinishedGoods  
    Total 945,755us-gaap_InventoryNet 1,206,508us-gaap_InventoryNet  
    Increase (Decrease) in Raw materials inventories 36,089us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories    
    Increase (Decrease) in Work-in-process inventories (427,315)iccc_IncreaseDecreaseInWorkInProcessInventories    
    Increase (Decrease) in Finished goods inventories 130,473iccc_IncreaseDecreaseInFinishedGoodsInventories    
    Increase (Decrease) in inventories $ (260,753)us-gaap_IncreaseDecreaseInInventories $ (442,494)us-gaap_IncreaseDecreaseInInventories $ (17,463)us-gaap_IncreaseDecreaseInInventories

    XML 34 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Inventory (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Inventory [Abstract]  
    Schedule of Inventory, Current

      As of December 31,  Increase 
      2014  2013  (Decrease) 
    Raw materials $306,444  $270,355  $36,089 
    Work-in-process  355,745   783,060   (427,315)
    Finished goods  283,566   153,093   130,473 
    Total $945,755  $1,206,508  ($260,753)
    XML 35 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Cash, Cash Equivalents, Short-Term and Long-Term Investments (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Cash, Cash Equivalents, Short-Term and Long-Term Investments [Abstract]  
    Schedule of Cash, Cash Equivalents and Short-term Investments

      As of December 31,  (Decrease) 
      2014  2013  Increase 
    Cash and cash equivalents $850,028  $2,270,385  ($1,420,357)
    Short-term investments  2,489,000   2,985,000   (496,000)
    Subtotal  3,339,028   5,255,385   (1,916,357)
    Long-term investments  496,000   0   496,000 
    Total $3,835,028  $5,255,385  ($1,420,357)
    XML 36 R56.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stockholders' Equity (Details) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Stock options granted 25,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross 26,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross 2,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    Outstanding, Weighted Average Exercise Price $ 3.30us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice $ 3.13us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice $ 3.19us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    Grants, Weighted Average Exercise Price $ 4.69us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice $ 4.67us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice $ 5.93us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
    Terminations, Weighted Average Exercise Price $ 5.75us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice $ 3.15us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice $ 4.75us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
    Exercises, Weighted Average Exercise Price $ 3.15us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice $ 3.11us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice $ 3.39us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
    Outstanding, Weighted Average Exercise Price $ 3.42us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice $ 3.30us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice $ 3.13us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    Exercisable, Weighted Average Exercise Price $ 3.08us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice    
    Outstanding, Aggregate Intrinsic Value $ 223,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue $ 185,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue $ 344,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
    Outstanding, Aggregate Intrinsic Value 364,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue 223,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue 185,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
    Exercisable, Aggregate Intrinsic Value $ 357,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue    
    2000 Plan [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Outstanding 157,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 163,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 186,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember
    Stock options granted 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember
    Terminations 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 (8,000)us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember
    Exercise of stock options, Shares 0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 (6,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 (15,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember
    Outstanding 157,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 157,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 163,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember
    Exercisable 157,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		    
    Reserved for future grants 0iccc_ReserveForFutureGrant
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		    
    2010 Plan [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Outstanding 73,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 49,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 49,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember
    Stock options granted 25,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 26,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 2,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember
    Terminations (2,000)us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 (1,000)us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 (2,000)us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember
    Exercise of stock options, Shares (1,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 (1,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember
    Outstanding 95,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 73,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 49,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember
    Exercisable 42,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		    
    Reserved for future grants 202,500iccc_ReserveForFutureGrant
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		    
    XML 37 R44.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Accounts Receivable (Details) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Accounts Receivable[Abstract]      
    Trade accounts receivable, gross $ 1,004,990us-gaap_AccountsReceivableGrossCurrent $ 609,638us-gaap_AccountsReceivableGrossCurrent  
    Accumulated allowance for bad debt and product returns (16,194)us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent (13,952)us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent  
    Trade accounts receivable, net 988,796us-gaap_AccountsReceivableNet 595,686us-gaap_AccountsReceivableNet  
    Other receivables 16,496us-gaap_OtherReceivables 35,676us-gaap_OtherReceivables  
    Income taxes receivable 0us-gaap_IncomeTaxReceivable 48us-gaap_IncomeTaxReceivable  
    Accounts receivable, net 1,005,292us-gaap_AccountsReceivableNetCurrent 631,410us-gaap_AccountsReceivableNetCurrent  
    Increase (Decrease) In Trade accounts receivable, gross 395,352iccc_IncreaseDecreaseInAccountsReceivableGross    
    Increase (Decrease) In Less: allowance for bad debt and product returns (2,242)us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease    
    Increase (Decrease) In Trade accounts receivable, net 393,110us-gaap_IncreaseDecreaseInAccountsReceivable    
    Increase (Decrease) In Other receivables (19,180)us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables    
    Increase (Decrease) In Income taxes receivable (48)us-gaap_IncreaseDecreaseInIncomeTaxesReceivable    
    Increase (Decrease) In Accounts receivable, net $ 373,882us-gaap_IncreaseDecreaseInReceivables $ 20,056us-gaap_IncreaseDecreaseInReceivables $ 227,558us-gaap_IncreaseDecreaseInReceivables
    XML 38 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Accounts Receivable (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Accounts Receivable[Abstract]  
    Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

      As of December 31,  Increase 
      2014  2013  (Decrease) 
    Trade accounts receivable, gross $1,004,990  $609,638  $395,352 
    Accumulated allowance for bad debt and product returns  (16,194)  (13,952)  (2,242)
    Trade accounts receivable, net  988,796   595,686   393,110 
    Other receivables  16,496   35,676   (19,180)
    Income taxes receivable  0   48   (48)
    Accounts receivable, net $1,005,292  $631,410  $373,882
    XML 39 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Prepaid Expenses and Other Assets (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Prepaid Expenses and Other Assets [Abstract]  
    Schedule of Prepaid expenses and other assets
      As of December 31,  (Decrease) 
      2014  2013  Increase 
    Prepaid expenses and other assets $133,119  $159,117  ($25,998)
    Security deposits  15,280   0   15,280 
    Current subtotal  148,399   159,117   (10,718)
                
    Debt issue costs  26,489   26,489   0 
    Accumulated amortization of debt issue costs  (16,479)  (13,603)  (2,876)
    Security deposits  8,920   750   8,170 
    Long-term subtotal  18,930   13,636   5,294 
                 
    Total $167,329  $172,753  ($5,424)
    XML 40 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Business Operations
    		 12 Months Ended
    Dec. 31, 2014
    Business operations [Abstract]  
    BUSINESS OPERATIONS
    1.BUSINESS OPERATIONS

     

    ImmuCell Corporation (the Company) is a growing animal health company whose purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. The Company was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987, in conjunction with its initial public offering of common stock. The Company has developed products that provide significant, immediate immunity to newborn dairy and beef cattle and is in the late stages of developing a new product that addresses mastitis, the most significant cause of economic loss to the dairy industry. The Company is subject to certain risks associated with its stage of development including dependence on key individuals, competition from other larger companies, the successful sale of existing products and the development and acquisition of additional commercially viable products with appropriate regulatory approvals, where applicable.
    XML 41 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Property, Plant And Equipment (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Property, Plant and Equipment [Abstract]  
    Schedule of property, plant and equipment

      As of December 31,  Increase 
      2014  2013  (Decrease) 
    Laboratory and manufacturing equipment $3,522,465  $3,182,686  $339,779 
    Building and improvements  2,969,891   2,940,239   29,652 
    Office furniture and equipment  470,607   354,243   116,364 
    Construction in progress(1)  1,270,672   9,600   1,261,072 
    Land  50,000   50,000   0 
    Property, plant and equipment, gross  8,283,635   6,536,768   1,746,867 
    Accumulated depreciation  (4,445,988)  (4,012,003)  (433,985)
    Property, plant and equipment, net $3,837,647  $2,524,765  $1,312,882 

     

    (1) As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015.
    XML 42 R40.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Summary of Significant Accounting Policies (Details)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Net (Loss) Income Per Common Share      
    Weighted average number of shares outstanding 3,027,001us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 3,019,407us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 3,018,296us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
    Effect of dilutive stock options 0iccc_EffectOfDilutiveStockOptions 65,641iccc_EffectOfDilutiveStockOptions 90,123iccc_EffectOfDilutiveStockOptions
    Diluted number of shares outstanding 3,027,001us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 3,085,048us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 3,108,419us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
    Outstanding stock options not included in the calculation because the effect would be anti-dilutive 253,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 63,875us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 39,750us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
    XML 43 R53.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Income Taxes (Details 1) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Income Taxes [Abstract]      
    Computed expected tax (benefit) expense $ (86,853)us-gaap_IncomeTaxReconciliationNondeductibleExpense $ 69,788us-gaap_IncomeTaxReconciliationNondeductibleExpense $ 65,332us-gaap_IncomeTaxReconciliationNondeductibleExpense
    State income taxes, net of federal (benefit) expense (6,968)us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes 8,482us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes 8,015us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes
    Share-based compensation 10,201us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost 10,526us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost 9,766us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
    Research and development tax credit (19,405)us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment (21,887)us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment (10,813)us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
    Other 14,733us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther 20,956us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther 30,340us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther
    Total income tax (benefit) expense $ (88,292)us-gaap_IncomeTaxExpenseBenefit $ 87,865us-gaap_IncomeTaxExpenseBenefit $ 102,640us-gaap_IncomeTaxExpenseBenefit
    XML 44 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Balance Sheets (USD $)
    Dec. 31, 2014
    Dec. 31, 2013
    CURRENT ASSETS:    
    Cash and cash equivalents $ 850,028us-gaap_CashAndCashEquivalentsAtCarryingValue $ 2,270,385us-gaap_CashAndCashEquivalentsAtCarryingValue
    Short-term investments 2,489,000us-gaap_ShortTermInvestments 2,985,000us-gaap_ShortTermInvestments
    Inventory 945,755us-gaap_InventoryNet 1,206,508us-gaap_InventoryNet
    Accounts receivable, net 1,005,292us-gaap_AccountsReceivableNetCurrent 631,410us-gaap_AccountsReceivableNetCurrent
    Prepaid expenses and other assets 148,399us-gaap_PrepaidExpenseAndOtherAssetsCurrent 159,117us-gaap_PrepaidExpenseAndOtherAssetsCurrent
    Current portion of deferred tax asset 30,463us-gaap_DeferredTaxAssetsNetCurrent 15,212us-gaap_DeferredTaxAssetsNetCurrent
    Total current assets 5,468,937us-gaap_AssetsCurrent 7,267,632us-gaap_AssetsCurrent
    PROPERTY, PLANT AND EQUIPMENT, net 3,837,647us-gaap_PropertyPlantAndEquipmentNet 2,524,765us-gaap_PropertyPlantAndEquipmentNet
    LONG-TERM PORTION OF DEFERRED TAX ASSET 1,230,340us-gaap_DeferredTaxAssetsNetNoncurrent 1,154,681us-gaap_DeferredTaxAssetsNetNoncurrent
    LONG-TERM INVESTMENTS 496,000us-gaap_LongTermInvestments 0us-gaap_LongTermInvestments
    OTHER ASSETS, net 18,930us-gaap_OtherAssetsNoncurrent 13,636us-gaap_OtherAssetsNoncurrent
    TOTAL ASSETS 11,051,854us-gaap_Assets 10,960,714us-gaap_Assets
    CURRENT LIABILITIES:    
    Accounts payable and accrued expenses 851,677us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent 445,229us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
    Current portion of bank debt 150,382us-gaap_LoansPayableToBankCurrent 190,390us-gaap_LoansPayableToBankCurrent
    Deferred revenue 6,690us-gaap_DeferredRevenueCurrent 0us-gaap_DeferredRevenueCurrent
    Total current liabilities 1,008,749us-gaap_LiabilitiesCurrent 635,619us-gaap_LiabilitiesCurrent
    LONG-TERM LIABILITIES:    
    Long-term portion of bank debt 745,920us-gaap_LongTermLoansFromBank 896,224us-gaap_LongTermLoansFromBank
    Interest rate swap 38,817iccc_InterestRateSwap 33,002iccc_InterestRateSwap
    Total long-term liabilities 784,737us-gaap_LiabilitiesNoncurrent 929,226us-gaap_LiabilitiesNoncurrent
    TOTAL LIABILITIES 1,793,486us-gaap_Liabilities 1,564,845us-gaap_Liabilities
    STOCKHOLDERS' EQUITY:    
    Common stock, $0.10 par value per share, 8,000,000 shares authorized, 3,261,148 shares issued at December 31, 2014 and 2013 326,115us-gaap_CommonStockValue 326,115us-gaap_CommonStockValue
    Capital in excess of par value 10,042,305us-gaap_AdditionalPaidInCapitalCommonStock 10,011,339us-gaap_AdditionalPaidInCapitalCommonStock
    Accumulated deficit (574,567)us-gaap_RetainedEarningsAccumulatedDeficit (407,408)us-gaap_RetainedEarningsAccumulatedDeficit
    Treasury stock, at cost, 234,114 and 235,114 shares at December 31, 2014 and 2013, respectively (512,154)us-gaap_TreasuryStockValue (514,341)us-gaap_TreasuryStockValue
    Accumulated other comprehensive loss (23,331)us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax (19,836)us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax
    Total stockholders' equity 9,258,368us-gaap_StockholdersEquity 9,395,869us-gaap_StockholdersEquity
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 11,051,854us-gaap_LiabilitiesAndStockholdersEquity $ 10,960,714us-gaap_LiabilitiesAndStockholdersEquity
    XML 45 R45.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Prepaid Expenses and Other Assets (Details) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Prepaid Expenses and Other Assets [Abstract]    
    Prepaid expenses and other assets $ 133,119us-gaap_OtherPrepaidExpenseCurrent $ 159,117us-gaap_OtherPrepaidExpenseCurrent
    Security deposits 15,280us-gaap_SecurityDeposit 0us-gaap_SecurityDeposit
    Current subtotal 148,399us-gaap_PrepaidExpenseAndOtherAssetsCurrent 159,117us-gaap_PrepaidExpenseAndOtherAssetsCurrent
    Debt issue costs 26,489us-gaap_DeferredFinanceCostsNet 26,489us-gaap_DeferredFinanceCostsNet
    Accumulated amortization of debt issue costs (16,479)us-gaap_AccumulatedAmortizationDeferredFinanceCosts (13,603)us-gaap_AccumulatedAmortizationDeferredFinanceCosts
    Security deposits 8,920us-gaap_DepositAssets 750us-gaap_DepositAssets
    Long-term subtotal 18,930us-gaap_OtherAssetsNoncurrent 13,636us-gaap_OtherAssetsNoncurrent
    Total 167,329us-gaap_PrepaidExpenseAndOtherAssets 172,753us-gaap_PrepaidExpenseAndOtherAssets
    (Decrease) Increase in Prepaid expenses and other assets (25,998)us-gaap_IncreaseDecreaseInPrepaidExpense  
    (Decrease) Increase in Security deposits 15,280us-gaap_IncreaseDecreaseInSecurityDeposits  
    (Decrease) Increase in Current subtotal (10,718)us-gaap_IncreaseDecreaseInOtherCurrentAssets  
    (Decrease) Increase in Debt issue costs 0iccc_IncreaseDecreaseDebtIssueCosts  
    (Decrease) Increase in Accumulated amortization of debt issue costs (2,876)iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts  
    (Decrease) Increase in Security deposits 8,170us-gaap_IncreaseDecreaseInOtherDeposits  
    (Decrease) Increase in Long-term subtotal 5,294us-gaap_IncreaseDecreaseInOtherNoncurrentAssets  
    (Decrease) Increase in Prepaid expenses and other assets, Total $ (5,424)iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization  
    XML 46 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Statements of Stockholders' Equity (USD $)
    Total
    Common Stock
    Capital in Excess of Par Value
    Accumulated Deficit
    Treasury Stock
    Accumulated Other Comprehensive (Loss) Income Member
    Balance at Dec. 31, 2011 $ 9,020,433us-gaap_StockholdersEquity $ 326,115us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 $ 9,911,914us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 $ (614,315)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 $ (562,469)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 $ (40,812)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Balance (in shares) at Dec. 31, 2011   3,261,148us-gaap_SharesOutstanding
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     257,114us-gaap_SharesOutstanding
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		  
    Net income (loss) 89,512us-gaap_NetIncomeLoss 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 89,512us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Other comprehensive income (loss), net of taxes (9,308)us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent 0us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 0us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 (9,308)us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Exercise of stock options 50,800us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised   17,986us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 32,814us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 0us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Exercise of stock options, Shares   0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     (15,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		  
    Tax benefits related to stock options 7,261us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation 0us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 7,261us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Stock-based compensation 35,985us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 35,985us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Balance at Dec. 31, 2012 9,194,683us-gaap_StockholdersEquity 326,115us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 9,973,146us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 (524,803)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 (529,655)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 (50,120)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Balance (in shares) at Dec. 31, 2012   3,261,148us-gaap_SharesOutstanding
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     242,114us-gaap_SharesOutstanding
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		  
    Net income (loss) 117,395us-gaap_NetIncomeLoss 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 117,395us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Other comprehensive income (loss), net of taxes 30,284us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent 0us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 0us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 30,284us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Exercise of stock options 21,750us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised   6,436us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 15,314us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 0us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Exercise of stock options, Shares   0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     (7,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		  
    Tax benefits related to stock options 398us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation 0us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 398us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Stock-based compensation 31,359us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 31,359us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Balance at Dec. 31, 2013 9,395,869us-gaap_StockholdersEquity 326,115us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 10,011,339us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 (407,408)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 (514,341)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 (19,836)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Balance (in shares) at Dec. 31, 2013   3,261,148us-gaap_SharesOutstanding
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     235,114us-gaap_SharesOutstanding
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		  
    Net income (loss) (167,159)us-gaap_NetIncomeLoss 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 (167,159)us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Other comprehensive income (loss), net of taxes (3,495)us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent 0us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 0us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 (3,495)us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Exercise of stock options 3,149us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised   962us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 2,187us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 0us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Exercise of stock options, Shares   0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     (1,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		  
    Stock-based compensation 30,004us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 30,004us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Balance at Dec. 31, 2014 $ 9,258,368us-gaap_StockholdersEquity $ 326,115us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 $ 10,042,305us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 $ (574,567)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 $ (512,154)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		 $ (23,331)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AccumulatedOtherComprehensiveIncomeMember
    Balance (in shares) at Dec. 31, 2014   3,261,148us-gaap_SharesOutstanding
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     234,114us-gaap_SharesOutstanding
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_TreasuryStockMember    		  
    XML 47 R59.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Commitments and Contingent Liabilities (Details) (USD $)
    Dec. 31, 2014
    sqft
    Commitments and Contingent Liabilities [Abstract]  
    Purchase obligation current $ 326,000us-gaap_PurchaseObligationDueInNextTwelveMonths
    Purchase obligation total $ 550,000us-gaap_PurchaseObligation
    Area of facility 7,100us-gaap_AreaOfRealEstateProperty
    XML 48 R35.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Other (Expenses) Revenues, Net (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Other (Expenses) Revenues, Net [Abstract]  
    Schedule of other (expenses) revenues
      Year Ended December 31, 
      2014  2013  2012 
    License option fee(1) $0  $250,000  $0 
    Royalty income  0   (3,000)  15,166 
    Interest income  15,552   12,493   17,202 
    Interest expense  (57,827)  (66,689)  (75,274)
    Debt issuance amortization  (2,876)  (2,894)  (2,876)
    Other gains (losses)  (3,902)  34,902   (7,067)
    Other (expenses) revenues, net ($49,053) $224,812  ($52,849)

     

    (1) During the second quarter of 2013, we received a $250,000 exclusive option fee from a prospective partner for the development and marketing of Mast Out®. This payment was recorded as deferred revenue upon receipt. During the third quarter of 2013, this prospective partner decided not to execute a license after its final due diligence. Accordingly, the deferred revenue was recognized during the third quarter of 2013. At the same time, $47,604 in capitalized expenses pertaining to the development of Mast Out® were written off.
    XML 49 R65.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Unaudited Quarterly Financial Data Unaudited (Details) (USD $)
    		 3 Months Ended 12 Months Ended
    Dec. 31, 2014
    Sep. 30, 2014
    Jun. 30, 2014
    Mar. 31, 2014
    Dec. 31, 2013
    Sep. 30, 2013
    Jun. 30, 2013
    Mar. 31, 2013
    Dec. 31, 2012
    Sep. 30, 2012
    Jun. 30, 2012
    Mar. 31, 2012
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Condensed Financial Statements, Captions [Line Items]                              
    Product sales $ 2,205,275us-gaap_SalesRevenueGoodsNet $ 1,770,129us-gaap_SalesRevenueGoodsNet $ 1,539,719us-gaap_SalesRevenueGoodsNet $ 2,081,752us-gaap_SalesRevenueGoodsNet $ 1,559,248us-gaap_SalesRevenueGoodsNet $ 1,234,701us-gaap_SalesRevenueGoodsNet $ 1,366,493us-gaap_SalesRevenueGoodsNet $ 1,846,734us-gaap_SalesRevenueGoodsNet $ 1,420,951us-gaap_SalesRevenueGoodsNet $ 1,076,749us-gaap_SalesRevenueGoodsNet $ 1,175,126us-gaap_SalesRevenueGoodsNet $ 1,717,109us-gaap_SalesRevenueGoodsNet $ 7,596,874us-gaap_SalesRevenueGoodsNet $ 6,007,176us-gaap_SalesRevenueGoodsNet $ 5,389,935us-gaap_SalesRevenueGoodsNet
    Gross margin 1,342,722us-gaap_GrossProfit 1,077,896us-gaap_GrossProfit 878,523us-gaap_GrossProfit 1,149,895us-gaap_GrossProfit 607,644us-gaap_GrossProfit 615,717us-gaap_GrossProfit 783,677us-gaap_GrossProfit 1,053,567us-gaap_GrossProfit 750,215us-gaap_GrossProfit 620,958us-gaap_GrossProfit 670,518us-gaap_GrossProfit 1,012,568us-gaap_GrossProfit 4,449,037us-gaap_GrossProfit 3,060,606us-gaap_GrossProfit 3,054,259us-gaap_GrossProfit
    Product development expenses 462,965us-gaap_ResearchAndDevelopmentExpense 361,232us-gaap_ResearchAndDevelopmentExpense 760,672us-gaap_ResearchAndDevelopmentExpense 594,209us-gaap_ResearchAndDevelopmentExpense 325,010us-gaap_ResearchAndDevelopmentExpense 290,853us-gaap_ResearchAndDevelopmentExpense 271,858us-gaap_ResearchAndDevelopmentExpense 266,479us-gaap_ResearchAndDevelopmentExpense 234,316us-gaap_ResearchAndDevelopmentExpense 223,771us-gaap_ResearchAndDevelopmentExpense 211,706us-gaap_ResearchAndDevelopmentExpense 247,807us-gaap_ResearchAndDevelopmentExpense 2,179,079us-gaap_ResearchAndDevelopmentExpense 1,154,200us-gaap_ResearchAndDevelopmentExpense 917,600us-gaap_ResearchAndDevelopmentExpense
    Net operating income (loss) 198,856us-gaap_OperatingIncomeLoss 40,853us-gaap_OperatingIncomeLoss (458,667)us-gaap_OperatingIncomeLoss 12,561us-gaap_OperatingIncomeLoss (209,975)us-gaap_OperatingIncomeLoss (159,967)us-gaap_OperatingIncomeLoss 23,722us-gaap_OperatingIncomeLoss 326,666us-gaap_OperatingIncomeLoss 12,497us-gaap_OperatingIncomeLoss (86,126)us-gaap_OperatingIncomeLoss 37,397us-gaap_OperatingIncomeLoss 281,233us-gaap_OperatingIncomeLoss (206,398)us-gaap_OperatingIncomeLoss (19,552)us-gaap_OperatingIncomeLoss 245,001us-gaap_OperatingIncomeLoss
    Net income (loss) $ 130,626us-gaap_NetIncomeLoss $ 10,330us-gaap_NetIncomeLoss $ (294,781)us-gaap_NetIncomeLoss $ (13,335)us-gaap_NetIncomeLoss $ (150,703)us-gaap_NetIncomeLoss $ 57,336us-gaap_NetIncomeLoss $ 6,452us-gaap_NetIncomeLoss $ 204,310us-gaap_NetIncomeLoss $ (16,862)us-gaap_NetIncomeLoss $ (63,574)us-gaap_NetIncomeLoss $ 15,187us-gaap_NetIncomeLoss $ 154,761us-gaap_NetIncomeLoss $ (167,159)us-gaap_NetIncomeLoss $ 117,395us-gaap_NetIncomeLoss $ 89,512us-gaap_NetIncomeLoss
    Earnings Per Share [Abstract]                              
    Basic (in dollar per share) $ 0.04us-gaap_EarningsPerShareBasic $ 0.00us-gaap_EarningsPerShareBasic $ (0.10)us-gaap_EarningsPerShareBasic $ 0.00us-gaap_EarningsPerShareBasic $ (0.05)us-gaap_EarningsPerShareBasic $ 0.02us-gaap_EarningsPerShareBasic $ 0.00us-gaap_EarningsPerShareBasic $ 0.07us-gaap_EarningsPerShareBasic $ (0.01)us-gaap_EarningsPerShareBasic $ (0.02)us-gaap_EarningsPerShareBasic $ 0.01us-gaap_EarningsPerShareBasic $ 0.05us-gaap_EarningsPerShareBasic $ (0.06)us-gaap_EarningsPerShareBasic $ 0.04us-gaap_EarningsPerShareBasic $ 0.03us-gaap_EarningsPerShareBasic
    Diluted (in dollar per share) $ 0.04us-gaap_EarningsPerShareDiluted $ 0.00us-gaap_EarningsPerShareDiluted $ (0.10)us-gaap_EarningsPerShareDiluted $ 0.00us-gaap_EarningsPerShareDiluted $ (0.05)us-gaap_EarningsPerShareDiluted $ 0.02us-gaap_EarningsPerShareDiluted $ 0.00us-gaap_EarningsPerShareDiluted $ 0.07us-gaap_EarningsPerShareDiluted $ (0.01)us-gaap_EarningsPerShareDiluted $ (0.02)us-gaap_EarningsPerShareDiluted $ 0.01us-gaap_EarningsPerShareDiluted $ 0.05us-gaap_EarningsPerShareDiluted $ (0.06)us-gaap_EarningsPerShareDiluted $ 0.04us-gaap_EarningsPerShareDiluted $ 0.03us-gaap_EarningsPerShareDiluted
    XML 50 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Related Party Transactions
    		 12 Months Ended
    Dec. 31, 2014
    Related Party Transactions [Abstract]  
    RELATED PARTY TRANSACTIONS
    15.RELATED PARTY TRANSACTIONS

     

    Dr. David S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc. (formerly Stearns Veterinary Outlet, Inc.), a domestic distributor of ImmuCell products (First Defense®, Wipe Out® Dairy Wipes, and CMT) and of J-t Enterprises of Melrose, Inc., an exporter. His affiliated companies purchased $426,358, $395,042 and $326,513 of products from ImmuCell during the years ended December 31, 2014, 2013 and 2012, respectively, on terms consistent with those offered to other distributors of similar status. We made marketing-related payments of $7,330, $6,010 and $1,000 to these affiliate companies during the years ended December 31, 2014, 2013 and 2012, respectively. Our accounts receivable (subject to standard and customary payment terms) due from these affiliated companies aggregated $18,796 and $31,445 as of December 31, 2014 and 2013, respectively.
    XML 51 R36.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Income Taxes (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Income Taxes [Abstract]  
    Summary of company's benefit for income taxes

      Year Ended December 31, 
      2014  2013  2012 
    Current $252  $301  $708 
                 
    Federal  (77,986)  74,713   89,788 
    State  (10,558)  12,851   12,144 
    Deferred  (88,544)  87,564   101,932 
    Total ($88,292) $87,865  $102,640 

     
    Summary of reconciliation of the federal statutory rate

     

      Year Ended December 31, 
      2014  2013  2012 
    Computed expected tax (benefit) expense ($86,853) $69,788  $65,332 
    State income taxes, net of federal (benefit) expense  (6,968)  8,482   8,015 
    Share-based compensation  10,201   10,526   9,766 
    Research and development tax credit  (19,405)  (21,887)  (10,813)
    Other  14,733   20,956   30,340 
    Total income tax (benefit) expense ($88,292) $87,865  $102,640 
    Schedule of deferred tax asset

      As of December 31, 
      2014  2013 
    Product rights $130,036  $165,527 
    Property, plant and equipment  225,229   52,094 
    Research and development tax credit  266,078   235,567 
    Federal net operating loss carryforward  464,998   525,012 
    State net operating loss carryforward  165,901   201,698 
    Interest rate swap  15,486   13,166 
    Prepaid expenses and other  (6,925)  (23,171)
    Deferred tax asset $1,260,803  $1,169,893 

     
    XML 52 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Unaudited Quarterly Financial Data Unaudited
    		 12 Months Ended
    Dec. 31, 2014
    Quarterly Financial Information Disclosure [Abstract]  
    Quarterly Financial Information [Text Block]
    17.UNAUDITED QUARTERLY FINANCIAL DATA

     

    The following tables present the quarterly information for the years ended December 31, 2014, 2013 and 2012, respectively:

     

      Three Months Ended 
      March 31  June 30  September 30  December 31 
    Fiscal 2014:            
    Product sales $2,081,752  $1,539,719  $1,770,129  $2,205,275 
    Gross margin  1,149,895   878,523   1,077,896   1,342,722 
    Product development expenses  594,209   760,672   361,232   462,965 
    Net operating income (loss)  12,561   (458,667)  40,853   198,856 
    Net (loss) income  (13,335)  (294,781)  10,330   130,626 
    Net (loss) income per common share:                
    Basic ($0.00) ($0.10) $0.00  $0.04 
    Diluted ($0.00) ($0.10) $0.00  $0.04 
                     
    Fiscal 2013:                
    Product sales $1,846,734  $1,366,493  $1,234,701  $1,559,248 
    Gross margin  1,053,567   783,677   615,717   607,644 
    Product development expenses  266,479   271,858   290,853   325,010 
    Net operating income (loss)  326,666   23,722   (159,967)  (209,975)
    Net income (loss)  204,310   6,452   57,336   (150,703)
    Net income (loss) per common share:                
    Basic $0.07  $0.00  $0.02  ($0.05)
    Diluted $0.07  $0.00  $0.02  ($0.05)
                     
    Fiscal 2012:                
    Product sales $1,717,109  $1,175,126  $1,076,749  $1,420,951 
    Gross margin  1,012,568   670,518   620,958   750,215 
    Product development expenses  247,807   211,706   223,771   234,316 
    Net operating income (loss)  281,233   37,397   (86,126)  12,497 
    Net income (loss)  154,761   15,187   (63,574)  (16,862)
    Net income (loss) per common share:                
    Basic $0.05  $0.01  ($0.02) ($0.01)
    Diluted $0.05  $0.01  ($0.02) ($0.01)
    XML 53 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 54 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Statements of Cash Flows (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    CASH FLOWS FROM OPERATING ACTIVITIES:      
    Net (loss) income $ (167,159)us-gaap_NetIncomeLoss $ 117,395us-gaap_NetIncomeLoss $ 89,512us-gaap_NetIncomeLoss
    Adjustments to reconcile net (loss) income to net cash provided by operating activities:      
    Depreciation 446,045us-gaap_Depreciation 414,307us-gaap_Depreciation 399,640us-gaap_Depreciation
    Amortization 2,876us-gaap_AdjustmentForAmortization 2,894us-gaap_AdjustmentForAmortization 2,876us-gaap_AdjustmentForAmortization
    Deferred income taxes (88,590)us-gaap_DeferredIncomeTaxesAndTaxCredits 87,166us-gaap_DeferredIncomeTaxesAndTaxCredits 94,370us-gaap_DeferredIncomeTaxesAndTaxCredits
    Stock-based compensation 30,004us-gaap_ShareBasedCompensation 31,359us-gaap_ShareBasedCompensation 35,985us-gaap_ShareBasedCompensation
    Loss on disposal of fixed assets 4,519us-gaap_GainLossOnDispositionOfAssets 35,179us-gaap_GainLossOnDispositionOfAssets 12,265us-gaap_GainLossOnDispositionOfAssets
    Changes in:      
    Receivables (373,882)us-gaap_IncreaseDecreaseInReceivables (20,056)us-gaap_IncreaseDecreaseInReceivables (227,558)us-gaap_IncreaseDecreaseInReceivables
    Inventory 260,753us-gaap_IncreaseDecreaseInInventories 442,494us-gaap_IncreaseDecreaseInInventories 17,463us-gaap_IncreaseDecreaseInInventories
    Prepaid expenses and other assets 2,548us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets 45,917us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (123,628)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
    Accounts payable and accrued expenses 178,560us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (57,995)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities 51,715us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
    Deferred revenue 6,690us-gaap_IncreaseDecreaseInDeferredRevenue 0us-gaap_IncreaseDecreaseInDeferredRevenue (8,250)us-gaap_IncreaseDecreaseInDeferredRevenue
    Net cash provided by operating activities 302,364us-gaap_NetCashProvidedByUsedInOperatingActivities 1,098,660us-gaap_NetCashProvidedByUsedInOperatingActivities 344,390us-gaap_NetCashProvidedByUsedInOperatingActivities
    CASH FLOWS FROM INVESTING ACTIVITIES :      
    Purchase of property, plant and equipment (1,535,558)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (597,697)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (275,395)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
    Maturities of short-term investments 2,985,000us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments 2,489,000us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments 4,178,000us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
    Purchases of short-term investments (2,489,000)us-gaap_PaymentsToAcquireShortTermInvestments (3,234,000)us-gaap_PaymentsToAcquireShortTermInvestments (2,240,000)us-gaap_PaymentsToAcquireShortTermInvestments
    Purchases of long-term investments (496,000)us-gaap_PaymentsToAcquireLongtermInvestments 0us-gaap_PaymentsToAcquireLongtermInvestments 0us-gaap_PaymentsToAcquireLongtermInvestments
    Net cash (used for) provided by investing activities (1,535,558)us-gaap_NetCashProvidedByUsedInInvestingActivities (1,342,697)us-gaap_NetCashProvidedByUsedInInvestingActivities 1,662,605us-gaap_NetCashProvidedByUsedInInvestingActivities
    CASH FLOWS FROM FINANCING ACTIVITIES:      
    Debt principal repayments (190,312)us-gaap_RepaymentsOfDebt (181,445)us-gaap_RepaymentsOfDebt (172,853)us-gaap_RepaymentsOfDebt
    Proceeds from exercise of stock options 3,149us-gaap_ProceedsFromStockOptionsExercised 21,750us-gaap_ProceedsFromStockOptionsExercised 50,800us-gaap_ProceedsFromStockOptionsExercised
    Tax benefits related to stock options 0us-gaap_DeferredTaxExpenseFromStockOptionsExercised 398us-gaap_DeferredTaxExpenseFromStockOptionsExercised 7,261us-gaap_DeferredTaxExpenseFromStockOptionsExercised
    Net cash (used for) financing activities (187,163)us-gaap_NetCashProvidedByUsedInFinancingActivities (159,297)us-gaap_NetCashProvidedByUsedInFinancingActivities (114,792)us-gaap_NetCashProvidedByUsedInFinancingActivities
    NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (1,420,357)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (403,334)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 1,892,203us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
    BEGINNING CASH AND CASH EQUIVALENTS 2,270,385us-gaap_CashAndCashEquivalentsAtCarryingValue 2,673,719us-gaap_CashAndCashEquivalentsAtCarryingValue 781,516us-gaap_CashAndCashEquivalentsAtCarryingValue
    ENDING CASH AND CASH EQUIVALENTS 850,028us-gaap_CashAndCashEquivalentsAtCarryingValue 2,270,385us-gaap_CashAndCashEquivalentsAtCarryingValue 2,673,719us-gaap_CashAndCashEquivalentsAtCarryingValue
    INCOME TAXES PAID 252us-gaap_IncomeTaxesPaid 0us-gaap_IncomeTaxesPaid 708us-gaap_IncomeTaxesPaid
    INTEREST EXPENSE PAID 58,413us-gaap_InterestPaid 67,015us-gaap_InterestPaid 75,681us-gaap_InterestPaid
    NON-CASH ACTIVITIES:      
    Capital expenditures included in accounts payable and accrued expenses 251,383us-gaap_CapitalExpendituresIncurredButNotYetPaid 23,495us-gaap_CapitalExpendituresIncurredButNotYetPaid 4,550us-gaap_CapitalExpendituresIncurredButNotYetPaid
    Net change in fair value of interest rate swap $ 3,495us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1 $ (30,284)us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1 $ 9,308us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1
    XML 55 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Balance Sheets (Parenthetical) (USD $)
    Dec. 31, 2014
    Dec. 31, 2013
    Statement Of Financial Position [Abstract]    
    Common stock, shares authorized 8,000,000us-gaap_CommonStockSharesAuthorized 8,000,000us-gaap_CommonStockSharesAuthorized
    Common stock, par value (in dollars per share) $ 0.10us-gaap_CommonStockParOrStatedValuePerShare $ 0.10us-gaap_CommonStockParOrStatedValuePerShare
    Common stock, shares issued 3,261,148us-gaap_CommonStockSharesIssued 3,261,148us-gaap_CommonStockSharesIssued
    Treasury stock, shares 234,114us-gaap_TreasuryStockShares 235,114us-gaap_TreasuryStockShares
    XML 56 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Other (Expenses) Revenues, Net
    		 12 Months Ended
    Dec. 31, 2014
    Other (Expenses) Revenues, Net [Abstract]  
    OTHER (EXPENSES) REVENUES, NET
    10.OTHER (EXPENSES) REVENUES, NET

     

    Other (expenses) revenues, net, consisted of the following:

     

      Year Ended December 31, 
      2014  2013  2012 
    License option fee(1) $0  $250,000  $0 
    Royalty income  0   (3,000)  15,166 
    Interest income  15,552   12,493   17,202 
    Interest expense  (57,827)  (66,689)  (75,274)
    Debt issuance amortization  (2,876)  (2,894)  (2,876)
    Other gains (losses)  (3,902)  34,902   (7,067)
    Other (expenses) revenues, net ($49,053) $224,812  ($52,849)

     

    (1) During the second quarter of 2013, we received a $250,000 exclusive option fee from a prospective partner for the development and marketing of Mast Out®. This payment was recorded as deferred revenue upon receipt. During the third quarter of 2013, this prospective partner decided not to execute a license after its final due diligence. Accordingly, the deferred revenue was recognized during the third quarter of 2013. At the same time, $47,604 in capitalized expenses pertaining to the development of Mast Out® were written off.
    XML 57 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Document And Entity Information (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Mar. 18, 2015
    Jun. 30, 2014
    Document And Entity Information [Abstract]      
    Entity Registrant Name IMMUCELL CORP /DE/    
    Entity Central Index Key 0000811641    
    Current Fiscal Year End Date --12-31    
    Entity Filer Category Smaller Reporting Company    
    Trading Symbol ICCC    
    Document Type 10-K    
    Amendment Flag false    
    Document Period End Date Dec. 31, 2014    
    Document Fiscal Period Focus FY    
    Document Fiscal Year Focus 2014    
    Entity Well-known Seasoned Issuer No    
    Entity Voluntary Filers No    
    Entity Current Reporting Status Yes    
    Entity Public Float     $ 9,582,000dei_EntityPublicFloat
    Entity Common Stock, Shares Outstanding   3,028,034dei_EntityCommonStockSharesOutstanding  
    XML 58 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Income Taxes
    		 12 Months Ended
    Dec. 31, 2014
    Income Taxes [Abstract]  
    INCOME TAXES
    11.INCOME TAXES

     

    Our income tax (benefit) expense aggregated ($88,292), $87,865 and $102,640 (amounting to 35%, 43% and 53% of the (loss) income before income taxes, respectively) for the years ended December 31, 2014, 2013 and 2012, respectively. The income tax provision consisted of the following:

     

      Year Ended December 31, 
      2014  2013  2012 
    Current $252  $301  $708 
                 
    Federal  (77,986)  74,713   89,788 
    State  (10,558)  12,851   12,144 
    Deferred  (88,544)  87,564   101,932 
    Total ($88,292) $87,865  $102,640 

     

    The actual income tax (benefit) expense differs from the expected tax computed by applying the U.S. federal corporate tax rate of 34% to income before income tax as follows:

     

      Year Ended December 31, 
      2014  2013  2012 
    Computed expected tax (benefit) expense ($86,853) $69,788  $65,332 
    State income taxes, net of federal (benefit) expense  (6,968)  8,482   8,015 
    Share-based compensation  10,201   10,526   9,766 
    Research and development tax credit  (19,405)  (21,887)  (10,813)
    Other  14,733   20,956   30,340 
    Total income tax (benefit) expense ($88,292) $87,865  $102,640 

     

    The significant components of our deferred tax asset consisted of the following:

     

      As of December 31, 
      2014  2013 
    Product rights $130,036  $165,527 
    Property, plant and equipment  225,229   52,094 
    Research and development tax credit  266,078   235,567 
    Federal net operating loss carryforward  464,998   525,012 
    State net operating loss carryforward  165,901   201,698 
    Interest rate swap  15,486   13,166 
    Prepaid expenses and other  (6,925)  (23,171)
    Deferred tax asset $1,260,803  $1,169,893 

     

    We have a state net operating loss carryforward of approximately $1,858,000 that expires in 2028 through 2031, if not utilized before then, and a federal net operating loss carryforward of approximately $1,368,000 that expires in 2029 through 2031, if not utilized before then. The $965,000 licensing payment that we made during the fourth quarter of 2004 was treated as an intangible asset and is being amortized over 15 years, for tax return purposes only. Approximately $1,112,000 of our investment to produce pharmaceutical-grade Nisin for Mast Out® was expensed as incurred for our books. Included in this amount is approximately $820,000 ($65,000 during the fourth quarter of 2013 and $755,000 during the year ended December 31, 2014) that will be capitalized and depreciated over statutory periods for tax return purposes only.

     

    Deferred tax assets are recognized only when it is probable that sufficient taxable income will be available in future periods against which deductible temporary differences and credits may be utilized. However, the amount of the deferred tax asset could be reduced if projected income is not achieved due to various factors, such as unfavorable business conditions. If projected income is not expected to be achieved, we would decrease the deferred tax asset to the amount that we believe can be realized.

     

    Net operating loss carryforwards, credits, and other tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the event of a change in ownership, as defined.

     

    The Company files income tax returns in the U.S. federal jurisdiction and several state jurisdictions. With few exceptions, the Company is no longer subject to income tax examinations by tax authorities for years before 2011. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying financial statements.
    XML 59 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Statements of Operations (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Income Statement [Abstract]      
    Product sales $ 7,596,874us-gaap_SalesRevenueGoodsNet $ 6,007,176us-gaap_SalesRevenueGoodsNet $ 5,389,935us-gaap_SalesRevenueGoodsNet
    Cost of goods sold 3,147,837us-gaap_CostOfGoodsSold 2,946,570us-gaap_CostOfGoodsSold 2,335,676us-gaap_CostOfGoodsSold
    Gross margin 4,449,037us-gaap_GrossProfit 3,060,606us-gaap_GrossProfit 3,054,259us-gaap_GrossProfit
    Product development expenses 2,179,079us-gaap_ResearchAndDevelopmentExpense 1,154,200us-gaap_ResearchAndDevelopmentExpense 917,600us-gaap_ResearchAndDevelopmentExpense
    Sales and marketing expenses 1,317,122us-gaap_SellingAndMarketingExpense 986,766us-gaap_SellingAndMarketingExpense 973,217us-gaap_SellingAndMarketingExpense
    Administrative expenses 1,159,234us-gaap_GeneralAndAdministrativeExpense 939,192us-gaap_GeneralAndAdministrativeExpense 918,441us-gaap_GeneralAndAdministrativeExpense
    Operating expenses 4,655,435us-gaap_OperatingExpenses 3,080,158us-gaap_OperatingExpenses 2,809,258us-gaap_OperatingExpenses
    NET OPERATING (LOSS) INCOME (206,398)us-gaap_OperatingIncomeLoss (19,552)us-gaap_OperatingIncomeLoss 245,001us-gaap_OperatingIncomeLoss
    Other (expenses) revenues, net (49,053)us-gaap_OtherNonoperatingExpense 224,812us-gaap_OtherNonoperatingExpense (52,849)us-gaap_OtherNonoperatingExpense
    (LOSS) INCOME BEFORE INCOME TAXES (255,451)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest 205,260us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest 192,152us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
    Income tax (benefit) expense (88,292)us-gaap_IncomeTaxExpenseBenefit 87,865us-gaap_IncomeTaxExpenseBenefit 102,640us-gaap_IncomeTaxExpenseBenefit
    NET (LOSS) INCOME $ (167,159)us-gaap_NetIncomeLoss $ 117,395us-gaap_NetIncomeLoss $ 89,512us-gaap_NetIncomeLoss
    Weighted average common shares outstanding:      
    Basic 3,027,001us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 3,019,407us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 3,018,296us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
    Diluted 3,027,001us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 3,085,048us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 3,108,419us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
    NET (LOSS) INCOME PER SHARE:      
    Basic $ (0.06)us-gaap_EarningsPerShareBasic $ 0.04us-gaap_EarningsPerShareBasic $ 0.03us-gaap_EarningsPerShareBasic
    Diluted $ (0.06)us-gaap_EarningsPerShareDiluted $ 0.04us-gaap_EarningsPerShareDiluted $ 0.03us-gaap_EarningsPerShareDiluted
    XML 60 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Accounts Receivable
    		 12 Months Ended
    Dec. 31, 2014
    Accounts Receivable[Abstract]  
    ACCOUNTS RECEIVABLE
    5.ACCOUNTS RECEIVABLE

     

    Accounts receivable consisted of the following:

     

      As of December 31,  Increase 
      2014  2013  (Decrease) 
    Trade accounts receivable, gross $1,004,990  $609,638  $395,352 
    Accumulated allowance for bad debt and product returns  (16,194)  (13,952)  (2,242)
    Trade accounts receivable, net  988,796   595,686   393,110 
    Other receivables  16,496   35,676   (19,180)
    Income taxes receivable  0   48   (48)
    Accounts receivable, net $1,005,292  $631,410  $373,882 
    XML 61 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Inventory
    		 12 Months Ended
    Dec. 31, 2014
    Inventory [Abstract]  
    INVENTORY
    4.INVENTORY

     

    Inventory consisted of the following:

     

      As of December 31,  Increase 
      2014  2013  (Decrease) 
    Raw materials $306,444  $270,355  $36,089 
    Work-in-process  355,745   783,060   (427,315)
    Finished goods  283,566   153,093   130,473 
    Total $945,755  $1,206,508  ($260,753)
    XML 62 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Employee Benefits Employee
    		 12 Months Ended
    Dec. 31, 2014
    Share-based Compensation [Abstract]  
    Compensation and Employee Benefit Plans [Text Block]
    16.EMPLOYEE BENEFITS

     

    We have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum amount allowed by the Internal Revenue Service. Prior to August 2012 we matched 50% of each employee’s contribution to the plan up to a maximum match of 4% of each employee’s base compensation. Since August 2012 we have matched 100% of the first 3% of each employee’s salary that is contributed to the Plan and 50% of the next 2% of each employee’s salary that is contributed to the Plan. Under this matching plan, we paid $65,633, $56,036 and $51,145 into the plan for the years ended December 31, 2014, 2013 and 2012, respectively.
    XML 63 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stockholders' Equity
    		 12 Months Ended
    Dec. 31, 2014
    Stockholders Equity [Abstract]  
    STOCKHOLDERS EQUITY
    12.STOCKHOLDERS’ EQUITY

     

    (a)Stock Option Plans

     

    In June 2000, our stockholders approved the 2000 Stock Option and Incentive Plan (the “2000 Plan”) pursuant to the provisions of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of the Company’s common stock at i) no less than fair market value on the date of grant in the case of incentive stock options and ii) no less than 85% of fair market value on the date of grant in the case of non-qualified stock options. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case by case basis. Originally, 250,000 shares of common stock were reserved for issuance under the 2000 Plan. The stockholders of the Company approved an increase in this number to 500,000 shares in June 2001. All options granted under the 2000 Plan expire no later than ten years from the date of grant. The 2000 Plan expired in February 2010, after which date no further options could be granted under the 2000 Plan. However, outstanding options under the 2000 Plan may be exercised in accordance with their terms.

     

    In June 2010, our stockholders approved the 2010 Stock Option and Incentive Plan (the “2010 Plan”) pursuant to the provisions of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of the Company’s common stock at i) no less than fair market value on the date of grant in the case of incentive stock options and ii) no less than 85% of fair market value on the date of grant in the case of non-qualified stock options. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case by case basis. At that time, 300,000 shares of common stock were reserved for issuance under the 2010 Plan. All options granted under the 2010 Plan expire no later than ten years from the date of grant.

     

    Activity under the stock option plans described above was as follows:

     

      2000 Plan  2010 Plan  Weighted Average Exercise Price  Aggregate Intrinsic Value 
    Outstanding at December 31, 2011  186,500   49,500  $3.19  $344,000 
    Grants  0   2,000  $5.93     
    Terminations  (8,000)  (2,000) $4.75     
    Exercises  (15,000)  0  $3.39     
    Outstanding at December 31, 2012  163,500   49,500  $3.13  $185,000 
    Grants  0   26,000  $4.67     
    Terminations  0   (1,000) $3.15     
    Exercises  (6,000)  (1,000) $3.11     
    Outstanding at December 31, 2013  157,500   73,500  $3.30  $223,000 
    Grants  0   25,000  $4.69     
    Terminations  0   (2,000) $5.75     
    Exercises  0   (1,000) $3.15     
    Outstanding at December 31, 2014  157,500   95,500  $3.42  $364,000 
                     
    Exercisable at December 31, 2014  157,500   42,500  $3.08  $357,000 
                     
    Reserved for future grants  0   202,500         

     

    During the year ended December 31, 2014, one employee exercised stock options covering 1,000 shares. These options were exercised for cash, resulting in total proceeds of $3,149. During the year ended December 31, 2013, four employees exercised stock options covering the aggregate of 7,000 shares. These options were exercised for cash, resulting in total proceeds of $21,750. During the year ended December 31, 2012, one employee exercised 15,000 stock options. These options were exercised for cash, resulting in total proceeds of $50,800. At December 31, 2014, 253,000 shares of common stock were reserved for future issuance under all outstanding stock options described above, and an additional 202,500 shares of common stock were reserved for the potential issuance of stock options in the future under the 2010 Plan. The weighted average remaining life of the options outstanding under the 2000 Plan and the 2010 Plan as of December 31, 2014 was approximately four years and nine months. The weighted average remaining life of the options exercisable under these plans as of December 31, 2014 was approximately four years. The exercise prices of the options outstanding as of December 31, 2014 ranged from $1.70 to $7.00 per share. The 25,000 stock options granted during 2014 had exercise prices between $4.25 and $4.80 per share. The 26,000 stock options granted during 2013 had exercise prices between $4.15 and $4.69 per share. The 2,000 stock options granted during 2012 had exercise prices between $5.61 and $6.25 per share. The aggregate intrinsic value of options exercised during 2014, 2013 and 2012 approximated $1,000, $8,000 and $25,000, respectively. The weighted-average grant date fair values of options granted during 2014, 2013 and 2012 were $2.26, $2.23 and $2.86 per share, respectively. As of December 31, 2014, total unrecognized stock-based compensation related to non-vested stock options aggregated $95,560. That cost is expected to be recognized at a declining rate over the remaining vesting period of the outstanding non-vested stock options, including $26,778 during 2015. The fair value of each stock option grant has been estimated on the date of grant by an independent appraiser using the Black-Scholes option pricing model, for the purpose discussed in Note 2(l), with the following weighted-average assumptions:

     

      2014  2013  2012 
    Risk-free interest rate  2.0%  1.6%  0.97%
    Dividend yield  0%  0%  0%
    Expected volatility  49%  49%  48.7%
    Expected life  6 years   6 years   6.5 years 

     

    The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term, while the other assumptions are derived from averages of our historical data.

      

    (b)Common Stock Rights Plan

     

    In September 1995, our Board of Directors adopted a Common Stock Rights Plan (The Rights Plan) and declared a dividend of one common share purchase right (a “Right”) for each of the then outstanding shares of the common stock of the Company. Each Right entitles the registered holder to purchase from the Company one share of common stock at an initial purchase price of $70.00 per share, subject to adjustment. The description and terms of the Rights are set forth in a Rights Agreement between the Company and American Stock Transfer & Trust Co., as Rights Agent.

     

    The Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being called the Distribution Date).

     

    Upon the Distribution Date, the holder of each Right not owned by the Acquiring Person would be entitled to purchase common stock at a discount to the initial purchase price of $70.00 per share, effectively equal to one half of the market price of a share of common stock on the date the Acquiring Person becomes an Acquiring Person. If, after the Distribution Date, the Company should consolidate or merge with any other entity and the Company were not the surviving company, or, if the Company were the surviving company, all or part of the Company’s common stock were changed or exchanged into the securities of any other entity, or if more than 50% of the Company’s assets or earning power were sold, each Right would entitle its holder to purchase, at the Rights’ then-current purchase price, a number of shares of the acquiring company’s common stock having a market value at that time equal to twice the Right’s exercise price.

     

    At any time after a person or group becomes an Acquiring Person and prior to the acquisition by such person or group of 50% or more of the outstanding common stock, the Board of Directors of the Company may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment). At any time prior to 14 days following the date that any person or group becomes an Acquiring Person (subject to extension by the Board of Directors), the Board of Directors of the Company may redeem the then outstanding Rights in whole, but not in part, at a price of $0.005 per Right, subject to adjustment.

     

    On June 8, 2005, our Board of Directors voted to authorize an amendment of the Rights Agreement to extend the Final Expiration Date by an additional three years, to September 19, 2008. As of June 30, 2005, we entered into an amendment to the Rights Agreement with the Rights Agent reflecting such extension. On June 6, 2008 our Board of Directors voted to authorize an amendment of the Rights Agreement to extend the Final Expiration Date by an additional three years, to September 19, 2011 and to increase the ownership threshold for determining “Acquiring Person” status from 15% to 18%. As of June 30, 2008, we entered into an amendment to the Rights Agreement with the Rights Agent reflecting such extension and threshold increase. On August 5, 2011, our Board of Directors voted to authorize amendments of the Rights Agreement to extend the Final Expiration Date by an additional three years to September 19, 2014 and to increase the ownership threshold for determining “Acquiring Person” status from 18% to 20%. As of August 9, 2011, we entered into an amendment to the Rights Agreement with the Rights Agent reflecting such extension and threshold increase. On June 10, 2014, our Board of Directors voted to authorize an amendment to the Rights Agreement to extend the final expiration date by an additional three years to September 19, 2017. As of June 16, 2014, we entered into an amendment to the Rights Agreement with the Rights Agent reflecting such extension. No other changes have been made to the terms of the Rights or the Rights Agreement.

     

    Our Board of Directors believes that there is some risk that the potential value of the Mast Out® product development initiative is not fairly reflected in the market price of our common stock, as it fluctuates from time to time, and that opportunistic buyers could take advantage of that disparity to the detriment of our stockholders. If this were to happen and result in a potential threat through an unsolicited acquisition effort or otherwise, our Board of Directors feels that the Rights Plan could enhance stockholder value by providing management with negotiating leverage.
    XML 64 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Accounts Payable and Accrued Expenses
    		 12 Months Ended
    Dec. 31, 2014
    Accounts Payable and Accrued Expenses [Abstract]  
    ACCOUNTS PAYABLE AND ACCRUED EXPENSES
    8.ACCOUNTS PAYABLE AND ACCRUED EXPENSES

     

    Accounts payable and accrued expenses consisted of the following:

     

      As of December 31,  Increase 
      2014  2013  (Decrease) 
    Accounts payable – capital $251,383  $23,496  $227,887 
    Accounts payable – trade  204,810   199,716   5,094 
    Accrued payroll  145,176   75,310   69,866 
    Accrued clinical studies  131,945   0   131,945 
    Accrued professional fees  42,250   50,500   (8,250)
    Accrued other  76,113   96,207   (20,094)
    Total $851,677  $445,229  $406,448
    XML 65 R60.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Segment And Significant Customer Information (Details)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Sales Revenue, Net [Member]      
    Revenue, Major Customer [Line Items]      
    Concentration Risk, Percentage 10.00%us-gaap_ConcentrationRiskPercentage1
    / us-gaap_ConcentrationRiskByBenchmarkAxis
    = us-gaap_SalesRevenueNetMember    		    
    Animal Health International, Inc [Member]      
    Revenue, Major Customer [Line Items]      
    Concentration Risk, Percentage 38.00%us-gaap_ConcentrationRiskPercentage1
    / us-gaap_StatementBusinessSegmentsAxis
    = iccc_AnimalHealthInternationalIncMember    		 38.00%us-gaap_ConcentrationRiskPercentage1
    / us-gaap_StatementBusinessSegmentsAxis
    = iccc_AnimalHealthInternationalIncMember    		 35.00%us-gaap_ConcentrationRiskPercentage1
    / us-gaap_StatementBusinessSegmentsAxis
    = iccc_AnimalHealthInternationalIncMember
    MWI Veterinary Supply Company [Member]      
    Revenue, Major Customer [Line Items]      
    Concentration Risk, Percentage 23.00%us-gaap_ConcentrationRiskPercentage1
    / us-gaap_StatementBusinessSegmentsAxis
    = iccc_MwiVeterinarySupplyCompanyMember    		 [1] 22.00%us-gaap_ConcentrationRiskPercentage1
    / us-gaap_StatementBusinessSegmentsAxis
    = iccc_MwiVeterinarySupplyCompanyMember    		 [1] 20.00%us-gaap_ConcentrationRiskPercentage1
    / us-gaap_StatementBusinessSegmentsAxis
    = iccc_MwiVeterinarySupplyCompanyMember    		 [1]
    [1] Assumes that the November 2013 acquisition of IVESCO by MWI had occurred as of the beginning of the periods being reported.
    XML 66 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Prepaid Expenses and Other Assets
    		 12 Months Ended
    Dec. 31, 2014
    Prepaid Expenses and Other Assets [Abstract]  
    PREPAID EXPENSES AND OTHER ASSETS
    6.PREPAID EXPENSES AND OTHER ASSETS

     

    Prepaid expenses and other assets consisted of the following:

     

      As of December 31,  (Decrease) 
      2014  2013  Increase 
    Prepaid expenses and other assets $133,119  $159,117  ($25,998)
    Security deposits  15,280   0   15,280 
    Current subtotal  148,399   159,117   (10,718)
                 
    Debt issue costs  26,489   26,489   0 
    Accumulated amortization of debt issue costs  (16,479)  (13,603)  (2,876)
    Security deposits  8,920   750   8,170 
    Long-term subtotal  18,930   13,636   5,294 
                 
    Total $167,329  $172,753  ($5,424)
    XML 67 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Property, Plant And Equipment
    		 12 Months Ended
    Dec. 31, 2014
    Property, Plant and Equipment [Abstract]  
    PROPERTY, PLANT AND EQUIPMENT
    7.PROPERTY, PLANT AND EQUIPMENT

     

    Property, plant and equipment consisted of the following, at cost:

     

      As of December 31,  Increase 
      2014  2013  (Decrease) 
    Laboratory and manufacturing equipment $3,522,465  $3,182,686  $339,779 
    Building and improvements  2,969,891   2,940,239   29,652 
    Office furniture and equipment  470,607   354,243   116,364 
    Construction in progress(1)  1,270,672   9,600   1,261,072 
    Land  50,000   50,000   0 
    Property, plant and equipment, gross  8,283,635   6,536,768   1,746,867 
    Accumulated depreciation  (4,445,988)  (4,012,003)  (433,985)
    Property, plant and equipment, net $3,837,647  $2,524,765  $1,312,882 

     

    (1) As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015.
    XML 68 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Bank Debt
    		 12 Months Ended
    Dec. 31, 2014
    Bank Debt [Abstract]  
    BANK DEBT
    9.BANK DEBT

     

    During the third quarter of 2010, we agreed to terms of certain credit facilities with TD Bank, N.A. (a wholly owned subsidiary of TD Financial Group, which is a multinational bank with approximately $944 billion in assets and over 22 million clients world wide) aggregating up to approximately $2,100,000, which are secured by substantially all of our assets. These credit facilities are comprised of a $1,000,000 ten-year mortgage loan, a $600,000 fifty-four month note and a $500,000 line of credit, which is renewable annually. Proceeds from the $1,000,000 mortgage were received during the third quarter of 2010. Based on a 15-year amortization schedule, a balloon principal payment of $451,885 will be due in the third quarter of 2020. We hedged our interest rate exposure on this mortgage loan with an interest rate swap agreement that effectively converted a floating interest rate based on the London Interbank Offered Rate (LIBOR) of 3.41% as of December 31, 2014 to the fixed rate of 6.04%. All derivatives are recognized on the balance sheet at their fair value. The agreement has been determined to be highly effective in hedging the variability of the identified cash flows and has been designated as a cash flow hedge of the variability in the hedged interest payments. Changes in the fair value of the interest rate swap agreement are recorded in other comprehensive (loss) income, net of taxes. The original notional amount of the interest rate swap agreement of $1,000,000 amortizes in accordance with the amortization of the mortgage loan. The notional amount of the interest rate swap was $799,964 as of December 31, 2014. Payments required by the interest rate swap totaled $22,116, $23,096 and $23,903 during the years ended December 31, 2014, 2013 and 2012, respectively. As the result of our decision to hedge this interest rate risk, we recorded other comprehensive (loss) income, net of taxes, in the amount of ($3,495), $30,284, and ($9,308) during the years ended December 31, 2014, 2013 and 2012, respectively, which reflects the change in fair value of the interest rate swap (liability) asset, net of taxes. The fair value of the interest rate swap has been determined using observable market-based inputs or unobservable inputs that are corroborated by market data. Accordingly, the interest rate swap is classified as level 2 within the fair value hierarchy provided in Codification Topic 820, Fair Value Measurements and Disclosures. Proceeds from the $600,000 note were received during the first quarter of 2011. Interest on the note is variable at the higher of 4.25% per annum or the LIBOR plus 3.25% per annum. As of December 31, 2014, the effective interest rate on this note was 4.25%. The $500,000 line of credit is available as needed and has been extended through May 31, 2015 and is renewable annually thereafter. The line of credit was unused as of December 31, 2014 and 2013. Interest on any borrowings against the line of credit would be variable at the higher of 4.25% per annum or the LIBOR plus 3.5% per annum. These credit facilities are subject to certain financial covenants. We are in compliance with all applicable covenants as of December 31, 2014. Principal payments due under debt outstanding as of December 31, 2014 are reflected in the following table by the year that payments are due:

     

    Period $1,000,000 
    mortgage    		  $600,000
    note    		  Total 
    Year ending December 31, 2015 $54,044  $96,338  $150,382 
    Year ending December 31, 2016  57,384   0   57,384 
    Year ending December 31, 2017  61,056   0   61,056 
    Year ending December 31, 2018  64,876   0   64,876 
    Year ending December 31, 2019  68,908   0   68,908 
    After December 31, 2019  493,696   0   493,696 
    Total $799,964  $96,338  $896,302
    XML 69 R64.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Employee Benefits Employee (Details) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Defined Benefit Plan Disclosure [Line Items]      
    Employee Savings Plan Description One month    
    Defined Contribution Plan, Employer Matching Contribution, Percent of Employees Gross Pay 50.00%us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent    
    Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent 4.00%us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch    
    Defined Benefit Plans, General Information August 2012 we have matched 100% of the first 3% of each employee's salary that is contributed to the Plan and 50% of the next 2% of each employee's salary that is contributed to the Plan.    
    Defined Benefit Plan, Benefits Paid $ 65,633us-gaap_DefinedBenefitPlanBenefitsPaid $ 56,036us-gaap_DefinedBenefitPlanBenefitsPaid $ 51,145us-gaap_DefinedBenefitPlanBenefitsPaid
    XML 70 R63.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Related Party Transactions (Details) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Related Party Transaction [Line Items]      
    Revenues from transactions with related party $ 426,358us-gaap_RevenueFromRelatedParties $ 395,042us-gaap_RevenueFromRelatedParties $ 326,513us-gaap_RevenueFromRelatedParties
    Accounts receivable, related parties 18,796us-gaap_AccountsReceivableRelatedPartiesCurrent 31,445us-gaap_AccountsReceivableRelatedPartiesCurrent  
    Related party transaction, expenses from transactions with related party $ 7,330us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty $ 6,010us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty $ 1,000us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
    XML 71 R34.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Bank Debt (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Bank Debt [Abstract]  
    Schedule of principal payments due

     

    Period $1,000,000 
    mortgage    		  $600,000
    note    		  Total 
    Year ending December 31, 2015 $54,044  $96,338  $150,382 
    Year ending December 31, 2016  57,384   0   57,384 
    Year ending December 31, 2017  61,056   0   61,056 
    Year ending December 31, 2018  64,876   0   64,876 
    Year ending December 31, 2019  68,908   0   68,908 
    After December 31, 2019  493,696   0   493,696 
    Total $799,964  $96,338  $896,302
    ZIP 72 0001213900-15-002097-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-15-002097-xbrl.zip M4$L#!!0````(`%9/>D8](&ATK^```$D,#0`1`!P`:6-C8RTR,#$T,3(S,2YX M;6Q55`D``Y,0%%63$!15=7@+``$$)0X```0Y`0``[%UK<^LVDOV>JOP'C;_K MB@#?WGL]Y6?B&[_*=C))[6ZY:`J6N9!#Z^('!Z;^'?Q[=7LS;#]0O\(OP11C\IR".H#R" M`I`'@KHO:?N2.KBY_._!<#A_U9'AX]?@-M$+X!<0W\-WWQX]V]HG_SO`V!Q_ MWS)-\]O>CU]?7+]9T&IK(MK^8[I1\1`)0!'L__Y0\;UO.C\SSY%U? M7&^"G\7`R.U'_/6]P6#1A#PQMA:-T@V447PS\WCN$Z]B]#S0=7T4WZ;DV&CT99C!$ M;S/;<(S`]=[/\-_IEWGHJ?0MR@C?S._9YWUD?IFX+Z/D)F&M.!3`$/,VW33T/-S[RMHF=R/*YQN/D57<#M\H:8+> MS.?B-N0.:03SC2SG!?E!<;/X7HETCF&9?G&[Z!9I!O+-?,LL;H1OE#4)9EY) M&WRGI%'H#R>&,5NT>S+\Q\C.R8T2'29WAT80E#?%-SWK,0R0O]*4]`^_L%UT MI^2;;W9%]_[S8L7]A(%7P7A\EW@)W]KW(V]TBYX&D1_;3SIAM;<;S3QW MAKS`PI"7_C5^`1'DVYYO36?VXMISU&6)8Q_._?>7-W^\-QC-QX=CUPG06S"X M0V9`AI9DZ(@'!S.Y:6'OD3SX<.@_7#\]B,+#]]!YP)()]X+P$/]W?UU\_08[ ME"MCB@[?+#_ZX_[5O7]V0__9<,:7:/J(O+WE1Y$36,'[\F]K3*X\6<@;1#K+ MJFA.N./SW_8.\%<%#0!%`E]'JXV7+_319(JOSB^,\2>QS[-,*XBQ#,86OA\/ MU`FQ]M,B[!T0A>X7"_)U5/A.\K%1[O.C8HFQA2UWG-)`-/R0%D2O0T$9BL*R M]?+N_,JR_2ACQVK#'H=^X$X?!,`MVYIEL>6\X`0/SRG;"B#UQM3]A1+'*PW2 M9%C>[1@9#IWQ/7)VAA)I<3X5,5;=/RCA!>!.HA'W#YIR_^+E*>GNUV9`S"=E MS0H>3I"YD'C\_MA\E+Q]@[FCZPE9PO>01H"H99WP`T@#G4;]PZ@9-0`?-1HW%.`Q@+% MQ%-\#^U"$]^AVR&1)S+TI>L%$V.">N(,\A(LO<"**,WW=V)9 MM4Y_)PWT1J(!%E2X<@-T8[P;V&_VEPQ1=\])\JFXL/#]>:N7L*$=0V_H._5& M?&=])7'OR7I4[+)EN3/<6=->6`ZZ?CKVT'@N>A]M.[^7E^:SVQ=/_Y"'_.`6 M#Z9WK\:L_S8NEJB_=IY'JT8T!P6K*8Y+P\M>[U1\LA+W10MK=>(^_+38X)Q? MT!\.PTE>KX77;PUG$D_X+XTW:QI.^]%7%K!3X4L:?^,]`]M0PYVC*0^XJ0TM MI]\V3./ONPV!/A^MLC8LO,[[X<8VU(>@3CC-SU3L49*TI: M62C8GI+X,B);]O?$L'P%:#>,?!?@N081YO3O$$MP[$YGKH/_C%>,\9]3U[D+ M7/-'/TQ=*&R1+8>&?6-8XW/GV)A9@6'OE/TK9>1<6'#A M%@6&Y:#QJ>$YEC/IR;K&FB0H%HY;?V']>P\9?NB][Y[_+Y",VWTY`IAF.`UM M4IUR'3PCC]SVT#/1]0LZ=TQWVI-%L'5'@W7E[2]'LBEV6))BA]V<^JZDV&'= M%#ML*L6>:/5PYA5H=;&IKC=:E>IJM9FMS-G-2SFM)JFVWFBUWC8@V/"6L'@? M<=X#)&-$7[1:;V,M:=#,QMJSORK]:L^T6MNO=D2K/`?)=O/BKC*!)RT_*2MX MEI.3A)(D/"W*R;,Q>7@>E=.E!EUXXI43A6=JNY:IW1U2X88FEM8SR&!_:_D_ MCMZ/D&,^3PWO1\2K.\-&_BUZ04Z(KE"BO(=+XW]<+SZ!`GDQ`6\\"S=Z7USL M!]L^DG])N$)%5)!K;0AY784:Y7QNA\]GKH>LB(2Q?T6&'3Q'I62.$4_Z<0"U.PSZ6$K.H2H.7<^(NLA1.F]H?.^>^WZ(O7<< MGM^_S^($^^ET9KOO"$73N;A%/QBTCG3+4;-4S$]%H=5]1CU;[`(J?5I("B M-UJM5T`AME-`D?,`R1C1%ZW6+*`0V\E+]UVKM?UJ1[3*M/RD MK.!93DX22I+PM"@GS\;DX7E43I<:=.&)5TX4GJGM6J9V=TC%"RBZN^%\:P44 MG,^\@&*7"BAZS&=>0-&!`HJ=Y0\OH.`<^IA#O("B&P44W:'0ZCZCGJUV9C;: MY)34U&8LOGC9;@%%;PS+UR)WP\A\:9';G*\4MEM`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`>&VI M.<'H)U7361@@;Y?GXR4R&=)TQS6WXX)1) M)E:+-68R.25J3LJ)7O!$A%SNT^[*"HG2=45%HGTJJJR>0]2S4P!6#O5HZ;`F M7M3?[C'=O3$LK]'?#2,75-5>NEXP,29]F>97E=.NB/+9+&,YEO MMWJSIN&T'U9=P$YOHTKA_ZPVM)Q^VS"-_U/9D!]#P&W.3Q5H]P@:^4;REC>)] M8P#?][V3UBXY[]I/CHF^=X\,YT=/4@55JS2E0O77VO&1-ZF?ZBC[6:N.;B=9 MV:8C=N:G.C90+-_4U?*FKNZP)7:Z0)O_?IB<(4O1]4[UPHRODLF/A`%M4U_U MC^%P\+MC!8,[%$5/@\%P.+_^\T_G_P?^Z^R/FU_1&SJ1%57[ZQ;];1VP=)!>G47(0'5B^*T&@[N-[<^3S6_._2?N" MM_G/AH?\W`L3VD4W:[X18WC`>GRX(XT7+QY;+]B"!ZF'K_!`YAF!ZVTH3*X] MN7B"''=J.46O75>DS"M&6?35DL_"E,#9SY);=2WS]U.0>UL8>/ODQD?O(J0\ MM2/?EN'KUS&R]D^C7G.+)A8.)W`'('NW!@G3;]$3S<\ZG5]>_GY\>G$Q.+Z^ MO1F,3DY'7T=EGR0XE_>.$=F2;4>G"OV&WAGA2?N1TF_-@1R'GH?OG%D^GBC] MA0SO-/:BC+`,8R<=`RG[5E8I9Y:-O&-\>>)ZK%1R-S5L_-;!+9JY7F`YDT&2 M$$AK*//A.:9[SR`%@7?OTT?79D68X^/C^,.9M\\_>>*:4;Q+2CD8?1$/K;_% M7TR_?/[!0WQA3"Z>V<:$T1>?#-M'\2*@9#NP1(&^;,(R.([V4[X+V3;OSGNJW.'G:WKH'%\ MX!DC,%=NNM^5?"L+Z`_7QC-ZPXM[*2NM9(&L?&/%5\?.:^%!2!S-S#I_D>'Y MHV]E\=R$CS@2/[-=(R@$L<'OC0[(2!J]A,1;@S$R24+=_[:'$>JR!O&XDD:9 M0K"BJN7^G2@@\J_#@$2=Q-558*T5<2^Q)M%<"N[YU=G>@2A`31"EC%HK0B') MW3-V4/?(FR[3!L4ND;4-=`)=6"(O`L($**6&H:3IM8"2RPZ>AKU?H4J_SDJ3 M``J*+*0XD`9`!8Q2<[HDJ[+\,:Y#TR2Y?O\6F0@S]M$F5:O)`-J&`A412"!E MX"H\3'%3ZA<(@@QU6!_XC8=FAC4^?9LAQR=K;*D"\Q;U#F0=`'4)?PU834A! M:P5)$W5]8RE.T!/"%\=D02QZIEWN`QF"%(,JT+`$3:ER49`4L3;HUOFMXI!) M$=/]LXP$K9-6EA1-%]4UH)4>5-'2Z`9E**F*G.Y?Y8"8`JM,MA`*I[`6(&`!D%*EDJYD M(N`/4*8&O)9Y*RIB:JY=B(,-4%J.8NCY`KXNU-7FI MLQ%`456V\EZXAI/=)=1F>*P+HI[Q?"5@V"&F[3*R(&JP)N+Y$)D<&M6B@@O& MZ2P(1C`IM:HH>BVD>7ZWD\B0E72&-H^"`4;ZI(6F2NN#3$*-B,9GGCLE#&Y# MEYJN0"CE8YX,$#9(*36J2K(."Z*S'-)H5_WJT1AMZ%(4!0&[I,+OTP&CGJ-I M)`%5"JR`H^T&$#K4(50*.TO):+DQ4EH6:I*:3BC40=I.HDN1-$DN!$@#B]8= MJKHH:<46SBPX+1<^6ULF$Z$"0'J5;`4#-3[:WEL#7\F!!*DF[8=JC&L4N%^X/DD\7C_=&V^M MT!OH6CH95A-BT]+1\AZ*H@B82!=9]-FUQXL?`VUC7Y`N0$$24XM8>1BM@*Q] M/E6=`;F;,E6?OU1I-!T`/9T;[::`)8<*5?8G!?OD[INNZ,"ZI&A-N[V/0?;/[5'+1./V5!%(2M<%W,3MR5#2 MA,[3L;[;@[HB=Y^1;-R>C#\I-"PK;1I/U&6M\7'H8Y#][*>%&\=Y*NK2;DFW@][+9RFZ*Q'4DR!5M)B=__1N-V:N_I)94$Z)_"A<+5T&QQ%Y+\-H M\>(&>5'+1NB?.DA<22+K1^(8\BZ6+C72@',^E":U?>BY(J-,'-;!>BWOHH MZS`];C;4A6AWKPMXDJ0VZ3=+3O-)NM"ZYT$(&G;PL/$N1'G:#Y!%/7-<2T-= M*`/K>_#@)15%6TIU\!0$=..HS:21%5H6&P-'N=@:2JJ5WV%>`^\5S??_&,D[%#R-3;,F$Y95"L`%D%S#"QB8`5/->5 M),8LIZVN$13R+V.64P:W`$BZIM/[`Z:AK*9J,A09LYPV;A545=.968]-E`I$ M":H0,N8Y[>$ADJ0+XL<.X1;YR/!,=QL@B$(154%;>)F$S!!41)!._IF&E3I0%72:X@M\(1) MW`4515+U+?1+RM`,JD"3M2WT2\KP#>J")HM;Z)?4Q\.\*L+T[+L<"S/$M+41FJ(J2JN(J:=90`7I M:=9ZD']!#O(,FQR"-IY:3O230H'U@EH,`34IO3O^`T!LL=-7T(#T4=>M8J?> M/2GK,+WH7@/\]8S\6MB24.O\7`GM#$<3R+[]U/&4JQAH`5)GSC0!-`J0>LB3 M92F]&60]@,MS"EI(=V@XFA`+$"Y!4&!DD]H055%7FX+()HLQU)3,5B^V&!GM MH()2`VIDZW(D64COHV%L:B:)"!$JBM*8J1DE'<1,^K>1'D.97QCBP5!7&NO6 M;)()0SRSU=4B!\ZRT]"?\"/+S5F;S7H2E)7&^C6;?,!0DC6E.4*RF?Q+V:1< M(WV&-LK5-4UF[Q^9!F:X7RNB7A0YEH`D96I7KN.NQ&\M[">&6GIO=AD01F"I MW264,D?/-`R7^N<,A$QG6@/LDA[D0%V"RG)"_&C"']?QC]"3ZR55C/?&&_)/ MW_"LSO7&EF-X[^>:JIL@M0:7E MD:9E?M9N#:Q7*&@S>P)D24W'M9G/;X2+4>F9##25)2Q&61)%E-.[TNEQLDLN^H>>]))@[`YY(2- M:&PW8@F2")CB8I/S5"29#9N9ICEE54P?SL5LQ*/.&A1KE\,@2B*;'C#=M$"ZI*J M,9V!LJJ+$46F=F15&2,HD,UXS#;5`105I$L=6P36^7%OBV=@=E*<30Z\["Z_ MNC#P=>1(RW5$^Q>R)L_X,X%;)NL4 M5?[4L&@;'M!@N@2R%L0F9:,\O"V639?2Y8"=D8WRM+=(-JAF=ENQENW$LD-\ M-=>^'58"09/2Y][4!-FL?"R8J5XAUBP+!)P!NN,U4";D;#=`M058P0&V7$ M9KGI*KQJ"SVN;LZZ"J_00H^KF\VNPMM&AV-VY/2P,1=,E_ZN4K#40H>KFQ>K M5'"C#-XP858%&+31Y>HFTK;F(C;,L+7/8+K,6R6#%0K`223:G;@R`42)N=W8 MD@WFEN-+-J!;CC$I06\ESF3$CE9C3::]L*5XDVDO;"GF9-H)VXH[F7;"EF)/ MIIVPK?B3:2]L*P9EV@U;BD.9=L.68E&FO;"M>#0%VC)-$7%K!.CNU9C% M)151,47S.Y6'0)8T#/8C)(S04FXRDP51DUH#2[LU0-;(PSF6V9 MQJ.-[MW5ALTS0@&JMD"]!B+F^.E+OP'Q!D_?ZRQ?,`:=KN!=@F19.]Q7VD M+=KF5I9\E.34^]??S)"2:,=)G,B294?]T#B.1,X,AS,_#H?#0+4Z+^O6F[?R?H&5W)&?-@F[WNG;)N4)H MSIS"UJMW.R\7]';;R^N7W34>(=;Z_O5I;=O>._CDIO.>^'HZG>JQ:_\ZO95K M_W)@+-U"3&_/V>WCN/6; ME=5;<78E.3%^R!:_^,C\`;%>.;M=B.GM.;M]G+%^L[)Z*\ZN)*?$\[/X-(!7 M01`)YT.D0.V_""5]Y]_/E]K95K._LH-Q=`+9>=6-THDH:_7R1J]SV.SE9CV[ M[5:9C>>>HS7')X^7&L]&IU5JXUF2R$N9=29C9`7&?W#0W.5F.P=VL?3C$\R1 MF<["U_?-E!V$Y=;Y2CM#\B\N]:SX3)!+\Y>[>OYOZ43#EGK-MEA76 MH=YB??\$,Z47Q87GW`EO6X$J5YXCOPKGSB0(5 M:"G=+>=Z.GV]8X`GF\,4N[G[S] ML]X1:$K>AK;T,MH"\N_$SAZW%([-QA9\8&:K-=]!R^.56/8(]"1W*+M#&5TX M?T9!B(,8W/F/!`'QDLWQ6(Q"O+`U+G\G'!QOX05T9VO^>_^]IGVWYH[(+JLD M\LIT>]MB>WV,NU*^707$W[;L7A0\/VM5DLLOS'[0XLQZ)FK0?S."J%QIN5)M M*MVK/.E^SU2];<$=BR.E5H;KK7P5P',@0W$KU$*.A%X+?Q4C?^)1*[2-GO]J MM=49]#LODU$6A@Y.>/OTRI6@=^+'*PTO]RJZDG9QZ^Y*UGL&&$\$>50:7NZH0R7MPN(4E:@KX+&K`MRNK5\(KJ'I- M)>BB3KI5&IY)\!7P*%+:%?`HSJ(<,O#X((#6D2PHBZ\U&'3;%J=V[QFHRA@S M:3?:+?O6SAU1E1%0M=O=>KOS/%6IMGSRU<4,JSO]5=!P-ON][B:U72-D5]1F M+8#2'VQTWSE1F_7&KI?+]H,8"Z6$D]SP]?$[6@;Q7GAB+`NX6:!1;PQ:35ME MGR1HM[1GU(Y^K]-M[XGTK&4_^_U.^W6T[RN=>VW[\/F<@+WERJU&&W,D=+?K M[^<)_170.-8%O/$^R&#N!X0/;L8702#"0FX);3:[E@H\2\W=T+WE;<`N.(K6+^1*,(K\(W*A+.;Y(/I0M^M0C[!YBD MT7F*T6W(+(31K+K;Z0T&A\%I1MUM]/J=;CU?3F.]_RK`5!>1&'W6;W:>Y&F- MHEV3GU'[]DEZ1G7J=@>OI?Y:A)<\F'Y1_D(ZPGF__#W`X,+-7"A857J3BU$H M%P49NE:[W;(9V9ZVW#C*>K]W?=#O=LO%4N98!&"I=E:.P*S%>R"C_T92"7@? MW@B76(LD!&N'NS%S?*2`92A@7=OM;$];;AQE5+O.H-<=]$K%45:'V6EU5F(% MKV1)^2,AG`#/*GWF8:1(,0DHZN;@Q4ONNL'-^';JJS`4:H9+';-CE[\NM@$9 MK)0`R4AQLLV_'U]ZU6"3FRE3DCI=YJM=JE8RNS"K9AL#J]['PEJ=PBP&-`!3C5^FK>C-U[ M-L)VN@6_.[*R1DD[S2T)"X4205C0*':Z_89-5]IY!J(RCF"W5U_-5=H)41G' MK]-O-UK/$V5.WQ%R<608P3,PV!$"FO=1>.V'_Q$%#6V[8R^\MJ4K)UZRKJ%; M;7MS?<_,9+8$C5:_E8V;A^DYG[A4='CS9ASKYE<>BN3K?PEG`ACFR@M"%5&H MJY&_#@Y:]2>S*U]!]#ZDD/E$2+W9?S*%^T#DD#68TGXZ,3.C%*YQ?QO>-5E# ML%#<#4O__P\W?.?(Q3\FX3O\&&(N)0O"I2O^[V]C:/47UJC/PY\]7P&K[)^A MG,'RQ1/W#-:MW/MGC=$W-18`BAN_8_?2":?P3J?;FW]_QY"HLU!Q+QA#`[\P MS_>$^59ZCL#FZ_B<*W!W_BR8D8J MYG57C,,-/_[[=7UQ]M;=O/EX]>+NZN; MZ]M'._TY5.E'U*/XMWD&A9IQ!?/B4?)'ONNK7]C?Z_0O'X6;RE#0=\)Z;ET+ M7ZIM)!L^F[_[>Z-;US*;YRHOG"!RO'R=R+2&ED)H5[-9=`G3D5WZ:NYK8\A. MPJE@>-:3>\M3)@/&V43Y]T`/XQX::385W`VGP#P]`_3YL`:>1]`$_(070I^A MJ0[!^(TD,"W'.)W=Y=E<^0OA03,.FRL^HED.GWPG&H7PVI2'#(QYY(9,PE-L M1I5'R(H*L-#^3(Z8A#Y'(?.]-6)TF]02QEZ6V`(RXH!36-)?AT*,X5L'Q@Y/ M$IVSNY1/=L\#YBL)PXV$PF,C(Q'A8$N?L>`,?F@,^DUJ38GU9SX(E]]S%3_6 MJ^$'(/O/R!N18.\ET"F!48DE-)#S:.@"2_YX+/"^+?B`,IW!HP%&,5+`@+:#;?;6Y3+B80AB MQM]E$,O.I2$,^01F"=!F>B=%H%ECB-`T@&V$L0O@T1F'V1%*F$?8R,P/0ILP MZ"H"-8'VDC%U_8"4)ATO,TS+51$`94$T_%-@EZ!BX"9@6)B2P3=0TB#PL:8% MR":1,Y%N44[9HS!L;H1F'+Y%("V\D4!U^B:H6U`>)P(@4B/U%B$=9V5C,!#, MQY,\(!0U@1]:^:4P7`;1:`30CA5*EWBTR,'O^$@76\&> MX$6>%&HA=<`8-BGE0M)42)HC/OD!Q:\7Q,<]4"WP"]`U M;.!\U4#^;!"+%=Y\@(]6CJ6G0VF.C>!5<3XT#L*X`V/SW@7=K1#56T=4S0(0 MU>WOGS]??/T/N_G$;J]^O;[Z='5Y<7W'+BXO;WZ_OKNZ_I5]N?GMZO+J8UF` M5B;@4'JL54W/4DS/1,F>F3TG_#33%-VVG_<\D`0@Y@`0X!GR*=6$W.6$C$6] M-C-3^5;KH6WD^(<`F+U`B"7F@.0U6N,CL]`AX`O0$3'F6._U@M2"N*1?`/AK M[`(XI>=@4<73ZGLU^@*F`-`^`M"F""%R0QR\B&%.94E.?KVX^'*JV;A/*$OYNZ>]5C`G(3`$S<$X M^2HD`:4A)6H6+L@M3C"Y.@\WRNK2=PA")X;0>JG?[C??L1/[ M$9#GI5GL@*Q\Q9;`0"S!0*LLK.(\U",7%D+P(NJNCY+`>:=7"D@DPNM-NK%B MFL_+;C'*8W!1%1A^LT"(_"RB"T0N4SF9@KMU)2@O!CMC/86/R1Z;]MHS`C#D<M0:.+L*>+$C%8,%%:I$-'7P.$ M4#HA<,A'W^!+`UM^/[\]9Q,?3(N'9*:NE#H<3DXW M"GX<&9H!+;J>.=(`HA)+U*]O`+P2#P]RW=A4GR+(&]4?.R94GKYX+]S%@S=C707`*D`Y\.6$:.(&R`#,2+#U>7V1!*B3 M<<'AK:6S]N%X;VP/Y`T<7H,RL5:%&G-8K5=`LA1`@@.\$ M\;:S$B.<\^3):/_9OP?/0[OB`0`:WS.A+16@+&KFDQ^![Q3AU`?P`]C&8*<3 M3V`R`4C[+[*A"TP,.SUG?SQ/C;3*GQJF;'Y`2,J=XC`=K=K1)7&!QQ`IJ7:1 M=B)'K:+*JK9.ZTJNE$Q]6YQLAM[&E["JX[3V!@[(*3&L(8).!\3EX(Z#8HX? M#4-,,`+QN'KU?LX^K37!=Q%0+YCQ2$\6C!&`?YY*C&60"E\XCLL$25E4E&>D=Y] M`"[XQ.2UQ4V"@P_0GWR."#(X`KAT5>S"UF+N&\1SW9\)W9%^78#;OGC0((*2.`ZF>1H*-N!XI(O]5AV6\DL03)S*3IU.,<>)+ M_"@AV&CJ/-%4D53+-:MF:(G+R30\X1P"-!/I*R3AQ0@"YIIFT MKR@0B%9<\,S!:BZ.P:S.7GN@Z@HY/Q!ZW3)/FZ6:\W MS/9!O9?D6A-F@I'PB>"A,/GA1L3X)H"AR11>:K8H:08$+7%S(+2&@D`3!NIC M@N+634(+#VAW`50(6G1TU""):+#_1ER%.M[1K#=Q."8$Q9C^9W`$0WDYE9H M]V)E9)+MA#3#9T5?`"[%?4.G=!7&6D>8=@,RB9#S5&EWV#^)3@\^;L<0*0]V MC6(N+[W%+?!$ M-XTW.CZL=$5'$#UAG4",S\V-`![)D(U!\.8F(D$1"$?W;.&3<"J5LX9/ZC5, MQI6F_@0XZR$&+H)(\VK28;JU=G]0,TG/^OL47L7C0,+29^N,R`+,<@X3I\\P MKI5P]H#LU'T'K$N>?E!Y\.0U,)$_O=N(>KE,,Z?,?$1D(BC##.:] MP.U48[+'!C66#M8,FV5C7AXRLF-+Q M09:SD4 MQ<4XN3D^,L3`\4QZ*!XZ7-.4<6N"@YO01SKH7`@M5FM@4K[IX@-+Z_"+=;BFLO;5 MFNVMK-DF!:S9P%V,7)_.6V$N--J=?\>V+CT$9E57(@MQZ8-?\T*3&PV/?I7! MMVJU]^:P6JL[#TLBLT\K.XOG8N$)LVJ"6NE/#A&L1/V32&3!Q(@A``>7-C-X;.;6P&X,GZ<]4<2 MUS4*T7T3!$ZQDJDA))+6US'X!IC=;VZ$V98A_&PWBLRD)M/"T_'"UQ%CRLI( MJ:HA1@+I8-8AUE<:*SX3F">I9"/L*\ M1HV;\&2^4V!5,>B=*P-33$ ME":J9(8UKW!6XCK0B<"V(@44*5!@DL#ZK49*[!/H2G@3(-3LY:;=@=FH8:X6 M)X<-1@G3R\!["E>*A:ET@&]L8LL6@_@^UU@6>#7\&9^DS]U1FMI*KESB8.-V ML#X9:M40K&N:]88Y9J9>!![?2G/@G-5R9W8;0*0;QX?)\\?UQA+&,5XS`:'- MM=M.Q$&$+NEHGQQ%+E=)C31Z0_@3Q>?@;M!P\5+;G#(%\RJC\ZH`Z,HD#")* M^=1`:.7L1Q*.C`LS:B.%LS:MB8>U-Q9-Q?[Y1(M;+*_$.L[MEO#"8Q'L\$=%&X=0].-"Z.;+;PTD

    C/UW4E#K&8LTV?ZL$\+J9V\DL\,^>NP#=]/S9 M-IT`WKSZ.[06<^P2V$*>=[N=_7:H':`:2),*Q0,R,_T93=?:!Y:K4H$4+M5> MD*?!9R?M-GQ49HR)^7;5N+,0C,S&DNW!DI4?V<(!.F=Q-;+KCP'Y?8*EV42-!W^/;' M(B4*W.S?>&C/Q[##T:UD!8FL!7XP@6`F-J^G!21@]'!JCH/0`S0))#ZK;B'$ M3L`FRB?48O?=)Z^"IT;K\I4L=Y$%ARKJBB)JAMX+K'1`I!/GD.)Z%-D<(@^5 MPAY:->`I+&71/9'T?7)(95STAD/4D3@H"#_O!7_TM+W$\C(T?TEO0LM&*X,J M5&N^\-Q'@DJT.'.A(DQ=,_W^]WPE%E?$D3$2AR/YN'#`J;Z-ZIHD*FJCHFW_ M..!4+Z;Z2#0*.B'O"P&].B%66='-=&IAD_?077V6@>`R]?<'&V;ZJKNB8JVK9+T@/#`*=Y(0BR;(BJL?P7K M@'--;D3&97U]&?]#,.N$(KWU5= M["I100TZZ)]MR*G>'M7A-""UW+.*4[Q7%(=];LBBU,-]WJLS8&7GYP&@GH#!&9DS,F=DSLAYRSH8'N[U-4-^ MOF?6&N-T'U%88,)/^NY<%`!PG_N!NSL:#$5EB+4F&@V7VC\..-4+03!$737$ M@9%?N/H@<<"ION4:8*`9XM#HTF%V@-<`#2CR9+G6"5EX9&S1+]"&C.PYR'2_.PJH(< M;OF`5)N##^**H&2=J!WN#1S2:.!=0>64@]K06^O*=)6-T<0VKK,851RJ`]'0 M6C[[]()O>@$$9][F%J.(NJ*)@V9S&CGS.\*(IW"]3+6%WT(>#F1D(3R8^.5_`ZO&&DA4S"&9$F%J>'PA_AZ8'6,$A M8#K]8D7(50G`[67[DD7^;L_F%[UHM;%>W#''E$GGLBR>"2HH5 M+RD]0U:!EA+#MU+6O4;]N?81M1]2U)BU<@6XME;88`VWM1QYOJ'*;J@25=2. M=0OU"/GYE_D<^>TBOT3EKSZ(OVHN^I+%N38[HE([$G0+-20%!OE0D64X#;"2 MU+E(RBB@5%T(ERJ$M#9L_LF^9,FK]1[`.AROA_D;SCC]5 MU$;YA:!*5>W9?>5Z$^BK`EOCZ%,&XG"8?Z?>*/[VWX(Y7^`$GCDI+DI\&-UI M%$D3AW)[;;0/$2?R:"0.Y-I]AX\*)[HH56I;UNE.K]^?++J2PJWNN7:^'7$X M!),U793K-\\^*B8>Z*+*95UJ**P)9[3')?M7X71;CVW+P1GA]7!BD>)\D\,@ MG*S*XDC+=Q"?(C/SK=TEA_1':7ONE/B^Y3JPPZ?D*+:WIHA*I:;TQ\_/NB3J M!5G(IXB2LV$37-)59&G%(-BYBH[G<)?,^UAV!-S!$N<`Q4(_6S?D%CI70 M+U]T!^#($)6"HINRI\\4J>(U3Q72-*QFVLX!;3K`K'1*1-E(M#(Q9\4= MMW?`4R=8:1(#7<4+=Q"/V$(4[\YH;3MB^<30.=1ET1BTG*O"]RX785R$<1'6 M#CJQ>H&BM-QHA.]=+L*X".,BK"41)AFBIJT78,E,$%OEQ=3)=,G.F'E'[H-K MFNY#FZ0=7E[,+FS#LF?VF)V5EE"E\G3J;@<*[=2<6_;SSR4Z"N9NGHQ$H:UK M[BJ1:-\1U0C=9T"@NZUP]SY[)]>')0OE^VM8_4K&@L&T:'!JR?>>\!/^/G>] MX,%\*`Z@/'22]`F6GK&'(2TK2LD%%\H'U4N2G'2WE_$]`3B MT%SK]7SM_)B;/N=15,I#T351TO(]13P-I1A](T-4U?Q*CSP-94MHFRZ):D&! MD8-+0]E=UA0WM3^,,"9]`-1L+[O@$%'"X]PZ9)!N(EEWW^/%?L'#("'V(]-Y M.@K?XWMBD'YK\>*BWP="0$T<\H0SOL/WQ2!]U^+%KO$#(>%0'$GYPNH4N9KO M\0X9I%,M7BD[98KU$\MO>1[3WA%XVD@5C8**+SQ[H3-*OWS1,H!51#&G,M_/ MO3,N=VJ>L;:$:AXZK6]+`?48#021T:=]*E:U."D;0^H+?XZ M3MF#I>P022NMNQ)+QWSFQ6IF1W;>8.[Z)]?!2NIF`"2]=L;NG%Q]7Q#')ZU5 M09]8CTN<'V@X(X#J/OD`:_\C&WD@47$@D2RMKLJN@*\F^RV5WF"9;UXTG]?X M/E3D\QK?>T1^?B13'Z1>%]6]/UAC-($$=T&;UDP)#09.M,M!F)-MA@XM/+!2 M=&7^118/K-Q6'WT968VW-=T"_NLVD'SX)%CU^Y2SXZ&+7[D[(XZ)JU^Y5Q5$EB[!.Z5Y. MW\[IJVHMTK>/`8XO7YPJJ<\&HF2T56]]G[9B^3@FIF/.HO.?_UKPR"-Q0@P? M<4A0FDD/-%#JK)>14MI(E/0Z'1_RJ5%>OQPH17M)4$7!WI]U=`J/:NSK9M7A M0*)5N6/9?;-FQDKB7ZT4F>RLSFMF?EAIIX[Q?P\512>"-@68V(]DHE@ M"J^B^`&!?!_;H0_?)B)2A"D@&AY:>*Z_(.,`?UW`<`Z,!PBCTTS`3K'=!08# M"R;,!T3X1C#2%V91"N)M9M"DUG>3) M]'$!*`]@`3X`,"6>!Y\CBTD(%P`]7>(BN!`2&`EFEI>!D(".GK'$"1E;.(GC M!D+@`H;(.`P(X,..8G=,F@-I!;XPM;`5WP1FGUC`<\09DPL!R^-Z*&/L9S'" MU1JH\5H>'!`Y$WB_&%88,F"T->>$,K\HO-(&HB%I@N4(8W-A!<#R.%1L2`H+ ML&Q-RZ'CNAL4VX%&Z2V\0:TGXL&Z/`LVC`/#3R_2^_NG*#0[*[2\2K!X=KCY M6W<.Q,>X])LI>_G._!Z]_X8X9&H%K<6<]TYRJ09JM#T6&$X1_E#C\/<9?+\# M)^7'??+JGSQHOT1!#\X2/&Z_U\CG:1^]GB#@C)+!Q>K7]L(.YQ0D4Z! MVC\$'"U]1TL?ZB:^)V!V;>E4?!@$.QL,Q-&0AP>BAM+$0<'YY!2W\W`D#H8G M6![Q-C`+VOOP(+*N(HMD2=3U.G6,>)1@KPDL*^)0SS]3'5^4X`D36B[HO]02 MH3LV%7-@+GT']2YR,'-VW3>[G@V'HMX:OW+%LQ<"OWR1!'`X$/5:Q2^YZNDO MJ5.J1Y+%D=IY*L)>SS:\!.^!Q+V"GE%&[80T\R#UO1!T(`Z-_(:J/$;]8"DK M2XIH:'5J]N]`C0,)5M][L&(:?S1L,2M&M7*$:7:@ZM5TRH*-EV-\,0/R!4.V MQY9MT-!JSQHE0>M\J#50T<^#UKE0:M[+#:- M5FL81&EA8_P0F-^%LWMFL+[>6G9N;_&7!737?-$8DN=_2Q%+Z4 M)5$I2-@X16;&>#JEO?KJAX@2L(WZ6W&^=N,(XA/3&\]H;8]DY0@\0(P],K'R M,]X.AX1G\DC4I-I"^ACT]YDBB\,AK]O]P(*'A_7C^?M4@'!KF=NZ5R4\VJAV MM)$F#M0Z50=Y6-EA$%J1Q)'>>5]W3NCN*QE+HEHK[*,7X8,8_%HI3J5:]&#B MSJC"#=&1A"OQT,)CHV@_"[98=-1>G-\$`E[Y/`O_2 MF7RPS'L8(["(SP/F>&G'0PF3*Q,RP0,\B@,\#`K^I8_.Q6.)<^.\P,/<#A?Y MW8>YM1]I)8\V8CV*@U$_>^XD'`?,!/1S,=+GX*!*(56R*HF2FG^1U7)-P(./ M#I(-7=0+.J4>7'C0UNV!->F?16%AFU'3`/)W:%&WXA%XC11%%Q6E=K?7HW*1 MZXHHU>^;V9OE59PZ'EIJAB:,1Y^^T\-;%HB2*8Y#>+&SY^/D;;4!;'\)?,#=&J>-UYI7P^DU?!<3.H*T:K`U'SW99%2UV M5],K`!,=UJ69E<=&-!@;(2J&)`ZE=CIY5W<+O7S!R=LH>65C)`Y''9/W0.IJ M21>ZY?2MME)6C%"EV)[L\"":B?@&$Q'?)O(0;P-XX8;V-/8O,0K)"I[;CQ3* M/9PQCA#6.&$[(Z1"?\H&X4C2CT41,*T7@DKM_VRMWX!OO11*R\Z3DC>1?&*3 M139/;HO5LTE2?ALF_GYLEVM_'@Q+',,MXKA/VF\!ABZER`>S`"^!]\N'!X\\X)W>M1-XEN-;8^$/TP[WA?'6@W%TY<>J MP-Z$@1^8#JY:,(-4G*``DF%[.\;*,U8(._DQ+Z"CC=E&/^;&I)2?3AX:HB[E M!YKO966<1JGIM!$G4=79M@9U-4(9]4+.#PSB=-D?731-E/:\9=JZV"Q_Z,RX MV*3C_>:93D$@:^/LTP'WU^:8*JE6C4-_DAA7"G?H*6*]\G5L^:'UBTKWJ:W@ MN@E?_::X;F0DAM.N@&KO6%5?-]P1;VXY]**5:XC4'&?#5@56<8&ET\-VN^KA M@+#=HE;0+@95:Z1QK=!3K9![7JA[19BK*N)+X7P]T<][VI:8N1H0NPE%62^4 MBCGX;D]8<@(W2^#.2=LC9TM+*]Q4GZO"5R6FW/%:4,V_%MP?)1OVX)<>UY"#PYX97QE^2E`O3."NSARR(9:Z&Y[ZGWG,']ST=(\85@SN?NKQFK%Q-@5\S]O2:D3N?N(HX"8R? MR=P!U<5AA#N@CD0S<`?4\?LGSHKM9NY_.G3Z%BN]HZ5O9[ZG]CU/!1DPW//$ M/4_]\#SEWT#WSOKMQ/.D#[@+9`]X'^SD\'OYXJ@1W^IQ3^5,WA&N%47EOB?N M>^(7BWW#N+(GGW"/T=ZN[ZEJZ7Y^P]C3&T;N>^(JXB0PSI.?.DF)Y=3WBY)9X;8 M*JZ.O3<9GP=#*[ZN3%SO095S&N].XY%^PB1N977E-?G&=#OJ<2T_.Y33K__T M,XH+('9+PC9=@EUV`%M_[^6+H[A\X7=2'"T<+;WU;36@]J+;2MI2A)]\^,F' MT[@E&FO*"9/X."SG"RF_=3"G7__I!U*6GWRXR<8M68X6CI:C._?4E=1?"/SQ M2";PFB=,PR#TB/!0'!?.[>/F[..^Z&5.W3:HJTC]//YL=79K33K_LU?5WO`- M._X[`/^08.T;JC/[5&_*V7LR?S>6FW)C51EHW!LNU;VDWCL_EK8I".S7G MEOW\\W:T9^`@OY/UUC6WV>DZR1/)IJZ[V/P%$80IT4"_>*)]=Q$T>U)ZAC+0 M9@POI,R!V!RG1L'Z;S';,-#3OU$@?HX"0+-:-9?W+32/FI-'?GZ=!8[\UI%? M/H"F*=2TWJ]9EB1U76NN;/8-^?C%\K^=3SU"!`NI0_Q`\,P@OYMU/(N!<^PJ M<5.#E`2TPK":LCYNXJBT,;!RL;T):15`?SQLW,E5<"=?&%M'U!O%G=X$[JJ` MU!KNI(M1?LG=)I#7EF.C)#COX.`"%NI$>+:(/6G\IK8Y\I4F6%U8\KF;(^&T MD=">55`2H*OO"S(.R$1X=&TSL&PK>#X".FE5ZTH<);=R+%`L#"^J5KCONX9= M;EK;FN9;[(=#(D-X)J:7[^5K#B*.DX/&R87>,E9VN,'?_+;QW!W MGT#%/J_QHV'H3/2?9$IS"DEUI!J[F*O&QE4A6V.EML'+NE?=!"V^Q`SN8!635`[$81&XBF'(MP7?%@7; MHH27[DB)V7/PCIG7MA5_/SIB]AR\8^:U;2VN>T;,+@JD[K12:M07>X"K(.#2 ML1"$?Q'3#F;"-?(<*[UJVB+\.;[80K8&UK%R<3:]`QL%;F<4=PENKD^\"L!J M?MI=G_!:?%W-6;-GX.:ZS?O&FCG.^)ZQIMYGUFP`A8?'FOGE%ON$UZZ<6[77 M7)-]`!C\M08X^8-__/-:^(.`J60YIO[;8):^[;+^RX&:.U\ITT1M+\AK40_UF8;'R67;3M">L9GF>Y[[MC>+3VM=S@K=)IW'@N0L.C2"(Q^H&$?@*1@9@;P+R)\ MK`GN5+C^X^KV[8UP_RR@*3DS)X(['H>>1R:"Z>,# M.,(]`:0Z6"([^F(!V'8G/OR`7WIDX7H!F5RDZ?A3%.#QCY]V#3;)"%2Y'(_! MZ`_\+V1,K$=\^EU(W@,S\-"5F%LO=,OI$;_V>6/W%E4\S*>),)]MR70=.?FR MP>B!1V\?;CB#.7NH;NDBWJ8!Y#<37,.9L7_,V'ZL2R_0W2=8>D?ZUD)/.I8\ MK?O^8]S+HPTG13+D?>^^_8RLY^XN:4IE2W?&-RCA.Y0.A+"F3T0_GTA?#2#8$:>?"ZM.N?C5L-*_D]K`2+[ MQS+GJT(0Y$:=K@W)QYX[5?OF1[C/X*7[%OTQ!^U3_3^7<_0H"I8/\/C4;^H` M+GXLZ\VLX9',+JO[WZ'I`5KLY_=P('#&EFE?.XA'>F'"79H]V%_<3\>KZO:F MMJBL4?CO9EA3\R/,/O-9.GOGF*KI)\N4%IP;=JDT^]'TQC-!E?>(GM,FP+]# MAPAJ^:X7'/_-XO^6+`(:6K!:!Z?&WJ@1QWDDB-&]:*JIG5H^_+ZW?``#0S2U MGPL/X&W5.5NG68<]S_@R^#)V!*?UZO;#2A6Q/WON)!P'@H\1SKE+W%M9]OR^ MJSM6LA>EH2P.]/Q\H):+QQ\\!F515T?B0,YWJ+>,P<[+VY?`8+6.`.)@((FR MLAV#+17A/W@,*J(BZ:(RR(_W:12#>ZYA_)OG^GYT3=FJ3NRF-*TLRMI('([R MB=<<3(>#E>%@*.H%R="GB!-9E`8#X)3\^(?3Q(JJ*>*@(*5YS_*N?JN%V"B= MD$=BNPLL&BV0[]C]L!"EH`K:G?&.R[QIH+=7Y#A<`3V7$JX M82$:`3[,74?PL3-2N[[3;HC8*5#[AX"CA:/E(-'2I:V7[J&0"(!9A_:-Z5OC M?='O+-\U599NTH546Z7OS;AI9/T%"3A]7W\_R+]_.=8('O)+TAR.%5=:;+VS M[#`H"%D_A(W+!=?!KK\?Y.>"JT<65T\I=%@F,D<+1PM'R\&8:YEPK3(35'Z[ MQOF8HX6CY0"D7G-A<\6Y'+TWR&5QJ!GB0&W/*C\H9*B&(6JC;H,B7K[H+3H4 M51,'TA$$$36!#%T?B8J6W]?QP`VYH\M\D'15U#."O0Z.>9N,_!VJHC'@.$D. M9-9#"B<#,';U]O3W0>)DQ(.`UX=2 M%5V4ZGNK^FKG'7?6@ZH8HF'P),;4)E=;S6`\1)28^\`%V)$+L,JU3[@(.V815M(&J]V!@]O-'"T<+1PMO3E\-I<( MH?`K-\[''"T<+0<@]7@B1#2"C#&@HGP,E8*;0(8\T$6YQ5)A!X4,:6"(`XUS M!D6&IDCB2&\O)X2G032 M%D#G:1#;HN6T@3@\!N]#DSB1P=25CL"R:Q(G&"(].((\UT:CQC'2]*B+!1]O M&H0RQ.1MGM>3'$H=B.J(ZX*4"W-H-''*/X8=`Z MXV8-)Z(\/%0I5Z<42J&<,U11']1.9S^&/7,F&^+0J!U^P],@CM.=Q-'"T<+1 M^X)`GP7/GIO-?HD"_$06?>-;TER@(Y&=! M6GS_1=@$++;6)/J_Z(G`,QU_"A/\+#BN0Z)O+6="<'HZDDV"@'CG_L(<@P3$ MYQ"<7X0GUYNLOJ6/4H%*OR.)YZR)^^3#6F+W@ZLW`#S^^6HZ)>/@ M9DHEN_5(;@/X]6:!;_B`5`?!_D*F__SA+?O\]?U?5U\E^>N_3>__T$('8L-08_^_@_"A(PMP(W_SQ^D'WX=P]B@;]WY(@PH8]U,KTS/@6WB?R;>+4Y_.0<[).B$>]310)=6>Z$1P/>!B0:X M4AT.]"/`1'UN5W055$`+J*![B'X'QW(X]/7`$B/P)?73OS?:WH!^L'U M_3<$A#!A?]^9WY<#-[U!?K]]]W5!O*]T\"1.%)``H.8C(=#<`O:#DTI;Y41P M4FG3[`4GR\TXH2=8'W;8%0MM:V$;K`D$>:"ILI80"!LPU(:P*E.N0ZC+TE!J M%<*J++*N7@QYI)8%\*WIS]Z_NWY[[?BA1R8%LO_2_WHSS81F)R@574J)_DQ` MDI"^(_?!M>^'8"Z3MZX?-&Z/9BOY[&&H6O#\V3:=X-*9 M7/T=6C18]W>?3$/[@S5M9C]^S9WHS?/=\X)3F96*B%EBM4]"-98>XS-\&,>/C8$9*5V=W$ M6_ZV7*)Z)"NDU+OT?9+8E358%O49_H.//9HV;G9XZ7;F>L$=\>;7SB/Q`RH# MNE`*NJ+KZE!/J]MRX+6XJ)KJ0575D:0,=UT4-9WQ<7AF[:WE*_#3!]=YV"?% M=@>S@T76I>!0U2D%&UAD?,Q9'7M*\V6C1N.Y-C*HU5(!JH)%9".ERJYK=G7R M2#94?9"[O$KP%JR[+$B>@IHB5:?@%KB36@*_=@+7>_YB M/GTTX4$+YNY"9BH#6%A"R64"T@RD=06?9&B:M@ND?[K>MVL'C)$Q\3M!ZF`( MP$H9H*8@:0C6NFC5]8&6Q0#;87UO.98_(Y/?7'?2"5YE7962]S39D#0$:]V+ M$-#3AE$-UG6QDN3LS^;XF_D`I\3E-Z@@PL7"AO-\/#A\;%\:JH:4O.)I!NP" MI9!BQ$Y7>JXI`U76<\5^'F0%BTE1O]/%R*JD#=30!EKJ:'8_QBM'_0L8$ ME-R]36@)B[>AYY&25Z`U)8`AC0PU<7PIAJAAV.L20)*TT4C:"7C;=I_P#O6] MZ[USP_L`3L^;;W=(AW-9'>E*8BE5`&QW9;5M/4,>:4VL;.,AS!SIXA@\THVA M4<1F`$@SD-;$]6@X'(RJ0$HOG%:_=F)T@!H?)&!'6EBJ&-2H*W]%VN M?N\"@=HP92RL@]`$A#5Q*&T%,$=IYDCP#FRPD:ZB_*T&5W7!^QEL-G>R/D$' MEI>B:)752S:PQ2;VYBA=$$^59:G(@MZ$JMPJP+8N)8,:O]\:EEI.!GC%ZUKN M1M(I@<[71%89J#;TP&>/+$QK$@40=&B;R?I(E@=K*B$3F@9AKGTX@2TQJ@IS MY-!^?D<6KF]U@MP$GZ_-7A>PNAC4E6$YX-Z1*0%43E@<-0O+Z,@TW8@.R82D M*6";#F79"BS(N7`>VF9`@W&\P/I/%%6V^68G@D`U)#5E79>%KLU%U;=W!Z/: MBXJV!?-==W(EG`SD3LU>#ZR:V!R.E#)PI25QK,:[PYX\4`9Z@I6+X&D4[MK, M.E"5476X-VV.])M=&.#Z:%1H!:4A*H9^31MU8I2F]>%VF(I70`D5F2`%_-/P M&J2!7$B#3:AR#ZMQ)&97@:!Y+N$T'+G@YLCUFVG7ZU"&>/M3!\82C-7AOAC* M@\)MD8*G!.B?7&?<[;;0E9&V=07K8!5@.J*5K MBI9[R[,SX$FR?C3',\LAWG,R/B__%JOIRU5YJ*0NJ_/!:1#HVBYS1=$,O2K0 M<9@O7H,D`YH[0S;L&TE1$^9((43-@EY7"H^,T7`D[P#Z^]"#84,/]\5[ZSM^ MZ@[C*N[?A-V:"TQS$-<-YQI(AC2H"#'`X@=>.$;90OWA#_!49U@6K,D_?[@. MR/RK_,.O&(V6B&[-!ZQ)^.OA?`6_"B<&!0@P4"HOX8/I3#IQ+J8397#:G<"H M:P,4@Y$;>-[9SC=TU1@8P^31KPBDAH&O>RN@#%5#U7_-L65;P7.4Q%.<0#(:#$:G@J6"_,,M MUFHR..JX<70SG5ICLI[D5KC59$,UM%/!3[8!MQU-*[-00[/0D*7!R?`4VG,E M&$EJ#A]-*;J]!>:DT["9T6@@Y^,Z"4Z34-?% MM:0-D[%DY:'V0C*!ISS7MFDH4X>H'NCJ&LPYP#0(:OA7*=61[[A1,)]!6IOV>=,JQNJ1+ M&1R;#5##H->]T544?2?0F1SPT=L32(T.1UF,:R\#6WH)J MDF5@R+):U49?NJX)>!;+.D]9&!P$`4G$`0!946]>!%+PU;;.;9$QC-$PG!V^! MJ#@'I:P6;_J4M=+A9<':OHYUQ=1%2`Q5D-7`*A$9L[.F:7C/2UNV2R75LR7A M:./U*"BEBT(D6!]BN#4E*A?"E!LSJEJ"@5P?S2"JFO>%+,QG>@=\,_WL6<[8 M6F`1\D^X+#@$@-"\>R+V(_D(RYMU8T?KDCI,W`HV`7=/\?"5!M71JU2 MW$YB#`;J<%>.24/;KT77WDDGA)?=]HW4'^S,/-))"K4A2[K1P+(1WKXMO.Z& M.37<[&_3-(6A]V[H=;)KM.&@`.((T:^E,\8JT3#EN+IHF^Z29,W5"D.*-H%R#ZLL.X&&8Q& M(T,[0B34NARKA8UX!]%<=`S4NR]T:4I?;\D"UR.EUYGQ?7'0D"RE\V<2\[<+ M5ET>9(#W!7)DG(AOREAH?0+]@^60F^E;F,@J$[*MEX,]/5&D"Y[?F0%Y1_RQ M9RUR=[+ZD;F"0KLY1OHU(,[Y,^B8M7Y4VP#LSXHV&>S7J34-GL^G>!Z=XXWZ M7M96.>B['`?^>C^#:SK^C?.%F/:5'\#S+,K8&G]F]A#J`/\-S.NZ3OR5^X:P M4G*D,'VR0TFKZ?(P&4_>T.IV1EAW4N/)LFU@)V$2$L%RD#?@'\N;"'^S#M3( MDXJ4K)M4:2%YQP)X=@S/P#!O0&1A5I;UG4RN8:$>\8,O,%J+G)&J:"VN;D`7'F^WK2B0=C4$+^=AE.7F(*)153&?*Z\OZ:'KI M[RO9DGF0Y*O[A!*[F?X!S(F/([K>F+[53+A.28OF?]O!+Q/K\7\_!+_$9!-< M)G<=>!I5]F,$GV`&]/N9]3!C@EB[4/0?A07\@?>##]9N;+\+"#GU! MA2>$'W&2GZ)9\G1\,4IZA\HL`RH'EZ;S+-R[GN<^8RO5C1'B.4$DB'83_!/!-G[PWG6_"S70*[TP$JKC.*(Y>(Q+5"TUN M"$?T!F(EKOQU,"/CHPQ>:K:B5M21%'<8*0%0P\#73K631L;>@*^;!J;(@ MP6XW63DZ//1A!V1!481Y].O8MBA9GEP/A-V3-2$)\ZT8'6G,C6EAZMQ"A)'* MOQD'@`XI!TW)[]^;ED<[,K]YIN7;WMJPBDCV3,C4`@8@-AZC@+"F\V!A(&NR M_6KQ?:6>KIF3@+[2JIH4&:LD=SWM4F@&N*8*2PUH052I#?PU53MJ6`I_7]QG MTPZ>607[3Z[CQND>[2L'69>3*0^YD#0%;MT.1VJ*VJV#6U,!5`4UU@SL*9H" MT`$+#!0I$:V>`4-]$.MF@2M:NL-@"R#6#OK7]>I8C-(<.J+T0%<&VB:,22`: M`+)NC3;#2#C"_#!8@QMKWY4N&U[7^5Y62BP!I M"MJZYOYPI'4(;5W[OCQN4QG%2?'_&Q[Z/[A^N6RLFLQPCF4LU]*;@DX\PU=&9H#C7E:&6$+RYH#0%;UU1H6A#6>D0WMJU MH$92LEM&(;Q4IEQ]']NA#P?+&WK(C:X)8I_=C?../!+;I563+IW)1]/[1G+- MVNC0>[GP,E`O??UWZ%1!?73HJ@/E% MZK#?8L@"#50<[X5O9$5.IFB7@JJ-9=2^0ACJF_*F^V74Y2=9TO7-;5Q^'[L[F]/0535U:5(:MO:65/?Z(BUF>[&DVJ58C*&N MMK6F%.LFFKAVH!$E6=^ZJCSPVEU9328<:L/MVVH_*ZO+B\;(V+Z]:BPMBXMO M9Z:'GGTR>>O.\1OZ)+IQVF?2T6"M)%5]H/>!A;K:6]*58T!#72>#I"0/3?M$ MPQ?B$],;SV"7;3NH-WM-)4M#>3=EE`URU^NOZP%5Y/5B@8>U_MH&\$B3MJOM MUM??D[-O5`W4U.I=V'<2-)>)5% M%<&'M>:2GST7A_AB/Q'\'\MOX]@O7F,GYKKWZ%G^1.+]DHKLP6&^LY;8`-/9>VP]9R* M3JQ@E<9.[PIBZ\NK'=&J#6LN+Y\#&>73])UH"U_MVVHM<" MM;-&RC)*_F1(=C8H#0%;EY$50QI*E8"]FD[)&).U5L=V8&N$SW)"$%R1!'.= MQMU4Z[GL"N:R)[UOY4%K;4&5F"=S05J_%E2)P3(7E.S+W>2"]N-WRUZBMFV) MU9UP\`5+ZDM:`8W7N=G1R`$#5QDNB]8HDIK0(]L`[\TBLX\PN+11`TM[3Y,? M/V0E/WXAAZ,1E@WW-4C M4:3K):*'Q;[Z-V'@P\S8G/I3B(@NI=XVJDYL?H]W6)_,.>O#BW_7V$T4]NX.M/[]$P-U+]\AI?[>&C$J3!'=D\Y.0@5!L=.SZWFRX-L::A M)"ZRJ@9 MFW^94N,N(@=+BM0DDC+6<0AH:F8'.(;N!L\5MS` M)\"9E2YB\_"DN-R4TNW\Y1X^,P_-AH[C,6.SAX[(: M=YXW:R'V$J,':/D<)1XKL0C4^Q"9EQJFO>*MN!Y7)J0]6$?5JSQ&V>(EM7!1 M_R?!5"XRN7PDGOE`(HX@GSUK7*['S?80A'2PXM<%\;Y2Z-8BKM0+>=2*+Z)H MB7W%:M4TVB*LJARK.T8!%V!5;<=O=HA8K1JN7(!53>%8+:]_OB!8K'V<^=V: MA_.L;)5<;`\N6O+]'C^V+:ZFZR,\7IE(G+QJE^,JNBWYA;9 M7]PVIN6TBV1:-L=MD[H.<%O%VNTI;C-N-_HB&+2+@=X@@BNNM.=8;M`0ECF6 M6Q<6^O'PT#VNX6/RC%>#>,U2V&HQNE(E81&V2?&]4$7 M&-^^V%3:?MS1^-+WPSD;^(OE?WOOD50=G[:+FVA85T*21HE;M;*@M;2<6J5- M5+HC-:FH5_6"K4:3F5Q.S[COKT9H09](%JRF,U8H7DP582XNI7T.G1XNI M7URFS<7\X=H@9+%E?!>,1K>--MPBTK)A:VU%#51L&O5J0?4YKMT%W1%OW@RG M_?K9^,OX6`Y6G+5A"$MP#D*X-_A*U0FJ"A^-.KL-W/$W9G5=.V,PPZQ'@D%M MVRHWO0W]P)VSUI0(HB2E090ROB\3`?CK_[:#7R;6X_]^"'[YY`HV\7TA@-^% MH?ZCX$Z%*2Q,F-/^FL(C-6\!P&!&A`EN*7C@@<;Z6>S+,=B7^*7C.N=_AZ9M M32TR$7Q"60TC\$ID(/#PF-,<_"46&.!=7@I:@Y*3TC M^%%@Y&09&1EWGBXZV62AKPY?ELL)2^CWRJMI'Q5R#BJ:+L%%,=%K5,@Y7"'O MM-FV(D3M+4+V%?BLJ_41PEK23R86"A+3WACC`-&2C`???64;UT[WVV]B[BO' MG"W+#2+N/',<@&)`TT+I+DGJU\_:7Z./:]=.W2[V^'&=MBN."^/Y_KB\Z9NI MZEF:NYO#]`Y+/7Y,;_!VO_"]<8/.!']4^_8_9/*[,R%>PLS&]?DI5S*-7_[@ M/A&/?;+FK;33+@AB,K:&?S2SJAYAK\%8W.VA'4>'O0:C;95#Q][OB\6^=J[1 M'O;65M4C[#491;\UL/#HL-?@SAUN]29WA;W*T5VKR+D[-\"F`%N]\8TV4VVX M.%&91?40B75[RW,<-M#'^R!QB!TT@^=KQP^\D,;+THY$=W!<*)-U0W]\9P9D MZ8'I4F,GUWED(7.TP2`5C6HW$7EJ'N8NXP9&N M&PD=L;>U-GG3M82/%=>YF3)#M7ETYCD1C,%@/66A^>4T(CI@.]`?UC8$-=;C MB3Z'WGB&+W:;]S&0FBF44&F)J7U/9;R34E`8YY\^00SY]9"Q@7/>HP M5`%>I-'7R_!A,T\C\_OM=24R(XR2H9.E8>[+0G-*.F0N5![V8*'RZ.LM66PN M-//['2EZT`NM1%&]!PO=478UNQ>IPWGUU.\"WP[,* MPJIWN$3OB^70=WJ2>R+V M(_D(ZY]U8B2J:P7S2X)6O)HN`-?70L(VH4C">.D1\V;ZA9CVE8\].S][+K!& M\-R"X?CW-%@#=2`G` M*E;>NQX(`Z++^(`&`4[D<7[C\=N"+C^0L;$>L2X43C6OO?< M^2WL+VMJC4TG6&ZSICH>M\CRR.5&G,M096U]QD@#>V!T;#CYXL*R@W]_-(-@ M1I[\2APB2SW#QG[51!_W3`_TAJ8?&TXJ[9GOOO6S8]G__"'P0I(T)=0??DJJ MRDA%X-.IR06D*WIKQ?>I(EY)M!UJ'M^95 MLJ88JCZL".\FWZ>??1MZ'BG9&*NV3&X<(<_3Z179"\:1)JKPC4]#.$YS:L^[# M.'$@"IBX=)P0H\M6/_IP=(M'CTYQG7G%&X2Y!`JB-SRP4<:S.%LQ_IV-^C6L03&+&!_F*,%:,X^NA_-JUF&B@7.^)E.6E] M%(/3*.`UE9%N2*JQ%\!KZA)#-U1U1\`)F$L3.!O"<>S._$Y\3-(VO[^%+^'Y M]IEEI*F#M+`M!*AAX.OF+0UDP]@;\#69YGPXU$<544_5_2J^S<<`M\D;D&C. M&(.:G+&U,.W+.1KHF0M0/](%W(R#)FQ'EGI7`:8FEE#YPIOARFIWMFXWZGM9]JJ`VA;BE>2^H2(=R#*:)J`LR\H.2X?%_W_GY\)[ MUPT<-R#"+:%'`>'\'/%B6\ZWGZ?1;Q_@#^$[_2IX7I!__@`K)\Z$3'Z(OO5< M&[Z=!<'BYY]^>GIZNOA^[]D7KO?P$T"F_H0__X0/_K`3QB M_/H4CDRIR>-YW'_^$"/QJ_*#X'H3XOWS!_E"2H!78;EJWG+5?2Y7;6NY6MYR MM7TN5VMKN7K>8M=[C/Y0[;6NXH;[FC M?2YWE+E<6:J_7CE?%>U7%V4KHT:6K.0N6=GKDI7VEIRK@>6]JF`Y6P?+6LZ2 MX^%2T'G$=T-O3-:6F%1QY4VZ!,!S&X9R'L`T=,Y_O_WAUTL?[ZK`]J7VJZ#* M(EZ;:2(:T9AGS6Q-RQ$6GOO@87UC_,'"3%5\T13N0\O&?"'!C`IILANN)Q.? MG"]L@D].0@\?6=VY_1V:7@#SP1`PG7[QCY]2J*B'&Z,AW+Q;0>T36/9D#6Q5 MQ-M%C_JC8)&F\$K1)1%,?(%\']NA#]]&=9N%*8&5`YO`0X!('RN$XZ\+&,Z! M\::NQ\I"DT=BNPL\%=";158Z&H&`&3^:@+B;,+@0[F:6#^_2_".*:8`!60M@ M\&$,=IR'+ZGS4@@7``"%<@'O)A85S"PO8TT!'3T#2CS-X"2`+KRR)-_).`32 MF()MC=%;(9A3'`@O,::68]I`=EB295L/!$XV%P)Z\#SD%?M9C):[!FJ\%I9. MGF2;3%AAR("1QYS#(]:N2:0G MT`RT]0`BSPK@#`4_3)ME4I2`#>U@/YP3GVT[7,\G]Y%M9D218([_#BV?[4Q8 MW?4?5[=O;X3[9^'CG]?"S(1=/!Z'E`BF']]BWY,'RW$BML,O%K2@@@\_X)<> M6;A`ADG#"-&:0@B[!0`F7M5CEZ4?,X!-?X.G9_HM3F?]C/^&/_]_4$L#!!0` M```(`%9/>D94.*9^J!```-T@`0`5`!P`:6-C8RTR,#$T,3(S,5]C86PN>&UL M550)``.3$!15DQ`4575X"P`!!"4.```$.0$``.U=VW+;.!)]WZK]!Y?GV5'L MS.Y,4I.=DNTXY2HG5DF>G=VG*9B$+*PI0@.2LC5?OP`OLGC!C9*(INRG)`H: M[(,#-+IQ:?SRZ_,\.%IB%A$:?CX^???^^`B''O5)^/#Y^+>[JY.?CX]^_=?? M__9+0,+'>Q3A(RX01I^/9W&\^#08/#T]O7N^9\$[RAX&9^_??Q@4!8^SDI^> M(U(J_?2A*'LZ^,^WFXDWPW-T0L(H1J'W(B6J:9([_?CQXR#]7UXT(I^B5/Z& M>BA.(6CU.I*6$/\Z*8J=B)].3L]./IR^>X[\8]$&C`9XC*='Z><_Q:L%_GP< MD?DB$&JGO\T8GGX^)I[G%$7W:1,FT&6)(FXDG0A%$#!\=$3)@^SF/_7<=<<3F:4Q7>8S:_#)8[BN5!< M05ESN=$W(&B1"A8,CK7GW'JJ%?+@:?@+*^><-_@-3P0\^C">\68^QA M/H3O`\Q5-;#!2C'XQ*CUSXGZ$1)1(X87B/A?GA<*A``-D1&^,E#A-L'DY7!7I"CTQ] M8^?K%4TT1D994MZ5HYH.ORO>0<3(,W!5*^6A].)ZT\M\UPJ`W4X$]3U7\8QRC&DR>T:&AG23GX[2M1W-AVOR+[8&85'-B"G?C*`'JI=.PWZ`S2 M`]SA7-(/.AI\\C>3,8FI]SBC`6^.2"Q-QBO5,8&&PIV?3J'S.0U33;0'46I% MG?96>5/7#I[4%(=H08:^3S(M1HCXU^$%6I`8!1O*J]8+#(1[PI8)%(CAY1C' MB(38_X)82,*':.AYR5PT-?9Y)$8\HIH.3(1[PI\)%(CK_W<,HRAA*R-;V%2X M)_PTJ:[?"#AQ3;6K MJ2=46N-ZVV.H^['#T+?RVO2B#F,/JS@50)RA;'Q%\`'3A=N-]]\W6II*;A40 MMK\F,8FY+4PWMV^GMPO,TFJ-[TM(I/=Q<4+RJ8[[ZU?&9X<1HU.E;UHJU?F0 M0@&.\AV,KY3ZD?I<4W-QI\.JH9%K(ZA1:X@6[H)&W)=(=9SP$:]<+:B4A$Y" M36&]#3OISEN"83#R+X(6T>7?'0%-#TIF.NCC,:5 MARN!`'1NDQXE^?(N,;?$'O$&RA5)E\AU`^F5`@@KG1]Q2%'%H@S M._ZP'85H8D(Y8`)LY7I8E3.:.S=*==_.6WK'S[EMOXEH' MWE0:XDRP"T>C!SPTJ/[F=39<]BW:41S^N:`A;[&$-]J+1N=X2EF^XGF'GG'T MY9F;9-Z4)$1L=@+NPVJ;V MD.R[+ER)]N5&R-PD(Y-`[1UO8(244ET["=MXS*YZO4&S5]V#BOH0 MW;7NIK8>\69U:M#E81Z1-/(JH$^MSO*\"._=C5M_J7L[([X]8G1)N/KGJ]\B M[%^'ZS6LH1>3I>Z$H$TE;X;4*+*R)*6'=O42<^/AD;0]%+R4B_6Z\X4N<_7D=OJ1Q5C&ID>LYDQIT.9,_ M`6>RR)BNCFPT<@?'9`E=SN3/P)G,(C\$YA MDB;0JE.857APG<(,]GI]`9(?5@=326QGQ7]-]N"HKB$L6-4O&W6]S01LM33+ MC;SE:FEC)9UGA4>KM(WOZ-#[,R$,2].F*P#:5`)Q%"GHK&65MX"J7X1U,'-R M?3V,_?3LU3<4)RR%F[H"&;+TX:T@X*,N?>0I-DYTOG7-?>\:V^*'N#Q=>C.4^B5D%P:AJKM(HFHQZHW$#XW?1I#FN9%>N?MT14(4>ENZ3XV5 M=']OO##NM]-+?*].W%8M"G%0**BI7QNO`@+O\*0):&Y3K:(OSYAY),*JU!0& MLCTGT0`A1+=DX]F@?-FJ#;U6M?2<:"NL4&^E.YO(FE\D'F%&J%]=6%&=.+6J MQL')*0='PYP=@FQ!:<.I*V.P$(]DN5G>.D#&&\%"G#C=>.0'R'@CV*WFS2W. M/XOF8*O;Z80\A&1*/+$4F>WC<`5'-"`>5^]2I%L.S,]%6U6ZE_/25AIT/)!^ M3PG%_G#);?T#_I[,[S'C@1`)$OYK>GPINDWB*$:AS[55C";KFKJV&1(%:YJ= MHXAX]D!E]3BU'"WIK1H/2\B=7,;[,IUB+\ZQD"7>C`$:V#.0Z3-3!O`VT]UB^ZM>M?C9WMZF\R@*62(MM"L)RM+'PB3C47?#&*>I:-R M=E(R^QM;C-U4"\,S[&(;Q,GPVA'M9IZC#'Y7"7HJ2+?KQ]"FO!TS:87ZS83: M,%"=O/0GT79;_1Z&$J"Y`O3@,Z1>,P@MF\61>;4(H`R%7PN_NW=3VR_1%KOB'>(PD*U/<$&\L[3H9= M;^CZ[:]&O2%&Y&M5?Z?L4=Q2I1Y69G*2"?2'E(KB$`^.K'6]$L_8S+"?OG]F MPDI%H#^L5!2'="C2O6W?7WH%IS`VS>,(>8_H@80/ZU^$%YF(1*TX:HNWW0=< M/[:@)]L@:4@KY([\\Y)%5G-M74-_R+2&MMN9RYBMDJ5NQ9:\AMZS)8?FZ+AB MGG>D>,D*E1*.6$921G7M([HR^G#G5YTV=2HG4BW95XIJ0""M_$.T5QL:B/=\ MS,9UO;RKRX?9%0`LG@/7/#8OE7#_:(6L^67W!VL0(!J?H>N>]:%#XC/.CA0#T3WR/Z]3"%M36"]AIWO M/HC45]=1E$C#22,IB/U?UOS*_88JL!WG!#,D11+C9HG*[-DRKNY@:#1&#'*! M0-(2K>:JBF0?&38&9YZ@M'<3E?%>LLFK"%PJ2$0V`BLX.L5>>?(#K9_\*$ROY9D,X_KV<2[#^./= M;TEIWU71+_-:U>)@UVU3N4TS9PZI+.74VVI!6<->FQP<1)M?4?B.(=_@P(U2 MZL`X+(.#>%0_1\CUY4T5I"^?&E$H%3H`!J78=ONLKR3*R!6XX"4);\=)S'T' M^>E46>F^TJ`$!?$1WJ*_,#K%492J/L M)%Z0ZF$809C+]YHV2ZR[#35LJ:LZS=;HH+&F_BW*.PD=Q.,)RLZ0JMH\]D>HWMK5Q=Y0[M!MM+NK.P\J1V`[CO>XE M\VC^B\SX)!TO\C8;Q MS"2M[';5NQOZVW0(61K:[=H"XMZ*%;(LVM?=6[(V@+B[U1H16>[#MF35 MOO+.DK8!Q`BW#:+A-,9L3SVF4O?K[3:5AG`4]*9A>1'-C_$2APD6:2$L@V!= M-?L(BG7?['B@?:F)-*DU"@7<[I7KFWPVB@M MZ0YR-V],5RB(5QF<38`*2A0R_>)'`01BC'<=<@..HSC3-[5&RC7AAM+]XJ<1 M`L1HJE`TQV-*3;EX/[DI8]!'+[NXNYE?HP,@^HC` MP2137%Y9H_R*2!C=T*CYJ).96#\H,\/BR!?/-$]/-UL_1U&3W,^#%+7/=+]? MFVF0\WN.0SQ5)J>42G3^]%H66]HCT`FZOM"L@E-[.4V#!>*N3W&/T)XYK62? MJ-."S3T2$!28OCLS5E(O)C(D#NIBK;_KMH.X# M[24RN!"WPBU@Z5Q]N_-G[=WYLX[<^;.NW?DB&.-*9+EG MOC*J?&)1)K#UXF^M8OZ72N:=$:.BBXU%KY'>FK"OQ^GP4Q-06B&V1P;12Z^A MX#HO,(M7HP"%,9\KQ#O!NDG7II(>T-L&%D2OO*;_^FTX:[?*OJH^\ZP%!]&K MKJ%8WW06^Q\7B+'5E+(GQ/SHDL]S44P\&\)-:NLSYR;X(+K*%D!*:PJ[X;Y2 MY6%V@`K(W1X';>]_%6<#QER[R1-:;.&"U:OJ`9/MP1EO!#L=QYK`5B;0`^9T M$')^?FH5HP[$I^Y1A/D__@]02P,$%`````@`5D]Z1L4'UP!+&```0)X!`!4` M'`!I8V-C+3(P,30Q,C,Q7V1E9BYX;6Q55`D``Y,0%%63$!15=7@+``$$)0X` M``0Y`0``[5U;<^.XL7X_5?D/+N^SQR-[-]F9RB0EW_8H95LN6;-[\L2"24A" MAB(5`+2M_/H#D**L"W'A36@I>MI9&0#[ZVX`C>Y&XZ]_?Y^&)Z^8,A)'WTX[ MGSZ?GN#(CP,2C;^=?A_>G?UZ>O+WO_WI?_X:DNC'"V+X1'2(V+?3">>SK^?G M;V]OG]Y?:/@IIN/SB\^?+\_SAJ=9RZ_OC*RU?KO,VW;._^_A_MF?X"DZ(Q'C M*/(_>LEABOIUOGSYSSL79 M9>?3.PN6=(DV`5]^9G6`7\ZS/YZ>2'XAZM,XQ`,\.EG\\_N@M]V/1/P\(-/S M19MS%(;B4Y*(KWP^P]].&9G.0IS_-J%XI,28$R!)_T42_9,<[;P&->+?.)*J M<1;@$4I"WB!MVV,W1&D\121JA]!LZ%ITID.<3?'T!=,FB5P;MPZ%$T$,]9,7 M?+8$WB"=1:/7H3:*>;?1*;,8,*4I)\@T./%]7XS0^;ESD:T6/SUSQ+'`QUE_ M],QC_\B0')I)KFW^(PM[<9Q:M)YA:(?-_BE+%F;W9JEHJ1\%;UKTM03EL<4#]%[ M5;53#U![/F_.OI+24P_0%F5E9ZQIG+ITXK&<0V(^K2P)UPGC0F"T%XUB.DTM MN+)\+3GL;E%T6H+1V3&.LKI4;?2:F`8X%-ME\(3$VCVD*&+(EQ]A)37*-$Q* MI3!9243D[_>"I#5B!1@XL3C@_+7[VEM0(:+@G_LGRKX3H!8?IMSUU M8T\<(<]=D3Q$+Q^*HB,W;>AU%J1^B+-+UXD6=F8^W,+D+'6&&]%X:L.PQ2=C M$[4Q%7KQ[53T2)B@))Y)FN7$/,GLV*]^''&A@;=AVD],G6PJGB[_'L8,!]]. M.4VP0SEEFGT=3V=Q)/6^^TZLM*RHGW?1BA0UYR"-5)>2,DA4!40MX%W+:H/" MF[5C=8&,"MM[EZW(1G7:UPA&Q?!B.2G!')Q\O)O@<1I'Z?;^L.;]*9#55EOOYW;D4^2-VI:-C@3IQL$)/OX$R)! M+[I&,\)1:!2*MI_WRQX)R(AD(:P.`&D-I-D=X>`6T8A$8V844W$'[\][)!\U MA(5@+@`(9D@Q8@F=VZUH!:V]O^R12!3T+^1Q"4`>7=]/IDEZ=NWS":82&L43 MN?^^XLPQ9E[B;,?P?MTCV95"M9#HSP`D6A0XT!R1-AM[7US*J-PYMXAV0)O0 M\P11S/H)ET%J&1O7"6*SK=?YO#>"**0=T*;SB'DV8>]CIG,8K+7S.NWX>5H0 MP#;=@'88U>(I:16$]T=#]/X4TY2]G%/RDG#I#1G&3T*K(JX15\V1O4X[+J`6 M!-P$4FA;5(^Q!`HR:EJY:K-B MH76_JK3N?#TFWD*4O$I.F?5\V,XGD+]XVF_=:P+D)7J7BYA7(505%K?LN4F^K4^($GCV/)*N3%*\F@_%MPWQ=(O>+J/J)<18O"!:XH,3DU(2+,DUAG8M M>CL/Q%N*I*0\UP'^5\D32N"^?<$V&LQ7;)]7"0FEPS.WGI2A$DUKMT%ZRSE2 ML&&JT<"94#F-O>F,QJ]9LJ0QG*7NY#9<7TE4=J``!4V4*%,?J(1JEJ#U&&[C M^[4$6@HCH%B,/$'G7C#UAF@ZBE&AC7W"42E!)9D5B;Y81<*S3T@$0E7??2:)" M`^*UP`7(,NT&KV)/(4P@O'V75.KC#)N-':4;-"@F!29(QB5BD[N;WG4O8@G% M07I,RZ+VCA($&A24&A8@\U)>!)9G["=4,!FS+K]&E,X%8E.DU:J_HUA\@W*TAPDH+T=Y/OK. M\"@)[\E()UF+WH["X`W*U1:D*0.G]0"WL?`(%-VZM[@8;N[LY**X/\%!$N+^ M2.U8,%TAMQS"Q>5R.Z8K3/<2N([!<[C!\RKR/$;1CU'T8Q3]&$7?L7P?4)2, MA.V6IDG?(9^$A,^-$0I-KSV,P%NB@C,ICY'XO8O$]T?B$(7MX[2%[?W&^SAE>CPG0CI1OG4P0NKI]FH2F[>?XHGT= MP9EQ`=JJ[A(JF)M0+(B](^_R7T;!*?LXOIQ?1VAZ3("VJ.+=U"0R32_'%^[K M",V$"M"V)O=;@TWA^`I\'4$LR=^':)IIKN@[.KZ]7D=*%L`@W5S_J/1T@V<4 M^V21838+<Q2>YY>FJ>;5E[-BX?S.C"]+;77>`W>9T*MHS(D M/FTWAI#GI!",C13A93"MT_>(IN8T%U47Y[E*Q;RVDQ]%XB.E4(GQ`?''U98!G:)Z&(64.,8E\,D-A+WH4YLP@#@41X^$; M#E_Q@S!Q)CK#H8GAW:8?E387FX*\KTJR@/-/C.CP+6Y*-]9'=9O?U*Y*;",% ME`!0&8D@0GCU%X&W'" MYPJ#MJ!52T[WYBU9!>V-A]=LN9V1H;2#-INTY(!]3%ZU[X\W]`7'U[I+JT*3L`$E')2"U916.+Z^W:[L MH14Y7UVM!+V^H%-`N<(HK95(WG&PZKVS3!@P#^3X\G:M[`!+=(W7;LB/:21Z M%=^1(KY<_%L*]W)%N-FO`B4EKXB+A>4QSKZM?.O#T,/Q#6S[T+\%#%A5$98& MQ&H^NZ45M=K%\6WF6K;3%@Y`Y0_6@:W8YOW1[V+R2Y+EC+]"K$2@6C^,XQO* M-8\R%M@:J6V@\*M\3'VV&79:;,-%8K+MZEWL1[9C*3S-7/5O\#E-^;X9Q1/I MW7O%'P_6/6+>'PW1NV::V73W+O;+LV.-R7C5WU&\*:^X;>?M,?3T+O;+SV,# M)Q>L[A\A5(F2CI,NVP/\,4R:>(I':GKT.-8OJ&:/#Q[JEN^IM[NTA' M5)-E2DTT]'21IFC)8\5:9L:SY^F+RYG43?@DINJ(K[X#A#1&"V$52UD-"4Y` M:)M&8^*-N27)%]M[(G"7BUE5.[2J%#B@B\WR]U+T:^M#,R21H:2_Z6$]@$) MSC+8DM1@&1[-B@^@"=)+`T"2V(QVBQL611W<%KPPSAJ5M%10X,RR.T1H^MCW MU;S+&.;7(6+,L*,I^[24N;N;_4R+"E#.UY+.E$KV@!&3B88RS\%/J`Q_IX&= M[U'\PC!]E:![T2SAXL]Q)/V=J>ZN@C0NJ6U]LK7\6>M-5"MT@YZTP0R`"\-! MJ!F471^6OH&T%Q:RP:',O^M%'$5C(C#EZ(WF@T5_Q[GDK:X@*E/$EBU-K$"* M5("E5^"&,!D4$*`74:WN"^,4^86)4'8]':>;5PK"E($&[C@M*+Y]GXEU#U_A M2+!I;IMDJM7=J?J:NC_/;Z8K4"!NE"$/&EC7D=L\),Z:)FCA+6Z\MF M"P2@]U;OTN/S?='Q>8`E7V3]T=5'WM++9AV-R"J.Z"CGO;YTZ^!MY)*0TB^1 MQVE8_RW"P14*YI8%=BD5&I_&#Z_F'TT6%S^ZRBW)C\ MYO`M'D[BA$U0%.C+CA6W=IN%O:VX!0:DFO`6XXR;'^U&P1"K<]Z-?=SF4E?B M\R;Y@((6E4V=?DHSZR>Q"F)&/'3:ZXM:G-EFAP7 MT(>LW_5X:JR=N_\:O[(`@-%X,TV.'R380XVWY&FN\[K5FXJM%W;FA>`[F*8:#8>]>P&:"V?U=H0L!9.-=FNP(2SGNY.N%#L MCEU)&:"]0%AZ]E6+$@],#@S]!JQB5%*'XT<9[O6 M%LLⅅ,((739T7RO<@7.SAYQ=(KHJ_W9]OU`+,T2T$'9,`*#DQE,5I!^#6: M$8["[,K9XJI)L+QK(M55UNO2S;2R8QUP;F,U7@`R;5W?]#S@G,%JS`!T"_B) MQC[&`;L3?"NK"L:^!YQ-9X>]D4N]BGV]&P0D&VUK@2J_[M<<\0"3R)K@"*!R MP2FY+V86O92^!KBLT2J?1I!50Q,4#C&=7N@VD=U3XZCX\<[R'!UP$]I-Y1HL M4"?OJUB@J^#L@!I'U9_W0;VK"X)5CG/3TL;5IE8:W[^,W3+-_D:GV:;LV M/^M=_)=5>FB0;?`O#5<$^WTV"MV_S#F,NG\79T M&=+F\][%P08L=L:^@[C4FT5M>Q'C-$F3GOI\@NEP@B*;ZD'I'V\0Q\O7F]O0 MZZ9I]"X.-R0#BL?&2\`N\F(P?14;43&C'N/T;2>!*WW!,)WYJW^7;[`]QOR? M.'UV?!S)3>]CI*S3)N-L\FYV39-W<;"A*;<\S34>3"';&I[#)9.RL#BB!M\//PHWWVD;$)F`IQ,CQ-X=-N\[1C>Y<&&L`5EXV_?A6?[025LAR')CT7JA21,P]O!]RK9WS@E)&!BODL@EB[^4`Y?9I,P+9 M1;FI;D2F*/Q?C$(^Z8FEEV8VE@QW^?K"2.:>;LM0;6EW@5%JAZ'%BE0/;^1W M++XK3%LZ?TYFLW`NS6,4S?7,-_5S6YG*AO4V"$!=+DQO0=)4/P:$_;B:7^'( MGTP1_6'8_$U=896R:F'_MV$`:%'GQ!JW(U-7YU6P;$1A*\1M:'#LAU9E",7* M:%.8`.M:/*-07CA+%Z5'S(W5$@K;NZW+93.)%*:A"@S@.??A,M9=%M)U'95'1R5,1V5KGC+P3DH; M!"VZ*%OU$(-W4]IA:+-^W2`6'^'_>$"<3_`;LU)Z79^6W(T-\MQ$?2.EQ53: M[OMQ(M:_`?8Q>97FPDV"TR)'VP>D(D.J_"!M^01;/N-6`[IO)UY'+\4=S[W' M<^_QW`LL3'?HIU\;!L`Y>+49X7%]3+:11,7`#JC#;.),S>=@FW;O-VD=F\8Z_K,49'#`-UAW=&(A$1.Q(Q4HS^LN(,;AUB1#A?O M%VJJX9S+%\:C#$^OK(U$6\],V<=MYDKUC5T+"-`A9CNS8)W2UID14+Q/_\/4$L#!!0````(`%9/>D;?>M[*&FL``*Y&!@`5`!P` M:6-C8RTR,#$T,3(S,5]L86(N>&UL550)``.3$!15DQ`4575X"P`!!"4.```$ M.0$``.6];7/C-K(H_/U6/?\!E7-N[:1*DV0VNSG)UCE[2[;EB[:]_\$)2E$B``-^ZG?MA-QX;W4"#_89&H_L__\_G74"> M:9SX4?A?7[S[ZILO"`W=R//#I__ZXN/Z^NWW7Y#_\]?_[W_]9^"'GQZ=A!(& M$";_]<4V3?=_^?KKEY>7KSX_QL%74?ST]1^_^>;;KXN!7\B1?_F<^">C7[XM MQK[[^A\?;A[<+=TY;_TP29W0/4)Q-$UP[W[XX8>OQ5_9T,3_2R+@;R+7204) MK>LBRA'\7V^+86_YK]Z^^^/;;]]]]3GQON![$$1ZD3=%IQ M!7*BM=[2;GM;PDVUITS9T6Y[>H0<<*UI?9W6&WG<0:ZI^<\W;/Z3E='/*0T] MZA5KXY`:;2D0"RTKE'_DGB`+N+J-XE,Z?==U&2WO_O3NCU)G_AO_S3^O(C?; MT3"=ATSL4S\]+,--%.^$NIX_)FGLN&F!2"Q=H/_G=W_^[MOO?E@N__SC]7?_ MM$#T]5^++3A9<4R3*(M=:D6^_`JG2W,>__G]?WS_Y^_?_>UO__'?/WYOLS1F MV1@:;EAI^/;CPQ=_+<`(@R,2D%0@R:\%[/_\IUQ,2=L\/OT@3NP6"V4_MA"7 MC_C:C9C!W:=O3^CM]]_^V['_[TS8_??O?NVW?+O_UY^>'[;S0KJG%>\ ME`\EHMA"+9V!P2FE\_4K M5)(81HIQB/11X_ZW:*-3F'&Y9!T[/-CS<-@]1K7/HA.+,T!(K7-.PSF/Y'\G M<@`JY=*X_:T:Y11J7`8IW/4U0VNB/T['0RB.LQ4K3UW\[R@T1=,6*U7$R>!Q M/_V/QN:X#Y\E&-YP!0NJ&-U30J3ML(;Z2H%D"N:[RQX#W[T.(J?U8E\!!*>F3M>NX"4YB(A1B-13P[ZWJ*8JQ"1J M*=KMHO`AC=Q/#UN'?\FG-$B3XC?G#)O_^I]<9U)^\%AMKOW0 M"5V?'5^CQ+=)7;+#-;7BLZ3TG&5+,++:D!*0%)"8$IBZ?--&[6F%:&J.G2<) M31,-;S9*L@H:2H4JJ:D%[\4`#9OU7O)V3:1,_`6-O="RE-9` M-$-.+1*73K*=AQ[_S^*WS']V`K::9)Y>.G%\8$[53TZ0&2>>62*%MA^FM-=X MD0$0YG,2\4,%=$;F*2F@B0!'97%Z$^SR'^@1='#J]K67.--0>+%XO[R]7=Z^ M)Y?SAQ_)_/9*_K#X^\?E3_,;IGEJ=G@@6H\OI::A='%[944FN+MAI:&,O!`S MC).?)K=1G*YIO%N&SS1)^=&A-92OAP4[+3934CL=\F%O^3A2&8C"*[&B(.44 M^&H*X,ZR&H[2GUV;`*>6!SYWR'`?;JGU2?44%MK/.*/DG(O*/Z/R%<`6G58> MM0ZZ9/'F%9UY:V)S(RMV`CCY2=IUHXQIA7OJ4F9`'P/*5I&?98P/U%H<8.=J M/66UXW4^G!S'SPB#*`_<*.Q95Z+B"E$AA;_,LF$__>%;AV!J8;J+Z=[QO<7G M/0T3RCS35;JE\4E\P-8`&J&$MHMF=)\S9PY%1V3;!-[4"NJ(;RF;VULYGN1![8ZY% M`67+]735LF/ST80-+W4).E-N1U,A7B++)PI)M"%>06;*R!1:!(U9-^!#K577 MP8/>-76[:45CJ-N4^-B&M[M1:ENY.!,2-Y>29IL*;H*Z&QM8LW(71WL:IX<[ MMN6BG,MOF;_GP:3FB$ZC2M#C@#(L+935W3@Y?$8$@/#B2A!A8X87F4H9JY%I MVI+.Z??]VO;C_0.Y6]^OEZI:L MKLG5XGIQ?[^X(NOY/V3J!SKC;,:X1M:Z!=74(GD3A4\=[R,;0:&,=3,=-?YC MH^157F7&@!89ULB-/>1(';8_K1X6'^`RD@PYVH#0]L$-[4P M5Z),W[^ZG;E(:CND(;_M7* MC9%5;\8`$XXROIK-1\,F-RLC3=.RNMT*UZOU_(;`I>YKOZ?)S:@<.KFSZ3N/ M?N"G/DW8450\\-I&@L+Y[Z4/H MV[&RN"BL'TAS,U.%12W9USX!E)3*[9;^*, M>@UK#+WNQ[CN\T#;R!X[I,QQRW$)PYEC(Q5TT\9^)J=^7Z'>R:DOLHU0>0T# M$H\S$;BO])M="'>=9/K@LQ,6JUQ'%T[XR3(A28,`+A"MIJD>&F%C2]VTC@@? MCBL3R8:=:HKPJ:*B[U'OZ3,.,=LQ!4F&!]@&4U"GO M3/.1.!.#[TX>INL52&S!! MI=T(?_*:[05W)6T3;\Z`H5-OSFDQ/.W`7='WI*:XUD9^W-$PFE%"RRFDN:`H M6L$N0[9I-$GOG90^O#A[4S.C`(8R*RI:ZD_HY1#"QQ`^"(79L%Y^S)>?C+%\ M+R_L+WJ_#KW^]982MZC5Y.QX6(PX"1?5E/WET0EXOWF2;"E-B<=)9'_Q:S03 M+V.#Z2'B#S-#2@Z\I4(4"QP\O=H1M:3=@\N?4+]L?7?+CC8Q\1,2,"&B\5=H M[*I6!+5VM!D2AZ8"J,MMD3VFJ`(-FB>F*"AM MD2A5'5RD@\W3-/8?L[0X8]TY&!-3[,ALR/_"DYEBGNIENQ.35XD]EMWO5A"V M!@]M2QHHJMU9GG1:$*-FLHV5A^*@9D]*(DGY]V^^>O<-V;.#RC,?3]@QA9US MF#:8D>]GWWSS#?^?_$5"G"S=1K'_+^K-R+>S/W[W;O;N3]\7?_3%9A`G)5?4 MI;M'AN?;=S/"F4@DE+`?OD5GT52\;%8Z]!QX\APQSQ,M!)S@SO&]97CI['WF MFU3696KC3#"!Y?^;4%G+:2J!"(S21$0K M2CE&8_?,>53_$J$=S=32=T]3QP^IMW#BT`^?DKGK9KLL<%+J7=&-[_K65V,F M&*%MI1'5Y[Q:`)$"BKRIP)$<\$M4EK03H56J/#D*G=>*;#R=$/+?T\JHV2T_]T:9]^A& M2([?_EG\7'BA.@]S1MB0/753_YD&M7K$8%90S9%:J]<`!O`. MH1!G\7B56=Q]3+V?_;[H;,1\A7Z M"0XBD9`W',V7HK`+[YC&<*$RC\/N@RQCZI[L0\#`T1G/CN)@FH]OA1L^E-H] MA(HI=-HK9(K@>LV((GFWEE2&_D&4:$N'+]IOT+>G.QT7\BY^^@8\@R\942BZ M8P@:76&`'C>:"GS0[H8!Q68%`'!>@YK25+L;_?V\^.]ZD]J,#/`R2/9@GI=W M!*;.@18%E)>@ITM_.Y3WX3Y"H`@R=Z(H/Y;7[G_0V#(#_M,:-1T\H"PQWW(5 MBZ[1GCCVW]%8+*_'7:L:);2-,Z-;+W,,D*QB(D%E%(PP8"F+J`[.O:C-Y?%X M7?O×!8'#SBGEU6TMD`YN!"U8V_;J58D/W!3*](#.9K``1V,"2WI,S!]4 M=L0PI)S:/;^1$CPV[Y31[.Q=#@MZ12-78FO;&E%`V[)FNMIN;>1`5&;*DI`3 M@4%G?C3<9F1NFN"G;X'*`\#"T.TZ%%)3@D.9%S4]]<=%XD*D'*K)4@73R2U? M1ZN35;"3Q_>=@"9YM87W4>0E'9KM-N.`ULH*RFI1?S[L6"%$C!RG(TL?S6Q( MS%T<>9F;DH0/1Z>1=;QFI)(;$4SO\B?I:B.F?X@""U?_#`S.Q3]??]T?3L3U MLQA#^"`D#KW1PJ,->1(+3QH6#NB_-W)-B]]^"C,UI[^/HR1A*F5CG]5X`@IM M"4[I.&<:\5 M>E?,*@:1Z-Z5=Y8U-4PM2*#,5!MM]71C.5Y@R3'XEHP'`^L<5\<.)/E-=O4(N4WN'58((VBEHJ:XW1&LR(`K3%2\I991[0:-)AL'%/L3?N>?8#5 MP\.79'E[N?JP0&,%-5*AM7Q-<"#]36^C,#K3+=9&3XD'W/:I*6QN=%H=.[S_ M:/9,=%B*WA0&\:W7RRADB\G8>G*Y MC\+D@FZB.'^OMG8^TV3QF7F_4>SYH1,?EBG=B?IW#))M;2`TA:P6:9?*,-(2 M8-,AQMI714J%M/V$STB.4Y+CG$1.6O@*8MH9.9F8B)EEQJ1`/M<*CI M4Z@6-K3P,\B;?#2N`B_6)*6,I#>/.2G%>7SXAZA1XO-0T4^3D":?!?M3$M@] M8&))%BK_MANWY=_@2Y)_%73.;8O>,_)M53BFUN&W-+4/`9T!0;F/YVMO"IN< M.GTGY0S2\!3$@9-^[3Y1[$9-5RN?GB$3C&K6M>K)%&IQI%5>MLGD), MK5I^IO[3EIF..6,MYXG>9KQZU6HCGQ*LLC1)G=#C5[$=FVK9XX=V*#OLR#E[ M%BA(CH-()#SK,W^"7<$S(U=^D/'12#MS#;DA3KXA;OZ:3>Y&=$2"KX-75PDQ M\C"LD6/5#Q=.XKNFKHDE4BC7Q9;VGFI`H$'@Y@Q&=B'L84EV7=Y1N$A]*6[\ M1U;HH=AB1J*C+>_+PX_Q^@:?Y41N[:=TB)3"TT*@.8UJMHT`"[Z3&1>9## M2$\Z"B\5A<0/0PM:"W\F'58&OH"=OKY]7H%GM9%71?/0:ZC!W_6.QAH]M$]@ MOQ_U,OI%R:;51M?K`K:@T[!?S<*PV>(&R:-OZ4)Q)^KFL]_S$FGTBLK_VIXG MAY@)[-W-$+O4G.-NV!@&V_%UQ!TY;1%SDE"!Y[@[G-SHG]KTG\9Z/N9;@O_EGD7![SS39PXNSEQF[(E?7U#ZVXX$RA`84UI/WY&C"AQ,^GN0I M]`("Q;FR#UDQ)RMAXV?D4=*5CD*7%[D9MXPB#WQ$PDXUK%0DIZ3-")=VPG[Q MXL0>>63BXQ&1G=@7Z7HE(KF:*"1. M7K:"K:?ZI=A1QZ.?Q<]?DH@Q"QO(V^/Y&Y_!R85]A<;G,M4H6N>J%.;$P^B6SK+F<;GLD"#\91F&ZMX M';TX.S:>A&VZV:->2!]R-0[UB_:;"CE[Y_$XCF^#VTX(_VQJ/*.$!`_WU%GH# MA/=U2*%MIBGMVE!^4WOMI%[#48POEYSM6AJ-LZAX!HSGZU>S8*_ MBB%XNG\T;WQ+-]T3$#!6D2S+M7,4\M/=_+-O71RP!1D:E:>@M9;O(!7:<1S3 M;6PD8KVF^XAV^JP1T^2I-J>+N(IVCE^+="@S$9J!P=)L%+2T,1WY50[%H^2T M7T6?X-$("=B?\0/E^=BV:JX!`;1J:Z))UYV1_"J'#7]/W#U=TY8&=&I8R5BV MK4QSZ*D%8^YY/H\E.\&=XWO+\-+9^^Q8JA221NW0@@1*_;;15B].78PG'."M M'Y(,EETS$5C88P846MI]!BF[\F2,D-'O2+! ML9O946&!MCU*ZNKM6.1`4B82([1"QM3,73?;98'H,WY%-[Z+L"J3GO&,S)(" M!6B?8#N+U`@*98>:Z=#W!4:CES4?0:N-F^`F=VZ.XJJZ]^FFEBT00VMJFSW0 MJ;NFBU-^-X-(C8]):EXX+;^5DFC0J7YK?C>R!N98P0*9-\Q:B8JPUG'O"B1X M[+M*A2;^S8?)PLMXXD/J+V$6"#^"3T9[W=1ACTZS@$XJ MW.HS]'KO@DP*`-PAZ[`G]1,`O\.32(C$0B2: MF0SES_)KOAP7*9$A.J(/L1'%WT2I,4%Q)('P>4Q=1<$P;\,6.Q)5(%U!4UV@ M.&_:8X8[WW?8A<;CVEOYY(\;`V8)'.DLQ3$;)T,#CP=2'75E-%%[D:R/5K`7*^*0F-5JA#\R#*2>C8)DU MVNFS2?YOEJ3B>?(Z4MS'\UXOFPUU4][XJZCI1;VJ4K.^CAEJ6F@_<;C]J^>V ME)CYDYFS5!=R3'695?K]D;P;CWP%KS)!B-S+\?:/[T;>ARDA,9471?R1/VH' M=&!Y-+LN&FA.C+I++/7Q?*GW]+?,3_R4/M#XV7>IU,OWU(V>9&1%N.3FR71C MKP,N'V_T'=:IO75=[2TK:D^JMXN:>IN1+(!%[1+UD*I]JDD!R`"XI6\ MD%1^2]N'D75$``T=^2+NXNC9]ZAWZG,W]9]]7K')MEYA%\R` MK2'M=Z&I?:%@Y0(-N3B0-QP3,Z!?DA(9.6+#5I5PD'VXG#_\2*YO5C\_D.O[ MU0>RNEO_K1<+Q`H1=A>`MEZ*MFA!/7EN*D/7#^A)$\AU MU%\YF)^\!EL#M#$<:6=;O/9R(E+O9,O^_'I4$[:]32,2EWL;GC>IY7_FOW3Y M_NZ+_7T\D*C<5:><$5]3R3&U@'T@9*@%3*U+KWCI-]=7A64;+<\I#)3K<[;R M6A']RI]1N"@]U@OF8S1QA]9[.`&`\PNNHWB^XSDS_^IYWU!#A,="UVFLF8+* MGY&:PGY$(+)!"HZS-"3G6*:W!AL:Q]Q&Y<4PF64*/?;?2_9+/S5^?M&.!\YJ MM%)8U\P2I')QQLM`AYZX0LOAD)B8[L0="[\BRK\TY<<6F]2"!.1)2N]+<:QW MW,97KI/=-_;4(+HHZ<0W-H%@'#>Z[QT_Y*>L57CE)_LH$?`4E'5<<_]#9XKZ`89?ZY# M5GX@C-I[)SF.%U;.%XU_B]^AL'2VV\/'\GWQQ&@GX)N2]V<0("ARZ<8F"LR, M&PFJUH;K,4RM>,Y;[E1".OEE;]>PL@UF:$-OM0L-318$$'E3@//']Y6`;EF9 M"6TLW3L_&%5>UYV\AEL$`++\WWU*7^,W]E9>Q&M""!9P$MWB.B<`IL::S\%8W]-Y(PK?W7 M8X#7&,OPF;G34>R;M\8S1(;/RI_2:JA!_",0HJXKF(DSTQD#DR?_6COC(?1* M&B2NHR-2Q02O2>YBNG=\KPA:+C[S^`IO'BS>B=O%-KIBQ^.M&.Z&H9SFV$B. M1D0W9$V"^8T1B#V308'#_;E#?I^-FM%*- MV%6R40B6/I01:GB56/CG=\Z!^WML?>PW<<:8R7<>_4`DT/3WNLQFP>>.&>Z. MH8HLST(Y.B$I.4)2P8CH4>!@6U+2OJ_0[N2T%ZH#>12J-S=X56YP=#L2J+D! MH;]HHT0Z.I)&4\"KTT+=WU/F]YJ_6S1`A,=OK--HJ/_*?(@<$D'AC"[4E63$ MS60@\F\4[&CIRIQCP?L&A%C.RAX?Z7;"4^!+91*][[$WS(+MP_NQP>?O3XN'LV2%! M_^[0@/^[O#O4H9U:\O-Z:_R)O_M;YL>T2(D2657,W2_SJFQMO`UF:!MOM0NU M0%P.+(IU2/`RL6PFL]-FXI!9(D%UH=*/=K;2K2,+NNU+FO\8W,O(6:"<7]3AR*?427K_H@Y-FL=`\(EXJU\Q6=^D$0;+:/&RC.&6F8R=5 ME?BKJ<7O/0V4^>^_/_40O<1(.$IRQ#DC%:Q"3@1>T:F<8WZ[9JA)!3>*S)3A M]^>(111)%*1S*''YK"`=S$<82'RT#D/?.<"]![&J=:OBL-/,S4C1^0P*VDW< MA;&E?@PWP93S;X0+S+:;4:J4U?0HJQQ2 MLC"@J`Y*9%5"@Y(ZE#;8@F'UAM8$$=XHW$#Q]D;,T';5:A<&B+[AC[>;DR[B M[6\R3NXFBK\\";W[)>VO+_2N$8$^H?I> MC9<,$&&(.9MVEBFCRK+#!8;^:2/11DV[IH''PT?]=BA"WMU[`+5C@2H)QEMZ MR!1H&QVC5;E6J*'-M=T^*/,Q>5.&-8)$9(N,U#8#Q7$B(SU")3[H11X3KGX@8Y)>><+ M@9Z4WR[6C.C%Y?UB_K!@G_M6_L1^(")&.+^]DC\L_OYQ^=/\9G&[?D#GMG31 M`$9^BQ5B@"=N16%7WG'+U#NI@0$^7SM;?X-8'BL/\S$H#O4&Z[Z]7'U8D/7\ M'XL'VUW`G,]/+)[!E-4H5PMCSDK<)"^Q5GE-3% M5/X91$1[+?QVO;A?/*S)XA]WBUMF]2!D=70"P,USDR`8OC6O`$X>%V`4,[M_ M3``(O?*TLTSISOZRW1PA6%3`@N::)REA*PDTW',^Q@($/+K+]#X$KV[?2A\9 MXY6Y+??J3__&V*8__(LJJB*JZ/EIQAB'V?V,!QLOLO0V2G^AG0RP.5YHXVRQ M`[4LD+S8N@O MXBW4=XR1171XNHGZ$`KNQ`S*0D8>SC`S3AZ=X4^?F2Y8E5_5.`S3``D6 M;VFBHF8LQ"!N&E85%E[3SRFY8%1^0E$1R(20BX\/R]O%PP-9W2WNY^OEZA;D M*M&8*TP"(W6PR=O_RG,9LWUW3'1=_2L@?5M7#29H\Z"ELM:4,-OMG/C`1>;! M?PK]C>_R:C-''*1`@MD4M']8LS:[:C23=P`]?HSZJKA"$_K,5)&;8H-2[L;4 MUMBWC6=QZ?[N='[\\&%^_PM979.'Y?O;Y?7RN@YVHWX;>6>R`-@NF+<92]5[LJ\484T,J[ MF2YEFZCC<,3:6_.M#$M;U.&GYK>;R`F3VRBER3IVO+)!765I/=1X1^10^KWK M7IQSL<`S(P+3C`AY$'VA[(_>)RP0X7%S<+-):C%^]K M34HWS%#U)RZC)$WR)#3_7]3+>U>>-JOL?[CH/1VT#>N_7ZKFJ8MJ\]1JVUS, MAY>!V,>JN$/7N8V5L1Q]>A)ZO^`OH(KG4`\B.K9:_[BX)_.'AT4]*-:;-B]R1;:9N/P?E[CU MEA(V$R\P[1U]$]%5I:7-\U?@9KV#G#8:<1L\`,7HFMNX=#7*!@BAS:X)S0T% MSJJ-CT[['F$VJL8?V*S>?RLV-`SY[*M_Z% M$7XC4C>8N>4757?\!@K8(@?(!M>VX+_D#)K%T_K(S_T>_K,$> M\T$;L0%V3!DLO:L\(LRQ'MUPQ+9N*"ZR25'L/AE&&>MA-#NCA[*?W??#2G`J MV!"'9P?S?_A4=GA7UEO[S_N#B><=&8V9Y"H;6X77%/'[9]3(>(QC9C M@3:42NIJ+SV<\),HW(_9Q.F_E6'HLQ$%+-=9FQLE.)0Y4=/3V&@!\P'+G)2+ M^>W?R-7B`L^YJ86MM`I;!3OYDUP>&925X/A!K0@9=GUKVX(-6D&W4GO.=/(2 MX$TQ\DMR3Y]IF/&[=W0XX5MT7H`LZ7H3;JXYGI3'`N8*"]^6MQ^7#PP45[@,2J=N%MK:NPP@E7I M'2(#7(,*VO3HZ=16]D5L90R^GF$2N!H/`H[LD`2NPP%>4=HT";Q@0M2&P9:J M2A%G-%K?A.?,BCECT.G\OB<]=%7CY]#0FKM&3>V=-N_3LXT"C\8)D:,QZ^SF MKV.DIL]`)Z^/4-EHN12>I]I#35L@!*N28$&SCC'_4'`F!T>MSWM1O%Y=_NW' MU9>?7D$8VR3/_:.=CL_?W`>>I>1*-Q`0_?D"J)S<00[ MY-"VPW8O:@^VU!LS MOHO[4 M/O&UW=-]%(M:_QTMF1H/M-'24%CSM^1067JD4I;K,DM2=A[EH>9-%.]$]C]F M*]7V48T,DA()-(OV.2&9H`([&QG1J>+9$@SW::@;C8OWW(0("U*M'7?YD9V0 M/BSNR?+V>G7_010916-++-A6?S0RP#-];031XOK.B=/#.G;"A+?$C<(>A1+: M\$%;$0.*S[DV!R$"AE2!,-L.TT]K6%>A!1D6QNUA4ZQ00MD6.[HM.!FSL>E) M].)FOEYN$D_.7YCM_W MRZKU78\K+=B@S4TKM347B0.\?>00I`J"V=28?5*SPXH>%4"X[+B(T%OL]D%T MH/2"AG3CI_PA68?2H%8X`4-E-I0W!,J.K"L>5N8(2(Y!O+E$5,%@(+K%3<_; MB_G#@L?(/O"D+ERGF2X4"T^YV MWU:KUPU137Y\R!X3^EM&PW3QW*>=@1H/M([64%COF%,,)7(L8*/NL6B:D2N: MN+&_YWR'SI"TL:/9H4>%!%JX[.]EU`C`;F,T-!G($[;SB14Y'R\>%G__R&]< M^*,21,T%6AE-?Y.BA)Y:8"ZR4=:!_)K_%RR!9F22]Y7FG.C,F1T_&QDW0Y00O7]X'L]I)Y)VP57V M2C%`!MG?QX36IHX^,LVMUM0'B[`.3F^]@Y&F@1$:>VK%S:WM>=HQ@75`Z6E9 MU7B@;:F&0F47%#QB.#AIZ"QC&P?:-16"EJ>3&OI%E:9C+7VY/%/K9X@,ROJ9 MTEHKW'S69:*AD\JD`MCEM-B/]DIS!326SHISM9;.#!.::KX]+9\Y7FA+:+$# M5A5]7XFU'(M\=!;5EM/[E>>&MKA+=N0/GWQ>!5$4O+_V0S^E-_XS]>RLK0$B MN$(.[336/;X")F]J,2,2[*V`PR.TXU&,QK8:\VA+S8S>-8LJ%,O9)[YV4/KPX^_E3 M3*F9>USO;&..#*1QE`6M#39&@!(.2S@P*:'1'5;')!9!YZ@>E)VJ(*>\0B%[ M^04W44P\RM#OF(UEOV8G6>(7NQ'SW4CX;CC%C$@Z2MD*L;JGE#&FZ=\GB8*L M]]2-GIC[PWBEY_G=`"&TJV%"<_U%DH`A%:!7XE8,1"TZU\"8W`H33Z`]$'`(CWXF2IJZ0S48^[Q%)XB-^ M)+;<6/K41KP=!5BMU=[7S2H\T+9:0Z&ZWBJFZZ[AJ8.YY.K(/U:7S@HD.%[^ MKO;YR[&E")SXSU2\&;,+BG="#9:1W&D?3!\*SXC$)*)1):[\N246SWK,?>$5 M*-]>U/8%W%P.(`;ZK.@.>"S$/%"1W-%8++>G?6U%!VUFV^FM.84Y!&$@ M1,"\&JMK3RQO5O/F)DJ2+XOF'YQJ7FF/Z2^!`YU)-N1@L[K5+;BFELZ/"5UM M%DGJ[YR4)J:V]QP*RJS65G_.;6P`/V&50_`$FH:A!XV%:^8CK?$Z`YF:\V_I M2^6!0AR%[$>75FZN>AHJ>_S0EJO#CM2U^TOE@0\Y18)'^$"W`9U]ZRH)1@;/ M&OGD1U1W2[TL8+KH9^H_;5/JS9E'Y#S1VVSW2./51MCI9,T31.T?QW9##G9, M[;@7M0-9CH?;J@(3R5$1B8O_26(COPI\:,+48VY&R+W?0'B_OO1^]VPK7.G] M)E#>[Y"L:W)J[8093B_PAU%GCZ/8X5H\#^.OPRJ/PUJ5A+ZPP``S0OL0@^R: M4H)6&V+]8`^!>@'"45?G>[#*+8_937[^E#1^\ MJ])*L4Z=5!Y6YN`(],5H!$=-!"/T.,R8V-#):$$&)ZK%`S3>+BNYB9R0*Y<\ MDS9\.CY+&\"AZ#`5'D^BRS[I1*#`-Q,=Z-A_!$YA$$NLE8>0!@H!D87LS%26 MIM%^GJD%[8IN*!-X[S)*TN32V?NI$_C_HMY=3/>.[Y7/0,6+E1Y%Y/O/`V5# M!]BA6OIRCI((G-SM++'.2(YW5GUA+7"?EJ)':7Y'V*NJ3LK1%%E?4AM%8HL< M7"_&AA(KK?7N/0F:-]S#O]Y&9*.-J+9ZLHQ`_(>GN"KH^Y+Z?4D]?7T/M@=^ MJHW)';]S#IP%V?+8;^*,>I7^IGU/TUWF@#]A=]H9$P^RS,_+>";B02X*]K';OA^1.H@N-*WZ<*6B\ M*VB\REY9)*5-FBT#)DIT"_'^)0S!W@D/?TC(8]Y1CC^4S1.I4I3/^0:0*MNMY MX#3-8K.A+G^@5"Z45_7@KX*9]QCXLN]03S>DRQSPSDBGG=$IEQ)A5;&(ZCFG M2/'[)<-LS5&KQ*?TL]_PFCH;ZC$C'9`D==*,9P^(XCH(_97N,F3HM728`#($ M(R^.V"KEY=`\M(K?&I\-K:;!X[/8[H].I91WO5R5Y!>Y/%XY<0!WJ$#'MN&0C*J$I?R3+T M53I/@T'GY*'R^8L3>]4E\QJKLM=VDF0[^;NA')EA9L?CWPRTFZ9Z*I^$B%EJ MBJJ3+C''! MCL:6N37=\8+4=.RV`[H[)H&'K"-2P41*5&2=IZXC\8W&V`3N"HE-2".25#;! M+5`A*!(Y#,EL0!8X\5G=2#WQ)-TZ*7%V/'V&'T4C\NZ;_TVBF&E+"9Y&*<]! MB",O<],-!!+]XU2CF4GI97)28WM/8CSPD!2A[J!-U2$\O@&W36=>FUH_2926#ARM"H7<,NJR8OQ<4IL1S4@JBUT?7408.\X#3 MP440_IXY<4KCX%#IPK*)XMT@UZ=6R.%CDW9[H=-F)::3SC\E+B2YC$-^/:M( MFPUFZ)*CO!^].W],F')T4]M860LRZ-!7&ZTFQ48%#/FU@,*42V1+WN^@O&@C MMW8J+GJ*J7_7#9$(L-I<^4'&\P&J422C<(T>`4RO#3U-->D1P_GYH``XC?D" MOD[J00Z_LB[(J5XN80B@6%)T+"[73!'/%@PRCWG0?DA<)W"9)@*HZ;FA@Y[:1,_#U"^^T`-ULU@D`BP^RX_#76Y^@9=) M1EEMSC7;7)R#;$WY0)-"F_RA]NY<=JIXR1$Q*3#+TVD%M\@K;/`GY`R(O(BQ M=FR5I4GJA!Z/DIZJF3!*3U0-/W=7UU- MF-%M5<1E1C@D^97#XGOA:_&A^Q4UJ>!#P\Q\15?1SO%KIR]5,-$(%53@UXS. M3LPKH>%U;H=/J@WAFN#I;>4O,C_@_MS<\T1WQP^4'\NM+JI5*$!OGI5TG;-8 M,9`4(\FO9:\, MI0`UZ@H=!BA5K:5*R7#5T>.)4)! MFSNU6'7S(.N(T7KW#7M@Z2;)(B<"!2@7#_6IAG#Y:UBGYGD9PZ%QN2([PZ$$ MA[(::GK.N;486:TEBDVWMGP=K6)5P4[-897"N]VT9P,":"W91%,M2EVM5XU6 MWRF_CI%>JT./&^^]\4.Z3.G.+'W`%!6^N&^53NO8+PD77XI!V#P$<\ M(U\YT,]IY@2VV6$=$,.FS-OM@2V3YA@T.63`&<4=6,`@<=@&:W\V;GS;?$7= MF+)?+L/BOS+OC>?`7=!-%!_+MI1W>6;:=L#I8#3RD/M5$PC^>W)1*U9`"ORD MF(#]4*0B\CF(G*12A:F2.@&=/C;JEI4[\\;/$?$FF$7YMCSEZE'NCJZFV^@! MTXGW99F2F.X9(2(>)/+-B'P2[589R\MG.]V]935?K6'S>+5AEZ++9!M>EVG< MC.'FFCQ+SGNF<>KS-_!Y!3_KE+<&#-"GK4:J:LEHQT%%_4M,"66V)-!F$L#/ MBVH.,TLJJH-/'O%RDNWUU?)R&?+'=9XR,[0Y(-,,#!;M4M!2BW6)EJY\),F' MCI5SV>5FQ)2*Z[S$HD?W4>+S3#\V7KQ,=*-X'\72[@7^SD?4_DK+;OH`7B/D M]%WQ'M-EDF1\GT5W+5N+TH``VJ`TT53W/GF3B7R0Z$Z'R)P8$^"S05P\$H1= MFI6<961)ZM!32\;'A_<14W09]G>5'[U\!5Y.M+I/#W%],GA[^Z=1C,+9HVL M>%9KGV'OD, MT?6^'N+S,.1GTY5S\8K;4?C4+GOJ2[2.,X#>>W;=E2;9)&QT33RE9!(AF?SO M'!V!E=/Q=V/=)+2CW\M,])7S!Z<)84YP3$/W0**0;+D2=A+R0H.`_]>C._Z; M/'3%?N^G6_+HA)\27I-K4U8,\L,D]=-,/&?]BBR9FQ(DT7$*V1CMDQ]ZR4E9 M,%'L:^L\RZ>M3S04@3)WZ_"K9!K[#*F;R%8#I^L0CV09K'@IFU>J(COG4`;9 MB@Q^AFZ3\6EY5;'P0%)_EW>;+=I]!`E83C_4Y2E_(Z)$1U&*;]J M8C_M*4.?'KZ2PD*KMHR*]Z;\D.CSY`[B!DZ2^!N?BMW=.?$GFHJZ2DGE;)EO M%TF$$10]0_E*@Z*#Z(QL_:QG&(N_EMPZ87QN%;*5^A1;!9%'L M/_G\\^5KX>D7HK!;3"G916&Z%2P8T"0AOV4.Y0QI^"`K\CJ M#!7[X-0)D]H4![Y'E;J@VT@FL_-?'=>'[#%(+WO8GOO1#7UO*U]<5QZO+[NX MU%:H0)(WC.FLW:87:1>51(RJC1[3*EL71.Y,Y9L"XLMCG@E3)A4%Z8](IWT" M16="UT+%%(DC7DEUI31QS"Q;+-+19)'B*QY/$82$5ZP0.S>X/VFRLZ_4LS34@L-YF&T33IT. MP.<.>1OU>^?E@\.O,)S`^.9?`0QUR:^BY5Q`V)])^7<4F=DV*]^I5@YV.:_E M(>T]?#,DF`S\',6?EN%='+DTLEDX]_ZJ!NW.<3\Y3\S;+G_#XXS9?A_X-"DH M8#_:6YQA9H6W4`/MGO+<73E,LI/.B?\W(^4$QU_*^YI\#E*9!)E1G'[?2N]3 M'/X4NX+`R@XICX96>9`I1XC_G;@)>G5C$OQ4HT-RYZ"AUX31ER'A&/A_SN([BF\@) M^44.O5CO1DU$"P1D$\6$HQ#!$X%$ M%%:,2DFU28U2*S0PVI#ZZB[#'=9$%=9=E:8#ND8`;9DG:] M\!<82*/9'LM>VY>?Z4VURUQ_WNJ4/X[L+/)C*SS$I,-Y,UUD7>_<6&&$/T[< M4OONW,U(P#T7!6U&9P@V=$;&>2W?YT;'E";-\2&D(%6PNG"0C0_1B`&DQGY* M$B<0MUGR$DL\?*;QL^]2O(\'6_2'S:6\"A7.$-J=8(-S*OH$V.WG@O8]>NY4 MG_B;1$H:5!X94-2L!^,91!",$.$1T7GH&038+/.^M@V%&TE<<@)BC_U9 M,80N^[%?)VO=C`ODTNLNIGO']_)>@NID&*W.TV&"-L5:*IMOFO+111=,L(S4 MX>@J*,J;8DH'0I9"=Y*$(NQMULZ<1C93@V9J</7U MUYJ+Y"-(/@2%Z;)8=E'3'XT54K",UMJ69VA(KE(!OB2SHUN6Q5L%GI%D<4=BHX4AV*N"R6XU>8KN3VR=7&8Q< MR-=6ML+<]O3*&-_T'H#P/.;B8&%O]T^`X:W]*2UUBRB;/,T;3U'`9EV_=!1N MKPTO6-GP*N3T/72KY\TB.*N4AT:%H<3%_LE01XJ, M`RG]2;)N$&I)4N-C"3!#:2([6LNH10!_*7*ZO/[7H.?XH`VF`<6&!<&G%[5A M[SLGHQO<3IMR><=;SC-D\#)\%F*S*(W:C@G/=68#E88WF>=Q8!R'[$X4*F2T MU7<&.5=/2B&BJUF5/%K>RM;0P&L:X;OD%U;=SM-F./%Y#8V4&^H?><3(@4<[ M:ECW5>E)K$)0"S*3[#&%\N0'X,!>'D(#PL'?A_&[CR6/+!I%W(U0H'@)5J.K M_?F7N`82,`ABZ-V(4@A3VP57;\KZO^LR_U[>R??B5(EK#T$8TD=4S4)F_G+J M#'YP):`(NZ\VK=K!O!"B\1RHBIN:[TR[?E'=X9'5!ESW3+HCE?>7_(UED?V] M=P[BO2T/#+!?QAG;I\!W'OW`3W%71!U@3TJMYEC<`];4W=CGLRFV1&'#L-^/ MCJ`)#9S'7A,@.0CVCS>=H<$3;#JGS^JD-WR8:=`@3!MMOX,(3"-[6H9?3G$@ M$;E;MCTCA%_J:)%&8!KHMQ+-(_RKB<,8D*R06-[V\ZWHG_K:@C$J-N\3CZGA M'*%D3WXU5*0]-5[Z,J@@\_SPJ6KB.\5O>LV'(MC3;\>,"@,5UY=ENF61_#$_ M2_X@Y30GASS`!(H)MJSKG>]8-2V'J#,T"DN5QSS1F$?NCE>P%*WD$U5WB5O)!&NP:0'W9U!3J/MGD+Z7<+?6R@*XV=W&TIW%ZN&-,DK*E\G[;>\ZO MZRY%"\WQ0GMC%CM0SU"3`#,B0(2,E$#D5P'V/^C\$MM/;N28&".=FL$_.&&V M<=Q4U%2[=EP>N#M\H+M'&KKK..?5D-"F&DU\E0(U'09)&["AB MJ*.8,\U!B-WNA$!Z%$(%A6`'>@-^U![F=?"3OVK?;'R7E@*NE"K]Z^-F)-!F M045;[1F[&%=5^T`R-20UFRP.?<9BTNW#(4U=F,C"@#5CF%JB+J,P2>/,Y;Z@ MZ!3YQ#@EL3-7>AQ0]JJ%LG-&K`Z7IS8)@$^AFWPRK4;7(IB:`6^8P'?3XU5( M:.5]0D7==G$Y6X?1\^4+R8QZO9@B`3* M(K31=LZ4Y7C!DU4(('D;E"I!E%\!0&/1C'A0:\ST&*:6J>OB<,Y6<^U_YC\I MY4FK;C2(H*V8CL9S#KP^"584HS':,!NJ])$8=*:KE2F-+)<:"XY`C)79TJ+` M%891,:$J"C.6<'ETXS,&8+.]SWR//Z&8AJY]/AZ-S3)@OPXQ)1A1XJ&)+L$D M>"N4K[PI@(3*KEBL$]Q05+G!.+*%)Z9E90':L*"+9:GTI3:.A>GTTH.R?4D9 M/5+6V'$.7VS.W#"TH``LO'G%&^.Y?EY;;Q]0_@-;834]2KEZ6_LRW+S0-FK` M'=15?ZSBYO4]<^Q"7DYK?Y[IBMFILIBV#!G4SN6=T2K[YU5F0&>3AY9"TV[D MPTR*RS!>86B].LQ=J?Z2I:>PK\5',>BD.M\&O MU9\9J,WKR*OYO?@^YJUBA_"(SO4;'L6&:[/U3A1Y4VA!$-T'*G<`7E9O_:IX M9ZB<,*3F2K#^_J<+6I!7@YWH5SD-N7Z95_7++4UK&J9`!5],:E#R%3X30U5Z M3`@>]0U",I/9C%$:;9I\0?[K@+^/#OQGZK%=V1X2WW6"XN5>EC!=ZH[ M_%]NM-MG[/1_'(_D[6%WE:9^8M@!)X#K*THFWZKV3XU*\VL`@4Y;ROI4/%,,9+D0P%-2C<"W(*`9"0"[(_`QC1<.G%\ MX,GESTZ0L4-@P@^H_-CZZ`2BP'*RI>QT[SDIY7^)'@/_22Q#G$LS4<`FW<91 M]K1E_W7RD?ST6-9UC?V$3\`EE9O:,'%?G:Z3/77]C7\\.*?. MYRB,=@":]C;'*FQ83+*26J59KD`0#H+9 M-%M3MZ]2MZ%U587&4.O9U,I8*U!-7LI#%*8Z=<[YW8!%8KWN05HL70>'K/8W9@25\ MNI2Q(%LBD_;6E53K-`&U9AZ0V%5W,8@.IH.0'&;\()=UPS"DA:&UA`E"I'F]O_! M"9S8X@!K@`B/A:W3:"ZSP@,N(!&<5/M1=RZ?T!<_77FKDT$]QS)"&PCCBR#S MWE-JI*C:[FEH-Q&VY5'88.^41J;8JU)<""#X)=0H1*^WM#'_TI.%QO@UT5ZF MWOKJK0"Y0!I".`U\!3N,XVFK\RB[T;VU!38D#6?4U%HJJ-H]$_2M]S"T-OL& M;;=.`!?D?E)AN:>KDOSLXZ76MI> M>C@O]D!VIU%I@MT$CL?=O4(?8]P>VC@YS?/F?:=ZN#MM>/$X/JT[8-11KR;W M\XK<%\CPM4@O2J?TFT3E.+KL1LNAR5'X`1M%SK-QS.RP4WPL`PX_^P;7RXT M04+=)C12<:O5@UP%J/M+&_QO`8"7@ MUMG1JVCG^$T]GRVT014/+F5\0F&+C,P('TU^E>.Q:^#ZM^N@ABM()N_N$L7I MD_-$+9NEU<#`^GG6UE]KUE*,&*_%H/UE;?NR__W=[)MOON'_([M\,+XF;@KN MT7?B/(.9FN-OHY26N1;1A1-^4O.^5A%H$$%K7QV-YXPFQI8']S0B8CB0L`Q& MU7>Y[(0,!F_7NE9>-#(F:BRP?LV-;2,[)3@.'_]&T[*NYNC?(&Q2U_)Y++SF M&[!V=/S,OF9'=KZ>#P[O3<;#:O=T[QS$R9UW4O=#U]\[P3*\I9_3^RA@BWA: MO]#@F7Z(PG1K??TSS)S01F&@G:L=$4^"*#-R1#TC1^3\$%FBYZ%"/@')9R!R M"B+G0%6^<:1-^X4Z,:&AZ`!V15VAKH3C?KWNBL$NZ73*?[QN/T4E3\,[*+697HN> MN6:\.[9K(N=X;;Y)OC-C*!6.^E5[)XJ]T:F2[U^]>U(5E5'\$S'!JU$<_O-D M_HFB.F.-R`2O8B*=>:_ M,76]>DP`^L2\XYXT5OBJ/DN2:<`Y)I(#BAQVCHQP;,5O43A6PV]&E*5)Z@C1 M1U#(;7#Z$+V?'XBLLM2S4[8V$OM/\X/W$E\ICL8[KSL]TL;V#$9RX0R\9'8?E/L:#Z:X_^>\Z6$T1)%M/W MF>_Q>M8HY06V'D$?L]%>FZ`3]NG?!S/.IDEZ[Z3TX<79VV6XJJ#ABA:/Z3]-2O:<1M+>?Q9/H\APZNW10%32HA]1$35/B9YGWB2C= MTYB`?S=*\@2T\;9?`5E-&Z5(M!N(.NCDD24_I*L-?[?DIW::OPD2+/;31(7N MD9:?CB<(G>(4Q@2L6@F`"S8H>4D?/:B#=9."A+I?/47/7WO4EP+`?CCG>_:K M?][0)R=8A*F?'A2O*AN%O1$4RGPUTU%OH@3.TOE!U/.RKM/P>YW#EI/2*)F[L[VWN3"R10N>EF-+> M^BB_`"4<=D8JT"BN0@#I!4\ML>+O#N4)5!BGEN.[.'(I]9)KMBW+),EXZ'^U MJ=[1FAHI$TQ0MLN(RG/V+8`(AR(%&#]3BTR/=9'I@<+<]:-P^I2_YEZMA9WL&FA;?)P^Z>J=4($:A*%A",G$ON,%/A)CDUD-"0SDL]1_CJ- MR",EQ3SH[-W`_&=D$8>:$[6LFII/2Z30M8%,:6^1II61-*&PL`-3;J9'T%C> M3CQO5+/(#"-D$C5;D,OO*I_H!75XY?IK_S/UJI?FMF;7%CNT=;7>C<;(R$Y%B+0D`+/R1".%-6)>)C]2(?<#W`/HIO$6#^_,$#=[X+'#Y\9(JXI MOLU_YCKBVXJ.D+]E!_K8?W92YH+<1JEHV3`7Z7EM%K\5?/)*YJWTU",[Q=`9 M*083.1K<8AE^G>9ZTRVPD-&9:D4R6WNCQ@-M6304ZN,Q)R7V4!F'+B1M6DD" MU^]MO&BDR95(8.\O*A'8U>8G9E;XFK@MN7"2KI6TVW#BJ+_72GEK4+^"@<=& M"QPR559@07%\&Y/LR(AL)"4*S7C=HFYA"\+>&1=':YR<)RKG1T2[GI]&^$!S M,\PH5CME"6E(6"\@$>7R=J/SGN[92)JW1!&QDIC^EOG\/O_Q(+K*^07Y,2<_ MX>37>LXA2PRVX/+V%!<39)#)P]>.RU^Y'/2Y`JUYHXUH,*05-]/7DF-<`($F M`@Q,FBM)VY2D>;!W_MU8RL`DMN&87MI)/Q/Q M=P0O;2R7[8ZR[%ZQ3;.%1]+UW5#ZYMV7PQ'P@R0@I$_,7GE@!("?MIODURQ6 M6@6<6NO<1P1=B?#$8C;5NY3&MG59#0SVEEDL175MM#74C"FA[W4R7\D5U(2JKIC:^ MH(;0DA`X,;'G$0M[T@0/)2IY>T^5K&B?Q9_"0E<<.*-$R53YN,'%P\S-&H2$ MO$4M&ONA8R:C*@DG@+VCF_.B)(P(JN;)J/D45F%-/2+0>&8+C;4:<665'!EU M+_*2%\V:EU(J*A\=`[$Q%262V+\4(5F0<^2X'QYB3H<4`Y"RV4G?.@&'YRY"0"@+R1(`-&:7J<0#L1]23I")KI M`',E3%A/ZU)H$4S?Q/.X#NGM6[HA!HB@#Z3-_GPX67)OI)C M%YJD.+W)K73R)3/!SS3,>(GBD(+D[G7E)(LCK!I+;^]]\=D-LL1_IBL13"_.GN?V3-^ M1A"ZUO/3+*;745R9T2JZ8880-,IA2'.]VG`)1BIPA`%6M1R*T/A0=-(*G6>2 MBB@8TI'09E7%DV',=@!98IJ-*+>'#HRP37WRR*#CJ[QH60V&TF=SQ3D(6,_ M";$PY&VXIL]UR]=Q3_D6^8$O`A>W4>A1+W-3_S'0W,LI,IXL4,)EQMG078N4 M;S;4Y>_=JAI&O'T\12=2LH\(C_EUS<4K0(Q^OYVXC';[+,TC3"[_@?.8 M*UF$Z7C6_-Z2I6>.#XELG[@SY9C&[)665%]+]-".A/U^=)?[$F#S^@T`O#,K6%[;?%C41?-.FRAZT3\X(+U.,&@/U&C.2O MP$;P$G23O0+_0;M7@WL68K:WCWPZ4IU/O%A]K8Z'U196=\"M#'^-/DB[G`WE MG6AF0JR'[FE"V:?8,O79X:I_P`F1^C96>S:X+BIF$GY09:[7Y`#UVL&3#:CF M!_%#DBQ6\5H\('OIZ^,36JD4@?JWNC&I7&E]= MO@8WQ>95HR72`>JYR8@KFW.>)#1-V`_%[_*9[N*(SWWO/VVMB[O9(@>N]&:] M%\J0/9=8B43\6/Z^N&C)$1&)"<%MRU`[4!`6CT-8G_IV`].&+#6PJR2;%+"S MQ`QUYULND"UG3^/T<,<^'T^F7OR6^:JSCZ)*ISE&N-JQ%E0;**H9*1"PGS@* MX9>72!`D&?:B^$C9/#)HI? MG-A+KM@)*4E]M[,I-T&-QJ8;[8.1%B@Q$8Z*G.":D0(;1BO?:0^*G&YQQUJ2 MSHL6$+>"`D5P!)1B/*Z.N!'KNY,+\-Y.D/$\Z)PA\QT:0!V>):A@ M=H^Z[XLD$IF"1$T\/B_14F]T\Q9-)YDB&GW>0J'-#>R.%Z1R1[<=Z!R&KKD\.YDA'2@%-7Y@!'4)W8ES>AE]D.K2M66\CYG/T3G6DT.C"><4 MU!A)CA@\;6V[@:C@<5:'#P6W2V9\91=/D*"3EU95.N'K+EUH6]%!6YUV>FL) M0IHC/?E50/T/.M5M^%F-='@;+K!DP'F6;J/83P_SS^8=7%70X(E]Y]34_?,R M::\<2G[E@T'8SVIS#?2A`A2>N:ZBG>,W]2XTR^BMX8'6@!H*S5A.#L>G\]H^ MG5UN]#F2J1GQ)`;VWUGL)Y[O\I#`![I[-,]P;D4#I??:Z6N.K1Z?=U:!R*\2 M#(\J-/Q^6IW8AF/R8U1^L77)$\#C@Y(3]:?*9B30:E%%6^TTDH\[UXJ`_-=E MNVW.\(T88`RSD`@>'>4BP27!WO53H(#U_U1T*2QR.9P4XW%Z@MK/9>`.-L,C M8;T^CJ$2&;0:;*/5@B%Q^XDMG]/"651AFIY-GYF>WI6U0NT<114TG%Y44%/G MP&)@\:Y-98LGO73L0P$QL\\MKH,]UEZ^FJS2H;2`VD4XO'FA[(1(^ZH5EX`/9N)OZR! M@A]M\NG])X]N_-!/:=UH*N+<"D!PA MBPPQ*&]L)'I+\L1---ZXCQ4W&YYV3##BN<"^\4.Z9"^[Z8!GMZ9Q>5MT96?N$'$#=^:?DXS)Y@_)FGLN'8=L$S0 M@=:R,*)7EE%#(MD#%%D&N$*#0V"#88H>R"%=7=2T+=448$BG(-O0A>EI5R99K[7I#E MI$]XJF7;L['6#EJ@PR&PXQ3.[C<7]/&LYTZ-55(;1"E,N5$?OWKXJBRD[4;Q M/A):HU`?*#R6D4C_7506'T+#&)V->TTTM=YELUZ*&K*P+P?4][4^CRM M2":_^A%ALYNFL-D]Y<%NYHC-=U&<^O\2JH(95C_RWEG?37:=!MJ_Z;X_M7(E M,AA]TQR,YN6QQ.6>.-4]V3?N";A-[RE+9I?& M'><8(*!89$LDJY>0>A<.^Y(NO8N9(^;OG4#67FXST%:H0`H2&-.ISI))B(`D M.2@I83$4J!Z*2`35!3I3<1W%3-LR+S^< M(U#-2+JEQ6^9FGK,/_"6!AYQF!,3L*_`SR%202&I4F`GN>K"!(9X)G^.XFZI MEP5TM6EN6C*/8_;M11ID/C3MN/:P>@(`Q1_=WC*<0T,KV!HU&J[!^CJA^8L8J:DST-Z' M$8YO_1*MMU&6;)W0,WM0H`4%.6PHZ6AD#S:2E$-QO"6PHX+-\8THM8_G'8$! M.ZD]8@7'F`FL#L(0NZ1KQZHZ`;8<`&\0YH8.QU'Z ML@O]IWDULK82%V+)*DN3E"D,/WRZS;J\(//_MJT_'LV M4'3I$5QL50-UE*E?G<^EW<>(P M%$>7'43TOSZ_O%TOC>.H:^9];3K].HHWU$\SQN\%(5/[[HU+>.W>>_.^CJGC M*S,>%3VJE+1I]G1-XYT?RC:O:^)DR MO7B=<;4H?$*KZS\%!M![/Q5533V-V3CN>Q`Y4AXU4;@=72CQR(:1LI&DB'/2 M\(?DMAS:_L3,GYYB^B1:"0HVYUE]"1>,A,0-=,IS#$@BK+58F%YE-H._-E>E M$C/\F?I/6W9JGS-1<)YHKLIX8J_;E!0[BM8V7LYK=6O,]WNRFYAB'21?2.$* MB1<+[N1OB)%M>P62O!0[Y>0[18N=VH^R4P:767AW:WK&:KW[^AUMUJOURRT- MSJC>NNE:T!EU91)_8]S8TK#W"R\-N33T(=I!OT,7@Z]_):.]GT-F]A%_"`F, M4D7CD=4A0\0#KNO5J>Z&^/NDVOOD=(O!C_0U1O MZE#J;R2R.H2O/?2B7IWF+I:/T^^V7-VK=[UMO\:H.KQK\+K7PVJ%J?)- M?E>:]R>:<%)";_%Y3UWVXSKBOZH$[,L,A&68QGZ8^*[H\31U:G&/A:)WL4?\ M1F/J;[DN41.\6!E)(_'KLYOO8Q9+N4`B5OBZ?.\)OQ/0]D&_ZOS=;"'4PU#X M#<1_#!S;)$Z2OM]]E;\3%Z7BD9F[**/XJ3T6^%H/D'V^"9A+R&?44VGUUD"VNLYU<_;V??+J.*5\:98*4\L8HML=(<[S0 MISZ+':C5RV:@4JY(!7A&.#CA\*1`('HU(2C$-@#1?-C;#2?.+XAKZJP$[E[: M1;*#:5V](5*>`!Q'9H6DM2 M#CX-\!2@L.57XX;V6F28I/*G*&!>1>"GAZ'LJPHS1@NKW`5K63UB>`U&UICN MDK[G0,"$K#G*^]QC3R[WA:C6@W7:MG3B&F9A(9 MZU^&'OW,`_Q+YD8QEW3Q6\8.)VLV>1=7Q@PGM%XRI+R6IR#`2`['[_LDY!\2 M(F%GA$-C=9%LOK>1CC-"B(VKE7W'&F7:%!N4LC2FMC,O8_/E[+ZO5OT:HIJ: M@Q>[?1`=*!45F.4:NWF#&D30&EA'8RV&D8\ELB1USKE0;=(&(\N(&G"CT<'VCM;JX,KQW@!1'`CU9M(V<>`^"61>TZD M-R*1W4MV=J.S\E=>NY,WM%^>4ILQ1R,"%XKGI0/N0")WP,UW0%,QV%?L M`)R#TE46]'Z,-=;>[L[<\WRN39R@-KF]=*N58Y]I0)VC7OM3JY-=(B-5)9#K M@)H*N)Y`!71TI\;:%K>B&7+%T$4O`#I@8^V,TU!CO=BM]@WZ:CA,N+RN_OJK MW1GK,0?(,[;']K<;C]8U<.\ICV>RWU]&81H[;IHY`<^4^:.IEP>R--"G:Y-_ M![@B\>6J2&59XZ2^=:Z)`OXY)U MO38%KRX1HZ+QG>W-$<@2H>^D8+X+7.$K/`K_%7R60O'3(S;LBA^?A%O<&$*L M#T?!"GD>F6?I-HK]?U'O(P_;5X+)/(:5/_LYOZB=G\8Y] MJ#7@*CLQV,Z:ZNQ9$0\ZSGER"Y-?O8EY9V?5]8B8<4;$[/(?1,R/X"'*U-M; MO<+C5UG)69\FLI.)E+C5[!9Q^ZLBRWZ..VD`+P:%1K:O4'JN$KZ/4"6"J MHIFM!9GX4&Q#X5F_/\NRI:9B/V4U3)UB_DU2A5 M^>)@&29I+&ZLDU6ZI?%ZZX0F[='$'Z^1YHVXC<)G60&4TYP(XUK]^V64I+=1^@M-[ZD; M/87\Y'/$)('.-\;T.`"X0*@S`N0W43^VDXLA*JLS(^6*I'5A=N/$*K'%D`-- MR7$YLQ-D$JC!_J`X2V#Z)A_#N`27>95OZ\:#/\UP\C+4812^S3]-4HG\U'86 M["`"KH6TIQ.XU;VV5)1R$VY%&NIJ(^-A4Z>;*)>!XC@QROZ.&?`I9V4_ENG% M25H9*N<)(U81I'*HUO)K8#CL'B#^] M:I]>7R"]DSH8)Y1NMY3)XQ0BT/*!IMO(6PH;P!>^>@EIG&S]/5L\?U+-UFOK M:UH@AO8>;?:@=HZ7D5X)3([0S,TKX,D1`2JW;@"R=Y)LOX0F44GU7DDUN,=F MS?1FQ7>,L?9^BGS$M=I4?&;YYDYXRVTNCC&:J7T3<_K.>?((1%:;ZB,L4H$# M=0$&H8W9Z^JKJ.HSX,G?]@Y$W7I+*^I"1R'QLIC_+I40?@13VJ2;*&F\#%,< M_6LV]?`EZH3]J7>1'K7S@CAOM_3/:\-P&^5N;)**G?1^WQ[';&]:65?:_?2I]FCR`H*3*M+ M#"I!3;.>J8]HQ>%P]1CX3V)Y5QE=AK?T<[I^H<$S_1"%Z=;XXM<8'514RIS> MFI>40Y(CZ(PP8)YAP\&)A"<2`8IHT`#$1B4H<;,X9DP-[A)U9%UM`,84%[QX MVH9*FC!`QT0:J3*0-U01#CLB*G*4\EMF-,:VG=.,XA,-X%/+RCRFSFIS3YU@ MP4XW*3.H$3O%I0=3VZ6&AS)6&HIJ%:K84'ZVY8.)'$V*X2AL40=:-HX+UG+0 MDD,,3(P2>/)K4'=+O2R@J\TB3-GV_NQ[])X^TS"C%XO8T7V+JD8!= M_K?0=BX%Q;`*9X/UW^FRSR9WO%H,DS.?G%S92$+0WSG!C\Q'2;?+,*6QC%CQ5WFN6<,-8S0@5W]&]-7<40%$ M)!0Y`>-/:-WQNMC8WY"-0B"26S!SYE3?@AG@Z"U$'U[\GRA#[8=.?'C(]OO@ MP$/&3GBPZP!EB`STYLF`UEKKQQ>?'&&(!"(Y%*Z.4)U)_'D)06+WBZRA:41V MEV0JD>VW0*V8IF\&(MJ2Q.*;W_O)IXO#!0W=[B M`D(X#"E!L!TL3#]@2\.*%B3P;%DLI]N)HQT?]"'$@&([-L5Z6#']M$;GEU9D MDY^+G8#W$1"1HUN:VG495`"#!6$4M-3.QWQ<$7R<$3847R="[7?1QUT:(2=/ MA3\/2YX$)6_\D"Y3NK-^=&F,%EH]FM-?SW7*^?(T)$Y^Y4!$0.%3DI:?VRP% MW!`GN*T_IIHVU:PW\X).<*!Q/4\I:[?G,\WS##P>9\/WLO,VJPAZAT_N(Z:? MT__^X*3IEKXDW4,G>D2@89,6&FLJ4`PG__T5*2!:@PFP!VZ3;]A^V-9BZ1_K M=MTH"U/F&KC4?^8W@%<9O6;$/?A/H;_Q72=,RTM#L["W'4:8"+@EU;58<0Y/ MC@A$$B1'02HXCE?7@*7.AZ4X/E+L,8JY')"D0K$[&L4=[@%Z$GWV:,;9%5MP MS#N/B&.],\1)BK[&CT[`.[.19$O9><-S4I@$]-Y2W'KC8(5N:M_M-#5"$3#4 M>KI-&*`/&XU4U;RU\B`!%A"TWEB+TT(#^-3,=>OLZ&ISLA!E]*_14]4@@#H2 MZ&A2EM*\<^+TL(Z=,'%< M48V,Y_]6_M(OG=UJ$FBWN.O>Z%/69<%2`4"JN/*4]>J?\6>K=V`:R_QTFQDF M?T&UV?B!SQ MW,&H!<-/%W0I2TS8V@)CM-`FP9Q^@WNWV;DPSLAE?/:>!L[)]]\?80>0= M'B56:=G6-4M^:]\A,WB)(LIIT/DX9(H=T'4]K/!2.'(SF@Z+E-CJ"X#Y=6']S( MG)IA['U;4W8@2O*-<]^CGD9H$T4[SH5 M6C9$BL0S:J7=)(:0S$@.2RK`&!V;"VG;9[T5`@0,*3$@$Y8IB1`@?N@'PGCC"M!F2!67"# MW!SVRT]_93^S__`N2.P/_S]02P,$%`````@`5D]Z1@G9EEP^/```,%P$`!4` M'`!I8V-C+3(P,30Q,C,Q7W!R92YX;6Q55`D``Y,0%%63$!15=7@+``$$)0X` M``0Y`0``[7W;=^,X6WWS+=/.C`) MR4A3I)87VYJ__@-XD4@)5Q)DD6@_)-LCHT#\J@I`H5"H^H__>EL'/[S@."%1 M^.N'DY]^_O`##KW()^'JUP]?'Z]^_.N''_[K/__U7_XC(.&W)Y3@'RA!F/SZ MX3E--W_[^/'U]?6GMZJX8>BY=_>$M)H_?JI:GOR\?]] MN7GPGO$:_4C")$6AMZ=BW?#H3G[YY9>/^5]ITX3\+Q']M./)Z<_?CKYZ2WQ/S`>Q%&`[_'RA_SS?TNW&_SKAX2L-P$;=O[; MK->9AX/@)R]:?V0-/DK[^-AM?&,8X370'U"2R.8([%%.@SS@E M'@I:#:?90\>Q/:0HQ8SUR7PYW^`X9[DVFP34%L=T'JTW,7[&84)>\$V4)-=T M"J]QFP&*NK(XVH+(*R9).*[H2>5Z4T:4H7-U%`?$(UF>77F\= MQ\P$P?Z/Z<<+"IAT'IZC.$UQO*:KZ$T4KM@_K\,7G*2Y\'3'WZ+GCEA85V$: MQ=J394_0\TT4^GB6) MP;XE[Z3S"",ZY]+M78"*K9IJR(9I@/[H1!U8DN,=VC)1T*[I+W&&=XPP%:NX MH\ZV0/CM`C]ILVS7ON-W9:D M5#1QBQ.`=G\=QWV/`VK-^-2&3K>/,0H3Y!E9'T+ZCN.ZI(VB+<9G.,1+DB;5 M?^N.2TC?<5Q?0Y3YA"+^>T8AXSC87I&0GD4("BY0BG9_UAVG=G^=;;JG!/\S MHRIU^6)B_1S1#6);]F-CVK(URZ]%\J\]L@W3%(%>GX/;RF986O=ORVXV&^XA MF74;VFPX0GJ[]C1JF,)F0]3IJB_;VG2D\F[LVMGHR#QN)WI5=Y9L;K/!'5#U M9'^;C4G1BSU;W'1%.22T;I<;[BXB^H&L7L/1FO4ZD$5GAL&PUT&LJ@N<(A)8 M-JJJ3H=$\(C?TDS_MJ!5WX/;6(;2:?\!6U:6X8"/Z*S;688#$G?0IZ5E.$BM MOOJRM8S'JNBG;VNKI0(H^[-D;QD.[Y#,[B@,UU`!=4]6H"&G5-WT.\J2%[9& MN^O.GO5JO%(?45H?RTG[P9S8'\UI^]&$I-(MR.IWM*BV--C\=IS,@]!^DJM8EQ M0O>\?%^[H<-H#)!N<#CT68A!\2OKH$L\>1[R'WF-;P0LR#Z*52L[^V4AZWSV ME*0QW?.JC@(&,N]^H4V[^/G##Q^U!UGR(>=Q@KV?5M'+1Q^3CVS<[!\Y@!]_ M/BF#_?^-_K0H/GV/5X1],4QOT1IS1BQJNC@I!U@7VRQN#A;%7M4E_>>1S)K/ M$\H6'S=Y:/N/WC,)=N)>QM&Z!0?+L41J*%%,CQR_?J`T64('&6U85\Q>&T(( MYQ1*C()KJN!O_XNW4BD6AX9*)T6BY^-,DY2!`4HK@T]`B MH(A&5Y!>*3="OA=;[+X\R39?0BA MY/:_#\WM&1V$SP9R%:"5@-V--HN_3)+?1QA*AO\92KUWAVG)#LMMN_CK)`4@ MQ%(*XB]0@B@V_&)85_2W1"&,H_:+7R8M$"Z>4BA_A14*L\+T1;)KO3CYV0&) M-.&4`OD%Q@+]'0?!_X;1:_B`41*%V+].D@S'`K%(:18G4SXTRT#MCFTP,OHM M"C+*S;@PG453AMMV<3+E$S0/3"6+P<_0Y:&^.$O>XTT4L[M0]G)7AX</U`\2TQW4F*>V?)^//!O^#X*=K=$L+(LMSXM$5Z MT![J0D,L&YD,.8-W0I3LD07+&M!\:S%+SU$<;^FB_!L*,I[GQH@>ZK)$*4*^ MQ+4Q.:$!^;N:Q\/L0>+]A=,C.HVYR6 M\CL&5/)'MK1(RJ&NCEG)501'?CDY)SLTW;\V<76IQ:U!# M75ZUE+HF(O%-[92$?U$.]1&]%0BUYKB$"NJBK*6P%4C$%\13$K+N7&[J.-`% M6]NU^G#LXJMF,]&EM8CBX9=FP1-?N2DE(P.[IC,]YBI!N&$=\Q:@VRCT6JW! M>T*P"S]3,6O`<,.<9BDB]$^UG-9@]X6F(A6-W0USN68-:LU3;GNP&T9368I' M[X;]6^4W5MA$8->0[9S#]\O,7J0>O='6\/7K=@%VCVGG9L<( MIANF4PVR_M6/F&AQ`NR=,A*A4@MXZ)RX'Q`F2>>`#WVM/;IMEXL38->60MYR MMV8KM)94**V]*1W>$D=A!?XQ8JF6U*X1(8WRK>F*LD;[Q2FPCTPM+;G/[!@-L,TNR$)Q M'5(+#B?I/3VS/KRB#4=0W':+4V#'EZF`Q"@Y8-,\3^)8I#$JZ2F>=EZRS/4GJ!E\0CLL5<3;PX!79.M=(`35QN+.>/,49) M%F^U%O3CQHM/P(ZJ5A(6X.ALEO&RN$)<0%7JFH='-"J[%^GA67WW6YS.EX_H M37[O9-+3XA/XX\,VZWT+D&X$E_#J^QI8[HM/P,ZL5N(6X/@>HE$Z1*$L/@'[ MQ5K)6@M5;X'8PS^]O\M9^8Q3XM'QO[_#MWS<+3(PS++T.8K)'WLQR4^^AU33 M?J&O`.;$L;B&D9QSS,_-Q#LV\MH MZA<4T&_Z+4_[/2@'C\$%1-US<-$:^DU_-_D*`/7X)&(0ZVC'E&2^G&]PG'<\ M>(:BXA"Y&XN&,22@@+!_'E"PJTOX.8K\1/ZVC]<@: MD<-ZB`+Y3M9H"6VU&(N1,WXWC)+/<90D=W&TE+KG:ZV@C0]CT1V,W85HAWO* M> M4[6DQ430"8?,=U`I%#?0%JP6MH(1.0V2^6JOQ MN)&II#Q#[)19=D8\:@N=9\A8K%P$+N0MV0';7^_I"'+?&CJ+4'M1-C&(RVQ, M2)CLTO8V"J,#;95)5$`"G5/(7*P2(.)J'5,*9MCK*WMU4%01SRC0O3?G#"^C M&-?*WE^^4:Y1]"1$\?::LC*/U:64%$Z03X$B6E[I?^GEJ^`)CHR5K&]FB*N8 M3&<1VF$O)V!9.UNI8D<4X(F16JH''XBD^LF4S+Y;G&I9"HUVX/F0C"5Y/'Q) MQ93IS,W?,5D]TQUL1I4(K?!MMG["\7QY5$]!PR]OVA5X'B5C'6B%4%*W94K3 M7!?[&4J(9T%+\G[`4S>UDG@WY=D#=^)&10#[@@09_56GE$W+GL!S0O6O.U+H M;MSF5,\,JN`9C7U(1`*>(\IXOY$BD=2CFK*`5?L'MSUX+B>II/2$NP?BQ+I_ M"*]H*(.6IYWAY-`)XN7[6.X8XLECIOJXIZT_1W%HV(+W#QOQHZW;USZ.`F:]IC MAQ70EK5F6I_"\9R[G#G:H2*!CHJR(ZJF&NA@'FO*IM*//-ML`N(5J1_U\SAI M$$,'2_4H;TWTT--ZN*VDXV8!'7#5AZJ8XG1L,=YUKFT=*@!WDN4@WLD>U".@CRAB,ZO,GYR9\YQV`LV5@!5&:( M$D_!`+8P1"&;.[,W(BUV*Z,;S1%K)R2%,$4@IBW;`U07T1J14.:SY+6'/CHI M921P6HJP3%NDM=>Y7S"[-Y/;-LVVT*4IY0.^AAC M*%LE%EOG5TA!'V:74TJ83P!]$#$4K1B$M6,FH$P;S^>5`N6TAGX;8BA-`0); M)T2@;50C$YQZ.=;M`_H)B>G2;(++UOL^R"F]LS!OZ+*5A[#KG'MVC:&?DA@? M=AHCM[7/@AU?NR4VA'ZBP1>*2(#Y*Y&.)TZAYJ%!^"0G2G`L?B4= M27)';VLJPDMRFJ\H3"0H?$`Q:>-6Z\HABG.YI&E,GK*TN($LTE%V#=L0]PS^ MNL)$-VQ@=20W!MNQBOQQ%UE,U[GBOBI/()C_;9[#2B[?<.R11!I0:=P7^',+ MX[W=&)T;UC<7>;%%6E(226?@#RLL:(D*GK6,UZ!.T__+DC2_U7V,!-Y#]C)U MN<1>REXO5V'H.`^NH^MP+EBI>]7*%\`?9I@HE$W,UM*%C%S+8R]:A7DOJH(;?7\:_%6);;WLS`Q;*5%&8&-U\8"`5V[J MY@'9.R';YS]I')PO0Z@,*!T=(&/Q0[9S@.Q]D9W3@W#E./QS(I0\7P71Z^!) MB&L13KLQF`6:'9$!/0UBX[B+HQ="I7"V_4J7^NMPE]]JYJ7DI:CXH09GWMF( MXM2XXA#ZI5K@=.+943NG([#/L9V\='R2\`6[>S#)F1T7>B3`#:R/D;V%HH_/ M08?0V52ROOCCQGN5"TQ'ZQ&5JZ'>##HHKR^!\M7G$+EC2]15%,_6S+7_A[ZW MZ8`&.I!O6'V0LL&5-:$8:BUIXBSTZ?^>TQ])*C-55*30D8%#KQUJ;KA1HLC8 M=RUPRP)[_(95#S$/W+A,_8Q(R%@V#R](LBGK/H6I-#N!#H`<5H?,^.)&,81CS)3-F+RPL!79TB.E M`X^]-).DKC8<(NQZPAGIBG(=OE`61S$Q5(`:'7C(9C\*<(BP\REFI!IP%^,- M(GYEE9_*C6TGP`1NP M2A="2?7O.:S<%(.'CMK0#D.XUD))`3-%"2`SNRVQ%5@@Z6P\`:(V(@M40%UX MQT\WTBH4T?MG1F),F4#G1[J]"U"8TOV5Q:+EU4TEBJ+?"7BD9DM1\_7&$+<3 MQV4*TUP_;X3E%7)$2A9^D4)>EL<3J6 M;`$V3E$JH&Z$M=SO#+/Y\@(_R13BL.GB=)PQM"K!\;6`B\ZYDX_IXVTE[>(4 MV!UK50GTX+K@/ZG\S?O*P6W4PZ"7Q2FP9]:JHI@"=R$3C3X#K5@5BU-@GZQ5 MA3'$W5NV_P'UA>'-O3W),_,GOJ"`[:[\\@@2C3'I9G$ZE@?U1A:H,41WU6-& MITD<;^F,4"5GT*)?G([E*;T%A>!ALW5LA4]0-Y`^C.5%?A_Z8#&X%3KO0NU! M"`QVH7%1"4XIQWVSQ:9(/_8\@N)'-YC8* M/,T]'=F:YY31,>9J-O'XM,T?8A&^&PEQX'5BS*>*3__^B3-J+SH*I:Q MT9]EZ6V4_@.K)KUN%XM/T*Y&(_F*-G$#L`[45#D.A;M"),Y-%59F=U\?<_?S M?V-_Q1@:4EYFN2_V1+[Q=^]_\0G:?VE!L^QQ8NJUX\^RA(0X2HTBFV;:-_D-Q1+!J(ZF---!)[ MX:@Q=.XG:WP7&!!LQ7 M/'R9F8,1Z&0@$A*!5/F4\?.12NJ,?OR;!(Y>!]`S3LYT_C321S;IJ<5.)@?. MH%TT)5V/>&%D`-Z\0W=5Z//B^32FGWEG$--2?Y0Z<[1%;]`3MIV8Q![/%O#[ MRUTUR+RNWBD/7A%[]^$+DGA!E%!;1"L?A9`*8@)RAJ,STV1DT%-*P6'1<5`. M:.*3I'I+N\_J,/1LJ>63T)@EG-80L^,F0F%R&Z74#HJ1OWO(7AN=V;1IU1_T M?!+(@C^/6B.S:; MP<3SO!SBR6D)D/VRD+):-@<-J*%GG`4^-V>G(?:);W;B9ZW#1Q'S!Z(QUY2T M$/NA<%!FVZ!)-]!S44L._+W0%.;$IYTP7TNUX@"Y+:4)9,[976(N'7:I5/Z' MMG.S==<0DU=GS&;SN&6/T%/:AO#X,[X#0R9M_YZA\%O^$FIP4_000 ML[$Y$IW9)J"`GDUBEO+GB`3&Q#?`W)RN-KLR*16KE#OX=3H;1Q$7$D+,DN:(Z@PVFSM&_4#/*+48^#/+&.3$YULM_G=XWW_Y:4/?OY`*QO=_ M-!P]W[^8#'KJ*#@L\OW+`4U\FG`J:PZL:,57-29(LR%(G,@1LY@SVVR":/%V4 M&QIZ!RG&=8\WK`I8N-(I62L@`=D`#\9BN/6IJ:%GFXS9@NU/#]3$-[Y['+"$ M.W/,0H3RA.(QP"B<6A%C:3:$QF\\J@%^CYI2,$_CPS!#GQ^7:Y MW@31%N,S'.(E29/JOP??K[CUYG1V+2DAD/VX'T?H'W"87,+BLX#K:[IT87*$6[/P\]ZXZ'4S-9C4YU MACU!S$OI$'5FI%X'T'.QA23XDU,?[E2GY4/VE.!_9K3+RQ>(IS:'W]?9[@0D M((>T@[%H'"]#WEZ"M(5!CB23SY<&@ML7_UYE( M>AU`SZHV+T'UD3F0:D.00%!;#;3H%\"9>=IH@38P%W+Z[MY]Z0M>1+(`SK?3 M1M8R+"[DWVT\0CI^!%>@ELA:BWX!G`ZGC>"U@=E*FPI<6$@4BJ\_[76[6`#G M[&ZC#2;87*BP>4W%$JX("]'.7S_1 M^FY$OP!.C6TB66-@;J1>+0/OJ2T3K>@B1A'H[_%*V@5P*NPV,UL+E*WTJE9G M=1F];B1*/<+%"7#&:^.)K`>I%.,OTY["NX!LDT,YGV1Q,D$_G!3,SNLR;1GS M+ZZ+0D#T!$)90)E+[<_\*EIIEK7H;7$R0=]<6YR5TDS:5W>)XI!RBQ5YR?F@ MOSHH*!ZVQ(XY"^D\/U\Z6^K/9M*O%R01=>KA>BFH M&G.-II9QK]"SS2A#<4WUQ<)#]%C6SWX),/D<2-8,R0R]Q7K>NH:>W]730 M-ADS\8U8&/D&LR1\/QFC.X5H1.(M!1AXRQVDHR,)[D^C"VP912[.^TA?^:(6=I M\:0AF;$%J6*JV;1KVSFT/:"=E-\*TOYLN&ND>C852YYV'V`K`,]()GO#7]090=CQ&':>HYV+8K MZ/5]3LKS%IL;60;]0:_RUG(_MT8_U\3YUF:I"CT*1-R[!+A&_4#;4,I!H).;FMW MO8Z.Z%D%-GW9+:+?&'*G"9"1Y>2QN`PGR5U)-;(Z*GT&\B-:(A*V> M/NVHH4UU32D:JD`3'Y0*"-;PLXQRA'GI?3]/P?H%,[-2M&[S6T,;U)JBAQK0LFJB:#-VU8"UH-EZR0]MB4YCV1G[%'+7;L/Z#(0 MG=3`"*6M@S.05A2G-ASO,"IU0$`!7?:AD\0EF&R=5X'D6\MAH)3L45OH@@^= M9,I%8ZM^CRV;2GJ0N"$AOD[Q6NC+UJ.&*MO0^J1DB`UL7V[EZRA\0A*/C'$? M8.4<#.5D[`GAP!S9D8@??'R!O1C3'Z_#ZG^+AP4W49*6O1+TZ`W&LV=4`?J0NE5X6NC*\)7F;!#5G*M$*#>G$"Y("SJ1.Z.&V5 M89U.;0F@$/#OL+@$&R$=UN%`M5=P+7KHF!6;)2*T`;OQW)K#(^F!^[@Y=,BX MU?H@`GQN'+GU.65EV8,.:K&]*NBC=B'\F.W:^EK!:0T='&-3_`)XO47_=O'B M\S>P'>[2(%.+MGUGT%$S-B3?#;VULS_@`L`'?X=C$OG5[41U6V%L0/*[@8ZS MZ=^.%..&=0L(UI+#@5Z'FM:"`35TJ(VUU4(?;H\'?KO2%AR&M(U&&]U"A^WT MJ!_&?"@5YR\P^XJVVA@8&%K$4#$_`ZB``&TIZ+].=(4X-)%2NRN%HGNP$"*P M)4.'(:5*_6)][1BV:"F0Z]B)JJ6[X=RCUR^(*@E!@>Q4SVT/[>QM58]4B,0) M+^X.W>]1_.TZO(LC#R=:@FT00'MRNTGV"(H;3ML=OBL2DN09^Y^CR->2;8,` MVAG;3;9'4'K,-0TAVUNLM8O09M!>U6YR+`%8\YL"NL>.3;/ZUG*'O&]H1<+5 M[A=F`&:;34!P4K&#_E,J=1L?@/;%MM076]!M.6)[/T%QJI@T@^TEZ2U9F@A<^%=V3%`N>^$ MVQ[:B=)Q+[#L18'=`_+$%C6&2&1YV!3:MV$D1M[@H;T3ULXU98W)'3KY:>:P M-;2'PDB.@O%#>R%Z7%W;6-Y[,FC?1/>UM@8$VA&A[6L2'"#T74V"#J#=#5K2 M-(=DR]\PGN.4V"`TCN#MTBUTY%8/!K48*'305E]NRF,>&'DKC\G!`[1,=WP] M1+8BK,8J_UGH&UCK1OV`I7.RK!$B:#N?C&NZL3.'<=OE@=L#6`XG2_H@!E5I MPN3#DHZNZ%NN"HVI,B7_FQI*)>L^PI0&N=+[8&T4(1KEO%MR2KANU=M"7>3VN%@^?;PU'8C,=@,+4H`*_"+0N;%W0X!>%FE(6'(WGRW;BU^P. M_*IP&+TPX4;WV\8Q[R"MC(P&)5@U&:A]HP&\TH[V+LTQ:\?^<-[6Q#CL`:PR M#92V.>2*17/N,=T2A5D>='SVDJJ'Q'=^A-@]6V&W:JZX9<$$>?0N+O0"%R0C'HQ$(HZ2%"'5Y\)ZQGP5XOA074E8$'^IV`1T&H\5_ M0-H,-*.HFR"<-6SH^Q6=LW),37*5ZW.G3MB*'C1'H\.R'GM!$YK84EE/F-GO?7#$BKP,(TN$E?ALF6#^WA) MJ&I1VL\9\=E#$AB#7&&*@\=/=)'E#H`;.?>$K%#-53DA>-!#%Q%K0'/CR4XM M*.P"TX%[I'R,M@EP+J^P$2PFY(M$36Q]`CSVH8M"666"M0=#@,EWA0CE[XIE M9(N3L7KINJPX%3!KKX+&*/1\637.)MBFN\7)6/U_G;PECTM3B?HY>R"M<^DAX,6\KE#6^;T MIT=(^DN<[4);H5*@'8QKMAO7#4%/+-R#X"J;#?U;+;!;'?K9M6O(BD'EF.MO MYO21UJF@XS]M"$&X\LM`6[JL&$.!D!+A8XQ\G2HQ8BKH,-#!E.$0M*T+#&!M M8*RB".E0@CP?JY8R"(B@0T%[U04)9MC*00);KASR.6U)/!0\I)DOJ:;);PT= MZ&E?H`JPUDHOCV!2Q]$2)TD^_"ML,K'YA-!!H/U/;C%N6[R=;U!&FK6`=_8R4A1>!]#1LT,JBPB_K5L3R!V)BY;Q M\0$%R+A:_`$M>+#MP%IRA-W6U835PZQPZ)K'6UUZ\*#;GDZ\1OCMI4\;1`4. MSVW&.G#8`7@<[M!*P&6`M01KX]HJ;!R#._0*'O$[J,5JQ!5KY:#Z7W;X@*IK M3Z,%2-X5>%#QD$N1!BNZIVD#S8)TAL)O+#4A6&TP^FFSDE\\`HA+[#RA8_[> M0">3$:2"34QW:*U.H.0 MB`3ZKI@O'AU1-C%,6Z!?HCA=H156IY(X:`E],RP3"5^('``.Q//<1BG>.?DB M9E^H12FD@;[B-1>J%(H+$3I-EMQH9)$04$#?R';8.QL8)IX:XB8*5X\X7C.$ M7Q!+0L9.4/=X@[;Y`WF668.$'MF@X#J\I4>,^RB@@U@]ON+@!7^)PO19)GP; MW4/?OTJ$S]<66Z"=R$5AQ(R2$?_`*'Y\C6SI5;-7Z"O:?M7I&*L;B2U:,X$. M0G8R[]0O]`7N<*I4H74C;T9;-EQ%F30!6H=NP:]Y!].E'5HWBO:V9@-YZ6-= M8MV"7QH/ITL56C?2A+1APVQ)CX,]*52C;_!;Z$&TZA@R;,RLX!;P,;\NVE]Y M,8CEM=<=>PF_B*X!V_0%?FVLK0S=(/86\@IQO?=(N\CHV-]O^=YO M^=YO^=YO^:8IO_=;OLG?\EV'U!C"27J/4OSPBC;*&R(^P?3N_,0XIBW0]M>V MD[OAXP``NP(2'`[8)61Y!RF4![_AN"[E9.(0C]^6BQ+J0HX>9>;+S^MHI>//B:%'.D_#L5'?UK.'KE]'%*(1&X&$3J&L:`=>.67LX6*$QT-UOY#.?P"V2[PO- M5F!7$SS6\)P[QZ.=MC5E+\9F7!8FPO:#'MPN<>#'9"!SK1O2C=::+A:V/RXWPD[LX\C#V MDRO*N^LDR5C5A_FR?L$D40(U,?BS*G,-T`3E1L!(=>B_B5"8S,-[3&VZA`H) M%^E4B7=77"DRZ,D9"H(H"JN?HC-\CSU,7O97-Q*_2,$,%-$'[[,.^'+ M*<"+-^@+6P>)K0`.H!VA;F75WQ9I6IMU$O`2"-ULS",HMHJUC.F`63L\S9>_ MT<6*H64KU!E*#*(6Y-V`%S;H>MS4@`==C$7@?MTO5Z3+MTFD&QE``-:PXNL_=&:#O89APF%>QUZT9I:KTERB]/Y\A&]2::V#OGB M='+N0FU8UK)_C>!"]PIY+`)UJ^<\5%`N3B?G-M1!9"W/%U09FERSJRQ!]_@% MAQEF*@V49"IHPBK^Y]M$5!NBW8<1N%495!6"),(0UT6&Y;R4H!N7%;4EES!<:<41K! MG;76T&&Z;64K@.+&)4@%KF2'KECKS:$C=KO*]1!+Y_N&CLNRJ-1.40VRN(RO M+N?*L8O.ES(:Z"A=4[%I`>I\)3"*+35G37T7^8Q(F+!#E+IPBH`,.@BX[215 M81J3@[]+@JT]P())XHFMI(&.%FXK:BF@:;_95)P>RS>&0$T(OD`HN\RT--20'DK:6(*\P18*"%A(744*OEEU$ M+L/DAINN!/K`(N?R_"=>*^'+Z:%=>5U40(W,#<_>13E4\Q5?00GM[VLE?`U, M+I1E-A>VB"'`WL%60I9@L59<&<1_<&P#G[P;P5U`T,-P%+)0A5Q$MQ&31^:E MY"G0\+P9]#))\]@0GQ-O`@68&\9";1:::X>HITE:TRTPNF%=&TR-AV?*_S.4 M8)\%Q-%?\I8L]L/.TB+N?Y+6N37D;ECO!NRXIT*F`GJF$T_N#[76]R1/`%90 MCRF#S2#*I0X(,>MJVN<*`Y!N/$ZT=YX$CC^P>IZT&'>PB1+"'DO\-IK;E=/O M[&0I?-532)%^898D.$W8I\K?2G6XBR,V^^_)ZEGVQ,>LGTF=&%LC=.!^Y0@V M!;G!<;J]"U!^L7[YSXRH3#']3B9Y3C2#YT8IO0/$UV'^X#5)C,UTTZXF>>QK M`]+6"6]4>C*O0M]8;.,YBN/M,HI?4>PG%Y2K24H\$U51]S;),UQ+G&Z4D3W%=P$*?YMH;J8>/L#O8J8==3>I,UP6D&T'FQ_JO\.WP":## MRRW-_0J*M<#R,1D3GV.ZHIE(-B>`SEIM1[([*+9RR8SERA^HTI,3%__BK5Y5 M_TE!.2EWC0&F:2?;WG%EEJ7/42S.W2\G@/:Y:,A)X;@^@N.:7)5%HT0DH_&6 M'(E(5Z2N%(YJ'+;^)XM)XA./(5!62E%0CL;%P1$97\@:@*8MZ\HK<\YR.<9; MI82Y[4?C?="6JQ`&6)4IF^MQKK5YMBCV)28+G\>QVD4<>01C,.3()&22+@B,$[$.%\A$O^& M@@R?;7-7R7F`DD2Q5@MIH.IO=5ZII8@F7I)HAZUPA7W!B#D$?)9-W\MBEB8] MSZ;[-8R>$AR_,$9=AYLL;<:UU1FC7.+[^B18@3(M/5&H5A^\F/K&XN,E"4F* M`Y:$XIK*,URQN,F*5O#1:KPH@VK-T&>/$'B9>]F\T2NII4(,7:6N] ML>F"`ZNG([C$YKBPRZL.R3V#)B5X%39=H7`NJS71.3&M[<690Q5=,Q&9PL/+ M0>2$D"^72^RENZ3P[#T%/:"=1R&='QF=(N5,`E5;:V[*G6"[$).%?A0;:CJ;8,J3P.M MM70M@'I#,1=%4>HP]8K$J$C!RKYUUP@M:+8";B'%WZ:N"501M^YB/8+A0ESM M5>Y7N^'YU>XQ\\O1=:S,2)]+JJA4>R*1=LL>P8K`=5>,+HBAJT$*'5;5-6$R M?PVQ?X8"5H;@+B;4N-[(JK3J4X,5?VLO<5-T/99S'"1"^R&-O&_/44!1).P= M*ZMZ!I*?N/BX1E!VLR%$'/:#]XS]+,#S)3^)SRR.Z1*17]HG9]M]FS*'^8P9 M"ZJ(;6O?@([M/A87?XFU"GC:UXSL7?DM6F-%5$.]&720MU7I\17D$*X;,E:& M)C0;0@=\'PI!+BKXX&Z!\<,&^/@:/3Y'6?*,0E]XO0SZKG?]DC574;S$>4FP'7]ZU%O. MUZ`?"(Q9;P7LX79;5YL7^1L9CG`F#.D"3_8\F%RS<<>R3!4L4T[@S\ MX4"OBM>.'6XD0)NV!0K]-F',ZR&?6[:"0`HC]#*$*N?=E3OE7&9GU-[U]NA; MX.\AQJRW?&Y!IXL3.`A90M7XA56(ORPXP`[/W'%)8K$Q[:BKV9@`=(Z!;F>AGZ MTG][HP![^#**.6"9CSU&*4UI#G`\%E`3P7`H8*]X)C$;VC"SG!*_..U>53&N M8@OX=#`:"-@[I$E,!G-6[FX:'-\>W#D>O-^F6>%AI?B=[]@< MC$U!]4UX6*G^U*_I.K+L-YPP+H5YX0R/_O,Q8C_5%I'9:A7C%4I938V8A`GQ M\MQ(/4Z%UF,">WDWA+S1[XFHU9;[[FT\!&VN[ M]6@FC'I,8$\Z)SQA-+E:31C["0-@7Y*>O#\EUK&#>*N,E> MXVMV,96'H"9X'*C`S(-;+1\7Y(7X=!ZVT`!>%]"/1+MH@`B/"U'2,KR_10$5 M4T#YUD$)FIU`OR&UH0;'B%S(]29#_(CC=4OQ,U+HUZHVA%[AZ"T?&ZR=!%0: M<4+6TGOBC??$&^^)-]X3;[PGWE"(ZCWQQMAR.KPGWIB`D%Q,O''/EG_%AK9K M\QVDP6A@G7@VBQR+LNI0K15T!HD&\R7RV8]VVL;&%_1&UME:*:)&.^A<"0<2 MX(OI:,03%Q0)]015;P>='$!/4(5:*>-\(_'EX9YD>8)GX?M\]WJ>/,*J;?=U# MZ*?:D\@<>6+QVLZ6+[*VYEV''ATS><',(R2O;J-+ZL+[928UCMM,%[T#T3F4 M=6M69(X"/D<;DJ*@R%)5IMKP=[DVV#+-:D3(]AC3OEQX]'NL0MW886LW^\ZS MRTW_`:U8L5KRPXV\A7=QY&'L)U>4YZ:*I*1UX>&I6&_TX$-G(108,S/?)\5` MCM95\QVK8X\N/-(4F#X=F>)"1<@OU&^M(PM M08L#CR05DV`@)D(73QV'XL.7[SB=?L[<_A1:Q#"7LRX6IYU9ECY',?D#^U]# MBK5V:F;^X*0QG_-HE9OH%KBC=-@G'O/@MCP=N[VL\;#`.6LM^.%&% M+T)JKL,DC;,\/&*>/N/X\1F%.DFV\S]>H!3O7BSW,2MLCW%QZO3-WZC8;"W% M(J2=M`L0Q/$+W3WY'+Z-PIANE_\#I/?:B5T^+4Y?M/6+9:R[`X@MVH@X=XQ]^B%%,9U:=T]]C_XN+4Q4O< M(9AF+?'A"#2Y#?_I'IG_X6"7S$]?%:/NLMA[1HJXID$&L/CD_&WN,#RTEKX0 M5NT+4_`+3I\C_SJ?Y(PG\]>0&F'/9$/YPB)>*2MD!HIN'XM/+M^6FK&ATA^P M2TY19H3=,.?+VM55$?^3,%>3*()*3;GXY.)%H0GX2NI@-WRBQP'=O##LZIZ$ M.8WA5?6`7U]\56)#@I4],-G9.N-K)9;60>&Q%)O"!*LAAKI*PSZ@OPEDKS\14'+_@+'?.S-!F97@_0V>B,)2&(T=9'Z\3CU6.\1JH`G9VN-ZG; M3/T+*^%9C-%\>8]1<$EMI)1N+-$&Q^E6(F<1"72..DO2EL'K\9'.,,E?\2HW M-4+_@:Q"LB0>"M/SC-K#:QQ?A\LH7A>K&LR^6P[O'F^BF`E/8XL5D<#FA[VD MNI=N?R<^OL25+A4R0;DM)![\V6)"M0&Q7RB2M$@4:9/*C1#GI[5LI$ M(,I##"-+*3L+R1H%_TW-A?0YKP]2G-M9R(LGSU^JIH1.-7O$>XZK0P_%R(3V MY97\ANE828CB[4.VV01;YJA!X58N,A4==-I9'8'I8'#C;$./`,P''.=28#5\ MSK9G]#SPO$;Q-\76J2(=3Z;:'G9/'?`33^MT#+$"J-Q45:3026YUI*<4,#>R.?SY!:GRKQLW/;0"7)UQ"2PI41PIBW5HR6PL0#>:"1BT^P!.N-N MKZN^`0\FGI3U:`+M+XMES]EE9.`Y>PVDI[GX'Z+K88T8H\]S\'*A[T[/=Z?G MN]/SW>GY[O1\=WI.Q>G9F_]L`@Y/'0SC+++5JZMZ`IY//11@GBV!U.XC.K#T M?[Z@-'W&KXG6/)/1@+LN-22E&O_$#Z##.2R@G]N.P6'QE_'-Z9GG11E%>(\] M3%X8S(L,YXE?CX^H/#4P[P3::6D@+-[*;0JUK]SO8_18`!7N?O=;O/LMWOT6 M@UXZN^R]T`'OFF;8NW,&#[U6"Z_EG3.@\V-,=\[`CA$=,9G<.0.&A-F1:G.Y M4RSLQXW!W25]+N5\N!./&&+5W.?+!C3ELBVD@?;!\"7$EZ84Q,C\TGW-,)61&(6M51$T2=M[ M_-5[_-5[_-5[_!77FWF/`Y2R+!=QNGV,49@@CW4-E=M!-!P-]Z6*%-:-*1H= M6XEJ?]%V7!KT!^VJU!&,RF5I"'<,I]<$>S^MHI>//B:%PM!_'.H)_6EQ@UTS'>M.BA_0UJ MMO/GG3:XD5VK[4ISH!<2KI)\X#CQ8I*/2W1U(Z>"]B]HRX)SG:-&YH0U5K(H M+PE-GC(&@4']@M[(.EO/PC!CQ5?V?TSN<%RQIO1>JV=ZE]ZAPYY:ZI!E#KAA MY@F84>*-OZ"4"J.L3U[]O>`!NXBE?S17-?V^H<.O^E$T,_P]YCX%M4^2S_3? M,7L$M@NL-[)/./30'B8[ZJ+&6*K$Q&MF'<.MC@5WB,@J!,D)H?U,UI7@$%PI M_3[J3`UR"/P:HLPG]%#[]XR>:G$<;*](B$*/H.`"I6CW9Z!#X?&HZD]_3,H0 M&/8$<6RD6X_/?`_^;HB[E_/).2J*GND<'XWZ@3Y&MI"+,';$#/6T[X;J(>6? MH\A/;K'42<)I#GWZ-):8('Q!`,V)X^?G.$J2NSA:2DO:UUI!'P$VVD$?DRR)]0B3K=,1:&`_BL/< MP5U68]4X:XA(H"_<+8E9!J^4>.<"M%!):0Z@G:&$>`:2SMM#WXG+Y*,GT1V, MOE*(`(KT@@19*BUZ+:"`?GC37:PU(+T9U%ROU4`L``00E#@``!#D!``#M7=USVS82?\],_@>.7BZ=B:+(3M+& M$Z?CSYYODMAGJ]>^=2`2DC#AAPJ`MG5__2W`;P*@0,EII$,?FLK$[@+[6W"Y MBP6)#S\_1J%WCRDC27P\&+]Z/?!P["?'@U\GE\.?!M[/'Y\_^\#\!8Z0 MQQ&=8_X%19@MD8^/!PO.ET>CTK]I&PX1VA9*'H]5'OU4TIAQIIX\U;#D`-,]'S08&#!C_Y"SR-:#$PDOL>, MZ]FR-H-V,2(^T_/))L$V5MD8\?5,T&!@`0/QU1(SK>EDBT$WQI?4T!FT&'JC M>&:(XC?2"`DY' M0M41$`V!"E/B-WC7,]:8A-=$<9QPQ,&Y?OR`EDL2SQ)Q6=RJ1V*X$V#RQ(]? M;Z_,SD\J=I[XJ?"C)W%P$7/"5U<@C$92^,`C@$TG1=EM@&P MU7^"""^3X=6$?!BU)11"4X:#Z_BC_`W&8B!#<@BWEW/E)#J.2J`=O8]"/PW- M'8P:^&X*^"D*A0>^6V#,689P\Y(>T@/`\0ZTQSFF.8^7,3D,X0T"5\P7F!/H M7(-GLUT/[F$GN-Z+AHP?W`*[Q(5=SZZ7F,K^\HEK:-.#_*8%X"?X;8XC),'C0.IFK2P_QC]S0' M;D^RNP7N:G))Z+GU(!!>/2PB&,0,'<`TY'SUAK,S4NTGT0!^V M@(44Z0FD'"\3Y!KL"002?'43HFR1"?SE4CC"`G)3LQ[N-RK0.\)!K=`D\ZQF"^W&![X*69?<`ZBL54/ZH]M4#/7 M^Z*0\(-7R'CI@12WD,X6?B;HL?`%]0MZ/)4$,6/Q)(];Z)F7C>R6BL9JQN?\ MZM!9$D4D2XS@0726R#P7_OI$T)2$,-QBIMH0:E$_4+.W2I1\9%7"O)HTM^QP MA^=Y%;"V]'"6,@[W.E6*AM;4>HLH65XN3P9O]:6/0J2[]<1;'(H:]@V"$'=" M42PIS?DP*\N@2W4+Z(EF&RPO@4QS`^SHJ_,Y2-K7J4E8RP MH/<*`>45MU#^-49I0&"^_3N%^89IN+HD,8I]@L)SQ%'9G*%N3:VW@I(HE@Q> M*=`K)7I"9$7BEEWNTBG#?Z:@RL5]M7JJ7-7CK&2%%9^7,;H&IDU)8),R0GQ5$M"=5"-K5IT#Y5<65,VN(]?90LFFKJI.C=BD*3G7X6]?T*"O9B- MHF2F?/'IC*7ELG_5I1XUEMTYZCCDB8:^EU8)%:ZHW2E+< M9\$N%_VWI@LH:7AMV=5-.-65U0:NYF8]P$H&KEUY=1/JSA75!NI6 ME'H#*(FYQ>*KJ^8P+*RV3+&&2F\&)75?L_[JI@G6KJEJ?=%::KU)E&3?<@G6 M3=,4ZZT-"[0OZH%67\:M5F'_!K.=*1C:]-`JZ;8*K:.AOFD5NS%_UQ%I07^K M),[KUKK=G.1KP,VGI9TE2F*]1924V-(BQ;WAFFEJ!8=6UJ1V!"]L"`K)*(ZI$]I3= M#$G48F1S3=_8K,=:W1FM+5:ZZ8N-8([7@&WRS):E85<]M!'/9A5D'94>>[4" MW(F]F]ZE]OHG,KQ)VBQFV-/KK:+DGG8OH#KKD2SW0C2?"3V9M)9ZIU9Z>^V@ M^-M>%M"/-S*8X6GS;JM7B1U^"O5#O_ELVHQ7;S\E/][,?FX^R4RO?S<\XSHB MO5V4_-K\JKBK?L_T6G@#_75$>O25'-S\"KFKZ-MNPFM8HR^3WCI*[MYOZ][_ MB;W$/^+TDUL\\^0Q(D<VB".:1D6I['\`2J]>HS"@D1( M[CC41%J[C4+><2$B/\>A^Y@3$"(KR1!:CXK!#T9/H`\`WE>?IHUV2IL03?MJ M`RPXW#E%8%[W5:1U*SRM.J/B+`_X59WP`0V@24*Y%VO/1S*=\),=K?0I\:68 M#A;QU[#@&XI+P_'!\'#\ZI$%V@.TO)9A!UON*/;8:A M.Y;):AQUQO*O+8RB'-ID,XJ22?[:HG?U#">;[BNN[.>P$M!W`.WSH&RZ+WC$ MCVVZ;I\.9=5WP21_]>M]W0%H-LXHI+3!)3S2>^$$Q^^V&8&E*ZSUSK?MN?N\ M+-O1U*5<5$+Z#:[SY#6;65'PB!_][L8UIWC9P-#FVL(P^O/'^@TBB;]L,H[N MT]XV?V9*65J;Y,="RK%TGUUV,F61 M2'T&'LJIC@>\JAEP2GMVWX#7N'M"RIHO:5!]WE,#-CNA*-_(9"IEVZ%F, MR(NF:79*UO'`IQ@RUV^BT"D&`]2_1ZO5K4&UM9J5A;ZEGOEN@)/E,B2^_.Q* MTFE-*_J]T+WS(_IBG?8T3/RO->5M&3+MLZ,8CWAQ?4/]O\%D/IE3+-OE2V0K MG:KV++NF;&Z=6^PG\VSAPJRE!>VNJ2?._@W2$%_/[E"(V231E#:R3P[H%-Z( M>WT^]H/&=:-:D'\%P=0`3]:`"?UTRF^,FIYFI)0G$]^$@32(WW&T133 MFF8F@L;\"Y((D?B[Q8.=Z'\BL=2?V9JKQK!#,6_W#,O*O)K8OA_;+NDK;O]3 MQ'`@CNJ$YV9>.X>(#"Y"8)C_/PL1Q?F=63A*%;_'U?\VKY9/JU?*)[C`XBF+2D])^PE7]UUC2;^?JMNY!.WYDKUFS%J)^PG?;PG]>A7? MT,3'XISJ[)L0!'XF!>)_XBK$4GR6LTTNT"??QY@?3I5$J=P6>1.#0F!SFNV:N**#>Q]@F20P#/&=H2<"5"A-+LX(;2RF^3&A-J\8ZLPWY/BA> MI!EB;TI^@,UC*_6`@"-(?7Y+YHN6$^C+N@?K[!9*=>SSV8A[#U`IZT;5:U'F M4IT-\0X5Z&J+M-E"YA9`=,O4-IL)D:(ZO9]FJ(LDCXI,'1(-L,HNLF\22YS,A#LDM7@T0A^+C8K82+8)26*3WW`Q0````(`%9/>D8](&ATK^```$D, M#0`1`!@```````$```"D@0````!I8V-C+3(P,30Q,C,Q+GAM;%54!0`#DQ`4 M575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`%9/>D94.*9^J!```-T@`0`5 M`!@```````$```"D@?K@``!I8V-C+3(P,30Q,C,Q7V-A;"YX;6Q55`4``Y,0 M%%5U>`L``00E#@``!#D!``!02P$"'@,4````"`!63WI&Q0?7`$L8``!`G@$` M%0`8```````!````I('Q\0``:6-C8RTR,#$T,3(S,5]D968N>&UL550%``.3 M$!15=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`5D]Z1M]ZWLH::P``KD8& M`!4`&````````0```*2!BPH!`&EC8V,M,C`Q-#$R,S%?;&%B+GAM;%54!0`# MDQ`4575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`%9/>D8)V99`L``00E#@``!#D!``!02P$"'@,4````"`!63WI&;2VU>.T.``!! MJ```$0`8```````!````I(&!L@$`:6-C8RTR,#$T,3(S,2YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``N<$!```` ` end XML 73 R51.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Other (Expenses) Revenues, Net (Details Textuals) (USD $)
    		 3 Months Ended
    Sep. 30, 2013
    Jun. 30, 2013
    Other (Expenses) Revenues, Net [Abstract]    
    Exclusive option payment received on development and marketing   $ 250,000iccc_ExclusiveOptionPaymentReceivedOnDevelopmentAndMarketing
    Capitalized expenditure for development $ 47,604iccc_CapitalizedExpenditureForDevelopment  

    XML 74 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Segment And Significant Customer Information
    		 12 Months Ended
    Dec. 31, 2014
    Segment and Significant Customer Information [Abstract]  
    SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION
    14.SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION

     

    We principally operate in the business segment described in Note 1. Pursuant to Codification Topic 280, Segment Reporting, we operate in one reportable business segment, that being the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Almost all of our internally funded product development expenses are in support of such products. The significant accounting policies of this segment are described in Note 2.

     

    Our primary customers for the majority of our product sales (83%, 83% and 80% for the years ended December 31, 2014, 2013 and 2012, respectively) are in the U.S. dairy and beef industries. Product sales to international customers, who are also in the dairy and beef industries, aggregated 13%, 14% and 16% of our total product sales for the years ended December 31, 2014, 2013 and 2012, respectively. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:

     

      Year Ended December 31, 
      2014  2013  2012 
    Animal Health International, Inc.  38%  38%  35%
    MWI Veterinary Supply Company(1)  23%  22%  20%

     

    (1) Assumes that the November 2013 acquisition of IVESCO by MWI had occurred as of the beginning of the periods being reported.

     

    Accounts receivable due from significant customers amounted to the percentages of total trade accounts receivable as detailed in the following table:

     

      As of December 31, 
      2014  2013 
    Animal Health International, Inc.  45%  39%
    MWI Veterinary Supply Company  26%  26%
    Robert J. Matthews Company  *   10%

     

    *Amount is less than 10%.
    XML 75 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Summary of Significant Accounting Policies (Policies)
    		 12 Months Ended
    Dec. 31, 2014
    Summary of Significant Accounting Policies [Abstract]  
    Basis of presentation
    (a)Basis of presentation

     

    We have prepared the accompanying audited financial statements reflecting all adjustments, all of which are of a normal recurring nature, that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB Accounting Standards Codification™ (Codification). Certain prior year accounts have been reclassified to conform with the 2014 financial statement presentation.
    Cash, Cash Equivalents and Short-Term Investments
    (b)Cash, Cash Equivalents and Short-Term Investments

     

    We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $567,000 and $1,770,000 at December 31, 2014 and 2013, respectively. Short-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than three months from their purchase dates and not more than twelve months from the balance sheet date and are held at different financial institutions that are insured by the FDIC, within the FDIC limits per financial institution. See Note 3.
    Inventory
    (c)Inventory

     

    Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or market (net realizable value). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. See Note 4.
    Trade Receivables
    (d)Trade Receivables

     

    Trade receivables are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded as income when received. A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Interest is charged on past due trade receivables. See Note 5.
    Property, Plant and Equipment
    e)Property, Plant and Equipment

     

    We depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The cost of our building (which was acquired in 1993) and the 2001 and 2007 additions thereto are being depreciated through 2023. We anticipate depreciating the building addition that was completed during the first quarter of 2015 over twenty-five years. Related building improvements are depreciated over ten year periods. Large and durable fixed assets are depreciated over their useful lives that are generally estimated to be ten years. Other fixed assets and computer equipment are depreciated over their useful lives that are generally estimated to be five and three years, respectively. See Note 7.
    Intangible Assets
    (f)Intangible Assets

     

    We amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. In connection with certain credit facilities entered into during the third quarter of 2010, we incurred debt issue costs of $26,489, which costs are being amortized to other expenses, net over the terms of the credit facilities. See Notes 6 and 9.

     

    We continually assess the realizability of these assets in accordance with the impairment provisions of Codification Topic 360, Accounting for the Impairment or Disposal of Long-Lived Assets. If an impairment review is triggered, we evaluate the carrying value of long-lived assets by determining if impairment exists based on estimated undiscounted future cash flows over the remaining useful life of the assets and comparing that value to the carrying value of the assets. If the carrying value of the asset is greater than the estimated future cash flows, the asset is written down to its estimated fair value. The cash flow estimates that are used contain our best estimates, using appropriate and customary assumptions and projections at the time. We also review the estimated useful life of intangible assets at the end of each reporting period, making any necessary adjustments.
    Disclosure of Fair Value of Financial Instruments and Concentration of Risk
    (g)Disclosure of Fair Value of Financial Instruments and Concentration of Risk

     

    Financial instruments consist mainly of cash, cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable, bank debt and an interest rate swap. Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, long-term investments and accounts receivable. We make short-term and long-term investments in financial instruments that are insured by the FDIC. We account for fair value measurements in accordance with Codification Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and requires additional disclosures about fair value measurements. The estimated fair value of cash, cash equivalents, short-term investments, long-term investments, accounts receivable and accounts payable approximate their carrying value due to their short maturities. The estimated fair value of bank debt approximates its carrying value because the interest rates are variable. The interest rate swap is carried at fair value. See Note 9.

     

    Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area.

     

    We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies.
    Interest Rate Swap Agreement
    (h)Interest Rate Swap Agreement

     

    All derivatives are recognized on the balance sheet at their fair value. We entered into an interest rate swap agreement in 2010. On the date the agreement was entered into, we designated the derivative as a hedge of the variability of cash flows to be paid related to our long-term debt. The agreement has been determined to be highly effective in hedging the variability of identified cash flows, so changes in the fair market value of the interest rate swap agreement are recorded as comprehensive (loss) income, until earnings are affected by the variability of cash flows (e.g. when periodic settlements on a variable-rate asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreement and the related hedged items. We also formally assess, both at this interest rate swap agreement’s inception and on an ongoing basis, whether the agreement is highly effective in offsetting changes in cash flow of hedged items. See Note 9.
    Revenue Recognition
    (i)Revenue Recognition

     

    We recognize revenue in accordance with Staff Accounting Bulletin (SAB) No. 104, “Revenue Recognition”, which supersedes SAB No. 101, “Revenue Recognition in Financial Statements”. SAB No. 104 requires that four criteria are met before revenue is recognized. These include i) persuasive evidence that an arrangement exists, ii) delivery has occurred or services have been rendered, iii) the seller’s price is fixed and determinable and iv) collectability is reasonably assured. We recognize revenue at the time of shipment (including to distributors) for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably assured. We recognize service revenue at the time the service is performed.
    Expense Recognition
    (j)Expense Recognition

     

    Advertising costs are expensed when incurred, which is generally during the month in which the advertisement is published. Advertising expenses amounted to $66,193, $151,080 and $174,314 during the years ended December 31, 2014, 2013 and 2012, respectively. All product development expenses are expensed as incurred, as are all related patent costs.
    Income Taxes
    (k)Income Taxes

     

    We account for income taxes in accordance with Codification Topic 740, Income Taxes, which requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. We believe it is more likely than not that the deferred tax assets will be realized through future taxable income and future tax effects of temporary differences between book income and taxable income. Accordingly, we have not established a valuation allowance for the deferred tax assets. Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. We have evaluated the positions taken on our filed tax returns. We have concluded that no uncertain tax positions exist as of December 31, 2014. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 11.
    Stock-Based Compensation
    (l)Stock-Based Compensation

     

    We account for stock-based compensation in accordance with Codification Topic 718, Compensation-Stock Compensation, which generally requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model, as detailed in Note 12(a). Accordingly, we recorded $30,004, $31,359, and $35,985 of compensation expense pertaining to stock-based compensation, which resulted in a decrease (increase) in income (loss) before income taxes of approximately $0.01 per share during the years ended December 31, 2014, 2013 and 2012, respectively. Codification Topic 718 requires us to reflect gross tax savings resulting from tax deductions in excess of expense reflected in our financial statements as a financing cash flow.
    Net (Loss) Income Per Common Share
    (m)Net (Loss) Income Per Common Share

     

    Net (Loss) Income per common share has been computed in accordance with Codification Topic 260-10, Earnings Per Share. The Net (Loss) per common share has been computed by dividing the Net (Loss) by the weighted average number of common shares outstanding during the period, without giving consideration to outstanding stock options because the impact would be anti-dilutive. The basic Net Income per share has been computed by dividing Net Income by the weighted average number of common shares outstanding during this period. Diluted Net Income per share has been computed by dividing Net Income by the weighted average number of shares outstanding during the period plus all outstanding stock options with an exercise price that is less than the average market price of the common stock during the period less the number of shares that could have been repurchased at this average market price with the proceeds from the hypothetical stock option exercises.

     

      Year Ended December 31, 
      2014  2013  2012 
    Weighted average number of shares outstanding  3,027,001   3,019,407   3,018,296 
    Effect of dilutive stock options  0   65,641   90,123 
    Diluted number of shares outstanding  3,027,001   3,085,048   3,108,419 
    Outstanding stock options not included in the calculation because the effect would be anti-dilutive  253,000   63,875   39,750 

     

    For additional disclosures regarding the outstanding common stock options, see Note 12(a).
    Use of Estimates
    (n)Use of Estimates

     

    The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual amounts could differ from those estimates.
    New Accounting Pronouncements
    (o)New Accounting Pronouncements

     

    We adopted Accounting Standards Update (ASU) No. 2011-05, Presentation of Comprehensive Income (Loss) (Topic 220) during the three-month period ended March 31, 2012, and retrospective application was required. Under ASU 2011-05, we have the option to present the total of comprehensive (loss) income, the components of net (loss) income, and the components of other comprehensive (loss) income either in a single continuous statement of comprehensive (loss) income or in two separate but consecutive statements. We elected to present two separate but consecutive statements. The statements of other comprehensive (loss) income immediately follow the statements of operations and include the components of other comprehensive (loss) income and a total for other comprehensive (loss) income, along with a total for comprehensive (loss) income. The adoption of Topic 220 only impacts the presentation of the financial statements.

     

    In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. ASU 2014-09 is effective for the Company on January 1, 2017. Early application is not permitted. ASU 2014-09 permits the use of either the retrospective or cumulative effect transition method. We have evaluated the effect that ASU 2014-09 would have on our financial statements and related disclosures. We expect that ASU 2014-09 will have no significant effect on our ongoing financial reporting, but we continue to evaluate this pending accounting standard.
    XML 76 R49.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Bank Debt (Details Textual) (USD $)
    		 3 Months Ended 12 Months Ended 3 Months Ended
    Mar. 31, 2011
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Sep. 30, 2010
    Debt Instrument [Line Items]          
    Secured Debt         $ 2,100,000us-gaap_SecuredDebt
    Proceeds from Notes Payable 600,000us-gaap_ProceedsFromNotesPayable        
    Derivatives Interest Rate Swap Payments   22,116iccc_DerivativesInterestRateSwapPayments 23,096iccc_DerivativesInterestRateSwapPayments 23,903iccc_DerivativesInterestRateSwapPayments  
    Other Comprehensive Income (Loss), Net Of Tax   (3,495)us-gaap_OtherComprehensiveIncomeLossNetOfTax 30,284us-gaap_OtherComprehensiveIncomeLossNetOfTax (9,308)us-gaap_OtherComprehensiveIncomeLossNetOfTax  
    Line of credit facility, description   a wholly owned subsidiary of TD Financial Group, which is a multinational bank with approximately $944 billion in assets and over 22 million clients world wide      
    Interest Rate Swap [Member]          
    Debt Instrument [Line Items]          
    Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate   3.41%us-gaap_LongTermDebtPercentageBearingFixedInterestRate
    / us-gaap_DebtInstrumentAxis
    = us-gaap_InterestRateSwapMember    		     6.04%us-gaap_LongTermDebtPercentageBearingFixedInterestRate
    / us-gaap_DebtInstrumentAxis
    = us-gaap_InterestRateSwapMember
    Derivative, Notional Amount   799,964invest_DerivativeNotionalAmount
    / us-gaap_DebtInstrumentAxis
    = us-gaap_InterestRateSwapMember    		     1,000,000invest_DerivativeNotionalAmount
    / us-gaap_DebtInstrumentAxis
    = us-gaap_InterestRateSwapMember
    Debt Instrument, Description of Variable Rate Basis  
    London Interbank Offered Rate (LIBOR) of 3.41%
    		      
    Mortgages [Member]          
    Debt Instrument [Line Items]          
    Secured Debt         1,000,000us-gaap_SecuredDebt
    / us-gaap_DebtInstrumentAxis
    = us-gaap_MortgagesMember
    Debt Instrument, Maturity Date, Description         ten-year
    Mortgage Loans on Real Estate, Periodic Payment Terms, Balloon Payment to be Received         451,885us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived
    / us-gaap_DebtInstrumentAxis
    = us-gaap_MortgagesMember
    Mortgage Loans on Real Estate, Periodic Payment Terms         will be due in the third quarter of 2020
    Note Payable [Member]          
    Debt Instrument [Line Items]          
    Secured Debt         600,000us-gaap_SecuredDebt
    / us-gaap_DebtInstrumentAxis
    = iccc_NotePayableMember
    Debt Instrument, Maturity Date, Description         fifty-four month
    Debt Instrument, Description of Variable Rate Basis  
    Interest on the note is variable at the higher of 4.25% per annum or the LIBOR plus 3.25 %
    		      
    Line Of Credit [Member]          
    Debt Instrument [Line Items]          
    Secured Debt         $ 500,000us-gaap_SecuredDebt
    / us-gaap_DebtInstrumentAxis
    = us-gaap_LineOfCreditMember
    Debt Instrument, Maturity Date, Description   The $500,000 line of credit is available as needed and has been extended through May 31, 2015 and is renewable annually thereafter      
    Debt Instrument, Description of Variable Rate Basis  
    Interest on any borrowings against the line of credit would be variable at the higher of 4.25% per annum or the LIBOR plus 3.5%
    		      
    XML 77 R41.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Summary of Significant Accounting Policies (Details Textual) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Significant Accounting Policies Textual [Abstract]      
    Decrease (increase) in income (loss) before income taxes $ 0.01iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxsPerShare $ 0.01iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxsPerShare $ 0.01iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxsPerShare
    Stock-based compensation $ 30,004us-gaap_ShareBasedCompensation $ 31,359us-gaap_ShareBasedCompensation $ 35,985us-gaap_ShareBasedCompensation
    Advertising expense 66,193us-gaap_AdvertisingExpense 151,080us-gaap_AdvertisingExpense 174,314us-gaap_AdvertisingExpense
    Federal deposit insurance corporation limits 250,000us-gaap_CashFDICInsuredAmount    
    Debt issue costs 26,489us-gaap_DebtIssuanceCosts    
    U.S. government aggregated amount $ 567,000us-gaap_USGovernmentSecuritiesAtCarryingValue $ 1,770,000us-gaap_USGovernmentSecuritiesAtCarryingValue  
    Building Addition [Member]      
    Significant Accounting Policies Textual [Abstract]      
    Property, plant and equipment, useful life 25 years    
    Building Improvements [Member]      
    Significant Accounting Policies Textual [Abstract]      
    Property, plant and equipment, useful life 10 years    
    Property, Plant and Equipment, Other Types [Member]      
    Significant Accounting Policies Textual [Abstract]      
    Property, plant and equipment, useful life 10 years    
    Computer Equipment [Member]      
    Significant Accounting Policies Textual [Abstract]      
    Property, plant and equipment, useful life 3 years    
    Other Assets [Member]      
    Significant Accounting Policies Textual [Abstract]      
    Property, plant and equipment, useful life 5 years    
    XML 78 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Statements of Comprehensive (Loss) Income (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Statement Of Other Comprehensive Income [Abstract]      
    Net (loss) income $ (167,159)us-gaap_NetIncomeLoss $ 117,395us-gaap_NetIncomeLoss $ 89,512us-gaap_NetIncomeLoss
    Other comprehensive (loss) income:      
    Interest rate swap, before taxes (5,815)iccc_InterestRateSwapBeforeTaxes 50,384iccc_InterestRateSwapBeforeTaxes (15,486)iccc_InterestRateSwapBeforeTaxes
    Income tax applicable to interest rate swap 2,320iccc_IncomeTaxApplicableToInterestRateSwap (20,100)iccc_IncomeTaxApplicableToInterestRateSwap 6,178iccc_IncomeTaxApplicableToInterestRateSwap
    Other comprehensive (loss) income, net of taxes (3,495)us-gaap_OtherComprehensiveIncomeLossNetOfTax 30,284us-gaap_OtherComprehensiveIncomeLossNetOfTax (9,308)us-gaap_OtherComprehensiveIncomeLossNetOfTax
    Total comprehensive (loss) income $ (170,654)us-gaap_ComprehensiveIncomeNetOfTax $ 147,679us-gaap_ComprehensiveIncomeNetOfTax $ 80,204us-gaap_ComprehensiveIncomeNetOfTax
    XML 79 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Cash, Cash Equivalents, Short-Term and Long-Term Investments
    		 12 Months Ended
    Dec. 31, 2014
    Cash, Cash Equivalents, Short-Term and Long-Term Investments [Abstract]  
    CASH, CASH EQUIVALENTS, SHORT-TERM AND LONG-TERM INVESTMENTS
    3.CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND LONG-TERM INVESTMENTS

     

    Cash, cash equivalents, short-term investments and long-term investments consisted of the following:

     

      As of December 31,  (Decrease) 
      2014  2013  Increase 
    Cash and cash equivalents $850,028  $2,270,385  ($1,420,357)
    Short-term investments  2,489,000   2,985,000   (496,000)
    Subtotal  3,339,028   5,255,385   (1,916,357)
    Long-term investments  496,000   0   496,000 
    Total $3,835,028  $5,255,385  ($1,420,357)
    XML 80 R58.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stockholders' Equity (Details Textual) (USD $)
    		 12 Months Ended 1 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Jun. 30, 2000
    Dec. 31, 2011
    Sep. 19, 2011
    Aug. 09, 2011
    Jun. 30, 2001
    Jun. 30, 2010
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
    Proceeds from Stock Options Exercised $ 3,149us-gaap_ProceedsFromStockOptionsExercised $ 21,750us-gaap_ProceedsFromStockOptionsExercised $ 50,800us-gaap_ProceedsFromStockOptionsExercised            
    Outstanding weighted average exercise price $ 3.42us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice $ 3.30us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice $ 3.13us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice   $ 3.19us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice        
    Stock options granted 25,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross 26,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross 2,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross            
    Stock option plans exercise price minimum $ 4.25us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit $ 4.15us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit $ 5.61us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit            
    Stock option plans exercise price maximum $ 4.80us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit $ 4.69us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit $ 6.25us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit            
    Options exercises intrinsic value 1,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue 8,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue 25,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue            
    Share based compensation, weighted average grants per share $ 2.26us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue $ 2.23us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue $ 2.86us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue            
    Unrecognized stock-based compensation related to non-vested stock options 95,560us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions                
    Outstanding non-vested stock options 26,778us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares                
    Weighted average price of shares purchased $ 70.00us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased                
    Equity method investment ownership percentage 20.00%us-gaap_EquityMethodInvestmentOwnershipPercentage                
    Percentage of outstanding common stock 50.00%iccc_PercentageOfOutstandingCommonstock                
    Share Based Compensation Arrangement By Share Based Payment Award Option Termination Weighted Average Exercise Price $ 0.005iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionTerminationWeightedAverageExercisePrice                
    Stock Option [Member]                  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
    Exercise of stock options, Shares 1,000us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_OptionIndexedToIssuersEquityTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 7,000us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_OptionIndexedToIssuersEquityTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 15,000us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_OptionIndexedToIssuersEquityTypeAxis
    = us-gaap_EmployeeStockOptionMember    		            
    Proceeds from Stock Options Exercised $ 3,149us-gaap_ProceedsFromStockOptionsExercised
    / us-gaap_OptionIndexedToIssuersEquityTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 21,750us-gaap_ProceedsFromStockOptionsExercised
    / us-gaap_OptionIndexedToIssuersEquityTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 50,800us-gaap_ProceedsFromStockOptionsExercised
    / us-gaap_OptionIndexedToIssuersEquityTypeAxis
    = us-gaap_EmployeeStockOptionMember    		            
    Maximum [Member]                  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
    Outstanding weighted average exercise price $ 7.00us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		                
    Equity method investment ownership percentage           18.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		 20.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		    
    Minimum [Member]                  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
    Outstanding weighted average exercise price $ 1.70us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		                
    Equity method investment ownership percentage           15.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		 18.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		    
    2000 Plan [Member]                  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
    Stock option incentive plan description      
    No less than 85% of fair market value on the date of grant in the case of non-qualified stock options.
    		          
    Common stock, capital shares reserved for future issuance       250,000us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		       500,000us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		  
    Exercise of stock options, Shares 0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 (6,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 (15,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		            
    Options outstanding weighted average remaining contractual term 4 years 9 months                
    Options exercisable weighted average remaining contractual term 4 years                
    Stock options granted 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandMember    		            
    2010 Plan [Member]                  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
    Stock option incentive plan description      
    No less than 85% of fair market value on the date of grant in the case of non-qualified stock options.
    		          
    Common stock, capital shares reserved for future issuance 253,000us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		               300,000us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember
    Exercise of stock options, Shares (1,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 (1,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		            
    Additional common stock capita shares reserved for future issuance 202,500iccc_AdditionalCommonStockCapitaSharesReservedForFutureIssuance
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		                
    Options outstanding weighted average remaining contractual term 4 years 9 months                
    Options exercisable weighted average remaining contractual term 4 years                
    Stock options granted 25,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 26,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		 2,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_PlanNameAxis
    = iccc_PlanTwoThoushandAndTenMember    		            
    XML 81 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Summary of Significant Accounting Policies (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Summary of Significant Accounting Policies [Abstract]  
    Schedule of net (loss) income per common share
      Year Ended December 31, 
      2014  2013  2012 
    Weighted average number of shares outstanding  3,027,001   3,019,407   3,018,296 
    Effect of dilutive stock options  0   65,641   90,123 
    Diluted number of shares outstanding  3,027,001   3,085,048   3,108,419 
    Outstanding stock options not included in the calculation because the effect would be anti-dilutive  253,000   63,875   39,750

     
    XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 134 307 1 true 34 0 false 5 false false R1.htm 001 - Document - Document And Entity Information Sheet http://www.immucell.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 002 - Statement - Balance Sheets Sheet http://www.immucell.com/role/BalanceSheets Balance Sheets false false R3.htm 003 - Statement - Balance Sheets (Parenthetical) Sheet http://www.immucell.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) false false R4.htm 004 - Statement - Statements of Operations Sheet http://www.immucell.com/role/StatementsOfOperations Statements of Operations false false R5.htm 005 - Statement - Statements of Comprehensive (Loss) Income Sheet http://www.immucell.com/role/StatementsOfComprehensiveLossIncome Statements of Comprehensive (Loss) Income false false R6.htm 006 - Statement - Statements of Stockholders' Equity Sheet http://www.immucell.com/role/StatementsOfStockholdersEquity Statements of Stockholders' Equity false false R7.htm 007 - Statement - Statements of Cash Flows Sheet http://www.immucell.com/role/StatementsOfCashFlows Statements of Cash Flows false false R8.htm 008 - Disclosure - Business Operations Sheet http://www.immucell.com/role/BusinessOperations Business Operations false false R9.htm 009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.immucell.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R10.htm 010 - Disclosure - Cash, Cash Equivalents, Short-Term and Long-Term Investments Sheet http://www.immucell.com/role/CashCashEquivalentsShorttermAndLongtermInvestments Cash, Cash Equivalents, Short-Term and Long-Term Investments false false R11.htm 011 - Disclosure - Inventory Sheet http://www.immucell.com/role/Inventory Inventory false false R12.htm 012 - Disclosure - Accounts Receivable Sheet http://www.immucell.com/role/AccountsReceivable Accounts Receivable false false R13.htm 013 - Disclosure - Prepaid Expenses and Other Assets Sheet http://www.immucell.com/role/PrepaidExpensesAndOtherAssets Prepaid Expenses and Other Assets false false R14.htm 014 - Disclosure - Property, Plant And Equipment Sheet http://www.immucell.com/role/PropertyPlantAndEquipment Property, Plant And Equipment false false R15.htm 015 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://www.immucell.com/role/AccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses false false R16.htm 016 - Disclosure - Bank Debt Sheet http://www.immucell.com/role/BankDebt Bank Debt false false R17.htm 017 - Disclosure - Other (Expenses) Revenues, Net Sheet http://www.immucell.com/role/OtherExpensesRevenuesNet Other (Expenses) Revenues, Net false false R18.htm 018 - Disclosure - Income Taxes Sheet http://www.immucell.com/role/IncomeTaxes Income Taxes false false R19.htm 019 - Disclosure - Stockholders' Equity Sheet http://www.immucell.com/role/StockholdersEquity Stockholders' Equity false false R20.htm 020 - Disclosure - Commitments and Contingent Liabilities Sheet http://www.immucell.com/role/CommitmentsAndContingentLiabilities Commitments and Contingent Liabilities false false R21.htm 021 - Disclosure - Segment And Significant Customer Information Sheet http://www.immucell.com/role/SegmentAndSignificantCustomerInformation Segment And Significant Customer Information false false R22.htm 022 - Disclosure - Related Party Transactions Sheet http://www.immucell.com/role/RelatedPartyTransactions Related Party Transactions false false R23.htm 023 - Disclosure - Employee Benefits Employee Sheet http://www.immucell.com/role/EmployeeBenefitsEmployee Employee Benefits Employee false false R24.htm 024 - Disclosure - Unaudited Quarterly Financial Data Unaudited Sheet http://www.immucell.com/role/UnauditedQuarterlyFinancialDataUnaudited Unaudited Quarterly Financial Data Unaudited false false R25.htm 025 - Disclosure - Subsequent Events Sheet http://www.immucell.com/role/SubsequentEvents Subsequent Events false false R26.htm 026 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R27.htm 027 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.immucell.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) false false R28.htm 028 - Disclosure - Cash, Cash Equivalents, Short-Term and Long-Term Investments (Tables) Sheet http://www.immucell.com/role/CashCashEquivalentsShorttermAndLongtermInvestmentsTables Cash, Cash Equivalents, Short-Term and Long-Term Investments (Tables) false false R29.htm 029 - Disclosure - Inventory (Tables) Sheet http://www.immucell.com/role/InventoryTables Inventory (Tables) false false R30.htm 030 - Disclosure - Accounts Receivable (Tables) Sheet http://www.immucell.com/role/AccountsReceivableTables Accounts Receivable (Tables) false false R31.htm 031 - Disclosure - Prepaid Expenses and Other Assets (Tables) Sheet http://www.immucell.com/role/PrepaidExpensesandOtherAssetsTables Prepaid Expenses and Other Assets (Tables) false false R32.htm 032 - Disclosure - Property, Plant And Equipment (Tables) Sheet http://www.immucell.com/role/PropertyPlantAndEquipmentTables Property, Plant And Equipment (Tables) false false R33.htm 033 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://www.immucell.com/role/AccountsPayableandAccruedExpensesTables Accounts Payable and Accrued Expenses (Tables) false false R34.htm 034 - Disclosure - Bank Debt (Tables) Sheet http://www.immucell.com/role/BankDebtTables Bank Debt (Tables) false false R35.htm 035 - Disclosure - Other (Expenses) Revenues, Net (Tables) Sheet http://www.immucell.com/role/OtherExpensesRevenuesNetTables Other (Expenses) Revenues, Net (Tables) false false R36.htm 036 - Disclosure - Income Taxes (Tables) Sheet http://www.immucell.com/role/IncomeTaxesTables Income Taxes (Tables) false false R37.htm 037 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.immucell.com/role/StockholdersEquityTables Stockholders' Equity (Tables) false false R38.htm 038 - Disclosure - Segment And Significant Customer Information (Tables) Sheet http://www.immucell.com/role/SegmentAndSignificantCustomerInformationTables Segment And Significant Customer Information (Tables) false false R39.htm 039 - Disclosure - Unaudited Quarterly Financial Data Unaudited (Tables) Sheet http://www.immucell.com/role/UnauditedQuarterlyFinancialDataUnauditedTables Unaudited Quarterly Financial Data Unaudited (Tables) false false R40.htm 040 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) false false R41.htm 041 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) false false R42.htm 042 - Disclosure - Cash, Cash Equivalents, Short-Term and Long-Term Investments (Details) Sheet http://www.immucell.com/role/CashCashEquivalentsShorttermAndLongtermInvestmentsDetails Cash, Cash Equivalents, Short-Term and Long-Term Investments (Details) false false R43.htm 043 - Disclosure - Inventory (Details) Sheet http://www.immucell.com/role/InventoryDetails Inventory (Details) false false R44.htm 044 - Disclosure - Accounts Receivable (Details) Sheet http://www.immucell.com/role/AccountsReceivableDetails Accounts Receivable (Details) false false R45.htm 045 - Disclosure - Prepaid Expenses and Other Assets (Details) Sheet http://www.immucell.com/role/PrepaidExpensesandOtherAssetsDetails Prepaid Expenses and Other Assets (Details) false false R46.htm 046 - Disclosure - Property, Plant And Equipment (Details) Sheet http://www.immucell.com/role/PropertyPlantAndEquipmentDetails Property, Plant And Equipment (Details) false false R47.htm 047 - Disclosure - Accounts Payable and Accrued Expenses (Details) Sheet http://www.immucell.com/role/AccountsPayableandAccruedExpensesDetails Accounts Payable and Accrued Expenses (Details) false false R48.htm 048 - Disclosure - Bank Debt (Details) Sheet http://www.immucell.com/role/BankDebtDetails Bank Debt (Details) false false R49.htm 049 - Disclosure - Bank Debt (Details Textual) Sheet http://www.immucell.com/role/BankDebtDetailsTextual Bank Debt (Details Textual) false false R50.htm 050 - Disclosure - Other (Expenses) Revenues, Net (Details) Sheet http://www.immucell.com/role/OtherExpensesRevenuesNetDetails Other (Expenses) Revenues, Net (Details) false false R51.htm 051 - Disclosure - Other (Expenses) Revenues, Net (Details Textuals) Sheet http://www.immucell.com/role/OtherExpensesRevenuesNetDetailsTextuals Other (Expenses) Revenues, Net (Details Textuals) false false R52.htm 052 - Disclosure - Income Taxes (Details) Sheet http://www.immucell.com/role/IncomeTaxesDetails Income Taxes (Details) false false R53.htm 053 - Disclosure - Income Taxes (Details 1) Sheet http://www.immucell.com/role/IncomeTaxesDetails1 Income Taxes (Details 1) false false R54.htm 054 - Disclosure - Income Taxes (Details 2) Sheet http://www.immucell.com/role/IncomeTaxesDetails2 Income Taxes (Details 2) false false R55.htm 055 - Disclosure - Income Taxes (Details Textual) Sheet http://www.immucell.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) false false R56.htm 056 - Disclosure - Stockholders' Equity (Details) Sheet http://www.immucell.com/role/StockholdersEquityDetails Stockholders' Equity (Details) false false R57.htm 057 - Disclosure - Stockholders' Equity (Details 1) Sheet http://www.immucell.com/role/StockholdersEquityDetails1 Stockholders' Equity (Details 1) false false R58.htm 058 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.immucell.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) false false R59.htm 059 - Disclosure - Commitments and Contingent Liabilities (Details) Sheet http://www.immucell.com/role/CommitmentsandContingentLiabilitiesDetails Commitments and Contingent Liabilities (Details) false false R60.htm 060 - Disclosure - Segment And Significant Customer Information (Details) Sheet http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails Segment And Significant Customer Information (Details) false false R61.htm 061 - Disclosure - Segment And Significant Customer Information (Details 1) Sheet http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails1 Segment And Significant Customer Information (Details 1) false false R62.htm 062 - Disclosure - Segment And Significant Customer Information (Details Textual) Sheet http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetailsTextual Segment And Significant Customer Information (Details Textual) false false R63.htm 063 - Disclosure - Related Party Transactions (Details) Sheet http://www.immucell.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) false false R64.htm 064 - Disclosure - Employee Benefits Employee (Details) Sheet http://www.immucell.com/role/EmployeeBenefitsEmployeeDetails Employee Benefits Employee (Details) false false R65.htm 065 - Disclosure - Unaudited Quarterly Financial Data Unaudited (Details) Sheet http://www.immucell.com/role/UnauditedQuarterlyFinancialDataUnauditedDetails Unaudited Quarterly Financial Data Unaudited (Details) false false All Reports Book All Reports Columns in Cash Flows statement 'Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 28 values. Shorter duration columns must have at least one fourth (7) as many values. Column '1/1/2012 - 3/31/2012' is shorter (90 days) and has only 2 values, so it is being removed. Columns in Cash Flows statement 'Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 28 values. Shorter duration columns must have at least one fourth (7) as many values. Column '4/1/2012 - 6/30/2012' is shorter (90 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 28 values. Shorter duration columns must have at least one fourth (7) as many values. Column '7/1/2012 - 9/30/2012' is shorter (91 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 28 values. Shorter duration columns must have at least one fourth (7) as many values. Column '10/1/2012 - 12/31/2012' is shorter (91 days) and has only 2 values, so it is being removed. Columns in Cash Flows statement 'Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 28 values. Shorter duration columns must have at least one fourth (7) as many values. Column '1/1/2013 - 3/31/2013' is shorter (89 days) and has only 2 values, so it is being removed. Columns in Cash Flows statement 'Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 28 values. Shorter duration columns must have at least one fourth (7) as many values. Column '4/1/2013 - 6/30/2013' is shorter (90 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 28 values. Shorter duration columns must have at least one fourth (7) as many values. Column '7/1/2013 - 9/30/2013' is shorter (91 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 28 values. Shorter duration columns must have at least one fourth (7) as many values. Column '10/1/2013 - 12/31/2013' is shorter (91 days) and has only 2 values, so it is being removed. Columns in Cash Flows statement 'Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 28 values. Shorter duration columns must have at least one fourth (7) as many values. Column '1/1/2014 - 3/31/2014' is shorter (89 days) and has only 2 values, so it is being removed. Columns in Cash Flows statement 'Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 28 values. Shorter duration columns must have at least one fourth (7) as many values. Column '4/1/2014 - 6/30/2014' is shorter (90 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 28 values. Shorter duration columns must have at least one fourth (7) as many values. Column '7/1/2014 - 9/30/2014' is shorter (91 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 28 values. Shorter duration columns must have at least one fourth (7) as many values. Column '10/1/2014 - 12/31/2014' is shorter (91 days) and has only 2 values, so it is being removed. Process Flow-Through: 002 - Statement - Balance Sheets Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 003 - Statement - Balance Sheets (Parenthetical) Process Flow-Through: 004 - Statement - Statements of Operations Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2014' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2014' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2014' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2014' Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2012' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2012' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2012' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2012' Process Flow-Through: 005 - Statement - Statements of Comprehensive (Loss) Income Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2014' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2014' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2014' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2014' Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2012' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2012' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2012' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2012' Process Flow-Through: 007 - Statement - Statements of Cash Flows iccc-20141231.xml iccc-20141231.xsd iccc-20141231_cal.xml iccc-20141231_def.xml iccc-20141231_lab.xml iccc-20141231_pre.xml true true XML 83 R38.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Segment And Significant Customer Information (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Segment and Significant Customer Information [Abstract]  
    Schedule of sales to significant customers

      Year Ended December 31, 
      2014  2013  2012 
    Animal Health International, Inc.  38%  38%  35%
    MWI Veterinary Supply Company(1)  23%  22%  20%

     

    (1) Assumes that the November 2013 acquisition of IVESCO by MWI had occurred as of the beginning of the periods being reported.
    Schedule of accounts receivable due from significant customers

      As of December 31, 
      2014  2013 
    Animal Health International, Inc.  45%  39%
    MWI Veterinary Supply Company  26%  26%
    Robert J. Matthews Company  *   10%

     

    *Amount is less than 10%.
    XML 84 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Commitments and Contingent Liabilities
    		 12 Months Ended
    Dec. 31, 2014
    Commitments and Contingent Liabilities [Abstract]  
    COMMITMENTS AND CONTINGENT LIABILITIES
    13.COMMITMENTS AND CONTINGENT LIABILITIES

     

    Our bylaws, as amended, in effect provide that the Company will indemnify its officers and directors to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings to each director through a separate indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically unlimited and is impossible to determine. We maintain directors’ and officers’ liability insurance, which may provide reimbursement to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification obligations were grandfathered under the provisions of Codification Topic 460, Guarantees. Accordingly, we have recorded no liability for such obligations as of December 31, 2014. Since our incorporation, we have had no occasion to make any indemnification payment to any of our officers or directors for any reason.

     

    As of December 31, 2014 we had committed to contracts and purchase orders covering approximately $326,000 related to our 7,100 square foot facility addition and an additional $550,000 principally related to the production of inventory.

     

    We enter into agreements with third parties in the ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging any of these indemnification obligations, and based on our analysis of the nature of the risks involved, we believe that the fair value of these agreements is minimal. Accordingly, we have recorded no liabilities for such obligations as of December 31, 2014.

     

    The development, manufacturing and marketing of animal health care products entails an inherent risk that liability claims will be asserted against us. We feel that we have reasonable levels of liability insurance to support our operations.

    AT3QR_."-J]3XC@"`W:7.%7L0O MAIA34Q<.51KDZ_@CBL*9X:?!P\#B5,YA%,)[')O-TK%EXUEO0TND--!K*&9! MNHV8]*E7B[#F\K'(,2H_U:5^O`-3/:W9Z+VC`SZ"=B^I6_H!_T]\5`PZZT1E MD2GG9%7]H9--2N6/QRA=?-U2E70+%@9GE9\#B?\A#2U1>]A@FYJ&$2,J$\/ZP`!VFQI!Z;MA]N@W!Y=OU5-]'+C``3Y[< M7KP_!1=R#I)MUUCLW9KUC=H>_[61;#H%$>""0&`]#FC)--1XKB&D,=UZO$U* MQUH=G%OMM=,M*8J-C"F$JR3%?W1U,ZP?*\:^LL006&"7L%X@DCH;\A3Q3!!Q M0DP";[5`8>G=/Y"?4NA]K:RQ&I/PCB,PVTSI6S+\D4E*!:QC\F=7BZ1ZCDYD MD_@J)?R"Z11J!4',E=0G=\UQ%3PI8^!GLJLE%Z?Q8>P841%S//#Q(9U%I4R\ M^:$^6'E4%*::FL,O)^D5%9B'*_&^DF$4^@K`(P:QK,`[]N&F5ZA0P#R4\4T> M%+2B=+P`=][22S;28+.7BB[^F[Z!1.]K*8"D(=UVD9*$0_&_]MZUN6TC:13^ M[BK_![PYSGGD4Y"".\ED-U6R+6>UQ[;\6$IR\LD%D4,1CT&`P46R]M>_W3,` M"9``"!`7@N1L;1**!&9ZNGNZ>Z9O.ZPZCF3.6CVC`?O=HO7&<)?#$-QVXM=D M)V(H_4\'AE+4)YT;2MQ0Z@G2+B=TL]%HY%6"2)0',F$7''&226S:6,F"\HDT M%5K,!"T8]A@]V$?#+P_WM.46UOJZ$))3QXDG428/NV!Z91BB/%)%X96LRZ(T MC"N3#C11E;7DS#2I%*.8X<6-6J7TWVIJW3OQ.M)`0;=#.-2G7I'O.;$V$P$8E MK@+DS))QKP,M,^YU@\=9<.OR]S5JT>^8!DY?#CPE3X.F0)48``L0)CP26%F3 M^BEP#8E'R"IT%'[PR#1T)JOH4@RQ)?3(7S!:9C(6/L]N^EF"*9EC-70X#<>5 MM,=18`N-'(5AGF@#ES@=]SO5MLODW56]47KXC<-D+&IZT/`4V_J&L7`T2@6C MQI8->U(KB+*CGBS0[/?QL(DJ)"O@610?HQ`M95IA6;'KYMYUOR7'2`][0:^G M/)22]K.8#GE;!C%/J+<)4P*ISR453I>SNHL<%CR7)2S5[J&?+JIDE\YO3''V M_3-M73/VK'N:(R9@@N$\G,>L%E5?@4=F+A9\I_=(%`I:O!U_G8>8#$!6%U4L M/3GAD(V]@AD]E6B&-:OG!QA"#`.L'NMO>H])=M2)Q0*):+,@E"?F>)58!UH1 MP_G8%ZQ5)PX7VE'Y/P35#0.Z9&"BT(D",^G$<1PX)0OM`K!JC[IT"]*656PR M\MW$^RLV6>1CI*$3&$D>7P?>1A7*Q5%`ON8OMDF:3OKT1'TKDGR]S& MYC;V"=O8=@T\"5%)AQL9KU MM8#1/8]"I>/++@R..J=14=$SK$`.B]I*9V+1A'XZG."R<)P'STQ&=*WL<3<1 MD09OLN=6D[ZQ38#I=@Q6'!:Y88.ACPX?F+L38M/KL`D!L\%F)AO3T,J9^7K3 MA%T&/;U2LOB./JJUS98CT06=Q,>@<4U[\#B^H3]4SY0011=_GP&\?&6!0;W MO?:'LTW^7-`8%CUIM?GI1/DYD#0`BN,]R3VKA'P^L>P0#0AF M!6*(]9@N)$&?,NM/O-+(VEDPD876Z3N$$,9I&ZHRI!`6-EA1M"5\+LHIAV(C MD._$&UL^B2+2Z(46IC*S7.JHR%@,1I2SP!Z-"R9&:**C;X)BQTG9&TN((KV6 MN8Y1]%S<2QN$F.IC-=8XQA.;"!Y3$GU)(V6JZU;;7[MT@<.=9)EN22\8T M&RIA>#+VR\1_EBV6-58$YCF#``:\T%&YKD_!OF"R!L&U)[5F+3%\3!L&V'FT M-^[Q\+W^6\Q5#/3T;Q2(GP7?M:T)4LI%0CG__$%F9/D+2]%?;1Q.>X'"A`'+ M.:<_G*-0\/'VX@#0=?)$4@\`7;TETLL779%)Z07"JDAR^,XDQ@M_VL, MUN5TFB6,8^1(DIIM^V5*YC^KV/:Y&(SG-G#F735`:I"2X%<85E/6Q_5PZ3D# MJZ*D#$1)DO<%;J]1*5=$I3P2-6FP=5R]'7#U)E#9$FS543D4E9'1#;@UA14] M"6ZS&QE<)<4M'>N*AGJAA(KO8=*7"=LNBDM-4E'C96.W%=6V`W0Y+-4:>%(% MG#5,%$[CCL`S=-'0\K4C)_2Q$'HDB;)2[HS3(*';LY.W`ZSE@AM?J^]D))>? M9D_\JN6RPX3VQMXONY:#;KO=7H?^.\@E3N5VJ#S414D;<,G?$:<$6I>Z;U)=SD^E,Q8<6*,PVBC(Y$\D7*QG@[B0JIQ)=H7H<'!BJ.)PH'.4).]61N)`;X]+NHT5JY7G MV7N'?^]0UJ-PL?>8!IK=,<4C#Z:WC+Q*!N.DHF8B'8(8(\FX\I[3H/]LRT./ M#RCTV.D@]/AWECI[%2=;YL[(`XV/57-4+JKP\D6+:+NC$8QD8:Z:[&0FIUBT MT38N"@L/T.#'53*6.<9RQ&223&6/^N[85`M%J36`8S.J;D@;6WPCR;QE9Y)J MR\IRV=E)A156QL:I.$G4C1P3AE:-;^.J"'&GCDFJRR-K:?Q`"S7GO!.D$K3R M$N(3=9XWP8EJ_\7)Z%&!HXV85,S7HCG9\:M9.=EN*B>[`YX^8AG`U?!^U7"! MTG5W5+I%V3U/R8JSGSW7<;'B`BOTNC]]>]@[RS["BC=7=^7U#]?I3%D]Y-N0616A)VARW7#N;PU2.<73L@4Y^CB@6TU?/E[1O! M@A/0%NT0Z07M7!IEZ86XSA4]1[QUL7WJ.(CR[=[&_3:S4CO/(@&-`[]>%7>( M>S([V#<)#W^I8Q('(-9+E=:R985>Z2ZC+8WH&%C!(BZ=QNC%0BL6 M`+*%F7V%\-OEY>>H$"^62$/)X:^ZXZ3GLA*_+%<0-R:'P?]M.B$626-: MGH\3FM%BKKH%EMH/:+/6Y`3L:R:20G97%"DA=N9,ZEM:07!._7N/ M2Y\>16=4^"VJ6Q(7(DL7,HN?QU-V"IVKA$BWJ%B%L^IRE;AQ9MKK^R)[:*14 M5%TOU4,V@B6:+VYDM)J7G;7A.]:C]FFIABFGQ>N*\V'9!7?B*L*/=M":[/YI M8CWBYW_\%/KG#Z:Y^/EV!=-J`W[&9IP6\>]@+[^QW?&W7U^^^$?\QEO3G^$_ M5ZNFXI?.Y!;[>=\!*:]7S<.7KU/8X8\O9/K/']ZRSU_?_W7U59*_`O]\16S= M2=)7]O^[FZ^J_/4=&:>__^%77$&T`'[$[?,15[VH=:V<'3>P.9RIHH6BNIRJYQE^T5D[_0\@\^K;T5 MF?/T8(-KZ(\-WR/^Y:GV;:?:UXMJZ6U"9\OIG`8%_W*C*NX>$75P&;WKR;%G M[Z(J?:\[7V.#!0CX?FJIU,"Q[J`>(3\_O88COUWD7T=E27LM^;HH!("6=E2C M/VULYV)F;YGJK[:.5BW7?ZA+HJ3DYY(<6Z9_"?Q5RDI71&4@B>HP/Y[\V!+\ MSYI&H2QJ"J!0;[9&PKH]U\]\_MO,LWQ=@1\JK4>8 M4,EI?0*T/M-&1HND;ECI[)3)OS5S\C:\IU$CN3@XH+PU455'A?;K*6;SZ:*B MZX4VZ2EBY4P61[)1:&<>E6GY(:6@`R'N+D8^)^XF'@NN ML_=(W>UWXG6H6W"`20WRTCI7DX\(F&`VL[A@/G MCXC!NY_N;K[\E3LP#]WM7>CN@4?I+B4:#[/E8;8]"[-=1L+SR$`>:;OO2-N# MB#;C&XJ'VAXO\GFH[;Z0?R!I!HT%VQ8+RB_FDX#5O#S+M$\@QE:5#%'3\B4? MC['=$F.+$;;ZZ438-HT_U1"E87XA^8-KFU4L7/YTO6]P&CRGW:C]?/%R.)$K MP/OB0./1/,FA!D-5E`Q>V#X5X:0I`U&5:S-*'Z(8RSC'WUN.Y<_B(CEU#2L> M"E$[D!KVI&[D]V?D02_'0FD9VXJ,.F^,QBG=/:552=0&A]8"KT9(+0]NVBW^ MY>6+KF,D1AJ8Q07'0A[_T$MI4%)N4 MC&'ZX)J.C[V!_#O/G)!+9W*#=2F_D#&Q'G$*GPGMU_>FNVIM@Q0Q6<7I7#)I$9E9W%XOFQ7-U#A!5G M7AZ.52L*\,@K'GG%]PX/LCH5Y/,@*QYDU4V058$+E]Y,Q)T?DC:T*,#, M!5$1?0X:JA1T)8N2I(FC47Z(``^[*L:@(8U$0]U>&I*'7>6$[8QT4=65;O#7 MSQHT<(AG?7FP.RP>U6F_(6P7=&].A`FY#VC9U87G3L)Q@%U]0L_AD1Q[]_J> MR88HC_+-R'I<45L]J'1WIF92+^L;QA MOXD&!IC&]_9:&H1H##A*DD.=R2-1'M;>VGW0YV7LCJB5>V!^)TF%SJW-?5N; MO-#E\=-8JQ.,R8E\&$0^:XW*_2F:72W"/R,.J?@`>22AP[V,'$:GCBXJHSH7 M&SPNO*?$-519U"J=4SEI#X2TZD`5A\..=VV%T/^=0OHQ)\`:C\<_?_;(PK0F M5]\7Q/&)'[]]Z?LD40:UP0R`_H?]\UA_HYM8_\]?KCY?7K\3KO[?YZM/MU>W MPN6G=\+-W;^NO@B7M[=7=[>Y4)Q8Y'^-R&B[^Z*H3:%.-5!N[@]WD6@42"0; MJ;O?I3>V)A6/!QS3OV_<'EO$?E^JIN:%-?(@3!ZZ7XH4#8;N'TA(*]]1/*#_ M:)'/`_KWA?R#2%SJ(IQ_JQF=BZ$^1Z-7B^=7,8IE>Q5+'LV?@S]]!/C+[R=T M;-'\!:5/=JQ"JXNC4;/9$/WQB15Y[F[)./2LX%F8D(7K6^6;R'(W;7OU]T2E M4M@/]\!]4*KC(>;8MGM6&HCK* MM\:Y=#H:2F\Y-W1-:0S=Y[1N*RM0$@?R\44`'G\B0*=`[1\"CI:^HZ5+\S(3 MLG=87,#R_1#+!OH%EQ:'0S;%$+6"/CZGR,D<)1M#'6VB9ZJ8R-R%:?]C!I;K M8+S!Y/AV.];@T`:U>3L_<."04*&*AE2E8/CQHD(1A_638`\EX9.['GIW1AR* M(X7?2A\_G0T_6P?JHN:4L=P; M^MES%Z"`GC_;IA/`\U=_A]9B3IR@W7:A_2\6PGN$LD'OZ;UK5W5#;CY??;G[ M2Q0^?[C\=$?+AES]]^_7GS]>?;K+A>"`:H:TU.+RJ/N"-E/1HA&GI/X1,1126JX9P2"?H.WUY9)/_F[Y1(T'?X]LJJ[=]X:,]%7>,:<$OA MHJP%?C"!8&;@>L_T&`^CAU-S'(0>H&EUJ-]"B)V`353MJ<7NNT]>!4_YM^TU MH-A292D+#E74%474#+T76.F`2"?.(<5ED+(Y1!XJA8WVZC@:^L4A^CXYI#(N M>L,AZD@<%&0O]8(_V@H2V6%QF5>D^4MZ$UHV6AE4H5KSA><^$E2BQ8EO%6'J MFNGWO^<[BW279-$16U4N.T?!YSJQ50?B49!P_1] M(:!79\0J*[J93JTQ$::AYUAP%"1I#R]G[,X86QM(HB'E%W@Z2`QPFA=;Y[HF M*MJV2](#PP"G>2$(LFR(JK'-=W)P&JRM0]C6]#[<$S+FUB. M`.>[!X_X]'3GAS3LY$QF5]?1G_0S#KA"*]]57>PJ44'].>B?9[O->G0`K.S\_P+&O292VY_*N2=GN?-V=[IANEZ5+ MHM2VX.T)!_4$#,[(G)$Y(W-&SEO6P?!PKZ\9\LL%9*VQ,#=*%`!PG_N!NSL: M#$5EB*6*&@V7VC\.NIH/7=5]67,ENANBKAKBP,COE\#I?A`KKG@1,-`,<6CT MSV'6JXN`!E1YLM[WA"P\,K9HO6]NG'+CM-RRSC11TW1Q-&Q91%?FHFU9!YR' M.0^O>%B2%5$J*'_/>9CS<,]Y6%5!"K=\0*K-P0=Q15"RS.`.]P8.:33LKJ#L MUD%MZ*U%R;K*QFAB&]=9C"H.U8%H:"V??'K!-[T`@C-O3GS=K$8653A"#`SD>PVDD\#^;S[CGX$WXQ@O) MY(-EWELV`$G\4Z\TRYCJE,O+#KLI+WOY]NW-[Y_N;H7/EW]=OOEP1>O+PI=? M?K]Z)US]O\]7GVZO;G,A.1P%THC4JR'J#J5R9T/E>'?'5"P=P?IA, M0`HD*N)=4%>V[^5D>\J(AUH8=9_54/.!L>K2>X:_XAIQZ_A316V47SVP5*FWW5>N-X&^ M*K`UCCYE(`Z'^8[81O'772O%Z@('CH^3XDKVA]$14Y$T<2A7Z6J]*T2'@Q-Y M-!('/$UV4*K5*[G2GU^^)''DL<*M[KIUO1QP.P61-%^4!9^+D4`-= M5+FL2PV%A42-]KAD_RJ<;NNQ;3DX([P>3BQ2G*1X&(2355D<:?E11:?(S'QK M=\DA_5':GCLEOF^Y#NSP*[P=S;LT` MV.(J:(4ERP$UU&71&-21/;6HP4G;'E!8($%1\GN9<-(>+FDE0]2T]=H7F<'5 MJ_2#'=,(DID([\A]5K)"?S,-E@0IDQ;0J[!_QN5;@O%']6+^2\WQYO+3_Q7> M7;VYRYUJ3T']V31,P;XF65;`=Q3NG14IGP_VNU5243"SO,E:4I$D"D]$,!\\ M`D?TP(7!O3D-A!T#YYF6(XP],K$"80I,RW8SL%"6],YYLH?+JXO!#. M3.%IYMKVL^`^.3"0'][[UL0RO6<<"IY];SFF,[8``;^!.;@0\;)A/!,L7S"% M>6@'\'/`;@+O850VA;E8>.YW:VX&!`9^-=(T`22*'65:F;Y/`I_&Y;NP2P1% M$>;1KV/;PMYV&,-M3W`WD->P0ECB`TP"N`@7N-*UX151EFB5U1@VTP.10<8@ MDB;"_3-=4F`Z`:P!'H=_XC"<3#'R[/\.!OLE4PG@G\` MW\[Y,S$]8>YZP8/Y0`3;-1T1'S*B1Z;6-'@^G^)<LBV M'$+)1N=/X-<]9>\I_,!=L6%"J:K0?G%C(.`!O``*"<4#83),(4QJ&, ME1[B/L8'POW!=2;P\1J?H"Q^`X,A:WW!1\\^7+^Y^?(:UZ->:/*/P%29"8=T MA]+TP._P*IT%'C,N).W'"^$2D`6*QGHT$4;&>$`^]\$!5;4$!#`/.Q$6.",D M$$Q<&K$\8%CXUZ-IAX1R(X39"R46M;40N^>Z<\0=4]L$R>F\4'>T3)N)HJ'Y7.,PO%(R<$C MWH@X8$F%B*5@;[Z=F&EL>;(%8B?`.R_@ZM2&[FC!C@ MX1R>>*6`X)4-$3ZHHC0R*"_@YY&D)F4.BA-?(`Z2(",/%\.=Z:L*5K\"`/Q% MO%5A8_AT"/@2-$TLMB=D;/DT$=>-&(O*AC2H(+._406Y)']%VHLQRZU0?/8* M@QGUU[!D51*5(4"/@)^]&HFJ-'S=S*)C!>"1J0W?,02,Z2Y`B$IM@#,[WF"O MF9++8NM2(V6)D-#'5;KW8/8\4O4$AL\W$IPSJ6DYBQ"@=CTA=!+/1%]3:YM%L\8S8VAC`Q`Q/(3G<&S(+HR($,*#ZV87%,)`&8-@'T"0K=2YO28F81 MS_3&LV?T7CY:D3QXZT[@_3';;G?NPAH+0T42TW:BA<;8>QSJ#SK41V*B4F(; M!HFX.@(Q3RA](5-7QX8!M0-RM716"KE\P300(B'2!W000`.3IV@F!$R8@G!G M[VD7BOZCL(`_T(*8(U&H1D.5)2SLT`>=E7J"[KCL?'E\,:DOD@2)U3-;%M"" M3LS8+,?.H0;DHVG9#'*TJPD2):50P%QF6RB8@>WY,!,^FL\Q2#KKB)QE)B&L M'C&G`"*#86UJA#!T0I_Q3::VCO:FFL:ZZ3SCF="CB:(`_P.8V3Y#^OH4;@@& M[#VI29PT;8KL5#!R_P=H@S(QMO^G2\M]#'8V?$9]"N86/H['`ZQ>8*W4#QK& M8%G;L!T0WN4[!5ICW03TJ;T7`LE02M\#SF#/@^G-ZB?DH9KN`BKLV*9,I>,* M[`8@4D?4-*4R9#DCO@ZS=IJV6W#4W"$]-C\[M;/LTWVGX2!TGP'[[K8600A" MO1I)S16.YB M,?I&AJBJ^17E>>[BEGAH71+5@E*&!Y>[N+NLR4_XZ'GDZ\L727$R`'JVEY1V M,$CA&1!Y^J9=!NDF@&WW75Y<+_LP2(B]CW6>Q(<,TJD6KY32B$[A"EN>IT)U M!)XV4D6CH%`83WH[%DI7$<2'+%(`O]BWN M@*=.L-(D!DI'`/2,7?(+XS>8C[8[6MMNY'5BZ(QBO@^+10]T[W(TWHO#IJDZIB'5Q04DW+=L++CNF.=K; MJ?9R-$_+"=:^C:.?XR_SV!"SO\YG:P^[WF(&C/VS8(:!F\?JV[KC9C#X%C[- MX>[!:#MK2A\J^86SN+'E:\$CC\0)$<4.YOU6;W3) M";I7@NZ205A7BU8C<;4&FPG,[K/7Y@9?)@D2Y>_LZN;/2O/)]FMU;SC:IR!-VBG!_*))OMN5GDR2-_G\TB3Q[Y^=E-?9!Z MM;(L2\K'#]88+4_!7=`B*E-"$X3]D!HN9S(K0AS]F8NLYE,&2T)?-N.R<#AV ML[4EN&47Z/:2;-DSDX%BNIYO#Y[B=I8541OEGT].$B4#4=EP!_9F7]=5S\M='=U' M'P'!SO2!.%3*IW8?L4XZ,PS1&);/CSMF5`QT41D41U?N@(K]J.67+Q(@8>R! M8/E^2"M#)NL1'P/9E,+4UE-B8,!$0>>I$\-$\SRQ/T5<=.'*O,6T;"VK?4W\ M\B2L>9/;7B7#)KBE<^C2I]Y1@4U8]B:Y[A;E]&V)OJK6(GUWD82'IJ/KU[;1*I+^Z*-W#X)B<1`HGL!0Z,-XVZRDRP.9*[8$W18#[6 M;HGV<9JN=7]`4#^:?B#^PL6V_!YPF9 M$@\;BT7VH!`N`'JZQ$5P(6SI=:F*K,%0UA*Q'1A.XKBT^PWY3L8A=ED$)F.1 M2;01D&`%/NV(8],>-1,+2$><,OWXYIS0#28* MK[2!:$@:[;MC+JP`.`>'BLUD[/*#/7OHN.X&Q7:@45IB;%"+]IYZ\BS8GMAG M;GJQ$B>K-+1*.6;)Y#3VSIWY?:^Y:&O"+B\339)^3`B^XVP,+,L==`:^_O3V MYN.5<'?Y_ZYN MPT9_PMD]<;[4%FUIWYAE5&5%99=&S_[B7,O7$K^\#P?9\=^=,75>SE+ M]#LEY^21O\^4G)-'_A&FY!C:CSEF8U:UQTR9^3:$(ZV3[X")4?[C[C(W,42! M890<=&L.Q.C'K'O2[,&4@N#;ZJ!56^^!HDR59(ZR:B@;%%1-;Q!E^V^#&>R).IZ%?ZK0II\F<4)W!%XLB(.]?R# M5#WZ\JXFO2*T7-!.O25"=VPJYL!<^J+I710]T3:[OGS!&7:KZAD.1;TUCN6J M9^\$'@Y$O:#'!U<]QT)H69+%D9I_P=U/W5/O;)/;SBIS#<5]J4J%3>^33;<& MD&\+66^%.\M!Q0*):O!F/C7*ZY@#I6@_"4KCP5HAZ`Y*A5.V.:"BZ+YN2=M] MS&(!VOR8,T2!CP/UN3!FH>'?!ZLR8,U6PW6+'`JOXUMK)3EM6&I MY2)I+_%T!9<0.P34#0UQ6%"N3\WO3!=,`+&]C1[=1JW8#GY8O6:2=+HE*0H7"*[(RQ9$KM M0->C0@F81`6-$@YT$]&X57G$"'YTI;NBMJL2R>#:?!'LM M/]A&MBT6I#,<@O5EH\?'S-]J:(QYTF);?DBP:+>[Y M_[#1]J:6;E\0L- MQB^(BB&)0ZE.U"L/3NDM<65C)`Y''1-WSS6?HD:I)Q2Q\B<19N8C]CWVRQS5 MT?]O+A:>^]V:P^/VL_!*%H?ZD':9#F9F@):B!6[0*(:N9",RD/"6H6^&L&9'@=C#:$1 MB+A+-1W^B0"-)B39UWGJAEXP2S=VEC3:"!IP3_NGFFA"`TB!Z3Q8&"C#8H!P MZ98/0.!0YMP%M8M`N:"`!5EG;4]%@79!Q7I9)`@]1UB$WL)%H]QUL+_IY3HV M9%FA"XA"CRSG$M5=FP/8FX/CZ\@\Z$457=-Z@^+*<<4C5/<*#"[EW MW6_^A7#MC.T0*R(!J+3--VL]BWA<8XRAPMJ@G[V*2+J%9E$3V5<#?>-QI$1> M_]G7$6-8M@V43'7L9LZ+A4?&%F4#2EC<<6'@>L_8Q]MR)WXQ@5N7++P(7I9M M"=P$B",/,*,301BD(*T6Y,$$!"2O['U9?)EH"K!:% MICF>63`T]K0G*$L>38`^!/8UQ\#.2+,0'7:^$#I3\Q'`QA7DN#%Q-)CH7U/;!P(MJ?#ELNV M:/O;JUE&+;?#(F=\OT#_5*S9`9Z(I\75=1,C:Q!XUGT8$+8G_?`>.0?I[)%' M"U:%CX/$])EFI>!0?7?_3#F!WMQ_;,`PQMF=ARLHFE;FXA*8!EC`2VZ)!#3D.]AG3L2)N!=P+X7!S/5` M#A-F=E`3,[:"P9J186I@=];_%10>/27`1!OCP1)A+SR`I>W35TS;=^.G`X'> M'N.Y$!]&XK'R0E;L.8&9P=(S;0H'&L>`.C^TF:9:GPK0#X=4%.+LS`*K#YV$ M9L87HC0TMBA\(MK.L8:-*&*.QPQ_N.-@FY@.6&81"5!D^(E=\X^?0O_\P307 M/U]3G-Z9W]]9_ACV*>SE.V"F-[8[_O;KRQ?_B)^[#>"+F6L#P?VKOT,K>/[D M!B3C)2I/X(\O9/K/']ZRSU_?_W7U59*__MMTOJ)9>2=)7]G_[VZ^JO)7L#O3 MW__P*SV9)^/N*^^:5*!^M?M__W7SX=W5EULFY(:*//A%N/KOWZ_O_LJ= M?_L%2/9%%2-V%=E8/HF#,U,!G<_,UQTP$\H3X8:*?^&S;3I^WQDH<[:4G5!] MPBS%'?GAA7^'#JHM21+I%8&?$,#L-@"/*RCX\1DAA4]4P2#885`+E`IB5SC# M)^-=JTB_T)?PE^5W\B^O\7CNAZ:S/&@D3,)"&Q)^E$=#0P3E!?!%9STXW]GN M,XD/=<#)8&8B%M!`94/3Q43'O`%"0%JS-$DC@\$;Q.USRB8*<:`7\&`#PB)4?G&C2X>W\&X]*B+ MT)H,+!B2_=?T+8#BQK.`<4W;?A8%16?W3RO"I`CP1.@%`](ZNN6R?&0LH#OC MD"7?(@NRV\D4@Z)W>M,8G9'C2S(GI'=6P"^ZE(+*6FTBL/TN;7M)OYC7 M,H")+EDI:A%WGOR;T7XC4'6#BPE\UIL-PA M=`B8:(H7=GA5%X&WO+DH@#-Q&^*&`5AY#HK:Y1!9*XLV&OE.O+'E,^C0:O0F ME#)/:)?#&\"^R%5^WBFK-?E'3]][EL$K&%8B6"XA@N5=1+#,13`7P55$\&5T MZ8?<+`JJU(00EF-YLDU`RK4$9(F-7,=T:T22M`'`Y1B8%X[+"50F68LF-^'% MEC_VK'O4Y?C66/@##;L]8:+UP@&Z\F-58&\2IT`P M$==C.?*C;M?RXAMEE*T9Z6W,5I!27WXZ&\[/`KZ.=-;4O,7`V(W82BK!=*Q1Q\MR:KSQ(3[G@MJ.9?"^Z/C@U[\$L.UZ!J+DVO/2^A!\>[,KZR M_`J&O3.!NSAPR(9:Z&7C!EGDYD>^I(`>&^YZX[ZD?OJ?\.^C> M6;^=^)[T`7>"[`'O`^[RZ_2PIW)<=X1K15&Y[XG[GOBU8M\PKNS))]QCM+?K M>ZK:>9S?+_;T?I&G/7$5<1(8YZE/G23$\M2G?FJ&54`!]SUQWP3/C3DE&G/_ MT^'[G_+5*O<_\W"ZUC3FEM-*,N\/^QH>?F"(Z8/_-+QR:>NK/Z2;!4Z#8/0BSK"E@_DX!9R%T$< MQV5=_]JK:&[YAQW\'X!\2K'U#=4+?_D2[!,=_G5K# MY'>AAX$W(+!)Z8;%YNBH+KD&6/>(%$<9M(I&2G];$+-@N.)R>ZC5\( M=S."?=.CAVBS\=4(:$*,37\F8@/RT*:MT['=NAN8-O:=!\MF0CN6OU)%61M= M".5`5D48.?02?>VW`HTCFLOVH3#CH(U5*+(XT*6RRU!R,<^JV`MKS><;`E*7 MQ*$DT2[R&;R@Z&JU;O*1B;C65-ZT;<%-1!.ER;+6YUP4X"GX1\#=CT\`R)&F M+`\'(GOA!K`'+'A]"0Z\F)X;D0*/1F!G=+:GB(8)HAZ_9M3CUR-STW)P+;8U MI>/B6_&HR;4FQXR:7=,%IF;!ONXPQ@8%6,_W!5#LNS4'7K6?&:\C'_ET&("! M"(")8.;O!"I).#N6H`)CL1;TNX#%P(AY$;C-&C.2Y6$H;Q(X9CP@.4'D":_D MBX$$_"N\&EP`%A?P'.4%-IF2L4/8,07>G[#M1X>T-L5*[%G+KLF/V#49 M:;#&%&GD,6%+1Z9`).@/)>``)`[X,"7%A M!C"2'X"$`J0C6&R4>]RVRWGA(1.DY-AFV]BC2NLQDBJK[8W3XG]AK98[6>ZX MQ$[+`TX$9AC;(7WF%:!O,!@F$*TSHJT(@T,31KF7/W3^CB$OU)V6J%A2"W5>,:X_ZHD_?B+$)U*Q[`&<^&#J1Q_P@;IQ,8. MZ8B,%@B#/6D\X'Q[+D8&#%E+ M7&]"7Q@/L(>%'C8JB^L<<5160&5QNY(V%MINOGH*XD@B&EI62VIV;VWYW\ZG M'J%F#M@%H&)1;99'RJKI]<[D+>J;77?0[,;?C/@7^3>*U6'\\110)E\8'&75 M4"9=C/++U-?'65>A`#G@O+,>+3!*)\*S1>S)$7@V*XB$NDS=D+>:H^%@>*%# MS9\-T%5\='YTX2!NV5;P?`1TTO)K,9T0MW(L4"P,+RJHVX/0L*ILP31!Z8$PD?!WQS?3RMCZZE(;1YR+*1)NP:W?XEY>\3Q9, MCP@3`/\Q]FE%E\[,S1%ZPLSR`]=#X8MWY>9%"=2U3+LRM].KR7]R7&\.P&^! M(76=O63U1I;TB\*0+ MW7+2.V_)IRG$451&$R=O]F'0>_QP=L_JY=ROMF3&EJ\_SUOF$+^E+IDO*&Y\ MZEK.G;P[*;%GDF MP#`T5!3I%SKJ\F_YE]=4(%&?6^36@W^<=$S%,C0"?TZ%1T3?P4(6IO-\(5SA M.'0*`0,D`O2M,5?B`X@@@L#/7)O&`K@K.*G,2HQ#E\36LAZ/@0Y+=.Y9-/IB M.0+U5-.HDX&4\N(#$0_CC8TD&>7`*.=SDG*'1C"M]YIN-/`3**?OP'O@*`X)T+ M$6,5E@,CA/M3;WU1L1$ZSC`B9$Y#FUX#JH$=2"JVA%(N0BW[8F%ZP8JI4OP3 M+B*?,9A)M@6T`&I;KP%L4(S/?L*!:P)SW=O6&(9WX&PR9I0.9M1C#NSEPSBP MN1+/=]>E-[@I6)$WR*Q*B`44R`D`;VN%-D:Y0CWV$_.@\D^H:AWP%+ M9<["&>`E,&1@:4]N:$^B$#)P]?JCMWZ/-\0&'D3Z=22NX[@,)ML=-Z`4FR"U\*EU M_H_H>T]B-3!)"?P-D4Y#*V";43&-`U:1\`1X+8JZ$QKP" MR/@&8GPYC)FC8)(A)9DK8Q((0^0V?KL0KJ>P%Z=!Q/HY*(U5A#^C2,(-@CY9 M&L0"#$X\V#\TI(2J0FKM4RP^+Z/[XA%H7!(2`[^$0\8CF`5L+^#/8(%XHF!- M-U_)>9P&4WH"%9]IS1X;#/+@%S\C0))M^DE2`J"TBFCIDS&>=2QF0ZPO2J3R M9LHV-LA71]!QI^=/#R#4]:N``%@P0P.1&3K,H8,>)"P8(7-PT0 M$7EP)5D3LU%CZ!S`]U#DI9D1WA*F;R(.97%0 M9J1K<$>OF#IX0NY=0IH:-!VU=U(R[#*@7$5QQ7;?I@8IV+9T6S'U''$L)9]/ M0X11PE'UD:&2]/(JB>W\C--`FM%AO<\K)9I0]F=LR]#]$7VU%,"9X#$U"\Q% M8IOIT;4FKS$>#WYS;2IKX#-N=C$RJY<3>ZBMX[-%MIQ$^!-)F%DL,OEC/&.]+H=G-Y$,`!?%36](9B0@+:&027G[C. M6)<'B9L-X%HS"'UV$)3U'ZGT&?Z812K@MBX(%=EO\;+B=5/Z788/>!6@,]14 MXOL8S/6KB^8(F$D_K5/Z#2G]X!`8TR]"V"A&V+X)2/E)EI:Y;KMMP3Q`TQ2< M4@J2%04G.U%PD-H+LA'#WHW0^N1&YP!F=/BQL0**=FY.2#Q1UJ5<%)>_#D/; M?HW^:,ELYKHGMD4>Z94K.]#0?#DX$\V9OVKY?2*!;9EV@5\OK_P_FK"U;L(@ M?<7OAXL$!@8:PT#T+2;_34*P9R8`@NTN*%.P8SR>S1$0-(\PU\-^COEB=:FU M?C['_9,VH$VPMN!]&^8(Z54.N^%#ZQ)9!?XK1OL3%NDN%JX7A`Z?3SJ MPU-6E!\)K\S,Q8(P";&ZUC(3F,;=2-$/-NT#'NZ%D![\QQ;U!B2.'&2*M\W( MY72#/%EX1,T1*%-"[!7!4UZ$<73TG=$$Q03T$=%!7@#-'BUJSP(G`C96.]DA M#RXE'6;W$>9/3.RO?_P4^N"6]O/MU=?_H-_A8^7%^^N?YP?7=]=?=GV39-C)L[`!F]#'.G4Q"X4<;O9"E5 M(A$X-[];\W#.M':`AU?8M0&[=7A'``:\&8#_@#1<&1[4?IBCD/6MN66;7CPE MB%::!PP"&-B!3D(OZN)I5Z(1$`*RF*62,FB!^YF;;MW>H)*;O<^<>C',"_-Y MY;*A$#VSY,?(4P*S4R!9:C*[0T'$^2Q[F_HM7=C$N.]LA-R&U5!)#9B"GZWY MPO5]"\4)#!6;MV`+_HES@=T$_ZPPFKQ3-*G?EN$]^;UMF?,@\#%9/6+-[T//)TES+";QE-[?/K/C0&1&T1M6>G,=78B+>61?P+"AF;R% M3V-_A2`P>4-OXW?W'GC?3-0-P(S,R=2DIL@DD;">P#1HL[?N9#7&G;L`C:T9 M-);80HX7A=]"DR;I1DV^Z+=@NX['(%.!E>QGRG/4?L3D5@^K(#AN`J&(%DKB M)(0YV>$7PJU%,_KI`F$TL"3,)6/323!+&L9WQV.3'@MB7D(*;.`LYD.777TS M6V))`#P:K90YQ@8Y:!V9Z$XXJ3O*7K$AT-#%8P M6Q941B1&CI@<#>+([VDYC[!FUWL^?K*N#BI_1B?)Z!P9"V\_EMX6F+-X6XJ^ MH>@@0+>TZ3VC^>KYU#Z_Q[1MXON1`(D\R(3&9D0;FD0W$;%N8_[SU/@L,@XI M^0"BV4=/BV>YH4^/1HR5P.[THS(M0#U"W2G+\R<=,E9E..`C0KD\]CHF+?01 M.X"69U)4C7/E*R M1;HN1X-1%47E&+NOINZM"88D`F'9O0*+H&I74$O M4*ZHHAE.:.>R^*CE25Y$'@Y!,@:L>`-2F!W9\2_JUD7D"S-BVK`AQC0.CEDP`8Y&L-FSH4];%(^_2K(N( MB_J2'NWPK&I3\F684R@C_)!>#3`M#!8M(WGFT;;:*35YOKTE#_C:%X)3P4OM M'FHGUF/)`-K_6N.,_\H[X>K&8,D<++@*!HA/N)M'/)N`;O;.HT/M\M0K/,&> M6WU+'X49W"WU[]]NGY__?82_G[[^^W=S<>K+\+UI_ MWEW??*IQSMZ!U3:E4&I=<0J?1/_7#BMBGA']CB2>6^?/JGR80O^:*%\A=U.H M-XG"I5+8`8M4!_0#C7^2E'W-Q#6)+<6E6>@S:9LH]Q;7YY$OA,^),VW&05,9 M2F*:2/1T&0EP82G!5P=/:E,D0,$8"8\^1F7O.E0B4U4L[C!8UZJ):]^DBF51 MK;YI4VMGJ4CI2-8<3\_,VQ:I6Q;`PDX;CZCQ:+3&D[^L8#0!ZXF%C]T3@F>1 M28BA:6CK7MIS+!-%8[]B\Q,H[U",3T-:43#K:G]I):*J1X,TUJO3Y64*!9I9 MTSZP)44]EF,:TU`_%KF%]]]QW)2U(B5+:5DGIY)G@?5E[_1(`FVS(?N"LAZ) M&[S2`GDSIZ=/6!(9RZ9-L4^`N]86SH?JC*,"_Z"X;2C\N MWV/^U]RBJ*E*<^D:*+AW8M'TW M'CUW8#%97D[&-5?"+?Q6I+B8T49%C!&C\[L_"^O M!>1E@,4$"YY'5K['1"P:BO"\^FQ\QW`ITY!MN*4>7T.G+PKCU)Q;]O//)8Y^ MFTC(+PF81,76@UF+U0.3IR/Z3[);>@I)==*X6?&R:FQ<%;)UAW'+X"4W5E3L M+=]U>P['X;5O/%;4+?4='MS2G,,(%]=UH&7HUG^+>9YA)_T;7>//J9)UFX[U M984ZF;'27U@)^VI#WQP6@:M4T.#;@F^+@FU1LISH$1*SY^`=,Z\5UUL]0F+V M'+QCYK7B@K2](V:[->TJ'K8R'1JR)*DEG0T%"+AD'L%_L2O*Z^1MA`A_CB^V MD*V!=1B;$2<-[.V!-O<^LV0`*#X\U]8/`:Y=U0&NMN2;[`##X:PUP\@?_^.>U M\`=&D[,HR-MPL;"?EX4P5EE89_+K9/H5_8RC%@:3-(.X'NVR_LN!FCM?V7:2 MWAOR6M1#?:;A<7+9MC,TYS+.9?6YK+@_0(^XK-N`QV-Q;!]*,$"/HK32]EP: M@=$/EUCI.9'4+WQR'YE7D\7.)!+'W:EP_A'H MM=8W78%NV.-/*=S@8NYN!MF5WCIL0NYRC*V>G&;0G37'+9_'J_$ MU4IQ^_46%]^HC.-4/A`J]\JXJ[*0+RZA*[+"1VTD_;_7+*"BI8/\/@^ZYLD M2S^N>;1_BBJG):J9;R_L$S;>]ITGJ?+1%GVI]U90 MW4W?L;I;_I!?KCYN,,%N<=CW8Q(WX'3I MH-?S>?@6),.JH-K9D@'>6YX?"._(%(N:9=GA2_^Z_SR_=Q,&>V%7E$V;F\ZV M5G*.?O>GM2!QSY4:DV?&D*7`>$=K/>%T?A*BHJU@.I.,W]]^O%L]\CJJ:R_\ M^SP0KM`;L/`LGP7K?"2VYV(3$R21R%H-TA`S8)M_(1-,IY9MT1)3K%\FEH2+ MZWI/A%>:8HBJ/A2%5^I(%R5-H7/1BMZZK*9*Y-&(HB6A)ZQ:;;TZ5")M"DO+ M0&.O5FQDONH_0$LO8[/CJ*(X[6B4X#M6.CIJA,`Z6D4M`B9D54'W/"X=OJS= M3SO=BBHV*'MEB)(LL27+M.@X"XG""L@QXA)X:V3-K+Y_5F!5LN$B[8:(VQH' M8:%;N"&7)>\19Z]7@5YK,">)G2@R]DH>BH.1$9%8%C5-SRO('`.OK@&_SUOJ M2GAS]>GJ_?7=/JV\S3/_8=M]/)YQIVJ\M-JZ*6B2?/;MM>#3UM6@J;';V!DJ M')2!KUE37.S1@$5E220E:=OKA1T5C`?#;@Z`S*AV)-XC=GU;ME*(F]E@K48" M.(R;[-!.#E@,."`7PN?X#];IYIG9D:ATB1`NUCL810T63(P`7K6MCX(6;.$+ M>20.J*E;!@I6TXSZ%4=M)E%#LBY"@#88(.I13OL7Q2M`;P2ED:$OA-^C/D'8U`'702L%VR9KP+,PX93QRM!% M0P6U_TH'XTB-C`5=%F4P%I:-YRF^&ZA#NLV+WTW[]??KF[^O+A+^']]:?+ M3V^O+S\([R[O+KGYP$OV-Q"AI@*48;D/]=)`H= M,5/SQ)=:B2]9T=6[)AJ4S%M@7SP15O,/8Z5+SU`&VHSAVX@73U8&UB()@OW0 M/^*YPV<5@CO'5,W$DTRYSKFA&C>P+(&/I@?G%%7>(WI.FP#_#ATBJ/F1*1S_ M[>+_EBP":@6MUL&IL3=JQ"9I@AC=BZ::VJGE6++WE@]@4'O]Y\)XMEV486X\ M76*H=9J5C.S;-264+X,OHP%PV@M)CZ3=L#C+9PW.5)^JW"5FY/M51W^I_+2U M85]M'6U+VMW:>(HH#65QH.<76-L%RJJ+/V0,RJ*NCL2!G)^?UC(&]28P6&6+ ME,!@<7[?!@8'`TF4E>T8K`+E*6%0$15)%Y5!?OILHQAL*^FQ)%R_>:[O1W>5 MK>K$>MQ5GOUE;20.1_G$:PZFP\'*<#`4]8+JLJ>($UF4!@/@E/QTPM/$BJHI MXJ"@1NR>Y5V!B5K1*,UJ<'RH%'SY(C&8/M)`A>4;`*?(UP-#$HU!>UQ]B#A1 M#5E45(Z3Y%":H8@CHSWK8<_6WB<21.WLT:]N.6-W3H0S&TS`UT=`/%D1=2/_ M)O44^?E,TX>B80SJ@G0,[*%)XE#G1G!JQXR&@)/V3."]&WLH\)A\BZ3=$1#M M3%9%M:!+T`EMZ3,%;-W!L+;,/P9E9]7W\_R+]_.=8('O)KO!^.%5=:;+VS;$R5 M/.B-RP77P:Z_'^3G@JM'%E=/*718)C)'"T<+1\O!F&N9<*TR$U1^NY8./.&< MS#DFZ*NKU0[WVS[Q-QOT.5=$8<)PDAS)D71S( M'"$D,I:,4,>,Y#"B<#,'7U]O3W0>)DQ(.`UX=2%1V+ MSO=5]O&"CICDV^*9(FJBTJIT/$"9BZ!35F3A$C.K;/X4IP3>)+XD"J;>HV+.6:L.92 M,H[G/)P.3W.T[!^H_4/0([3PG(?F'4_2A;3;,:5GL2@\B+9!/!R!N=M,4'W? M3JU'F/VP1Q'6*X;E`HP+L.,78"5ML-H=.+C=S-'"T<+1TIO#9W.)$`J_X"63(`UV46RP5=E#(D`:&.-`X9U!D:(HD MCO3VTU%C`PD49 M[F->S\L7^\.*.A#5$=<&*2?FT&CBG'\,>P;.25J+W+%W6^\8TR%D71,'O,?- M&DY$>#@"<[>9V-G&K9@#6W_C?=YX\@,77%QP<<%UR(+KI\"\M\GRKXGU MB)__\5/HGS^8YN+G_PY-+R">_?S>.^3OT/B!%>/\"]_^1`<,!T$^`N9_O.'M^SSU_=_77V5Y*__-IVO MBB1K=Y+TE?W_[N:K*G]]1\;I[W_X%>&,P*3(0/B3Y&0+_\E!(&WAOP)K3GS! M(4^"Y\Y-Y[]$@7XC"C[QK.DOPI,U"6;PCFX,%M]_$2A&`\]T?%SESX+C.B3Z MUG(F!(>7\#F;!("6I/5M_11F,%]\F&*!'7.S0GFA,3C ML^\#CP3CV6JL\R=R_\T"<'!V^-7]1LXC<''@'T"W>!/B_?,'Z0=A3&P[FG;Y M=Z0U\._M>BIP%UFZ*!ICM10Z^X5N.1%64MRW@:?EB/?X01Y>4"Z[7W%?!E.G MIZP\R>WO;VZO_OOWJT]WPM4?\._;W"ESM\&B!C^Q6*A?<&="F_=B36%C8KR5KAS%]98&.KZN2R=Z]*Y M+*8I8=$-L!3``I/`E#+T)Q%7-9ZQ*29`A(?0FH!8)[#]!>+C)K#\F?!`'.(! MI>`+9V)Z$PJ(.1Z#]4K]OX!D`7Y)`$V?('0V6(X9".YX',)#4\`V7=^]:=-Y M_!DA@3`Q`_@J#(1[`F,181HK%YPR(',ZC@D_6+X?DLF%<`43!Q9A7WJP.LM# MQ+DQ"(0A$8<-9F!E/\RBE?HK9$3@/1$8@CR:=F@B\DW\QK;QOSB$1Q%M@DK! M13[-GMERZ,A/\(Q/;#(.$*2[F>4GR>;/W-"&\6P0K/!O6PB!G2E>,E='AS4= M@>#*GH$A8$>X00*P3S8SR*E/)-K`D%G?&T(UASV#,`DB.XP`(KL$#]LS%%F,8/[8`B M)XHJ`&X7!6)Z#L#KT^MH>@\M`!'&)K#DU(9]=R%\#H%#QPQIR`YSD`A+G&6@ M+&:&!'<`]K:RVR7PNH=*"%?[%&W7(M(DYT%AQ@AB(_(!#Q]-#UA1,43,=]+% M%33QT&Q>^!Y8ZM)Q0H#L"UFX'L7B>Q`M($#/_^]%6L1N&FNYIE?2/L.;+?]F M>KGRI*X92)!1>5!3\RV.C8' MM]P:P2)CX%[@,3;=@%$7IA?9;F@9@`QD3S@3Z'-@>5 M*_0GD7X!6X"9+53U@H$_PMG[R]LWK]%\@A?@(P[@QQ:G_8R3$&H5)V9;P,K' MUL(&WCO[[?+R\VNVC*@N4"9N$J::2OSG;TTU(;*+\)9\A'` MYUM0$28``+@"F^D9%A!CT&T^(@WQDF[X/+S+S&3"!^PXV1\",%]3?6;R1 M$LU;#9%R-D;2*GD+F+UT)OB?*S!!P=1"AN1&R>D8):4N=\[NZUDDI29!)A0% M_+>0X$4J`&YG($W.[PALF6OGD43"NR>FRC'<,*7-$VZ4E#1*J,Y#38]6Q,QZ MF('JLRU@W@DHI9A/X2.,$";N'^;4F*#2G^HNCQ!A#G#,J$($?6!YPB*$PZOI MLQ,KU77WA"E"LMH<%VR[D.1VH5=95'%3Q<[@(`@04`;,&7:"1[\H?!F9$+]? MW%X(#RZ(%@?!7*DU.F%TB>3C$.0[6CD(YGLRH;=5[T#5^U8`&Q,L`7K9]-;U M0/NSNXZS]^^NW[X&I,PMINY?*;HD`KFIBE]I/,21%83T'?QEPD;%&R]8T!Q@ M07C8,@!5Y!GYZQL804MMF[I@2`SG+VTVMGXRH;8;V)&!&*__=H48)E]@WL\> M6!)C"E!B01?"Y9S-ET(&LS]PK?%2<1'WIO-M-3M:>+M00S`?'CSR0*]`7H&V MH]A#J?A*%@<#ADR8`C0NF=_#K*HL,GL"G\&6M]3<6N!:'HG]?!%)TP"EZ8I+ M&>E^&(]#$PO#W+AZ>2K`9X&*-RHN81NYN,R)AB>TI! M9A.O,?\4)$DV^^/$U$)>O?A$[,>--[,N/&.@Z6KP$L^:4A-R.[]8U+A=T@7) M*ZYV[2:],\<#?,,*/P$S">I6"ZZ4/98TX)!='6!7?I%T0C9;Z8ND<3<724LF M[(E%=B271]PHJXZT)2MBI+T=HK/-,Y]0]0`"3!LP`>!\`]#/%YY+M3>J!Q#< M%FB,"6A==\*^LO#:"-T1A"H-%/>V^P1"'K6@``:$S(^8DH7^TK?HG3YTD5#.@/*BL&(^?B?`?1<]TTB,1;T5B[(3E.EYUDJU@'0' M+-"#PZ-KP?G%I*=,6`'5"1@D8J',!W1-6(S$Q`WO@VF(M^JVSC)*O;P\/8,R,]EA"@YR]]0Q"*<>"]$)1$!]`JL+ M`?Q)XL3MT*-1Z.//,PM/S2AD:&T66!Q.9BX6=G3G#:LP'ZAB6@:U^!="-G:> MX+09$`<>1<\,?)@06-5$")UXM?`H^@+&J.4L=M8,-H9:>.311;0[X%W!NQ2(/EV M?#1%GVL84%=.'-6S.M:J$AQ:GP$QUZ`RX=@>T$EGL$E@1KP;B:?;6&U"S^M; M]7PI'9Y4^I\]]-,$SY]A#0&\B*=36HF'GSNYWD^I"]*!VH^Y410H/U))M.1( M;@+P$^A^W0(3`IIG;*&^7BPY=;'D5!)S:GR$A)%,S$4XMT%?1X='U*Q,[M/+ M_Y67'.]/S>@..C8+J#**2J+1$?&$&JL@TZ>^_N45:1201YZI(J2'5F$1XMTT M#`)4>K3&2^FG)V'Q!?'DZ/V_#RV;JKDS%F&!P9SF M.`HDA97(HY'Z.HYL%!1)DJ-K:VFP#(;T6=0CVA`>B6(K5RB>+*,`%4E1:>`$ M(-K"2^D@00IJPN`%<0Q0/'H4U&#Z]%8;6`A&G+`C]/)X+_S-\C%P51A+2`_7 M>`7M!,_G4\`#]?S3Z`2;@K2_45*&$S!Z%WIJG*+.\QEY%>:3X!8R7>&Z8E%H":Q-AZ`7@),25 MKYBVP?DIZACQT0U`0=GP5L16S6"K55/62$E?H(,A]H#VY"5=]7O+`9OY[0P_F$S9PP%H*9Y4W6C`6)IC)8#D:2HFE! M[@.6>$#7&L5$&*(V',5I0NS[E:T3TX$BRZ5Z.BY_BV&GP5(#"WCELUS9!M@K M7>H+!E6[HXL.=@27("A<]$^QW%!$T$ MHK=ERQ!9S&^RO"@H=DNJGFI(62EZE^E<.ASU>C4J?//.\A>N;]*(\`^N\W!. M[<"D0J;C@+28QBE7TXGM2-/SZ%TJ]?[A)#9. M8M-)HM6#](RO;NGY89JD4G-*)K_'F]D]X/D/ M1//--%&C8!GHR,]._.Q$STX/'9R=WJW2@3$P%27`'['4667')+B3[E7@QS'\ M$06JPJ-?+/\;/W6=G,W4HQ(%[U,!I#&S1IE5-`HZ"K.EJ1+KT>`B)L-G1/:* MS,S8_'KIR5VY$1-?+LQG]@T-8Z;G%AI*ZZ""8KY)CZ9_/YF+"R$;=*II%RYF MA5G4"O3#>U205)V]9>E[44+4:B]2JRXZO7BP)S=BVAM9/EO,)@:HK@9=2I+# MX;/9HX#A,,U?>DX4,;,'V-S4%%U9+7"*-O'YY>CKMG!6*0$ET]Q-",*/R4%Q M,2N1F5&G8D*F-'!@!96X*E.!+GHXDYMS@I%TS'U-1Z=F]6H=.,NVN@;F/4;+ MY2R>V6]9EEV[6R#-&-$N8#;@=Q:$P2Z[URS16M);+#5 M+#XU;-7B/438Q2P/&-K&4ET4"^+Y@M"VN-UA?I))8$12.I M4N%<2P4;CX/5Q9&KL-;/*C`+PZ"B1'I:\V89I@5V.#`9U2J@CU)C`)!V?$]+ M-3^/Q^.F:&,_"@@0PI+CN070CRAH%\FP*4-AVA8ZZ,94$=V M',X.%MQ_F%MH,Q&:.1`L+W7D^Y.D'=F9-SN"&>\$U!?HSP:-YJ3\\8E',(PN M.2:UJ"<$S4MS67-S"3NSEF=D\K!T$+$3[-(QF'!AQ>'VUB1IDZ(B7!WM\0S- MSKXKD+#$(RW"L\R(B*//HH(-H`-9M!DN$(&)O?EKL$3)$'AV3OJF?!?#'9P' M5A^!'A80QU'>7\K[58C=]:P$FF-/9L3Q$;2H81!+51`%]&+:JW))U":ARUC= M,^5C\HQ M1[6KD*$!NQ-W3$V`B/B4='C'-[,60(/@"2FS'3=.XFT8B;(,S!J0N;_RK2WG M9`_$+300AUZ=%IZ7_@WP\NL@7-C,%K,D+#,-+, M#Y-DL90[G2)V\?4$HZS\DD"<]'IRKV)69E6;UR"Y+P"SFBC$2D61,KD]_E5>NEW@L$T\..`#'6"D:"!YVT`(X\KY M=KNL*IF8X"(QGK9RRK"BS/02T[/H#0@KMD26!<*7:/`3%B8UL'RRK$5@T3Z& M?FA20X5@A7-:VCRJM&UZ'BJ]1/R2*%CPSH1@W)/':G#3NN5H-(*)$45RINLG M.A,64F7AJZS\-F#=2RGNA6>Q],HHBP$3*"*;;^G7L1Y?QQFSL2%#%V?Z+C[$ M(GJ\Z,9UDQ\2,3WTHF86Y42<,610RY%61P\\ZSX,7`]L-KS&25P]XQQ@P<>W M-_3*.+"""#YZ;4,#PWST/?G^,NAJ>=WJK%`7_\9:2#+/3ES^'5VJ,4A(BAU6 M'T8#];M'R1[C+88AM-T5;+9#E+=$5"W+EM@JW57)ME?_IP%:)^)#; M*MQ6Z0G2+B=TL]'@U%6V0)04,&%'^SCC(+8NK&2YYT3.`BWZ@$8$>XP>::/A ME\?:11A1&#E$0(*_(0H<.,[DML>WF? M@*FBZ/E$5!:?N;?JI'1N(=[6W)G?N=[B>BNMM[YUXM:@=4V`_WA=)*ZP]GVX M3H8[1A5W`N3,DC&.`RTSQG&#QUD@X_+W-6K1[YBB2Q^#GY+G'E.@N@*`!0@3 M5]Y89X]>A.,:$H^059@@_."1:>A,5I&$&$Y)Z.&V8+3,%!A\GETELZ0^,L+%"@]_&PB3(,*^!9Q!:C$"UL6&%9L6_@WG6_)<=( M#YO3,XJ&-RT#5B?4G8%I6/12/Q4ZE;.ZS(Y=P(+GLH0UDCUT`T6%M=(Y92G. MOG^F_1O&GG5/,W,$3.J:A_.8U:+R$_#(S,5*R_3&A$)!JR;CK[33UIRLKF18 M2FC"WQ<[G3(:B]"L5E9>##"$&`98/9_%G&)J$_62L*`1VC$#Y8DY7J4S@5;$ MT"WVQ1-]#H<+[:@:&8+JA@%=,C!1Z$1!>'3B..:7DH66WXYCO]V5WXGV;6&3 MD>\FWM2PR2(G%G5Q.+0O%[N"N(VN'*AKAOE@S.\4N6$P<^-@VS\W>H?1H)X( MJ4`X\QO6`HM;I=D1[4&PA9Z3>#^Z0R$1;1QWM<04F7QVLX6F):!VPY9%MDN6:='^2G`D?4>R7"+?*]L\ M3;65Q28L;S#?$*/UP?2E]+FA_K%+9W)-PSG!)L>2&SSIBUNWS+JU.[!N;P-@ MU7/*FD*2-[FE>W*6;K]B39.&KD^9E.5KCQ-,6M;HE8=91F^2W<_I/MC<`:F$ MGM7%S]+J#:F=N+)Y`:WG-"8A!69R`5-& M)I93764-`8E?8>_Z1`>UAF[(N$&T/YQM\N>"!B=0 M_F0*:JGVHV*3DY+6D6+@?4R6@12+9KH7Z":XR+H(1,LD`5\)P+`Z#R;`Q0HU M\79T8_%$L"`:WCF!R#$?P+`*J99E-L-R['0-\(2*CJNYX*(Q.?K!>F1>/E9W MG*V?!CZO7D^:4GXZ1Y@UA7^B%P?WK#+J^<2R0]1KS#3#D-8Q74B"/F76GWBE MD;6S*!(+3<9W""&,TS9494@A+&PP;6B;X%R44P[%,OW?B3>V?!*%(M$;'LSB M9&FD4:6C&(PH0IP]&M=LB]!$1]\$Q8[S43>6$(7X+-.\HK"IN(W:9!D&G3G[ MLL@6;4-#)HFB>[/G!=ZS4>69MMGCQ:Y[3+GVJ*8]4B9=P_89A79JSBW[^><2 MQN$F.IC-=8[!8^;"!Y3$GU)(V6JZU;;7[MT@<.=9)EN22\8T]R1A>#+VR\1_ MEBV6-58$YCF#``:\T%&YKD_!OF"R!L&U)[5F+3%\3!L&V'FT-^[Q1+S^6\Q5 M#/3T;Q2(GP4?3B\3I)2+A'+^^8/,R/(7EJ:^VC@Q]@*%"0.6AX.,Y M]@#0=?)$4@\`72=/)*47Z*HB;VE/8ZP+XDQBM/RO,=B6TVF6*(Z1(TEJMN67 M*9?_K&+9YV(PGMO`F7>5_ZE!2H)?85A-61_7PZ7G#*R*DH)MHN5]@=MK5,H5 M42F/1$T:;!U7;P=ZHG%/ MM#5Z=`N3ODK8=DU<:I**^BX;NZVHMAV@RV&IUL"3*N"L8:)P&G<$GJ&+AI:O M'3FACX70(TF4E7(GG`8)W9Z=O!U@+1?<^%*]DI'\\D4>S^9/M">.U7(98D([ MU^Z78<,G?$:<$6IFZ;U)=SD^E,Q?\.*0^^C!(=$+D+*Q8%9G=+,(C#Z:WC+Q*!N.DHF8B'8(8(\E@[S0--J.!MX3S)B-_?_?)S?1J MF;7%`WU//=#7Z2#0]W>6M[EDN]P9>5COL$.>\TT'"5C62.L=0JF22SJ*/V'C:5^%%N"6#8C$K(T?KYWT@R:=:9I/HP MLC1J=BI@16.Q4R).$C4?QHR95:?+."$_;@@P23638QU,'V@1VIQW@E2&4EXN M=J*&[28X48&U.`\Z*F&S$?^)"4LT(3A^-2LAV$TE!&_3>FE5EE1RG\C3JLCA M9\]U7,Q]3E3SY_DN)Z`&"Y2>NZ/2*\IE>4H6UDPSW1[UW6%K-_MPR^[WZ&"" MB;T3ERJK!(O>XA&$%EWY?4$UP-GE[>^L!BS(-?E>Q6F>BAAUYH-E MQNF=F$!JQ[DU6,(_4KR@<'['PJL"+&JYGF61%7H*6\3Y*`NV)@:)&[`>VH4U M[-=:V\#CV,M^[:%8:Z8?9)4_"D87B$4?H:FUF"UL+YN1NZ&_4LM;@!1H11'*!S:FI0VA/+=K@:QR';ZS*K6!'A2AC-8F2LJ^C396P&$HMU)K/R<1BF;]3 M%VO;L-*LZ6$6)&ZM28O@1I5[=T$L*VG$*(Q9X5O?`!IB@X8H1R;Q9L$[40^' M2<1>`-B2Y047>Z"RO"8_REE)[Z;<:C@M";O#EFL'<_CI$GG[1K#@#+)%.T1Z03N71EEZ(2YR1"UY-*$]RN0L_S%NK)>5R'@6"6@<^/6J MOD#4$"MD M,2TYN!"N3`]/J`G-:#''U`(KB@>T*V-R`O8U$TDANZN)E!`[]27U+2T?-Z?> MK,>E!XNB,ZKZ%97.R*YC%3^/Y]P4.E?I?VY1O01GU4$G<;_*M-?W1?;02*FH MM%JJ660$2S1?W"9E-2\[[<)WK!GETU(-4TZ+UQ5G?[+KW,1E@!_MH*WGV*JG MU52-J_&,3$(;#L)Q0/DEBR?_1"-E;J;T/MB_P[-%E\==G@O(,[KZD8?"YX^Q',!CY_&/!?P M1`C-"6'$W^W\L7 M^PJNRNA%L4L,0G80PUO3G^$_5W^'UJ-I8PC$I3.YG;E><$>\^;7S2/R`1D9T M$='0/_[H41)-FBMX\$=CP1_U).VINA@-"O[E1A/#/2+JX'S,ZP[;LW=18Z?7 MG:^QP9`8OI]:"GXYUAW4(^3G7_ERY+>+_.NHDUVO)5\7P2EHCD<-E>$#61GF MN9C96_3$JZVC58L_&>J2*"GY]YO'%GU2`G^5(B4441E(HCK,O^,XMJ"3LZ91 M*(N:`BC4FXW;6;?G^AEC0H_]6+ M(XE;+FUNWA7:FD<2X)A_)[;7N,:AJE>TCGGTZH$0=Q?#BKVC8>Y\3"WPNA['IG# M(]WV'>EV$-$>?$/Q4+?C13X/==L7\@\DS+>Q8+=B0?G%?!*PH81GF?8)Q+BI MDB%J6K[DXS%N6V+<,,)-/YT(MZ;QIQJB-,Q/+CZX4DK%PN5/U_L&I\'SA>>. MB9\O7@['-W*,H06*(<'&K:-16@XL*`X% MR`X?B)H+^=A0WO_@F@[&(KQG;8ZD MM^H>YXX[[@GGGG"^=[C3^U20SYW>W.G=C=.[X$K]SC,G).YFBJN>W1SLX M/WCU^U8XIK*^PM@(#9O!TW[)V.[XWIP($W(?T#)4"\^=A.,`NQ*''F\TM/]; M^#/9$.51N1Z9]:M&<`+O@<"J."J039S`ATY@152TKNC;R[(O!2:P0X);RQARG*3M4%64Y?9"U[HS/3/AN@EFQ$ML[V.(P`3S M2^,[>RTH530&'"7)H<[DD2@/:V_L/FCS,E;'M3-VYT0(S.\DJT!'SY@I/YV,A\5JOU8X=GQERK<8>@E,V%-=WGJW309]DZ&&7*7%SN MY=C@8NPK@(:QR=ZD`5A\-U*RPS MRR,KLZ-RED8RV>,=F1+/(Y.WKA_X;\V%%0`I_D,FGSVR,*T)C$0]'Y>^3P+_ MG>6/;=#%**%+P!,-]1/$7D:)#/4T3VA?R# M2(7K(D$DLB(%\GU!'!]L+HS#=FDHC4DMREP,]3F_H5J&B(IQ4=OKU/'\D!S\ MZ2/`7[-=;/N<'])X(V!%%T>C9O-K#J-5VRT9AYX5/`L3LG!]B[=IV[_C7]9% MI5(H&8_P.$Q"[8IGM:&HCO*M<2Z= MCH;26\X-G-+'0NDS61('\J%'E)YB:LG>@#K"Y>T?@AZAI4LC,1.R=UATPO+] MD`AC]*P?`=D40]0*^FTDAGGYXF1XN3Q23@8E1YL"G"HS,W=AVO^8@>4Z&#